PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Rokhlin, OW; Gudkov, AV; Kwek, S; Glover, RA; Gewies, AS; Cohen, MB				Rokhlin, OW; Gudkov, AV; Kwek, S; Glover, RA; Gewies, AS; Cohen, MB			p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP	ONCOGENE			English	Article						p53; prostatic neoplasms; TNF-alpha; apoptosis	ONCOGENE-DEPENDENT APOPTOSIS; FAS-MEDIATED APOPTOSIS; CANCER CELLS; DNA-DAMAGE; KAPPA-B; DEATH; RESISTANCE; CASPASES; CLEAVAGE; MITOCHONDRIA	The human prostatic carcinoma cell line LNCaP is sensitive to TNF-alpha treatment and expresses wild-type p53, To analyse the possible role of p53 in TNF-alpha-mediated apoptosis, we generated a derivative of LNCaP, LN-56, expressing a dominant-negative element of p53, GSE56, P53 inactivation in LN-56 was associated with an increased resistance to apoptosis induced by TNF-alpha, Surface expression of TNF-alpha receptors was unchanged in LN-56 compared to LNCaP, TNF-alpha treatment resulted in accumulation of p53 in LNCaP and upregulation of p21/WAF1, Activation of caspase-7 and PARP proteolysis were delayed in LN-56 under TNF-alpha treatment. TNF-alpha-induced apoptosis in LNCaP cells was accompanied by caspase-dependent proteolysis of p21/WAF1 and Rb, which was significantly attenuated in LN-56, Cytochrome c release was induced by TNF-alpha treatment in both cell lines, but caspase-9 was not activated. LNCaP and LN-56 were injected s.c. in nude mice and tumors were identified in all LN-56, but not LNCaP, bearing mice indicating that p53 plays an important role in growth control of prostatic neoplasms, Interestingly, accumulation of p53 in TNF-alpha-treated LNCaP cells was decreased in the presence of the caspase inhibitor Z-VAD-FMK, suggesting a new role of activated caspases in acceleration of p53 response, In summary, these results indicate that p53 is involved in TNF-alpha-mediated apoptosis in LNCaP.	Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rokhlin, OW (corresponding author), Univ Iowa, Dept Pathol, 1175 ML, Iowa City, IA 52242 USA.			Gudkov, Andrei/0000-0003-2548-0154; Gewies, Andreas/0000-0002-7606-6482	NCI NIH HHS [CA 60730, CA 75179, CA 76673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060730, R01CA075179, R01CA076673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae I, 1996, CANCER RES, V56, P840; Bellamy COC, 1997, APOPTOSIS AND CANCER, P116; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Brooks JD, 1996, CANCER RES, V56, P3814; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; GOTLIEB WH, 1994, AM J OBSTET GYNECOL, V170, P1121, DOI 10.1016/S0002-9378(94)70106-7; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISAACS WB, 1991, CANCER RES, V51, P4716; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; LAZEBNIK YA, 1994, NATURE, V346, P371; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marcelli M, 1999, CANCER RES, V59, P382; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; MIRCHANDANI D, 1995, AM J PATHOL, V147, P92; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Nakajima Y, 1996, PROSTATE, V29, P296; Nikiforov MA, 1997, ONCOGENE, V15, P3007, DOI 10.1038/sj.onc.1201723; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3042; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; Rokhlin OW, 1998, CANCER RES, V58, P5870; Rokhlin OW, 1997, CANCER RES, V57, P3941; Rokhlin OW, 1997, CANCER RES, V57, P1758; SENSIBAR JA, 1995, CANCER RES, V55, P2431; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Srikanth S, 1998, CANCER RES, V58, P834; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; THOMPSON TC, 1995, ONCOGENE, V10, P869; VANSTEENBRUGGE GJ, 1989, UROL RES, V17, P71, DOI 10.1007/BF00262024; Wong GHW, 1997, APOPTOSIS AND CANCER, P245; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN DL, 1995, NEUROSURGERY, V37, P758, DOI 10.1227/00006123-199510000-00021; ZHAO X, 1992, UROL RES, V20, P193, DOI 10.1007/BF00299716	45	61	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1959	1968		10.1038/sj.onc.1203453	http://dx.doi.org/10.1038/sj.onc.1203453			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773886				2022-12-28	WOS:000086424300012
J	Plyte, S; Majolini, MB; Pacini, S; Scarpini, F; Bianchini, C; Lanfrancone, L; Pelicci, P; Baldari, CT				Plyte, S; Majolini, MB; Pacini, S; Scarpini, F; Bianchini, C; Lanfrancone, L; Pelicci, P; Baldari, CT			Constitutive activation of the Ras/MAP kinase pathway and enhanced TCR signaling by targeting the Shc adaptor to membrane rafts	ONCOGENE			English	Article						Shc adaptor; Ras; TCR; lipid raft; membrane localization	T-CELL RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; DEPENDENT GENE ACTIVATION; ANTIGEN-RECEPTOR; TYROSINE KINASES; PLASMA-MEMBRANE; NUCLEAR FACTOR; ZAP-70; PROTEIN; RAS	The Shc adaptor is responsible for coupling receptor tyrosine kinases and tyrosine kinase-associated receptors to the Ras/MAP kinase pathway. Shc is believed to be regulated by a change in subcellular localization from the cytosol to the plasma membrane, where it recruits Grb2/Sos complexes and hence permits juxtaposition of the guanine nucleotide exchange factor Sos to Ras, resulting in GDP/GTP exchange and Ras activation. Shc has been recently shown to inducibly colocalize in detergent-resistant membrane rafts together with the activated TCR and associated signaling molecules, To understand whether Shc localization in membrane rafts is sufficient to regulate Shc function, we constructed a Shc chimera containing the Ras membrane localization motif at the C-terminus, We show that membrane targeted Shc was constitutively localized in the plasma membrane of T-cells, and was mostly compartmentalized in lipid rafts. Membrane targeted Shc was phosphorylated on tyrosine residues and bound Grb-2/Sos in the absence of TCR engagement. Furthermore, expression of membrane targeted Shc resulted in constitutive downstream signaling, including Erk2 activation and enhancement of TCR dependent activation of the TCR responsive transcription factor NF-AT, Hence localization of Shc in membrane rafts is sufficient for Shc to acquire a signaling competent state. Interestingly, a membrane targeted Shc mutant lacking both Grb-2 binding sites was not only incapable of signaling in the absence of TCR triggering, but transdominantly inhibited endogenous Shc, supporting a non redundant role for Shc in the activation of the Ras/MAP kinase pathway in T-cells.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; European Inst Oncol, Milan, Italy	University of Siena; IRCCS European Institute of Oncology (IEO)	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Mattioli 4, I-53100 Siena, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019	Lanfrancone, Luisa/0000-0002-4523-3815; Baldari, Cosima/0000-0002-4414-6744	Telethon [E.0651] Funding Source: Medline	Telethon(Fondazione Telethon)		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Baldari CT, 1999, BIOL CHEM, V380, P129, DOI 10.1515/BC.1999.020; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1995, ONCOGENE, V10, P1141; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Graef IA, 1997, EMBO J, V16, P5618, DOI 10.1093/emboj/16.18.5618; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Milia E, 1996, ONCOGENE, V13, P767; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; ULIVIERI C, 1999, IN PRESS EUR J IMMUN, V29; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	40	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1529	1537		10.1038/sj.onc.1203451	http://dx.doi.org/10.1038/sj.onc.1203451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734312				2022-12-28	WOS:000086108100005
J	Wery-Zennaro, S; Zugaza, JL; Letourneur, M; Bertoglio, J; Pierre, J				Wery-Zennaro, S; Zugaza, JL; Letourneur, M; Bertoglio, J; Pierre, J			IL-4 regulation of IL-6 production involves Rac/Cdc42-and p38 MAPK-dependent pathways in keratinocytes	ONCOGENE			English	Article						mRNA stabilization; cytokines; p38 MAP kinase; Rho family GTPase	ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA DEGRADATION; WISKOTT-ALDRICH-SYNDROME; UA-RICH SEQUENCES; NF-KAPPA-B; FACTOR-ALPHA; TRANSCRIPTIONAL ACTIVATION; INTERLEUKIN-6 PRODUCTION; SELECTIVE ACTIVATION	The stress-activated pathways leading to activation of p38 MAP kinase (p38 MAPK) and c-jun N-terminal kinases (JNK) have been shown to be activated by proinflammatory cytokines, physical and chemical stresses as well as a, variety of hematopoietic growth factors. One exception is interleukin (IL)-4, which does not activate this pathway in hematopoietic cell. We report here that in A431, a keratinocytic cell line, IL-4 activates Rac and Cdc42 and their downstream effector p21-activated kinase (PAK). Pac and Cdc42 appear to regulate a protein kinase cascade initiated at the level of PAK and leading to activation of p38 MAPK, since IL-4 stimulates tyrosine phosphorylation of p38 MAPK and increases its catalytic activity. As A431 cells are able to produce IL-6 in response to IL-4 stimulation, we assessed the involvement of p38 MAPK in IL-6 gene expression. A pyrimidazole compound, SB203580, a specific inhibitor of p38 MAPK, inhibits production and gene expression of IL-6. SB203580 reduced significantly the stability of IL-6 mRNA, Here we provide evidence that p38 MAPK is activated in response to IL-4 and is involved in IL-6 synthesis by stabilizing IL-6 mRNA.	Fac Pharm, INSERM, U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Pierre, J (corresponding author), Fac Pharm, INSERM, U461, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.		Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Bennett BL, 1997, J BIOL CHEM, V272, P10212; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Blanque R, 1997, DRUG EXP CLIN RES, V23, P63; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chomarat P, 1997, EUR CYTOKINE NETW, V8, P333; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DEROCQ JM, 1994, FEBS LETT, V343, P32, DOI 10.1016/0014-5793(94)80601-2; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Duncliffe KN, 1997, IMMUNITY, V6, P175, DOI 10.1016/S1074-7613(00)80424-0; ELIAS JA, 1990, J IMMUNOL, V145, P161; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; FEGHALI CA, 1992, CLIN IMMUNOL IMMUNOP, V63, P182, DOI 10.1016/0090-1229(92)90011-C; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Gollob JA, 1999, J IMMUNOL, V162, P4472; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOWELLS G, 1991, EUR J IMMUNOL, V21, P97, DOI 10.1002/eji.1830210115; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KUPPER TS, 1989, ANN NY ACAD SCI, V557, P454; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; NEUNER P, 1991, J INVEST DERMATOL, V97, P27, DOI 10.1111/1523-1747.ep12477880; NG SB, 1994, J BIOL CHEM, V269, P19021; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PRICHETT W, 1995, J INFLAMM, V45, P97; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rhodes K, 1998, J BIOL CHEM, V273, P26534, DOI 10.1074/jbc.273.41.26534; Ridley SH, 1997, J IMMUNOL, V158, P3165; Ruckdeschel K, 1997, J BIOL CHEM, V272, P15920, DOI 10.1074/jbc.272.25.15920; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wery S, 1996, J BIOL CHEM, V271, P8529, DOI 10.1074/jbc.271.15.8529; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; YAMAMOTO T, 1995, J INVEST DERMATOL, V104, P784, DOI 10.1111/1523-1747.ep12606990; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	75	53	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1596	1604		10.1038/sj.onc.1203458	http://dx.doi.org/10.1038/sj.onc.1203458			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734320				2022-12-28	WOS:000086108100013
J	Maritano, D; Accornero, P; Bonifaci, N; Ponzetto, C				Maritano, D; Accornero, P; Bonifaci, N; Ponzetto, C			Two mutations affecting conserved residues in the Met receptor operate via different mechanisms	ONCOGENE			English	Article						Met oncogenic mutations; receptor tyrosine kinases	HEPATOCYTE GROWTH-FACTOR; LIGAND-INDEPENDENT ACTIVATION; PROTEIN-TYROSINE KINASES; CELL-LINE; HGF-RECEPTOR; C-KIT; CONSTITUTIVE ACTIVATION; INVASIVE-GROWTH; POINT MUTATION; PROTOONCOGENE	We leave investigated the mechanism by which two oncogenic mutations (M1268T and D1246H/N; Amino-acids are numbered according to Schmidt ct a]., 1999) affecting conserved residues in the catalytic domain of the Met receptor, activate its transforming potential. Both mutations were previously found in tumorigenic forms of the Ret and Kit receptors, respectively, The mutated residues are located either in the P+1 loop (M) or within the activation loop (A-loop) (D), which in a number of receptor tyrosine kinases harbors a pair of tandem tyrosines (Y1252-1253 in Met), Ligand-induced dimerization promotes their phosphorylation, and locks the A-loop into an open conformation. When unphosphorylated, the tandem tyrosines inhibit enzymatic activity by blocking the active site. Upon Y-->F mutation of Y1252-1253, neither ligand binding nor Tpr-mediated dimerization ran release this block. Here we show that the M1268T mutation partially rescues the kinase activity (and the transforming ability) of the Y1252-1253F Tpr-Met mutant, but is completely dependent on dimerization for its effect, In contrast, the two D1246H/N mutants strictly depend on Y1252-1253 for activity. Surprisingly, however, they constitutively activate the isolated cytoplasmic TK domain of Met (Cyto-Met), These data indicate that the two mutations operate via distinct mechanisms.	Univ Turin, Dept Biomed Sci & Oncol, I-10126 Turin, Italy; Amedeo Avogadro Univ, Dept Med Sci, Novara, Italy	University of Turin; University of Eastern Piedmont Amedeo Avogadro	Ponzetto, C (corresponding author), Univ Turin, Dept Biomed Sci & Oncol, C Massimo Azeglio 52, I-10126 Turin, Italy.		Accornero, Paolo/B-1396-2008					Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUBBARD SR, 1994, NATURE, V372, P766; Iwashita T, 1996, ONCOGENE, V12, P481; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Lam LPY, 1999, BIOCHEM J, V338, P131, DOI 10.1042/0264-6021:3380131; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LONGATI P, 1994, ONCOGENE, V9, P49; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Park WS, 1999, CANCER RES, V59, P307; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; YEE CJ, 1993, BIOCHEMISTRY-US, V32, P7922, DOI 10.1021/bi00082a013; ZHEN Z, 1994, ONCOGENE, V9, P1691; ZHU H, 1994, J BIOL CHEM, V269, P29943	47	22	22	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1354	1361		10.1038/sj.onc.1203431	http://dx.doi.org/10.1038/sj.onc.1203431			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713677				2022-12-28	WOS:000085743800012
J	Cull, V; Tilbrook, PA; Adenan, AS; Chappell, D; Ingley, E; Sarna, MK; Palmer, TN; Watowich, SS; Klinken, SP				Cull, V; Tilbrook, PA; Adenan, AS; Chappell, D; Ingley, E; Sarna, MK; Palmer, TN; Watowich, SS; Klinken, SP			Dominant action of mutated erythropoietin receptors on differentiation in vitro and erythroleukemia development in vivo	ONCOGENE			English	Article						erythroleukemia; erythropoietin; erythropoietin receptors	J2E ERYTHROID-CELLS; PRIMARY FAMILIAL POLYCYTHEMIA; TYROSINE PHOSPHORYLATION; STAT5 ACTIVATION; EPO RECEPTOR; TERMINAL DIFFERENTIATION; ENDOPLASMIC-RETICULUM; HEMATOPOIETIC-CELLS; KINASE PATHWAY; POINT MUTATION	J2E cells produce rapid, fatal erythroleukemias in vivo but still respond to erythropoietin (epo) in vitro by differentiating, proliferating and remaining viable in the absence of serum. Mutant epo receptors were introduced into these cells to determine whether they could influence the different biological responses to epo in vitro and the development of erythroleukemias. Three mutant receptors were used as cytoplasmic truncation mutants Delta 257 and Delta 321 (above box 1 and below box 2 respectively), and the cytoplasmic point mutant W282R (defective for JAK2 activation). Strikingly, the Delta 321 mutation produced a hyper-sensitive response in vitro to epo-induced differentiation and viability, but not to proliferation. In contrast with the Delta 321 receptor, the Delta 257 and W282R mutants inhibited all biological responses to epo due to impaired JAK2 phosphorylation. Significantly, erythroleukemias took almost twice as long to develop with cells containing the W282R mutation, indicating that JAK2 plays an important role in the emergence of these leukemias. These data demonstrate that mutant epo receptors dominantly altered responses of J2E cells to epo in culture and the development of erythroleukemias.	Univ Western Australia, Lab Canc Med, Dept Biochem, Perth, WA 6000, Australia; Royal Perth Hosp, Perth, WA 6000, Australia; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Texas System; UTMD Anderson Cancer Center	Klinken, SP (corresponding author), Univ Western Australia, Lab Canc Med, Dept Biochem, Level 6,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.		Fear, Vanessa/A-6876-2013; Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/GYR-3271-2022; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013; Fear, Vanessa S/AAF-9805-2020	Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134; Fear, Vanessa S/0000-0001-8363-6685; Watowich, Stephanie/0000-0003-1969-659X				Arcasoy MO, 1999, EXP HEMATOL, V27, P63, DOI 10.1016/S0301-472X(98)00003-4; Arcasoy MO, 1997, BLOOD, V89, P4628, DOI 10.1182/blood.V89.12.4628; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BITTORF T, 1994, CELL SIGNAL, V6, P305, DOI 10.1016/0898-6568(94)90035-3; BUSFIELD SJ, 1992, BLOOD, V80, P412; BUSFIELD SJ, 1993, GROWTH FACTORS, V9, P317, DOI 10.3109/08977199308991592; BUSFIELD SJ, 1993, GROWTH FACTORS, V9, P307, DOI 10.3109/08977199308991591; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; Chappell D, 1997, CELL DEATH DIFFER, V4, P105, DOI 10.1038/sj.cdd.4400219; CHRETIEN S, 1994, BLOOD, V83, P1813; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; FARR TJ, 1995, LEUKEMIA, V9, P900; Furukawa T, 1997, BRIT J HAEMATOL, V99, P222, DOI 10.1046/j.1365-2141.1997.3583172.x; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HAWLEY RG, 1994, GENE THER, V1, P136; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JOHANNSEN H, 1989, ERYTHROPOIETIN, P80; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1990, LEUKEMIA, V4, P24; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; Kralovics R, 1997, BLOOD, V90, P2057, DOI 10.1182/blood.V90.5.2057; KRANTZ SB, 1991, BLOOD, V77, P419; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAI CM, 1995, J INTERF CYTOK RES, V15, P669, DOI 10.1089/jir.1995.15.669; LeCouedic JP, 1996, BLOOD, V87, P1502, DOI 10.1182/blood.V87.4.1502.bloodjournal8741502; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MITIAVILA MT, 1991, J CLIN INVEST, V88, P789, DOI 10.1172/JCI115378; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA Y, 1994, J BIOL CHEM, V269, P29962; NAKAMURA Y, 1994, SCIENCE, V264, P588, DOI 10.1126/science.8160019; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; Sharlow ER, 1997, BLOOD, V90, P2175, DOI 10.1182/blood.V90.6.2175.2175_2175_2187; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1996, CELL GROWTH DIFFER, V7, P511; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TORTI M, 1992, J BIOL CHEM, V267, P8293; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Watowich SS, 1999, J BIOL CHEM, V274, P5415, DOI 10.1074/jbc.274.9.5415; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WINKELMANN JC, 1995, BLOOD, V85, P179, DOI 10.1182/blood.V85.1.179.bloodjournal851179; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZHUANG HM, 1995, J BIOL CHEM, V270, P14500, DOI 10.1074/jbc.270.24.14500	74	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					953	960		10.1038/sj.onc.1203370	http://dx.doi.org/10.1038/sj.onc.1203370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702804				2022-12-28	WOS:000085567700013
J	Yustein, JT; Li, DS; Robinson, D; Kung, HJ				Yustein, JT; Li, DS; Robinson, D; Kung, HJ			KFC, a Ste20-like kinase with mitogenic potential and capability to activate the SAPK/JNK pathway	ONCOGENE			English	Article						Ste20; KFC; mitogenesis; SAPK/JNK; chicken embryo fibroblast	GERMINAL CENTER KINASE; N-TERMINAL KINASE; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; MYOSIN-I; STRESS; APOPTOSIS; CASCADES	The Sterile-20 (Ste20) family of serine-threonine kinases has been implicated in the activation of the stress-activated protein kinase pathways. Howe,er, the physiological role has remained ambiguous for most of the investigated mammalian Ste20's, Here we report the cloning of a novel Ste20-like kinase, from chicken embryo fibroblast (CEF) cells, which me have named KFC, for Kinase From Chicken. The 898 amino acid full-length KFC protein contains an amino-terminal kinase domain, an adjacent downstream serine-rich region, and a C-terminal tail containing a coiled-coil domain. Here we show that the coiled-coil domain of KFC negatively regulates the intrinsic kinase activity. We have also identified a splice variant of KFC in which there is a 207 nucleotide in-frame deletion. This deletion of 69 amino acids encompasses the serine-rich region. These two isoforms, called KFCL, for full-length, and KFCS for spliced (or short) form, not only differ in structure, but also in biological properties. Stable CEF cells overexpressing KFCL, but not KFCS, have a significant increase in growth rate when compared to parental cells. This mitogenic effect is the first such reported for this family of kinases. Finally, we found that KFC, when activated by truncation of the regulatory C-terminus, has a specific activation of the stress-activated protein kinase (SAPK/JNK) pathway.	Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	University of California System; University of California Davis; Case Western Reserve University	Kung, HJ (corresponding author), Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA.		Kung, Hsing-Jien/C-7651-2013		NATIONAL CANCER INSTITUTE [R37CA046613, R01CA046613, U01CA057179, R37CA039207, R01CA057179, R01CA039207] Funding Source: NIH RePORTER; NCI NIH HHS [CA46613, CA57179, CA39207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Ling P, 1999, MOL CELL BIOL, V19, P1359; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; POPOVA O, 1997, J BIOL CHEM, V272, P14041; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Robinson D, 1998, J BIOMED SCI, V5, P93, DOI 10.1159/000025318; Schrick K, 1997, GENETICS, V147, P19; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	33	15	17	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					710	718		10.1038/sj.onc.1203342	http://dx.doi.org/10.1038/sj.onc.1203342			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698516				2022-12-28	WOS:000085192000013
J	Reichert, TE; Nagashima, S; Kashii, Y; Stanson, J; Gao, G; Dou, QP; Whiteside, TL				Reichert, TE; Nagashima, S; Kashii, Y; Stanson, J; Gao, G; Dou, QP; Whiteside, TL			Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression	ONCOGENE			English	Article						human carcinoma; IL-2 expression; cell cycle; antisense oligonucleotide; p27	NATURAL-KILLER-CELLS; IL-2 RECEPTOR; BETA-CHAIN; FUNCTIONAL INTERLEUKIN-2; CANCER-PATIENTS; DOWN-REGULATION; GAMMA-CHAIN; TUMOR-CELLS; IN-SITU; PROLIFERATION	Human carcinomas were shown to express mRNA and protein for IL-2R alpha, beta and gamma chains. Recently, human carcinomas were also shown to constitutively express protein and mRNA for IL-2 in vivo and in vitro. Here ape report that the expression levels of cytoplasmic IL-2 as well as IL-2R beta- and gamma-chain in human carcinoma cells change during the cell cycle progression, Carcinoma cells synchronized in the G2/M phase of the cell cycle expressed significantly more intracytoplasmic IL-2 as web as IL-2R beta and gamma proteins than tumor cells in the G0/G1 phase, The level of mRNA for IL-2 was 5-10-fold higher in the M phase than in the G0/G1-phase, as shown by quantitative competitive RT-PCR, Expression of the cyclin-dependent kinase (CDK) inhibitor p27(kip1) in these carcinoma cells was found to be high in the G0/G1 phase, nearly absent in the S phase, and it increased again in the G2/M phase of the cell cycle, In synchronized cells, the decrease in p27 expression coincided with high levels of expression of IL-2. Using the IL-2 specific antisense oligonucleotide to block synthesis of endogenous IL-2 in tumor cells, we observed increased levels of p27 as well as p21. The antisense oligonucleotides specific for p27 or p21 blocked expression of these proteins but not of IL-2. Thus, endogenous IL-2 is important in regulating expression of p27 as well as p21 and, therefore, in controlling cell cycle progression of tumor cells, while its own expression remains independent of the CDK inhibitors.	Univ Pittsburgh, Pittsburgh Canc Inst, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Otolaryngol, Sch Med, Pittsburgh, PA 15213 USA; H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Biol, Tampa, FL 33612 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Whiteside, TL (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Sch Med, Biomed Sci Tower,W 1041,211 Lothrop St, Pittsburgh, PA 15213 USA.			Dou, Qingping/0000-0002-6465-1473	NCI NIH HHS [R0-1 CA 63513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS B, 1994, MOL BIOL CELL, P911; ALILECHE A, 1994, INT IMMUNOL, V6, P1585; ALILECHE A, 1993, ONCOGENE, V8, P1791; ARZT E, 1992, J CLIN INVEST, V90, P1944, DOI 10.1172/JCI116072; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; CHEN K, 1987, LAB INVEST, V56, P114; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIACCI C, 1993, J CLIN INVEST, V92, P527, DOI 10.1172/JCI116598; DUPREZ V, 1988, J BIOL CHEM, V263, P12860; HATAKEYAMA M, 1990, PEPTIDE GROWTH FACTO, V1, P523; HEMAR A, 1994, EUR J IMMUNOL, V24, P1951, DOI 10.1002/eji.1830240902; HEO DS, 1989, CANCER RES, V49, P5167; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Lai P, 1996, CLIN CANCER RES, V2, P161; LIN WC, 1995, J IMMUNOL, V155, P4805; Liu JB, 1997, J IMMUNOL, V159, P812; MCMILLAN DN, 1995, INT J CANCER, V60, P766, DOI 10.1002/ijc.2910600606; Miyazaki M, 1998, BIOCHEM BIOPH RES CO, V246, P873, DOI 10.1006/bbrc.1998.8712; NAKANISHI K, 1992, P NATL ACAD SCI USA, V89, P3551, DOI 10.1073/pnas.89.8.3551; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OCONNOR PM, 1995, CELL CYCLE MAT METHO, P63; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PLAISANCE S, 1992, INT IMMUNOL, V4, P739, DOI 10.1093/intimm/4.7.739; PLAISANCE S, 1993, INT IMMUNOL, V5, P843; RABINOWICH H, 1992, J IMMUNOL, V149, P340; RALPH P, 1984, J IMMUNOL, V133, P2442; Reichert TE, 1998, J HISTOCHEM CYTOCHEM, V46, P603, DOI 10.1177/002215549804600506; Reichert TE, 1999, BRIT J CANCER, V81, P822, DOI 10.1038/sj.bjc.6690770; RIMOLDI D, 1993, ANTICANCER RES, V13, P555; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; SANETO RP, 1986, P NATL ACAD SCI USA, V83, P9221, DOI 10.1073/pnas.83.23.9221; SEIGEL LJ, 1984, SCIENCE, V223, P175, DOI 10.1126/science.6318318; SHIMIZU Y, 1991, CANCER RES, V51, P6153; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; SUMINAMI Y, 1995, J IMMUNOTHER, V17, P238, DOI 10.1097/00002371-199505000-00006; Suminami Y, 1998, ONCOGENE, V16, P1309, DOI 10.1038/sj.onc.1201640; TAKESHITA T, 1989, J EXP MED, V169, P1323, DOI 10.1084/jem.169.4.1323; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WEIDMANN E, 1992, CANCER RES, V52, P5963; WHITESIDE TL, 1995, CURR OPIN IMMUNOL, V7, P704, DOI 10.1016/0952-7915(95)80080-8; YASUMURA S, 1994, INT J CANCER, V59, P225, DOI 10.1002/ijc.2910590215	44	28	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					514	525		10.1038/sj.onc.1203391	http://dx.doi.org/10.1038/sj.onc.1203391			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698521				2022-12-28	WOS:000085104200005
J	Brenner, C; Cadiou, H; Vieira, HLA; Zamzami, N; Marzo, I; Xie, ZH; Leber, B; Andrews, D; Duclohier, H; Reed, JC; Kroemer, G				Brenner, C; Cadiou, H; Vieira, HLA; Zamzami, N; Marzo, I; Xie, ZH; Leber, B; Andrews, D; Duclohier, H; Reed, JC; Kroemer, G			Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator	ONCOGENE			English	Article						anti-oncogene; mitochondrial transmembrane potential; oncogene; permeability transition; planar lipid bilayer	PERMEABILITY TRANSITION PORE; CYTOCHROME-C; ION-CHANNEL; IN-VIVO; APOPTOSIS; MEMBRANES; RELEASE; CYCLOPHILIN; PROTEINS; FORMS	Bcl-2 family protein including anti-apoptotic (Bcl-2) or pro-apoptotic (Bax) members can form ion channels when incorporated into synthetic lipid bilayers. This contrasts with the observation that Bcl-2 stabilizes the mitochondrial membrane barrier function and inhibits the permeability transition pore complex (PTPC). Here we provide experimental data which may explain this apparent paradox. Bax and adenine nucleotide translocator (ANT), the most abundant inner mitochondrial membrane protein, can interact in artificial lipid bilayers to yield an efficient composite channel whose electrophysiological properties differ quantitatively and qualitatively from the channels formed by Bax or ANT alone. The formation of this composite channel can be observed in conditions in which Bax protein alone has no detectable channel activity. Cooperative channel formation by Bax and ANT is stimulated by the ANT ligand atractyloside (Atr) but inhibited by ATP, indicating that it depends on the conformation of ANT. In contrast to the combination of Bax and ANT, ANT does not form active channels when incorporated into membranes with Bcl-2. Rather, ANT and Bcl-2 exhibit mutual inhibition of channel formation. Bcl-2 prevents channel formation by Atr-treated ANT and neutralizes the cooperation between Bax and ANT. Our data are compatible with a menage a trois model of mitochondrial apoptosis regulation in which ANT, the likely pore forming protein within the PTPC, interacts with Bax or Bcl-2 which influence its pore forming potential in opposing manners.	Ctr Natl Rech Sci, UPR420, F-94801 Villejuif, France; Univ Technol Compiegne, Ctr Natl Rech Sci, UPRESA6022, F-60205 Compiegne, France; Univ Rouen, Ctr Natl Rech Sci, UMR6522, IFRMP 23, F-76821 Mont St Aignan, France; Burnham Inst, La Jolla, CA 92037 USA; McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS); Universite de Rouen Normandie; Sanford Burnham Prebys Medical Discovery Institute; McMaster University; McMaster University	Kroemer, G (corresponding author), 19 Rue Guy Moquet,BP 8, F-94801 Villejuif, France.		Vieira, Helena/AAZ-9562-2021; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Marzo, Isabel/E-6918-2016; brenner, catherine/AAE-8632-2020	KROEMER, Guido/0000-0002-9334-4405; Marzo, Isabel/0000-0002-2315-9079; Vieira, Helena/0000-0001-9415-3742; Leber, Brian/0000-0001-5502-1480	NIA NIH HHS [AG 15393] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015393] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BRULLEMANS M, 1994, EUR BIOPHYS J BIOPHY, V23, P39, DOI 10.1007/BF00192204; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANKE W, 1984, BIOELECTROCH BIOENER, V12, P329, DOI 10.1016/0302-4598(84)87013-0; HILLE B, 1984, IONIC CHANNELS EXCIT, P226; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUSIN SA, 1999, IN PRESS METH ENZYMO; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Xie FK, 1998, J PERIPHER NERV SYST, V3, P37; YING XM, 1994, NATURE, V369, P321; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	40	288	317	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					329	336		10.1038/sj.onc.1203298	http://dx.doi.org/10.1038/sj.onc.1203298			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656679				2022-12-28	WOS:000084873700002
J	Chu, W; Pak, BJ; Bani, MR; Kapoor, M; Lu, SJ; Tamir, A; Kerbel, RS; Ben-David, Y				Chu, W; Pak, BJ; Bani, MR; Kapoor, M; Lu, SJ; Tamir, A; Kerbel, RS; Ben-David, Y			Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications	ONCOGENE			English	Article						malignant melanoma; drug resistance; tyrosinase-related protein-2; chemotherapy; cis-diamminedichloroplatinuim(II)	HUMAN OVARIAN-CANCER; DOPACHROME TAUTOMERASE; DNA-REPAIR; CELL-LINES; IN-VITRO; CISPLATIN; GENE; OVEREXPRESSION; CHEMOTHERAPY; GLUTATHIONE	A major obstacle in the systemic treatment of advanced malignant melanoma is its intrinsic resistance to conventionally used chemotherapeutic agents. In order to investigate the mechanisms of this intrinsic resistance, we have previously utilized retroviral insertional mutagenesis on an early-stage, drug sensitive human melanoma cell line (WM35) to establish mutated cell lines that exhibited increased resistance to cis-diamminedichloroplatinum(II) (CDDP), Here, we demonstrate that this increased resistance to CDDP is mediated by the over-expression of tyrosinase-related protein-2 (TYRP2), an enzyme that normally functions in the biosynthesis of the pigment, melanin. Northern and Western blot analyses revealed that the expression of TYRP2 in the virally-derived cell lines as well as in a panel of human melanoma cell lines positively correlated with their levels of resistance to CDDP, Furthermore, enforced expression of TYRP2 in WM35 cells by transfection elevated their resistance to CDDP, The increased CDDP resistance in the virally-derived clones and TYRP2 transfectants was accompanied by a reduction in CDDP-induced apoptosis, Interestingly, the virally-derived CDDP-resistant clones also showed cross resistance to carboplatin and methotrexate, but not taxol, suggesting that TYRP2 over-expression may confer resistance specifically to DNA damaging agents, Overall, these results demonstrate a novel mechanism of drug resistance in human melanoma cells that is mediated by the over-expression of TYRP2, Since TYRP2 is expressed only in cells of melanocytic lineage, this may represent the first report of a lineage-specific mechanism of drug resistance, In summary, these findings suggest a significant role for TYRP2 in the intrinsic drug resistance phenotype of human melanoma cells and may have important implications in the development of chemosensitization strategies for the clinical management of this disease.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Res Bldg,Room S2-18,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Bani, Maria Rosa/AAB-3397-2020	Bani, Maria Rosa/0000-0001-8178-1432	NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PA, 1985, CANCER RES, V45, P6250; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BALCH CM, 1989, CANCER PRINCIPLES PR, V2, P1499; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BATIST G, 1986, J BIOL CHEM, V261, P5544; BERND A, 1994, MELANOMA RES, V4, P287, DOI 10.1097/00008390-199410000-00003; BORCHERS AH, 1990, CANCER RES, V50, P1786; Chan HSL, 1997, CANCER RES, V57, P2325; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1994, J BIOL CHEM, V269, P787; Citro G, 1998, CANCER RES, V58, P283; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dolan ME, 1999, CLIN CANCER RES, V5, P2059; Fillpits M, 1997, BRIT J CANCER, V75, P208; HO RCS, 1995, CANCER, V75, P735, DOI 10.1002/1097-0142(19950115)75:2+<735::AID-CNCR2820751418>3.0.CO;2-Q; ISHIKAWA T, 1994, J BIOL CHEM, V269, P29085; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; Kawakami Y, 1998, J IMMUNOTHER, V21, P237, DOI 10.1097/00002371-199807000-00001; Koo HM, 1999, JNCI-J NATL CANCER I, V91, P236, DOI 10.1093/jnci/91.3.236; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; KURODA H, 1991, INT J CANCER, V47, P732, DOI 10.1002/ijc.2910470518; LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006-2952(88)90325-5; LAI GM, 1989, JNCI-J NATL CANCER I, V81, P535, DOI 10.1093/jnci/81.7.535; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Legrand O, 1998, LEUKEMIA, V12, P1327, DOI 10.1038/sj.leu.2401096; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LORICO A, 1988, CANCER RES, V48, P2036; LU SJ, 1995, CANCER RES, V55, P1139; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MORIWAKI S-I, 1992, Journal of Dermatological Science, V4, P6, DOI 10.1016/0923-1811(92)90049-H; ORLOW SJ, 1995, P NATL ACAD SCI USA, V92, P10152, DOI 10.1073/pnas.92.22.10152; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Parkhurst MR, 1998, CANCER RES, V58, P4895; PAWELEK JM, 1990, BIOCHEM BIOPH RES CO, V166, P1328, DOI 10.1016/0006-291X(90)91011-G; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Young RC, 1989, DRUG RESISTANCE CANC; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	41	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					395	402		10.1038/sj.onc.1203315	http://dx.doi.org/10.1038/sj.onc.1203315			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656687				2022-12-28	WOS:000084873700010
J	Matise, MP; Joyner, AL				Matise, MP; Joyner, AL			Gli genes in development and cancer	ONCOGENE			English	Article						Ci; Gli1; Gli2; Gli3; hedgehog; nervous system	HEDGEHOG SIGNALING PATHWAY; PROTEIN-KINASE-A; GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; CUBITUS-INTERRUPTUS PROTEIN; KINESIN-RELATED PROTEIN; BASAL-CELL CARCINOMA; SONIC-HEDGEHOG; FLOOR PLATE; LIMB DEVELOPMENT; TRANSDUCING HEDGEHOG	With the realization that many proto-oncogenes and tumor suppressor genes are expressed and have important functions during mammalian development, it is clear that cancer often involves the inappropriate activation of genetic pathways used during normal development. A signaling cascade that has been of considerable interest to both developmental and cancer biologists involves the Hedgehog (Hh) family of secreted proteins. To date, the only transcription factors shown to be directly downstream of Hh are the zinc-finger containing proteins Cubitus interruptus (Ci) and Gli, in flies and vertebrates, respectively, The identification of many of the genes and proteins involved in Hh signaling has come largely from genetic and biochemical studies in Drosophila. Ci mediates Hh signaling through a Hh-dependent set of protein modifications that alter the activity of Ci on Hh target genes, Recent evidence suggests vertebrate Gli proteins may be similarly regulated. The interest in this pathway has taken on added importance with the identification of mutations in Hh pathway genes, including Gli genes, in several human developmental disorders and cancers. We discuss models for how Gli proteins mediate Hh signaling in both vertebrate development and cancers.	NYU, Sch Med, Dev Genet Program, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol Neurosci, New York, NY 10016 USA	New York University; Howard Hughes Medical Institute; New York University; New York University; New York University	Matise, MP (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, 675 Hoes Lane,Room R325, Piscataway, NJ 08854 USA.							Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; ALBERLE H, 1997, EMBO J, V16, P3797; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Biesecker LG, 1997, NAT GENET, V17, P259, DOI 10.1038/ng1197-259; Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1999, DEVELOPMENT, V126, P3607; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Ding Q, 1998, DEVELOPMENT, V125, P2533; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grindley JC, 1997, DEV BIOL, V188, P337, DOI 10.1006/dbio.1997.8644; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; IALTABA AR, 1998, DEVELOPMENT, V125, P2203; IALTABA AR, 1997, CELL, V90, P193; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1997, COLD SPRING HARB SYM, V62, P205; Kalderon D, 1997, CURR BIOL, V7, pR759, DOI 10.1016/S0960-9822(06)00398-8; Kalff-Suske M, 1999, HUM MOL GENET, V8, P1769, DOI 10.1093/hmg/8.9.1769; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Lee J, 1997, DEVELOPMENT, V124, P2537; Lessing D, 1998, DEVELOPMENT, V125, P1469; Lewis KE, 1999, DEVELOPMENT, V126, P2397; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Matise MP, 1998, DEVELOPMENT, V125, P2759; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Mo R, 1997, DEVELOPMENT, V124, P113; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Motoyama J, 1998, MECH DEVELOP, V78, P81, DOI 10.1016/S0925-4773(98)00149-X; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; Price MA, 1999, DEVELOPMENT, V126, P4331; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; ROBERTS WM, 1989, CANCER RES, V49, P5407; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; Shin SH, 1999, P NATL ACAD SCI USA, V96, P2880, DOI 10.1073/pnas.96.6.2880; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; VORTKAMP A, 1992, MAMM GENOME, V3, P461, DOI 10.1007/BF00356157; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	78	137	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7852	7859		10.1038/sj.onc.1203243	http://dx.doi.org/10.1038/sj.onc.1203243			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630638				2022-12-28	WOS:000084405900002
J	Zhu, KC; Wang, J; Zhu, JH; Jiang, JY; Shou, J; Chen, XB				Zhu, KC; Wang, J; Zhu, JH; Jiang, JY; Shou, J; Chen, XB			p53 induces TAP1 and enhances the transport of MHC class I peptides	ONCOGENE			English	Article						p53; TAP1; MHC class I; interferon gamma; tumor surveillance	MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN CANCERS; ANTIGEN PRESENTATION; GENE-EXPRESSION; DOWN-REGULATION; BREAST-CANCER; CELLS; APOPTOSIS; PROTEIN; IDENTIFICATION	The transporter associated with antigen processing (TAP) I is required for the major histocompatibility complex (MHC) class I antigen presentation pathway, which plays a key role in host tumor surveillance. Since more than 50% of tumors have a dysfunctional p53, evasion of tumor surveillance by tumor cells may be linked to loss of p53 function. Here we found that TAP1 is strongly induced by p53 and DNA-damaging agents through a p53-responsive element. We also found that p73, which is homologous to p53, is capable of inducing TAP1 and cooperates with p53 to activate TAP1. Furthermore, me found that by inducing TAP1, p53 enhances the transport of MHC class I peptides and expression of surface MHC-peptide complexes, and cooperates with interferon gamma to activate the MHC class I pathway. These results suggest that tumor surveillance may be a mechanism by which p53 and/or p73 function as tumor suppressors.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.			Zhu, Kuichun/0000-0002-3594-5616	NCI NIH HHS [CA81237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; Alpan RS, 1996, CANCER RES, V56, P4358; Amiot L, 1998, BRIT J HAEMATOL, V100, P655, DOI 10.1046/j.1365-2141.1998.00631.x; BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN XB, 1995, CANCER RES, V55, P4257; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gobin SJP, 1997, IMMUNITY, V6, P601, DOI 10.1016/S1074-7613(00)80348-9; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Johnsen A, 1998, CANCER RES, V58, P3660; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAKLAMANIS L, 1995, CANCER RES, V55, P5191; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Khanna R, 1998, CANCER RES, V58, P310; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ma WL, 1997, J BIOL CHEM, V272, P16585, DOI 10.1074/jbc.272.26.16585; Martin BK, 1997, IMMUNITY, V6, P591, DOI 10.1016/S1074-7613(00)80347-7; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MUNGER K, 1989, J VIROL, V63, P4417; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; RESTIFO NP, 1993, J IMMUNOTHER, V14, P182, DOI 10.1097/00002371-199310000-00004; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Vitale M, 1998, CANCER RES, V58, P737; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang ZG, 1998, CANCER RES, V58, P2149; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061	47	72	72	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7740	7747		10.1038/sj.onc.1203235	http://dx.doi.org/10.1038/sj.onc.1203235			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618714				2022-12-28	WOS:000084256900003
J	Ashcroft, M; Vousden, KH				Ashcroft, M; Vousden, KH			Regulation of p53 stability	ONCOGENE			English	Review						p53; Mdm2; protein stability	TUMOR-SUPPRESSOR P53; DNA-DAMAGE; ONCOPROTEIN MDM2; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; IONIZING-RADIATION; PROTEIN STABILITY; ACTIVATES P53; FEEDBACK LOOP; HUMAN CANCER	Leading the way in imposing a policy of zero tolerance of cellular abnormalities that might lead to tumor development is the p53 protein. The efficiency of p53 in preventing cell growth is a strong deterrent to malignant progression, but this activity must be kept tightly restrained to allow normal cell growth and development. Essential components of this regulation are the mechanisms by which the p53 protein is degraded, and efficient turnover of p53 in normal cells prevents the accumulation of the protein. Modulation of these degradation pathways in response to stress leads to the rapid stabilization and accumulation of p53, and activation of the p53 response. It is now becoming clear that the Mdm2 protein is central to the regulation of p53 stability and multiple pathways exist through which the activity of Mdm2 can be inhibited. Defects in the ability to stabilize p53 are likely to contribute to malignant development, and restoration of this activity represents an extremely attractive possibility for tumor therapy.	NCI FCRDC, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Vousden, KH (corresponding author), NCI FCRDC, ABL Basic Res Program, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.							Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; BALINT E, 1999, IN PRESS ONCOGENE; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hach A, 1999, MOL CELL BIOL, V19, P4324; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; TYLER M, 1999, SCIENCE, V284, P601; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	92	352	366	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	1999	18	53					7637	7643		10.1038/sj.onc.1203012	http://dx.doi.org/10.1038/sj.onc.1203012			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618703				2022-12-28	WOS:000084634500002
J	Loging, WT; Reisman, D				Loging, WT; Reisman, D			Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53	ONCOGENE			English	Article						mutant p53; gene expression; TIMP-3; tumor suppressor	MOUSE-TISSUE INHIBITOR; TATA-BINDING PROTEIN; CELL-CYCLE ARREST; TRANSCRIPTIONAL REPRESSION; MATRIX METALLOPROTEINASES; GROWTH-FACTOR; FUNCTION MUTATIONS; MOLECULAR-CLONING; CARCINOMA-CELLS; DNA-ELEMENTS	The p53 gene is a tumor suppressor that regulates the expression of genes required for cell cycle arrest or apoptosis. Mutations in p53 have been observed in over 60% of all human cancers. Certain classes of mutant p53 proteins maintain some of their activities or acquire novel activities and thus may contribute to the transformed phenotype. By carrying out an analysis of differential gene expression using cDNA expression arrays, we compared the expression patterns of cells expressing no p53 to isogenic lines expressing the codon 248 Arg to Trp mutant p53 allele (R248W). In this report, we show that the R248W and D281G p53 mutants, two of the more commonly occurring mutations, as well as wild type p53, repress transcription of the tissue inhibitor of metalloproteinases type 3 (TIMP3) gene by greater than tenfold. TIMP3 expression has been observed to be repressed in many tumors and its reduced expression is thought to contribute to tumor metastasis and invasiveness by allowing increased activity of metalloproteinases in the extracellular matrix. Since mutant forms of p53 tend to be expressed at greatly elevated levels in many human tumors, the retention of their ability to repress TIMP3 illustrate one mechanism by which mutant forms of the p53 gene may contribute to tumorigenesis.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Reisman, D (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ahonen M, 1998, CANCER RES, V58, P2310; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Balint E, 1996, CANCER RES, V56, P1648; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P2433; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Bian JH, 1996, CARCINOGENESIS, V17, P2559, DOI 10.1093/carcin/17.12.2559; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chan EC, 1998, BBA-MOL BASIS DIS, V1407, P200, DOI 10.1016/S0925-4439(98)00041-6; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Foley J, 1996, CANCER RES, V56, P4056; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIAO M, 1994, AM J PATHOL, V145, P702; HSIAO M, 1995, MOL CARCINOGEN, V13, P112, DOI 10.1002/mc.2940130208; Hussain SP, 1998, CANCER RES, V58, P4023; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim HT, 1997, BIOCHEM J, V324, P547, DOI 10.1042/bj3240547; Kinzler KW, 1998, COLORECTAL TUMORS GE, P565; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LILL J, 1995, ONCOGENE, V10, P2387; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIYASHITA T, 1995, CELL, V80, P293; Muller BF, 1996, ONCOGENE, V12, P1941; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHOHAT O, 1987, ONCOGENE, V1, P277; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1994, CANCER RES, V54, P1139; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Ueno H, 1997, CANCER RES, V57, P2055; VAN MEIR EG, 1994, CANCER RES, V54, P649; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XIAO H, 1994, MOL CELL BIOL, V14, P7103; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	90	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7608	7615		10.1038/sj.onc.1203135	http://dx.doi.org/10.1038/sj.onc.1203135			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602522				2022-12-28	WOS:000084119600024
J	Yin, ZN; Spitz, MR; Babaian, RJ; Strom, SS; Troncoso, P; Kagan, J				Yin, ZN; Spitz, MR; Babaian, RJ; Strom, SS; Troncoso, P; Kagan, J			Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3	ONCOGENE			English	Article						chromosome 13; prostate cancer; loss of heterozygosity; tumor suppressor gene	ALLELIC LOSS; RETINOBLASTOMA GENE; FREQUENT LOSS; P53 PROTEIN; LOCI; CARCINOMA; HETEROZYGOSITY; DELETION; BRCA2; 13Q	We studied loss of heterozygosity (LOH) on human chromosome 13q in prostate cancer specimens to determine the location of a putative tumor suppressor gene (TSG) and to correlate these losses with the clinicopathological stage of the disease. Overall 13 (21%) of 61 specimens analysed had an allele loss on the long arm of chromosome 13, The most frequent (37%) LOH among the informative cases with allele losses was detected at the D13S284 locus on chromosome 13q14.3. A portion of the DNA segment that spans this locus and is flanked by the microsatellite loci D13S153 and D13S163 was lost in 85% of the specimens with allele losses and was designated as a LOH cluster region (LCR). The LCR spans more than 6 Mbp of DNA, The results suggest that a TSG relevant for the development of prostate cancer is located telomeric to the RE locus. There was a significant correlation (P=0.0024) between chromosome 13q LOH and advanced metastatic disease, suggesting that loss of 13q14.3 region is associated with prostate cancer progression, However, further research must be conducted to establish the identity and function of this putative TSG.	Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Sect Expt Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kagan, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Sect Expt Lab Med, Box 054,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA68758-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, AJCC CANC STAGING MA; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOVA GS, 1993, CANCER RES, V53, P3869; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; Brooks JD, 1996, CANCER RES, V56, P3814; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; Cairns P, 1997, CANCER RES, V57, P4997; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Cooney KA, 1996, CANCER RES, V56, P1142; Cunningham JM, 1996, CANCER RES, V56, P4475; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; KAGAN J, 1995, ONCOGENE, V11, P2121; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P291, DOI 10.1002/gcc.2870130410; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LATIL A, 1995, B CANCER, V82, P589; Li CD, 1998, ONCOGENE, V16, P481, DOI 10.1038/sj.onc.1201554; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu Y, 1997, ONCOGENE, V15, P2463, DOI 10.1038/sj.onc.1201643; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1995, CANCER RES, V55, P5390; MASTERO R, 1996, CANCER RES, V56, P1146; Melamed J, 1997, CLIN CANCER RES, V3, P1867; Mottaz AE, 1997, PROSTATE, V31, P209; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Pearce SHS, 1996, CLIN ENDOCRINOL, V45, P195, DOI 10.1046/j.1365-2265.1996.d01-1561.x; PEI L, 1995, CANCER RES, V55, P1613; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; Salem CE, 1997, J UROLOGY, V158, P510, DOI 10.1016/S0022-5347(01)64520-8; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Sigurdsson S, 1997, J MOL MED-JMM, V75, P758, DOI 10.1007/s001090050162; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; Suzuki H, 1998, CANCER RES, V58, P204; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1997, CANCER RES, V57, P5221; TRAPMAN J, 1994, CANCER RES, V54, P6061; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; VISAKORPI T, 1995, CANCER RES, V55, P342; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Weinstein IB, 1996, J CELL BIOCHEM, P23; YOO GH, 1994, CANCER RES, V54, P4603; ZAR JH, 1991, BIOSTATISTICAL ANAL; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	49	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7576	7583		10.1038/sj.onc.1203203	http://dx.doi.org/10.1038/sj.onc.1203203			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602517				2022-12-28	WOS:000084119600019
J	Foray, N; Randrianarison, V; Marot, D; Perricaudet, M; Lenoir, G; Feunteun, J				Foray, N; Randrianarison, V; Marot, D; Perricaudet, M; Lenoir, G; Feunteun, J			Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2	ONCOGENE			English	Article						BRCA1; BRCA2; DNA repair; radiation	DOUBLE-STRAND BREAKS; SUSCEPTIBILITY GENE BRCA2; ATAXIA-TELANGIECTASIA; CANCER-CELLS; REPAIR DEFICIENCY; CHROMOSOME-DAMAGE; CYCLE ARREST; DNA-REPAIR; P53; RADIATION	There is now evidence to suggest that BRCA1 and BRCA2 are involved in the response of cells to DNA damage and cell cycle checkpoint control. This report examines the death pathways of human cells with various BRCA1 and BRCA2 genotypes after exposure to gamma-rays, A lack of functional BRCA1 and BRCA2 led to defective repair of DNA double-strand breaks in irradiated cells. This impairment resulted in a relaxation of cell cycle checkpoints, production of micronuclei, and a loss of proliferative capacity, Heterozygous BRCA1 and BRCA2 mutations also led to enhanced radiosensitivity, with an impaired proliferative capacity after irradiation. The existence of a phenotype related to radiosensitivity in BRCA1(+/-) and BRCA2(+/-) cells raises the question of the response of heterozygous women to radiation.	Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS UMR 1582, Lab Vectorol & Transfert Genes, F-94805 Villejuif, France; Univ Lyon 1, CNRS UMR 5641, Lab Genet & Canc, F-69365 Lyon, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Feunteun, J (corresponding author), Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, Rue Camille Desmoulins, F-94805 Villejuif, France.		Foray, Nicolas/I-4755-2018; Foray, Nicolas/Q-2363-2019; Feunteun, Jean/AAZ-1267-2020	Foray, Nicolas/0000-0002-1282-1303; Foray, Nicolas/0000-0002-1282-1303; Feunteun, Jean/0000-0003-1212-9189				Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; BADIE C, 1995, CANCER RES, V55, P1232; BADIE C, 1995, RADIAT RES, V144, P26, DOI 10.2307/3579232; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Chong J P, 1996, Prog Cell Cycle Res, V2, P83; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; DAMICO AV, 1994, RADIOTHER ONCOL, V33, P3, DOI 10.1016/0167-8140(94)90079-5; Davies MA, 1998, CANCER RES, V58, P5285; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; EVANS HH, 1993, RADIAT RES, V134, P307, DOI 10.2307/3578190; Fajac A, 1996, INT J CANCER, V68, P67, DOI 10.1002/(SICI)1097-0215(19960927)68:1<67::AID-IJC13>3.0.CO;2-3; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Foray N, 1996, RADIAT RES, V146, P53, DOI 10.2307/3579395; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Johnston PJ, 1997, MUTAT RES-DNA REPAIR, V385, P1, DOI 10.1016/S0921-8777(97)00034-7; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI CY, 1995, ONCOGENE, V11, P1885; LIN JY, 1995, ONCOGENE, V10, P2387; LIU N, 1993, MUTAGENESIS, V8, P503, DOI 10.1093/mutage/8.6.503; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Otto AM, 1996, J CANCER RES CLIN, V122, P603, DOI 10.1007/BF01221192; Paglin S, 1997, BIOCHEM BIOPH RES CO, V237, P678, DOI 10.1006/bbrc.1997.7117; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; SCOTT D, 1994, LANCET, V344, P1444, DOI 10.1016/S0140-6736(94)90615-7; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shiloh Yosef, 1998, Biochimica et Biophysica Acta, V1378, pR11, DOI 10.1016/S0304-419X(98)00020-1; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	40	134	135	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7334	7342		10.1038/sj.onc.1203165	http://dx.doi.org/10.1038/sj.onc.1203165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602489				2022-12-28	WOS:000084119400019
J	Umemori, H; Hayashi, T; Inoue, T; Nakanishi, S; Mikoshiba, K; Yamamoto, T				Umemori, H; Hayashi, T; Inoue, T; Nakanishi, S; Mikoshiba, K; Yamamoto, T			Involvement of protein tyrosine phosphatases in activation of the trimeric G protein G(q/11)	ONCOGENE			English	Article						tyrosine phosphorylation; tyrosine phosphatase; metabotropic glutamate receptor; G protein; G alpha(q/11); IP3	METABOTROPIC GLUTAMATE RECEPTORS; HETEROTRIMERIC G-PROTEINS; SIGNAL TRANSDUCTION; PHENYLARSINE OXIDE; RAT-1 FIBROBLASTS; ALPHA-SUBUNIT; PHOSPHORYLATION; KINASES; TRANSFORMATION; CELLS	A variety of receptors coupled to the heterotrimeric guanine nucleotide-binding protein G(q/11) stimulate intracellular Ca2+ release through inositol (1,4,5)-trisphosphate (IP3) formation. We previously reported that tyrosine phosphorylation of the alpha subunit of the G(q/11) protein by protein tyrosine kinases (PTKs) regulates the activation of G(q/11) protein. Here we show that protein tyrosine phosphatases (PTPs) are also essential for G(q/11) protein activation. We find that G(q/11) protein-coupled receptor-mediated formation of IP3 is blocked by PTP inhibitors as well as PTK inhibitors. These inhibitors act prior to G(q/11) protein activation. Tyrosine phosphorylation of the alpha subunit of G(q/11) appears to inhibit its interaction with receptors. Thus, PTP is required for controlling the level of tyrosine phosphorylation of the alpha subunit of G(q/11) to promote its interaction with receptors. Therefore, we conclude that PTKs and PTPs co-operate to proceed activation cycle of the G(q/11) protein through tyrosine phosphorylation and de-phosphorylation of the alpha subunit of G(q/11).	Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo 1088639, Japan; Kyoto Univ, Fac Med, Dept Sci Biol, Kyoto 6068501, Japan	University of Tokyo; University of Tokyo; Kyoto University	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan.		Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015	Inoue, Takafumi/0000-0002-2728-0060; Umemori, Hisashi/0000-0001-7198-2062; Hayashi, Takashi/0000-0003-3591-2109				ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLUML K, 1994, J BIOL CHEM, V269, P18870; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; Fusaki N, 1996, J IMMUNOL, V156, P1369; GREENWALT DE, 1994, BRIT J HAEMATOL, V88, P830, DOI 10.1111/j.1365-2141.1994.tb05124.x; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Helgadottir A, 1997, ARTERIOSCL THROM VAS, V17, P287, DOI 10.1161/01.ATV.17.2.287; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; MATTINGLY RR, 1992, J BIOL CHEM, V267, P7470; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; YANAGA F, 1995, FEBS LETT, V368, P377, DOI 10.1016/0014-5793(95)00670-5; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	25	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7399	7402		10.1038/sj.onc.1203152	http://dx.doi.org/10.1038/sj.onc.1203152			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602498				2022-12-28	WOS:000084119400028
J	Chen, G; Templeton, D; Suttle, DP; Stacey, DW				Chen, G; Templeton, D; Suttle, DP; Stacey, DW			Ras stimulates DNA topoisomerase II alpha through MEK: A link between oncogenic signaling and a therapeutic target	ONCOGENE			English	Article						topoisomerase II alpha; Ras; ERK; JNK; MEKK; cell cycle	ACTIVATED PROTEIN-KINASE; C-JUN; REGULATED KINASE; NIH-3T3 CELLS; MAP KINASES; TRANSFORMATION; GROWTH; EXPRESSION; PATHWAY; GENE	Topoisomerase II alpha (topo II alpha) is a major target of antitumor treatments. In an effort to determine why this protein might be a better target in tumor cells than in normal cells, we attempted to determine if the altered proliferative signaling in a tumor cell might effect the levels of expression of the topo II alpha gene. In support of this idea, it was found that topo II alpha was elevated following microinjection of oncogenic Ras protein. Oncogenic was was further shown to stimulate the topo II alpha promoter. Stimulation by pas was independent of the normal cell cycle regulation of this promoter. Transactivation of topo II alpha by ras required both the MEK/ERK pathway, and the stress-associated protein kinase (SAPK) signaling pathway. As a direct confirmation that both ERK and SAPK were involved in topo II alpha regulation, a constitutively active MEKK that stimulates these two kinases simultaneously was shown to strongly induce topo II alpha promoter activity. Activation of either pathway alone, on the other hand, only slightly stimulated the topo II alpha promoter. Deletion analyses showed that elements near both the 5' and 3' ends of the promoter were responsible for the ras stimulation. Site-directed mutagenesis further demonstrated that an Ets-like binding site near the 5' end (-480 to -475) was one of the responsive elements. Taken together, these studies demonstrate the direct role of Ras signaling in stimulation of topo II alpha expression, and thereby establish a link between the action of a common tumor mutation and the target of multiple anti-tumor reagents.	Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA; Univ Tennessee, Dept Pharmacol, Memphis, TN 38163 USA; Vet Adm Med Ctr, Res Serv, Memphis, TN 38104 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Case Western Reserve University	Stacey, DW (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, NC2-150, Cleveland, OH 44195 USA.		Templeton, Dennis J/F-7695-2011		NATIONAL CANCER INSTITUTE [R01CA047941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER; NCI NIH HHS [CA47941] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BOS JL, 1989, CANCER RES, V49, P4682; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DOBROWOLSKI S, 1994, MOL CELL BIOL, V10, P5314; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HSIANG YH, 1988, CANCER RES, V48, P3230; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KAUFMANN SH, 1991, CANCER RES, V51, P3534; Koo HM, 1996, CANCER RES, V56, P5211; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NELSON WG, 1987, CANCER RES, V47, P3246; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1994, EMBO J, V13, P6107, DOI 10.1002/j.1460-2075.1994.tb06957.x; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WOESSNER RD, 1990, CANCER RES, V50, P2901; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067	55	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7149	7160		10.1038/sj.onc.1203149	http://dx.doi.org/10.1038/sj.onc.1203149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597316				2022-12-28	WOS:000083901900022
J	Robertson, K; Hensey, C; Gautier, J				Robertson, K; Hensey, C; Gautier, J			Isolation and characterization of Xenopus ATM (X-ATM): expression, localization, and complex formation during oogenesis and early development	ONCOGENE			English	Article						xenopus; ATM; development; cell cycle; checkpoints	ATAXIA-TELANGIECTASIA GENE; DNA-DAMAGE; IONIZING-RADIATION; PROTEIN-KINASE; DEFICIENT MICE; BREAST-CANCER; P53 PROTEIN; C-ABL; LAEVIS; ACTIVATION	ATM, the gene product mutated in Ataxia Telangiectasia (A-T) encodes a 350-KDa protein involved in the regulation of several cellular responses to DNA breaks. We used a degenerate PCR-based strategy to isolate a partial clone of X-ATM, the Xenopus homologue of human ATM. Sequence analysis and confirmed that the clone was most closely related to human ATM. Xenopus ATM protein (X-ATM) is 85% identical to human ATM within the kinase domain and 71% identical over the carboxyl-terminal half of the protein. Polyclonal antibodies raised against recombinant Ii-ATM are highly specific for the ATM protein and recognize a single polypeptide of 370-kDa in oocytes, embryos, egg extracts and a,Xenopus cell line. We found that X-ATM, mas expressed maternally in eggs and as early as stage II pre-vitellogenic oocytes, and the protein and mRNA sere present at relatively constant levels throughout development. Subcellular fractionation showed that the protein mas nuclear in both the female and male germlines. The level of X-ATM protein did not change throughout the meiotic divisions or the synchronous mitotic cycles of cleavage stage embryos. In addition, we did not observe any change in the level or mobility of X-ATM protein following ii-irradiation of embryos. Finally, we also demonstrated that X-ATM was present in a high molecular weight complex of approximately 500 kDa containing the X-ATM protein and other, as yet unidentified component(s).	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA	Columbia University; Columbia University	Gautier, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 630 W 168th St, New York, NY 10032 USA.		Gautier, jean/A-2774-2008; Hensey, Carmel/L-7456-2013	Hensey, Carmel/0000-0003-3319-4094				Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BODER E, 1970, PSYCHIAT NEUROL MED, V14, P8; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chen JD, 1998, CANCER RES, V58, P1376; Chen P, 1999, ONCOGENE, V18, P249, DOI 10.1038/sj.onc.1202257; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; COX LS, 1994, ONCOGENE, V9, P2951; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DREYER C, 1983, DEV BIOL, V100, P412, DOI 10.1016/0012-1606(83)90235-X; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FORD CC, 1977, J EMBRYOL EXP MORPH, V37, P203; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hensey C, 1995, Prog Cell Cycle Res, V1, P149; Hensey C, 1997, MECH DEVELOP, V69, P183, DOI 10.1016/S0925-4773(97)00191-3; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scott SP, 1998, BIOCHEM BIOPH RES CO, V245, P144, DOI 10.1006/bbrc.1998.8137; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shiloh Yosef, 1998, Biochimica et Biophysica Acta, V1378, pR11, DOI 10.1016/S0304-419X(98)00020-1; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; SOUSSI T, 1987, ONCOGENE, V1, P71; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; SWIFT M, 1990, CANCER GENET CYTOGEN, V46, P21, DOI 10.1016/0165-4608(90)90004-T; Taylor AMR, 1998, INT J RADIAT BIOL, V73, P365, DOI 10.1080/095530098142185; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; WANG Y, 1995, ONCOGENE, V10, P779; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yuille MAR, 1998, RECENT RES CANCER, V154, P156	57	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7070	7079		10.1038/sj.onc.1203194	http://dx.doi.org/10.1038/sj.onc.1203194			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597308				2022-12-28	WOS:000083901900014
J	Roubin, R; Naert, K; Popovici, C; Vatcher, G; Coulier, F; Thierry-Mieg, J; Pontarotti, P; Birnbaum, D; Baillie, D; Thierry-Mieg, D				Roubin, R; Naert, K; Popovici, C; Vatcher, G; Coulier, F; Thierry-Mieg, J; Pontarotti, P; Birnbaum, D; Baillie, D; Thierry-Mieg, D			let-756, a C-elegans fgf essential for worm development	ONCOGENE			English	Article						C-elegans; FGF; nematode; let-756; egl-17; worm development	FIBROBLAST GROWTH-FACTOR; CAENORHABDITIS-ELEGANS; SKELETAL DISORDERS; CHROMOSOME-III; SEX MYOBLASTS; FACTOR FAMILY; MUTATIONS; SEQUENCE; GENE; EXPRESSION	In vertebrates, Fibroblast Growth Factors (FGFs) and their receptors are involved in various developmental and pathological processes, including neoplasia. The number of FGFs and their large range of activities have made the understanding of their precise functions difficult. Investigating their biology in other species might be enlightening. A sequence encoding a putative protein presenting 30-40% identity with the conserved core of vertebrate FGFs has been identified by the C. elegans sequencing consortium. We show here that this gene is transcribed and encodes a putative protein of 425 amino acids (aa), The gene is expressed at all stages of development beyond late embryogenesis, peaking at the larval stages. Loss-of-function mutants of the let-756 gene are rescued by the wild type fgf gene in germline transformation experiments. Two partial loss-of-function alleles, s2613 and s2809, have a mutation that replaces aa 317 by a stop. The truncated protein retains the FGF core but lacks a C-terminus portion. These worms are small and develop slowly into clear and scrawny, yet viable and fertile adults. A third allele, s2887, is inactivated by an inversion that disrupts the first exon. It causes a developmental arrest early in the larval stages. Thus, in contrast to the other nematode fgf gene egl-17, let-756/fgf is essential for worm development.	INSERM, U119, Oncol Mol Lab, F-13009 Marseille, France; INSERM, U119, Lab Plast Genome & Evolut, F-13009 Marseille, France; CNRS, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France; Simon Fraser Univ, Inst Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Simon Fraser University	Roubin, R (corresponding author), INSERM, U119, Oncol Mol Lab, 27 Blvd Lei Roure, F-13009 Marseille, France.		THIERRY-MIEG, Jean/F-1975-2017; , pontarotti/ABB-1753-2021; POPOVICI, Cornel/A-2027-2009; Coulier, François/G-6098-2015	THIERRY-MIEG, Jean/0000-0002-0396-6789; POPOVICI, Cornel/0000-0001-8226-3127; Coulier, François/0000-0002-6288-7773; Birnbaum, Daniel/0000-0001-7920-9883; Thierry-Mieg, Danielle/0000-0001-9568-4211; Pierre, Pontarotti/0000-0001-7202-3648				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BRENNER S, 1974, GENETICS, V77, P71; Burdine RD, 1998, DEVELOPMENT, V125, P1083; Burdine RD, 1997, P NATL ACAD SCI USA, V94, P2433, DOI 10.1073/pnas.94.6.2433; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fiore F, 1997, INT J DEV BIOL, V41, P639; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Janke DL, 1997, GENOME RES, V7, P974, DOI 10.1101/gr.7.10.974; KIEFER P, 1983, MOL CELL BIOL, V13, P5781; MANSOUR SL, 1994, MOL REPROD DEV, V39, P62, DOI 10.1002/mrd.1080390111; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stewart HI, 1998, MOL GEN GENET, V260, P280, DOI 10.1007/PL00013816; STEWART HI, 1991, MUTAT RES, V248, P37; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wood WB, 1988, NEMATODE CAENORHABDI; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	42	37	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6741	6747		10.1038/sj.onc.1203074	http://dx.doi.org/10.1038/sj.onc.1203074			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597282				2022-12-28	WOS:000083792000016
J	Slosberg, ED; Klein, MG; Yao, Y; Han, EKH; Schieren, I; Weinstein, IB				Slosberg, ED; Klein, MG; Yao, Y; Han, EKH; Schieren, I; Weinstein, IB			The alpha isoform of protein kinase C mediates phorbol ester-induced growth inhibition and p21(cip1) induction in HC11 mammary epithelial cells	ONCOGENE			English	Article						protein kinase C; mammary; cell cycle; TPA; HC11; p21(cip1)	CYCLIN-DEPENDENT KINASES; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; MUTANT FORM; WILD-TYPE; CANCER; OVEREXPRESSION; SUPPRESSION; INVOLVEMENT	To clarify the roles of specific isoforms of PKC in regulating growth and cell cycle progression of the HC11 mammary epithelial cell line, we investigated the effects of activating endogenous PKC isoforms,vith the phorbol ester tumor promoter TPA, and also the effects of TPA on genetically engineered cells containing increased levels of individual PKC isoforms. We found that TPA treatment of HC11 cells induced a transient cell cycle arrest in G0/G1. Western blot analyses of the TPA treated cells provided evidence that the endogenous PKC alpha present in these cells mediated these effects, Indeed, derivatives of the HC11 cell line that inducibly overexpress an exogenous PKC alpha or ectopic PKC beta(1) exhibited more marked growth inhibition by TPA than control cells. Immunohistochemical staining of cells following treatment with TPA revealed selective translocation of PKC alpha into the nucleus, whereas PKC beta(1) remained in the cytoplasm. The transient arrest of HC11 cells following treatment with TPA was associated with marked induction of both p21(cip1) mRNA and protein. This induction was exaggerated in the derivatives that overexpressed either PKC alpha or PKC beta(1). Therefore, in mouse mammary epithelial cells activation of the endogenous PKC alpha can transiently arrest cells in G0/G1 which may be due, at least in part, to induction of the transcription of p21(cip1).	Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Novartis Pharmaceut Corp, Summit, NJ 07901 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Abbott Labs, Abbott Pk, IL 60064 USA	Columbia University; Novartis; Yeshiva University; Albert Einstein College of Medicine; Abbott Laboratories	Weinstein, IB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, HHSC 1509,701 W 168th St, New York, NY 10032 USA.				NCI NIH HHS [T32CA09503, CA02656] Funding Source: Medline; NIGMS NIH HHS [T32GM07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; Alvaro V, 1997, ONCOGENE, V14, P677, DOI 10.1038/sj.onc.1200880; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BLUMBERG PM, 1994, PROG CLIN BIOL RES, V387, P3; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BORNER C, 1992, PROTEIN KINASE C CUR, P297; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; CACACE A, 1993, ONCOGENE, V8, P2094; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOCK DL, 1995, EXP CELL RES, V221, P92, DOI 10.1006/excr.1995.1356; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; Fabbro D, 1992, Cancer Treat Res, V61, P229; FABBRO D, 1986, CANCER RES, V46, P2720; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; Kiley SC, 1996, J MAMMARY GLAND BIOL, V1, P177, DOI 10.1007/BF02013641; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1993, BIOCHEM SOC T, V21, P879, DOI 10.1042/bst0210879; LEACH KL, 1992, J BIOL CHEM, V267, P21816; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; LIVNEH E, 1994, SIGNAL ACTIVATED PHO, P165; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MERLO GR, 1994, ONCOGENE, V9, P443; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OBRIAN CA, 1989, CANCER RES, V49, P3215; OBRIAN CA, 1985, CANCER RES, V45, P2462; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SAVART M, 1992, INT J CANCER, V52, P399, DOI 10.1002/ijc.2910520312; Schmalz D, 1996, J CELL SCI, V109, P2401; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TIEFENBRUN N, 1991, ONCOGENE, V6, P1001; VILCEK J, 1976, J INFECT DIS, V133, pA22, DOI 10.1093/infdis/133.Supplement_2.A22; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Weinstein I. B., 1996, ENCY CANC, V1, P256; ZHOU W, 1993, J BIOL CHEM, V268, P23041	56	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6658	6666		10.1038/sj.onc.1203083	http://dx.doi.org/10.1038/sj.onc.1203083			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597271				2022-12-28	WOS:000083792000005
J	Takimoto, R; El-Deiry, WS				Takimoto, R; El-Deiry, WS			Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site	ONCOGENE			English	Article						p53; KILLER/DR5; p53 DNA-binding site; apoptosis	TUMOR-SUPPRESSOR P53; DEATH RECEPTOR GENE; NF-KAPPA-B; P21(WAF1/CIP1) EXPRESSION; LIGAND TRAIL; MDM2 GENE; BAX GENE; CYCLIN-G; APOPTOSIS; IDENTIFICATION	KILLER/DR5, a tumor necrosis factor-related apoptosis-inducing Ligand (TRAIL) death receptor gene, has been shown to be induced by DNA damaging agents and radiation in a p53-dependent manner. Although TRAIL is a potential therapeutic agent for cancer, the induction mechanism of its receptors is poorly understood, Here we show the identification of three p53 DNA-binding sites in the KILLER/DR5 genomic locus located upstream (BS1; -0.82 Kb) of the ATG site, within Intron 1 (BS2; + 0.25 Kb downstream of the ATG) and within Intron 2 (BS3; + 1.25 Kb downstream of the ATG), A modified p53-binding and immunoselection protocol using a wildtype p53-expressing adenovirus vector (Ad-p53) was used to identify the binding sites and to show that each binding site can bind specifically to wild-type p53 protein (wt-p53), A reporter assay revealed that only BS2 could enhance luciferase expression driven by a basal promoter. We constructed a reporter plasmid carrying the genomic regulatory region of KILLER/DR5 including the three p53 DNA-binding sites but no additional basal promoter. The genomic fragment showed basal transcriptional activity which was induced by wt-p53 but not by mutant p53, and human papilloma virus E6 inhibited the p53-dependent activation. Mutation of BS2 abrogated not only the binding activity of wt-p53 but also the induction of the KILLER/DR5 genomic promoter-reporter gene, indicating that BS2 is responsible for the p53-dependent transactivation of KILLER/DR5, In p53-wild-type but not -mutant or -null cell lines, doxorubicin treatment stabilized p53 protein, and increased specific binding to BS2 as revealed by EMSA, and upregulated the KILLER/DR5 promoter-luciferase reporter gene. These results suggest that the transactivation of KILLER/DR5 is directly regulated by exogenous or endogenous wt-p53 and establishes KILLER/DR5 as a p53 target gene that can signal apoptotic death.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med Pharmacol & Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst, 415 Curie Blvd,CRB 437A, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [P01 CA75138-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim KH, 2000, CLIN CANCER RES, V6, P335; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; TSANG NM, 1995, ONCOGENE, V10, P2403; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zeng YX, 1997, BIOTECHNIQUES, V23, P88, DOI 10.2144/97231bm19; Zeng YX, 1996, ONCOGENE, V12, P1557	50	306	313	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1735	1743		10.1038/sj.onc.1203489	http://dx.doi.org/10.1038/sj.onc.1203489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777207				2022-12-28	WOS:000086292500001
J	Wang, Y; Prywes, R				Wang, Y; Prywes, R			Activation of the c-fos enhancer by the Erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62(TCF) sites	ONCOGENE			English	Article						c-fos; FAP1; Erk; MAPK	SERUM RESPONSE ELEMENT; EPIDERMAL GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; TERNARY COMPLEX FACTORS; COFFIN-LOWRY SYNDROME; TRANSCRIPTIONAL ACTIVATION; CYCLIC-AMP; BINDING PROTEIN; REGULATE CREB; TFII-I	The c-fos enhancer can be activated by many signaling pathways through distinct elements of the enhancer. The enhancer contains at its core the serum response element (SRE) that binds serum response factor (SRF), On the 5' side of the SRE is a site for p62(TCF) which binds only when SRF is bound as well. p62(TCF) is encoded by three ets-related genes, Elk-l, SAP1 and SAP2, Each of these factors contain a transcriptional activation domain that is activated by phosphorylation by MAP kinases, On the 3' side of the SRE is the 'c-fos API site) (FAP1) whose role has been less clear, We find here that the FAP1 site contributes strongly to phorbol ester (TPA) and Erk MAP kinase activation of the c-fos enhancer and that both the p62(TCF) and FAP1 sites are required for effective activation of the enhancer. We further find that the FAP1 site binds ATF1 and CREB from HeLa nuclear extracts and that the phosphorylation of these factors is induced by TPA. ATF1 and CREB can be phosphorylated by Rsk2 which is a protein kinase directly activated by Erk MAP kinases, These results suggest a signaling pathway in which Erk MAP kinase activates the c-fos enhancer by direct phosphorylation of p62(TCF) and by activation of Rsk related kinases that phosphorylate ATF1 and CREB.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prywes, R (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild 813B,MC 2420, New York, NY 10027 USA.				NCI NIH HHS [CA50329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chen X, 1999, MOL CELL BIOL, V19, P4695; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; LIU F, 1993, J BIOL CHEM, V268, P6714; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; METZ R, 1991, ONCOGENE, V6, P2165; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	53	104	106	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1379	1385		10.1038/sj.onc.1203443	http://dx.doi.org/10.1038/sj.onc.1203443			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723128				2022-12-28	WOS:000085942700002
J	Jamerson, MH; Johnson, MD; Dickson, RB				Jamerson, MH; Johnson, MD; Dickson, RB			Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models	ONCOGENE			English	Article						transgenic mice; mammary gland; c-myc; TGF alpha; p53	GROWTH-FACTOR-ALPHA; TRANSGENIC MICE; EPITHELIAL-CELLS; MOUSE MAMMARY; TGF-ALPHA; INDUCED TUMORIGENESIS; FACTOR RECEPTOR; BREAST-CANCER; CHROMOSOMAL INSTABILITY; GLAND INVOLUTION	Recent progress in the study of c-Myc has convincingly demonstrated that it possesses a dual role in regulating both proliferation and apoptosis; however, the manner in which c-Myc influences these cellular response pathways remains incompletely characterized. Deregulation of c-Myc expression, via many mechanisms, is a common feature of multiple cancers and is an especially prominent feature of many breast cancers. Of significant interest to those who study mammary gland development and neoplasia is the unresolved nature and contribution of apoptosis to breast tumorigenesis. Recently, the use of transgenic mice and gene-knockout mice has allowed investigators to evaluate the pathological mechanisms by which different genes influence tumor development and progression. In this review, we address two distinct c-myc-containing bitransgenic murine mammary tumor models and discuss the contribution and possible future directions for resolution of cancer-relevant molecular pathways influenced by c-Myc.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [R01CA072460] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA72460] Funding Source: Medline; NIA NIH HHS [1R01AG1496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Amundadottir LT, 1996, ONCOGENE, V13, P757; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; ARTEAGA CL, 1988, CANCER RES, V48, P5023; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BRINSTER RL, 1983, NATURE, V306, P332, DOI 10.1038/306332a0; BRINSTER RL, 1972, GROWTH NUTRITION MET, P251; Canman C E, 1997, Adv Pharmacol, V41, P429, DOI 10.1016/S1054-3589(08)61068-6; Dahiya R, 1998, BREAST CANCER RES TR, V52, P185, DOI 10.1023/A:1006101729631; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEMING SL, 1999, P ANN M AACR PHIL PA; DERYNCK R, 1987, CANCER RES, V47, P707; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; EDWARDS PAW, 1988, ONCOGENE, V2, P407; EELES RA, 1993, CANCER SURV, V18, P57; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELSON A, 1995, ONCOGENE, V11, P181; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Harris A L, 1988, Cancer Treat Res, V40, P93; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260, DOI 10.1073/pnas.73.4.1260; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEE LW, 1991, CANCER RES, V51, P5238; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LIAO DJ, 2000, IN PRESS ONCOGENE; LISCIA DS, 1990, DEV BIOL, V140, P123, DOI 10.1016/0012-1606(90)90059-R; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Lozano G, 1998, SEMIN CANCER BIOL, V8, P337, DOI 10.1006/scbi.1998.0096; Martinez-Lacaci I, 1999, CONT CANC RES, V3, P31; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; Nass SJ, 1998, CLIN CANCER RES, V4, P1813; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PURDIE CA, 1994, ONCOGENE, V9, P603; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Siegel Peter M., 1998, P397; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; TELANG NT, 1990, CELL REGUL, V1, P863, DOI 10.1091/mbc.1.11.863; TRAVERS MT, 1988, BRIT MED J, V296, P1621, DOI 10.1136/bmj.296.6637.1621; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; WANG JK, 1999, P ANN M AACR PHIL PA; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	75	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1065	1071		10.1038/sj.onc.1203268	http://dx.doi.org/10.1038/sj.onc.1203268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713691				2022-12-28	WOS:000085796400013
J	Jerry, DJ; Kittrell, FS; Kuperwasser, C; Laucirica, R; Dickinson, ES; Bonilla, PJ; Butel, JS; Medina, D				Jerry, DJ; Kittrell, FS; Kuperwasser, C; Laucirica, R; Dickinson, ES; Bonilla, PJ; Butel, JS; Medina, D			A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development	ONCOGENE			English	Article						p53; knockout mice; DMBA; carcinogenesis; tumor incidence; hormonal stimulation	TRANSGENIC MICE; MOUSE MAMMARY; BREAST-CANCER; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; TUMORIGENESIS; MUTATIONS; APOPTOSIS; DEFICIENT; 7,12-DIMETHYLBENZ<A>ANTHRACENE	Although alterations in the p53 tumor suppressor gene are detected frequently in human breast cancers, mammary tumors are observed infrequently in p53(null) mice. This has led to the suggestion that absence of p53 alone is not sufficient for induction of mammary tumors. However, early death of p53(null) mice from thymic lymphomas may obscure tumor phenotypes that mould develop later. Therefore, p53(null) mammary epithelium was transplanted into cleared mammary fat pads of wild type p53 BALB/c hosts to allow long-term analysis of mammary tumor phenotypes. Five treatments were compared for their effects on tumor incidence in hosts bearing transplants of p53(null) and p53(wt) mammary epithelium, The treatment groups were: (1) untreated; (2) continuous hormone stimulation with pituitary isografts; (3) multiple pregnancies; (4) DMBA alone; and (5) DMBA + pituitary isografts, The tumor incidences in p53(null) vs p53(wt) mammary transplants for each treatment group were 62% vs 0%, 100% vs 0%, 68% vs 0%, 60% vs 4% and 91%, vs 14%, respectively. The mammary tumors that developed in the p53(null) mammary epithelium were all adenocarcinomas and were frequently aneuploid, These data demonstrate that the absence of p53 is sufficient to cause development of mammary tumors and that hormonal stimulation enhances the tumorigenicity of p53(null) mammary epithelium to a greater extent than DMBA exposure alone. This model provides an in situ approach to examine the molecular basis for the role of p53 in the regulation of mammary tumorigenesis.	Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	University of Massachusetts System; University of Massachusetts Amherst; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Jerry, DJ (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.			Butel, Janet/0000-0002-6876-3245	NATIONAL CANCER INSTITUTE [R01CA025215, R29CA066670] Funding Source: NIH RePORTER; NCI NIH HHS [CA66670, CA25215] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; COLES C, 1992, CANCER RES, V52, P5291; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Kito K, 1996, MOL CARCINOGEN, V17, P78, DOI 10.1002/(SICI)1098-2744(199610)17:2<78::AID-MC4>3.0.CO;2-P; KUMAR R, 1990, ONCOGENE, V5, P1271; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Maroulakou IG, 1997, MOL CARCINOGEN, V20, P168, DOI 10.1002/(SICI)1098-2744(199710)20:2<168::AID-MC3>3.0.CO;2-J; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; McKenzie KE, 1997, MOL CARCINOGEN, V20, P194, DOI 10.1002/(SICI)1098-2744(199710)20:2<194::AID-MC6>3.3.CO;2-7; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; Medina D, 1999, J NATL CANCER I, V91, P967, DOI 10.1093/jnci/91.11.967; Medina D, 1998, MOL CARCINOGEN, V22, P199, DOI 10.1002/(SICI)1098-2744(199807)22:3<199::AID-MC8>3.0.CO;2-G; Medina D., 1982, MOUSE BIOMEDICAL RES, VIV, P373; MEDINA D, 1973, METHOD CANCER RES, V7, P3; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PETO R, 1974, BRIT J CANCER, V29, P101, DOI 10.1038/bjc.1974.45; Qing WG, 1997, CARCINOGENESIS, V18, P553, DOI 10.1093/carcin/18.3.553; Ritland SR, 1997, CANCER RES, V57, P3520; Ross JA, 1999, MUTAT RES-FUND MOL M, V424, P155, DOI 10.1016/S0027-5107(99)00016-0; RUSSO J, 1990, LAB INVEST, V62, P244; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; WELLINGS SR, 1975, J NATL CANCER I, V55, P231	40	141	144	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1052	1058		10.1038/sj.onc.1203270	http://dx.doi.org/10.1038/sj.onc.1203270			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713689				2022-12-28	WOS:000085796400011
J	Li, Y; Hively, WP; Varmus, HE				Li, Y; Hively, WP; Varmus, HE			Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer	ONCOGENE			English	Review						Wnt-1; breast cancer; cancer models; mammary; transgenic; MMTV	MAMMARY-TUMOR VIRUS; PROTO-ONCOGENE INT-1; PROVIRAL INSERTION; ESTROGEN-RECEPTOR; GROWTH-FACTOR; BETA-CATENIN; CHROMOSOMAL INSTABILITY; PROGESTERONE RECEPTORS; CELL-PROLIFERATION; CANDIDATE ONCOGENE	Wnt-1 was first identified as a protooncogene activated by viral insertion in mouse mammary tumors. Transgenic expression of this gene using a mouse mammary tumor virus LTR enhancer causes extensive ductal hyperplasia early in life and mammary adenocarcinomas in approximately 50% of the female transgenic (TG) mice by 6 months of age. Metastasis to the lung and proximal lymph nodes is rare at the time tumors are detected but frequent after the removal of the primary neoplasm, The potent mitogenic effect mediated by Wnt-1 expression does not require estrogen stimulation; tumors form after an increased latency in estrogen receptor alpha-null mice. Several genetic lesions, including inactivation of p53 and over-expression of Fgf-3, collaborate with Wnt-1 in leading to mammary tumors, but loss of Sky and inactivation of one allele of Rb do not affect the rate of tumor formation in Wnt-1 TG mice.	NCI, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, Y (corresponding author), NCI, Div Basic Sci, 49 Convent Dr,Bldg 49,Room 4A56, Bethesda, MD 20892 USA.		Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X				Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; BARISH GD, 1999, SIGNAL NETWORKS CELL; BERGSTEIN I, 1999, BREAST CANC MOL GENE, P181; BERNS EMJJ, 1995, INT J CANCER, V64, P140, DOI 10.1002/ijc.2910640212; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bieche I, 1999, CANCER RES, V59, P2759; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Cunha GR, 1996, J MAMMARY GLAND BIOL, V1, P21, DOI 10.1007/BF02096300; DANIEL CW, 1987, CANCER RES, V47, P6052; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; de Lange T, 1999, SCIENCE, V283, P947, DOI 10.1126/science.283.5404.947; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; ELSON A, 1995, ONCOGENE, V11, P181; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Fisher GH, 1999, ONCOGENE, V18, P5253, DOI 10.1038/sj.onc.1203087; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howe LR, 1999, CANCER RES, V59, P1572; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; Jiang M, 1997, INT J CANCER, V74, P529, DOI 10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Li YX, 1999, VIROLOGY, V255, P138, DOI 10.1006/viro.1998.9571; Lijam N, 1997, CELL, V90, P895, DOI 10.1016/S0092-8674(00)80354-2; LIN TP, 1992, CANCER RES, V52, P4413; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MCGUIRE WL, 1985, SEMIN ONCOL, V12, P12; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOOLGAVKAR SH, 1980, J NATL CANCER I, V65, P559; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; Patapoutian A, 1999, SCIENCE, V283, P1180, DOI 10.1126/science.283.5405.1180; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PETERSEN OW, 1987, CANCER RES, V47, P5748; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Prives C, 1999, J PATHOL, V187, P112; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Redston M, 1998, NAT GENET, V20, P13, DOI 10.1038/1666; RICKETTS D, 1991, CANCER RES, V51, P1817; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THEILLET C, 1989, ONCOGENE, V4, P915; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wakasugi E, 1997, AM J CLIN PATHOL, V107, P684; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wiesen JF, 1999, DEVELOPMENT, V126, P335; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Woodage T, 1998, NAT GENET, V20, P62, DOI 10.1038/1722; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	106	193	196	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1002	1009		10.1038/sj.onc.1203273	http://dx.doi.org/10.1038/sj.onc.1203273			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713683				2022-12-28	WOS:000085796400005
J	Mattot, V; Vercamer, C; Soncin, F; Calmels, T; Huguet, C; Fafeur, V; Vandenbunder, B				Mattot, V; Vercamer, C; Soncin, F; Calmels, T; Huguet, C; Fafeur, V; Vandenbunder, B			Constitutive expression of the DNA-binding domain of Ets1 increases endothelial cell adhesion and stimulates their organization into capillary-like structures	ONCOGENE			English	Article						Ets; transcription factor; endothelial cells; adhesion; angiogenesis	TRANSCRIPTION FACTOR; PLASMINOGEN-ACTIVATOR; CHICK-EMBRYO; INTEGRIN ALPHA(V)BETA(3); EPITHELIAL-CELLS; GENE; DIFFERENTIATION; C-ETS-1; GROWTH; PROMOTER	We previously reported that the Ets1 transcription factor is expressed in endothelial cells during angiogenesis both in normal and pathological development. We analyse here the effects of the stable expression of an Ets transdominant negative mutant (Ets1-DB), consisting in an Ets1 protein lacking its transactivation domain. A retrovirus containing the Ets1-DB sequence fused to an IRES-Neo sequence was designed and used to infect brain capillary (IBE) and aorta (MAE) mouse endothelial cell hues, Cells expressing this Ets1 mutant were examined for proliferation, migration and adhesion, Consistent changes were observed on cell morphology, with increased spreading and modifications in the organization of the cytoskeleton, and increased cell adhesion. We investigated the ability of endothelial cells to organise into capillary-like structures using three-dimensional gels, On Matrigel, all endothelial cell lines formed a cord-like network within 24 h, with an increased ability of Ets1-DB cells to spread on this substrate. In long term cultures, IBE cells expressing Ets1-DB showed a higher capacity to form branched structures; this effect was potentiated by FGF2, These results demonstrate a role of the Ets transcription factors in the regulation of the adhesive and morphogenetic properties of endothelial cells.	Inst Pasteur, CNRS EP560, Inst Biol, F-59021 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Vandenbunder, B (corresponding author), Inst Pasteur, CNRS EP560, Inst Biol, 1 Rue Calmette, F-59021 Lille, France.		Fafeur, Veronique/L-9072-2018; SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673				AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; BOLON I, 1995, AM J PATHOL, V147, P1298; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHEN JH, 1990, ONCOGENE RES, V5, P277; Chen ZQ, 1997, CANCER RES, V57, P2013; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; GREVIN D, 1993, INT J DEV BIOL, V37, P519; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; Hierck BP, 1996, DEV DYNAM, V207, P89; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KLEINSOYER C, 1986, THROMB HAEMOSTASIS, V56, P232; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; Remy P, 1996, INT J DEV BIOL, V40, P577; SAGE EH, 1991, J BIOL CHEM, V266, P14831; Sapi E, 1998, CANCER RES, V58, P1027; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WASYLYK C, 1994, ONCOGENE, V9, P3665; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119	51	35	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					762	772		10.1038/sj.onc.1203248	http://dx.doi.org/10.1038/sj.onc.1203248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698494				2022-12-28	WOS:000085192100006
J	Newman, SP; Bates, NP; Vernimmen, D; Parker, MG; Hurst, HC				Newman, SP; Bates, NP; Vernimmen, D; Parker, MG; Hurst, HC			Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer	ONCOGENE			English	Article						ERBB2; oestrogen receptor; SRC-1; breast cancer; transcriptional repression	DEPENDENT TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; MEDIATED TRANSACTIVATIONS; COACTIVATOR-1 INTERACTS; PROTEIN EXPRESSION; MAMMARY-CARCINOMA; NEU ONCOGENE; CELLS; GROWTH	Overexpression of the ERBB2 proto oncogene in breast tumours, which occurs in 25-30% of patients, correlates with poor prognosis, In oestrogen receptor (ER) positive breast epithelial cells oestrogens reduce ERBB2 mRNA and protein levels, an effect that is reversed in the presence of anti-oestrogens such as tamoxifen and ICI 182780. Our previous studies have shown that the major effect of oestrogen on ERBB2 expression is at the level of transcription and that this is mediated through a region within the EXBB2 first intron which can act as an oestrogen-suppressible enhancer in ER positive breast cells. in vitro footprinting of the smallest DNA fragment that retained full activity revealed four transcription factor binding sites. We report here that two of these sites are recognized by AP-2 proteins and the other two are bound by a variety of bZIP factors, including CREB and ATF1, with a major complex containing ATFa/JunD. However, by using ER mutants it is clear that repression occurs essentially off the DNA. Indeed, the essential domain of the ER responsible for repression of the ERBB2 enhancer is a region termed AF2 which is required for the ligand-dependent association of non-DNA binding cofactors, We further demonstrate that one of these ER cofactors, SRC-1, can relieve oestrogen repression of the ERBB2 enhancer and conclude that these data fit with a model whereby the ER and the ERBB2 enhancer compete for this limiting, non-DNA binding cofactor, Thus, in oestrogenic conditions SRC-1 preferentially binds to the ER which effectively sequesters it thereby reducing enhancer activity, but in antioestrogenic media the cofactor is released from the ER and is therefore available to activate the EXBB2 enhancer.	Hammersmith Hosp, Imperial Canc Res Fund, Mol Oncol Unit, ICSM, London W12 0NN, England; Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK; Imperial College London; Cancer Research UK	Hurst, HC (corresponding author), Hammersmith Hosp, Imperial Canc Res Fund, Mol Oncol Unit, ICSM, London W12 0NN, England.							ANTONIOTTI S, 1994, BRIT J CANCER, V70, P1095, DOI 10.1038/bjc.1994.454; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Berns EMJJ, 1998, BREAST CANCER RES TR, V48, P87, DOI 10.1023/A:1005903226483; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bocco JL, 1996, ONCOGENE, V12, P1971; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CHATTON B, 1994, ONCOGENE, V9, P375; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DATI C, 1990, ONCOGENE, V5, P1001; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DSOUZA B, 1993, ONCOGENE, V8, P1797; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; HURST HC, 1996, PROTEIN PROFILES, V3; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nass SJ, 1998, NAT MED, V4, P761, DOI 10.1038/nm0798-761; Newby JC, 1997, CLIN CANCER RES, V3, P1643; ONATE SA, 1995, SCIENCE, V270, P1354; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; READ LD, 1990, CANCER RES, V50, P3947; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Turner BC, 1998, CANCER RES, V58, P5466; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WARRI AM, 1991, INT J CANCER, V49, P616, DOI 10.1002/ijc.2910490425	46	84	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					490	497		10.1038/sj.onc.1203416	http://dx.doi.org/10.1038/sj.onc.1203416			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698518				2022-12-28	WOS:000085104200002
J	Ramos-Morales, F; Dominguez, A; Romero, F; Luna, R; Multon, MC; Pintor-Toro, JA; Tortolero, M				Ramos-Morales, F; Dominguez, A; Romero, F; Luna, R; Multon, MC; Pintor-Toro, JA; Tortolero, M			Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product	ONCOGENE			English	Article						PTTG; cell cycle; proliferation; phosphorylation; Cdc2	MITOSIS-SPECIFIC PHOSPHORYLATION; TUMOR-TRANSFORMING GENE; DEPENDENT KINASES; MICROTUBULE DYNAMICS; HUMAN HOMOLOG; CDC2 KINASE; M-PHASE; PROTEINS; P34CDC2; IDENTIFICATION	We recently isolated a cDNA for hpttg, the human homolog of rat pituitary tumor transforming gene, Now we have analysed the expression of hpttg as a function of cell proliferation. hPTTG protein level is up-regulated in rapidly proliferating cells, is down-regulated in response to serum starvation or cell confluence, and is regulated in a cell cycle-dependent manner, peaking in mitosis, In addition, we show that hPTTG is phosphorylated during mitosis. Immunodepletion and in vitro phosphorylation experiments, together with the use of a specific inhibitor, indicate that Cdc2 is the kinase that phosphorylates hPTTG. These results suggest that hpttg is induced by, and may have a role in, regulatory pathways involved in the control of cell proliferation.	Univ Seville, Dept Microbiol, Fac Biol, E-41080 Seville, Spain; CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Rhone Poulenc Rorer, CRVA, F-94403 Vitry Sur Seine, France	University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); Sanofi-Aventis; Sanofi France	Ramos-Morales, F (corresponding author), Univ Seville, Dept Microbiol, Fac Biol, Apdo 1095, E-41080 Seville, Spain.		Tortolero, Maria/K-5744-2014; Ramos-Morales, Francisco/C-5734-2008; Romero, Francisco/K-2101-2014; LUNA, ROSA/F-3974-2016; Pintor-Toro, Jose/L-4737-2014	Tortolero, Maria/0000-0003-1797-9940; Ramos-Morales, Francisco/0000-0002-1151-4547; Romero, Francisco/0000-0002-9588-6881; LUNA, ROSA/0000-0002-6131-6610; Pintor-Toro, Jose/0000-0002-9060-5243				BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; BUDAY L, 1995, ONCOGENE, V11, P1327; BUENDIA B, 1991, COLD SPRING HARB SYM, V56, P523; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HERSHKOVITZ M, 1995, P NATL ACAD SCI USA, V92, P2379, DOI 10.1073/pnas.92.6.2379; HIRAMA T, 1995, BLOOD, V86, P841; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Jackman MR, 1997, CANCER SURV, V29, P47; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219; Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; Reed SI, 1997, CANCER SURV, V29, P7; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; YAMASHIRO S, 1991, BIOESSAYS, V13, P563, DOI 10.1002/bies.950131103; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	43	92	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					403	409		10.1038/sj.onc.1203320	http://dx.doi.org/10.1038/sj.onc.1203320			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656688				2022-12-28	WOS:000084873700011
J	Rozovskaia, T; Rozenblatt-Rosen, O; Sedkov, Y; Burakov, D; Yano, T; Nakamura, T; Petruck, S; Ben-Simchon, L; Croce, CM; Mazo, A; Canaani, E				Rozovskaia, T; Rozenblatt-Rosen, O; Sedkov, Y; Burakov, D; Yano, T; Nakamura, T; Petruck, S; Ben-Simchon, L; Croce, CM; Mazo, A; Canaani, E			Self-association of the SET domains of human ALL-1 and of Drosophila TRITHORAX and ASH1 proteins	ONCOGENE			English	Article						SET domain; oligomerization; chromatin alterations	ACUTE LEUKEMIAS; GENE-PRODUCT; COMPLEX; CONTAINS; ENCODES; REGION	The human ALL-1 gene is involved in acute leukemia through gene fusions, partial tandem duplications or a specific deletion, Several sequence motifs within the ALL-1 protein, such as the SET domain, PHD fingers and the region with homology to DNA methyl transferase are shared with other proteins involved in transcription regulation through chromatin alterations. However, the function of these motifs is still not clear. Studying ALL-1 presents an additional challenge because the gene is the human homologue of Drosophila trithorax. The latter is a member of the trithorax-Polycomb gene family which acts to determine the body pattern of Drosophila by maintaining expression or repression of the Antennapedia-bithorax homeotic gene complex. Here we apply yeast two hybrid methodology, in vivo immunoprecipitation and in vitro 'pull down' techniques to show self association of the SET motifs of ALL-I, TRITHORAX and ASH1 proteins (Drosophila ASH1 is encoded by a tr trithorax-group gene). Point mutations in evolutionary conserved residues of TRITHORAX SET, abolish the interaction. SET-SET interactions might act in integrating the activity of ALL-1 (TRX and ASH1) protein molecules, simultaneously positioned at different maintenance elements and directing expression of the same or different target genes.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Weizmann Institute of Science; Jefferson University	Canaani, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Young, Richard A/F-6495-2012; Rozenblatt-Rosen, Orit/HDN-4182-2022	Young, Richard A/0000-0001-8855-8647; 	NCI NIH HHS [CA 50507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Corda Y, 1999, NAT GENET, V21, P204, DOI 10.1038/5991; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Ekwall K, 1996, J CELL SCI, V109, P2637; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Heim S, 1995, CANC CYTOGENETICS; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RAIMONDI SC, 1993, BLOOD, V81, P2237; Rasio D, 1996, CANCER RES, V56, P1766; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286	24	40	48	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					351	357		10.1038/sj.onc.1203307	http://dx.doi.org/10.1038/sj.onc.1203307			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656681				2022-12-28	WOS:000084873700004
J	Bauvois, B; Djavaheri-Mergny, M; Rouillard, D; Dumont, J; Wietzerbin, J				Bauvois, B; Djavaheri-Mergny, M; Rouillard, D; Dumont, J; Wietzerbin, J			Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells	ONCOGENE			English	Article						CD26 antigen; dipeptidylpeptidase IV; B-CLL; IFN; retinoic acid; STAT	DIPEPTIDYL-PEPTIDASE-IV; CHRONIC LYMPHOCYTIC-LEUKEMIA; PERIPHERAL-BLOOD; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; TYROSINE KINASES; EPITHELIAL-CELLS; ACTIVATION; STAT1; GAMMA	Interferons (IFNs alpha, beta and gamma) and all trans retinoic acid (RA) have the ability to activate genes with GAS sites. We have found that the promoter of CD26/dipeptidylpeptidase IV (DPPIV) contains a consensus GAS site TTCnnnGAA located at bp-35 to -27, and computer analysis confirmed this sequence to be a putative Stat binding site. Consistent with this finding, we show that IFNs and RA rapidly enhanced CD26 gene and protein expression in chronic B lymphocytic leukemia (B-CLL) cells. Immunoblot analyses revealed that unstimulated B-CLL cells expressed detectable levels of serine/tyrosine-phosphorylated Stat1 alpha, and RA and IFN-gamma treatment led to increased levels of tyrosine phosphorylation of Stat1 alpha and its nuclear accumulation. As shown by electrophoretic mobility shift assay, RA and IFN-gamma increased the binding of a nuclear protein to the GAS-CD26 element. Shift-Western blotting identified Stat1 alpha as the GAS-CD26 binding factor. Augmented levels of CD26 protein in malignant B cells cultured with IFNs or RA coincided with the enhancement of DPPIV activity. Taken together, our results are in favor of the IFN-/RA-mediated upregulation of CD26/DPPIV in B-CLL through the signaling pathway involving Stat1 alpha and the GAS response element of CD26 promoter.	Inst Curie, Unite 365 INSERM, F-75231 Paris 05, France; Inst Curie, Sect Rech, F-75231 Paris, France; Serv Hematol Clin, F-75231 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Bauvois, B (corresponding author), Inst Curie, Unite 365 INSERM, F-75231 Paris 05, France.		Bauvois, Brigitte/F-6776-2013; Djavaheri-Mergny, Mojgan/N-6315-2017; Djavaheri-Mergny, Mojgan/L-3890-2019	Bauvois, Brigitte/0000-0002-1751-6922; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505				ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; BARON S, 1991, JAMA-J AM MED ASSOC, V266, P1375, DOI 10.1001/jama.266.10.1375; Bauvois B, 1999, BRIT J CANCER, V79, P1042, DOI 10.1038/sj.bjc.6690167; BOHM SK, 1995, BIOCHEM J, V311, P835; BUHLING F, 1995, IMMUNOL LETT, V45, P47, DOI 10.1016/0165-2478(94)00230-O; Cordero OJ, 1998, IMMUNOL LETT, V61, P7, DOI 10.1016/S0165-2478(97)00154-5; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; DE LUCA LM, 1991, FASEB J, V5, P2924; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Djavaheri-Mergny M, 1999, BIOCHEM J, V338, P607, DOI 10.1042/0264-6021:3380607; EGUCHI K, 1989, J IMMUNOL, V142, P4233; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; EILERS A, 1995, MOL CELL BIOL, V15, P3579; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; Floyd-Smith G, 1999, EXP CELL RES, V246, P138, DOI 10.1006/excr.1998.4296; FOON KA, 1985, AM J MED, V78, P216, DOI 10.1016/0002-9343(85)90429-2; Gaetaniello L, 1998, HEPATOLOGY, V27, P934, DOI 10.1002/hep.510270407; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; HAFLER DA, 1985, NEW ENGL J MED, V312, P1405, DOI 10.1056/NEJM198505303122201; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; Hochhaus A, 1997, LEUKEMIA, V11, P933, DOI 10.1038/sj.leu.2400723; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Iwata S, 1999, J EXP MED, V190, P301, DOI 10.1084/jem.190.3.301; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kondo S, 1996, LEUKEMIA RES, V20, P357, DOI 10.1016/0145-2126(95)00159-X; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lambeir AM, 1996, BBA-GEN SUBJECTS, V1290, P76, DOI 10.1016/0304-4165(96)00012-8; Lehtonen A, 1997, J IMMUNOL, V159, P794; Matikainen S, 1998, LEUKEMIA LYMPHOMA, V30, P63, DOI 10.3109/10428199809050930; Matikainen S, 1996, BLOOD, V88, P114; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; MCSWEENEY EN, 1993, BRIT J HAEMATOL, V85, P77, DOI 10.1111/j.1365-2141.1993.tb08648.x; MORIMOTO C, 1994, P NATL ACAD SCI USA, V91, P9960, DOI 10.1073/pnas.91.21.9960; NAKAO H, 1989, J RHEUMATOL, V16, P7; Osorio LM, 1998, LEUKEMIA LYMPHOMA, V30, P247, DOI 10.3109/10428199809057538; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RIEMANN D, 1995, CLIN EXP IMMUNOL, V100, P277; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; Silvennoinen O, 1997, APMIS, V105, P497, DOI 10.1111/j.1699-0463.1997.tb05047.x; Stecca BA, 1997, J HEPATOL, V27, P337, DOI 10.1016/S0168-8278(97)80180-8; STEFANOVIC V, 1993, IMMUNOLOGY, V80, P465; TANAKA T, 1995, INT J CANCER, V64, P326, DOI 10.1002/ijc.2910640508; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; Yamabe T, 1997, IMMUNOLOGY, V91, P151, DOI 10.1046/j.1365-2567.1997.00230.x	51	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					265	272		10.1038/sj.onc.1203292	http://dx.doi.org/10.1038/sj.onc.1203292			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645005				2022-12-28	WOS:000084844400012
J	Bader, S; Walker, M; Heindrich, B; Bird, A; Bird, C; Hooper, M; Wyllie, A				Bader, S; Walker, M; Heindrich, B; Bird, A; Bird, C; Hooper, M; Wyllie, A			Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency	ONCOGENE			English	Article						MBD4; colorectal cancer; RER; mismatch repair	MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; DNA METHYLATION; RECEPTOR; CPG; CARCINOGENESIS	Defects of mismatch repair are thought to be responsible for carcinogenesis in hereditary non-polyposis colorectal cancer and about 15% of sporadic colon cancers. The phenotype is seen as microsatellite instability and is known to be caused either by mutations in mismatch repair genes or by aberrant methylation of these genes stabilizing their downregulation. Lack of repair of microsatellite sequence errors, created during replication, leads to a mutation-prone phenotype, Where mutations occur within mononucleotide tracts within exons they cause translation frameshifts, premature cessation of translation and abnormal protein expression. Such mutations have been observed in the TGF beta RII, BAX, IGFIIR, MSH3 and MSH6 genes in colon and other cancers, We describe here frameshift mutations affecting the gene for the methyl-CpG binding thymine glycosylase, MBD4, in over 40% of microsatellite unstable sporadic colon cancers. The mutations all appear heterozygous but their location would ensure truncation of the protein between the methyl-CpG binding and glycosylase domains, thus potentially generating a dominant negative effect. It is thus possible that such mutations enhance mutation frequency at other sites in these tumours, A suggestion has been made that MBD4 (MED1) mutations may lead to an increased rate of microsatellite instability but this mechanism appears unlikely due to the nature of mutations we have found.	Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie CRC Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Bader, S (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie CRC Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.		Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bubb VJ, 1996, ONCOGENE, V12, P2641; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	19	106	110	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					8044	8047		10.1038/sj.onc.1203229	http://dx.doi.org/10.1038/sj.onc.1203229			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637515				2022-12-28	WOS:000084634600013
J	David-Pfeuty, T				David-Pfeuty, T			Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells	ONCOGENE			English	Article						cyclin-dependent kinase; protein-kinase inhibitor; wt p53; apoptosis; anti-tumor agent	PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN FIBROBLASTS; CHEMICAL INHIBITORS; PHASE-TRANSITION; DNA-REPLICATION; PURINE ANALOGS; CDC28 MUTATION; RIBOSOMAL-RNA; CANCER-CELLS	The cdk2 gene has been identified as a human cdc2/CDC28-related gene that encodes a protein kinase essential for the G1/S transition in mammalian cells, but not for the G2/M transition, which requires Cdk1, another p34(cdc2/CDC28) homolog, Novel potential functions of Cdk2 have been uncovered by using two potent and specific inhibitors of its kinase activity, roscovitine and olomoucine, on human wt p53-expresser untransformed and tumor-derived cells. At concentrations equal or superior to respectively 30- and 20-fold their in vitro IC50 values for cyclin B/Cdk1, cyclin A/Cdk2 and cyclin E/Cdk2, the Cdk inhibitors precipitately induce a dramatic nuclear accumulation of wt p53 and a delocalization of nucleolin from the nucleolus In all interphase cells, whatever their cell cycle status, acting in this way like the DNA-damaging drug, mitomycin C (7 mu g/ml). These early events are soon followed by a nucleolar fragmentation in both normal and tumor cells in the presence of the Cdk inhibitors but not in the presence of the DNA-damaging drug. Yet, treatment with either type of compounds eventually triggers rapidly the death of the tumor cells and, much more slowly, that of the normal cells. The Cdk inhibitors, however, stimulate cell death from any stage of the cell cycle, whereas the DNA-damaging drug kills more efficaciously S phase cells. These observations provide a hint that the Cdk2 kinase might be involved in controlling the nuclear le,els of the tumor suppressor wt p53 protein and in maintaining the nucleolar integrity and function, linking in this way the cell division cycle machinery to survival functions and overall cell metabolism via the control of nucleocytoplasmic transport and of ribosome production.	Ctr Univ Orsay, Inst Curie Rech, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	David-Pfeuty, T (corresponding author), Ctr Univ Orsay, Inst Curie Rech, CNRS, UMR 146, Batiment 110, F-91405 Orsay, France.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; An B, 1997, ONCOL REP, V4, P1129; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BATES S, 1994, ONCOGENE, V9, P71; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DavidPfeuty T, 1997, CANCER RES, V57, P4482; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DavidPfeuty T, 1996, ONCOGENE, V13, P1447; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAUTIER T, 1992, J CELL SCI, V102, P729; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; JIANG W, 1993, ONCOGENE, V8, P3447; KARN J, 1989, ONCOGENE, V4, P773; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; Meijer L., 1995, PROGR CELL CYCLE RES, V1; MEIJER L, 1997, PROGR CELL CYCLE RES, V3; Meijer L., 1996, PROGR CELL CYCLE RES, V2; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHIELI P, 1994, CANCER RES, V54, P3391; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ONGKEKO W, 1995, J CELL SCI, V108, P2897; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; SEDLACEK HH, 1996, ANN ONCOL         S1, V7, P77; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; WIMMEL A, 1994, ONCOGENE, V9, P995; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016/0006-2952(93)90590-S; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU Z, 1994, TRENDS CELL BIOL, V4, P414; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; [No title captured]	79	81	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7409	7422		10.1038/sj.onc.1203103	http://dx.doi.org/10.1038/sj.onc.1203103			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602500				2022-12-28	WOS:000084119600002
J	Pim, D; Banks, L				Pim, D; Banks, L			HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6	ONCOGENE			English	Article						HPV E6; p531 E6*; apoptosis	HUMAN PAPILLOMAVIRUS TYPE-16; OPEN READING FRAME; MESSENGER-RNA; CELL-LINE; EARLY GENES; TRANSCRIPTION; ONCOPROTEIN; PATTERNS; DNA; IDENTIFICATION	We have previously demonstrated that ectopic expression of the HPV-18 E6*I protein has an antiproliferative effect in cells derived from HPV-containing cervical tumours. This effect correlated with the ability of E6*I to inhibit the E6-mediated degradation of p53 both in vitro and in vivo and with an increase in p53 transcriptional trans-activation. The observation that the E6*I protein can interact with both full-length HPV-18 E6 and E6-AP proteins in vitro indicated the mechanism by which this activity was mediated. In this study we describe a mutational strategy to attempt to differentiate between the E6-AP and full-length HPV-18 E6 interactions, with respect to the biological function of E6. We identify regions of the E6*I protein essential for its interaction with full-length E6 and important for its interaction with E6-AP. We show that a mutant of E6*I which is unable to bind to full-length HPV-18 E6 protein is unable to inhibit the E6-directed degradation of p53 and is also unable to inhibit the proliferation of a cervical tumour-derived cell line. Finally, we show that inhibition of transformed cell growth by E6*I protein correlates with its ability to induce apoptosis in a p53-dependent manner. These results raise the intriguing possibility of using E6*I as a basis for therapeutic intervention in HPV-associated tumours.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Pim, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.							BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; BUTZ K, 1995, ONCOGENE, V10, P927; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; LOWE SW, 1993, CELL, V74, P847; Mantovani F, 1999, ONCOGENE, V18, P3309, DOI 10.1038/sj.onc.1202688; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHERMAN L, 1992, VIROLOGY, V191, P953, DOI 10.1016/0042-6822(92)90271-P; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1995, J VIROL, V69, P7023, DOI 10.1128/JVI.69.11.7023-7031.1995; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	25	72	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7403	7408		10.1038/sj.onc.1203134	http://dx.doi.org/10.1038/sj.onc.1203134			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602499				2022-12-28	WOS:000084119600001
J	Ricol, D; Cappellen, D; El Marjou, A; Gil-Diez-de-Medina, S; Girault, JM; Yoshida, T; Ferry, G; Tucker, G; Poupon, MF; Chopin, D; Thiery, JP; Radvanyi, F				Ricol, D; Cappellen, D; El Marjou, A; Gil-Diez-de-Medina, S; Girault, JM; Yoshida, T; Ferry, G; Tucker, G; Poupon, MF; Chopin, D; Thiery, JP; Radvanyi, F			Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer	ONCOGENE			English	Article						bladder; fibroblast growth factor receptor; human; urothelial cell carcinoma; tumour suppressor gene	LIGAND-BINDING SPECIFICITY; PROSTATE EPITHELIAL-CELLS; HUMAN PANCREATIC-CANCER; K-SAM; DIFFERENTIAL EXPRESSION; TRANSGENIC MICE; GASTRIC-CANCER; GENE; ACTIVATION; BFGF	FGFRs (fibroblast growth factor receptors) are encoded by four genes (FGFR1-4). Alternative splicing results in various receptor isoforms, The FGFR2-IIIb variant is present in a wide variety of epithelia, including the bladder epithelium. Recently, we have shown that FGFR2-IIIb is downregulated in a subset of transitional cell carcinomas of the bladder, and that this downregulation is associated with a poor prognosis. We investigated possible tumour suppressive properties of FGFR2-IIIb by transfecting two human bladder tumour cell lines, J82 and T24, which have no endogenous FGFR2-IIIb expression, with FGFR2-IIIb cDNA, No stable clones expressing FGFR2-IIIb were isolated with the J82 cell line, For the T24 cell line, stable transfectants expressing FGFR2-IIIb had reduced growth in vitro and formed fewer tumours in nude mice which, in addition, grew more slowly. The potential mechanisms leading to decreased FGFR2-IIIb mRNA levels mere also investigated, The 5' region of the human FGFR2 gene was isolated and found to contain a CpG island which was partially methylated in more than half the cell lines and tumours which do not express FGFR2-IIIb, No homozygous deletion was identified in any of the tumours or cell lines with reduced levels of FGFR2-IIIb, Mutational analysis of the entire coding region of FGFR2-IIIb at the transcript level was performed in 33 bladder tumours, In addition to normal FGFR2-IIIb mRNA, abnormal transcripts were detected in two tumour samples, These abnormal mRNAs resulted from exon skipping which affected the region encoding the kinase domain. Altogether, these results show that FGFR2-IIIb has tumour growth suppressive properties in bladder carcinomas and suggest possible mechanisms of FGFR2 gene inactivation.	Inst Curie, CNRS, UMR 144, Sect Rech, Paris 05, France; CHU Henri Mondor, Grp Etude Tumeurs Urol, F-94010 Creteil, France; CHU Henri Mondor, Serv Urol, F-94010 Creteil, France; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan; Inst Rech Servier, Div Cancerol Expt, F-92150 Suresnes, France; Inst Curie, CNRS, UMR 147, Sect Rech, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; National Cancer Center - Japan; Servier; Institut de Recherches Internationales Servier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Radvanyi, F (corresponding author), Inst Curie, CNRS, UMR 144, Sect Rech, 26 Rue Ulm, Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424	NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; AVIVI A, 1992, ONCOGENE, V7, P1957; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DELL KR, 1992, J BIOL CHEM, V267, P21225; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; DEMEDINA SGD, 1999, IN PRESS ONCOGENE; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Feng SJ, 1997, CANCER RES, V57, P5369; Fenig E, 1997, CLIN CANCER RES, V3, P135; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GIROLDI LA, 1994, INVAS METAST, V14, P71; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1988, ONCOGENE RES, V3, P177; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; ITOH H, 1994, CANCER RES, V54, P3237; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KISHI T, 1994, BIOCHEM BIOPH RES CO, V202, P1387, DOI 10.1006/bbrc.1994.2084; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Lamm DL, 1996, CA-CANCER J CLIN, V46, P93, DOI 10.3322/canjclin.46.2.93; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; Matsubara A, 1998, CANCER RES, V58, P1509; MATTEI MG, 1991, HUM GENET, V87, P84, DOI 10.1007/BF01213098; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; REED JA, 1994, AM J PATHOL, V144, P329; Rubin J. S., 1995, V74, P191; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SCHWEIGERER L, 1987, J CLIN INVEST, V80, P1516, DOI 10.1172/JCI113236; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159	56	104	115	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7234	7243		10.1038/sj.onc.1203186	http://dx.doi.org/10.1038/sj.onc.1203186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602477				2022-12-28	WOS:000084119400007
J	Smart, P; Lane, EB; Lane, DP; Midgley, C; Vojtesek, B; Lain, S				Smart, P; Lane, EB; Lane, DP; Midgley, C; Vojtesek, B; Lain, S			Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B	ONCOGENE			English	Article						leptomycin B; senescence; p53 response; normal fibroblasts; neuroblastoma	CYTOPLASMIC SEQUESTRATION; ANTICANCER ACTIVITY; DNA-DAMAGE; IN-VIVO; PROTEIN; CYCLE; EXPRESSION; IRRADIATION; ANTIBODIES; SENESCENCE	p53 tumour suppressor protein levels and p53-dependent transcriptional activity have been recently shown to increase in cells treated with leptomycin B (LMB), an inhibitor of nuclear export. Experiments presented here show that LMB treatment leads to growth arrest and a senescence-like phenotype in human normal fibroblast cultures. This effect is reversible after removal of the drug and further passage by trypsinization. Instead, LMB has a strong cytotoxic effect on human neuroblastoma cell lines even at nanomolar concentrations. In both these cell types the effects of LMB are attenuated when the activity of the endogenous wild type p53 protein is abrogated by overexpression of a dominant negative p53 mutant. We conclude that the induction of the p53 response by LMB plays an important role in the effects of this drug on cultured cells.	Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, Dundee DD1 5EH, Scotland; Univ Dundee, Dept Anat & Physiol, CRC, Cell Struct Res Grp, Dundee DD1 5EH, Scotland; Masaryk Mem Canc Inst, Dept Cellular & Mol Oncol, Brno 65653, Czech Republic	University of Dundee; University of Dundee; Masaryk Memorial Cancer Institute	Lain, S (corresponding author), Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, MSI-WTB Complex, Dundee DD1 5EH, Scotland.		Lane, David P/C-4920-2008; Lain, Sonia/B-6980-2014	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; deLaat A, 1996, PHOTOCHEM PHOTOBIOL, V63, P492; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; JENNEY M, 1994, LANCET, V344, P210, DOI 10.1016/S0140-6736(94)92991-2; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Kuhnt M, 1998, APPL ENVIRON MICROB, V64, P714; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; LAIN S, IN PRESS EXP CELL RE; LEOPOLD WR, 1984, CANCER RES, V44, P1928; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Melino G, 1997, APOPTOSIS AND CANCER, P222; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Newlands ES, 1996, BRIT J CANCER, V74, P648, DOI 10.1038/bjc.1996.415; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Renzing J, 1996, J CELL SCI, V109, P1105; ROBERTS BJ, 1986, CANCER CHEMOTH PHARM, V16, P95; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SHAULIAN E, 1995, ONCOGENE, V10, P671; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TUNAC JB, 1985, J ANTIBIOT, V38, P460, DOI 10.7164/antibiotics.38.460; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Wynford-Thomas D, 1999, J PATHOL, V187, P100; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	40	71	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7378	7386		10.1038/sj.onc.1203260	http://dx.doi.org/10.1038/sj.onc.1203260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602494				2022-12-28	WOS:000084119400024
J	Li, H; Cao, Y; Berndt, MC; Funder, JW; Liu, JP				Li, H; Cao, Y; Berndt, MC; Funder, JW; Liu, JP			Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro	ONCOGENE			English	Article						telomerase reverse transcriptase (TERT); telomerase-associated protein 1 (TEP1); p53; telomerase inhibitory polypeptide 1 (TEIPP1); breast cancer cells	CATALYTIC SUBUNIT GENE; BREAST-CANCER CELLS; RNA COMPONENT; SPONTANEOUS IMMORTALIZATION; TETRAHYMENA TELOMERASE; REVERSE-TRANSCRIPTASE; MAMMALIAN TELOMERASE; MOUSE TELOMERASE; MUTANT P53; LIFE-SPAN	The telomere DNA polymerase (telomerase) and the tumor suppressor protein p53 are frequently associated with human cancers, and activation of telomerase and inactivation of p53 involved in cancer cell immortalization. In this report, we demonstrate a direct interaction of telomerase with p53 in the nuclear lysates of human breast cancer cells, and with recombinant human p53, by affinity chromatography and immunoprecipitation. On activity criteria, the interaction is between the carboxyl-terminal region of p53 and a region close to the amino-terminus of human telomerase-associated protein 1 (hTEP1). Incubation of recombinant p53 with nuclear telomerase extracts results in inhibition of telomerase activity, with the C-terminal region of p53 being essential for inhibition. This effect is not mediated by binding to telomerase substrate DNA, but requires the region near the N-terminus of hTEP1, in that a synthetic peptide derived from this region of hTEP1 similarly inhibits telomerase activity. Together, these in vitro interactions between telomerase and p53 suggest that the activity of telomerase may be regulated by p53, downregulation of which in turn would favor up-regulation of telomerase activity in cancer cell development.	Baker Med Res Inst, Mol Signalling Lab, Prahran, Vic 3181, Australia	Baker Heart and Diabetes Institute	Liu, JP (corresponding author), Baker Med Res Inst, Mol Signalling Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.		Berndt, Michael C/D-5580-2012; Liu, Jun-Ping/AAA-5521-2020	Liu, Jun-Ping/0000-0001-7442-2116				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOND JA, 1994, ONCOGENE, V9, P1885; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; de Lange T, 1998, NATURE, V392, P753, DOI 10.1038/33790; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gollahon LS, 1996, ONCOGENE, V12, P715; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Oren M, 1998, NATURE, V391, P233, DOI 10.1038/34551; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Takakura M, 1999, CANCER RES, V59, P551; Tsao DA, 1998, GENE, V221, P51, DOI 10.1016/S0378-1119(98)00432-6; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; WHITEHEAD RH, 1984, JNCI-J NATL CANCER I, V73, P643; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; WynfordThomas D, 1996, J PATHOL, V180, P118, DOI 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	58	69	89	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6785	6794		10.1038/sj.onc.1203061	http://dx.doi.org/10.1038/sj.onc.1203061			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597287				2022-12-28	WOS:000083792000021
J	Somasundaram, K; MacLachlan, TK; Burns, TF; Sgagias, M; Cowan, KH; Weber, BL; El-Deiry, WS				Somasundaram, K; MacLachlan, TK; Burns, TF; Sgagias, M; Cowan, KH; Weber, BL; El-Deiry, WS			BRCA1 signals ARF-dependent stabilization and coactivation of p53	ONCOGENE			English	Article						p53; BRCA1; p14(ARF)	CELL-CYCLE CONTROL; TUMOR-SUPPRESSOR; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; GENE BRCA1; DNA-DAMAGE; BREAST; EXPRESSION; APOPTOSIS; ARREST	The hereditary breast and ovarian tumor suppressor BRCA1 can activate p53-dependent gene expression. We show here that BRCA1 increases p53 protein levels through a post-transcriptional mechanism. BRCA1-stabilized p53 has increased sequence-specific DNA-binding and transcriptional activity, BRCA1 does not stabilize p53 in p14(ARF)-deficient cells. A deletion mutant of BRCA1 which inhibits p53-dependent transcription confers resistance to topoisomerase II-targeted chemotherapy, Our results suggest that BRCA1 may trigger the p53 pathway through two potentially separate mechanisms: accumulation of p53 through a direct or indirect induction of p14(ARF) as well as direct transcriptional coactivation of p53, BRCA1 may also enhance chemosensitivity and repair of DNA damage through binding to and coactivation of p53.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med & Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA; NCI, Med Branch, Bethesda, MD 20892 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, CRB 437A,415 Curie Blvd, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NATIONAL CANCER INSTITUTE [R01CA076417] Funding Source: NIH RePORTER; NCI NIH HHS [CA7641701] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; EASTON DF, 1995, AM J HUM GENET, V56, P265; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Garcia-Patino E, 1998, CANCER GENET CYTOGEN, V104, P119, DOI 10.1016/S0165-4608(97)00460-3; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Katayose D, 1995, CLIN CANCER RES, V1, P889; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	57	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6605	6614		10.1038/sj.onc.1203284	http://dx.doi.org/10.1038/sj.onc.1203284			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597265				2022-12-28	WOS:000083709200025
J	De Graeve, F; Bahr, A; Chatton, B; Kedinger, C				De Graeve, F; Bahr, A; Chatton, B; Kedinger, C			A murine ATFa-associated factor with transcriptional repressing activity	ONCOGENE			English	Article						transcription; repression; JunD; GTF; RNA polymerase	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; TBP-BINDING; EUKARYOTIC TRANSCRIPTION; MULTIPROTEIN COMPLEXES; ESTROGEN-RECEPTOR; MAMMALIAN-CELLS; IN-VIVO; DNA; FAMILY	The ATFa proteins, which are members of the CREB/ATF family of transcription factors, have previously been shown to interact with the adenovirus Ela oncoprotein and to mediate its transcriptional activity; they heterodimerize with Jun, Fos or related transcription factors, possibly altering their DNA-binding specificity; they also stably bind JNK2, a stress-induced protein kinase. Here we report the identification acid characterization of a novel protein isolated in a yeast two-hybrid screen using the N-terminal half of ATFa as a bait. This 1306-residue protein (mAM, for mouse ATFa-associated Modulator) is rather acidic (pHi 4.5) and contains high proportions of Ser/Thr (21%) and Pro (11%) residues. It colocalizes and interacts with ATFa in mammalian cells, contains a bipartite nuclear localization signal and possesses an ATPase activity. Transfection experiments show that mAM is able to downregulate transcriptional activity, in an ATPase-independent manner. Our results indicate that mAM interacts with several components of the basal transcription machinery (TFIIE and TFIIH), including RNAPII itself. Together, these findings suggest that mAM may be involved in the fine-tuning of ATFa-regulated gene expression, by interfering with the assembly or stability of specific preinitiation transcription complexes.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67400 Illkirch Graffenstaden, Communaute Urba, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chatton, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67400 Illkirch Graffenstaden, Communaute Urba, France.		CHATTON, Bruno/R-3813-2019	DE GRAEVE, Fabienne/0000-0002-3455-7507; CHATTON, Bruno/0000-0003-4515-7119				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Ashraf SI, 1998, CURR BIOL, V8, pR683, DOI 10.1016/S0960-9822(98)70435-X; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BERGER I, 1994, DNA CELL BIOL, V13, P249, DOI 10.1089/dna.1994.13.249; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bocco JL, 1996, ONCOGENE, V12, P1971; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHATURVEDI SK, 1994, NIMHANS J, V12, P9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen WB, 1999, CANCER LETT, V142, P43, DOI 10.1016/S0304-3835(99)00111-1; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; De Graeve F, 1999, ONCOGENE, V18, P3491, DOI 10.1038/sj.onc.1202723; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harlow E., 1988, ANTIBODIES LAB MANUA; Jensen RT, 1999, ANN ONCOL, V10, P170, DOI 10.1023/A:1008350517079; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MELLSTROM B, 1991, ONCOGENE, V6, P1959; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ohkuma Y, 1997, J BIOCHEM-TOKYO, V122, P481; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROY R, 1994, J BIOL CHEM, V269, P9826; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; TRATNER I, 1991, ONCOGENE, V6, P2049; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	71	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1807	1819		10.1038/sj.onc.1203492	http://dx.doi.org/10.1038/sj.onc.1203492			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777215				2022-12-28	WOS:000086292500009
J	Shennan, MG; Badin, AC; Walsh, S; Summers, A; From, L; McKenzie, M; Goldstein, AM; Tucker, MA; Hogg, D; Lassam, N				Shennan, MG; Badin, AC; Walsh, S; Summers, A; From, L; McKenzie, M; Goldstein, AM; Tucker, MA; Hogg, D; Lassam, N			Lack of germline CDK6 mutations in familial melanoma	ONCOGENE			English	Article						familial melanoma; CDK6	DEPENDENT KINASE CDK6; TUMOR-SUPPRESSOR; CYCLIN-D; P16; RETINOBLASTOMA; BINDING; P16(INK4A); PREVALENCE; INHIBITION; PROTEIN	Germline mutations in genes encoding several components of the retinoblastoma pathway have been linked with inherited predisposition to melanoma, Most commonly, such mutations involve CDKN2A, a cyclin-dependant kinase inhibitor of two kinases, CDK4 and CDK6, which phosphorylate the retinoblastoma protein (pRB) and thereby promote passage through the G(1)/S cell-cycle restriction point. Less frequently, germline mutations in the CDK4 gene have also been linked with an increased risk of melanoma, Despite the sequence and functional homology between CDK4 and CDK6, the role of germline mutations in CDK6 in melanoma predisposition is unknown. We detected no CDK6 mutations within the p16 (CDKN2A) binding domain in index cases from 60 melanoma-prone kindreds that lacked germline mutations in the coding regions of either CDKN2A or within the entire CDK4 coding region. We conclude that germline mutations in CDK6 do not make a significant contribution to melanoma predisposition.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; New York Gen Hosp, New York, NY USA; Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Dermatol, Toronto, ON, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON, Canada; NCI, Bethesda, MD 20892 USA	University of Toronto; University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lassam, N (corresponding author), Univ Toronto, Dept Med, Room 7360,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.		Tucker, Margaret A/B-4297-2015		NATIONAL CANCER INSTITUTE [ZIACP004410, Z01CP004410] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Ceha HM, 1998, BIOCHEM BIOPH RES CO, V249, P550, DOI 10.1006/bbrc.1998.9183; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Dracopoli NC, 1996, CANCER SURV, V26, P115; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; GOLDSTEIN AM, 1995, DERMATOL CLIN, V13, P605, DOI 10.1016/S0733-8635(18)30066-4; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KATO J, 1993, GENE DEV, V7, P331; LIU L, 1995, ONCOGENE, V11, P405; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; TRABOULSI EI, 1988, ARCH OPHTHALMOL-CHIC, V106, P1059; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	24	18	19	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1849	1852		10.1038/sj.onc.1203507	http://dx.doi.org/10.1038/sj.onc.1203507			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777219				2022-12-28	WOS:000086292500013
J	Dai, CY; Enders, GH				Dai, CY; Enders, GH			p16(INK4a) can initiate an autonomous senescence program	ONCOGENE			English	Article						p16(INK4a); senescence; tumor suppressor; retinoblastoma protein	HUMAN-DIPLOID FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; REPLICATIVE SENESCENCE; RETINOBLASTOMA-PROTEIN; CYCLE INHIBITION; P16 EXPRESSION; GROWTH; INACTIVATION; P53; INVOLVEMENT	The tumor suppressor p16(INK4a) is a potent mediator of cell cycle arrest in transient expression studies, is induced in senescing cells, and can impose morphological features of senescence, Nonetheless, it is unclear whether p16(INK4a) can block cell proliferation irreversibly. We explored this issue using osteogenic sarcoma cell clones with inducible p16(INK4a) expression. Induction of p16(INK4a) for 1 day arrested most cells in G1 phase. If the induction was then interrupted, p16(INK4a) levels returned to baseline and robust growth resumed within 3-5 days. When p16(INK4a) was induced for 6 days DNA synthesis remained strongly inhibited and the cells acquired morphological features of senescence. Moreover, if p16(INK4a) induction was interrupted at this point and the cells were followed for 12 more days, most cells retained these morphologic features and either failed to divide or died. This occurred despite the prompt return of p16(INK4a) expression and retinoblastoma protein phosphorylation toward baseline levels. In fact, some senescing cells appeared to enter S phase. These results demonstrate that a sustained period of p16(INK4a) expression is sufficient in this setting to impose a durable block to cell proliferation and that this state becomes independent of p16(INK4a) expression, hypophosphorylation of pRB, or a strict G1 arrest.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cell & Mol Biol Program, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Enders, GH (corresponding author), Penn GI Div, 600 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL CANCER INSTITUTE [K08CA061412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER; NCI NIH HHS [7-K08-CA61412] Funding Source: Medline; NIDDK NIH HHS [P30 DK50306] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM 07229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Asamoto M, 1998, CANCER LETT, V127, P9, DOI 10.1016/S0304-3835(97)00447-3; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Baylin SB, 1998, ADV CANCER RES, V72, P141; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Cohen JA, 1997, HUM PATHOL, V28, P893, DOI 10.1016/S0046-8177(97)90003-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erickson S, 1998, ONCOGENE, V17, P595, DOI 10.1038/sj.onc.1201965; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Geradts J, 1996, AM J PATHOL, V149, P15; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Higashi H, 1997, BIOCHEM BIOPH RES CO, V231, P743, DOI 10.1006/bbrc.1997.6181; Jarrard DF, 1999, CANCER RES, V59, P2957; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rossi FMV, 1998, NAT GENET, V20, P389, DOI 10.1038/3871; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Sayama K, 1999, J CELL PHYSIOL, V179, P40, DOI 10.1002/(SICI)1097-4652(199904)179:1<40::AID-JCP5>3.0.CO;2-Z; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139	37	119	120	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1613	1622		10.1038/sj.onc.1203438	http://dx.doi.org/10.1038/sj.onc.1203438			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763818				2022-12-28	WOS:000086083800001
J	Di Renzo, MF; Olivero, M; Martone, T; Maffe, A; Maggiora, P; De Stefani, A; Valente, G; Giordano, S; Cortesina, G; Comoglio, PM				Di Renzo, MF; Olivero, M; Martone, T; Maffe, A; Maggiora, P; De Stefani, A; Valente, G; Giordano, S; Cortesina, G; Comoglio, PM			Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas	ONCOGENE			English	Article						metastasis; carcinoma; missense mutations; somatic mutations; MET oncogene	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; C-MET; HGF RECEPTOR; MET/HGF RECEPTOR; INVASIVE-GROWTH; RENAL-CARCINOMA; MUTANT-ALLELE; PROTOONCOGENE; EXPRESSION	A metastatic cancer develops by accumulation of mutations in genes that control growth, survival and spreading. The latter genes have not yet been identified. In lymph node metastases of head and neck squamous cell carcinomas (HNSCC), we found mutations in the MET oncogene, which encodes the tyrosine kinase receptor for Scatter Factor, a cytokine that stimulates epithelial cell motility and invasiveness during embryogenesis and tissue remodeling. We identified two somatic mutations: the Y1230C, known as a MET germline mutation which predisposes to hereditary renal cell carcinoma, and the Y1235D that is novel and changes a critical tyrosine, known to regulate MET kinase activity. The mutated MET receptors are constitutively active and confer an invasive phenotype to transfected cells. Interestingly, cells carrying the MET mutations are selected during metastatic spread: transcripts of the mutant alleles are highly represented in metastases, but barely detectable in primary tumors. These data indicate that cells expressing mutant MET undergo clonal expansion during HNSCC progression and suggest that MET might be one of the long sought oncogenes controlling progression of primary cancers to metastasis.	Inst Canc Res & Treatment, IRCC, Canc Genet Lab, I-10060 Candiolo, Italy; Inst Canc Res & Treatment, IRCC, Div Mol Genet, I-10060 Candiolo, Italy; Univ Turin, Sch Med, Dept Biomed Sci, Otolaryngol Unit, I-10126 Turin, Italy; Amedeo Avogadro Univ, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Sch Med, Otolaryngol Unit, Dept Clin Physiopathol, I-10126 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Eastern Piedmont Amedeo Avogadro; University of Turin	Di Renzo, MF (corresponding author), Inst Canc Res & Treatment, IRCC, Canc Genet Lab, SP 142,Km 3-95, I-10060 Candiolo, Italy.		olivero, martina/J-4811-2018; Valente, Guido/B-9714-2013; Giordano, Silvia/J-9858-2018; MARTONE, Tiziana/AAD-2706-2022; Comoglio, Paolo/G-6323-2011; DI RENZO, Maria Flavia/B-6091-2012	olivero, martina/0000-0002-6815-3498; Giordano, Silvia/0000-0003-1854-1086; MARTONE, Tiziana/0000-0002-4019-6082; DI RENZO, Maria Flavia/0000-0002-5093-3373; Comoglio, Paolo/0000-0002-7056-5328				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Califano J, 1996, CANCER RES, V56, P2488; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; GALEAZZI E, 1997, EUR ARCH OTO-RHINO-L, V1, pS138; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; HASEGAWA Y, 1995, ONCOGENE, V10, P1441; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; LONGATI P, 1994, ONCOGENE, V9, P49; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; NALDINI L, 1991, ONCOGENE, V6, P501; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; Otsuka T, 1998, CANCER RES, V58, P5157; Park WS, 1999, CANCER RES, V59, P307; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sawatsubashi M, 1998, VIRCHOWS ARCH, V432, P331, DOI 10.1007/s004280050174; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Sonnenberg E, 1993, EXS, V65, P381; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; YAMASHITA J, 1994, CANCER RES, V54, P1630	44	284	291	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1547	1555		10.1038/sj.onc.1203455	http://dx.doi.org/10.1038/sj.onc.1203455			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734314				2022-12-28	WOS:000086108100007
J	Pandita, TK; Lieberman, HB; Lim, DS; Dhar, S; Zheng, W; Taya, Y; Kastan, MB				Pandita, TK; Lieberman, HB; Lim, DS; Dhar, S; Zheng, W; Taya, Y; Kastan, MB			Ionizing radiation activates the ATM kinase throughout the cell cycle	ONCOGENE			English	Article						ATM; p53; kinase activity; cell cycle	ATAXIA-TELANGIECTASIA CELLS; DNA-DAMAGE; CHECKPOINT PATHWAY; P53; PHOSPHORYLATION; GENE; PROTEIN; CANCER; REPAIR; REGION	The ATM protein kinase is a critical intermediate in a number of cellular responses to ionizing irradiation (IR) and possibly other stresses. ATM dysfunction results in abnormal checkpoint responses in multiple phases of the cell cycle, including ct, S and G2, Though downstream targets of the ATM kinase are still being elucidated. it has been demonstrated that ATM acts upstream of p53 in a signal transduction pathway initiated by IR and can phosphorylate p53 at serine 15. The cell cycle stage-specificity of ATM activation and p53Ser15 phosphorylation was investigated in normal lymphoblastoid cell line (GM536). Ionizing radiation was found to enhance the kinase activity of ATM in all phases of the cell cycle. This enhanced activity was apparent immediately after treatment of cells with IR, but was not accompanied by a change in the abundance of the ATM protein. Since IR activates the ATM kinase in all phases of the cell cycle, DNA replication-dependent strand breaks are not required for this activation. Further, since p53 protein is not directly required for IR-induced S and GZ-phase checkpoints, the ATM kinase likely has different functional targets in different phases of the cell cycle. These observations indicate that the ATM kinase is necessary primarily for the immediate response to DNA damage incurred in all phases of the cell cycle.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38205 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan	Columbia University; St Jude Children's Research Hospital; National Cancer Center - Japan	Pandita, TK (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020; Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555	NCI NIH HHS [CA71387] Funding Source: Medline; NIGMS NIH HHS [GM52493] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BRIDGES BA, 1982, ATAXIA TELANGIECTASI; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Maki CG, 1996, CANCER RES, V56, P2649; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Morgan SE, 1997, CANCER RES, V57, P3386; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401	25	128	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1386	1391		10.1038/sj.onc.1203444	http://dx.doi.org/10.1038/sj.onc.1203444			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723129				2022-12-28	WOS:000085942700003
J	Rubinstein, YR; Driggers, PH; Ogryzko, VV; Thornton, AM; Ozato, K; Pontzer, CH				Rubinstein, YR; Driggers, PH; Ogryzko, VV; Thornton, AM; Ozato, K; Pontzer, CH			An IFN regulatory factor-2 DNA-binding domain dominant negative mutant exhibits altered cell growth and gene expression	ONCOGENE			English	Article						interferon; interferon regulatory factor; cell growth	FACTOR-I IRF-1; TRANSCRIPTION FACTOR; PROTEIN-KINASE; INTERFERON SYSTEM; CYCLIN KINASES; INHIBITOR P21; DIFFERENTIATION; INDUCTION; ARREST; TRANSFORMATION	In order to study interferon regulatory factor (IRF) family mediation of cell growth regulation, we established U937 cell lines stably transfected with a truncated form of IRF-2 lacking the transcriptional repressor domain. The truncated IRF-2 contained the DNA binding domain (DBD) and bound the ISRE, Phenotypically, the IRF-2 DBD transfectants exhibited reduced cell growth, altered morphology and increased cell death, Consistent with alterations in growth characteristics, the IRF-2 DBD transfectants constitutively expressed higher levels of the cyclin dependent kinase inhibitor p21(WAF1/Cip1) than did control clones. The level of p21(WAF1/Cip1) expression was positively correlated with the level of DBD expressed, as well as with the level of growth inhibition in these clones, DBD expression also correlated with expression of other members of the growth regulatory complex, cyclin dependent kinase 2 and cyclin A, but not proliferating cell nuclear antigen. These results imply active repression by IRF-2 to keep p21(WAF1/Cip1) transcriptionally silent.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland College Park; Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Pontzer, CH (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301; Beretta L, 1996, ONCOGENE, V12, P1593; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARPER JW, 1993, CELL, V75, P805; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAMPHIER M, 1994, IMMUNOLOGIST, V2, P167; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SCHRODER FH, 1989, PROSTATE, P17; STEWART HJ, 1987, J ENDOCRINOL, V115, pR13, DOI 10.1677/joe.0.115R013; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Thornton AM, 1996, J IMMUNOL, V157, P5145; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	36	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1411	1418		10.1038/sj.onc.1203435	http://dx.doi.org/10.1038/sj.onc.1203435			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723132				2022-12-28	WOS:000085942700006
J	Li, ML; Lewis, B; Capuco, AV; Laucirica, R; Furth, PA				Li, ML; Lewis, B; Capuco, AV; Laucirica, R; Furth, PA			WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis	ONCOGENE			English	Article						breast carcinogenesis; mouse model; SV40TAg; apoptosis; proliferation	SV40 T-ANTIGEN; MAMMARY-GLAND INVOLUTION; CANCER FORMATION; APOPTOSIS; PATHWAYS; ANIMALS; DEATH	Understanding the process of carcinogenesis is key to developing therapies which might interrupt or reverse tumor onset and progression. Cell growth and death signals are dependent not only upon molecular mechanisms within a cell but also upon external stimuli such as hormones, cell-cell signaling, and extracellular matrix, Mouse models can be used to dissect these complex processes, to identify key signaling pathways operating at different stages of tumorigenesis, and to test the strength of specific interventions. In the WAP-TAg mouse model, carcinogenesis is initiated by expression of the Simian Virus 40 T antigen (TAg), TAg expression is triggered by hormonal stimulation, either during estrus or pregnancy. Breast adenocarcinomas (ranging from well to poorly differentiated) develop in 100% of the female mice by approximately 8-9 months of age, Three distinct stages of tumorigenesis are easily identified: an initial proliferation, hyperplasia; and adenocarcinoma. The mean time to first palpable tumor in mice which undergo at least one pregnancy is 6 months. The tumorigenic process is marked by a competition between proliferation and apoptosis and is characterized by cellular acquisition of genetic mutations and increased stromal fibrosis. Protein levels of cell cycle control genes cyclin D1, cdk2, and E2F-1 are increased in these adenocarcinomas. c-Fos protein levels are slightly increased in these cancers, while c-Jun levels do not change. Hormonal exposure alters progression, Estrogen plays a role during the early stages of oncogenesis although the growth of the resulting adenocarcinomas is estrogen-independent. Transient hormonal stimulation by glucocorticoids that temporarily increases the rate of cell proliferation results in tetraploidy, premature appearance of irreversible hyperplasia, and early tumor development. Tumor appearance also can be accelerated through over expression of the cell survival protein, Bcl-2, Bcl-2 over expression not only reduces apoptosis during the initial proliferative process but also decreases the total rate of cell proliferation. This block in cell proliferation is lost selectively as the cells transition to adenocarcinoma, The WAP-TAg model can be utilized to investigate how the basic processes of cell proliferation, apoptosis, DNA mutation, and DNA repair are modified by external and internal signals during mammary oncogenesis.	Univ Maryland, Sch Med,Inst Human Virol, Dept Med, Div Infect Dis, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA; ARS, Inst Livestock & Poultry Sci, USDA, Beltsville, MD 20705 USA; Baylor Coll Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; United States Department of Agriculture (USDA); Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; University System of Maryland; University of Maryland Baltimore	Furth, PA (corresponding author), Univ Maryland, Sch Med,Inst Human Virol, Dept Med, Div Infect Dis, 725 W Lombard St,Room N545, Baltimore, MD 21201 USA.				NCI NIH HHS [CA70545] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA070545] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DEMERIL D, 1996, CANCER, V77, P1494; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; HORAK E, 1991, ONCOGENE, V6, P2277; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; MEITZ JA, 1992, EMBO J, V11, P5013; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Newcomb PA, 1997, J MAMMARY GLAND BIOL, V2, P311, DOI 10.1023/A:1026344707161; Santarelli R, 1996, ONCOGENE, V12, P495; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Tzeng YJ, 1996, FEBS LETT, V380, P215, DOI 10.1016/0014-5793(96)00021-X; TZENG YJ, 1993, ONCOGENE, V8, P1965; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503	25	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1010	1019		10.1038/sj.onc.1203271	http://dx.doi.org/10.1038/sj.onc.1203271			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713684				2022-12-28	WOS:000085796400006
J	Vomachka, AJ; Pratt, SL; Lockefeer, JA; Horseman, ND				Vomachka, AJ; Pratt, SL; Lockefeer, JA; Horseman, ND			Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth	ONCOGENE			English	Article						breast cancer; polyoma virus; differentiation; Stat5 protein	SIGNAL-TRANSDUCTION PATHWAYS; BREAST-CANCER CELLS; PRL RECEPTOR; EXPRESSION; MICE; TRANSCRIPTION; PROTEINS; PHOSPHORYLATION; ACTIVATION; CARCINOMA	Prolactin (PRL), interacting with other hormones from the pituitary, gonad, and placenta, activates specific signals that drive the appropriately timed morphological and functional development of the mammary gland. A mouse model of isolated PRL deficiency (PRL-/-) was created by gene disruption in an effort to further understand the molecular basis of mammary gland development and breast cancer. Whereas primary ductal growth was normal in PRL-/- mice, ductal arborization was minimal (branches/mm(2) = 1.5+/-0.5), and lobular budding was absent. Replacement therapy with PBL injections stimulated a modest degree of lobular budding and ductal arborization (3.75+/-0.9). Pituitary transplants to the kidney capsule of PRL-/- mice restored lobular budding and ductal arborization, to the full extent of that seen in control animals (20.3+/-5.5). Pregnancy, established by mating progesterone-treated PRL-/- females with PRL-/- males, led to complete morphological development of the mammary gland, appropriate to the gestational stage. PRL treatment stimulated tyrosine phosphorylation and DNA binding activity of Stat5a, but not Stat1 in PRL-/- or PRL+/- females, and Stat5a, but not Stat1, was elevated by estradiol within 24 h, PRL-deficient mice were crossed with mice expressing a dominant oncogene (polyoma middle-T antigen driven by the MMTV promoter, PyVT mice). Palpable (1 mm(3)) tumors were detected an average of 9 days earlier in hormonally normal females (PRL+/-:PyVT) compared with littermates that were PRL-deficient (PRL-/-:PyVT). The growth rate of PyVT-induced tumors was 30% faster in PRL+/-, than in PRL-/- females.	Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Beaver Coll, Dept Biol, Glenside, PA 19038 USA	University System of Ohio; University of Cincinnati	Horseman, ND (corresponding author), 231 Bethesda Ave,ML 0576, Cincinnati, OH 45267 USA.							BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; FORSYTH IA, 1982, OXFORD REV REPROD, P47; Gao J, 1996, MOL ENDOCRINOL, V10, P847, DOI 10.1210/me.10.7.847; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GINSBURG E, 1995, CANCER RES, V55, P2591; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HASLAM S, 1998, J STEROID BIOCHEM, V31, P9; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu SY, 1997, TROP MED INT HEALTH, V2, P179, DOI 10.1046/j.1365-3156.1997.d01-242.x; LYONS WR, 1958, RECENT PROG HORM RES, V14, P219; NICOLL CS, 1974, HDB PHYSIOLOGY, V4, P253; ORMANDY CJ, 1992, DNA CELL BIOL, V11, P721, DOI 10.1089/dna.1992.11.721; SIDIS Y, 1994, ENDOCRINOLOGY, V134, P1979, DOI 10.1210/en.134.4.1979; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; SWANSON SM, 1994, CARCINOGENESIS, V15, P1341, DOI 10.1093/carcin/15.7.1341; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WELSCH CW, 1977, CANCER RES, V37, P951	29	81	81	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1077	1084		10.1038/sj.onc.1203348	http://dx.doi.org/10.1038/sj.onc.1203348			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713693				2022-12-28	WOS:000085796400015
J	Bahl, R; Arora, S; Nath, N; Mathur, M; Shukla, NK; Ralhan, R				Bahl, R; Arora, S; Nath, N; Mathur, M; Shukla, NK; Ralhan, R			Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer	ONCOGENE			English	Article						p21(waf1/cip1); cyclin-dependent kinase inhibitor; p53; esophageal squamous cell carcinomas	TUMOR-SUPPRESSOR GENE; CELL NUCLEAR ANTIGEN; C-TERMINAL REGION; DNA-REPLICATION; BINDING DOMAINS; P53 GENE; P21; EXPRESSION; PCNA; MUTATIONS	p21(waf1/cip1), an important regulator of the cell cycle, binds to PCNA and acts as a mediator of the growth suppressing and apoptosis promoting functions of p53. We report a hitherto unobserved polymorphism in the carboxy terminal domain (codon 149) of p21(waf1/cip1) gene, the domain encoding the PCNA binding motif, The codon 149 polymorphism (G (A) under bar T-->G (G) under bar T) was observed in 42 of 50 (84%) esophageal squamous cell carcinomas (ESCCs) and eight of 50 (16%) normal individuals, The resultant amino acid substitution from aspartate to glycine may have vital implication in PCNA mediated cell cycle regulation by p21(waf1/cip1). The second polymorphism at codon 31, involving a C-->A transversion at nucleotide 168 (AG (C) under bar-->AG (A) under bar) changing the amino acid from serine to arginine, was observed in 2/50 (4%) ESCCs at a relatively lower frequency in the Indian population than that reported in the West. No significant association was observed between p21(waf1/cip1) polymorphism at codon 149 and p21(waf1/cip1) protein expression in ESCC in this cohort of patients. Interestingly, the frequency of p21(waf1/cip1) variants (codon 149) in ESCCs (18 of 19 cases) with wild-type p53 was significantly higher than in tumors with p53 mutations, suggesting that this polymorphism affects the p53 pathway and may play an important role in esophageal tumorigenesis, Analysis of p21(waf1/cip1) expression in relation to p53 gene and protein status revealed its induction by p53-dependent as well as independent pathways in esophageal tumorigenesis.	All India Inst Med Sci, Dept Biochem, New Delhi 110029, India; All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; Inst Rotary Canc Hosp, All India Inst Med Sci, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; DR. B.R.A. Institute Rotary Cancer Hospital	Ralhan, R (corresponding author), All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.							AGARWAL S, 1998, ORAL ONCO EUR J CANC, V34, P1; Barbareschi M, 1996, BRIT J CANCER, V74, P208, DOI 10.1038/bjc.1996.339; Bukholm IK, 1997, INT J CANCER, V73, P38, DOI 10.1002/(SICI)1097-0215(19970926)73:1<38::AID-IJC7>3.0.CO;2-2; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEN J, 1995, NATURE, V375, P386; Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6; Elbendary AA, 1996, CLIN CANCER RES, V2, P1571; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Facher EA, 1997, CANCER, V79, P2424, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2424::AID-CNCR19>3.0.CO;2-T; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gaur D, 1997, CLIN CANCER RES, V3, P2129; GOUBIN F, 1995, ONCOGENE, V10, P2281; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Heinzel PA, 1996, INT J CANCER, V68, P420, DOI 10.1002/(SICI)1097-0215(19961115)68:4<420::AID-IJC3>3.0.CO;2-2; HUPPI K, 1994, ONCOGENE, V9, P3017; KOOPMANN J, 1995, BRIT J CANCER, V72, P1230, DOI 10.1038/bjc.1995.491; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Marchetti A, 1996, ONCOGENE, V12, P1319; MARCHETTI A, 1996, INT J ONCOL, V6, P187; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; Munoz N, 1996, CANC EPIDEMIOLOGY PR, P681; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NOTANI PN, 1988, E EPIDEMIOL COMM HLT, V187; RALHAN R, 1999, IN PRESS INT J CANC; SABIN LH, 1997, TNM CLASSIFICATIN MA; Sambrook J., 1989, MOL CLONING; Shimada Y, 1999, BRIT J CANCER, V80, P1281, DOI 10.1038/sj.bjc.6690499; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SIDDIQI MA, 1991, DIETARY SOURCES NNIT, P210; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P707; YU MC, 1988, CANCER RES, V48, P345	36	57	61	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					323	328		10.1038/sj.onc.1203325	http://dx.doi.org/10.1038/sj.onc.1203325			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656678				2022-12-28	WOS:000084873700001
J	Zegerman, P; Bannister, AJ; Kouzarides, T				Zegerman, P; Bannister, AJ; Kouzarides, T			The putative tumour suppressor Fus-2 is an N-acetyltransferase	ONCOGENE			English	Article						Fus-2; acetyltransferase; tumour suppressor	CELL LUNG-CANCER; HISTONE ACETYLTRANSFERASE; DELETION; YEAST; ACETYLATION; SUPERFAMILY; NAT2	Acetyltransferases are essential enzymes for a wide variety of cellular processes and mutations in acetyltransferase genes have been associated with the development of certain cancers. For this reason, we conducted a computerized sequence homology search for novel acetyltransferases. Here, we show that the putative tumour suppressor protein Fus-2 has homology to the catalytic domain of acetyltransferases. We demonstrate that Fus-2 can acetylate the N-terminus of proteins using a ping-pong mechanism and that it has a specificity for substrates. Consistent with other N-acetyltransferases, Fus-2 localizes to the cytoplasm, as shown by GFP-tag experiments, Since the Fus-2 gene maps to the chromosomal region 3p21.3, which contains at least one tumour suppressor gene, the N-acetyltransferase functions of Fus-2 may be relevant to its potential role in cancer.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Bannister, Andrew/0000-0002-6312-4436; Zegerman, Philip/0000-0002-5707-1083; Kouzarides, Tony/0000-0002-8918-4162				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; Cascorbi I, 1996, CANCER RES, V56, P3961; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HIBI K, 1992, ONCOGENE, V7, P445; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; JORNVALL H, 1980, FEBS LETT, V111, P214, DOI 10.1016/0014-5793(80)80796-4; KOK K, 1994, CANCER RES, V54, P4183; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WONG LJ, 1983, BIOCHEMISTRY-US, V42, P4637; Zenser TV, 1996, CANCER RES, V56, P3941	18	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					161	163		10.1038/sj.onc.1203234	http://dx.doi.org/10.1038/sj.onc.1203234			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644992				2022-12-28	WOS:000084844300019
J	Macho, A; Calzado, MA; Jimenez-Reina, L; Ceballos, E; Leon, J; Munoz, E				Macho, A; Calzado, MA; Jimenez-Reina, L; Ceballos, E; Leon, J; Munoz, E			Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms	ONCOGENE			English	Article						Tat; apoptosis; Bcr-abl; CPP32; mitochondria	MITOCHONDRIAL-PERMEABILITY-TRANSITION; HIV-INFECTED PERSONS; CERAMIDE-INDUCED APOPTOSIS; NF-KAPPA-B; T-CELLS; CYTOCHROME-C; TAT PROTEIN; PROGRAMMED DEATH; LYMPH-NODES; ACTIVATION	The effects of HIV-1 Tat protein on mitochondria membrane permeability and apoptosis were analysed in lymphoid cells. In this report we show that stable-transfected HIV-Tat cells are primed to undergo apoptosis upon serum withdrawal. This effect was observed in both the Jhan T cell line and the K562 cells, the latter expressing the bcr-abl chimeric gene, which confers resistance to apoptosis induced by different stimuli. Using a cytofluorimetric approach we have determined that serum withdrawal induces a disruption of the transmembrane mitochondrial potential (Delta psi(m)) followed bq an increase of reactive oxygen species (ROS) and the subsequent DNA nuclear loss in K562-Tat cells but not in the K562-pcDNA cell line. These pre-apoptotic events were associated with the cleavage of the caspase-3, while the expression of Bcl-2, Bcl-X-L and Bas proteins was not affected by the presence of Tat, Regardless of the steady state of the Bar protein, we found that in both K562 and K562-Tat cells, this protein is located in the nucleus, but after serum withdrawal its localization was mainly in the cytoplasm, The activity of caspase-3 detected in K562-Tat cells after serum withdrawal paralleled with the mitochondria permeability transition. Nevertheless, in Jhan-Tat cells the inhibition of this caspase with the specific inhibitor, z-DEVD-cmk, did not affect the disruption of the mitochondria potential induced by serum withdrawal. Interestingly, ae found that HIV-Tat protein accumulates at the mitochondria in the K562-Tat cells cultured under low serum conditions, and this mitochondrial localization correlated with the Delta psi(m) disruption detected in these cells. In addition, HIV-Tat protein synergies with protoporphyrin IX (PPIX), a ligand of the mitochondrial benzodiazepine receptor, in the induction of apoptosis in both Jhan and K562 cells. Thus, HIV-1 Tat protein may induce apoptosis by a mechanism that involves mitochondrial PT and may contribute to the lymphocyte depletion seen in AIDS patients.	Univ Cordoba, Fac Med, Dept Fisiol & Inmunol, E-14071 Cordoba, Spain	Universidad de Cordoba	Munoz, E (corresponding author), Univ Cordoba, Fac Med, Dept Fisiol & Inmunol, Avda Menendez Pidal S-N, E-14071 Cordoba, Spain.		Munoz, Eduardo/I-5225-2012; Quirós, Antonio Macho/H-1403-2012; Calzado, Marco A./S-2295-2019; Leon, Javier/K-4615-2014; Calzado, Marco/E-9046-2016	Munoz, Eduardo/0000-0001-8478-5842; Quirós, Antonio Macho/0000-0002-9294-8709; Calzado, Marco A./0000-0002-5338-535X; Calzado, Marco/0000-0002-5338-535X; Jimenez Reina, Luis/0000-0003-4434-7308; Leon, Javier/0000-0001-5803-0112				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gougeon ML, 1996, J IMMUNOL, V156, P3509; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Herbein G, 1998, J VIROL, V72, P660, DOI 10.1128/JVI.72.1.660-670.1998; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kim CN, 1997, CANCER RES, V57, P3115; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; LEWIS DE, 1994, J IMMUNOL, V153, P412; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Macho A, 1998, CELL GROWTH DIFFER, V9, P277; MACHO A, 1995, BLOOD, V86, P2481; Macho A, 1997, J IMMUNOL, V158, P4612; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCloskey TW, 1997, J IMMUNOL, V158, P1014; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MEYAARD L, 1994, J CLIN INVEST, V93, P982, DOI 10.1172/JCI117105; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Munoz E, 1997, BIOCHEM J, V325, P23, DOI 10.1042/bj3250023; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Nishita M, 1998, EXP CELL RES, V244, P357, DOI 10.1006/excr.1998.4203; Patki AH, 1996, CELL IMMUNOL, V169, P40, DOI 10.1006/cimm.1996.0088; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; ROTHWELL NJ, 1983, BIOSCIENCE REP, V3, P217, DOI 10.1007/BF01122453; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Sastry KJ, 1996, ONCOGENE, V13, P487; Slater AFG, 1996, CELL DEATH DIFFER, V3, P57; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tuosto L, 1995, EUR J IMMUNOL, V25, P2907, DOI 10.1002/eji.1830251030; Wadia JS, 1998, J NEUROSCI, V18, P932; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zauli G, 1996, J IMMUNOL, V157, P2216; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	66	57	57	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7543	7551		10.1038/sj.onc.1203095	http://dx.doi.org/10.1038/sj.onc.1203095			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602513				2022-12-28	WOS:000084119600015
J	Gilmore, TD				Gilmore, TD			Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel	ONCOGENE			English	Review						v-Rel; Rel; NF-kappa B; malignant transformation; transcription factor; retroviral oncogene	VIRUS-STRAIN-T; NF-KAPPA-B; AVIAN RETICULOENDOTHELIOSIS VIRUS; CHICKEN SPLEEN-CELLS; TRANSFORMED LYMPHOID-CELLS; RECEPTOR FUSION PROTEIN; BONE-MARROW CELLS; C-REL; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION	The avian Rev-T retrovirus encodes the v-Rel oncoprotein, which is a member of the Rel/NF-kappa B transcription factor family. v-Rel induces a rapidly fatal lymphoma/leukemia in young birds, and v-Rel can transform and immortalize a variety of avian cell types irt vitro. Although Rel/NF-kappa B transcription factors have been associated with oncogenesis in mammals, v-Rel is the only member of this family that is frankly oncogenic in animal model systems. The potent oncogenicity of v-Rel is the consequence of a number of mutations that have altered its activity and regulation: for example, certain mutations decrease its ability to be regulated by I kappa B alpha, change its DNA-binding site specificity, and endow it with new transactivation properties. The study of v-Rel will continue to increase our knowledge of how cellular Rel proteins contribute to oncogenesis by affecting cell growth, altering cell-cycle regulation, and blocking apoptosis, This review will discuss biological and molecular activities of v-Rel, with particular attention to how these activities relate to structure-function aspects of the Rel/NF-kappa B transcription factors.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARBACID M, 1979, J VIROL, V30, P508, DOI 10.1128/JVI.30.2.508-514.1979; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BARKETT M, 1999, UNPUB ONCOGENE; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BENATAR T, 1992, P NATL ACAD SCI USA, V89, P7615, DOI 10.1073/pnas.89.16.7615; BENATAR T, 1991, EUR J IMMUNOL, V21, P2529, DOI 10.1002/eji.1830211033; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHARMAN HP, 1979, J VIROL, V29, P1221, DOI 10.1128/JVI.29.3.1221-1225.1979; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen E, 1998, J BIOL CHEM, V273, P35201, DOI 10.1074/jbc.273.52.35201; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; CHEN ISY, 1982, CELL, V31, P111, DOI 10.1016/0092-8674(82)90410-X; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; CHEN L, 1988, P NATL ACAD SCI USA, V85, P549, DOI 10.1073/pnas.85.2.549; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; Enrietto P J, 1990, Semin Cancer Biol, V1, P399; EPINAT JC, 1999, IN PRESS ONCOGENE; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; Fujii M, 1996, ONCOGENE, V12, P2193; Fujii Masahiro, 1997, Leukemia (Basingstoke), V11, P402; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARRY RF, 1981, VIROLOGY, V113, P403, DOI 10.1016/0042-6822(81)90167-7; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GARSON K, 1990, ONCOGENE, V5, P1431; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; Gilmore TD, 1996, ONCOGENE, V13, P1367; GILMORE TD, 1995, DNA PROVIRUS, P109; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1991, Critical Reviews in Oncogenesis, V2, P293; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; HODGSON J, 1995, J VIROL, V69, P1971, DOI 10.1128/JVI.69.3.1971-1979.1995; HOELZER JD, 1979, VIROLOGY, V93, P20, DOI 10.1016/0042-6822(79)90272-1; HOEZLER JD, 1980, VIROLOGY, V100, P462; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HU SSF, 1981, J VIROL, V37, P899, DOI 10.1128/JVI.37.3.899-907.1981; HUNTER E, 1978, P NATL ACAD SCI USA, V75, P2708, DOI 10.1073/pnas.75.6.2708; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INUZUKA M, 1994, ONCOGENE, V9, P133; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KABRUN N, 1994, SEMIN CANCER BIOL, V5, P103; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KELLER LH, 1979, INFECT IMMUN, V25, P694, DOI 10.1128/IAI.25.2.694-701.1979; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; KOCHEL T, 1992, ONCOGENE, V7, P567; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LAROSE RN, 1965, AVIAN DIS, V9, P604, DOI 10.2307/1588144; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lee RM, 1999, GENE DEV, V13, P718, DOI 10.1101/gad.13.6.718; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; MALDONADO RL, 1971, J VIROL, V8, P813, DOI 10.1128/JVI.8.5.813-815.1971; MARMOR MD, 1993, J EXP MED, V177, P647, DOI 10.1084/jem.177.3.647; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MILLER CK, 1988, J VIROL, V62, P1219, DOI 10.1128/JVI.62.4.1219-1226.1988; MILLER CK, 1986, J VIROL, V58, P75, DOI 10.1128/JVI.58.1.75-80.1986; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1988, MUTAT RES, V195, P79, DOI 10.1016/0165-1110(88)90016-4; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; MOSIALOS G, 1993, THESIS BOSTON U; MUSSMAN HC, 1971, AVIAN DIS, V15, P483, DOI 10.2307/1588725; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NOORIDALOII MR, 1981, NATURE, V294, P574, DOI 10.1038/294574a0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OLSON LD, 1967, AM J VET RES, V28, P1501; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PENTRENKO O, 1997, ONCOGENE, V15, P1671; PETERSON DA, 1971, AVIAN DIS, V15, P874, DOI 10.2307/1588878; PETRENKO O, 1995, GENE, V160, P305, DOI 10.1016/0378-1119(95)00210-W; PURCHASE HG, 1973, J NATL CANCER I, V51, P489; PURCHASE HG, 1975, CURR TOP MICROBIOL, P103; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1982, J VIROL, V42, P237, DOI 10.1128/JVI.42.1.237-252.1982; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; RUP BJ, 1979, J IMMUNOL, V123, P1362; Sachdev S, 1997, ONCOGENE, V14, P2585, DOI 10.1038/sj.onc.1201108; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SARKAR S, 1993, ONCOGENE, V8, P2245; SASAKI T, 1989, AVIAN PATHOL, V18, P307, DOI 10.1080/03079458908418604; SCHAT KA, 1992, AVIAN DIS, V36, P432, DOI 10.2307/1591524; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SEVOIAN M, 1964, AVIAN DIS, V8, P336, DOI 10.2307/1587964; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SIF S, 1993, ONCOGENE, V8, P2501; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SMARDOVA J, 1995, ONCOGENE, V10, P2017; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STORMS RW, 1992, VIROLOGY, V188, P765, DOI 10.1016/0042-6822(92)90531-S; SWIFT RA, 1985, J VIROL, V54, P869, DOI 10.1128/JVI.54.3.869-872.1985; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TAYLOR HW, 1971, AVIAN DIS, V15, P629, DOI 10.2307/1588849; TAYLOR HW, 1973, AVIAN DIS, V17, P794, DOI 10.2307/1589047; TAYLOR HW, 1973, AVIAN DIS, V17, P782, DOI 10.2307/1589046; TAYLOR HW, 1972, AVIAN DIS, V16, P330, DOI 10.2307/1588797; TEMIN HM, 1990, CELLULAR MOL BIOL HU, P175; THEILEN GH, 1996, J NATL CANCER I, V37, P731; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; TUNG HYL, 1988, BIOCHEM BIOPH RES CO, V152, P441; Walker AK, 1996, ONCOGENE, V12, P2515; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WITTER RL, 1981, AVIAN DIS, V25, P374, DOI 10.2307/1589930; WITTER RL, 1979, INT J CANCER, V23, P673, DOI 10.1002/ijc.2910230513; WITTER RL, 1979, INFECT IMMUN, V26, P90, DOI 10.1128/IAI.26.1.90-98.1979; WONG TC, 1981, VIROLOGY, V111, P289, DOI 10.1016/0042-6822(81)90674-7; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Xu X, 1997, ONCOGENE, V14, P1521, DOI 10.1038/sj.onc.1200985; XU X, 1995, VIROLOGY, V207, P362, DOI 10.1006/viro.1995.1095; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806; ZHANG J, 1989, MOL CELL BIOL, V9, P4970, DOI 10.1128/MCB.9.11.4970; ZHANG J, 1991, VIROLOGY, V183, P457, DOI 10.1016/0042-6822(91)90975-H; ZHAO MK, 1999, IN PRESS GENE EXPRES; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zong WX, 1997, ONCOGENE, V15, P971, DOI 10.1038/sj.onc.1201266; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	176	153	155	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	1999	18	49					6925	6937		10.1038/sj.onc.1203222	http://dx.doi.org/10.1038/sj.onc.1203222			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602467				2022-12-28	WOS:000083896500009
J	Kiley, SC; Clark, KJ; Duddy, SK; Welch, DR; Jaken, S				Kiley, SC; Clark, KJ; Duddy, SK; Welch, DR; Jaken, S			Increased protein kinase C delta in mammary tumor cells: relationship to transformation and metastatic progression	ONCOGENE			English	Article						protein kinase C; metastasis; adducin; mammary; breast cancer	TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CHO CELLS; ACTIVATION; EXPRESSION; EPSILON; DOMAINS; GROWTH; ALPHA; BINDING	Relatively little is known about the molecular mechanisms of tumor promotion/progression in mammary carcinogenesis. Increased protein kinase C (PKC) activity is known to promote tumor formation in several tissues; however, its role in mammary carcinogenesis is not yet known. To determine if individual PKCs may selectively regulate properties of mammary tumor cells, we compared PKC isozyme levels in mammary tumor cell lines,vith low, moderate and high metastatic potential. All three cell lines expressed alpha, delta, epsilon and zeta PKCs; however, PKC delta levels were relatively increased in the highly metastatic cells. To determine if increased PKC delta could contribute to promotion/progression, we overexpressed PKC delta in the low and moderately metastatic cell lines, PKC delta overexpression had no significant effect on growth of adherent cells, but significantly increased anchorage-independent growth. Conversely, expressing the regulatory domain of PKC delta (RD delta), a putative PKC delta inhibitory fragment, inhibited anchorage-independent growth. The efficacy of RD delta as a PKC delta inhibitor was demonstrated by showing that RD delta selectively interfered with PKC delta subcellular location and significantly interfered with phosphorylation of the PKC cytoskeletal substrate, adducin, PKC-dependent phosphorylation of cytoskeletal substrate proteins, such as adducin, provides a mechanistic link between increased PKC delta activity and phenotypic changes in cytoskeletal-dependent processes such as migration and attachment, two processes that are relevant to metastatic potential. The reciprocal growth effects of expressing PKC delta and RD delta as gain and loss of function constructs, respectively, provide strong evidence that PKC delta regulates processes important for anchorage-independent growth in these mammary tumor cells.	Adirondack Biomed Res Inst Inc, Lake Placid, NY 12946 USA; Penn State Univ, Coll Med, Jake Gittlen Canc Res Inst C7810, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Jaken, S (corresponding author), Univ Vermont, Dept Pathol, Med Alumni Bldg,A249, Burlington, VT 05405 USA.		Welch, Danny R/B-7310-2009	Welch, Danny R/0000-0002-1951-4947	NCI NIH HHS [CA 071604] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; CACACE AM, 1993, ONCOGENE, V8, P2095; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JAKEN S, 1997, PROTEIN KINASE C, P179; KAHN SM, 1994, CARCINOGENESIS, V15, P2915; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; Kiley SC, 1999, CANCER RES, V59, P3230; LEACH KL, 1988, J BIOL CHEM, V263, P13223; Li WQ, 1996, ONCOGENE, V13, P731; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, FASEB J, V12, P35; NERI A, 1982, J NATL CANCER I, V68, P507; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; VAUX DL, 1993, MOL CELL BIOL, V13, P7000, DOI 10.1128/MCB.13.11.7000; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WAYS DK, 1992, J BIOL CHEM, V267, P4799; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; WEINSTEIN IB, 1979, J SUPRAMOLECULAR STR, V12, P527; WELCH DR, 1983, INVAS METAST, V3, P65; Wu SL, 1998, J BIOL CHEM, V273, P1130, DOI 10.1074/jbc.273.2.1130; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	41	93	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6748	6757		10.1038/sj.onc.1203101	http://dx.doi.org/10.1038/sj.onc.1203101			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597283				2022-12-28	WOS:000083792000017
J	McKay, LM; Carpenter, B; Roberts, SGE				McKay, LM; Carpenter, B; Roberts, SGE			Regulation of the Wilms' tumour suppressor protein transcriptional activation domain	ONCOGENE			English	Article						Wilms' tumour; WT1; transcription	DNA-BINDING SPECIFICITY; GENE-PRODUCT; REPRESSES TRANSCRIPTION; INHIBITOR DOMAIN; SELF-ASSOCIATION; MUTANT PROTEINS; WT1; RNA; EXPRESSION; INTERACTS	The Wilms' tumour suppressor protein WT1 contains a transcriptional regulatory domain that can either activate or repress transcription depending upon its cellular environment. The mechanistic basis for this dichotomy is unclear however. Here, we dissect the transcriptional regulatory domains of WT1. We find that a region within the domain of WT1 attributed to transcriptional repression is a potent suppressor of the activation domain at several promoters and in different cell types. In vitro transcription analysis suggests that the mechanism of suppression of the activation domain occurs at the level of transcription initiation. Furthermore we find that the WT1 suppression domain is able to inhibit a heterologous activation domain when fused in cis. Dissection of this domain resulted in the delineation of a 30 amino acid region that was sufficient to confer suppression of a transcriptional activation domain both in vivo and in vitro. Additionally, we find that the WT1 transcriptional activation domain interacts with the general transcription factor TFIIB and that this interaction is not affected by the suppression domain. Taken together, these studies suggest that the suppression domain of WT1 interacts with a cosuppressor protein to mediate inhibition of the WT1 transcriptional activation domain.	Univ Dundee, Dept Biochem, Div Gene Express, Dundee DD1 5EH, Scotland	University of Dundee	Roberts, SGE (corresponding author), Univ Dundee, Dept Biochem, Div Gene Express, Dundee DD1 5EH, Scotland.		Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365	Wellcome Trust Funding Source: Medline; Worldwide Cancer Research [02-0275] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission); Worldwide Cancer Research		AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; Bardeesy N, 1998, NUCLEIC ACIDS RES, V26, P1784, DOI 10.1093/nar/26.7.1784; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Cook DM, 1996, ONCOGENE, V13, P1789; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; JAYARAMAN PS, 1994, EMBO J, V13, P2192, DOI 10.1002/j.1460-2075.1994.tb06496.x; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Johnstone RW, 1998, J BIOL CHEM, V273, P10880, DOI 10.1074/jbc.273.18.10880; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; KENT J, 1995, ONCOGENE, V11, P1781; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Liu YZ, 1998, NUCLEIC ACIDS RES, V26, P2464, DOI 10.1093/nar/26.10.2464; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Renshaw J, 1997, GENE CHROMOSOME CANC, V19, P256, DOI 10.1002/(SICI)1098-2264(199708)19:4<256::AID-GCC8>3.0.CO;2-W; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; UM M, 1995, MOL CELL BIOL, V15, P5007; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243	50	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6546	6554		10.1038/sj.onc.1203046	http://dx.doi.org/10.1038/sj.onc.1203046			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597258				2022-12-28	WOS:000083709200018
J	Sadot, E; Simcha, I; Iwai, K; Ciechanover, A; Geiger, B; Ben-Ze'ev, A				Sadot, E; Simcha, I; Iwai, K; Ciechanover, A; Geiger, B; Ben-Ze'ev, A			Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system	ONCOGENE			English	Article						beta-catenin; plakoglobin; beta-TrCP; ubiquitination	GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; WNT SIGNALING PATHWAY; CELL-CELL ADHESION; XENOPUS EMBRYOS; AXIS FORMATION; E-CADHERIN; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; ALPHA-CATENIN	beta-Catenin and plakoglobin are closely related armadillo family proteins with shared and distinct properties; Both are associated with cadherins in actin-containing adherens junctions. Plakoglobin is also found in desmosomes where it anchors intermediate filaments to the desmosomal plaques. beta-Catenin, on the other hand, is a component of the Wnt signaling pathway, which is involved in embryonic morphogenesis and tumorigenesis. A key step in the regulation of this pathway involves modulation of beta-catenin stability. A multiprotein complex, regulated by Wnt, directs the phosphorylation of beta-catenin and its degradation by the ubiquitin-proteasome system. Plakoglobin can also associate with members of this complex, but inhibition of proteasomal degradation has little effect on its levels while dramatically increasing the levels of beta-catenin. beta-TrCP, an F-box protein of the SCF E3 ubiquitin ligase complex, was recently shown to play a role in the turnover of beta-catenin. To elucidate the basis for the apparent differences in the turnover of beta-catenin and plakoglobin we compared the handling of these two proteins by the ubiquitin-proteasome system. We show here that a deletion mutant of beta-TrCP, lacking the F-box, can stabilize the endogenous beta-catenin leading to its nuclear translocation and induction of beta-catenin/LEF-1-directed transcription, without affecting the levels of plakoglobin. However, when plakoglobin was overexpressed, it readily associated with beta-TrCP, efficiently competed with beta-catenin for binding to beta-TrCP and became polyubiquitinated. Fractionation studies revealed that about 85% of plakoglobin in 293 cells, is Triton X-100-insoluble compared to 50% of beta-catenin. These results suggest that while both plakoglobin and beta-catenin can comparably interact with beta-TrCP and the ubiquitination system, the sequestration of plakoglobin by the membrane-cytoskeleton system renders it inaccessible to the proteolytic machinery and stabilizes it.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Kyoto Univ, Dept Mol & Syst Biol, Sakyo Ku, Kyoto 6068501, Japan; Technion Israel Inst Technol, Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Inst Res Med Sci, IL-31096 Haifa, Israel	Weizmann Institute of Science; Kyoto University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		IWAI, KAZUHIRO/GSN-7385-2022; Ciechanover, Aaron J/C-9166-2017	ben-ze'ev, avri/0000-0001-6113-3921; Iwai, Kazuhiro/0000-0001-5620-5951				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ABERLE H, 1995, P NATL ACAD SCI USA, V92, P6384, DOI 10.1073/pnas.92.14.6384; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; KAM Z, 1993, BIOIMAGING, V1, P71; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Klymkowsky MW, 1999, MOL BIOL CELL, V10, P3151, DOI 10.1091/mbc.10.10.3151; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Kofron M, 1997, DEVELOPMENT, V124, P1553; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Miyoshi Y, 1998, ONCOL RES, V10, P591; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAVARRO P, 1993, J CELL SCI, V105, P923; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Palacios J, 1998, CANCER RES, V58, P1344; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; PEIFER M, 1993, DEVELOPMENT, P163; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; SOMMERS CL, 1994, CANCER RES, V54, P3544; Sparks AB, 1998, CANCER RES, V58, P1130; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2; Zurawel RH, 1998, CANCER RES, V58, P896	88	60	60	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					1992	2001		10.1038/sj.onc.1203519	http://dx.doi.org/10.1038/sj.onc.1203519			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803460				2022-12-28	WOS:000086613200003
J	Xu, XL; Brodie, SG; Yang, X; Im, YH; Parks, WT; Chen, L; Zhou, YX; Weinstein, M; Kim, SJ; Deng, CX				Xu, XL; Brodie, SG; Yang, X; Im, YH; Parks, WT; Chen, L; Zhou, YX; Weinstein, M; Kim, SJ; Deng, CX			Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice	ONCOGENE			English	Article						Smad4; Dpc4; juvenile polyposis; gastric cancer; TGF beta 1; cyclin D1	GROWTH-FACTOR-BETA; CYCLIN D1; TGF-BETA; JUVENILE POLYPOSIS; COLORECTAL-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; HELICOBACTER-FELIS; CHROMOSOME 18Q21.1; MESODERM INDUCTION; EPITHELIAL-CELLS	The tumor suppressor SMAD4, also known as DPC4, deleted in pancreatic cancer, is a central mediator of TGF-P signaling. It was previously shown that mice homozygous for a null mutation of Smad4 (Smad4(-/-)) died prior to gastrulation displaying impaired extra-embryonic membrane formation and endoderm differentiation. Here we show that Smad4(+/-) mice began to develop polyposis in the fundus and antrum when they were over 6-12 months old, and in the duodenum and cecum in older animals at a lower frequency, With increasing age, polyps in the antrum show sequential changes from hyperplasia, to dysplasia, in-situ carcinoma, and finally invasion. These alterations are initiated by a dramatic expansion of the gastric epithelium where Smad4 is expressed. However, loss of the remaining Smad4 wild-type allele was detected only in later stages of tumor progression, suggesting that haploinsufficiency of Smad4 is sufficient for tumor initiation. Our data also showed that overexpression of TGF-beta 1 and Cyclin D1 was associated with increased proliferation of gastric polyps and tumors. These studies demonstrate that Smad4 functions as a tumor suppressor in the gastrointestinal tract and also provide a valuable model for screening factors that promote or prevent gastric tumorigenesis.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NCI, Cell Regulat & Carcinogenesis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016; XIAO, YANG/GPW-5529-2022	Parks, W. Tony/0000-0001-7341-3277; Yang, Xiao/0000-0002-0298-9831	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chang H, 1999, DEVELOPMENT, V126, P1631; CORREA P, 1992, CANCER RES, V52, P6735; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fox JG, 1997, CANCER RES, V57, P3972; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; Friedl W, 1999, GENE CHROMOSOME CANC, V25, P403, DOI 10.1002/(SICI)1098-2264(199908)25:4<403::AID-GCC15>3.3.CO;2-G; Grady WM, 1999, CANCER RES, V59, P320; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 1998, AM J HUM GENET, V62, P1129, DOI 10.1086/301840; ITO M, 1992, CANCER RES, V52, P295; JARVINEN H, 1984, GUT, V25, P792, DOI 10.1136/gut.25.7.792; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Moss SF, 1998, ALIMENT PHARM THER, V12, P91, DOI 10.1111/j.1365-2036.1998.00002.x; MYEROFF LL, 1995, CANCER RES, V55, P5545; Naef M, 1997, INT J CANCER, V71, P131; Nagatake M, 1996, CANCER RES, V56, P2718; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; OSWALD F, 1994, ONCOGENE, V9, P2029; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHULZE A, 1994, ONCOGENE, V9, P3475; Schutte M, 1996, CANCER RES, V56, P2527; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; TAHARA E, 1995, WORLD J SURG, V19, P484, DOI 10.1007/BF00294705; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Yamamoto M, 1996, CANCER-AM CANCER SOC, V77, P1628, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1628::AID-CNCR31>3.3.CO;2-Z; Yang HK, 1999, ONCOGENE, V18, P2213, DOI 10.1038/sj.onc.1202535; Yang X, 1999, DEVELOPMENT, V126, P1571; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; YOSHIDA K, 1989, INT J CANCER, V44, P394, DOI 10.1002/ijc.2910440303; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	48	179	199	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1868	1874		10.1038/sj.onc.1203504	http://dx.doi.org/10.1038/sj.onc.1203504			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773876				2022-12-28	WOS:000086424300002
J	Wang, T; Hopkins, D; Schmidt, C; Silva, S; Houghton, R; Takita, H; Repasky, E; Reed, SG				Wang, T; Hopkins, D; Schmidt, C; Silva, S; Houghton, R; Takita, H; Repasky, E; Reed, SG			Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis	ONCOGENE			English	Article						lung squamous cell carcinoma (LSCC); microarray; cDNA subtraction; connexin 26; plakophilin 1; keratin	PROLINE-RICH PROTEIN; CANCER; PEPTIDE; TUMORS; P53; BREAST; TISSUE; LINES; ATM	In order to develop effective vaccine products against human cancer, we are interested in identifying genes over-expressed in tumor cells. Through a combination of cDNA library subtraction and microarray technology, we identified seventeen genes preferentially expressed in lung squamous cell carcinoma, including four novel genes. To date, expression profiles of these genes were confirmed by Northern and/or real-time analysis, and several genes were also found to be expressed in head and neck squamous tumors. Thus, these combined methods represent a high throughput approach for identifying tumor specific genes. Furthermore, the report of characterization on these genes will allow them to be exploited for their diagnostic, prognostic, and therapeutic potentials including immunotherapy and antibody based anticancer therapy.	Corixa Corp, Dept Tumor Antigen Discovery, Seattle, WA 98104 USA; Roswell Pk Canc Ctr, Dept Surg, Buffalo, NY 14263 USA; Roswell Pk Canc Ctr, Dept Immunol, Buffalo, NY 14263 USA	Corixa; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Wang, T (corresponding author), Corixa Corp, Dept Tumor Antigen Discovery, 1124 Columbia St, Seattle, WA 98104 USA.							AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Brechot JM, 1997, EUR J CANCER, V33, P385, DOI 10.1016/S0959-8049(97)89010-7; Davidson LA, 1996, J PATHOL, V178, P398; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Hibi K, 1998, CANCER RES, V58, P5690; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu R, 1998, LUNG CANCER, V20, P25, DOI 10.1016/S0169-5002(97)00097-4; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morita S, 1998, INT J CANCER, V78, P286, DOI 10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; OCCLESTON NL, 1993, CANCER LETT, V71, P203, DOI 10.1016/0304-3835(93)90117-R; Pastor A, 1997, EUR RESPIR J, V10, P603; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P432, DOI 10.1073/pnas.92.2.432; Robbins PF, 1996, CURR OPIN IMMUNOL, V8, P628, DOI 10.1016/S0952-7915(96)80078-1; ROBINSON PA, 1994, ARCH ORAL BIOL, V39, P251, DOI 10.1016/0003-9969(94)90051-5; SARGENT TD, 1983, SCIENCE, V222, P133; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P4305, DOI 10.1074/jbc.270.9.4305; Zhang JY, 1999, J EXP MED, V189, P1101, DOI 10.1084/jem.189.7.1101	29	90	120	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	2000	19	12					1519	1528		10.1038/sj.onc.1203457	http://dx.doi.org/10.1038/sj.onc.1203457			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734311	hybrid			2022-12-28	WOS:000086108100004
J	Oh, S; Song, YH; Yim, J; Kim, TK				Oh, S; Song, YH; Yim, J; Kim, TK			Identification of Mad as a repressor of the human telomerase (hTERT) gene	ONCOGENE			English	Article						telomerase; hTERT; Myc; Mad; repression	CATALYTIC SUBUNIT GENE; NORMAL HUMAN-CELLS; CELLULAR SENESCENCE; LIFE-SPAN; MYC; HUMAN-CHROMOSOME-3; IMMORTALIZATION; COMPLEX	Activation of telomerase, which has been frequently associated with cellular immortality, may constitute a key step in the development of human cancer. Derepression in the expression of its catalytic subunit hTERT gene has been proposed to directly link to the telomerase activation in tumor cells. Little is known about the mechanism how the hTERT gene is repressed in telomerase-negative mortal cells. This study was conducted, using an expression cloning approach, with the aim of identifying the gene(s) responsible for repressing the hTERT gene expression. Using this genetic screen, we isolated the transcription factor Mad as a repressor. Mutation of its DNA binding sites caused significant de-repression of hTERT promoter activity in mortal cells. This Mad-mediated repression of the hTERT promoter in mortal cells was counteracted by ectopic expression of Myc, The antagonism between Mad and Myc was also observed with an endogenous hTERT promoter. Their potential roles in differential hTERT promoter activities were further supported by the relative amounts of Mad and Myc proteins detected in immortal and mortal cells. Thus, Mad may be a direct negative regulator of hTERT in mortal cells and this repression mechanism can be inhibited by induction of Myc in immortal cells.	Harvard Univ, Sch Med, Inst Chem & Cell Biol, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Seoul Natl Univ, Natl Creat Res Initiat, Inst Mol Biol & Genet, Ctr Genet Reprogramming, Seoul 151742, South Korea	Harvard University; Harvard Medical School; Seoul National University (SNU)	Kim, TK (corresponding author), Harvard Univ, Sch Med, Inst Chem & Cell Biol, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.							AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dang CV, 1999, MOL CELL BIOL, V19, P1; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Horikawa I, 1998, MOL CARCINOGEN, V22, P65, DOI 10.1002/(SICI)1098-2744(199806)22:2<65::AID-MC1>3.0.CO;2-J; Horikawa I, 1999, CANCER RES, V59, P826; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OGATA T, 1995, JPN J CANCER RES, V86, P35, DOI 10.1111/j.1349-7006.1995.tb02985.x; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; Takakura M, 1999, CANCER RES, V59, P551; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010	32	138	149	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1485	1490		10.1038/sj.onc.1203439	http://dx.doi.org/10.1038/sj.onc.1203439			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723141				2022-12-28	WOS:000085942700015
J	Liao, DJ; Natarajan, G; Deming, SL; Jamerson, MH; Johnson, M; Chepko, G; Dickson, RB				Liao, DJ; Natarajan, G; Deming, SL; Jamerson, MH; Johnson, M; Chepko, G; Dickson, RB			Cell cycle basis for the onset and progression of c-Myc-induced, TGF alpha-enhanced mouse mammary gland carcinogenesis	ONCOGENE			English	Article						c-Myc; TGF alpha; E2F; cyclins; pRB; cell cycle	GROWTH-FACTOR-ALPHA; BREAST-CANCER CELLS; TRANSGENIC MICE; S-PHASE; SIGNAL-TRANSDUCTION; DEPENDENT KINASES; REDUNDANT CYCLIN; MESSENGER-RNA; EXPRESSION; D1	Using single and double transgenic mouse models, we investigated how c-Myc modulates the mammary epithelial cell cycle to induce cancer and how TGF alpha enhanced the process. In c-myc transgenic mice, c-myc expression was high in the hyperplastic mammary epithelium and in the majority of tumor areas. However, the tumors displayed focal areas of low expression of c-myc but high rates of proliferation. In contrast to E2F1 and cyclin A2, which were induced and co-localized with c-myc expression, induction of cyclins D1 and E occurred only in these tumor foci. Overexpression of cyclin D1 also occurred in the hyperplastic epithelium of tgf alpha-single and tgf alpha/c-myc-double transgenic mice. In tgf alpha/c-myc tumors, cells positive for cyclins D1 and E were randomly spread, without showing a reciprocal relationship to c-myc expression. In contrast to c-myc tumors, most tgf alpha/c-myc tumors showed undetectable levels of retinoblastoma protein (pRB), and the loss of PRB occurred in some cases at the mRNA level. These results suggest that E2F1 and cyclin A2 may be induced by c-Myc to mediate the onset of mammary cancer, whereas overexpression of cyclins D1 and E may occur later to facilitate tumor progression. TGF alpha may play its synergistic role, at least in part, by inducing cyclin D1 and facilitating the loss of pRB.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 3970 Reservoir Rd NW,Res Bldg,W417, Washington, DC 20007 USA.		Chepko, Gloria/B-2235-2010	Chepko, Gloria/0000-0002-4691-9894	NCI NIH HHS [R01 CA72460] Funding Source: Medline; NIA NIH HHS [AG1496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrow MG, 1998, J CELL BIOCHEM, V70, P528, DOI 10.1002/(SICI)1097-4644(19980915)70:4<528::AID-JCB9>3.3.CO;2-K; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Auvinen PK, 1996, ACTA ONCOL, V35, P995, DOI 10.3109/02841869609100717; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, MOL CELL BIOL, V19, P1; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; ELDRIDGE SR, 1993, ENVIRON HEALTH PERSP, V101, P211, DOI 10.2307/3431870; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAN EKH, 1995, ONCOGENE, V10, P953; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Johnson BE, 1998, MATH MECH SOLIDS, V3, P447, DOI 10.1177/108128659800300405; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOTANI S, 1995, ONCOGENE, V10, P663; Kwon TK, 1998, EXP CELL RES, V238, P128, DOI 10.1006/excr.1997.3816; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lavia P, 1999, BIOESSAYS, V21, P221; LEE DC, 1995, PHARMACOL REV, V47, P51; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Li JJ, 1999, CANCER RES, V59, P2340; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Liao DZJ, 1998, CARCINOGENESIS, V19, P2173, DOI 10.1093/carcin/19.12.2173; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lykkesfeldt AE, 1996, ACTA ONCOL, V35, P9, DOI 10.3109/02841869609083961; Marhin WW, 1996, ONCOGENE, V12, P43; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Pilichowska M, 1997, MODERN PATHOL, V10, P969; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Roussel ME, 1998, ADV CANCER RES, V74, P1, DOI 10.1016/S0065-230X(08)60763-0; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; Sgambato A, 1996, CANCER RES, V56, P1389; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Sweeney C, 1996, DEVELOPMENT, V122, P53; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Yang R, 1997, CANCER RES, V57, P913	70	43	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1307	1317		10.1038/sj.onc.1203430	http://dx.doi.org/10.1038/sj.onc.1203430			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713672				2022-12-28	WOS:000085743800007
J	Hennighausen, L				Hennighausen, L			Mouse models for breast cancer	ONCOGENE			English	Article						mammary; cancer; mouse models; transgenic; knock-out	TRANSGENIC MICE; GENES		NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hennighausen, L (corresponding author), NIDDKD, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.			Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	4	21	26	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		966	967		10.1038/sj.onc.1203346	http://dx.doi.org/10.1038/sj.onc.1203346			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713679	Green Published			2022-12-28	WOS:000085796400001
J	Alarcon-Vargas, D; Fuchs, SY; Deb, S; Ronai, Z				Alarcon-Vargas, D; Fuchs, SY; Deb, S; Ronai, Z			p73 transcriptional activity increases upon cooperation between its spliced forms	ONCOGENE			English	Article						p73; p53; Mdm2; gain of function; transcription	FUNCTION PHENOTYPE; MUTATION ANALYSIS; P53 HOMOLOG; CELL-CYCLE; GENE; APOPTOSIS; GAIN; NEUROBLASTOMA; ONCOPROTEINS; CARCINOMAS	The p53 homologue p73 efficiently activates p53-responsive genes. The well documented over-expression of p73 spliced forms in a wide variety of tumor types promoted us to elucidate the mechanisms underlying p73-mediated transcription. Using the luciferase reporter gene driven by Mdm2-minimal promoter in p53 null cells, we demonstrate that the weak transcriptional activity mediated by p73 alpha was increased by the mutant form p73 beta(292), which by itself is transcriptionally inactive. Similarly, cooperation between p73 beta and an inactive form of p73 alpha increased p73 beta-mediated transcriptional activities. Conversely, p73 beta elicited a silencing effect on a gain of function mutant, p53(281), which by itself mediated efficient transactivation of the MDR promoter. Neither anisomycin nor actinomycin D altered p73-mediated transcriptional activities, whereas sorbitol profoundly inhibited them through a rapid proteasome-dependent degradation of p73, Our observations point to plausible scenarios in which p73, through cooperation between p73 spliced forms and suppression of gain of function mutant p53 may elicit changes in the transcription of p53 target genes that play key roles in cell growth and death.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Wake Forest University	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER; NCI NIH HHS [CA78419] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; ELDIERY WS, 1993, CELL, V75, P817; Gorgoulis VG, 1998, BRIT J CANCER, V77, P374, DOI 10.1038/bjc.1998.60; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HANS S, 1999, EUR J SURG ONCOL, V25, P194; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Iwamoto KS, 1996, CANCER RES, V56, P3862; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Oren M, 1996, BBA-REV CANCER, V1288, pR13, DOI 10.1016/S0304-419X(96)00030-3; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; STENGER JE, 1994, EMBO J, V13, P11; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; Tsao H, 1999, CANCER RES, V59, P172; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yokomizo A, 1999, PROSTATE, V39, P94; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	42	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					831	835		10.1038/sj.onc.1203311	http://dx.doi.org/10.1038/sj.onc.1203311			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698502				2022-12-28	WOS:000085192100014
J	Zisch, AH; Pazzagli, C; Freeman, AL; Schneller, M; Hadman, M; Smith, JW; Ruoslahti, E; Pasquale, EB				Zisch, AH; Pazzagli, C; Freeman, AL; Schneller, M; Hadman, M; Smith, JW; Ruoslahti, E; Pasquale, EB			Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses	ONCOGENE			English	Article						signaling pathways; tyrosine phosphorylation; actin cytoskeleton; cell adhesion; mitogen-activated protein kinases	ACTIN-BUNDLING PROTEIN; MAP KINASE; AUTOPHOSPHORYLATION SITE; INTEGRIN ACTIVATION; NEURAL DEVELOPMENT; LIGAND ACTIVATION; POINT MUTATION; CELL MOTILITY; IN-VITRO; FAMILY	Eph receptor tyrosine kinases play key roles in pattern formation during embryonic development, but little is known about the mechanisms by which they elicit specific biological responses in cells. Here, we investigate the role of tyrosines 605 and 611 in the juxtamembrane region of EphB2, because they are conserved Eph receptor autophosphorylation sites and demonstrated binding sites for the SH2 domains of multiple signaling proteins. Mutation of tyrosines 605 and 611 to phenylalanine impaired EphB2 kinase activity, complicating analysis of their function as SH2 domain binding sites and their contribution to EphB2-mediated signaling. In contrast, mutation to the negatively charged glutamic acid disrupted SH2 domain binding without reducing EphB2 kinase activity. By using a panel of EphB2 mutants, we found that kinase activity is required for the changes in cell-matrix and cell-cell adhesion, cytoskeletal organization, and activation of mitogen-activated protein (MAP) kinases elicited by EphB2 in transiently transfected cells, Instead, the two juxtamembrane SH2 domain binding sites were dispensable for these effects. These results suggest that phosphorylation of tyrosines 605 and 611 is critical for EphB2-mediated cellular responses because it regulates EphB2 kinase activity.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NICHD NIH HHS [HD26351, HD25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, P01HD025938, R01HD026351] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; ADAMS JC, 1995, J CELL SCI, V108, P1977; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Giasson BI, 1997, J NEUROSCI, V17, P9466; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kalo MS, 1999, BIOCHEMISTRY-US, V38, P14396, DOI 10.1021/bi991628t; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin XH, 1996, MOL BIOL CELL, V7, P1977, DOI 10.1091/mbc.7.12.1977; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Veeranna, 1998, J NEUROSCI, V18, P4008; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; ZOU JX, IN PRESS P NAT ACAD	74	98	98	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					177	187		10.1038/sj.onc.1203304	http://dx.doi.org/10.1038/sj.onc.1203304			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644995				2022-12-28	WOS:000084844400002
J	Cruzalegui, FH; Cano, E; Treisman, R				Cruzalegui, FH; Cano, E; Treisman, R			ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry	ONCOGENE			English	Article						TCF; SRE; ERK; MAP kinase; Elk-1; SAP-1	SERUM RESPONSE FACTOR; TERNARY COMPLEX FACTORS; MAP KINASE PATHWAYS; C-FOS EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; TRANSACTIVATION DOMAIN; ELEMENT; BINDING; CASCADES	Elk-1, a member of the TCF family of Ets domain proteins, contains a C-terminal transcriptional activation domain with multiple copies of the MAPK core consensus sequence S/T-P. This region is phosphorylated by MAP kinases in vitro and in vivo, but the extent and kinetics of phosphorylation at the different sites have not been investigated in detail. We prepared antisera against the phosphorylated forms of residues T353, T363, T368, S383, S389 and T417. The antisera specifically recognize the phosphorylated Elk-1 C terminus and are specific for their cognate sites, as assessed by peptide competition and mutagenesis experiments. Analysis of cells stably expressing Elk-1 in vivo shows that following serum or TPA stimulation, residues T353, T363, T368, S383, S389 and T417 become phosphorylated with similar kinetics. Mutation of any one site does not prevent phosphorylation of the others. Mutation to alanine of S383, F378 or W379, which virtually abolishes transcriptional activation by Elk-1, does not affect phosphorylation of any sites tested. Analysis of Elk-1 using two-dimensional gel electrophoresis shows that following ERK activation Elk-1 receives at least six phosphates in addition to those present prior to stimulation. We propose that the Elk-1 C-terminal regulatory domain becomes stoichiometrically phosphorylated following growth factor stimulation.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Cano, Eva/A-2049-2010	Cano, Eva/0000-0003-2750-6135; Treisman, Richard/0000-0002-9658-0067				Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Shen F, 1996, J BIOL CHEM, V271, P4827; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	34	137	140	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7948	7957		10.1038/sj.onc.1203362	http://dx.doi.org/10.1038/sj.onc.1203362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637505				2022-12-28	WOS:000084634600003
J	Kiaris, H; Schally, AV; Sun, B; Armatis, P; Groot, K				Kiaris, H; Schally, AV; Sun, B; Armatis, P; Groot, K			Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide	ONCOGENE			English	Article						brain tumors; cancer therapy; peptide analogs; oncogene stimulation; autocrine; paracrine	CELL LUNG-CANCER; SOMATOSTATIN ANALOG RC-160; BINDING AFFINITIES; MESSENGER-RNA; IN-VITRO; C-FOS; RC-3095; RECEPTORS; CARCINOMA; LINES	The effects of antagonists of bombesin/gastrin-releasing peptide (GRP) on the growth of human malignant glioblastoma cell line U-87MG xenografted into nude mice were evaluated. Nude mice bearing s.c. implanted U-87MG tumors were treated with bombesin/GRP antagonists RC-3095 and RC-3940-II. RC-3095 and RC-3940-II administered s.c. at a dose of 20 mu g/day for 4 weeks decreased the volume of U-87MG xenografts by 60 and 74%, respectively, compared with controls. RT-PCR analysis showed that U-87MG xenografts expressed mRNA for bombesin receptor subtype (BRS)-1 (GRP receptor) and BRS-2 (neuromedin-B receptor), but the mRNA for GRP ligand was not detected in U-87MG cells suggesting that GRP may stimulate the growth of U-87MG glioblastomas by a paracrine mechanism. The levels of mRNA for c-fos oncogene mere decreased by 30-40% in U-87MG tumors treated with RC-3095 or RC-3940-II. In U-373MG glioblastoma cells, which also express BRS-1, and U-87MG cells, cultured in vitro, GRP(14-27) induced the expression of c-fos mRNA, and some c-jun mRNA, in a time-dependent manner with the maximal effect occurring 2 h after the stimulation and a return to basal levels after 8 h. Antagonist RC-3940-II inhibited the stimulation of c-fos by GRP(14-27), Our results indicate that antagonists of bombesin/GRP inhibit the growth of U-87MG glioblastomas by a mechanism that may involve the downregulation of c-fos oncogene.	Vet Adm Med Ctr, Inst Endocrine Polypeptide & Canc, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Med, Sect Expt Med, New Orleans, LA 70112 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Tulane University	Schally, AV (corresponding author), Vet Adm Med Ctr, Inst Endocrine Polypeptide & Canc, 1601 Perdido St, New Orleans, LA 70112 USA.			Schally, Andrew/0000-0003-1273-6747; Kiaris, Hippokratis/0000-0002-8999-8289				DRAOUI M, 1993, CELL GROWTH DIFFER, V4, P723; DRAOUI M, 1995, PEPTIDES, V16, P289, DOI 10.1016/0196-9781(94)00173-1; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Halmos G, 1997, P NATL ACAD SCI USA, V94, P956, DOI 10.1073/pnas.94.3.956; HOCHBERG F, 1987, HARRISONS PRINCIPLES, P1968; Koppan M, 1998, CANCER, V83, P1335, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5; LIEBOW C, 1994, P NATL ACAD SCI USA, V91, P3804, DOI 10.1073/pnas.91.9.3804; MAHMOUD S, 1991, CANCER RES, V51, P1798; MOODY TW, 1979, BIOCHEM BIOPH RES CO, V90, P7, DOI 10.1016/0006-291X(79)91582-1; MOODY TW, 1987, BIOCHEM BIOPH RES CO, V147, P189, DOI 10.1016/S0006-291X(87)80105-5; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOODY TW, 1989, J MOL NEUROSCI, V1, P235; OLSON JJ, 1988, CANCER, V61, P952, DOI 10.1002/1097-0142(19880301)61:5<952::AID-CNCR2820610516>3.0.CO;2-R; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PAOLETTI P, 1990, J NEUROSURG, V73, P736, DOI 10.3171/jns.1990.73.5.0736; PINSKI J, 1994, BRIT J CANCER, V70, P886, DOI 10.1038/bjc.1994.415; PINSKI J, 1994, INT J CANCER, V57, P574, DOI 10.1002/ijc.2910570422; PINSKI J, 1993, J CLIN ENDOCR METAB, V77, P1388, DOI 10.1210/jc.77.5.1388; PINSKI J, 1994, CANCER RES, V54, P5895; PINSKI J, 1994, CANCER RES, V54, P169; Poisson M, 1983, J Neurooncol, V1, P179, DOI 10.1007/BF00165601; QIN YF, 1994, J CANCER RES CLIN, V120, P519, DOI 10.1007/BF01221028; QIN YF, 1994, CANCER RES, V54, P1035; RADULOVIC S, 1991, INT J PEPT PROT RES, V38, P593; REILE H, 1995, INT J ONCOL, V7, P749; Schally A.V., 1997, CANCER MED-US, V4th, P1067; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; Sharif TR, 1997, MOL CELL ENDOCRINOL, V130, P119, DOI 10.1016/S0303-7207(97)00080-4; SIEGFRIED JM, 1994, J BIOL CHEM, V269, P8596; SPINDEL ER, 1993, RECENT PROG HORM RES, V48, P365; STALEY J, 1993, J MOL NEUROSCI, V4, P29, DOI 10.1007/BF02736688; SZEPESHAZI K, 1992, J NATL CANCER I, V84, P1915, DOI 10.1093/jnci/84.24.1915; SZEPESHAZI K, 1991, CANCER RES, V51, P5980; WANG QJ, 1996, INT J CANCER, V68, P1; YANO T, 1992, CANCER RES, V52, P4545	35	44	47	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7168	7173		10.1038/sj.onc.1203213	http://dx.doi.org/10.1038/sj.onc.1203213			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597318				2022-12-28	WOS:000083901900024
J	Okano, H; Saito, Y; Miyazawa, T; Shinbo, T; Chou, DZ; Kosugi, S; Takahashi, Y; Odani, S; Niwa, O; Kominami, R				Okano, H; Saito, Y; Miyazawa, T; Shinbo, T; Chou, DZ; Kosugi, S; Takahashi, Y; Odani, S; Niwa, O; Kominami, R			Homozygous deletions and point mutations of the Ikaros gene in gamma-ray-induced mouse thymic lymphomas	ONCOGENE			English	Article						tumor suppressor gene; Ikaros; allelic loss (or LOH) analysis; somatic mutation; gamma-ray-induced thymic lymphoma	TUMOR-SUPPRESSOR GENES; DNA-BINDING PROTEINS; CENTROMERIC HETEROCHROMATIN; TRANSCRIPTION FACTOR; P53; FAMILY; CANCER; CELLS; MICE; CHROMOSOME-16	Our previous genome-wide analysis of allelic loss for thymic lymphomas that were induced by gamma-irradiation in F-1 hybrid mice between BALB/c and MSM strains suggested the centromeric region on chromosome 11 as a site harboring a tumor suppressor gene. Interestingly, to this region the mouse Ikaros gene was mapped which was postulated to participate in oncogenic process from the study of Ikaros knockout mice. Here we show fine allelic loss mapping in the vicinity of Ikaros in 191 lymphomas, indicating that the critical region of allelic loss was centered at the Ikaros locus. PCR analysis revealed that nine lymphomas failed to give PCR-amplification for either of two exon primer pairs, indicative of homozygous deletion, Six and five mutations were detected in the N-terminal zinc finger domain and the activation domain of Ikaros, respectively, and six of the eleven were frameshift or nonsense mutations that resulted in truncation of Ikaros protein. The results strongly suggest a direct role for Ikaros in development of mouse thymic lymphomas, This provides the experimental basis for further analysis of Ikaros mutations in human cancer.	Niigata Univ, Sch Med, Dept Biochem, Niigata 9518122, Japan; Niigata Univ, Grad Sch Sci & Technol, Div Life Sci, Niigata 9502181, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyou Ku, Yoshida Konoecho 6068315, Japan	Niigata University; Niigata University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem, Asahimachi 1-757, Niigata 9518122, Japan.		Kosugi, S./K-5142-2019	Kosugi, Shin-ichi/0000-0002-6602-7412				BONHOMME F, 1989, GENETIC VARIANTS STR, P658; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HALEVY O, 1991, ONCOGENE, V6, P1593; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAYASHI T, 1993, GENOMICS, V17, P490, DOI 10.1006/geno.1993.1352; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; KEMP CJ, 1993, CANCER RES, V53, P6022; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; KNUDSON AG, 1985, CANCER RES, V45, P1437; Koide N, 1999, MOL CARCINOGEN, V24, P57, DOI 10.1002/(SICI)1098-2744(199901)24:1<57::AID-MC8>3.0.CO;2-5; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Molnar A, 1996, J IMMUNOL, V156, P585; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Sato S, 1998, ONCOGENE, V17, P105, DOI 10.1038/sj.onc.1201913; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; THACKER J, 1992, ADV RADIAT BIOL, V16, P77; TSUKADA T, 1993, ONCOGENE, V8, P3313; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1	40	53	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6677	6683		10.1038/sj.onc.1203100	http://dx.doi.org/10.1038/sj.onc.1203100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597273				2022-12-28	WOS:000083792000007
J	Yin, XY; Gupta, K; Han, WP; Levitan, ES; Prochownik, EV				Yin, XY; Gupta, K; Han, WP; Levitan, ES; Prochownik, EV			Mmip-2, a novel RING finger protein that interacts with mad members of the Myc oncoprotein network	ONCOGENE			English	Article						RING finger proteins; zinc finger proteins; helix-loop-helix; leucine zipper proteins; mad; mxi1; max; myc	C-MYC; TRANSCRIPTIONAL REPRESSION; DNA-BINDING; CELL-GROWTH; EPIDERMAL DIFFERENTIATION; GENE-EXPRESSION; ZIPPER PROTEIN; IN-VITRO; DOMAIN; COMPLEX	Mad proteins are basic-helix-loop - helix -leucine zipper (bHLH-ZIP)-containing members of the myc oncoprotein network. They interact with the bHLH-ZIP protein max, compete for the same DNA binding sites as myc-max heterodimers and down-regulate myc-responsive genes. Using the bHLH-ZIP domain of mad1 as a yeast two-hybrid 'bait', we identified Mmip-2, a novel RING finger protein that interacts with all mad members, but weakly or not at all with c-myc, max or unrelated bHLH or bZIP proteins. The mad1-Mmip-2 interaction is mediated by the ZIP domain in the former protein and by at least two regions in the latter which do not include the RING finger. Mmip-2 can disrupt max-mad DNA binding and can reverse the suppressive effects of mad proteins on c-myc-responsive target genes and on c-myc+ras-mediated focus formation in fibroblasts. Tagging with spectral variants of green fluorescent protein showed that Mmip-2 and mad proteins reside in separate cytoplasmic and nuclear compartments, respectively. When co-expressed, however, the proteins interact and translocate to the cellular compartment occupied by the more abundant protein. These observations suggest a novel way by which Mmip-2 can modulate the transcriptional activity of myc oncoproteins.	Univ Pittsburgh, Inst Canc, Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Univ Pittsburgh, Inst Canc, Childrens Hosp Pittsburgh, Hematol Oncol Sect, 3705 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline; NINDS NIH HHS [NS32385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Dang CV, 1999, MOL CELL BIOL, V19, P1; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FINKEL T, 1993, J BIOL CHEM, V268, P5; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HU HM, 1994, J BIOL CHEM, V269, P30069; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MA A, 1993, ONCOGENE, V8, P1093; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STARNAUD R, 1988, ONCOGENE, V3, P553; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yin XY, 1998, ONCOGENE, V16, P2629, DOI 10.1038/sj.onc.1201777; ZERVOS, 1994, CELL, V79, P389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	67	16	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6621	6634		10.1038/sj.onc.1203097	http://dx.doi.org/10.1038/sj.onc.1203097			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597267				2022-12-28	WOS:000083792000001
J	Ma, L; Gauville, C; Berthois, Y; Millot, G; Johnson, GR; Calvo, F				Ma, L; Gauville, C; Berthois, Y; Millot, G; Johnson, GR; Calvo, F			Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line	ONCOGENE			English	Article						epidermal growth factor receptor; amphiregulin; antisense RNA expression constructs; transformed phenotype	EPIDERMAL-GROWTH-FACTOR; MOUSE MAMMARY-GLAND; FACTOR RECEPTOR; FACTOR-ALPHA; CANCER CELLS; HUMAN COLON; CARCINOMA; EGF; INDUCTION; SURFACE	The epidermal growth factor (EGF) family of receptors and their respective ligands play a major role in breast cancer progression and are the targets of new therapeutic approaches. Following immortalization with SV40 T antigen of normal human breast epithelial cells, a transformed variant cell line (NS2T2A1) was selected for its increased tumorigenicity in nude mice. This cell line was shown to have a higher expression of EGF receptors (EGFR) and amphiregulin (AR) when compared to their normal counterparts or less aggressive transformed cells. Dual staining of EGFR and AR was observed in 50-60% of NS2T2A1 cells, while 30-40% cells expressed AR only, To explore the potential tumorigenic role of AR, a 1.1 kb AR cDNA in an antisense orientation was transfected in NS2T2A1 cells. Three clones, selected by hygromycin B, expressed AR antisense RNA (AR AS1, AR AS2 and AR AS3 cell lines) in which AR protein expression was reduced (ranging from about 50 to <5%), The anchorage-independent growth of AR AS cell lines was reduced to levels ranging from 32.4-6.8% relative to the control cell line transfected with the vector alone. The clones expressing AR antisense RNA showed a reversion of the malignant phenotype when injected in nude mice, since a significant reduction of tumor intake was observed coincident with a significant tumor mass reduction (>96%), Moreover, intra-tumoral vascularization decreased significantly in tumors derived from AR AS cells (26.7, 70.7 and 50.4% of control). These in vitro and in vivo data reveal the oncogenic nature of AR in transformed breast epithelial cells and imply a role for AR in tumor angiogenesis.	Inst Genet Mol, Lab Pharmacol Expt & Clin, INSERM, EP 9932, F-75010 Paris, France; Fac Med Nord, F-13916 Marseille, France; US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; US Food & Drug Administration (FDA)	Ma, L (corresponding author), Inst Genet Mol, Lab Pharmacol Expt & Clin, INSERM, EP 9932, 27 Rue Juliette Dodu, F-75010 Paris, France.		Berthois, Yolande/O-1168-2017	calvo, fabien/0000-0002-0298-7633; BERTHOIS, Yolande/0000-0001-9603-1626				BARNARD JA, 1994, J BIOL CHEM, V269, P22817; Bennett KL, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046925; BERTHON P, 1992, INT J CANCER, V52, P92, DOI 10.1002/ijc.2910520117; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DVIS LG, 1986, BASIC METHODS MOL BI, P130; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Funatomi H, 1997, INT J CANCER, V72, P512, DOI 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Herrington EE, 1997, J CELL PHYSIOL, V170, P47; IGLESIAS M, 1995, AM J PATHOL, V146, P944; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kenney Nicholas, 1993, Molecular and Cellular Differentiation, V1, P163; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; LEBEAU J, 1995, INT J CANCER, V60, P244, DOI 10.1002/ijc.2910600219; LEJEUNE S, 1993, CANCER RES, V53, P3597; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; Ma L, 1996, FUND CLIN PHARMACOL, V10, P97, DOI 10.1111/j.1472-8206.1996.tb00153.x; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; MartinezLacaci I, 1996, J CELL PHYSIOL, V169, P497, DOI 10.1002/(SICI)1097-4652(199612)169:3<497::AID-JCP10>3.0.CO;2-3; MODJTAHEDI H, 1994, INT J ONCOL, V4, P277; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Silvy M, 1998, ENDOCRINOLOGY, V139, P2382, DOI 10.1210/en.139.5.2382; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; VARDY DA, 1995, J CELL PHYSIOL, V163, P257, DOI 10.1002/jcp.1041630206; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840	45	43	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6513	6520		10.1038/sj.onc.1203042	http://dx.doi.org/10.1038/sj.onc.1203042			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597254				2022-12-28	WOS:000083709200014
J	Hadsell, DL; Murphy, KL; Bonnette, SG; Reece, N; Laucirica, R; Rosen, JM				Hadsell, DL; Murphy, KL; Bonnette, SG; Reece, N; Laucirica, R; Rosen, JM			Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis	ONCOGENE			English	Article						transgenic mouse model; IGF-I; apoptosis; mutant p53; tumorigenesis	GROWTH-FACTOR-I; HUMAN-BREAST CANCER; MESSENGER-RNA EXPRESSION; TRANSGENIC MOUSE MODEL; IGF-BINDING PROTEIN-3; PROGRAMMED CELL-DEATH; RECEPTOR OVEREXPRESSION; GENE-EXPRESSION; WILD-TYPE; INSULIN	Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53(172R-H)). Nonlactating, multiparous WAP-DES mice exhibited hyperplastic lesions termed mammary interepithelial neoplasia (MIN) which constitutively expressed WAP-DES, By 23 months of age, 53% of the WAP-DES mice developed mammary adenocarcinomas. A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice, Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2-3-fold greater than that of nontransgenic and p53(172R-H) females, Tumor latency, however, was reduced by 8 months in bitransgenic mice as compared to mice of the other three genotypes. Aneuploidy was frequently observed in tumors from bitransgenic and p53(172R-H) mice, but not from mice expressing only the WAP-DES transgene, Expression of IGFBP3 was elevated in tumors from WAP-DES, but not bitransgenic mice, indicating an alteration in the p53/IGF-I axis. These studies indicate that overexpression of des(1-3)hIGF-I increases the frequency of MIN and stochastic mammary tumors and that the appearance of tumors displaying genomic instability is accelerated by mutant p53(172R-H).	Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine; Baylor College of Medicine	Hadsell, DL (corresponding author), Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, 1 Baylor Pl, Houston, TX 77030 USA.		Hadsell, Darryl/GPF-9037-2022		NATIONAL CANCER INSTITUTE [R37CA016303, R01CA016303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052197] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline; NIDDK NIH HHS [DK52197-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Amundadottir LT, 1996, ONCOGENE, V13, P757; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BALE LK, 1992, ENDOCRINOLOGY, V131, P608, DOI 10.1210/en.131.2.608; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CARDIFF RD, 2000, IN PRESS ONCOGENE; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; CULLEN KJ, 1990, CANCER RES, V50, P48; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dunn T, 1959, PHYSIOPATHOLOGY CANC, P38; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gai X X, 1988, Oncogene Res, V3, P377; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kleinberg DL, 1997, J MAMMARY GLAND BIOL, V2, P49, DOI 10.1023/A:1026373513521; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; MURPHY KL, 2000, IN PRESS ONCOGENE; NEIMAN PE, 1994, MOL BIOL CELL, V5, P763, DOI 10.1091/mbc.5.7.763; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Quarrie LH, 1996, J CELL PHYSIOL, V168, P559, DOI 10.1002/(SICI)1097-4652(199609)168:3<559::AID-JCP8>3.0.CO;2-O; SCHULLER AGP, 1994, MOL CELL ENDOCRINOL, V104, P57, DOI 10.1016/0303-7207(94)90051-5; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Starborg M, 1996, J CELL SCI, V109, P143; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Turner BC, 1997, CANCER RES, V57, P3079; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Villafuerte BC, 1996, MOL ENDOCRINOL, V10, P622, DOI 10.1210/me.10.6.622; WADA J, 1993, P NATL ACAD SCI USA, V90, P10360, DOI 10.1073/pnas.90.21.10360; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; Webster NJG, 1996, CANCER RES, V56, P2781; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; YEE D, 1988, CANCER RES, V48, P6691; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	48	74	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					889	898		10.1038/sj.onc.1203386	http://dx.doi.org/10.1038/sj.onc.1203386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702797				2022-12-28	WOS:000085567700006
J	Tsihlias, J; Zhang, W; Bhattacharya, N; Flanagan, M; Klotz, L; Slingerland, J				Tsihlias, J; Zhang, W; Bhattacharya, N; Flanagan, M; Klotz, L; Slingerland, J			Involvement of p27(Kip1) in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells	ONCOGENE			English	Article						p27; cell cycle; prostate cancer; androgen; cyclin E/cdk2	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; CYCLE ARREST; TGF-BETA; TRANSCRIPTION FACTOR; ANDROGEN-RECEPTOR; EPITHELIAL-CELLS; MAMMALIAN-CELLS; PROTEIN-KINASE; CDK INHIBITORS	The cell cycle is governed by cyclin dependent kinases (cdks), which are activated by binding of cyclins, inhibited by cdk inhibitors and regulated by phosphorylation and dephosphorylation. Exposure to high dose dihydrotestosterone (DHT) inhibits population growth of the human prostate carcinoma cell line, LNCaP, To determine the mechanism of growth arrest by high dose DHT, we assayed the changes in cell cycle profile and the cell cycle regulators that mediate these effects. Treatment of asynchronously growing LNCaP cells with 100 nM DHT caused a G1 arrest, The proportion of cells in S phase fell from 22 to 2%, while the G1 fraction rose from 74 to 92% by 24 h, Loss of phosphorylation of the retinoblastoma protein was noted and cdk4 and cyclin E/cdk2 activities fell. Inhibition of these G1 cyclin dependent kinases was not due to loss of either cyclin or cdk proteins nor to increases in the cdk inhibitors p16(INK4A) and p21(Cip1). p21(Cip1) protein levels remained constant, and cyclin E-associated p21(Cip1) fell, suggesting that p21(Cip1) is not relevant to this form of cyclin E/cdk2 inhibition, Of note, total p27(Kip1) levels and cyclin E-associated p27(Kip1) increased as cells arrested and the amount of the CAK activated cdk2 bound to cyclin E decreased, p27(Kip1) immunodepletion experiments demonstrated that the DHT-mediated increase in p27(Kip1) was sufficient to fully saturate and inhibit target cyclin E/cdk2, The inhibition of cyclin E/cdk2 by p27(Kip1) contributes to G1 arrest of LNCaP following high dose DHT. p27(Kip1) may be a key effector of androgen dependent growth modulation in prostate cancer cells.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, Toronto, ON M4N 3M5, Canada; Gilead Sci Inc, Foster City, CA 94404 USA; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Urol, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Gilead Sciences; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Slingerland, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; BERNS EMJJ, 1986, PROSTATE, V9, P247, DOI 10.1002/pros.2990090305; Cariou S, 1998, BREAST CANCER RES TR, V52, P29, DOI 10.1023/A:1006154900130; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Cote RJ, 1998, J NATL CANCER I, V90, P916, DOI 10.1093/jnci/90.12.916; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Enders GH, 1996, ONCOGENE, V12, P1239; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Hakimi JM, 1996, WORLD J UROL, V14, P329; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAIGHN ME, 1979, INVEST UROL, V17, P16; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kim S H, 1996, Prog Cell Cycle Res, V2, P137; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Menjo M, 1998, ONCOGENE, V17, P2619, DOI 10.1038/sj.onc.1202193; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pagano M, 1996, PEZ FDN SYM, V7, P241; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PEEHL DM, 1994, ATLAS HUMAN TUMOUR C; PEELING WB, 1989, UROLOGY, V33, P45, DOI 10.1016/0090-4295(89)90106-4; Peng D, 1996, CANCER RES, V56, P3666; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REED SI, 1994, J CELL SCI, P69; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; StCroix B, 1996, NAT MED, V2, P1204; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tan P, 1997, CANCER RES, V57, P1259; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1998, CANCER RES, V58, P542; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang QM, 1996, CANCER RES, V56, P264; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Zi XL, 1998, CANCER RES, V58, P1920	76	55	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					670	679		10.1038/sj.onc.1203369	http://dx.doi.org/10.1038/sj.onc.1203369			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698512				2022-12-28	WOS:000085192000009
J	De Falco, G; Bagella, L; Claudio, PP; De Luca, A; Fu, Y; Calabretta, B; Sala, A; Giordano, A				De Falco, G; Bagella, L; Claudio, PP; De Luca, A; Fu, Y; Calabretta, B; Sala, A; Giordano, A			Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation	ONCOGENE			English	Article						CDK9; B-Myb; oncogenes	CYCLIN-DEPENDENT KINASE-5; C-MYB; V-MYB; TERMINAL DIFFERENTIATION; CDC2-RELATED KINASE; MYELOID-LEUKEMIA; EXPRESSION; ACTIVATION; BINDING; TRANSCRIPTION	B-Myb is a transcription factor belonging to the myb family, whose activity has been associated with augmented DNA synthesis and cell cycle progression, We showed recently that B-Myb autoregulates its own expression through promoter transactivation. We report in this study that CDK9, the cyclin T associated kinase, which phosphorylates and activates RNA-Polymerase II, suppresses B-Myb autoregulation through direct interaction with the carboxyl-terminus of the B-Myb protein, Downregulation of the transactivating ability of B-Myb is independent of the kinase activity of CDK9, because a kinase deficient mutant (dn-CDK9) also represses B-myb gene autoregulation, Overexpression of CDK9 did not result in suppression of p53-dependent transactivation or inhibition of the basal activity of the promoters tested so far, demonstrating that CDK9 is a B-Myb-specific repressor, Rather, transfection of the dominant negative dn-CDK9 construct inhibited the basal activity of the reporter genes, confirming an essential role for CDK9 in gene transcription. In addition, Cyclin T1 restores B-Myb transactivating activity when co-transfected along with CDK9, suggesting that the down-regulatory effect observed on B-Myb is specifically due to CDK9 alone. Thus, our data suggest that CDK9 is involved in the negative regulation of activated transcription mediated by certain transcription factors, such as B-Myb, This may indicate the existence of a feedback loop, mediated by the different activities of CDK9, which links basal with activated transcription.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, Philadelphia, PA 19107 USA; Univ Naples Federico II, Dept Sci Odontostomatol & Maxillo Facciali, Naples, Italy; Ist Regina Elena, Lab Cell Metab & Pharmacokinet, Ctr Expt Res, I-00158 Rome, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Dept Microbiol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, CH, Italy	Jefferson University; University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University; Consorzio Mario Negri Sud	Giordano, A (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, Jefferson Alumni Hall,Room 226,1020 Locust St, Philadelphia, PA 19107 USA.		De Luca, Antonio/AAD-9562-2020; Claudio, Pier Paolo/AAW-7282-2021; sala, arturo/C-4959-2008; Giordano, Antonio/F-1927-2010	De Luca, Antonio/0000-0002-3905-6154; Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X; BAGELLA, Luigi/0000-0003-2815-037X; Sala, Arturo/0000-0002-2841-7866				Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Bies J, 1996, ONCOGENE, V12, P355; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Katzen AL, 1996, P NATL ACAD SCI USA, V93, P13955, DOI 10.1073/pnas.93.24.13955; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Napolitano G, 1999, AIDS, V13, P1453, DOI 10.1097/00002030-199908200-00003; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Romano G, 1999, J CELL BIOCHEM, V75, P357, DOI 10.1002/(SICI)1097-4644(19991201)75:3<357::AID-JCB1>3.0.CO;2-K; Sala A, 1996, CANCER RES, V56, P1991; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saville MK, 1998, ADV CANCER RES, V72, P109; Sitzmann J, 1996, ONCOGENE, V12, P1889; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	41	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					373	379		10.1038/sj.onc.1203305	http://dx.doi.org/10.1038/sj.onc.1203305			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656684				2022-12-28	WOS:000084873700007
J	Ide, N; Hata, Y; Nishioka, H; Hirao, K; Yao, I; Deguchi, M; Mizoguchi, A; Nishimori, H; Tokino, T; Nakamura, Y; Takai, Y				Ide, N; Hata, Y; Nishioka, H; Hirao, K; Yao, I; Deguchi, M; Mizoguchi, A; Nishimori, H; Tokino, T; Nakamura, Y; Takai, Y			Localization of membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 at tight junctions of epithelial cells	ONCOGENE			English	Article						MAGI-1/BAP1; SAP97/hDLG; E-cadherin; ZO-1; tight junction	TUMOR-SUPPRESSOR PROTEIN; POSTSYNAPTIC DENSITY; SIGNALING PATHWAYS; HUMAN HOMOLOG; DOMAIN; FAMILY; APC; INTERACTS; BINDING; PSD-95	Membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 and Synapse-associated protein (SAP) 97/human Discs-large tumor suppressor gene (hDLG) are ubiquitous isoforms of synaptic scaffolding molecule (S-SCAM) and Postsynaptic density(PSD)-95/SAP90, both of which are implicated in the structures of synapses, respectively. SAP97/hDLG is localized at epithelial junctions and may function as a scaffolding protein, but the subcellular localization or the function of MAGI-1/BAP1 has not been clarified. In intestinal epithelial cells, MAGI-1/BAP1 was localized at tight junctions, whereas SAP97/hDLG was localized diffusely at cell-cell junctions. In Madine Darby canine kidney (MDCK) cells, MAGI-1/BAP1 was colocalized with ZO-1, whereas SAP97/hDLG was colocalized with E-cadherin. In MDCK cells, dominant active and negative mutants of Rad small G protein changed the amounts of SAP97/hDLG at cell-cell junctions, but not that of MAGI-1/BAP1. When MDCK cells were switched to a low Ca2+ medium, E-cadherin disappeared from the plasma membrane, and cells were dissociated. The phorbol 12-myristate 13-acetate-treatment after the low Ca2+ switch induced a tight junction-like structure. MAGI-1/BAP1 was recruited with ZO-1 to this structure, but SAP97/hDLG or E-cadherin was not. These findings suggest that MAGI-1/BAP1 is a component of tight junctions of epithelial cells, and that its role is different from that of SAP97/hDLG.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, ERATO, Takai Biotimer Project, JCR Pharmaceut Co Ltd, Kobe, Hyogo 6512241, Japan; Kyoto Univ, Grad Sch, Dept Anat & Neurobiol, Kyoto 6068315, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	Osaka University; Japan Science & Technology Agency (JST); Kyoto University; University of Tokyo	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Tokino, Takashi/AAI-9887-2021					Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Reuver SM, 1998, J CELL SCI, V111, P1071; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889	31	102	102	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7810	7815		10.1038/sj.onc.1203153	http://dx.doi.org/10.1038/sj.onc.1203153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618722				2022-12-28	WOS:000084256900011
J	Nass, SJ; Ferguson, AT; El-Ashry, D; Nelson, WG; Davidson, NE				Nass, SJ; Ferguson, AT; El-Ashry, D; Nelson, WG; Davidson, NE			Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells	ONCOGENE			English	Article						breast cancer; estrogen receptor; DNA methylation; S phase; p21	RECEPTOR GENE-EXPRESSION; ESTROGEN-RECEPTOR; SIGNALING PATHWAY; METHYLTRANSFERASE; GROWTH; CARCINOGENESIS; PROGRESSION; ISLANDS; TARGET	Estrogen receptor (ER)-negative breast cancer cells display extensive methylation of the ER gene CpG island and elevated DNA methyltransferase (DMT) expression compared to ER-positive cells. The present study demonstrates that DMT protein levels tightly correlate with S phase fraction in ER-positive cells, whereas ER-negative cells express DMT throughout the cell cycle. In addition, levels of p21(CIP1), which disrupts DMT binding to PCNA, are inversely correlated with DMT levels, Therefore increased DMT expression in ER-negative cells is not simply due to elevated S-phase fraction, but rather to more complex changes that allow cells to escape normal cell cycle-dependent controls on DMT expression. Because ER-negative breast tumors often have activated growth factor pathways, the impact of these pathways on DMT expression was examined in ER-positive cells. Stable transfection with fibroblast growth factors (FGFs) 1 and 4 led to increased DMT expression that could not be accounted for by a shift in S phase fraction. Elevated DMT protein expression in FGF-transfectants was accompanied by a significant decrease in p21, again suggesting a reciprocal relationship between these two proteins. However, acquisition of an estrogen-independent phenotype, even in conjunction with elevated DMT levels, was not sufficient to promote ER gene silencing via methylation, These results indicate that multiple steps are required for de novo methylation of the ER CpG island.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20007 USA	Johns Hopkins University; Johns Hopkins Medicine; Georgetown University	Davidson, NE (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 422 N Bond St, Baltimore, MD 21231 USA.			Nass, Sharyl/0000-0001-5874-5337				Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clarke M, 1998, LANCET, V351, P1451; CLARKE R, 1994, BREAST CANCER RES TR, V31, P237, DOI 10.1007/BF00666157; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; FERGUSON AT, 1995, CANCER RES, V55, P2279; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lapidus RG, 1998, CANCER RES, V58, P2515; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MIYOSHI E, 1993, CARCINOGENESIS, V14, P603, DOI 10.1093/carcin/14.4.603; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SAMAAN NA, 1981, CANCER, V47, P554, DOI 10.1002/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; VICKER PJ, 1988, MOL ENDOCRINOL, V2, P866; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891	34	32	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7453	7461		10.1038/sj.onc.1203138	http://dx.doi.org/10.1038/sj.onc.1203138			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602504				2022-12-28	WOS:000084119600006
J	Kieran, MW; Katz, S; Vail, B; Zon, LI; Mayer, BJ				Kieran, MW; Katz, S; Vail, B; Zon, LI; Mayer, BJ			Concentration-dependent positive and negative regulation of a MAP kinase by a MAP kinase kinase	ONCOGENE			English	Article						MAP kinase; stress-activated kinase; JNK	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; HIGH-AFFINITY INTERACTION; JUN NH2-TERMINAL KINASE; C-JUN; INFLAMMATORY CYTOKINES; NUCLEAR TRANSLOCATION; DUAL PHOSPHORYLATION; STRUCTURAL BASIS	There are at least three distinct MAP kinase signaling modules in mammalian cells, distinguished by the family of kinases (Erk, SAPK/JNK, or p38) that is ultimately activated. Many input signals activate multiple MAP kinase cascades, and the mechanisms that control the specificity of signal output are not well understood. We show that SEK1/MKK4, a MAP kinase kinase proposed to activate SAPK/JNK, is a very potent inhibitor of p54 SAPK beta/JNK3 both in vitro and irt vivo if present at equimolar or higher ratios. In contrast SEK can activate SAPK when present in substoichiometric amounts, but this activation is slow, consistent with the rate-limiting step in activation being the dissociation of an inactive SEK:SAPK complex. The N-terminal unique region of SEK is both necessary and partially sufficient for inhibition of SAPK, and is also necessary for activation of SAPK by SEK in vitro. We have also used the p38 MAP kinase and its activator MKK6 to examine the regulatory relationships among different kinases involved in stress responses. We show using purified kinases that inhibitory activity is specific for the combination of SEK and SAPK: SEK can activate but not inhibit p38, and MKK6 can activate but not inhibit SAPK beta and p38. These results reveal a potential mechanism for regulating stress-activated kinases, adding to a growing body of evidence suggesting that MAP kinases are controlled by relatively stable interactions with their activators.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Mayer, BJ (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Dept Microbiol & Mol Genet, 320 Longwood Ave, Boston, MA 02115 USA.			Kieran, Mark/0000-0003-2184-7692				Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI KY, 1994, CELL, V78, P499; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE LR, 1994, MOL ENDOCRINOL, V8, P746, DOI 10.1210/me.8.6.746; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Pelech SL, 1996, CURR BIOL, V6, P551, DOI 10.1016/S0960-9822(02)00540-7; PRINTEN JA, 1994, GENETICS, V138, P609; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SETH A, 1992, J BIOL CHEM, V267, P24796; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	52	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6647	6657		10.1038/sj.onc.1203057	http://dx.doi.org/10.1038/sj.onc.1203057			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597270				2022-12-28	WOS:000083792000004
J	Terris, B; Pineau, P; Bregeaud, L; Valla, D; Belghiti, J; Tiollais, P; Degott, C; Dejean, A				Terris, B; Pineau, P; Bregeaud, L; Valla, D; Belghiti, J; Tiollais, P; Degott, C; Dejean, A			Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas	ONCOGENE			English	Article						beta-catenin; hepatocellular carcinoma; APC; immunohistochemistry	FAMILIAL ADENOMATOUS POLYPOSIS; SOMATIC MUTATIONS; COLORECTAL-CANCER; TUMOR; APC; ACTIVATION; EXPRESSION; HEPATITIS; DELETIONS; PATHWAY	Several lines of evidence indicate that beta-catenin acquires oncogenic activity when its intracellular concentration increases as a result of either mutation in the beta-catenin gene itself or inactivation of the adenomatous polyposis coli (APC) gene. In an attempt to elucidate the molecular mechanisms underlying hepatocellular carcinogenesis, we have studied the frequency of beta-catenin gene alterations in exon 3, a region known to represent a mutation hot spot, and its inappropriate protein expression by immunohistochemistry in 73 hepatocellular carcinomas (HCCs). The results were correlated with different clinical and pathological data, particularly with the presence or not of an associated cirrhosis, Fourteen (19%) HCCs showed beta-catenin gene alterations with missense mutations in nine cases and interstitial deletions in five cases. These genetic alterations were present in both cirrhotic and non-cirrhotic groups. By contrast, we did not find any beta-catenin gene alterations in the nine fibromellar carcinomas we examined. Nuclear accumulation of the protein was observed in 18 of them (25%), Remarkably, these included ten of the 14 tumors harboring somatic mutations in the beta-catenin gene (P<0.001). Our results indicate that accumulation of beta-catenin resulting from genetic mutations is a frequent event in non-fibrolamellar type hepatocellular carcinoma. The close association between increased beta-catenin protein stability and mutation indicates that immunohistochemistry may he a powerful method for the detection of the mutated protein in future clinical practice.	Hop Beaujon, Serv Anat Pathol, Clichy, France; Hop Beaujon, Serv Hepatol, Clichy, France; Hop Beaujon, Serv Chirurg Digest, Clichy, France; Inst Pasteur, INSERM, Unite Recombinaison & Express Genet, U163, F-75724 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Terris, B (corresponding author), Hop Beaujon, Serv Anat Pathol, Clichy, France.		Terris, Benoit/P-1497-2017; Dejean, Anne/L-5145-2018; Pineau, Pascal/AAP-5614-2020	Pineau, Pascal/0000-0002-9407-1592; Valla, Dominique/0000-0002-4460-7643				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Alman BA, 1997, AM J PATHOL, V151, P329; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boige V, 1997, CANCER RES, V57, P1986; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Fukuchi T, 1998, CANCER RES, V58, P3526; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gruner BA, 1998, J PEDIAT HEMATOL ONC, V20, P274, DOI 10.1097/00043426-199805000-00018; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Inomata M, 1996, CANCER RES, V56, P2213; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Iwao K, 1998, CANCER RES, V58, P1021; Kitaeva MN, 1997, CANCER RES, V57, P4478; Koch A, 1999, CANCER RES, V59, P269; LAURENTPUIG P, 1992, HEPATOLOGY, V16, P1171, DOI 10.1016/0270-9139(92)90010-7; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Miyoshi Y, 1998, CANCER RES, V58, P2524; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller O, 1998, GENE CHROMOSOME CANC, V22, P37; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nollet F, 1996, GENOMICS, V32, P413, DOI 10.1006/geno.1996.0136; Oda H, 1996, CANCER RES, V56, P3320; OKUDA K, 1989, GASTROENTEROLOGY, V97, P140, DOI 10.1016/0016-5085(89)91427-3; Piao Z, 1997, CANCER-AM CANCER SOC, V80, P865; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; Terris B, 1996, J CLIN PATHOL-CL MOL, V49, pM203; TREVISANI F, 1995, CANCER-AM CANCER SOC, V75, P2220, DOI 10.1002/1097-0142(19950501)75:9<2220::AID-CNCR2820750906>3.0.CO;2-4; Voeller HJ, 1998, CANCER RES, V58, P2520; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; ZHANG X, 1994, CANCER RES, V54, P4177; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	38	105	108	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6583	6588		10.1038/sj.onc.1203051	http://dx.doi.org/10.1038/sj.onc.1203051			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597262				2022-12-28	WOS:000083709200022
J	Garcia, P; Frampton, J; Ballester, A; Cales, C				Garcia, P; Frampton, J; Ballester, A; Cales, C			Ectopic expression of cyclin E allows non-endomitotic megakaryoblastic K562 cells to establish re-replication cycles	ONCOGENE			English	Article						cyclins; cell cycle; re-replication; megakaryocytic differentiation; transcriptional regulation	DEPENDENT KINASE INHIBITOR; POLYPLOID DNA CONTENT; S-PHASE; DROSOPHILA EMBRYOGENESIS; DOWN-REGULATION; ENDOREDUPLICATION CYCLES; DEVELOPMENTAL CONTROL; MEGAKARYOCYTE PLOIDY; A GENE; TRANSITION	Megakaryocytes become polyploid by entering a truncated cell cycle, consisting of alternate S phases and abortive mitoses, We have investigated the regulation of the G1/S transition by comparing two megakaryoblastic cell lines, HEL and K562, which respectively do or do not become polyploid in response to phorbol esters, A pronounced downregulation of cyclin A, and to a lesser extent of cyclin E, occurred in K562 cells during the first 24 h after TPA treatment, in contrast with re-replicating HEL cells, in which both cyclins were present in individual G2/M cells, Transactivation experiments suggested that the absence of cyclin A in differentiated K562 cells could be due to a TPA-mediated inhibition of its transcription. To investigate the potential role of cyclin E in the establishment of re-replication cycles, we isolated K562 clones constitutively expressing cyclin E, The resulting clones, and also K562 cells transiently expressing cyclin E, entered re-replication cycles when treated with TPA, The transcriptional activity of the cyclin A promoter was not inhibited after TPA treatment, and although the Levels of cyclin A fluctuated during further re-replication cycles, they never decreased below S phase levels. We conclude that the presence of cyclin E in megakaryoblastic G2/M cells determines cyclin A expression and allows the entrance into an extra S phase.	Univ Autonoma Madrid, CSIC, Dept Bioquim, Inst Invest Biomed A Sols, E-28029 Madrid, Spain; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Oxford	Cales, C (corresponding author), Univ Autonoma Madrid, CSIC, Dept Bioquim, Inst Invest Biomed A Sols, Arturo Duperier 4, E-28029 Madrid, Spain.		Calés, Carmela/AAB-1595-2019	Cales, Carmela/0000-0002-6987-2259; Ballester Jareno, Alicia/0000-0002-6474-7248; Garcia, Paloma/0000-0001-5582-8575				CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Datta NS, 1998, CELL GROWTH DIFFER, V9, P639; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; DENARIER E, 1993, BIOCHEM BIOPH RES CO, V195, P1360, DOI 10.1006/bbrc.1993.2193; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dong XZ, 1997, GENE DEV, V11, P94, DOI 10.1101/gad.11.1.94; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Ebbe S, 1976, Prog Hemost Thromb, V3, P211; EDGAR B, 1995, CURR OPIN CELL BIOL, V7, P815, DOI 10.1016/0955-0674(95)80065-4; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Garcia P, 1996, ONCOGENE, V13, P695; GIRARD F, 1991, CELL, V67, P1; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; HEGYI E, 1991, EXP HEMATOL, V19, P87; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOFFMAN R, 1989, BLOOD, V74, P1196; HORIGUCHIYAMADA J, 1993, MOL CELL BIOCHEM, V119, P29, DOI 10.1007/BF00926850; Jallepalli PV, 1997, CURR OPIN CELL BIOL, V9, P358, DOI 10.1016/S0955-0674(97)80008-7; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KRISTENSEN SD, 1988, THROMB HAEMOSTASIS, V59, P357; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; KUTER DJ, 1990, BLOOD, V75, P74; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; MacAuley A, 1998, MOL BIOL CELL, V9, P795, DOI 10.1091/mbc.9.4.795; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SMITH AV, 1991, DEVELOPMENT, V112, P997; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; STERN B, 1993, DEVELOPMENT, V117, P219; TOMER A, 1989, BLOOD, V74, P594; VANDERLOO B, 1993, EUR J CLIN INVEST, V23, P621; VARMUZA S, 1988, DEVELOPMENT, V102, P127; Vitrat N, 1998, BLOOD, V91, P3711; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhang Y, 1996, J BIOL CHEM, V271, P4266; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	55	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1820	1833		10.1038/sj.onc.1203494	http://dx.doi.org/10.1038/sj.onc.1203494			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777216				2022-12-28	WOS:000086292500010
J	Itano, O; Ueda, M; Kikuchi, K; Shimazu, M; Kitagawa, Y; Aiura, K; Kitajima, M				Itano, O; Ueda, M; Kikuchi, K; Shimazu, M; Kitagawa, Y; Aiura, K; Kitajima, M			A new predictive factor for hepatocellular carcinoma based on two-dimensional electrophoresis of genomic DNA	ONCOGENE			English	Article						RLGS; HCC; postoperative recurrence; disease-free survival; genetic marker	INTRAHEPATIC RECURRENCE; CLONING METHOD; AMPLIFICATION; CANCER; HEPATECTOMY; RESECTION; CIRRHOSIS; SEQUENCES	Molecular genetic analyses have clarified that accumulation of genomic changes provides important steps in carcinogenesis and have identified a number of valuable genetic markers for certain cancers. To date, however, no prognostic markers have been identified for hepatocellular carcinoma (HCC). In this study, we used restriction landmark genomic scanning (RLGS), a new high-speed screening method for multiple genomic changes, to detect unknown genetic alterations in HCC. Thirty-one HCC samples and their normal counterparts were examined by RLGS. Eight spot changes were common in several cases, and all were seen only on the HCC profile. Five of these spots were detected in more than 12 of 31 cases (38.7%). Viral infection had no influence on changes in the RLGS spots. The disease-free survival rate for patients,vith greater than or equal to 16 changed RLGS spots was significantly lower than that for patients with fewer changed RLGS spots (less than or equal to 15 spots) (P < 0.001). In multivariate analysis, the number of changed spots,vas proven to retain an independent prognostic value (relative risk 1.095: P = 0.0031). These results suggest that the number of changed RLGS spots may be a useful biological marker for recurrence of HCC.	Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan; Tokyo Denryoku Hosp, Dept Surg, Shinjuku Ku, Tokyo 1600016, Japan	Keio University	Ueda, M (corresponding author), Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							ARII S, 1992, CANCER, V69, P913, DOI 10.1002/1097-0142(19920215)69:4<913::AID-CNCR2820690413>3.0.CO;2-T; BELGHITI J, 1991, ANN SURG, V214, P114, DOI 10.1097/00000658-199108000-00004; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Costello JF, 1997, CANCER RES, V57, P1250; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HIMENO Y, 1988, LIVER, V8, P208; HIROTSUNE S, 1992, CANCER RES, V52, P3642; HIROTSUNE S, 1993, BIOCHEM BIOPH RES CO, V194, P1406, DOI 10.1006/bbrc.1993.1981; HSU HC, 1988, CANCER, V61, P2095, DOI 10.1002/1097-0142(19880515)61:10<2095::AID-CNCR2820611027>3.0.CO;2-H; HSU HC, 1991, HEPATOLOGY, V13, P923, DOI 10.1002/hep.1840130520; JOW SC, 1992, HEPATOLOGY, V16, P1367; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KINOSHITA T, 1995, CANCER, V76, P2504, DOI 10.1002/1097-0142(19951215)76:12<2504::AID-CNCR2820761215>3.0.CO;2-I; Kitagawa Y, 1996, CLIN CANCER RES, V2, P909; Kubo S, 1998, JPN J CANCER RES, V89, P419, DOI 10.1111/j.1349-7006.1998.tb00580.x; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Lise M, 1998, CANCER, V82, P1028, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1028::AID-CNCR4>3.0.CO;2-A; *LIV CANC STUD GRO, 1997, CLASS PRIM LIV CANC, P1; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MIWA W, 1995, ELECTROPHORESIS, V16, P227, DOI 10.1002/elps.1150160138; OHSUMI T, 1995, BIOCHEM BIOPH RES CO, V212, P632, DOI 10.1006/bbrc.1995.2016; OHSUMI T, 1995, ELECTROPHORESIS, V16, P203, DOI 10.1002/elps.1150160135; SIRABE K, 1991, HEPATOLOGY, V14, P913; TAKAYAMA T, 1990, LANCET, V336, P1150, DOI 10.1016/0140-6736(90)92768-D; TSUDA H, 1988, GASTROENTEROLOGY, V95, P1664, DOI 10.1016/S0016-5085(88)80093-3; Yamanaka N, 1997, CANCER-AM CANCER SOC, V79, P1509, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1509::AID-CNCR10>3.0.CO;2-1; ZHANG XS, 1987, J BEIJING I CIVIL EN, V2, P2	27	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1676	1683		10.1038/sj.onc.1203459	http://dx.doi.org/10.1038/sj.onc.1203459			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763824				2022-12-28	WOS:000086083800007
J	Belka, C; Rudner, J; Wesselborg, S; Stepczynska, A; Marini, P; Lepple-Wienhues, A; Faltin, H; Bamberg, M; Budach, W; Schulze-Osthoff, K				Belka, C; Rudner, J; Wesselborg, S; Stepczynska, A; Marini, P; Lepple-Wienhues, A; Faltin, H; Bamberg, M; Budach, W; Schulze-Osthoff, K			Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis	ONCOGENE			English	Article						caspase-8; BID; radiation; apoptosis; mitochondria	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; DRUG-INDUCED APOPTOSIS; BCL-X-L; CELL-DEATH; ISOLATED-MITOCHONDRIA; SIGNALING COMPLEX; LYMPHOMA-CELLS; BAX; RECEPTORS	Activation of the CD95 death receptor as well as ionizing radiation induces apoptotic cell death in human lymphoma cells. The activation of caspases is a hallmark of apoptosis induction irrespective of the apoptotic trigger. In contrast to death receptor signaling, the exact mechanisms of radiation-induced caspase activation are not well understood. We provide evidence that both, radiation and CD95 stimulation, induce the rapid activation of caspase-8 and BID followed by apoptosis in Jurkat T-cells, To analyse the relative position of caspase-8 within the apoptotic cascade we studied caspase activation and apoptosis in Jurkat cells overexpressing Bcl-2 or Bcl-x(L). Caspase-8 activation, proapoptotic BID cleavage and apoptosis in response to radiation were abrogated in these cells, while the responses to CD95 stimulation were only partially attenuated by overexpression of Bcl-2 family members. In parallel, the breakdown of the mitochondrial transmembrane potential (Delta Psi(m),) in response to radiation was inhibited by overexpression of Bcl-2/Bcl-x(L) Jurkat cells genetically deficient for caspase-8 were found to be completely resistant towards CD95, However, radiation-induced apoptotic responses in caspase-8-negative cells displayed only a modest reduction. We conclude that ionizing radiation activates caspase-8 and BID downstream of mitochondrial damage suggesting that, in contrast to CD95, both events function as executioners rather than initiators of the apoptotic process.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Tubingen, Dept Physiol 1, D-72076 Tubingen, Germany; Univ Munster, Div Cell Biol & Immunol, D-4400 Munster, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; University of Munster	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013; Rudner, Justine/ABD-1397-2021	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Steemans M, 1998, J EXP MED, V188, P2193, DOI 10.1084/jem.188.11.2193; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wanner GA, 1999, FASEB J, V13, P1239, DOI 10.1096/fasebj.13.10.1239; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	117	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2000	19	9					1181	1190		10.1038/sj.onc.1203401	http://dx.doi.org/10.1038/sj.onc.1203401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713706				2022-12-28	WOS:000085567800008
J	Cogswell, PC; Guttridge, DC; Funkhouser, WK; Baldwin, AS				Cogswell, PC; Guttridge, DC; Funkhouser, WK; Baldwin, AS			Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3	ONCOGENE			English	Article						NF-kappa B; breast cancer; Bcl-3; NF-kappa B2/p52	CANDIDATE PROTOONCOGENE BCL-3; GERMINAL CENTER REACTIONS; INDUCED CELL-DEATH; SPLENIC MICROARCHITECTURE; ONCOPROTEIN BCL-3; INDUCED APOPTOSIS; IMMUNE-RESPONSES; TRANSGENIC MICE; FACTOR-I; PROTEINS	Members of the NF-kappa B/Rel transcription factor family have been shown recently to be required for cellular transformation by oncogenic Ras and by other oncoproteins and to suppress transformation-associated apoptosis. Furthermore, NF-kappa B has been shown to be activated by several oncoproteins including HER2/Neu, a receptor tyrosine kinase often expressed in human breast cancer. Human breast cancer cell lines, human breast tumors and normal adjacent tissue were analysed by gel mobility shift assay, immunoblotting of nuclear extracts and immunohistochemistry for activation of NF-kappa B, Furthermore, RNA levels for NF-kappa B-activated genes were analysed in order to determine if NF-kappa B is functionally active in human breast cancer. Our data indicate that the p65/RelA subunit of NF-kappa B is activated (i.e., nuclear) in breast cancer cell lines. However, breast tumors exhibit an absence or low level of nuclear p65/RelA but show activated c-Rel, p50 and p52 as compared to nontumorigenic adjacent tissue. Additionally, the I kappa B homolog Bcl-3, which functions to stimulate transcription with p50 or p52, was also activated in breast tumors. There was no apparent correlation between estrogen receptor status and levels of nuclear NF-kappa B complexes. Transcripts of NF-kappa B-regulated genes were found elevated in breast tumors, as compared to adjacent normal tissue, indicating functional NF-kappa B activity. These data suggest a potential role for a subset of NF-kappa B and I kappa-B family proteins, particularly NF-kappa B/p52 and Bcl-3, in human breast cancer. Additionally, the activation of functional NF-kappa B in these tumors likely involves a signal transduction pathway distinct from that utilized by cytokines.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr 22 000, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr 22 000, Chapel Hill, NC 27599 USA.			Guttridge, Denis/0000-0002-7276-6609	NATIONAL CANCER INSTITUTE [R01CA072771, P50CA058223, T32CA009156] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09156, CA72771, CA58223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1997, J CLIN INVEST, V100, P2935, DOI 10.1172/JCI119843; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F; Michaux L, 1997, CANCER GENET CYTOGEN, V94, P36, DOI 10.1016/S0165-4608(96)00247-6; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; Resnik JL, 1998, CANCER RES, V58, P1159; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SCHMID RM, 1994, J BIOL CHEM, V269, P32162; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	48	369	379	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1123	1131		10.1038/sj.onc.1203412	http://dx.doi.org/10.1038/sj.onc.1203412			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713699	Green Submitted			2022-12-28	WOS:000085567800001
J	Schuster, R; Gerlich, WH; Schaefer, S				Schuster, R; Gerlich, WH; Schaefer, S			Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts	ONCOGENE			English	Article						apoptosis; Bcl-2; E1B; HBV; HBx; HCC	PROGRAMMED CELL-DEATH; HBX PROTEIN; C-JUN; MALIGNANT TRANSFORMATION; IN-VITRO; ACTIVATION; EXPRESSION; P53; MURINE; DNA	Epidemiology shows a clear correlation between chronic infection with the hepatitis B virus (HBV) and development of hepatocellular carcinoma (HCC). The potential role of the transactivating hepatitis B virus X protein (HBx) in transformation by HBV is controversial, Here we report that HBx suppresses transformation of primary rat embryo fibroblasts (REFs), Cooperating oncogenes like c-Ha-ras and c-myc transform REF very efficiently but cotransfection with HBx suppressed transformation of REFs down to 5%, Similarly, transfection of HBx together with the cooperating oncogenes Ha-ras and SV40 LTAg or c-Ha-ras and mutant p53 reduced the number of foci to 13%. Comparable results were obtained with HBx in the context of the whole HBV, Suppression of focus formation in REF could be partly relieved by cotransfection of apoptosis inhibitors Bcl-2 or E1B, However, cotransfection of apoptosis inhibitors crmA and p35 did not influence the proapoptotic functions of HBx, Thus, HBx may specifically activate the Bcl-2 sensitive pathway leading to apoptosis. Experiments with 13 HBx linker scanning mutants revealed that the domains necessary for HBx dependent transactivation overlap with the domains needed for the apoptotic/growth arrest functions of HBx.	Univ Giessen, Inst Med Virol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Schaefer, S (corresponding author), Univ Giessen, Inst Med Virol, Frankfurter Str 107, D-35392 Giessen, Germany.							AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, P914; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; Brechot C, 1998, J HEPATOL, V29, P173, DOI 10.1016/S0168-8278(98)80001-9; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Cory S, 1998, BBA-REV CANCER, V1377, pR25, DOI 10.1016/S0304-419X(98)00003-1; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Kairat A, 1999, INTERVIROLOGY, V42, P228, DOI 10.1159/000024982; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LAND H, 1995, METHOD ENZYMOL, V254, P37; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Parker GA, 1996, ONCOGENE, V13, P2541; PEACOCK JW, 1990, ONCOGENE, P1769; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; PONCHEL F, 1994, CANCER RES, V54, P2064; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Schaefer S, 1998, J GEN VIROL, V79, P767, DOI 10.1099/0022-1317-79-4-767; Schaefer S, 1995, INTERVIROLOGY, V38, P143, DOI 10.1159/000150425; SCHAEFER S, 1999, ADV ONCOLOGY, V3; SCHLUTER V, 1994, ONCOGENE, V9, P3335; SEEGER C, 1989, J VIROL, V63, P4665, DOI 10.1128/JVI.63.11.4665-4669.1989; SEIFER M, 1990, VIROLOGY, V179, P300, DOI 10.1016/0042-6822(90)90298-6; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SEIFER M, 1990, VIROLOGY, V179, P287, DOI 10.1016/0042-6822(90)90297-5; SEIFER M, 1991, VIRAL HEPATITIS 1990, P58; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; WANG XW, 1995, CANCER RES, V55, P6012; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	62	63	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1173	1180		10.1038/sj.onc.1203417	http://dx.doi.org/10.1038/sj.onc.1203417			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713705				2022-12-28	WOS:000085567800007
J	Coldwell, MJ; Mitchell, SA; Stoneley, M; MacFarlane, M; Willis, AE				Coldwell, MJ; Mitchell, SA; Stoneley, M; MacFarlane, M; Willis, AE			Initiation of Apaf-1 translation by internal ribosome entry	ONCOGENE			English	Article						cap-dependent translation; Apaf-1; apoptosis; IRES; 5 ' UTR; Ced-4	CAP-INDEPENDENT TRANSLATION; PROGRAMMED CELL-DEATH; FACTOR MESSENGER-RNA; FACTOR 4G EIF4G; BCL-X-L; PROTEIN-SYNTHESIS; C-MYC; ALTERNATIVE TRANSLATION; BINDING-PROTEIN; CYTOCHROME-C	The apoptotic protease activating factor (Apaf-1) plays a central role in apoptosis: interaction of this protein with procaspase-9 leads to cleavage and activation of this initiator caspase, In common with other mRNAs whose protein products have a major regulatory function, the 5' untranslated region (UTR) of Apaf-1 is long, G-C rich and has the potential to form secondary structure. We have shown that the 5' UTR of Apaf-1 contains an internal ribosome entry segment, located in a 233 nucleotide region towards the 3' end of the leader, and that the translation initiation of this mRNA occurs only by internal ribosome entry. The Apaf-1 IRES is active in almost all human cell types tested, including Human cervical carcinoma (HeLa), Human liver carcinoma (HepG2), Human breast carcinoma (MCF7), Human embryonic kidney (HK293), African Green Monkey kidney (COS7) and Human lung (MRCS), The Apaf-1 IRES initiates translation as efficiently as the HRV IRES, but is less active than the c-myc IRES, We propose that the Apaf-1 IRES ensures that a constant cellular level of Apaf-1 protein is maintained even under conditions where cap-dependent translation is compromised.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Willis, Anne/0000-0002-1470-8531				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; Burgess DH, 1999, CELL DEATH DIFFER, V6, P256, DOI 10.1038/sj.cdd.4400489; Cardozo TJ, 1998, J MOL MODEL, V4, P83, DOI 10.1007/s008940050134; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Jackson RJ, 1995, RNA, V1, P985; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kevil C, 1995, ONCOGENE, V11, P2339; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PANNIERS R, 1994, BIOCHIMIE, V76, P737, DOI 10.1016/0300-9084(94)90078-7; Perkins C, 1998, CANCER RES, V58, P4561; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STONELEY M, 1998, THESIS U LEICESTER; STONELEY M, 2000, IN PRESS MOL CELL BI, V20; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; West MJ, 1995, ONCOGENE, V11, P2515; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; ZAMORA AJ, 1995, EUR J APPL PHYSIOL O, V71, P505, DOI 10.1007/BF00238552; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	170	175	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					899	905		10.1038/sj.onc.1203407	http://dx.doi.org/10.1038/sj.onc.1203407			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702798				2022-12-28	WOS:000085567700007
J	Balajee, AS; DeSantis, LP; Brosh, RM; Selzer, R; Bohr, VA				Balajee, AS; DeSantis, LP; Brosh, RM; Selzer, R; Bohr, VA			Role of the ATPase domain of the Cockayne syndrome group B protein in UV induced apoptosis	ONCOGENE			English	Article						Cockayne syndrome; transcription coupled repair; neurodegeneration; RNA pol II transcription; apoptosis; p53 independent pathway	RNA-POLYMERASE-II; TRANSCRIPTION-COUPLED REPAIR; CSB ERCC6 GENE; DNA-DAMAGE; HUMAN FIBROBLASTS; FACTOR CSB/ERCC6; P53 PROTEIN; CELLS; ACCUMULATION; SENSITIVITY	Cockayne syndrome (CS) is a human autosomal recessive disorder characterized by many neurological and developmental abnormalities, CS cells are defective in the transcription coupled repair (TCR) pathway that removes DNA damage from the transcribed strand of active genes, The individuals suffering from CS do not generally develop cancer but show increased neurodegeneration, Two genetic complementation groups (CS-A and CS-B) have been identified, The lack of cancer formation in CS may be due to selective elimination of cells containing DNA damage by a suicidal pathway. In this study, we have evaluated the role of the CSB gene in UV induced apoptosis in human and hamster cells. The hamster cell line UV61 carries a mutation in the homolog of the human CSB gene, We show that both human CS-B and hamster UV61 cells display increased apoptotic response following UV exposure compared with normal cells, The increased sensitivity of UV61 cells to apoptosis is complemented by the transfection of the wild type human CSB gene, In order to determine which functional domain of the CSB gene participates in the apoptotic pathway, we constructed stable cell lines with different CSB domain disruptions, UV61 cells were stably transfected with the human CSB cDNA containing a point mutation in the highly conserved glutamic acid residue in ATPase motif II, This cell line (UV61/pc3.1-CSBE646Q) showed the same increased apoptosis as the UV61 cells, In contrast, cells containing a deletion in the acidic domain at the N-terminal end of the CSB protein had no effect on apoptosis, This indicates that the integrity of the ATPase domain of CSB protein is critical for preventing the UV induced apoptotic pathway, In primary human CS-B cells, the induction and stabilization of the p53 protein seems to correlate with their increased apoptotic potential, In contrast, no change in the level of either p53 or activation of mdm2 protein by p53 was observed in hamster UV61 cells after UV exposure. This suggests that the CSB dependent apoptotic pathway can occur independently of the transactivation potential of p53 in hamster cells.	NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), NIA, Genet Mol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020	Proietti De Santis, Luca/0000-0002-2715-9113				Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; Guillouf C, 1998, INT J ONCOL, V13, P107; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LEE AT, 1994, FASEB J, V8, P545, DOI 10.1096/fasebj.8.8.8181674; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Mallery DL, 1998, AM J HUM GENET, V62, P77, DOI 10.1086/301686; MAYNE LV, 1982, CANCER RES, V42, P1473; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Ohta M, 1999, MUTAT RES-DNA REPAIR, V433, P23, DOI 10.1016/S0921-8777(98)00058-5; Orren DK, 1997, MOL BIOL CELL, V8, P1129, DOI 10.1091/mbc.8.6.1129; Orren DK, 1996, NUCLEIC ACIDS RES, V24, P3317, DOI 10.1093/nar/24.17.3317; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; Stecca C, 1998, BIOCHEM PHARMACOL, V55, P941, DOI 10.1016/S0006-2952(97)00448-6; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; vanOosterwijk MF, 1996, NUCLEIC ACIDS RES, V24, P4653, DOI 10.1093/nar/24.23.4653; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	36	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2000	19	4					477	489		10.1038/sj.onc.1203372	http://dx.doi.org/10.1038/sj.onc.1203372			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698517				2022-12-28	WOS:000085104200001
J	Jackson, S; Storey, A				Jackson, S; Storey, A			E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage	ONCOGENE			English	Article						HPV; UV; apoptosis; skin	RENAL-TRANSPLANT RECIPIENTS; HUMAN PAPILLOMAVIRUS TYPE-16; NONMELANOMA SKIN CANCERS; CARCINOMA CELL-LINES; EPIDERMODYSPLASIA-VERRUCIFORMIS; IMMUNOSUPPRESSED PATIENTS; P53; UBIQUITINATION; ASSOCIATION; LESIONS	In addition to their role in anogenital cancer, human papillomaviruses (HPVs) are also involved in the development of a range of cutaneous lesions. HPV types 5 and 8 are associated with the development of skin cancers in individuals with Epidermodysplasia verruciformis (EV). A broad spectrum of NPV types are also commonly found in non-melanoma skin cancers in immunocompromised individuals, such as organ transplant recipients. The skin cancers in EV and immunocompromised patients occur predominantly at body sites exposed to ultra violet (UV) radiation, pointing to a key role for UV in their development, Here rye show that the E6 protein from a range of cutaneous NPV types effectively inhibits apoptosis in response to UV damage, This occurs in both p53 null and wild type cells and does not require p53 degradation.	Ctr Cutaneous Res, Imperial Canc Res Fund, Skin Tumour Lab, London E1 2AT, England	Cancer Research UK	Storey, A (corresponding author), Ctr Cutaneous Res, Imperial Canc Res Fund, Skin Tumour Lab, 2 Newark St, London E1 2AT, England.		高, 雨莉/HGU-8187-2022	Storey, Alan/0000-0003-2001-9772				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BERKHOUT RJM, 1995, J CLIN MICROBIOL, V33, P690, DOI 10.1128/JCM.33.3.690-695.1995; CAMPBELL C, 1993, CANCER RES, V53, P2697; CROOK T, 1991, ONCOGENE, V6, P873; DEJONGTIEBEN LM, 1995, J INVEST DERMATOL, V105, P367, DOI 10.1111/1523-1747.ep12320803; Delius H, 1998, VIROLOGY, V240, P359, DOI 10.1006/viro.1997.8943; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elbel M, 1997, VIROLOGY, V239, P132, DOI 10.1006/viro.1997.8860; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAVRE M, 1989, J VIROL, V63, P4909, DOI 10.1128/JVI.63.11.4909-.1989; Grossman D, 1997, ARCH DERMATOL, V133, P1263, DOI 10.1001/archderm.133.10.1263; HALL PA, 1993, ONCOGENE, V8, P203; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hopfl R, 1997, J INVEST DERMATOL, V108, P53, DOI 10.1111/1523-1747.ep12285630; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JABLONSKA S, 1972, CANCER RES, V32, P583; JABLONSKA S, 1990, PAPILLOMAVIRUSES HUM, P46; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MAJEWSKI S, 1995, ARCH DERMATOL, V131, P1312, DOI 10.1001/archderm.131.11.1312; OBALEK S, 1992, J INVEST DERMATOL, V98, P936, DOI 10.1111/1523-1747.ep12460892; OKAN I, 1995, ONCOGENE, V11, P1027; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ORTH G, 1979, CANCER RES, V39, P1074; ORTH G, 1987, PAPOVAVIRIDAE, P189; Petrocelli T, 1996, ONCOGENE, V12, P1387; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PROBY C, 1996, PAPILLOMAVIRUS REPOR, V7, P53; PURDIE KJ, 1993, CANCER RES, V53, P5328; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; SHAMANIN V, 1994, CANCER RES, V54, P4610; SMITH ML, 1995, ONCOGENE, V10, P1053; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Surentheran T, 1998, J CLIN PATHOL, V51, P606, DOI 10.1136/jcp.51.8.606; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	44	159	166	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					592	598		10.1038/sj.onc.1203339	http://dx.doi.org/10.1038/sj.onc.1203339			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698529				2022-12-28	WOS:000085104200013
J	Liu, R; Liu, CB; Mohi, MG; Arai, K; Watanabe, S				Liu, R; Liu, CB; Mohi, MG; Arai, K; Watanabe, S			Analysis of mechanisms involved in the prevention of gamma irradiation-induced apoptosis by hGM-CSF	ONCOGENE			English	Article						cytokine receptor; signal transduction; JAK2; cell death; gamma irradiation	COLONY-STIMULATING FACTOR; RADIATION-INDUCED APOPTOSIS; CELL-PROLIFERATION; FACTOR-RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; ATAXIA-TELANGIECTASIA; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; RAF-1 KINASE	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) induces proliferation and sustains viability of the mouse interleukin (IL)-3 dependent lymphoid cell line BA/F3 expressing the hGM-CSF receptor. Caspase-3 like enzyme activity and DNA fragmentation were augmented by depletion of this factor from the cell, and exposure to gamma irradiation accelerated kinetics of these events. Anti gamma irradiation-induced apoptosis occurred through various mutant GM-CSF receptors and only the box1 region was essential while the C terminal region, including tyrosine residues which are required for MAPK cascade activation, was dispensable. Consistent with this notion, the addition of PD98059 had no effect on this activity thereby indicating that activation of MAPK is not essential for the activity. As expected, gamma irradiation increased p53 protein and bax mRNA levels and the presence of hGM-CSF dramatically modulated bax/bcl-X-L ratio. The PI-3K specific inhibitor wortmannin did not affect hGM-CSF dependent anti gamma irradiation induced apoptosis nor bcl-X-L induction, thus bcl-X-L but not PI-3K pathway seems to be involved in hGM-CSF dependent anti gamma irradiation-induced apoptosis. It is well documented that the boxl region is essential for GM-CSF dependent activation of JAK2 and JAK2 specific inhibitor AG490 suppressed anti gamma irradiation-induced apoptosis by hGM-CSF. An artificial JAK2 activating molecule in which extracellular and the transmembrane of beta c fused with whole JAK2 can sustain BA/F3 cells survival and proliferation mIL-3 independently, but these cells are susceptible to gamma irradiation. Furthermore GyrB/Jak2, which can activate STAT5 but not the MAPK cascade nor survival of BA/F3 cells, also could not prevent gamma irradiation-induced apoptosis. Although JAK2 is essential for hGM-CSF dependent anti gamma irradiation-induced apoptosis, it appeared that JAK2 does not seem sufficient for the activity.	Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo, Japan; Japan Sci & Technol Corp, CREST, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Watanabe, S (corresponding author), Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo, Japan.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GORCZYCA W, 1993, CANCER RES, V53, P1945; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; Liu CB, 1999, J BIOL CHEM, V274, P6342, DOI 10.1074/jbc.274.10.6342; Liu R, 1999, MOL BIOL CELL, V10, P3959, DOI 10.1091/mbc.10.11.3959; LIU R, 1999, IN PRESS J ALLERGY C; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; PESO LD, 1997, SCIENCE, V278, P687; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WATANABE S, 1995, J BIOL CHEM, V270, P9615, DOI 10.1074/jbc.270.16.9615; Wei S, 1996, J IMMUNOL, V157, P5155; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	46	15	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					571	579		10.1038/sj.onc.1203364	http://dx.doi.org/10.1038/sj.onc.1203364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698527				2022-12-28	WOS:000085104200011
J	Hutton, FG; Turnell, AS; Gallimore, PH; Grand, RJA				Hutton, FG; Turnell, AS; Gallimore, PH; Grand, RJA			Consequences of disruption of the interaction between p53 and the larger adenovirus early region 1B protein in adenovirus E1 transformed human cells	ONCOGENE			English	Article						p53; adenovirus E1B; penetratin peptides	WILD-TYPE P53; TUMOR-SUPPRESSOR; CELLULAR PROTEIN; APOPTOSIS; EXPRESSION; ONCOGENICITY; LOCALIZATION; ASSOCIATION; FRAGMENTS; BINDING	The adenovirus early region 1B (Ad E1B) genes have no transforming capability of their own but markedly increase the transformation frequency of Ad EIA following co-transfection into mammalian cells, The larger E1B proteins of both Ad2/5 and Ad12 bind to p53 and inhibit its ability to transcriptionally activate other genes. We have previously demonstrated that synthetic peptides identical to the binding sites for p53 on both the Ad2 and Ad12 E1B proteins will disrupt the interaction in vivo and in vitro . in the work presented here we have examined the effects of complex dissociation on Ad El-transformed human cells, If has been shown, using confocal microscopy, that when the peptide identical to the p53 binding site was added to Ad5 E1-transformed cells it initally located in the cytoplasmic dense bodies where it caused disruption of the p53/E1B complex. Peptide and p53 then translocated to the nucleus, In Ad12 El-transformed cells the peptide localized in the nucleus directly and there caused a reorganization of p53 staining from a highly organized, 'flecke' distribution to one in vc which nuclear staining was homogeneous and diffuse. Peptides added to either Ad5 El or Ad12 El transformed cells resulted in the release of transcriptionally active p53, interestingly, the level of p53 then fell presumably as a result of proteasomal action - this was probably a reflection of the short half-life of 'free' (i.e. dissociated) p53 compared to that of the bound protein, Free p53 did not cause apoptosis in target cells probably due to the presence of the smaller (19K) E1B proteins. However, addition of peptide leads to a significant reduction in cell growth rate. We have further demonstrated that a significant proportion of those cells which had taken up peptide had ceased DNA synthesis, probably due to a p53-induced cell cycle arrest. The role of the larger E1B protein during transformation is considered in view of these data.	Univ Birmingham, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.			Hutton, Fiona/0000-0002-9707-2988				BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; Chinnadurai G, 1998, SEMIN VIROL, V8, P399, DOI 10.1006/smvy.1997.0139; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Gabler S, 1998, J VIROL, V72, P7960, DOI 10.1128/JVI.72.10.7960-7971.1998; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GALLIMORE PH, 1985, SOC GEN MICROBIOL S, V37, P125; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HUEN DS, 1995, ONCOGENE, V10, P549; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; MERRICK RM, 1991, J GEN VIROL, V72, P955, DOI 10.1099/0022-1317-72-4-955; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	37	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					452	462		10.1038/sj.onc.1203316	http://dx.doi.org/10.1038/sj.onc.1203316			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656694				2022-12-28	WOS:000084873700017
J	Calvo, KR; Knoepfler, P; McGrath, S; Kamps, MP				Calvo, KR; Knoepfler, P; McGrath, S; Kamps, MP			An inhibitory switch derepressed by Pbx, Hox, and Meis/Prep1 partners regulates DNA-binding by Pbx1 and E2a-Pbx1 and is dispensable for myeloid immortalization by E2a-Pbx1	ONCOGENE			English	Article						Pbx; E2a-Pbx1; t(1;19) pre-B ALL; Hox; Meis; Prep1; leukemia	GLUCOCORTICOID RESPONSE ELEMENT; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN PROTOONCOGENE PBX1; ONCOPROTEIN E2A-PBX1; PRE-B; TRANSCRIPTION FACTOR; TRANSLOCATION PROTEIN; CHIMERIC ONCOPROTEIN; HOMEODOMAIN PROTEIN; MAPKAP KINASE-2	The Pbx/Exd family of homeodomain (HD) proteins contribute to the transcriptional and developmental roles of other Hox and Meis/Prep1/Hth HD proteins through heterodimer formation, E2a-Pbx1 is an oncogenic derrivative of Pbx1 produced by the t(1;19) translocation in pediatric pre-B cell acute lymphoblastic leukemia. E2a-Pbx1 heterodimerizes with Hox but not with Meis/ Prep1 proteins, produces acute myeloid leukemia in mice, and blocks differentiation of cultured murine myeloid progenitors, Here, we characterize negative and positive regulatory sequences that flank the Pbx1 HD and determine their importance for myeloid immortalization by E2a-Pbx1. A 25 residue predicted alpha helix preceding the Pbx1 HD bound the HD and prevented both its binding to DNA and its ability to heterodimerize with Hox proteins, Addition of 39 residues N-terminal to this inhibitory helix exposed a Pbs dimerization interface that orchestrated cooperative DNA-binding of E2a-Pbx1 and all Pbx proteins as homodimers and heterdimers, Sequences inhibiting DNA-binding and mediating Pbs dimerization coincided with those reported to have nuclear export function. An additional 103 residues N-terminal to the Pbx dimerization interface restored heterodimerization with Hox and Meis1/Prep1 proteins. This negative switch domain comprised of the inhibitory helix and N-terminal regions required for its partner-mediated derepression - was dispensable for myeloid immortalization by E2a-Pbx1, While stabilizing the heterodimer, the 3(10) helix C-terminal to the Pbx1 HD was also dispensable for the ability of E2a-Pbx1 to heterodimerize with Hox proteins and immortalize myeloblasts. Retention of myeloid immortalization by E2a-Pbx1 proteins lacking all Pbx1 sequences N- or C-terminal to the HD indicates that Has proteins, or a get undefined factor that binds the Pbx1 HD and derepresses DNA-binding by the HD, cooperate with E2a-Pbx1 in myeloid immortalization.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Calvo, KR (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Calvo, Katherine/A-8109-2009	Knoepfler, Paul/0000-0001-5444-334X; Calvo, Katherine/0000-0002-0771-4191	NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; CARROLL AJ, 1984, BLOOD, V63, P721; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DeCesare D, 1997, J BIOL CHEM, V272, P23921, DOI 10.1074/jbc.272.38.23921; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Green NC, 1998, J BIOL CHEM, V273, P13273, DOI 10.1074/jbc.273.21.13273; Grieder NC, 1997, EMBO J, V16, P7402, DOI 10.1093/emboj/16.24.7402; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, ONCOGENE, V14, P2521, DOI 10.1038/sj.onc.1201097; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUMATA SI, 1993, LEUKEMIA, V7, P1441; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Subramaniam N, 1997, DNA CELL BIOL, V16, P153, DOI 10.1089/dna.1997.16.153; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3	65	36	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 23	1999	18	56					8033	8043		10.1038/sj.onc.1203377	http://dx.doi.org/10.1038/sj.onc.1203377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637514				2022-12-28	WOS:000084634600012
J	Karsunky, H; Geisen, C; Schmidt, T; Haas, K; Zevnik, B; Gau, E; Moroy, T				Karsunky, H; Geisen, C; Schmidt, T; Haas, K; Zevnik, B; Gau, E; Moroy, T			Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc	ONCOGENE			English	Article						cyclin E; Ki-ras; p27(KIP1); MNU; lymphoma; oncogene cooperation	BREAST-CANCER CELLS; CDK INHIBITORS; RETINOBLASTOMA PROTEIN; RESTRICTION POINT; DEPENDENT KINASES; THYMIC LYMPHOMAS; NUCLEAR-PROTEIN; EXPRESSION; PROLIFERATION; P27(KIP1)	To study the oncogenic activity of cyclin E in an in vivo system we generated transgenic mice expressing high levels of cyclin Ii: in T-lymphocytes by using a construct containing the CD2 locus control region. These animals were neither predisposed to develop any tumors spontaneously nor showed an increased incidence when crossbred with E mu L-myc transgenic mice but developed hyperplasia in peripheral lymphoid organs at later age with an incidence of 27%. When treated with the DNA methylating carcinogen N-methylnitrosourea (MNU) that provokes the development of T-cell lymphomas, CD2-cyclin E transgenic animals came down with T-cell neoplasia showing a significant higher incidence (54%) than normal non transgenic controls (31%). In one of eight tumors that arose in normal MNU treated mice me could find an expected activating point mutation in the Ki-ras gene (12.5%). In contrast, the same mutation occurred in five of 16 tumors from CD2-cyclin E transgenic mice (31.2%). Whereas cyclin E overexpression alone did not lead to an increased CDK2 activity we observed in ail tumors that emerged from either MNU treated normal mice or treated CD2-cyclin E transgenics a downregulation of p27(KIP1) and a higher histone HI kinase activity: in CDK2 immunoprecipitates compared to normal tissue. These findings demonstrate that high level expression of cyclin E can predispose T-cells for hyperplasia and malignant transformation. However, the results also suggest that this activity of cyclin E is manifest only when other cooperating oncogenes in particular I as genes are present and activated. This would be consistent with our previous finding that cyclin E and Ha-Ras cooperate in focus formation assays in rat embryo fibroblasts.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011; Zevnik, Branko/AAB-7853-2020	Zevnik, Branko/0000-0001-7845-9522				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Erlanson M, 1998, BLOOD, V92, P770; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL M, 1995, ONCOGENE, V11, P1581; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hogan B, 1994, MANIPULATING MOUSE E; JOSHI VV, 1970, J NATL CANCER I, V44, P185; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LIU LL, 1994, CANCER RES, V54, P4648; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; NEWCOMB EW, 1995, MOL CARCINOGEN, V13, P89, DOI 10.1002/mc.2940130205; NEWCOMB EW, 1989, ANTICANCER RES, V9, P1407; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; SEWING A, 1993, J CELL SCI, V104, P545; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WOLOWIEC D, 1995, LEUKEMIA, V9, P1382; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	45	37	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7816	7824		10.1038/sj.onc.1203205	http://dx.doi.org/10.1038/sj.onc.1203205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618723				2022-12-28	WOS:000084256900012
J	Nur-E-Kamal, MSA; Kamal, JM; Qureshi, MM; Maruta, H				Nur-E-Kamal, MSA; Kamal, JM; Qureshi, MM; Maruta, H			The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation	ONCOGENE			English	Article						CDC42; ACK; NGF; neurite outgrowth; Ras transformation; tumor suppressor	PROTEIN; BRADYKININ; GTPASE; GAP; ACTIVATION; DOMAIN; GROWTH	Based on the previous experiments with the N17 mutant of CDC42, it has been speculated, but not proved as yet, that CDC42 is required for Ras-induced malignant transformation of fibroblasts. However, since this inhibitor could sequester many GDP-dissociation stimulators (GDSs), such as DBL, OST and Tiam-1 which activate not only CDC42, but also Rho or Rac, in fact it is not a specific inhibitor that inactivates only CDC42, Thus, we have taken the minimum CDC42-binding domain (residues 504-545, called ACK42) of the Tyr-kinase ACK-1 that binds only CDC42 in the GTP-bound form, and thereby blocking the interactions of CDC42-GTP with its downstream effecters such as ACKs, PAKs and N-WASP, First of all, using the ACK42-GST fusion protein as a specific ligand for the GTP-CDC42 complex, we have revealed that CDC42 is activated by oncogenic Ras mutants such as v-Ha-Ras in NIH3T3 fibroblasts, and similarly in PC12 cells by both NGF (Nerve Growth Factor) and EGF (Epidermal Growth Factor) which activate the endogenous normal Ras, providing the first direct evidence that CDC42 acts downstream of Ras and NGF/EGF. Furthermore, over-expression of ACK42 completely reversed Ras-induced malignant phenotypes such as focus formation and anchorage/serum-independent growth of the fibroblasts, and a cell-permeable derivative of ACK42 called WR-ACK42 strongly inhibited the growth of Ras transformants, with little effect on the parental normal cell growth, and also abolished Ras-induced filopodium/microspike formation of the fibroblasts which is CDC42-dependent. These observations unambiguously proved for the first time that the RAS-induced activation of CDC42 is indeed essential for Ras to transform the fibroblasts, and furthermore suggest that ACK42 or its peptidomimetics are potentially useful for genotherapy or chemotherapy of Ras-associated cancer.	Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Univ Med & Dent New Jersey, RW Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; UAE Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain 17666, U Arab Emirates	Ludwig Institute for Cancer Research; Rutgers State University New Brunswick; Rutgers State University Medical Center; United Arab Emirates University	Maruta, H (corresponding author), Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia.							Aramori I, 1997, MOL PHARMACOL, V51, P171, DOI 10.1124/mol.51.2.171; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MARUTA H, 1998, MOL B INT U, V3, P151; MARUTA H, 1996, REGULATION RAS SIGNA, P139; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Wang DZM, 1997, CANCER RES, V57, P2478; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819	27	47	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7787	7793						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618719				2022-12-28	WOS:000084256900008
J	Sullivan, MJ; Taniguchi, T; Jhee, A; Kerr, N; Reeve, AE				Sullivan, MJ; Taniguchi, T; Jhee, A; Kerr, N; Reeve, AE			Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation	ONCOGENE			English	Article						IGF2; insulin-like growth factor 2; genomic imprinting; Wilms tumour; methylation	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; BIALLELIC EXPRESSION; ALLELIC METHYLATION; HUMAN EMBRYOGENESIS; EPIGENETIC CHANGES; DNA METHYLATION; MOUSE IGF2; H19 LOCUS; GENE	Relaxation of IGF2 imprinting occurs in Wilms tumours and many other cancers, but the mechanism of loss of imprinting (LOI) remains unknown. To investigate the role of altered DNA methylation in LOI, we examined the pattern of methylation of the human insulin-IGF2 region in Wilms tumours and the normal kidney. The analysis included regions homologous to three 'differentially methylated regions' of the mouse Igf2 gene (dmrs 0, 1 and 2), In tumours displaying normal IGF2 imprinting, and in the normal kidney, maternal allele-specific DNA methylation was identified spanning exons 2 and 3, This region is homologous to dmr 0, a site of maternal-specific differential methylation in the mouse. In Wilms tumours with relaxed imprinting or 11p15.5 LOH this region was unmethylated. No other differential methylation was identified, In particular, two sites of paternal methylation in the mouse (dmrs 1 and 2), and all three imprinted IGF2 promoters were not methylated in the kidney or in Wilms tumours, We postulate that LOI in Wilms tumours is associated with loss of maternal allele-specific methylation from a region located upstream of the imprinted IGF2 promoters, This region may contain cis acting sequences that coordinately influence imprinting.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand	University of Otago	Sullivan, MJ (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, New Zealand.		Sullivan, Michael/B-5459-2012	Sullivan, Michael/0000-0002-8606-5889				CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; DoucRasy S, 1996, ONCOGENE, V12, P423; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; FEIL R, 1994, DEVELOPMENT, V120, P2933; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; Hashimoto K, 1997, HUM PATHOL, V28, P862, DOI 10.1016/S0046-8177(97)90162-3; Hibi K, 1996, CANCER RES, V56, P480; Hu JF, 1997, MOL ENDOCRINOL, V11, P1891, DOI 10.1210/me.11.13.1891; Hu JF, 1997, J BIOL CHEM, V272, P20715, DOI 10.1074/jbc.272.33.20715; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Joyce JA, 1997, HUM MOL GENET, V6, P1543, DOI 10.1093/hmg/6.9.1543; Kim KS, 1997, CANCER LETT, V119, P143, DOI 10.1016/S0304-3835(97)00264-4; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Nonomura N, 1997, J UROLOGY, V157, P1977, DOI 10.1016/S0022-5347(01)64913-9; Oda H, 1998, INT J CANCER, V75, P343, DOI 10.1002/(SICI)1097-0215(19980130)75:3<343::AID-IJC3>3.0.CO;2-2; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAINIER S, 1995, CANCER RES, V55, P1836; Randhawa GS, 1998, BLOOD, V91, P3144, DOI 10.1182/blood.V91.9.3144.3144_3144_3147; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TANIGUCHI T, 1995, ONCOGENE, V11, P751; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; Vu TH, 1996, J BIOL CHEM, V271, P9014, DOI 10.1074/jbc.271.15.9014; WEKSBERG R, 1993, HUM MOL GENET, V2, P549, DOI 10.1093/hmg/2.5.549; Wu HK, 1997, BIOCHEM BIOPH RES CO, V231, P466, DOI 10.1006/bbrc.1997.6127; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1993, AM J HUM GENET, V53, P113	50	74	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7527	7534		10.1038/sj.onc.1203096	http://dx.doi.org/10.1038/sj.onc.1203096			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602511				2022-12-28	WOS:000084119600013
J	Sjoblom, T; Boureux, A; Ronnstrand, L; Heldin, CH; Ghysdael, J; Ostman, A				Sjoblom, T; Boureux, A; Ronnstrand, L; Heldin, CH; Ghysdael, J; Ostman, A			Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein	ONCOGENE			English	Article						chronic myelomonocytic leukemia; chromosomal translocation; platelet-derived growth factor; TEL	ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL; TRANSFORMING PROTEIN; PHOSPHORYLATION SITE; TYROSINE KINASE; RECEPTOR-BETA; GENE FUSION; GROWTH; ETS; DOMAIN	The t(5;12) translocation, associated with chronic myelomonocytic leukemia, generates a novel gene encoding a protein, TEL-PDGF beta R, composed of the 154 amino-terminal amino acids of the transcription factor TEL and the transmembrane and intracellular part of the PDGF beta-receptor (PDGF beta R). TEL also occurs as a tumor-associated fusion partner for the tyrosine kinases c-ABL, JAK2 and TRK-C. Previous studies have demonstrated growth promoting activity of TEL-PDGF beta R and also indicated that the TEL moiety activates the tyrosine kinase of the PDGF beta R through the formation of TEL-PDGF beta R oligomers. We demonstrate that tyrosine phosphorylation of the fusion protein can be attenuated through overexpression of the TEL part of TEL-PDGF beta R, suggesting a strategy for antagonizing the signaling of TEL-PDGF beta R, and other TEL-fusion proteins containing tyrosine kinase domains. Comparison of BaF/3 cell lines expressing TEL-PDGF beta R and ligand-stimulated PDGF beta R revealed that only TEL-PDGF beta R expression conferred IL-3-independent growth, suggesting differences in signaling capacity of the two proteins. Finally, tyrosine residues 17 and 27 in TEL-PDGF beta R was identified as autophosphorylation sites in TEL-PDGF beta R.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Ctr Univ Orsay, Inst Curie, CNRS UMR 146, Sect Rech, F-91405 Orsay, France	Ludwig Institute for Cancer Research; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Ostman, A (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.		GHYSDAEL, Jacques/F-3377-2013; Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				Abe A, 1997, BLOOD, V90, P4271, DOI 10.1182/blood.V90.11.4271.4271_4271_4277; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HELDIN CH, 1986, MOL CELLULAR BIOL WO, P249; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; KOVALENKO M, 1994, CANCER RES, V54, P6106; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995	28	30	34	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7055	7062		10.1038/sj.onc.1203190	http://dx.doi.org/10.1038/sj.onc.1203190			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597306				2022-12-28	WOS:000083901900012
J	Theodosiou, A; Smith, A; Gillieron, C; Arkinstall, S; Ashworth, A				Theodosiou, A; Smith, A; Gillieron, C; Arkinstall, S; Ashworth, A			MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases	ONCOGENE			English	Article						dual-specificity phosphatase; JNK/SAPK beta; p38 MAP kinase	PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; CHROMOSOMAL LOCALIZATION; IN-VIVO; INFLAMMATORY CYTOKINES; GENOMIC ORGANIZATION; MAMMALIAN-CELLS; HEAT-SHOCK; EXPRESSION	Dual-specificity protein tyrosine phosphatases are a burgeoning family of enzymes, some of which, the MKPs, are implicated in the regulation of mitogen-activated protein (MAP) kinases. MKPs have been shown to reverse the activation of the MAP kinases by hydrolyzing phosphothreonine and phosphotyrosine residues present in the substrates. Here we describe the characterization of a novel member of the MKP family, MKP5. The MKP5 gene, which maps to human chromosome lq32, is expressed tissue-specifically as two transcripts of approximately 3.4 and 2.4kb in human liver and skeletal muscle. When expressed in mammalian cells, MKP5 blocks the enzymatic activation of MAP kinases with the selectivity p38 approximate to JNK/SAPK>>ERK. Immunoprecipitation of endogenous MAP kinases by the catalytically inactive transfected MKP5 demonstrates that it preferentially binds to the p38 and JNK/SAPK kinases. These findings suggest that the selectivity of this phosphatase may be determined at least in part at the level of substrate binding.	Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England; Serona Pharmaceut Res Inst, CH-1228 Geneva, Switzerland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, 237 Fulham Rd, London SW3 6JB, England.							Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Benitez J, 1997, CANCER RES, V57, P4217; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Loda M, 1996, AM J PATHOL, V149, P1553; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martell KJ, 1998, MOL CELLS, V8, P2; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nesbit MA, 1997, GENOMICS, V42, P284, DOI 10.1006/geno.1997.4737; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Smith A, 1997, GENOMICS, V42, P524, DOI 10.1006/geno.1997.4756; Steiner G, 1996, CANCER RES, V56, P5044; SUHAI S, 1994, COMPUTATIONAL METHOD; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YI HF, 1995, GENOMICS, V28, P92, DOI 10.1006/geno.1995.1110; Yokoyama A, 1997, BIOCHEM BIOPH RES CO, V239, P746, DOI 10.1006/bbrc.1997.7547	58	116	126	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6981	6988		10.1038/sj.onc.1203185	http://dx.doi.org/10.1038/sj.onc.1203185			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597297				2022-12-28	WOS:000083901900003
J	Chauhan, D; Hideshima, T; Pandey, P; Treon, S; Teoh, G; Raje, N; Rosen, S; Krett, N; Husson, H; Avraham, S; Kharbanda, S; Anderson, KC				Chauhan, D; Hideshima, T; Pandey, P; Treon, S; Teoh, G; Raje, N; Rosen, S; Krett, N; Husson, H; Avraham, S; Kharbanda, S; Anderson, KC			RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; irradiation; dexamethasone; apoptosis	FOCAL TYROSINE KINASE; HEMATOPOIETIC-CELLS; ACTIVATION; INTERLEUKIN-6; ASSOCIATION; PYK2; PHOSPHORYLATION; MEGAKARYOCYTES; STIMULATION; PAXILLIN	Related Adhesion Focal Tyrosine Kinase (RAFTK; also known as Pyk2), is a member of the Focal Adhesion Kinase (FAK) subfamily and is activated by TNF alpha, UV light and increases in intracellular calcium levels. However, the function of RAFTK remains largely unknown. Our previous studies demonstrated that treatment with dexamethasone (Dex), ionizing radiation (IR), and anti-Fas mAb induces apoptosis in multiple myeloma (MM) cells. In the present study, we examined the potential role of RAFTK during induction of apoptosis in human MM cells triggered by these three stimuli. Dex-induced apoptosis, in contrast to apoptosis triggered by anti-Fas mAb or IR, is associated with activation of RAFTK. Transient overexpression of RAFTK wild type (RAFTK WT) induces apoptosis, whereas transient overexpression of Kinase inactive RAFTK (RAFTK K-M) blocks Dex-induced apoptosis. In contrast, transient overexpression of RAFTK K-M has no effect on apoptosis triggered by IR or Fas. In Dex-resistant cells, Dex does not trigger either RAFTK activation or apoptosis. Finally, interleukin-6 (IL-6), a known survival factor for MM cells, inhibits both activation of RAFTK and apoptosis of MM.1S cells triggered by Dex. Our studies therefore demonstrate Dex-induced RAFTK-dependent, and IR or Fas induced RAFTK-independent apoptotic signaling cascades in MM cells.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med & Hematol Oncol, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Anderson, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02215 USA.				NCI NIH HHS [CA50947, CA75216] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050947, R01CA075216] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTEIR A, 1997, J BIOL CHEM, V272, P19719; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Avraham S, 1997, LEUKEMIA LYMPHOMA, V27, P247, DOI 10.3109/10428199709059681; Berg NN, 1997, J IMMUNOL, V159, P1753; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Derkinderen P, 1998, EUR J NEUROSCI, V10, P1667, DOI 10.1046/j.1460-9568.1998.00174.x; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; FU X, 1998, BLOOD, V92, P241; Hamel W, 1996, CYTOMETRY, V25, P173, DOI 10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I; HARDIN J, 1994, BLOOD, V84, P3063; HARDIN JA, 1992, J IMMUNOL METHODS, V154, P99, DOI 10.1016/0022-1759(92)90217-H; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Pandey P, 1999, J BIOL CHEM, V274, P8618, DOI 10.1074/jbc.274.13.8618; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965; THORNBERRY AT, 1997, APOPTOSIS, P155; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsuchida M, 1999, J BIOL CHEM, V274, P6735, DOI 10.1074/jbc.274.10.6735; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	31	94	95	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6733	6740		10.1038/sj.onc.1203082	http://dx.doi.org/10.1038/sj.onc.1203082			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597281				2022-12-28	WOS:000083792000015
J	Honda, R; Yasuda, H				Honda, R; Yasuda, H			Activity of MDM2, a ubiquitin Ligase, toward p53 or itself is dependent on the RING finger domain of the ligase	ONCOGENE			English	Article						MDM2; p53; ubiquitin ligase; E3; RING finger domain	DNA-DAMAGE; PHOSPHORYLATION; DEGRADATION	We previously showed that oncoprotein MDM2 has ubiquitin ligase activity toward tumor suppressor p53, In that paper, we showed very weak homology in the carboxyl terminal portion between MDM2 and E6AP (HECT domain). We mutated the cysteine residue (C464) corresponding to the residue essential for the ubiquitin ligase activity of E6AP and this mutation diminished the ligase activity of MDM2. The cysteine residue described above is also one of the cysteine residues that form the RING finger domain of MDM2. We tried to find out whether the diminishing of the activity by the mutation is attributable to the disruption of the RING finger domain or not. When the ring finger domain of MDM2 was deleted, the truncation mutant did not have the ubiquitin ligase activity. When we mutated the seven cysteine residues of RING finger domain of MDM2 in the carboxyl terminus, the disruption of each residue in the RING finger completely diminished the ubiquitin ligase activity of MDM2 toward MDM2 itself and toward tumor suppressor p53. These data indicate that the RING finger domain in MDM2 is essential for its ubiquitin ligase activity toward p53 and itself.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Yasuda, H (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.							Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Maki CG, 1996, CANCER RES, V56, P2649; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832	19	308	323	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1473	1476		10.1038/sj.onc.1203464	http://dx.doi.org/10.1038/sj.onc.1203464			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723139				2022-12-28	WOS:000085942700013
J	Suzuki, J; Kaziro, Y; Koide, H				Suzuki, J; Kaziro, Y; Koide, H			Positive regulation of skeletal myogenesis by R-Ras	ONCOGENE			English	Article						R-Ras; apoptosis; myogenesis; Ras; motility	GTP-BINDING PROTEINS; H-RAS; MUSCLE-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MYOBLAST DIFFERENTIATION; MYOCYTE DIFFERENTIATION; ACTIVATED RAS; BAF3 CELLS; IN-VITRO; EXPRESSION	Most of the proteins in the Ras-family proteins, including Pas, Rap and TC21, have been reported to be strong inhibitors of skeletal myogenesis. Here we show that R-Ras, another member of this family, promotes terminal differentiation of C2C12 skeletal myoblasts, In contrast to Pas, which induced markedly transformed phenotype of C2C12 cells, an activated mutant of R-Ras (R-Ras(Q87L)) did not exhibit any inhibitory effect on the differentiation of C2C12 cells, but enhanced the formation of multinucleated myotubes, Although R-Ras(Q87L) showed little effect on induction of two muscle-specific proteins, creatine kinase and myogenin, it prevented cell death during myoblast differentiation, probably through Akt activation and Bcl-x(L) induction. Motility of C2C12 cells, which may be involved in fusion of myoblasts, was also stimulated by R-Ras(Q87L). Furthermore, we observed a transient activation of endogenous R-Ras during differentiation of C2C12 cells. The ectopic expression of R-Ras GAP inhibited the differentiation. These results suggest that R-Ras has a positive effect on the terminal differentiation of myoblasts and may be involved in the program of skeletal myogenesis.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 226, Japan	Tokyo Institute of Technology	Koide, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 226, Japan.		Koide, Hiroshi/E-9000-2011	Koide, Hiroshi/0000-0001-5916-3179				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Crawley S, 1997, EXP CELL RES, V235, P274, DOI 10.1006/excr.1997.3671; Dominov JA, 1998, J CELL BIOL, V142, P537, DOI 10.1083/jcb.142.2.537; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Fimia GM, 1996, J BIOL CHEM, V271, P15575, DOI 10.1074/jbc.271.26.15575; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; GUTMANN DH, 1994, J NEUROSCI RES, V37, P398, DOI 10.1002/jnr.490370312; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Itoh N, 1996, DEVELOPMENT, V122, P291; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MCCLEARN D, 1995, DEV DYNAM, V202, P365, DOI 10.1002/aja.1002020406; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Olson E N, 1992, Semin Cell Biol, V3, P127; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; REY I, 1994, ONCOGENE, V9, P685; Rohwedel J, 1998, DEV BIOL, V201, P167, DOI 10.1006/dbio.1998.9002; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SAEZ R, 1994, ONCOGENE, V9, P2977; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; Suzuki J, 1998, FEBS LETT, V437, P112, DOI 10.1016/S0014-5793(98)01213-7; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Yao CC, 1996, J CELL SCI, V109, P3139; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	52	16	18	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1138	1146		10.1038/sj.onc.1203402	http://dx.doi.org/10.1038/sj.onc.1203402			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713701				2022-12-28	WOS:000085567800003
J	Jol, H; Zhang, R; Zhang, H; McKinsey, TA; Shao, JY; Beauchamp, RD; Ballard, DW; Liang, P				Jol, H; Zhang, R; Zhang, H; McKinsey, TA; Shao, JY; Beauchamp, RD; Ballard, DW; Liang, P			NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis	ONCOGENE			English	Article						Ras; NF-kappa B; abnormal cell proliferation; growth inhibition	INDUCED APOPTOSIS; ADHESION MOLECULE-1; CYCLIN D1; ACTIVATION; TRANSFORMATION; GENES; DEATH; PROTEINS; ALPHA; SUPPRESSION	Oncogenic mutations in I as lead to constitutive activation of downstream signaling pathways that modulate the activities of transcription factors, In turn, these factors control the expression of a subset of genes responsible for neoplastic cell transformation. Recent studies suggest that transcription factor NF-kappa B contributes to cell transformation by inhibiting the cell death signal activated by oncogenic Ras, In this study, inhibition of NF-kappa B activity by forced expression of a super-repressor form of I kappa-B alpha, the major inhibitor of NF-kappa B, markedly decreased the growth rate, saturation density and tumorigenicity of oncogenic H-Ras transformed rat embryo fibroblasts, Such clonally isolated cells overexpressing I kappa B alpha super-repressor not only were viable but also exhibited no sign of spontaneous apoptosis, Inhibition of NF-kappa B in these cells was functionally demonstrated by both the loss of cytokine induced DNA binding activity and a profoundly increased sensitivity to cell death in response to TNF-alpha treatment, In contrast, inhibition of NF-kappa B activity in non-transformed fibroblasts had minimal effect on growth, but rendered the cells resistant to a subsequent transformation by H-ras oncogene, Similar results were also obtained with rat intestinal epithelial cells harboring an inducible ras oncogene, Taken together, these findings suggest that NF-kappa B activity is essential for abnormal cell proliferation and tumorigenicity activated by the ras oncogene and highlight an alternative functional role for NF-kappa B in oncogenic Ras-mediated cell transformation that is distinct from its anti-apoptotic activity.	Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Howard Hughes Med Inst, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University	Liang, P (corresponding author), Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Dept Cell Biol, 658 Med Res Bldg 2, Nashville, TN 37232 USA.				NCI NIH HHS [CA76960, CA74067] Funding Source: Medline; NIAID NIH HHS [AI33839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076960, R01CA074067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; ANTWERP DJV, 1996, SCIENCE, V274, P787; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1997, CURR BIOL, V7, P258; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIARIS H, 1995, INT J ONCOL, V7, P413; KO TC, 1995, ONCOGENE, V10, P177; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; TAKEUCHI M, 1995, P NATL ACAD SCI USA, V92, P3561, DOI 10.1073/pnas.92.8.3561; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	46	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					841	849		10.1038/sj.onc.1203392	http://dx.doi.org/10.1038/sj.onc.1203392			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702792				2022-12-28	WOS:000085567700001
J	Hayakawa, F; Towatari, M; Kiyoi, H; Tanimoto, M; Kitamura, T; Saito, H; Naoe, T				Hayakawa, F; Towatari, M; Kiyoi, H; Tanimoto, M; Kitamura, T; Saito, H; Naoe, T			Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines	ONCOGENE			English	Article						Flt3; tandem duplication; MAP kinase; STAT proteins; AML	RECEPTOR TYROSINE KINASES; ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC-CELLS; GENE; LIGAND; PHOSPHORYLATION; PROLIFERATION; EXPRESSION; FAMILY; TRANSCRIPTION	We have recently identified an internal tandem duplication of the human Flt3 gene in approximately 20% of acute myeloid leukemia (ARIL) cases. In the present study, the,wild-type and the mutant Flt3 genes were transfected into two IL-3-dependent cell lines, 32D and BA/F3 cells. Mutant Flt3-transfected cells exhibited autonomous growth while wild-type Flt3-transfected cells with the continuous stimulation of Flt3 ligand exhibited a minimal proliferation. Cells expressing mutant Flt3 showed constitutive activation of STAT5 and MAP kinase, In contrast, Flt3 ligand stimulation caused rapid activation of MAP kinase but not STAT5 in cells expressing wild-type Flt3, Finally, we found constitutive activation of MAP kinase and STAT5 in all clinical samples of AML patients with mutant Flt3, Our study shows the significance of internal tandem duplication of Flt3 receptors for leukemia cell expansion.	Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Infect Dis, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Hemopoiet Factors, Minato Ku, Tokyo 108, Japan	Nagoya University; Nagoya University; University of Tokyo	Towatari, M (corresponding author), Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Hayakawa, Fumihiko/I-7288-2014; Kitamura, Toshio/AAA-2071-2021; Naoe, Tomoki/I-1888-2012					Adachi T, 1999, J IMMUNOL, V162, P1496; Brodsky RA, 1999, BLOOD, V93, P1749, DOI 10.1182/blood.V93.5.1749.405k09_1749_1756; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; Chin H, 1998, BLOOD, V91, P3734; Drexler HG, 1996, LEUKEMIA, V10, P588; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Hayakawa F, 1998, BRIT J HAEMATOL, V101, P521, DOI 10.1046/j.1365-2141.1998.00720.x; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Lavagna-Sevenier C, 1998, LEUKEMIA, V12, P301, DOI 10.1038/sj.leu.2400921; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; McKenna HJ, 1996, EXP HEMATOL, V24, P378; MERCEDES D, 1993, MOL CELL BIOL, V13, P6572; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; PIACIBELLO W, 1995, BLOOD, V86, P4105, DOI 10.1182/blood.V86.11.4105.bloodjournal86114105; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TORIGOE T, 1992, BLOOD, V80, P617; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zhang SL, 1999, J LEUKOCYTE BIOL, V65, P372, DOI 10.1002/jlb.65.3.372	34	444	462	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					624	631		10.1038/sj.onc.1203354	http://dx.doi.org/10.1038/sj.onc.1203354			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698507				2022-12-28	WOS:000085192000004
J	Banyard, J; Anand-Apte, B; Symons, M; Zetter, BR				Banyard, J; Anand-Apte, B; Symons, M; Zetter, BR			Motility and invasion are differentially modulated by Rho family GTPases	ONCOGENE			English	Article						cell migration; invasion; Rac; Rho; Cdc42; PDGF	GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; GROWTH-FACTOR; RAS TRANSFORMATION; CELL MOTILITY; PHOSPHOINOSITIDE 3-KINASE; 3-DIMENSIONAL CONTACT; EXTRACELLULAR-MATRIX; INDEPENDENT PATHWAYS; GENE-EXPRESSION	Cell migration in vivo often requires invasion through tissue matrices. Currently little is known regarding the signaling pathways that regulate cell invasion through three-dimensional matrices. The small GTPases Cdc42, Rac and Rho are key regulators of actin cytoskeletal and adhesive structures. We now show that expression of dominant negative forms of either Cdc42, Rac or Rho inhibited PDGF-BB-stimulated Rat1 fibroblast invasion into 3D collagen matrices, indicating that the activity of each of these GTPases is necessary for cell. invasion, In contrast, only Rac activation was required for PDGF-BB-stimulated locomotion across a planar substrate in the Boyden chamber. Interestingly, PDGF-induced invasion was also strongly inhibited by expression of constitutively active forms of Cdc42 or Rho, and to a lesser extent by constitutively active Rac, We also show that constitutively active V12-Rac significantly stimulated basal Rat1 fibroblast invasion, independent of PI-3-kinase activity, and that this effect was suppressed by the effector mutant V12/N40-Rac. These results suggest that cellular invasion may require an optimal level of activation of Cdc42, Rho and Rac, and that migration and invasion are differentially modulated by Rho family GTPases.	Harvard Univ, Childrens Hosp, Sch Med, Dept Surg Res, Boston, MA 02115 USA; Picower Inst Med Res, Mol Oncol Lab, Manhasset, NY 11030 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Northwell Health	Zetter, BR (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Surg Res, Enders 1074, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA037393, P01CA045548, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA45548, CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Allen WE, 1997, J CELL SCI, V110, P707; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUNDRA V, 1994, ONCOGENE, V9, P1429; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MAUCH C, 1989, FEBS LETT, V250, P301, DOI 10.1016/0014-5793(89)80743-4; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCONNOR TP, 1990, J NEUROSCI, V10, P3935, DOI 10.1523/JNEUROSCI.10-12-03935.1990; OHagan RC, 1996, ONCOGENE, V13, P1323; OLSEN MF, 1995, SCIENCE, V269, P1270; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROECKEL D, 1994, EXP CELL RES, V211, P42, DOI 10.1006/excr.1994.1056; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; SCHOR SL, 1980, J CELL SCI, V41, P159; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tang Y, 1999, MOL CELL BIOL, V19, P1881; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Xu JH, 1997, J CELL BIOL, V136, P473, DOI 10.1083/jcb.136.2.473; YAMADA KM, 1990, CANCER RES, V50, P4485; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	62	139	139	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					580	591		10.1038/sj.onc.1203338	http://dx.doi.org/10.1038/sj.onc.1203338			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698528				2022-12-28	WOS:000085104200012
J	Reddy, DE; Keck, CL; Popescu, N; Athwal, RS; Kaur, GP				Reddy, DE; Keck, CL; Popescu, N; Athwal, RS; Kaur, GP			Identification of a YAC from 16q24 carrying a senescence gene for breast cancer cells	ONCOGENE			English	Article						cell senescence; breast cancer; YAC contig; YAC transfer; functional complementation	YEAST ARTIFICIAL CHROMOSOMES; MAMMALIAN-CELLS; MOUSE CELLS; CELLULAR SENESCENCE; ALLELIC IMBALANCE; IN-SITU; CARCINOMA; FUSION; EXPRESSION; COMPLEMENTATION	We have identified a 360 kb YAC that carries a cell senescence gene, SEN16. In our earlier studies, we localized SEN16 within a genetic interval of 3-7 cM at 16q24.3. Six overlapping YACs spanning the chromosomal region of senescence activity, were assembled in a contig. Candidate YACs, identified by the markers located in the vicinity of SEN16, were retrofitted to introduce a neo selectable marker. Retrofitted YACs were first transferred into mouse A9 cells to generate A9/YAC hybrids. YAC DNA present in A9/YAC hybrids was further transferred by microcell fusion into immortal cell lines derived from human and rat mammary tumors. YAC d792t2 restored senescence in both human and rat mammary tumor cell lines, while an unrelated YAC from chromosome 6q had no senescence activity.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaur, GP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St,AHP Room 201, Philadelphia, PA 19140 USA.							ATHWAL RS, 1985, SOMAT CELL MOLEC GEN, V11, P177, DOI 10.1007/BF01534706; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; Davies N P, 1996, Methods Mol Biol, V54, P281; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOGGETT NA, 1995, NATURE, V377, P335; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; Julicher K, 1997, GENOMICS, V43, P95, DOI 10.1006/geno.1997.4787; Koreth J, 1999, ONCOGENE, V18, P1157, DOI 10.1038/sj.onc.1202372; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; MEDINA D, 1996, J MAMMARY GLAND BIOL, V1, P21; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1994, CANCER RES, V54, P1331; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; Perou CM, 1996, P NATL ACAD SCI USA, V93, P5905, DOI 10.1073/pnas.93.12.5905; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P11207, DOI 10.1073/pnas.90.23.11207; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; RADFORD DM, 1995, CANCER RES, V55, P3399; Reddy DE, 1999, ONCOGENE, V18, P5100, DOI 10.1038/sj.onc.1202888; Sandhu AK, 1996, ONCOGENE, V12, P247; SKIRNISDOTTIR S, 1995, INT J CANCER, V64, P112, DOI 10.1002/ijc.2910640207; STRAUSS WM, 1992, EMBO J, V11, P417, DOI 10.1002/j.1460-2075.1992.tb05070.x; TSUDA H, 1994, CANCER RES, V54, P513; WADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1693, DOI 10.1006/bbrc.1994.1647; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	37	8	8	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					217	222		10.1038/sj.onc.1203264	http://dx.doi.org/10.1038/sj.onc.1203264			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644999				2022-12-28	WOS:000084844400006
J	Inagaki, K; Noguchi, T; Matozaki, T; Horikawa, T; Fukunaga, K; Tsuda, M; Ichihashi, M; Kasuga, M				Inagaki, K; Noguchi, T; Matozaki, T; Horikawa, T; Fukunaga, K; Tsuda, M; Ichihashi, M; Kasuga, M			Roles for the protein tyrosine phosphatase SHP-2 in cytoskeletal organization, cell adhesion and cell migration revealed by overexpression of a dominant negative mutant	ONCOGENE			English	Article						cytoskeletal organization; cell migration; integrin signaling; SHP-2	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; GROWTH-FACTOR; FOCAL ADHESION; SIGNAL-TRANSDUCTION; SYP PHOSPHATASE; RAS ACTIVATION; MAP KINASE; PHOSPHORYLATION; INSULIN	SHP-2, a SRC homology 2 domain-containing protein tyrosine phosphatase, mediates activation of Ras and mitogen-activated protein kinase by various mitogens and cell adhesion, Inhibition of endogenous SHP-2 by overexpression of a catalytically inactive (dominant negative) mutant in Chinese hamster ovary cells or Rat-1 fibroblasts has now been shown to induce a marked change in cell morphology (from elongated to less polarized) that is accompanied by substantial increases in the numbers of actin stress fibers and focal adhesion contacts. Overexpression of the SHP-2 mutant also increased the strength of cell-substratum adhesion and resulted in hyperphosphorylation of SHPS-1, a substrate of SHP-2 that contributes to cell adhesion-induced signaling, Inhibition of SHP-2 also markedly increased the rate of cell attachment to and cell spreading on extracellular matrix proteins such as fibronectin and vitronectin, effects that were accompanied by enhancement of adhesion-induced tyrosine phosphorylation of paxillin and p130Cas. In addition, cell migration mediated by fibronectin or vitronectin, but not that induced by insulin, was impaired by over-expression of the SHP-2 mutant, These results suggest that SHP-2 plays an important role in the control of cell shape by contributing to cytoskeletal organization, and that it is an important regulator of integrin-mediated cell adhesion, spreading, and migration as well as of tyrosine phosphorylation of focal adhesion contact-associated proteins.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Dept Dermatol, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University; Kobe University	Noguchi, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Adachi M, 1996, CELL, V85, P15; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HORIKAWA T, 1995, J INVEST DERMATOL, V104, P256, DOI 10.1111/1523-1747.ep12612795; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; ILLC D, 1995, NATURE, V377, P539; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Manes S, 1999, MOL CELL BIOL, V19, P3125; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; Menzel D, 1996, CURR OPIN CELL BIOL, V8, P38, DOI 10.1016/S0955-0674(96)80046-9; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOBES CD, 1995, J CELL SCI, V108, P225; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwarzbauer JE, 1997, CURR BIOL, V7, pR292, DOI 10.1016/S0960-9822(06)00140-0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	58	74	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					75	84		10.1038/sj.onc.1203204	http://dx.doi.org/10.1038/sj.onc.1203204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644982				2022-12-28	WOS:000084844300009
J	Bertolotti, A; Bell, B; Tora, L				Bertolotti, A; Bell, B; Tora, L			The N-terminal domain of human TAF(II)68 displays transactivation and oncogenic properties	ONCOGENE			English	Article						oncogene; sarcoma; transcription factors II; histone acetylation; RNA polymerase II; recruitment	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; EWS/FLI-1 FUSION GENE; TRANSCRIPTIONAL ACTIVATION; EWINGS-SARCOMA; DNA-BINDING; CHROMOSOME-TRANSLOCATION; MESSENGER-RNA; IN-VIVO; ESTROGEN-RECEPTOR	In Ewing tumor, the (11;22) chromosomal translocation produces a chimeric molecule composed of the aminoterminal domain of EWS fused to the carboxyl-terminal DNA-binding domain of FLI-1. Previously, we have identified a novel protein TAF(II)68, which is highly similar to EWS and another closely related protein TLS (also called FUS), We demonstrate that the N-terminus of TAF(II)68 efficiently stimulates transcription when fused to two different DNA binding domains and that overexpression of TAF(II)68-FLI-1 chimeras in NIH3T3 cells leads to oncogenic transformation. We have also investigated the molecular mechanisms which account for the transcriptional activation ana the oncogenic transformation potential of the N-termini of TAF(II)68 and EWS, Thus, we have tested whether the artificial recruitment of components of the preinitiation complex (PIC) or a histone acetyltransferase (HAT) could bypass the requirement for the activation domains of either EWS or TAF(II)68. Recruitment of individual components of the transcription machinery or the GCN5 HAT is not sufficient to promote activation from FLI-1 responsive genes either in transfection experiments or in oncogenic transformation assays. These results suggest that the TAF(II)68 or EWS activation domains enhance a step after PIC formation in the transcriptional activation process.	CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Barberis A, 1998, BIOL CHEM, V379, P1397; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; Blau J, 1996, MOL CELL BIOL, V16, P2044; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROWN AD, 1995, ONCOGENE, V10, P1749; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CALVIO C, 1995, RNA, V1, P724; Candau R, 1996, MOL CELL BIOL, V16, P593; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Fujimura Y, 1996, ONCOGENE, V12, P159; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; He S, 1998, MOL CELL BIOL, V18, P2876, DOI 10.1128/MCB.18.5.2876; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Majello B, 1998, J BIOL CHEM, V273, P16509, DOI 10.1074/jbc.273.26.16509; MARSOLIER MC, 1994, P NATL ACAD SCI USA, V91, P138; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nevado J, 1999, P NATL ACAD SCI USA, V96, P2674, DOI 10.1073/pnas.96.6.2674; OHNO T, 1993, CANCER RES, V53, P5859; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; Roeder RG, 1996, METHOD ENZYMOL, V273, P165; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, J CELL SCI, V110, P1741	87	66	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					8000	8010		10.1038/sj.onc.1203207	http://dx.doi.org/10.1038/sj.onc.1203207			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637511				2022-12-28	WOS:000084634600009
J	Huntsman, DG; Chin, SF; Muleris, M; Batley, SJ; Collins, VP; Wiedemann, LM; Aparicio, S; Caldas, C				Huntsman, DG; Chin, SF; Muleris, M; Batley, SJ; Collins, VP; Wiedemann, LM; Aparicio, S; Caldas, C			MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines	ONCOGENE			English	Article						MLL2; MLL; amplification; tumor; cell lines	BREAKPOINT CLUSTER REGION; ALL-1 GENE; ACUTE-LEUKEMIA; TANDEM DUPLICATION; TRANSLOCATIONS; AMPLIFICATION; EXPRESSION; 11Q23; REARRANGEMENTS; INVOLVEMENT	The Mixed Lineage Leukemia (MLL) gene is commonly involved in translocations in infantile leukemia and is amplified in some cases of adult myeloid leukemia. A homolog of MLL denoted MLL2, which represents the second human homolog of the Drosophila trithorax gene, was characterized by assembling ESTs, the KIAA0304 cDNA clone, RT-PCR fragments and a new clone isolated from a cDNA phage library and compared to the available genomic sequence. The MLL2 gene maps to 19q13.1, a region of frequent rearrangement or amplification in solid tumors. MLL2 consists of an 8.5-9 kb transcript and spans 20 kb of genomic DNA, The predicted MLL2 protein possesses all of the major domains defined in MLL and the two genes have a similar genomic structure. We find that MLL2 is amplified in two of 14 pancreatic carcinoma cell lines and one of five glioblastoma cell lines and is a likely critical gene in 19q13.1 amplifications. It is also a candidate for chromosomal rearrangements involving this chromosome locus, MLL2 is one additional mammalian trithorax-group gene with involvement in human cancer.	Univ Cambridge, Addenbrookes Hosp, CRC Dept Oncol, Cambridge CB2 2XY, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Inst Curie, CNRS, UMR 147, F-75248 Paris, France; Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Histopathol, Cambridge CB2 2QQ, England; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Wellcome CRC Inst Canc Res & Dev Biol, Cambridge CB2 1QR, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Caldas, C (corresponding author), Univ Cambridge, Addenbrookes Hosp, CRC Dept Oncol, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.		Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008; Huntsman, David/ABE-6082-2020; Wiedemann, Leanne/E-3316-2010	Caldas, Carlos/0000-0003-3547-1489; Aparicio, Samuel/0000-0002-0487-9599; Wiedemann, Leanne/0000-0002-0964-4676; chin, suet-feung/0000-0001-5697-1082	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen RJ, 1998, LEUKEMIA, V12, P1119, DOI 10.1038/sj.leu.2401002; Ariyama Y, 1998, GENE CHROMOSOME CANC, V23, P267, DOI 10.1002/(SICI)1098-2264(199811)23:3<267::AID-GCC10>3.3.CO;2-0; BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BREEN TR, 1993, DEVELOPMENT, V117, P119; BREEN TR, 1995, MECH DEVELOP, V52, P89, DOI 10.1016/0925-4773(95)00393-F; Caldas C, 1998, ONCOGENE, V16, P3233, DOI 10.1038/sj.onc.1201873; CALDAS C, 1999, IN PRESS CANC MET RE; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; DJABALI M, 1992, NAT GENET, V2, P112; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Felix CA, 1998, BLOOD, V91, P4451; Ferbus D, 1999, INT J CANCER, V80, P369; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Lochner K, 1996, CANCER RES, V56, P2171; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; Michaux L, 1998, BLOOD, V92, p78A; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MULERIS M, 1994, CYTOGENET CELL GENET, V65, P82, DOI 10.1159/000133605; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Rasio D, 1996, CANCER RES, V56, P1766; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Tanaka K, 1997, BLOOD, V89, P596, DOI 10.1182/blood.V89.2.596; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Wiedemann LM, 1999, BRIT J HAEMATOL, V105, P256, DOI 10.1111/j.1365-2141.1999.01291.x; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	44	85	94	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7975	7984		10.1038/sj.onc.1203291	http://dx.doi.org/10.1038/sj.onc.1203291			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637508				2022-12-28	WOS:000084634600006
J	Thomas, M; Pim, D; Banks, L				Thomas, M; Pim, D; Banks, L			The role of the E6-p53 interaction in the molecular pathogenesis of HPV	ONCOGENE			English	Review						HPV; E6; p53; ubiquitination; transformation	HUMAN-PAPILLOMAVIRUS TYPE-16; CARCINOMA CELL-LINES; UBIQUITIN-PROTEIN LIGASE; G(2) CHECKPOINT FUNCTION; POSITIVE CANCER-CELLS; ARF TUMOR-SUPPRESSOR; VITAMIN-D-RECEPTOR; HUMAN P53 PROTEINS; WILD-TYPE P53; E6 ONCOPROTEIN	Human papillomaviruses (HPVs) are associated with a number of clinical conditions, of which the most serious is cervical carcinoma. The E6 protein of the oncogenic, mucosal-specific HPV types has been shown to complex with p53 and, as a result, target it for rapid proteasome-mediated degradation. As a consequence, p53's growth-arrest and apoptosis-inducing activities are abrogated. Since p53 is frequently wild type in cervical cancers, unlike other cancers in which it is often mutated, the notion has arisen that E6's activity with respect to p53 is equivalent to an inactivating mutation of p53, In addition, several studies have shown that the pathways both upstream and downstream of p53 are intact in cervical cancers; this suggests the potential importance of the E6-p53 interaction for therapeutic intervention. However, like all viral oncoproteins, E6 is a multifunctional protein and a plethora of other cellular targets has been identified. Indeed, E6's interactions with some of these additional targets appear to be equally important in the pathogenesis of HPV, and may also represent valid targets for therapeutic intervention.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Thomas, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.		高, 雨莉/HGU-8187-2022					AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURNETT AF, 1992, GYNECOL ONCOL, V47, P343, DOI 10.1016/0090-8258(92)90137-8; BUTZ K, 1995, ONCOGENE, V10, P927; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; Conger KL, 1999, J BIOL CHEM, V274, P2696, DOI 10.1074/jbc.274.5.2696; CONRADSTOPPLER M, 1996, J VIROL, V70, P6987; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; CROOK T, 1991, ONCOGENE, V6, P873; DEAU MC, 1991, VIROLOGY, V184, P492, DOI 10.1016/0042-6822(91)90419-C; deVilliers EM, 1997, INT J CANCER, V73, P356, DOI 10.1002/(SICI)1097-0215(19971104)73:3<356::AID-IJC9>3.3.CO;2-S; Di Leonardo A, 1997, CANCER RES, V57, P1013; Doorbar J, 1997, VIROLOGY, V238, P40, DOI 10.1006/viro.1997.8768; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elbel M, 1997, VIROLOGY, V239, P132, DOI 10.1006/viro.1997.8860; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; GARDIOL D, 1999, IN PRESS ONCOGENE; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; GROSSMAN SR, 1989, ONCOGENE, V4, P1089; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; IFTNER T, 1988, J VIROL, V62, P3655, DOI 10.1128/JVI.62.10.3655-3661.1988; Imai T, 1997, BIOCHEM BIOPH RES CO, V233, P765, DOI 10.1006/bbrc.1997.6531; Inoue T, 1998, MOL CARCINOGEN, V21, P215; ISHIWATARI H, 1994, J MED VIROL, V44, P243, DOI 10.1002/jmv.1890440306; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KANDA T, 1994, MOL CELL BIOL, V14, P2651, DOI 10.1128/MCB.14.4.2651; KANDA T, 1991, VIROLOGY, V185, P536, DOI 10.1016/0042-6822(91)90523-E; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Konig C, 1999, J VIROL, V73, P2253; Krajewski S, 1996, CANCER RES, V56, P2849; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; KUO SR, 1994, J BIOL CHEM, V269, P24058; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MANTOVANI F, 1999, IN PRESS ONCOGENE; Masterson PJ, 1998, J VIROL, V72, P7407, DOI 10.1128/JVI.72.9.7407-7419.1998; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MOREAU F, 1992, BIOCHEM CELL BIOL, V70, P1014, DOI 10.1139/o92-145; MUGANDA P, 1994, J VIROL, V68, P8028, DOI 10.1128/JVI.68.12.8028-8034.1994; Muganda P, 1998, CELL MOL BIOL, V44, P321; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Nuber U, 1998, EUR J BIOCHEM, V254, P643, DOI 10.1046/j.1432-1327.1998.2540643.x; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PAULES RS, 1995, CANCER RES, V55, P1763; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; RANKIN S, 1994, J BIOL CHEM, V269, P704; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; REMM M, 1992, NUCLEIC ACIDS RES, V20, P6015, DOI 10.1093/nar/20.22.6015; Rosenthal AN, 1998, LANCET, V352, P871, DOI 10.1016/S0140-6736(98)07357-7; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Shally M, 1996, VIRUS RES, V42, P81, DOI 10.1016/0168-1702(96)01301-9; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1995, J VIROL, V69, P7023, DOI 10.1128/JVI.69.11.7023-7031.1995; Steller MA, 1996, CANCER RES, V56, P5087; STEWART N, 1995, ONCOGENE, V10, P109; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; THOMAS M, 1995, ONCOGENE, V10, P261; Thomas M, 1996, ONCOGENE, V13, P265; THOMAS M, 1999, IN PRESS J GEN VIROL, V80; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Waddell S, 1998, ONCOGENE, V16, P1759, DOI 10.1038/sj.onc.1201848; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; Yamada T, 1997, J VIROL, V71, P2463, DOI 10.1128/JVI.71.3.2463-2472.1997; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zehbe I, 1998, CANCER RES, V58, P829; ZHANG JW, 1995, GYNECOL ONCOL, V57, P170, DOI 10.1006/gyno.1995.1120; Zhong L, 1997, J VIROL, V71, P3146, DOI 10.1128/JVI.71.4.3146-3160.1997; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zineb R, 1998, ENDOCRINOLOGY, V139, P1844, DOI 10.1210/en.139.4.1844; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	156	315	329	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	1999	18	53					7690	7700		10.1038/sj.onc.1202953	http://dx.doi.org/10.1038/sj.onc.1202953			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618709				2022-12-28	WOS:000084634500008
J	Nomoto, S; Haruki, N; Takahashi, T; Masuda, A; Koshikawa, T; Takahashi, T; Fujii, Y; Osada, H; Takahashi, T				Nomoto, S; Haruki, N; Takahashi, T; Masuda, A; Koshikawa, T; Takahashi, T; Fujii, Y; Osada, H; Takahashi, T			Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers	ONCOGENE			English	Article						lung cancer; mitotic checkpoint; hMAD1; somatic mutation; genetic instability	SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; ARREST	We previously reported the presence of mitotic checkpoint impairment in about 40% of lung cancer cell lines. To gain an insight into the molecular basis of this impairment, we examined 49 lung cancer specimens for alterations in the hMAD1 mitotic checkpoint gene and identified a somatic, non-conservative missense mutation, which substitutes alanine (GCG) for threonine (GCG) at codon 299, together with a number of amino acid substituting, single nucleotide polymorphisms. This is the first demonstration of hMAD1 mutation in any type of human cancers. The present finding marks hMAD1 as a potential target, although with low frequency, for genetic alterations in lung cancer. Thus, further studies of hMAD1 dysfunction caused by other mechanisms appear to be warranted, as well as potential involvement of other components of the mitotic checkpoint.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya City University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999; Gotoh K, 1999, CARCINOGENESIS, V20, P499, DOI 10.1093/carcin/20.3.499; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HIBI K, 1994, ONCOGENE, V9, P611; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Nagatake M, 1996, CANCER RES, V56, P2718; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Smith AL, 1996, BRIT J CANCER, V73, P203, DOI 10.1038/bjc.1996.36; *STAT INF DEP, 1998, VIT STAT JAP, V3, P384; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; WASHIMI O, 1995, CANCER RES, V55, P514	20	50	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7180	7183		10.1038/sj.onc.1203141	http://dx.doi.org/10.1038/sj.onc.1203141			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597320				2022-12-28	WOS:000083901900026
J	Budhram-Mahadeo, V; Ndisang, D; Ward, T; Weber, BL; Latchman, DS				Budhram-Mahadeo, V; Ndisang, D; Ward, T; Weber, BL; Latchman, DS			The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells	ONCOGENE			English	Article						BRCA-1; breast cancer; transcriptional control; Brn-3b; POU family transcription factors	NEURONAL CELLS; GENE BRCA1; DOMAIN; PROTEIN; DIFFERENTIATION; PROMOTER; GROWTH; MUTATIONS; DISTINCT; OPPOSITE	The BRCA-1 tumour supressor gene was identified on the basis of mutations which occur in familial breast cancer indicating that its inactivation can cause this disease. Although BRCA-1 does not appear to be mutated in sporadic breast cancer, its expression has been shown to be reduced in tumour material from such cases. We show here that mammary tumours which have reduced levels of BRCA-1 expression show enhanced expression of the Brn-3b POU family transcription factor at both the mRNA and protein levels. This elevated expression of Brn-3b is not found in normal mammary cells, benign tumours or in malignant tumour samples which do not exhibit reduced levels of BRCA-1. In contrast, no correlation was noted between BRCA-1 and expression of the related factor Brn-3a. Moreover, Brn-3b but not Brn-3a can strongly repress the BRCA-1 promoter approximately 20-fold in mammary tumour cells. To our knowledge, this is the first report of a transcription factor which regulates BRCA-1 expression. Thus, Brn-3b may play an important role in regulating expression of BRCA-1 in mammary tumours with enhanced expression of Brn-3b resulting in reduced BRCA-1 expression and thereby being potentially important in tumour development.	UCL, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of London; University College London; University of Pennsylvania; University of Pennsylvania	Latchman, DS (corresponding author), UCL, Windeyer Inst Med Sci, Dept Mol Pathol, Windeyer Bldg,46 Cleveland St, London W1P 6DB, England.							ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; DHILLON VB, 1993, ANN RHEUM DIS, V52, P436, DOI 10.1136/ard.52.6.436; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GUDAS JM, 1995, CANCER RES, V55, P4561; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Latchman DS, 1997, INT J ONCOL, V10, P1133; LeblondFrancillard M, 1997, J CLIN ENDOCR METAB, V82, P89, DOI 10.1210/jc.82.1.89; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; Rao VN, 1996, ONCOGENE, V12, P523; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VAHAUA O, 1995, NAT GENET, V9, P444; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	37	62	64	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6684	6691		10.1038/sj.onc.1203072	http://dx.doi.org/10.1038/sj.onc.1203072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597274				2022-12-28	WOS:000083792000008
J	Fang, XJ; Yu, SX; Eder, A; Mao, ML; Bast, RC; Boyd, D; Mills, GB				Fang, XJ; Yu, SX; Eder, A; Mao, ML; Bast, RC; Boyd, D; Mills, GB			Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway	ONCOGENE			English	Article						BAD; MAPK; Ras; Akt; phosphorylation; apoptosis	GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; AKT; SURVIVAL; APOPTOSIS; INSULIN; DEATH; TRANSFORMATION; EXPRESSION	The function of the pro-apoptotic molecule BAD is regulated by phosphorylation of two sites, serine-112 (Ser-112) and serine-136 (Ser-136), Phosphorylation at either site results in loss of the ability of BAD to heterodimerize with the survival proteins BCL-X-L or BCL-2, Phosphorylated BAD binds to 14-3-3 and is sequestered in the cytoplasm, It has been shown that phosphorylation of BAD at Ser-136 is mediated by the serine/threonine protein kinase Akt-1/PKB which is downstream of phosphatidylinositol 3-kinase (PI3K), The signaling process leading to phosphorylation of BAD at Ser-112 has not been identified. In this study, we show that phosphorylation of the two serine residues of BAD is differentially regulated. While Ser-136 phosphorylation is concordant with activation of Akt, Ser-112. phosphorylation does not correlate with Akt activation. Instead, we demonstrate that activated Ras and Raf, which are upstream of mitogen-activated protein kinases (MAPK), stimulate selective phosphorylation of BAD at Ser-112, Furthermore, phosphorylation of Ser-112, but not Ser-136 requires activation of the MAPK pathway as the MEK inhibitor, PD 98059, blocks EGF-, as web as activated Ras- or Raf-mediated phosphorylation of BAD at Ser-112, Therefore, the PI3K-Akt and Ras-MAPK pathways converge at BAD by mediating phosphorylation of distinct serine residues.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Box 317,1515 Holcombe Blvd, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FANG XJ, 1992, CANCER RES, V52, P173; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Parrizas M, 1997, J BIOL CHEM, V272, P154; Patton SE, 1998, CANCER RES, V58, P2253; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SOUTHERLAND C, 1993, BIOCHEM J, V296, P15; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	31	229	233	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6635	6640		10.1038/sj.onc.1203076	http://dx.doi.org/10.1038/sj.onc.1203076			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597268				2022-12-28	WOS:000083792000002
J	Wu, GS; Burns, TF; McDonald, ER; Meng, RD; Kao, G; Muschel, R; Yen, T; El-Deiry, WS				Wu, GS; Burns, TF; McDonald, ER; Meng, RD; Kao, G; Muschel, R; Yen, T; El-Deiry, WS			Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest	ONCOGENE			English	Article						p53; KILLER/DR5; TRAIL; ATM; G1 arrest; apoptosis	CELL-CYCLE CHECKPOINT; FADD-DEPENDENT APOPTOSIS; CYTOTOXIC LIGAND TRAIL; TUMOR-SUPPRESSOR P53; NF-KAPPA-B; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; IN-VITRO; BAX GENE	The TRAIL death receptor KILLER/DR5 is induced by DNA damaging agents in wild-type p53-expressing cells. Here me show that, unlike the p53-target CDK-inhibitor p21(WAF1/CIP1), the TRAIL death receptor KILLER/DR5 is only induced in cells undergoing p53-dependent apoptosis and not cell cycle arrest. Thus GM glioblastoma cells carrying an inducible MMTV-driven p53 gene undergo cell cycle arrest and upregulate p21 but not KILLER/DR5 expression upon dexamethasone exposure. W138 normal lung fibroblasts undergoing cell cycle arrest in response to ionizing irradiation also induce p21 but not KILLER/DR5 gene expression. KILLER/DR5 upregulation is also deficient in irradiated lymphoblastoid cells derived from patients with Ataxia Teleangiectasia suggesting a role for the ATM-p53 pathway in regulating KILLER/DR5 expression after DNA damage. Inhibition of transcription by Actinomycin D blocks both KILLER/DR5 and p21 induction in cells undergoing p53-dependent apoptosis. Our results suggest that the p53-dependent transcriptional induction of KILLER/DR5 death receptor is restricted to cells undergoing apoptosis and not cells undergoing exclusively p53-dependent GI arrest.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Genet,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Radiat Oncol,Lab Mol Oncol & Cell Cycle Regu, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Pathol,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Fox Chase Cancer Center	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Yen, Tim/0000-0003-2159-0997	NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER; NCI NIH HHS [CA75138-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HOPKIN K, 1997, J NIH RES, V9, P22; Kastan M, 1997, NAT GENET, V17, P130, DOI 10.1038/ng1097-130; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LEONARDO AD, 1994, GENE DEV, V8, P2540; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meng RD, 1998, CLIN CANCER RES, V4, P251; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	52	99	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6411	6418		10.1038/sj.onc.1203025	http://dx.doi.org/10.1038/sj.onc.1203025			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597242				2022-12-28	WOS:000083709200002
J	Miyata, Y; Yahara, I				Miyata, Y; Yahara, I			p53-independent association between SV40 large T antigen and the major cytosolic heat shock protein, HSP90	ONCOGENE			English	Article						stress protein; tumor antigen; molecular chaperone; SV40; p53; geldanamycin	LARGE-TUMOR-ANTIGEN; ROUS-SARCOMA VIRUS; 90-KDA STRESS PROTEIN; CASEIN KINASE-II; MOLECULAR CHAPERONE; GLUCOCORTICOID RECEPTOR; SV40-TRANSFORMED CELLS; TRANSFORMING PROTEIN; TYROSINE KINASE; DNA-REPLICATION	The simian double strand DNA tumor virus SV40 encodes the 90-kDa multi-functional protein, large T antigen (LT). LT functions by binding to DNA, as well as to many cellular target proteins such as p53 and retinoblastoma protein (pRB). We report here the identification of a cellular heat shock protein, HSP90, as a previously undescribed LT-associated protein. Immunoprecipitates by anti-HSP90 antibodies from LT-expressing cell lysates contained LT protein, as revealed by Western blotting. Conversely, anti-LT antibody co-immunoprecipitated HSP90. Co-immunoprecipitation of HSP90 and LT was observed even after complete immune-depletion of p53, indicating that the association of LT with HSP90 is p53-independent. LT-HSP90 complexes can be reconstituted from purified HSP90 and unfolded-LT in vitro in an ATP-independent manner but not from HSP90 and native LT, suggesting that non-mature conformation of LT is required for the efficient association with HSP90. Moreover, geldanamycin, an anti-tumor drug that specifically binds and inhibits HSP90, reduced the intracellular concentration of LT by destabilizing newly synthesized LT. The above results suggest that HSP90 associates with immature forms of LT both in vivo and in vitro, and thus might assist LT in the formation of a functional, mature structure.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Miyata, Y (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kitashirakawa Oiwake Cho, Kyoto 6068502, Japan.		Miyata, Y/X-7111-2019					ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DIXON RAF, 1985, J VIROL, V53, P1001, DOI 10.1128/JVI.53.3.1001-1004.1985; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hedge Ramanujan S., 1995, Journal of Cellular Physiology, V165, P186; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JEOUNG DI, 1991, GENE DEV, V5, P2235, DOI 10.1101/gad.5.12a.2235; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KELLEY WL, 1994, TRENDS BIOCHEM SCI, V19, P277, DOI 10.1016/0968-0004(94)90003-5; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Tjian R, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P103; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Yahara I, 1998, ANN NY ACAD SCI, V851, P54, DOI 10.1111/j.1749-6632.1998.tb08976.x; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	57	28	29	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1477	1484		10.1038/sj.onc.1203475	http://dx.doi.org/10.1038/sj.onc.1203475			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723140				2022-12-28	WOS:000085942700014
J	Wai, DH; Knezevich, SR; Lucas, T; Jansen, B; Kay, RJ; Sorensen, PHB				Wai, DH; Knezevich, SR; Lucas, T; Jansen, B; Kay, RJ; Sorensen, PHB			The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells	ONCOGENE			English	Article						ETV6-NTRK3; TEL-TRKC; receptor tyrosine kinase; translocation; chimeric oncoprotein	NERVE GROWTH-FACTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; CONGENITAL-INFANTILE FIBROSARCOMA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ETS-VARIANT GENE-6; NEUROTROPHIN RECEPTORS; SIGNAL-TRANSDUCTION; TRK FAMILY; TEL GENE; MYELOPROLIFERATIVE DISORDERS	The congenital fibrosarcoma t(12;15)(p13;q25) rearrangement splices the ETV6 (TEL) gene on chromosome 12p13 in frame with the NTRK3 (TRKC) neurotrophin-3 receptor gene on chromosome 15q25, Resultant ETV6-NTRK3 fusion transcripts encode the helix-loop-helix (HLH) dimerization domain of ETV6 fused to the protein tyrosine kinase (PTK) domain of NTRK3, We show here that ETV6-NTRK3 homodimerizes and is capable of forming heterodimers with wild-type ETV6, Moreover, ETV6-NTRK3 has PTK activity and is autophosphorylated on tyrosine residues. To determine if the fusion protein has transforming activity, NIH3T3 cells were infected with recombinant retroviral vectors carrying the full-length ETV6-NTRK3 cDNA, These cells exhibited a transformed phenotype, grew macroscopic colonies in soft agar, and formed tumors in severe combined immunodeficient (SCID) mice, We hypothesize that chimeric proteins mediate transformation by dysregulating NTRK3 signal transduction pathways via ligand-independent dimerization and PTK activation. To test this hypothesis, we expressed a series of ETY6-NTRK3 mutants in NIH3T3 cells and assessed their transformation activities, Deletion of the ETV6 HLH domain abolished dimer formation with either ETV6 or ETV6-NTRK3, and cells expressing this mutant protein were morphologically non-transformed and failed to grow in soft agar, An ATP-binding mutant failed to autophosphorylate and completely lacked transformation activity. Mutants of the three NTRK3 PTK activation-loop tyrosines had variable PTK activity but had limited to absent transformation activity. Of a series of signaling molecules well known to bind to wild-type NTRK3, only phospholipase-C gamma (PLC gamma) associated with ETV6-TRK3, However, a PTK active mutant unable to bind PLC gamma did not show defects in transformation activity, Our studies confirm that ETV6-NTRK3 is a transforming protein that requires both an intact dimerization domain and a functional PTK domain for transformation activity.	British Columbia Childrens Hosp, Dept Pathol, Vancouver, BC V6H 3V4, Canada; Univ Vienna, Dept Clin Pharmacol, Sect Expt Oncol Mol Pharmacol, A-1090 Vienna, Austria; Univ Vienna, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria; British Columbia Canc Agcy, Dept Med Genet, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada	BC Childrens Hospital; University of British Columbia; University of Vienna; University of Vienna; British Columbia Cancer Agency	Sorensen, PHB (corresponding author), British Columbia Childrens Hosp, Dept Pathol, 4480 Oak St, Vancouver, BC V6H 3V4, Canada.			Lucas, Trevor/0000-0002-5114-8035				ADAM LR, 1990, CANCER GENET CYTOGEN, V48, P193; ARGYLE JC, 1992, ARCH PATHOL LAB MED, V116, P972; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cave H, 1997, LEUKEMIA, V11, P1459, DOI 10.1038/sj.leu.2400798; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; COCKCROFT S, 1992, BIOCHEM J, V288, P1; COFFIN CM, 1994, PEDIATR PATHOL, V14, P133, DOI 10.3109/15513819409022033; Conover JC, 1997, REV NEUROSCIENCE, V8, P13; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Downward J, 1996, CANCER SURV, V27, P87; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Edel MJ, 1998, ANTICANCER RES, V18, P4505; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GUITON M, 1995, J BIOL CHEM, V270, P20384, DOI 10.1074/jbc.270.35.20384; GunnMoore FJ, 1997, BIOCHEM J, V322, P193, DOI 10.1042/bj3220193; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HAWLEY RG, 1994, GENE THER, V1, P136; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ichaso N, 1998, ONCOGENE, V17, P1871, DOI 10.1038/sj.onc.1202100; JANSSEN JWG, 1995, BRIT J HAEMATOL, V90, P222, DOI 10.1111/j.1365-2141.1995.tb03407.x; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MANDAHL N, 1989, CANCER GENET CYTOGEN, V40, P137, DOI 10.1016/0165-4608(89)90156-8; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCGREGOR LM, 1994, GENOMICS, V22, P267, DOI 10.1006/geno.1994.1383; MITRA G, 1991, ONCOGENE, V6, P2237; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; O'Connor HE, 1998, LEUKEMIA, V12, P1099, DOI 10.1038/sj.leu.2401070; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; SANKARY S, 1993, CANCER GENET CYTOGEN, V65, P152, DOI 10.1016/0165-4608(93)90225-B; SPELEMAN F, 1989, CANCER GENET CYTOGEN, V39, P21, DOI 10.1016/0165-4608(89)90224-0; Suto Y, 1997, GENE CHROMOSOME CANC, V18, P254, DOI 10.1002/(SICI)1098-2264(199704)18:4<254::AID-GCC3>3.0.CO;2-#; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; Tsoulfas P, 1996, J BIOL CHEM, V271, P5691, DOI 10.1074/jbc.271.10.5691; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Yagasaki F, 1999, GENE CHROMOSOME CANC, V26, P192, DOI 10.1002/(SICI)1098-2264(199911)26:3<192::AID-GCC2>3.0.CO;2-E	73	102	105	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					906	915		10.1038/sj.onc.1203396	http://dx.doi.org/10.1038/sj.onc.1203396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702799				2022-12-28	WOS:000085567700008
J	Blyth, K; Stewart, M; Bell, M; James, C; Evan, G; Neil, JC; Cameron, ER				Blyth, K; Stewart, M; Bell, M; James, C; Evan, G; Neil, JC; Cameron, ER			Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER (TM) mice	ONCOGENE			English	Article						c-myc; apoptosis; transgene; T-cell lymphoma	PROGRAMMED CELL-DEATH; WILD-TYPE P53; C-MYC; TRANSGENIC MICE; MEDIATED APOPTOSIS; THYMIC LYMPHOMAS; CYCLE ARREST; FACTOR-ALPHA; EXPRESSION; GROWTH	To study the effects of the Myc oncoprotein in a regulatable in vivo system, we generated lines of transgenic mice in which a tamoxifen inducible Myc fusion protein (c-mycER(TM)) is expressed under the control of the CD2 locus control region, Activation of the Myc oncoprotein resulted in both proliferation and apoptosis in vivo, Lines with a high transgene copy number developed spontaneous lymphomas at low frequency, but the tumour incidence was significantly increased with tamoxifen treatment. Surprisingly, we found that cellular sensitivity to Myc-induced apoptosis was retained in tumours from these mice and in most lymphoma cell lines, even when null for p53, Resistance to Myc-induced apoptosis could be conferred on these cells by co-expression of Bcl-2, However, acquired resistance is clearly not an obligatory progression event as sensitivity to apoptosis was retained in transplanted tumours in athymic mice, In conclusion, lymphomas arising in CD2-mycER(TM) mice retain the capacity to undergo apoptosis in response to Myc activation and show no phenotypic evidence of the presence of an active dominant inhibitor.	Univ Glasgow, Sch Vet, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland; Imperial Canc Res Fund, Biochem Cell Nucleas Lab, London WC2A 3PX, England	University of Glasgow; Cancer Research UK	Cameron, ER (corresponding author), Univ Glasgow, Sch Vet, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland.			Blyth, Karen/0000-0002-9304-439X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; ASKEW DS, 1991, ONCOGENE, V6, P1915; BLYTH K, 1995, ONCOGENE, V10, P1717; BOISE LH, 1995, P NATL ACAD SCI USA, V92, P5491, DOI 10.1073/pnas.92.12.5491; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hogan B., 1994, MANIPULATING MOUSE E; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Hundley JE, 1997, CANCER RES, V57, P600; JACOBSEN KA, 1994, BLOOD, V84, P2784; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Prasad VS, 1997, MOL CARCINOGEN, V18, P66, DOI 10.1002/(SICI)1098-2744(199702)18:2<66::AID-MC2>3.0.CO;2-O; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Rupnow BA, 1998, CANCER RES, V58, P1779; Sakamuro D, 1995, ONCOGENE, V11, P2411; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; STEWART M, 1993, INT J CANCER, V53, P1023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	53	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					773	782		10.1038/sj.onc.1203321	http://dx.doi.org/10.1038/sj.onc.1203321			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698495				2022-12-28	WOS:000085192100007
J	Murthy, SS; Shen, T; De Rienzo, A; Lee, WC; Ferriola, PC; Jhanwar, SC; Mossman, BT; Filmus, J; Testa, JR				Murthy, SS; Shen, T; De Rienzo, A; Lee, WC; Ferriola, PC; Jhanwar, SC; Mossman, BT; Filmus, J; Testa, JR			Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma	ONCOGENE			English	Article						proteoglycan; mesothelioma; differential mRNA display; gene regulation; tumor suppressor gene; promoter methylation	ASBESTOS; GLYPICAN; GROWTH; CELLS; INOCULATION; CARCINOMA; MUTATIONS; RATS; NF2	Gene expression changes in rat asbestos-induced malignant mesothelioma (MM) cells were investigated by differential mRNA display. A mRNA transcript identified by this approach was abundant in normal rat mesothelial cells but not expressed in rat MM cell lines. Northern blot analysis confirmed that this transcript is uniformly silenced in rat MM cell lines and primary tumors. Nucleotide sequence analysis revealed that this transcript is encoded by the rat glypican 3 gene (GPC3), whose human homolog is mutated in the Simpson-Golabi-Behmel overgrowth syndrome. Allelic loss at the GPC3 locus was infrequent (6.9%) in MM cell lines, and no mutations were found. GPC3 transcript levels were markedly decreased in 16 of 18 primary tumors and 17 of 22 human MM cell Lines. Most of the cell lines were shown to have aberrant methylation of the GPC3 promoter region. In two of four human MM cell lines tested, GPC3 expression was restored after 2-deoxy 5-azacytidine (DAC)-mediated demethylation of its promoter region. Ectopic expression of GPC3 inhibited in vitro colony formation of human MM cells, Collectively, these data suggest that down-regulation of GPC3 is a common occurrence in MM and that GPC3, an X-linked recessive overgrowth gene, may encode a negative regulator of mesothelial cell growth.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Chem Ind Inst Toxicol, Res Triangle Pk, NC 27709 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; University of Vermont; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45745, CA-06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHENG JQ, 1994, CANCER RES, V54, P5547; CRAIGHEAD JE, 1987, AM J PATHOL, V129, P448; CRAIGHEAD JE, 1987, HUM PATHOL, V18, P544, DOI 10.1016/S0046-8177(87)80354-4; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DAVIS JMG, 1974, J NATL CANCER I, V52, P1823, DOI 10.1093/jnci/52.6.1823; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; FUNAKI K, 1991, CANCER RES, V51, P4059; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HILL RJ, 1990, J EXP PATHOL, V71, P105; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; JANSSEN YMW, 1995, CANCER RES, V55, P2085; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIBBUS BL, 1988, CANCER RES, V48, P6455; Lin HC, 1999, CANCER RES, V59, P807; MOSSMAN BT, 1989, NEW ENGL J MED, V320, P1721, DOI 10.1056/NEJM198906293202604; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; SEKIDO Y, 1995, CANCER RES, V55, P1227; Song HH, 1997, J BIOL CHEM, V272, P7574, DOI 10.1074/jbc.272.12.7574; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; TAGUCHI T, 1993, CANCER RES, V53, P4349; WAGNER J C, 1960, Br J Ind Med, V17, P260; WAGNER JC, 1973, BRIT J CANCER, V28, P173, DOI 10.1038/bjc.1973.134; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	29	126	138	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					410	416		10.1038/sj.onc.1203322	http://dx.doi.org/10.1038/sj.onc.1203322			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656689				2022-12-28	WOS:000084873700012
J	Sengupta, S; Ralhan, R; Wasylyk, B				Sengupta, S; Ralhan, R; Wasylyk, B			Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53	ONCOGENE			English	Article						head and neck cancer; apoptosis; tamoxifen; oestrogen receptor; gene therapy	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; SQUAMOUS-CELL CARCINOMAS; C-TERMINAL DOMAIN; TRANSCRIPTIONAL ACTIVATION; GENE-TRANSFER; IN-VIVO; MUTANT P53; GROWTH SUPPRESSION; ESTROGEN-RECEPTOR	The p53 tumour suppressor induces cell cycle arrest and apoptosis in response to cellular stresses. p53 is inactivated by various cellular and viral factors. We set out to generate regulatable p53 derivatives that are highly inducible by synthetic ligands, escape inactivation and efficiently induce apoptosis. We have generated Ligand Inducible Chimeric Tumour Suppressors (LICTS), that are inactive unless provided with artificial ligands. They are resistant to inactivation, due to the replacement of domains that mediate p53 inhibition by heterologous sequences. LICTS are activated by micromolar concentrations of ligand in a variety of cell lines. Following ligand addition, they translocate to the nucleus, activate p53 inducible genes and induce apoptosis. We have established human head and neck squamous cell carcinoma lines that stably express LICTS, which are inducible. These lines form tumours in nude mice in the absence of ligand. Addition of ligand inhibits tumour formation, and moreover, regresses established tumours by apoptosis. Although regulatable p53 expression has been achieved previously, our study provides the first demonstration of regulatable in vivo regression of tumours in a p53 based approach. Regulated inhibition and regression of tumours with a ligand inducible chimeric tumour suppressor could provide a novel approach to p53 based gene therapy.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; All India Inst Med Sci, New Delhi 110029, India	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; All India Institute of Medical Sciences (AIIMS) New Delhi	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Wasylyk, Bohdan/ABG-6778-2020; Sengupta, Sagar/AGR-1063-2022	Wasylyk, Bohdan/0000-0002-1718-1237; Sengupta, Sagar/0000-0002-6365-1770				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bond J, 1996, ONCOGENE, V13, P2097; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063; Conseiller E, 1998, J CLIN INVEST, V101, P120, DOI 10.1172/JCI1140; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Ford LG, 1997, PROG CLIN BIOL RES, V396, P271; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gallardo D, 1996, CANCER RES, V56, P4891; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GomezManzano C, 1996, CANCER RES, V56, P694; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JIANG D, 1993, ONCOGENE, V8, P2805; JUVEN T, 1993, ONCOGENE, V8, P3411; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LE GLS, 1993, SCIENCE, V259, P988; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; LIU TJ, 1994, CANCER RES, V54, P3662; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; Mukhopadhyay T, 1998, ONCOGENE, V17, P241, DOI 10.1038/sj.onc.1201909; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Pirollo KF, 1997, ONCOGENE, V14, P1735, DOI 10.1038/sj.onc.1201116; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SAKAI E, 1992, ONCOGENE, V7, P927; Sankaranarayanan R, 1998, ANTICANCER RES, V18, P4779; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schuler M, 1998, HUM GENE THER, V9, P2075, DOI 10.1089/hum.1998.9.14-2075; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; SHAH JP, 1995, CA-CANCER J CLIN, V45, P352, DOI 10.3322/canjclin.45.6.352; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Treinies I, 1999, MOL CELL BIOL, V19, P321; Vater CA, 1996, ONCOGENE, V13, P739; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WAKELING AE, 1995, BIOCHEM PHARMACOL, V49, P1545, DOI 10.1016/0006-2952(94)00528-T; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Xu GW, 1996, HEPATOLOGY, V24, P1264; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	100	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					337	350		10.1038/sj.onc.1203256	http://dx.doi.org/10.1038/sj.onc.1203256			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656680				2022-12-28	WOS:000084873700003
J	Borriello, A; Della Pietra, V; Criscuolo, M; Oliva, A; Tonini, GP; Iolascon, A; Zappia, V; Della Ragione, F				Borriello, A; Della Pietra, V; Criscuolo, M; Oliva, A; Tonini, GP; Iolascon, A; Zappia, V; Della Ragione, F			p27(Kip1) accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation	ONCOGENE			English	Article						neuroblastoma; differentiation; p27; cyclin; cyclin-dependent kinase	KINASE INHIBITOR P27; CELL-CYCLE; CDK INHIBITOR; GROWTH ARREST; PROTEIN; PHOSPHORYLATION; ACTIVATION; LINES; MYC	Development of human neuroblastoma is due to an arrest in the differentiation program of neural crest sympathoadrenal progenitor cells. However, neuroblastomas, as well as their derived cell lines, maintain the potentiality of terminal differentiation. We investigated the molecular mechanisms by which retinoic acid, a molecule introduced in clinical trials for chemotherapy, induces differentiation in neuroblastoma cell lines. Our findings demonstrate that the retinoic acid-dependent growth arrest of LAN-5 neuroblastoma cell line is associated to a very large accumulation (>tenfold) of p27(Kip1) protein, a cyclin-dependent kinase inhibitor; the protein binds and inhibits cyclin-dependent kinase 2, 4 and 6 activities, thus hampering pRb and p107 phosphorylation, p27(Kip1) build-up was observable as an early phenomenon (12-24 h) after retinoic exposure and resulted in a time-dependent accumulation of high quantities of a free p27(Kip1) form, Furthermore, retinoic treatment causes an increase of cyclin-dependent kinase 5 level and activity; however, immunoprecipitation studies proved the absence of interaction with p27(kip1). No noticeable variation of other components of G1 phase cell cycle engine ws observed. Pulse-chase experiments showed a remarkable elongation of p27(Kip1) half-life in retinoic-treated LAN-5, while no enhancement of p27(Kip1) gene expression and of the translational efficiency of its messenger RNA were demonstrated. In vivo degradation of p27(Kip1) was sensitive to two highly specific proteasome inhibitors, LLnL and lactacystin, while the calpain inhibitor II ALLM and the cysteine protease inhibitor E64 did not modify the level of the protein. LLnL treatment caused a very rapid (2 h) build-up of the Cdk inhibitor content and the accumulation of higher molecular weight anti-p27(Kip1) immunoreactive bands, which probably represent ubiquitinated forms of the protein. Finally, in vitro experiments demonstrated that extracts prepared from retinoic-treated LAN-5 cells degraded recombinant p27(Kip1) at a rate remarkably slower than the untreated cells. Our results indicate that retinoic acid strongly increases p27(Kip1) le, els by down-regulating the ubiquitin-proteasome p27(Kip1) degrading pathway.	Univ Naples 2, Inst Biochem Macromol, Sch Med, I-80138 Naples, Italy; Giannina Gaslini Childrens Hosp, Lab Oncol, Adv Biotechnol Ctr, Genoa, Italy; Univ Bari, Dept Biomed Eta Evolut, Bari, Italy	Universita della Campania Vanvitelli; University of Genoa; IRCCS Istituto Giannina Gaslini; Universita degli Studi di Bari Aldo Moro	Della Ragione, F (corresponding author), Univ Naples 2, Inst Biochem Macromol, Sch Med, Via Constantinopoli 16, I-80138 Naples, Italy.		Borriello, Adriana/K-3464-2018; Iolascon, Achille/A-4461-2014	Della Ragione, Fulvio/0000-0002-0592-4283; BORRIELLO, Adriana/0000-0002-9026-8048				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; DELLARAGIONE F, 1995, ONCOGENE, V10, P827; DONGMING S, 1996, J BIOL CHEM, V271, P14245; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P815; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Iolascon A, 1998, PEDIATR RES, V43, P139, DOI 10.1203/00006450-199801000-00021; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Khan AA, 1996, CANCER CHEMOTH PHARM, V39, P34, DOI 10.1007/s002800050535; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MURAKAMI T, 1991, PROG CLIN BIOL RES, V366, P65; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Philip T, 1989, NEW DIRECTIONS CANCE, P605; PINKERTON CR, 1993, HUMAN NEUROBLASTOMA, P3; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089	32	66	71	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					51	60		10.1038/sj.onc.1203231	http://dx.doi.org/10.1038/sj.onc.1203231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644979				2022-12-28	WOS:000084844300006
J	Grishin, A; Sinha, S; Roginskaya, V; Boyer, MJ; Gomez-Cambronero, J; Zuo, S; Kurosaki, T; Romero, G; Corey, SJ				Grishin, A; Sinha, S; Roginskaya, V; Boyer, MJ; Gomez-Cambronero, J; Zuo, S; Kurosaki, T; Romero, G; Corey, SJ			Involvement of Shc and Cbl-PI 3-kinase in Lyn-dependent proliferative signaling pathways for G-CSF	ONCOGENE			English	Article						G-CSF; Lyn; PI 3-kinase; Cbl; Shc	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; FACTOR-RECEPTOR; ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; P21(RAS) ACTIVATION; DISTINCT REGIONS; GROWTH-FACTOR; B-CELLS	Granulocyte colony-stimulating factor (G-CSF) is the major hematopoietic factor which controls the production and differentiation of granulocytes. The G-CSF receptor (G-CSFR) belongs to the superfamily of the cytokine receptors, which transduce signals via the activation of cytosolic protein tyrosine kinases (PTK), To determine the role of specific PTK in G-CSF signaling we expressed the human G-CSFR in cell lines derived from DT40 B cells, which lack either the Src-related Lyn or Syk, Wild-type (wt) and syk-deficient cells underwent increased DNA synthesis in response to G-CSF; lyn-deficient cells did not. The purpose of these studies is to identify Lyn's downstream effectors in mediating DNA synthesis, While G-CSF stimulated Pas activity in all cell lines, G-CSF failed to induce the tyrosine phosphorylation of Shc in lyn-deficient cells. G-CSF induced a statistically significant activation of Erk1/Erk2 Kinase or p90Rsk only in the wt cells. G-CSF induced the tyrosine phosphorylation of Cbl and increased activity of PI 3-kinase in wild-type and syk-deficient, but non in lyn-deficient, cells. Inhibition of Shc by over-expression of its SH2 or PTB domains or PI 3-kinase by either treatment with wortmannin or expression of the CblY731F mutant decreased G-CSF-induced DNA synthesis, Thus, the Lyn, Cbl-PI 3-kinase, and Shc/non-Pas-dependent pathways correlate with the ability of cells to respond to G-CSF with increased DNA synthesis.	Childrens Hosp Pittsburgh, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45401 USA; Kansai Med Univ, Dept Mol Genet, Inst Liver Res, Moriguchi, Osaka 570, Japan; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; Wright State University Dayton; Kansai Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Corey, SJ (corresponding author), Childrens Hosp Pittsburgh, Div Hematol Oncol, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Gomez-Cambronero, Julian/0000-0002-7581-9227				BALDARI CT, 1995, ONCOGENE, V10, P1141; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Joseph DE, 1996, J BIOL CHEM, V271, P13088, DOI 10.1074/jbc.271.22.13088; KAWAUCHI K, 1994, J IMMUNOL, V152, P3306; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; PAN CX, 1993, J BIOL CHEM, V268, P25818; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	45	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					97	105		10.1038/sj.onc.1203254	http://dx.doi.org/10.1038/sj.onc.1203254			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644984				2022-12-28	WOS:000084844300011
J	Tsuneoka, M; Mekada, E				Tsuneoka, M; Mekada, E			Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras	ONCOGENE			English	Article						apoptosis; MEK; Myc; Ras; transformation	CYCLIN-E; INDUCTION; ONCOGENES; PROTEIN; KINASE; PROLIFERATION; ONCOPROTEIN; FIBROBLASTS; REQUIRES; CANCER	Cooperation of myc and activated ras has been suggested to cause malignant cell transformation but the mechanism is still unknown. Here we isolated a transformed cell line in which activation of c-Mye and Ras are independently controllable, and show that after establishment of the transformed state by c-myc and activated ras, removal of activated Ras initiates apoptosis that is dependent on c-Myc activity. Apoptosis is also initiated by an inhibitor of MEK (MAPK/ERK kinase), a kinase downstream of Ras, and apoptosis is blocked by activated Mek1. These results suggest that one of the conditions required for establishment of the transformed state is a block of apoptosis involving MEK activity. We tested the effect of MEK inhibition on cells transformed by various oncogenes, Suppression of apoptosis by MEK; is not critical in general, but in cells transformed by c-myc plus a gene that activates the MAPK cascade it is necessary to avoid cell death, Activated Ras/MEK did not suppress c-myc-dependent apoptosis due to serum-limitation. Overexpression of chicken bcl-xL suppressed apoptosis under serum-limiting conditions, but not apoptosis initiated by Ras/MEK inhibition in cells transformed by myc and activated ras. Altogether, these results suggest the existence of a novel el regulatory mechanism for myc-dependent apoptosis in certain transformed cells.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Kurume University	Tsuneoka, M (corresponding author), Kurume Univ, Inst Life Sci, 2432-3 Aikawa Machi, Kurume, Fukuoka 8390861, Japan.			Mekada, Eisuke/0000-0001-8858-4781				BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BOS JL, 1989, CANCER RES, V49, P4682; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PFEIFER AMA, 1989, P NATL ACAD SCI USA, V86, P10075, DOI 10.1073/pnas.86.24.10075; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; Tsuneoka M, 1998, J BIOCHEM-TOKYO, V124, P1013, DOI 10.1093/oxfordjournals.jbchem.a022193; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; YAMASHITA T, 1980, INT J CANCER, V26, P435, DOI 10.1002/ijc.2910260408	29	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					115	123		10.1038/sj.onc.1203232	http://dx.doi.org/10.1038/sj.onc.1203232			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644986				2022-12-28	WOS:000084844300013
J	Kannabiran, C; Morris, GF; Mathews, MB				Kannabiran, C; Morris, GF; Mathews, MB			Dual action of the adenovirus E1A 243R oncoprotein on the human proliferating cell nuclear antigen promoter: repression of transcriptional activation by p53	ONCOGENE			English	Article						PCNA; transcription; p53; E1A	CYCLIN-DEPENDENT KINASES; DNA POLYMERASE-DELTA; 19-KILODALTON PROTEIN; FUNCTIONAL DOMAINS; AUXILIARY PROTEIN; COACTIVATOR P300; TUMOR SUPPRESSOR; HOST-CELL; GENE; TRANSFORMATION	The promoter of the human proliferating cell nuclear antigen (PCNA) gene is activated by the adenovirus oncoprotein E1A 243R in HeLa cells. To understand the effect of this oncoprotein on PCNA expression in cells that are sensitive to oncogenic transformation by adenovirus, we studied the effect of E1A 243R on PCNA promoter-directed reporter gene expression in cloned rat embryo fibroblast (CREF) and primary baby rat kidney cells. In contrast to the results obtained in HeLa cells, EIA repressed the PCNA promoter in both cell-types. Promoter analysis identified a p53-responsive element that mediates E1A-induced repression. Repression required the intact N-terminus of EIA 243R, as shown by the ability of mutant EIA proteins to repress the promoter, and correlated with the p300-binding region of EIA. The adenovirus E1B 19K protein relieved repression by EIA 243R. These results reveal dual pathways for induction of this essential DNA replication factor and suggest a mechanism for oncogenic cooperativity between the EIA and E1B oncoproteins.	Cold Spring Harbor Lab, New York, NY 11724 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Cold Spring Harbor Laboratory; Rutgers State University New Brunswick; Rutgers State University Medical Center	Mathews, MB (corresponding author), LV Prasad Eye Inst, Rd 2,Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.		Kannabiran, Chitra/S-9361-2019	Kannabiran, Chitra/0000-0001-8435-0320	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HARPER JW, 1993, CELL, V75, P805; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HERRMANN CH, 1987, ONCOGENE, V2, P25; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRIS GF, 1994, MOL CELL BIOL, V14, P543, DOI 10.1128/MCB.14.1.543; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NEVINS JR, 1992, SCIENCE, V258, P424; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	69	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7825	7833		10.1038/sj.onc.1203294	http://dx.doi.org/10.1038/sj.onc.1203294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618724				2022-12-28	WOS:000084256900013
J	Turpin, E; Dalle, B; de Roquancourt, A; Plassa, LF; Marty, M; Janin, A; Beuzard, Y; de The, H				Turpin, E; Dalle, B; de Roquancourt, A; Plassa, LF; Marty, M; Janin, A; Beuzard, Y; de The, H			Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers	ONCOGENE			English	Article						TSG101; p53; stress , tumor grading; splicing; breast cancer	SUSCEPTIBILITY GENE TSG101; POOR-PROGNOSIS; TRANSCRIPTS; MUTATIONS; HETEROZYGOSITY; REARRANGEMENTS; METASTASIS; HYPOXIA; RNA	The TSG101 gene, identified through insertional mutagenesis, is localized in a region that exhibits LOH in human cancers, suggesting that TSG101 might be a tumor suppressor gene. Numerous studies have then shown the presence of abnormal transcripts in various tumors which appear to result from aberrant splicing of the gene, rather than from intragenic deletions. Moreover, many studies demonstrated that these aberrantly spliced transcripts mere not found in matched normal tissues, We have analysed TSG101 transcripts in 85 breast cancer samples and found that abnormal splicing of the gene is tightly correlated with tumor grade and p53 mutation. In addition, stress induced the appearance of these abnormal transcripts in primary lymphocytes. Hence, TSG101 splicing defects, while unrelated to the oncogenic process per se, could reflect the cellular environment of the tumor cells. The proposed role of stress and hypoxia to select p53 mutant cells could account for the tight association with p53 status.	Hop St Louis, Lab Biochim B, F-75475 Paris 10, France; Hop St Louis, Anat Pathol Lab, F-75475 Paris, France; Hop St Louis, Serv Oncol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Turpin, E (corresponding author), Hop St Louis, Lab Biochim B, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.							BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Carney ME, 1998, J SOC GYNECOL INVEST, V5, P281, DOI 10.1016/s1071-5576(98)00018-5; Chang JG, 1999, BRIT J CANCER, V79, P445, DOI 10.1038/sj.bjc.6690069; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES C, 1992, CANCER RES, V52, P5291; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; KNOWLES MA, 1994, CANCER RES, V54, P531; LAMOND AI, 1995, CURR BIOL, V5, P862, DOI 10.1016/S0960-9822(95)00174-6; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lin PM, 1998, BRIT J HAEMATOL, V102, P753, DOI 10.1046/j.1365-2141.1998.00815.x; Lin SY, 1998, J GASTROEN HEPATOL, V13, P1111, DOI 10.1111/j.1440-1746.1998.tb00585.x; LISUKA M, 1995, GENES CHROM CANC, V13, P40; Oh Y, 1998, ONCOGENE, V17, P1141, DOI 10.1038/sj.onc.1202029; SAITOH S, 1994, ONCOGENE, V9, P2869; Sato T, 1997, CANCER LETT, V115, P47, DOI 10.1016/S0304-3835(97)04705-8; Silvestrini R, 1996, CLIN CANCER RES, V2, P2007; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Valgardsdottir R, 1997, APMIS, V105, P121, DOI 10.1111/j.1699-0463.1997.tb00550.x; Wagner KU, 1998, ONCOGENE, V17, P2761, DOI 10.1038/sj.onc.1202529; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Willeke F, 1998, MOL CARCINOGEN, V23, P195; WINQVIST R, 1995, CANCER RES, V55, P2660	32	28	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7834	7837		10.1038/sj.onc.1203196	http://dx.doi.org/10.1038/sj.onc.1203196			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618725				2022-12-28	WOS:000084256900014
J	Chen, WX; Bowden, GT				Chen, WX; Bowden, GT			Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes	ONCOGENE			English	Article						UVB; p38; ERK; c-fos; AP-1	MAMMALIAN UV RESPONSE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CELLULAR STRESSES; SUBSTRATE-SPECIFICITY; AP-1 ACTIVITY; JUN; PHOSPHORYLATION; TRANSCRIPTION; INHIBITION	The effects of p38 MAP kinase and ERK on UVB induced c-fos gene expression were studied in a human keratinocyte cell line, FL30, UVB significantly increased c-fos gene expression at both the transcriptional and protein le,els. p38 and ERK were also significantly activated after UVB irradiation. Treating the cells with p38 inhibitor SB202190 inhibited p38 activation, but not ERK; treating the cells with MEK-1 inhibitor PD98059 inhibited ERK activation without suppressing p38 activation, The kinase activation was determined by Western blots using phospho-p38 or ERK antibodies, or an in vivo p38 activity assay. Further studies demonstrated that blocking p38 almost completely abrogated UVB induced c-fos gene transcription and c-Fos protein synthesis. Inhibiting ERK partially abrogated UVB induced c-fos transcriptional and protein levels, Suppression of both p38 and ERK not only completely blocked UVB induced c-fos expression, but also decreased c-fos gene basal expression. Our data indicated that p38 may play a more important role than ERK in UVB induced c-fos expression in human keratinocytes, Since c-fos expression may play an important role in UVB induced AP-1 activation, and AP-1 activation is known to play a role in tumor promotion, both p38 and ERK could be potential targets for chemoprevention of skin cancer.	Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [CA27502, CA23074] Funding Source: Medline; NIEHS NIH HHS [P30 ESO6694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barthelman M, 1998, CARCINOGENESIS, V19, P2201, DOI 10.1093/carcin/19.12.2201; Barthelman M, 1998, CANCER RES, V58, P711; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen WX, 1997, NUTR CANCER, V29, P205, DOI 10.1080/01635589709514625; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Huwiler A, 1999, J EXP BIOL, V202, P655; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JANKNECHT R, 1993, EMBO J, V12, P5057; Kaminska B, 1999, MOL CELL NEUROSCI, V13, P405, DOI 10.1006/mcne.1999.0757; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOZANO J, 1994, J BIOL CHEM, V269, P6687; MATSUI MS, 1995, SKIN CANC MECH HUMAN, P21; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; Rosenberger SF, 1996, ONCOGENE, V12, P2301; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; WOODGETT JR, 1995, CLIN EXP PHARMACOL P, V22, P281, DOI 10.1111/j.1440-1681.1995.tb01995.x; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	47	83	90	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7469	7476		10.1038/sj.onc.1203210	http://dx.doi.org/10.1038/sj.onc.1203210			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602506				2022-12-28	WOS:000084119600008
J	Chen, YR; Meyer, CF; Ahmed, B; Yao, ZB; Tan, TH				Chen, YR; Meyer, CF; Ahmed, B; Yao, ZB; Tan, TH			Caspase-mediated cleavage and functional changes of hematopoietic progenitor kinase 1 (HPK1)	ONCOGENE			English	Article						HPK1; JNK; caspase; apoptosis; adaptor	GERMINAL CENTER KINASE; RADIATION-INDUCED APOPTOSIS; JUN NH2-TERMINAL KINASE; PROTEIN-KINASE; CELL-DEATH; PROTEOLYTIC ACTIVATION; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; GAMMA-RADIATION; JNK ACTIVATION	Activation of c-Jun N-terminal kinase (JNK) by Fas ligation is caspase-dependent, suggesting that caspases may regulate activators of the JNK pathway. Here, we report that an upstream activator of JNK, hematopoietic progenitor kinase I (HPK1), was cleaved during apoptosis, Cleavage of HPK1 was blocked by peptide inhibitors for caspases. HPK1 was efficiently processed by recombinant caspase 3 in vitro. A conserved caspase recognition site, DDVD (amino acids 382-385), was found in the HPK1 protein sequence. By testing HPK1 proteins with in vivo and in vitro cleavage assays, we showed that aspartic acid residue 385 is the target for caspases. HPK1 cleavage separated the amino N-terminal kinase domain from the carboxyl C-terminal regulatory domain, and enhanced HPK1 kinase activity. Unlike the full-length HPK1, the N-terminal cleaved product failed to bind adaptor molecules Grb2 (growth factor receptor-bound protein 2) and Crk (CT10 regulator of kinase). The C-terminal fragment, although having three proline-rich domains, bound to Grb2 and Crk less efficiently than the full-length HPK1 protein. Taken together, the cleavage of HPK1 by caspase profoundly changed its biochemical properties.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Hoechst Marion Roussel, CNS Dept, Bridgewater, NJ 08807 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/E-3991-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002	NIAID NIH HHS [R01-AI42532, R01-AI38649] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Ling P, 1999, MOL CELL BIOL, V19, P1359; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shiah SG, 1999, CANCER RES, V59, P391; SONG O, 1996, EMBO J, V15, P3238; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO Z, 1997, J BIOL CHEM, V272, P2118; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	48	62	64	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7370	7377		10.1038/sj.onc.1203116	http://dx.doi.org/10.1038/sj.onc.1203116			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602493				2022-12-28	WOS:000084119400023
J	El-Naggar, AK; Lai, SL; Tucker, SA; Clayman, GL; Goepfert, H; Hong, WK; Huff, V				El-Naggar, AK; Lai, SL; Tucker, SA; Clayman, GL; Goepfert, H; Hong, WK; Huff, V			Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma	ONCOGENE			English	Article						imprinting; loss of imprinting; head and neck squamous carcinoma; epigenetic alterations; insulin growth factor-2 and H19 genes	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; CELL-CARCINOMA; REDUCED EXPRESSION; INVASIVE HEAD; HUMAN TISSUES; CANCER; INACTIVATION; METHYLATION	Genomic imprinting is an inherited epigenetic phenomenon that results in parental-origin-specific gene expression in somatic cells. Relaxation or loss of this feature in certain genes has been demonstrated in several pediatric and adult neoplasms, suggesting an association with tumorigenesis. We analysed 64 primary untreated head and neck squamous carcinoma for the loss of imprinting in the IGF2 and H19 genes to determine the implications of this alteration in the development and progression of these tumors. Forty-nine (77%) of the 64 tumors were informative for imprinting analyses of these genes. IGF2 and H19 were imprinted in all normal squamous epithelium examined. Twelve (37.5%) of 32 tumors informative for H19 and 11 (40.7%) of 27 tumors informative for IGF2 manifested loss of imprinting. Ten tumors were informative for both genes, of which four maintained the constitutional imprinting and six showed loss of imprinting at either H19 or IGF2. These data suggest that loss of imprinting at the IGF2 and H19 loci play a role in the oncogenesis of head and neck carcinoma.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Pediat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	El-Naggar, AK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.				NIDCR NIH HHS [1P50DE11906-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHSEE KW, 1994, CANCER RES, V54, P1617; *AM CANC SOC INC, 1997, CANC FACTS FIG; Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BARTOLOMEI MS, 1994, NAT GENET, V6, P220, DOI 10.1038/ng0394-220; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; CATTANACH BM, 1990, DEVELOPMENT, P63; CHAO LY, 1993, NAT GENET, V3, P127, DOI 10.1038/ng0293-127; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; CROUSE H, 1996, GENETICS, V45, P1425; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 1997, CANCER RES, V57, P4469; Dao D, 1999, HUM MOL GENET, V8, P1337, DOI 10.1093/hmg/8.7.1337; DAO DD, 1987, AM J HUM GENET, V41, P202; DAVIES SM, 1993, CANCER RES, V53, P4781; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ElNaggar AK, 1996, CLIN CANCER RES, V2, P903; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; ELNAGGAR AK, 1995, INT J CANCER, V64, P196, DOI 10.1002/ijc.2910640309; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; EZZELL C, 1994, J NIH RES, V6, P53; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; Fukuzawa R, 1999, INT J CANCER, V82, P490, DOI 10.1002/(SICI)1097-0215(19990812)82:4<490::AID-IJC4>3.0.CO;2-I; Greally JM, 1998, HUM MOL GENET, V7, P91, DOI 10.1093/hmg/7.1.91; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HERMAN JG, 1995, CANCER RES, V55, P4525; Hibi K, 1996, CANCER RES, V56, P480; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; Kim HT, 1998, AM J MED GENET, V80, P391, DOI 10.1002/(SICI)1096-8628(19981204)80:4<391::AID-AJMG16>3.0.CO;2-H; KONDO M, 1995, ONCOGENE, V10, P1193; Lee MP, 1999, HUM MOL GENET, V8, P683, DOI 10.1093/hmg/8.4.683; Li XR, 1997, CANCER RES, V57, P2048; Mannens M., 1994, European Journal of Human Genetics, V2, P3; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; Mitsuya K, 1997, HUM MOL GENET, V6, P2243, DOI 10.1093/hmg/6.13.2243; MONTAGNA M, 1994, J CANCER RES CLIN, V120, P732, DOI 10.1007/BF01194272; MORRISON IM, 1996, NAT MED, V2, P331; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Nonomura N, 1997, CANCER RES, V57, P2575; Oda H, 1998, INT J CANCER, V75, P343, DOI 10.1002/(SICI)1097-0215(19980130)75:3<343::AID-IJC3>3.0.CO;2-2; Ouyang H, 1997, CANCER RES, V57, P1851; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; PETERSON K, 1993, ANNU REV GENET, V27, P7, DOI 10.1146/annurev.ge.27.120193.000255; Rachmilewitz J, 1996, ONCOGENE, V13, P1687; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Randhawa GS, 1998, BLOOD, V91, P3144, DOI 10.1182/blood.V91.9.3144.3144_3144_3147; Reed AL, 1996, CANCER RES, V56, P3630; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Ross JA, 1999, CANCER, V85, P1389, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1389::AID-CNCR24>3.0.CO;2-V; Sabbioni S, 1997, CANCER RES, V57, P4493; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TEMPLE IK, 1995, NAT GENET, V9, P109; Thompson JS, 1996, CANCER RES, V56, P5723; Uyeno S, 1996, CANCER RES, V56, P5356; van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; Vrana PB, 1998, NAT GENET, V20, P362, DOI 10.1038/3833; WADA M, 1995, CANCER RES, V55, P3386; Wu MS, 1997, CANCER LETT, V120, P9, DOI 10.1016/S0304-3835(97)00279-6; Zhan SL, 1995, ONCOGENE, V11, P2503	67	43	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7063	7069		10.1038/sj.onc.1203192	http://dx.doi.org/10.1038/sj.onc.1203192			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597307				2022-12-28	WOS:000083901900013
J	Liu, XF; Baker, E; Eyre, HJ; Sutherland, GR; Zhou, MD				Liu, XF; Baker, E; Eyre, HJ; Sutherland, GR; Zhou, MD			gamma-Heregulin: a fusion gene of DOC-4 and neuregulin-1 derived from a chromosome translocation	ONCOGENE			English	Article						gamma-heregulin; neuregulin-1; DOC-4; gene localization; MDA-MB-175 cell line	NEU DIFFERENTIATION FACTOR; CARDIAC DEVELOPMENT; IDENTIFICATION; RECEPTOR; LIGANDS; DOMAIN; ERBB2	gamma-Heregulin was identified as an isoform resulting from alternate splicing of the neuregulin-1 gene, after cloning of its cDNA from the MDA-MB-175 breast cancer cell line, gamma-Heregulin was shown to promote growth of cultured MDA-MB-175 cells resulting from activation of its cognate ErbB tyrosine kinase reporters. We show here that gamma-heregulin is transcribed from a fusion gene resulting from a chromosome translocation in MDA-MB-175 cells. The fusion chromosome is described as dic(8:11)(8qter-->8p12::11q13-->11pter). As a result, the 5' end of the gamma-heregulin gene is derived from the stress-induced gene, DOC-4 (11q13), while the 3' end is from the neuregulin-1 gene (8p12). Thus, expression of gamma-heregulin is under the control of the DOC-4 promoter, By contrast with MDA-MB-175 cells, RT-PCR failed to detect a gamma-heregulin transcript in either E9.5 to E13.5 embryonic mouse tissues, adult mouse tissues or other human tumour cell lines. We conclude, therefore, that gamma-heregulin is not a native isoform of the neuregulin-1 gene, but a novel growth factor that may contribute to tumour cell proliferation.	Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia	Victor Chang Cardiac Research Institute; University of New South Wales Sydney; Womens & Childrens Hospital Australia	Zhou, MD (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St, Darlinghurst, NSW 2010, Australia.		Sutherland, Grant Robert/D-2606-2012					CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Chausovsky A, 1998, MOL BIOL CELL, V9, P3195, DOI 10.1091/mbc.9.11.3195; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELLESTOR F, 1994, HUM GENET, V94, P346; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	17	28	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7110	7114		10.1038/sj.onc.1203136	http://dx.doi.org/10.1038/sj.onc.1203136			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597312				2022-12-28	WOS:000083901900018
J	Vaillant, F; Blyth, K; Terry, A; Bell, M; Cameron, ER; Neil, J; Stewart, M				Vaillant, F; Blyth, K; Terry, A; Bell, M; Cameron, ER; Neil, J; Stewart, M			A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with MYC	ONCOGENE			English	Article						Cbfa1; myc; T-cell lymphoma; apoptosis	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR OSF2/CBFA1; CD2-MYC TRANSGENIC MICE; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; RUNT DOMAIN; TGF-BETA; DEFINITIVE HEMATOPOIESIS; NERVOUS-SYSTEM; DNA-BINDING	The C6fa1/PEBP2 alpha A/AML3 gene plays an essential role in osteogenesis but is also expressed in the T-cell lineage where it has been implicated in lymphoma development as a target for retroviral insertional mutagenesis. As lymphoma cells with til-1 insertion express at least five distinct Cbfa1 isoforms, it is important to establish which, if any, have intrinsic oncogenic potential. We have generated transgenic mice in which the most abundant lymphoma isoform (G1/p57) is expressed under the control of the CD2 locus control region. Co-precipitation analysis of transgenic thymus revealed high levels of Cbfa1 protein in an abundant complex containing the binding cofactor Cbfb. CD2-Cbfa1-G1 mice displayed abnormal T-cell development, with a pronounced skew towards CD8 SP cells in the thymus and developed a low incidence of spontaneous lymphomas (6% at 12 months) with cells of similar phenotype. Strongly synergistic tumour development was seen when CD2-Cbfa1-G1 mice were crossed with lines carrying myc transgenes (CD2-myc or tamoxifen-regulatable CD2-mycER(TM)) and Cbfa1 was found to rescue expression of the CD2-myc transgene in preleukaemic mice. However, synergy did not appear to be due to a dominant block of myc-induced apoptosis by Cbfa1 as explanted primary tumours and cell lines from CD2-Cbfa1-G1/CD2-mycER(TM) mice showed accelerated death on induction with tamoxifen at similar rates to CD2-mycER(TM) controls. Moreover, thymocytes from preleukaemic CD2-Cbfa1-G1 mice showed reduced survival in vitro and increased sensitivity to the inhibitory effects of TGF-beta. This study demonstrates that a full-length Cbf alpha-chain gene can act as an oncogene without fusion to a heterologous protein.	Univ Glasgow, Sch Vet, Dept Vet Pathol, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Sch Vet, Div Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Stewart, M (corresponding author), Univ Glasgow, Sch Vet, Dept Vet Pathol, Mol Oncol Lab, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.			Blyth, Karen/0000-0002-9304-439X				Alexandrow MG, 1997, J CELL BIOCHEM, V66, P427, DOI 10.1002/(SICI)1097-4644(19970915)66:4<427::AID-JCB1>3.3.CO;2-Y; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BLYTH K, 1995, ONCOGENE, V10, P1717; Cameron ER, 1996, BRIT J CANCER, V73, P13, DOI 10.1038/bjc.1996.3; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; STEWART M, 1993, INT J CANCER, V53, P1023; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	45	77	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7124	7134		10.1038/sj.onc.1203202	http://dx.doi.org/10.1038/sj.onc.1203202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597314				2022-12-28	WOS:000083901900020
J	Hall-Jackson, CA; Cross, DAE; Morrice, N; Smythe, C				Hall-Jackson, CA; Cross, DAE; Morrice, N; Smythe, C			ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK	ONCOGENE			English	Article						ATR; checkpoint; protein kinase; DNA damage; caffeine	ATAXIA-TELANGIECTASIA GENE; CELL-CYCLE CHECKPOINTS; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; SCHIZOSACCHAROMYCES-POMBE; INDUCED PHOSPHORYLATION; SIGNALING PATHWAY; MAMMALIAN-CELLS; FISSION YEAST	ATR is a large, >300 kDa protein containing a carboxy-terminus kinase domain related to PI-3 kinase, and is homologous to the ATM gene product in human cells and the rad3/MEC1 proteins in yeast. These proteins, together with the DNA-PK, are part of a new family of PI-3 kinase related proteins. All members of this family play important roles in checkpoints which operate to permit cell survival following many forms of DNA damage. We have expressed ATR protein in HEK293 cells and purified the protein to near-homogeneity. We show that pure ATR is a protein kinase which is activated by circular single-stranded, double-stranded or linear DNA. Thus ATR is a new member of a sub-family of PIK related kinases, founded by the DNA-PK, which are activated in the presence of DNA, Unlike DNA-PK, ATR does not appear to require Ku proteins for its activation by DNA, We show directly that, like ATM and DIVA-PK, ATR phosphorylates the genome surveillance protein p53 on serine 15, a site which is up-regulated in response to DNA damage. In addition, we find that ATR has a substrate specificity similar to, but unique from, the DNA-PK in vitro, suggesting that these proteins have overlapping but distinct functions in vivo. Finally, we find that the kinase activity of ATR in the presence and absence of DNA is suppressed by caffeine, a compound which is known to induce loss of checkpoint control. Our results are consistent with the notion that ATR plays a role in monitoring DIVA structure and phosphorylation of proteins involved in the DNA damage response pathways.	Univ Dundee, Dept Biochem, Prot Phosphorylat Unit, MCR, Dundee DD1 5EH, Scotland	University of Dundee	Smythe, C (corresponding author), Univ Dundee, Dept Biochem, Prot Phosphorylat Unit, MCR, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.							ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CROMPTON NEA, 1993, RADIAT RES, V135, P372, DOI 10.2307/3578877; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Morgan SE, 1997, CANCER RES, V57, P3386; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; Osman F, 1998, MOL GEN GENET, V260, P319, DOI 10.1007/s004380050901; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; STACK JH, 1994, J BIOL CHEM, V269, P31552; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	54	201	241	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6707	6713		10.1038/sj.onc.1203077	http://dx.doi.org/10.1038/sj.onc.1203077			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597277				2022-12-28	WOS:000083792000011
J	Sherman, L; Sleeman, JP; Hennigan, RF; Herrlich, P; Ratner, N				Sherman, L; Sleeman, JP; Hennigan, RF; Herrlich, P; Ratner, N			Overexpression of activated neu/erbB2 initiates immortalization and malignant transformation of immature Schwann cells in vitro	ONCOGENE			English	Article						Schwann cells; neu; erbB2; transformation; immortalization	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASE-ACTIVITY; HUMAN BREAST-CANCER; NERVOUS-SYSTEM; WALLERIAN DEGENERATION; INCREASED EXPRESSION; SIGNAL-TRANSDUCTION; PERIPHERAL-NERVE; MULTISTEP NATURE	The neu/erbB2 protooncogene is overexpressed in numerous human cancers and is mutationally activated in N-ethyl-N-nitrosourea (ENU)-induced rodent tumors of the Schwann cell lineage. We investigated whether expression of activated neu in Schwann cells is sufficient to initiate their immortalization and transformation. Clones of embryonic dorsal root ganglia cells infected with a retrovirus bearing activated neu (NID cells) were selected based on their expression of Schwann cell-specific markers. Compared to embryonic Schwann cells infected,vith a virus encoding empty vector, we found that NID cells have altered shapes and disorganized cytoskeletons, grow in the absence of growth factors required for normal Schwann cell survival and proliferation, and can be repeatedly passaged. Furthermore, NID cells are invasive in an in vitro matrix invasion assay and form metastatic tumors when injected into syngeneic animals. The neu-induced growth and invasive phenotypes could be reversed by drugs that inhibit Ras and Src activity. Interestingly, later stage Schwann cells infected with activated neu failed to become immortalized. These findings indicate that constitutive activation of erbB2 is sufficient to initiate the immortalization and transformation of immature Schwann cells, and support the notion that Schwann cells have particular developmental stages during which they are susceptible to immortalizing and transforming events.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	University System of Ohio; University of Cincinnati; Helmholtz Association; Karlsruhe Institute of Technology	Sherman, L (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687; RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10297, NS28840] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADBURY JM, 1993, ONCOGENE, V8, P1551; Carroll SL, 1997, J NEUROSCI, V17, P1642; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DRUCKREY H, 1973, Z KREBSFORSCH KLIN O, V79, P282, DOI 10.1007/BF00304022; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grinspan JB, 1996, J NEUROSCI, V16, P6107; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JANES PW, 1994, ONCOGENE, V9, P3601; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; KLEITMAN N, 1991, CULTURING NERVE CELL, P251; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; Nikitin AY, 1996, ONCOGENE, V12, P1309; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RAJEWSKY MF, 1983, RECENT RES CANCER, V84, P63; RHIM JS, 1990, CANCER RES, V50, pS5653; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Stancovski I, 1994, Cancer Treat Res, V71, P161; TOMOZAWA Y, 1978, P NATL ACAD SCI USA, V75, P6305, DOI 10.1073/pnas.75.12.6305; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0	57	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6692	6699		10.1038/sj.onc.1203055	http://dx.doi.org/10.1038/sj.onc.1203055			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597275				2022-12-28	WOS:000083792000009
J	Brockhaus, F; Brune, B				Brockhaus, F; Brune, B			p53 accumulation in apoptotic macrophages is an energy demanding process that precedes cytochrome c release in response to nitric oxide	ONCOGENE			English	Article						apoptosis; nitric oxide; macrophages; p53; cytochrome c; Bcl-2	BCL-X-L; CELL-DEATH; P53-DEPENDENT APOPTOSIS; MITOCHONDRIAL CONTROL; PROTEASE ACTIVATION; CASPASE ACTIVATION; SIGNALING PATHWAYS; FAMILY; INHIBITION; COMPLEX	Apoptosis in response to stress signals activates effector caspases known to be regulated by the release of cytochrome c (Cyt c) from mitochondria and the subsequent ATP-dependent activation of the death regulator apoptotic protease-activating factor I (Apaf-1). Experiments were carried out to determine whether the release of Cyt c is evoked by NO. in RAW 264.7 macrophages and to position signaling components relative to mitochondria. S-nitrosoglutathione and spermine-NO caused a fast p53 accumulation, followed by Bcl-x(L) downregulation, Cyt c release, and caspase activation. These alterations mere absent in p53 antisense expressing macrophages (R Delta p53asn-11). In Bcl-2 overexpressing cells (Rbc12-14) Cyt c relocation and caspase activation were abrogated although p53 accumulation remained intact. The use of caspase inhibitors revealed Cyt c release and decreased Bcl-x(L) expression to be caspase independent. ATP-depIeted cells showed a shift from apoptosis towards necrosis and no p53 accumulation or caspase activation upon NO. addition. Conclusively, NO.-mediated apoptosis in macrophages is entirely controlled by the mitochondrial pathway with the implication that Cyt c relocation demands p53 accumulation. Moreover, pulse-chase-experiments in combination with the ATP-depletion protocol identified p53 accumulation and stabilization as an energy requiring process. This allowed to dissect two ATP-dependent steps, one is in association with Apaf-1 formation, while the other resides in p53 accumulation.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Div Expt, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Div Expt, Loschgestr 8, D-91054 Erlangen, Germany.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Albina JE, 1996, J IMMUNOL, V157, P279; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brockhaus F, 1999, BIOCHEM J, V338, P295, DOI 10.1042/0264-6021:3380295; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Castedo M, 1996, J IMMUNOL, V157, P512; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chlichlia K, 1998, BLOOD, V91, P4311, DOI 10.1182/blood.V91.11.4311.411k07_4311_4320; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Eguchi Y, 1997, CANCER RES, V57, P1835; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1998, EUR J PHARMACOL, V349, P333, DOI 10.1016/S0014-2999(98)00189-7; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; Moreno MB, 1996, J IMMUNOL, V157, P3845; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stassi G, 1997, J EXP MED, V186, P1193, DOI 10.1084/jem.186.8.1193; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WULFF K, 1985, METHOD ENZYMAT AN, V7, P357; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	46	57	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6403	6410		10.1038/sj.onc.1203058	http://dx.doi.org/10.1038/sj.onc.1203058			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597241				2022-12-28	WOS:000083709200001
J	Haridas, V; Shrivastava, A; Su, J; Yu, GL; Ni, J; Liu, D; Chen, SF; Ni, YS; Ruben, SM; Gentz, R; Aggarwal, BB				Haridas, V; Shrivastava, A; Su, J; Yu, GL; Ni, J; Liu, D; Chen, SF; Ni, YS; Ruben, SM; Gentz, R; Aggarwal, BB			VEGI, a new member of the TNF family activates Nuclear Factor-kappa B and c-Jun N-terminal kinase and modulates cell growth	ONCOGENE			English	Article						VEGI; NF-kappa B; apoptosis; JNK	TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR FAMILY; LIGAND; APOPTOSIS; SUPERFAMILY; DEATH; ANGIOGENESIS; LYMPHOTOXIN; INHIBITOR; CYTOKINE	Recently a new member of the human tumor necrosis factor (TNF) family named as VEGI was reported. However, very little is known about the biological activities displayed by this cytokine. In this report, we show that in myeloid cells VEGI activated the transcription factor kappa B (NF-kappa B) as determined by the electrophoretic mobility shift assay, induced degradation of I kappa B alpha, and nuclear translocation of p65 subunit of NF-kappa B. VEGI also activated NF-kappa B-dependent reporter gene expression. In addition, VEGI activated c-Jun N-terminal kinase. When examined for growth modulatory effects, VEGI inhibited the proliferation of breast carcinoma (MCF-7), epithelial (HeLa), and myeloid (U-937 and ML-1a) tumor cells; and activated caspase-3 leading to PARP cleavage. VEGI-induced cytotoxicity was potentiated by inhibitors of protein synthesis. VEGI also induced proliferation of normal human foreskin fibroblast cells. The activity of VEGI could neither be neutralized by antibodies against TNF, nor could it compete with TNF binding, indicating that the activity of VEGI is not due to TNF and it binds to a distinct receptor. These results suggest that VEGI, a new member of the TNF family, has a signaling pathway similar to TNF and is most likely a multifunctional cytokine.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Sect, Houston, TX 77030 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; Human Genome Sciences Inc	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Sect, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; AGGARWAL BB, 1985, METHOD ENZYMOL, V116, P441; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Haridas V, 1998, J IMMUNOL, V161, P1; HIGUCHI M, 1992, ANAL BIOCHEM, V204, P53, DOI 10.1016/0003-2697(92)90138-W; Kumar A, 1998, J IMMUNOL, V161, P776; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; MAZZEI GJ, 1995, J BIOL CHEM, V270, P7025, DOI 10.1074/jbc.270.13.7025; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; TOTPAL K, 1994, J IMMUNOL, V153, P2248; VANLINT J, 1992, J BIOL CHEM, V267, P25916; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	35	62	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6496	6504		10.1038/sj.onc.1203059	http://dx.doi.org/10.1038/sj.onc.1203059			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597252				2022-12-28	WOS:000083709200012
J	Rao, RN; Stamm, NB; Otto, K; Kovacevic, S; Watkins, SA; Rutherford, P; Lemke, S; Cocke, K; Beckmann, RP; Houck, K; Johnson, D; Skidmore, BJ				Rao, RN; Stamm, NB; Otto, K; Kovacevic, S; Watkins, SA; Rutherford, P; Lemke, S; Cocke, K; Beckmann, RP; Houck, K; Johnson, D; Skidmore, BJ			Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene	ONCOGENE			English	Article						cyclin D1; cdk4; transformation; cell models	DEPENDENT KINASE-4 CDK4; BREAST-CARCINOMA CELLS; RETINOBLASTOMA-PROTEIN; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; TRANSGENIC MICE; CRYSTAL-STRUCTURE; HA-RAS; MALIGNANT TRANSFORMATION; PHYSICAL INTERACTION	Cyclin D1 gene overexpression is a frequent event in a number of human cancers. These observations have led to the suggestion that cyclin D1 alterations might play a role in the etiology of cancer. This possibility is supported by the finding that transfection of mammalian cells with cyclin D1 can accelerate progression through the G1 phase of the cell cycle. Moreover, cyclin D1 can function as an oncogene by cooperating with activated Ha-ras to transform primary rat embryo fibroblasts (REFs). In addition, cyclin D1 transgenics develop hyperplasia and neoplasia of the thymus and mammary gland. We have constructed a novel fusion gene consisting of full-length human cyclin D1 and cdk4 genes. This fusion gene was expressed in insect cells and the fusion protein was shown to be enzymatically active. The fusion gene was expressed in mammalian cells under the control of tet-repressor. This fusion gene immortalized primary REFs, and cooperated with activated Haras to transform primary REFs, in terms of anchorage-independent growth in vitro and formation of tumors in vivo. Utilizing a tet-regulated gene expression system, we have shown that proliferation of stably transfected primary REFs in vitro and in vivo is dependent on the continued expression of the cyclin D1-cdk4 fusion gene. These cell lines could be useful in the discovery of novel cancer therapeutics to modulate cyclin D1.cdk4 activity.	Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Indianapolis, IN 46285 USA; Lilly Res Labs, Res Technol & Prot, Indianapolis, IN 46285 USA; Sphinx Pharmaceut, Durham, NC 27707 USA	Eli Lilly; Eli Lilly	Rao, RN (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Drop Code 0424, Indianapolis, IN 46285 USA.		Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249; Johnson, David/0000-0002-6223-1790				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Andersen G, 1996, FEBS LETT, V397, P65, DOI 10.1016/S0014-5793(96)01143-X; Arber N, 1997, CANCER RES, V57, P1569; Arguello F, 1998, BLOOD, V91, P2482; BIGGS JR, 1995, J MOL MED-JMM, V73, P509; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Carlson BA, 1996, CANCER RES, V56, P2973; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fahraeus R, 1998, ONCOGENE, V16, P587, DOI 10.1038/sj.onc.1201580; FIFE RS, 1995, J LAB CLIN MED, V125, P407; Fife RS, 1998, CANCER LETT, V127, P37, DOI 10.1016/S0304-3835(98)00003-2; FILMUS J, 1994, ONCOGENE, V9, P3627; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harlow E, 1999, USING ANTIBODIES LAB, P495; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAMA T, 1995, BLOOD, V86, P841; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JIANG W, 1993, ONCOGENE, V8, P3447; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; Kim HG, 1998, BIOCHEMISTRY-US, V37, P2666, DOI 10.1021/bi972399i; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Konstantinidis AK, 1998, J BIOL CHEM, V273, P26506, DOI 10.1074/jbc.273.41.26506; KROON AM, 1984, CANCER LETT, V25, P33, DOI 10.1016/S0304-3835(84)80023-3; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, SCIENCE, V258, P424; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OBrien K, 1997, GENE, V184, P115, DOI 10.1016/S0378-1119(96)00583-5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Petronio J, 1996, J NEUROSURG, V84, P1020, DOI 10.3171/jns.1996.84.6.1020; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SAUTER C, 1988, BRIT J CANCER, V57, P514, DOI 10.1038/bjc.1988.117; SCHMIDT TGM, 1994, J CHROMATOGR A, V676, P337, DOI 10.1016/0021-9673(94)80434-6; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH MC, 1988, J BIOL CHEM, V263, P7211; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TUCKER RW, 1977, CANCER RES, V37, P1571; VANDENBOGERT C, 1986, CANCER RES, V46, P3283; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WORZALLA JF, 1990, INVEST NEW DRUG, V8, P241; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	91	18	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6343	6356		10.1038/sj.onc.1203009	http://dx.doi.org/10.1038/sj.onc.1203009			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597234				2022-12-28	WOS:000083934100019
J	Pandey, P; Farber, R; Nakazawa, A; Kumar, S; Bharti, A; Nalin, C; Weichselbaum, R; Kufe, D; Kharbanda, S				Pandey, P; Farber, R; Nakazawa, A; Kumar, S; Bharti, A; Nalin, C; Weichselbaum, R; Kufe, D; Kharbanda, S			Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3	ONCOGENE			English	Article						Hsp27; cytochrome c; caspase-3; apoptosis	HEAT-SHOCK PROTEIN; PROGRAMMED CELL-DEATH; EMBRYONIC STEM-CELLS; ALPHA-B-CRYSTALLIN; CAENORHABDITIS-ELEGANS; PROTEOLYTIC ACTIVATION; ICE/CED-3 PROTEASE; INDUCED APOPTOSIS; CARCINOMA-CELLS; DNA-DAMAGE	The release of mitochondrial cytochrome c by genotoxic stress induces the formation of a cytosolic complex with Apaf-1 (mammalian CED4 homolog) and thereby the activation of procaspase-3 (cas-3) and procaspase-9 (cas-9). Here we demonstrate that heat-shock protein 27 (Hsp27) inhibits cytochrome c (cyt c)-dependent activation of cas-3. Hsp27 had no effect on cyt c release, Apaf-1 and cas-9 activation. By contrast, our results show that Hsp27 associates with cas-3, but not Apaf-1 or cas-9, and inhibits activation of cas-3 by cas-9-mediated proteolysis, Furthermore, the present results demonstrate that immunodepletion of Hsp27 depletes cas-3, Importantly, treatment of cells with DNA damaging agents dissociates the Hsp27/cas-3 complex and relieves inhibition of cas-3 activation. These findings define a novel function for Hsp27 and provide the first evidence that a heat shock protein represses cas-3 activation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Novartis Pharmaceut, E Hanover, NJ 07936 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Novartis; University of Chicago	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA075216, R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA29431, CA75216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MANSER PW, 1999, J BIOL CHEM, V274, P22635; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MING Z, 1993, J BIOL CHEM, V268, P35; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; STAHL J, 1992, DIFFERENTIATION, V51, P33, DOI 10.1111/j.1432-0436.1992.tb00677.x; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	241	253	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2000	19	16					1975	1981		10.1038/sj.onc.1203531	http://dx.doi.org/10.1038/sj.onc.1203531			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803458				2022-12-28	WOS:000086613200001
J	Harhaj, EW; Good, L; Xiao, GT; Uhlik, M; Cvijic, ME; Rivera-Walsh, I; Sun, SC				Harhaj, EW; Good, L; Xiao, GT; Uhlik, M; Cvijic, ME; Rivera-Walsh, I; Sun, SC			Somatic mutagenesis studies of NF-kappa B signaling in human T cells: evidence for an essential role of IKK gamma in NF-kappa B activation by T-cell costimulatory signals and HTLV-I Tax protein	ONCOGENE			English	Article						IKK signaling; HTLV Tax; T-cell costimulation; somatic cell mutagenesis	VIRUS TYPE-I; KINASE-ALPHA; C-REL; TRANSCRIPTION FACTORS; LEUKEMIA; BETA; PHOSPHORYLATION; EXPRESSION; GENE; DEGRADATION	NF-kappa B plays a pivotal role in normal T-cell activation and may also mediate human T-cell leukemia virus (HTLV)-induced T-cell transformation. Activation of NF-kappa B by both T-cell costimulatory signals and the HTLV Tax protein involves stimulation of I kappa B kinase (IKK), As a genetic approach to dissect the intermediate steps involved in NF-kappa B activation in human T cells, me performed somatic cell mutagenesis to isolate signaling-defective mutant Jurkat T-cell lines, One of the mutant cell lines was shown to have a specific blockade in the IKK signaling pathway but remained competent in the c-Jun N-terminal kinase and MAP kinase pathways. Interestingly, this mutant cell line lacks expression of IKK gamma, a non-catalytic component of the IKK complex, Expression of exogenous IKK gamma in the mutant cells restored NF-kappa B activation by both the T-cell costimulation agents and Tax. These findings provide genetic evidence for the requirement of IKK gamma in NF-kappa B signaling triggered by both T-cell costimulatory signals and HTLV-I Tax protein.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAI JH, 1994, J BIOL CHEM, V269, P30077; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	59	99	100	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1448	1456		10.1038/sj.onc.1203445	http://dx.doi.org/10.1038/sj.onc.1203445			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723136				2022-12-28	WOS:000085942700010
J	Castagnino, P; Lorenzi, MV; Yeh, J; Breckenridge, D; Sakata, H; Munz, B; Werner, S; Bottaro, DP				Castagnino, P; Lorenzi, MV; Yeh, J; Breckenridge, D; Sakata, H; Munz, B; Werner, S; Bottaro, DP			Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors	ONCOGENE			English	Article						neu differentiation factor; neuregulin; heregulin; hepatocyte growth factor; keratinocyte growth factor; gene induction; tissue repair	FACTOR SCATTER FACTOR; EPITHELIAL-CELLS; FACTOR/SCATTER FACTOR; RECEPTOR EXPRESSION; LIVER-REGENERATION; FACTOR HEREGULIN; MET RECEPTOR; WOUND REPAIR; FACTOR-ALPHA; IN-VIVO	Hepatocyte growth-factor (HGF) is a potent, widely produced, pleiotropic mediator of mesenchymal-epithelial interaction. In a study of changes in gene expression initiated by HGF in Balb/MK keratinocytes, we observed the induction of Neu-differentiation factor (NDF) mRNA (also known as heregulin, or HRG). Further characterization of the regulation of NDF expression in Balb/MK keratinocytes revealed potent induction by keratinocyte growth factor (KGF) and epidermal growth factor (EGF), but not by HGF/NK2, an alternative HGF isoform with motogenic but not mitogenic or morphogenic activities. Sustained treatment (8 h) of Balb/MK cells with KGF stimulated secretion of mature NDF protein into the culture medium, and Balb/MK cells treated with purified recombinant NDF protein showed increased DNA synthesis. We also found evidence of NDF induction in two models of tissue repair in mice: in full-thickness skin wounds, following locally increased KGF production, and in kidney after partial hepatectomy, following elevation of circulating HGF levels. These results reveal that mesenchymally-derived HGF and KGF can activate autocrine NDF signaling in their epithelial targets, and suggest that this mechanism contributes to the coordination of stages of wound repair, and possibly development, where these growth factors act in concert to direct epithelial proliferation, morphogenesis and differentiation.	NCI, DBS, LCMB, Bethesda, MD 20892 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Max Planck Society	Bottaro, DP (corresponding author), NCI, DBS, LCMB, Bldg 37,Room IE24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Werner, Sabine/0000-0001-7397-8710	DIVISION OF BASIC SCIENCES - NCI [Z01BC005626] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balkovetz DF, 1999, INT REV CYTOL, V186, P225; Bardelli A, 1997, CIBA F SYMP, V212, P133; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Castagnino P, 1998, ONCOGENE, V17, P481, DOI 10.1038/sj.onc.1201957; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; DLUGOSZ AA, 1994, CELL GROWTH DIFFER, V5, P1283; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; Krane IM, 1996, ONCOGENE, V12, P1781; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LORENZI MV, 1995, ONCOGENE, V10, P2051; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Marikovsky M, 1996, J INVEST DERMATOL, V106, P616, DOI 10.1111/1523-1747.ep12345413; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Munz B, 1997, BIOCHEM J, V326, P579, DOI 10.1042/bj3260579; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RON D, 1993, J BIOL CHEM, V268, P2984; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; SCHIMIDT C, 1995, NATURE, V373, P699; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; TZAAHAR E, 1994, J BIOL CHEM, V269, P25226; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WOJTA J, 1994, BLOOD, V84, P151; Wong VV, 1997, J BIOL CHEM, V272, P5187, DOI 10.1074/jbc.272.8.5187; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	54	24	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					640	648		10.1038/sj.onc.1203357	http://dx.doi.org/10.1038/sj.onc.1203357			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698509				2022-12-28	WOS:000085192000006
J	Dumont, E; Fuchs, KP; Bommer, G; Christoph, B; Kremmer, E; Kempkes, B				Dumont, E; Fuchs, KP; Bommer, G; Christoph, B; Kremmer, E; Kempkes, B			Neoplastic transformation by Notch is independent of transcriptional activation by RBP-J signalling	ONCOGENE			English	Article						notch; transactivation domain; RBP-J; EBNA2; E1A; neoplastic transformation	EPSTEIN-BARR-VIRUS; J-KAPPA; CHROMOSOMAL LOCUS; PROMOTER ANALYSIS; ANKYRIN REPEATS; GENE; PATHWAY; DOMAIN; TRANSDUCTION; SEQUENCES	Signalling through the transmembrane receptor Notch is triggered by ligand binding, which induces the proteolytic cleavage of the Notch protein. This cleavage generates an intracellular fragment of the Notch protein (Notch-IC), which translocates into the nucleus and modifies transcription of target genes through its association with the RBP-J protein, Thus, the isolated Notch-IC protein represents the constitutively activated receptor. We have performed a deletion analysis of Notch IC in order to identify the transferable transactivation domain of Notch-IC and the minimal domain of Notch-TC required for RBP-J dependent transactivational activation. Functionally, Notch-IC has been Linked to cell fate decision in development and oncogenesis in vivo. In vitro, Notch-IC can cooperate in neoplastic transformation of baby rat kidney cells with the adenoviral E1A protein. We have defined the minimal domain of Notch-IC required for E1A cotransformation. This domain, consisting of the ankyrin repeats of Notch-IC only, can neither activate RBP-J dependent transcription nor does it carry a transactivation domain. Therefore, the ankyrin repeat domain of Notch-IC might trigger novel pathways relevant for transformation but unrelated to RBP-J signalling.	GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Mol Immunol, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Kempkes, B (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, Marchioninistr 25, D-81377 Munich, Germany.		Kempkes, Bettina/B-3322-2013; Bommer, Guido/A-8425-2011	Bommer, Guido/0000-0001-6898-4884				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Jehn BM, 1999, J IMMUNOL, V162, P635; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Nofziger D, 1999, DEVELOPMENT, V126, P1689; OKA C, 1995, DEVELOPMENT, V121, P3291; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; RABSON M, 1982, J VIROL, V44, P834, DOI 10.1128/JVI.44.3.834-844.1982; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shawber C, 1996, DEVELOPMENT, V122, P3765; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; vonBoehmer H, 1997, CURR BIOL, V7, pR308, DOI 10.1016/S0960-9822(06)00145-X; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	35	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2000	19	4					556	561		10.1038/sj.onc.1203352	http://dx.doi.org/10.1038/sj.onc.1203352			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698525				2022-12-28	WOS:000085104200009
J	Lucas, L; del Peso, L; Rodriguez, P; Penalva, V; Lacal, JC				Lucas, L; del Peso, L; Rodriguez, P; Penalva, V; Lacal, JC			Ras protein is involved in the physiological regulation of phospholipase D by platelet derived growth factor	ONCOGENE			English	Article						ras; oncogenes; growth factors; PDGF; phospholipase D	KINASE-C-ALPHA; ADP-RIBOSYLATION FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; XENOPUS-LAEVIS OOCYTES; GTP-BINDING PROTEINS; SMOOTH-MUSCLE CELLS; D ACTIVATION; SIGNAL-TRANSDUCTION; LYSOPHOSPHATIDIC ACID	Lipid-derived metabolites play an important role in the regulation of cell responses to external stimuli, including cell growth control, transformation and apoptosis, Phospholipase D (PLD) is one of the critical elements in the regulation of lipid metabolism and the generation of second messengers, some of them involved in cell growth control. Oncogenic Ras proteins affect the activity of PLD by two alternate mechanisms, involving a positive activation and a feedback negative loop. Here we investigate the involvement of the proto-oncogenic Ras protein in the physiological activation of PLD induced by platelet-derived growth factor (PDGF), Over-expression of the wild type Ras protein or some of its regulatory components, such as Shc or Grb2, induces an amplification of PLD activation by PDGF challenge. Furthermore, blocking the endogenous Ras by expression of the dominant negative mutant, H-Ras-Asn(17) completely eliminated the activation of PLD by PDGF, Thus, PDGF requires a complex system for PLD regulation implying the existence of at least two positive regulatory pathways, a Ras-dependent and a PKC-dependent mechanism. These results imply that PLD is an important element in signaling by Ras proteins that is altered after I as-induced transformation.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		del Peso, Luis/K-9391-2014; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; delPeso L, 1997, BIOCHEM J, V322, P519; delPeso L, 1996, J CELL BIOCHEM, V61, P599, DOI 10.1002/(SICI)1097-4644(19960616)61:4<599::AID-JCB14>3.0.CO;2-B; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FREEMAN EJ, 1994, BIOCHEM J, V304, P543, DOI 10.1042/bj3040543; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOASTIN AS, 1986, CANCER RES, V46, P1015; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HONG C, 1990, MOL CELL BIOL, V10, P5314; HUANG CF, 1990, J BIOL CHEM, V265, P14858; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KISS Z, 1992, BIOCHEM J, V285, P229, DOI 10.1042/bj2850229; KISS Z, 1991, BIOCHEM J, V276, P505, DOI 10.1042/bj2760505; KONDO T, 1992, J BIOL CHEM, V267, P23609; LACAL JC, 1994, ONCOL REP, V1, P677; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; LEE YH, 1994, J BIOL CHEM, V269, P26842; LEWOBITZ PF, 1995, MOL CELL BIOL, V15, P6613; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LIU B, 1995, BIOCHEM BIOPH RES CO, V214, P418, DOI 10.1006/bbrc.1995.2303; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIAN Z, 1989, J BIOL CHEM, V264, P21720; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YEO EJ, 1994, J BIOL CHEM, V269, P27823; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Yuryev A, 1998, Cell Res, V8, P81; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	63	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					431	437		10.1038/sj.onc.1203323	http://dx.doi.org/10.1038/sj.onc.1203323			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656691				2022-12-28	WOS:000084873700014
J	Javelaud, D; Wietzerbin, J; Delattre, O; Besancon, F				Javelaud, D; Wietzerbin, J; Delattre, O; Besancon, F			Induction of p21(Waf1/Cip1) by TNF alpha requires NF-kappa B activity and antagonizes apoptosis in Ewing tumor cells	ONCOGENE			English	Article						Ewing tumor; NF-kappa B; TNF alpha; apoptosis; p21(Waf1/Cip1)	COLORECTAL-CARCINOMA CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; IONIZING-RADIATION; FUSION PROTEIN; SARCOMA CELLS; GENE FUSION; TRANSLOCATION; FAMILY; INHIBITION	The Ewing family of tumors is characterized by recurrent reciprocal translocations that generate chimeric proteins, either EWS-FLI-1 or EWS-ERG, These proteins are potent transcriptional activators and are responsible for maintaining the oncogenic properties of tumor cells. Since apoptosis appears to be the main mechanism whereby chemotherapy and radiation kill tumor cells, identification of events that can antagonize apoptosis in Ewing tumors is essential for improving their response to conventional therapies. Here, we report that the transcriptional factor NF-kappa B is a survival factor for Ewing tumor-derived cells. In fact, inhibition of NF-kappa B activation as a consequence of the overexpression of a degradation-resistant form of I kappa B alpha, I kappa-B alpha (A32/36), sensitized these cells to TNF alpha-induced killing. Although treatment with TNF alpha did not modify the cellular expression of Bcl-2, c-IAP1, c-IAP2, D53 and EWS-FLI-1 proteins, it increased p21(Waf1/Cip1) levels. This induction required NF-kappa B activation since it mas not observed in the I kappa B alpha (A32/36) expressing cells. Moreover, overexpression of p21(Waf1/Cip1) in these I kappa B alpha (A32/ 36)-expressing cells, in which NF-kappa B and consequently p21(Waf1/Cip1) are no longer inducible by TNF alpha, decreased their susceptibility to TNF alpha-induced killing. Our results therefore identify p21(Waf1/Cip1) as a mediator of the antiapoptotic effect of TNF alpha-induced NF-kappa B in Ewing tumor cells.	Inst Curie, INSERM, U365, F-75005 Paris, France; Inst Curie, INSERM, U509, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Besancon, F (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75005 Paris, France.		Javelaud, Delphine/B-1129-2019	Javelaud, Delphine/0000-0002-7674-7739; delattre, olivier/0000-0002-8730-2276				Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DeLuca C, 1998, VIROLOGY, V244, P27, DOI 10.1006/viro.1998.9085; FISHER LJ, 1993, CAN J ANIM SCI, V73, P539, DOI 10.4141/cjas93-058; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Horowitz Marc E., 1997, P831; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jiang YL, 1998, BIOCHEM BIOPH RES CO, V245, P691, DOI 10.1006/bbrc.1998.8390; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LIPINSKI M, 1987, CANCER RES, V47, P183; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; MUNOZ E, 1994, J VIROL, V68, P8035; NOGUERA R, 1992, LAB INVEST, V66, P143; OHNO T, 1993, CANCER RES, V53, P5859; OREGAN S, 1995, J NEUROCHEM, V64, P69; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	57	58	58	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					61	68		10.1038/sj.onc.1203246	http://dx.doi.org/10.1038/sj.onc.1203246			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644980				2022-12-28	WOS:000084844300007
J	Porter, AC; Fanger, GR; Vaillancourt, RR				Porter, AC; Fanger, GR; Vaillancourt, RR			Signal transduction pathways regulated by arsenate and arsenite	ONCOGENE			English	Article						arsenic; Rac; Rho; PAK; MEKK3; MEKK4	ACTIVATED-PROTEIN-KINASE; HEAT-SHOCK; DIFFERENTIAL ACTIVATION; JUN KINASE; STRESS; CELLS; RAC; RHO; PHOSPHORYLATION; DOMAIN	Arsenate and arsenite activate c-Jun N-terminal kinase (JNK), however, the mechanism by which this occurs is not known, By expressing inhibitory mutant small GTP-binding proteins, p21-activated kinase (PAK) and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinases (MEKKs), we have identified specific proteins that are involved in arsenate-and arsenite-mediated activation of JNK, We observe a distinct difference between arsenate and arsenite signaling, which demonstrates that arsenate and arsenite are capable of activating unique proteins. Both arsenate and arsenite activation of JNK requires Rac and Rho. Neither arsenate nor arsenite signaling was inhibited by a dominant-negative mutant of Cdc42 or Ras. Arsenite stimulation of JNK requires PAK, whereas arsenate-mediated activation of JNK was unaffected by inhibitory mutant PAK. Of the four MEKKs tested, only MEKK3 and MEKK4 are involved in arsenate-mediated activation of JNK. In contrast, arsenite-mediated JNK activation requires MEKK2, MEKK3 and MEKK4. These results better define the mechanisms by which arsenate and arsenite activate JNK and demonstrate differences in the regulation of signal transduction pathways by these inorganic arsenic species.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA	University of Arizona; National Jewish Health	Vaillancourt, RR (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 06694] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMAN RS, 1973, SCIENCE, V182, P1247, DOI 10.1126/science.182.4118.1247; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; JACOBSONKRAM D, 1985, ENVIRON MUTAGEN, V7, P787, DOI 10.1002/em.2860070515; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KENNEY LJ, 1988, J BIOL CHEM, V263, P7954; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE TC, 1985, CARCINOGENESIS, V6, P1421, DOI 10.1093/carcin/6.10.1421; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Mikami K, 1998, PLANT J, V15, P563, DOI 10.1046/j.1365-313X.1998.00227.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; ROSSMAN TG, 1980, ENVIRON MUTAGEN, V2, P371, DOI 10.1002/em.2860020307; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sakurai T, 1998, CHEM RES TOXICOL, V11, P273, DOI 10.1021/tx9701384; Smith AH, 1998, AM J EPIDEMIOL, V147, P660, DOI 10.1093/oxfordjournals.aje.a009507; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIGON S, 1995, J BIOL CHEM, V270, P13091, DOI 10.1074/jbc.270.22.13091; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WHANGER PD, 1977, ENVIRON HEALTH PERSP, V19, P139, DOI 10.2307/3428465; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798; YEH S, 1968, CANCER, V21, P312, DOI 10.1002/1097-0142(196802)21:2<312::AID-CNCR2820210222>3.0.CO;2-K; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907	54	65	67	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7794	7802		10.1038/sj.onc.1203214	http://dx.doi.org/10.1038/sj.onc.1203214			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618720				2022-12-28	WOS:000084256900009
J	Jimenez, GS; Khan, SH; Stommel, JM; Wahl, GM				Jimenez, GS; Khan, SH; Stommel, JM; Wahl, GM			p53 regulation by post-translational modification and nuclear retention in response to diverse stresses	ONCOGENE			English	Review						p53; DNA damage; nuclear export signal; microtubule depolymerization; post translational modification	DEPENDENT PROTEIN-KINASE; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; NORMAL HUMAN FIBROBLASTS; DNA-BINDING FUNCTION; VIRUS-X PROTEIN; TETRAMERIZATION DOMAIN; TRANSCRIPTION FACTOR; CYTOPLASMIC SEQUESTRATION	p53 activation by diverse stresses involves post-translational modifications that alter its structure and result in its nuclear accumulation. We will discuss several unresolved topics regarding p53 regulation which are currently under investigation. DNA damage is perhaps the best-studied stress which activates p53, and recent data implicate phosphorylation at N-terminal serine residues as critical in this process. We discuss recent data regarding the potential kinases which modify p53 and the possible role of the resulting phosphorylation events. By contrast, much less is understood about agents which disrupt the mitotic spindle, The cell cycle phase, induction signal, and biochemical mechanism of the reversible arrest induced by microtubule disruption are currently under investigation. Finally, a key event in response to any genotoxic stress is the accumulation of p53 in the nucleus. The factors which determine the steady state level of p53 are starting to be elucidated, but the mechanisms responsible for nuclear accumulation and nuclear export remain controversial. We discuss new studies revealing a mechanism for nuclear retention of p53, and the potential contributions of MDM2 to this process.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92037 USA	Salk Institute; University of California System; University of California San Diego	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Stommel, Jayne M/M-3439-2017					Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSARI S, 1995, AM J PATHOL, V147, P790; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; ELKIND NB, 1995, ONCOGENE, V11, P841; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, ONCOGENE, V10, P789; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GANNON JV, 1991, NATURE, V349, P802; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Huang LC, 1996, CANCER RES, V56, P2940; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Isaacs JS, 1999, MOL CARCINOGEN, V24, P70, DOI 10.1002/(SICI)1098-2744(199901)24:1<70::AID-MC10>3.0.CO;2-5; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; KAHN SH, 1998, CANCER RES, V58, P396; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Komarova EA, 1997, CANCER RES, V57, P5217; Konig C, 1999, J VIROL, V73, P2253; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mayo LD, 1997, CANCER RES, V57, P5013; MAYR GA, 1995, CANCER RES, V55, P2410; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Metcalfe S, 1999, ONCOGENE, V18, P2351, DOI 10.1038/sj.onc.1202559; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rathmell WK, 1997, CANCER RES, V57, P68; RIEDER CL, 1992, J CELL SCI, V102, P387; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Scolnick DM, 1997, CANCER RES, V57, P3693; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; STENMARKASKMALM M, 1994, EUR J CANCER, V30A, P175, DOI 10.1016/0959-8049(94)90082-5; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TAKAHASHI K, 1994, ONCOGENE, V9, P183; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tarunina M, 1996, ONCOGENE, V13, P589; Thomas M, 1996, ONCOGENE, V13, P265; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Varley JM, 1996, ONCOGENE, V12, P2437; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	162	161	166	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	1999	18	53					7656	7665		10.1038/sj.onc.1203013	http://dx.doi.org/10.1038/sj.onc.1203013			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618705				2022-12-28	WOS:000084634500004
J	Hajra, KM; Ji, XD; Fearon, ER				Hajra, KM; Ji, XD; Fearon, ER			Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements	ONCOGENE			English	Article						E-cadherin; breast cancer; somatic cell hybrid; transcription factor; gene expression; E-box	INVASION-SUPPRESSOR GENE; CELL-LINES; GASTRIC-CANCER; UVOMORULIN; ADHESION; CARCINOMAS; MECHANISMS; MUTATIONS	Inactivation of the E-cadherin cell adhesion molecule is believed critical in the development and behavior of many epithelial cancers, though mutations in the E-cadherin gene account for inactivation in only a fraction of cases, In many breast cancer lines, E-cadherin transcription is extinguished, but the role and significance of alterations in trans-acting transcription factors, promoter hypermethylation, and chromatin changes remain unresolved, To gain further insights into mechanisms underlying E-cadherin in inactivation in breast cancer, we analysed somatic cell hybrids resulting from pairwise fusions between breast cancer lines with intact E-cadherin transcription (E-cad+) and lines lacking E-cadherin transcription (E-cad-), All hybrid lines failed to express E-cadherin transcripts and protein, despite the fact that E-cadherin alleles from E-cad+ lines were present in the hybrids, Elements in the proximal 108 bp of the E-cadherin promoter, when present in reporter gene constructs, mere sufficient to direct strong transcription in E-cad+ breast lines, but displayed weak activity in E-cad- parental lines and hybrids, E-cadherin expression could not be restored in E-cad- lines or hybrids by treatment with a DNA demethylating agent and/or a histone deacetylase inhibitor, Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.	Univ Michigan, Sch Med, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fearon, ER (corresponding author), Univ Michigan, Med Ctr, Div Med Genet, 1500 W Med Ctr Dr,4301 MSRB3, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA070097, T32CA009676] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA70097, 5 T32 CA09676-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P389; GAMALLO C, 1993, AM J PATHOL, V142, P987; Gayther SA, 1998, CANCER RES, V58, P4086; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Hiraguri S, 1998, CANCER RES, V58, P1972; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; NATT E, 1989, CYTOGENET CELL GENET, V50, P145, DOI 10.1159/000132745; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Poola I, 1998, ANAL BIOCHEM, V258, P209, DOI 10.1006/abio.1998.2629; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	28	98	100	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7274	7279		10.1038/sj.onc.1203336	http://dx.doi.org/10.1038/sj.onc.1203336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602481				2022-12-28	WOS:000084119400011
J	McCormack, MP; Gonda, TJ				McCormack, MP; Gonda, TJ			Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common beta subunit	ONCOGENE			English	Article						cytokine receptor; leukaemia; myeloproliferative disorder; mice	COLONY-STIMULATING FACTOR; HUMAN GM-CSF; ACUTE MYELOBLASTIC-LEUKEMIA; GROWTH SIGNAL-TRANSDUCTION; HEMATOPOIETIC STEM-CELLS; TRANSGENIC MICE; ALPHA-CHAIN; FACTOR GENE; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS	Several constitutively active mutant forms of the common beta subunit of the human IL-3, IL-5 and GMCSF receptors (hpc), which enable it to signal in the absence of ligand, have recently been described. Two of these, V449E and I374N, are amino acid substitutions in the transmembrane and extracellular regions of h beta c, respectively, A third, FI Delta, contains a 37 amino acid duplication in the extracellular domain. We have shown previously that when expressed in primary murine haemopoietic cells, the extracellular mutants confer factor-independence on cells of the neutrophil and monocyte lineages only, whereas V449E does so on all cell types of the myeloid and erythroid compartments. To study the in vivo effects and leukaemic potential of these mutants, we have expressed all three in mice by bone marrow reconstitution using retrovirally infected donor cells, Expression of the extracellular mutants leads to an early onset, chronic myeloproliferative disorder marked by elevations in the neutrophil, monocyte, erythrocyte and platelet lineages, In contrast, expression of V449E leads to an acute leukaemia-like syndrome of anaemia, thrombocytopaenia and blast cell expansion, These data support the possibility that activating mutations in h beta c are involved in haemopoietic disorders in man.	Hanson Ctr Canc Res, Inst Med & Vet Sci, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Gonda, TJ (corresponding author), Hanson Ctr Canc Res, Inst Med & Vet Sci, Frome Rd, Adelaide, SA 5000, Australia.		Gonda, Thomas J/A-3620-2012	McCormack, Matthew/0000-0003-1536-5611				BARRY SC, 1994, J BIOL CHEM, V269, P8488; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; CHANG JM, 1989, J CLIN INVEST, V84, P1488, DOI 10.1172/JCI114324; CHANG JM, 1989, BLOOD, V73, P1487; D'Andrea RJ, 1998, J CLIN INVEST, V102, P1951, DOI 10.1172/JCI3729; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DeJong MO, 1997, STEM CELLS, V15, P275, DOI 10.1002/stem.150275; Doi H, 1997, P NATL ACAD SCI USA, V94, P2513, DOI 10.1073/pnas.94.6.2513; FREEDMAN MH, 1993, BLOOD, V81, P3068; Gonda TJ, 1997, BLOOD, V89, P355, DOI 10.1182/blood.V89.2.355; GUALTIERI RJ, 1989, BLOOD, V74, P2360; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; Jenkins BJ, 1999, J BIOL CHEM, V274, P8669, DOI 10.1074/jbc.274.13.8669; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KAUFMAN DC, 1988, BLOOD, V72, P1329; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1986, BLOOD, V67, P37; METCALF D, 1986, J CELL PHYSIOL, V128, P421, DOI 10.1002/jcp.1041280311; Metcalf D, 1995, HEMOPOIETIC COLONY S; Metcalf D, 1984, CLONAL CULTURE HEMOP; MIYAJIMA A, 1993, BLOOD, V82, P1960; Nishijima I, 1997, BLOOD, V90, P1031, DOI 10.1182/blood.V90.3.1031.1031_1031_1038; OKADA S, 1992, BLOOD, V80, P3044; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; YOUNG DC, 1987, J CLIN INVEST, V79, P100, DOI 10.1172/JCI112769; YOUNG DC, 1986, BLOOD, V68, P1178	35	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7190	7199		10.1038/sj.onc.1203226	http://dx.doi.org/10.1038/sj.onc.1203226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602472				2022-12-28	WOS:000084119400002
J	Maung, K; Easty, DJ; Hill, SP; Bennett, DC				Maung, K; Easty, DJ; Hill, SP; Bennett, DC			Requirement for focal adhesion kinase in tumor cell adhesion	ONCOGENE			English	Article						FAK; tyrosine kinase; melanoma; antisense oligonucleotides; focal adhesion	PROTEIN-TYROSINE KINASE; NORMAL HUMAN MELANOCYTES; SIGNAL-TRANSDUCTION; MALIGNANT-MELANOMA; EXPRESSION; PP125(FAK); PHOSPHORYLATION; FIBRONECTIN; APOPTOSIS; MATRIX	Focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase and a major phosphotyrosine-containing protein. FAK is found in cell-matrix attachment sites (focal adhesions), and is activated on integrin-ligand binding and by other signaling pathways. Several roles have been proposed for FAK; here we report a novel function. We observed abundant FAK protein in all human melanoma cell lines tested except COLO839, a line that grows predominantly in suspension and was derived from peripheral blood. Five adherent lines, isolated from solid metastases in the same patient as COLO839, did express FAK. We derived four adherent sublines from COLO839. These did express FAK, even when plated on bacteriological plastic, to which they did not adhere. Thus, substrate attachment was not required for FAK expression. Three of the adherent sublines were then grown in the presence of antisense oligonucleotides to the initial FAK coding sequence. All showed substantially reduced FAK expression and, interestingly, the cells largely detached from the substrate while continuing to grow. Similar results were obtained with an independent melanoma line, DX3. Thus, FAK expression appears to be required by melanoma cells for substrate adhesion.	St George Hosp, Sch Med, Dept Anat & Dev Biol, London SW17 0RE, England	St Georges University London	Bennett, DC (corresponding author), St George Hosp, Sch Med, Dept Anat & Dev Biol, Cranmer Terrace, London SW17 0RE, England.		Bennett, Dorothy C/C-2418-2008	Bennett, Dorothy C/0000-0002-3639-7527				AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FURUTA Y, 1995, ONCOGENE, V11, P1989; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Ilic D, 1997, J CELL SCI, V110, P401; ILLC D, 1995, NATURE, V377, P539; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEE ST, 1993, ONCOGENE, V8, P3403; MIELE ME, 1994, EXP CELL RES, V214, P231, DOI 10.1006/excr.1994.1253; MORSE HG, 1993, CANCER GENET CYTOGEN, V69, P108, DOI 10.1016/0165-4608(93)90083-X; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; OWENS LV, 1995, CANCER RES, V55, P2752; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROZENGURT E, 1995, CANCER SURV, V24, P81; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCOTT G, 1995, EXP CELL RES, V219, P197, DOI 10.1006/excr.1995.1219; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; Shibata K, 1998, CANCER RES, V58, P900; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZHANG XA, 1995, GENE, V160, P219, DOI 10.1016/0378-1119(95)00153-W	38	49	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6824	6828		10.1038/sj.onc.1203094	http://dx.doi.org/10.1038/sj.onc.1203094			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597292				2022-12-28	WOS:000083792000026
J	Peterziel, H; Mink, S; Schonert, A; Becker, M; Klocker, H; Cato, ACB				Peterziel, H; Mink, S; Schonert, A; Becker, M; Klocker, H; Cato, ACB			Rapid signalling by androgen receptor in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; anti-androgens; growth factors; MAP kinase; rapid response	PROTEIN-KINASE CASCADE; MAMMARY-TUMOR VIRUS; DNA-BINDING DOMAIN; INTRACELLULAR CALCIUM; WITHDRAWAL SYNDROME; MAP KINASE; ACTIVATION; TRANSCRIPTION; GROWTH; MOUSE	Androgens are important growth regulators in prostate cancer. Their known mode of action in target cells requires binding to a cytoplasmic androgen receptor followed by a nuclear translocation event and modulation of the expression of specific genes. Here, we report another mode of action of this receptor. Treatment of androgen responsive prostate cancer cells with dihydrotestosterone leads to a rapid and reversible activation of mitogen-activated protein kinases MAPKs (also called extracellular signal-regulated kinases or Erks). Transient transfection assays demonstrated that the androgen receptor-mediated activation of MAP kinase results in enhanced activity of the transcription factor Elk-1. This action of the androgen receptor differs from its known transcriptional activity since it is rapid and insensitive to androgen antagonists such as hydroxyflutamide or casodex. Biochemical studies as well as analyses with dominant negative mutants showed the involvement of kinases such as MAPK/Erk kinase, phosphatidyl-inositol 3-kinase and protein kinase C in the androgen receptor-mediated activation of MAP kinase. These results demonstrate a novel regulatory action of the androgen receptor and prove that in addition to its known transcriptional effects, it also uses non-conventional means to modulate several cellular signalling processes.	Forschungszentrum Karlsruhe, Inst Genet & Toxikol, D-76021 Karlsruhe, Germany; Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria	Helmholtz Association; Karlsruhe Institute of Technology; University of Innsbruck	Cato, ACB (corresponding author), Forschungszentrum Karlsruhe, Inst Genet & Toxikol, Postfach 3640, D-76021 Karlsruhe, Germany.		Klocker, Helmut/AAI-7130-2020; Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834				AHN NG, 1991, J BIOL CHEM, V266, P4220; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERREVOETS CA, 1993, J STEROID BIOCHEM, V46, P731, DOI 10.1016/0960-0760(93)90313-L; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DiDomenico M, 1996, CANCER RES, V56, P4516; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; FABBRO D, 1986, BIOCHEM BIOPH RES CO, V135, P65, DOI 10.1016/0006-291X(86)90943-5; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HE WW, 1991, NUCLEIC ACIDS RES, V19, P2373, DOI 10.1093/nar/19.9.2373; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Kamano H, 1995, ONCOGENE, V11, P2575; KLOCKER H, 1992, AM J HUM GENET, V50, P1318; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCELLI M, 1991, J CLIN INVEST, V87, P1123, DOI 10.1172/JCI115076; Marcinkowska E, 1997, BIOCHEM BIOPH RES CO, V241, P419, DOI 10.1006/bbrc.1997.7832; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Moul J W, 1995, Semin Urol, V13, P157; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SMALL EJ, 1994, UROLOGY, V43, P408, DOI 10.1016/0090-4295(94)90092-2; STEINSAPIR J, 1991, BIOCHEM BIOPH RES CO, V179, P90, DOI 10.1016/0006-291X(91)91338-D; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang J, 1997, PROSTATE, V30, P117	46	213	220	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6322	6329		10.1038/sj.onc.1203032	http://dx.doi.org/10.1038/sj.onc.1203032			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597231				2022-12-28	WOS:000083934100016
J	Rameil, P; Lecine, P; Ghysdael, J; Gouilieux, F; Kahn-Perles, B; Imbert, J				Rameil, P; Lecine, P; Ghysdael, J; Gouilieux, F; Kahn-Perles, B; Imbert, J			IL-2 and long-term T cell activation induce physical and functional interaction between STAT5 and ETS transcription factors in human T cells	ONCOGENE			English	Article						T lymphocytes; IL-2/IL-2R; STAT5; ETS; transcription	RECEPTOR-ALPHA GENE; NF-KAPPA-B; DNA-BINDING ACTIVITY; COOPERATIVE INTERACTION; SYNERGISTIC ACTIVATION; PROTEIN INTERACTIONS; SIGNAL-TRANSDUCTION; CYCLE PROGRESSION; TYROSINE KINASES; INTERFERON-ALPHA	Activation of Stat5 by many cytokines implies that it cannot alone insure the specificity of the regulation of its target genes. Ne have evidenced a physical and functional interaction between members of two unrelated transcription factor families, Ets-l, Ets-2 and Stat5, which could contribute to the proliferative response to interleukin 2, Competition with GAS - and EBS-specific oligonucleotides and immunoassays with a set of anti-Stat and anti-Ets families revealed that the IL-2-induced Stat5-Ets complex recognizes several GAS motifs identified as target sites for activated Stat5 dimers, Coimmunoprecipitation experiments evidenced that a Stat5/Ets-1/2 complex is formed in vivo in absence of DNA. GST-pun down experiments demonstrated that the C-terminal domain of Ets-1 is sufficient for this interaction in vitro. Cotransfection experiments in Kit225 T cells resulted in cooperative transcriptional activity. between both transcription factors in response to a combination of IL-2, PMA and ionomycin. A Stat5-Ets protein complex mas the major inducible DNA-binding complex bound to the human IL-2rE GASd/EBSd motif in long-term proliferating normal human T cells activated by CD2 and CD28, These results suggest that the inducible Stat5-Ets protein interaction plays a role in the regulation of gene expression in response to IL-2 in human T T lmphocytes.	INSERM, U119, F-13009 Marseille, France; Inst Curie, CNRS, UMR146, F-91405 Orsay, France; Hop Cochin, ICGM, INSERM, U363, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Imbert, J (corresponding author), INSERM, U119, 27 Blvd Lei Roure, F-13009 Marseille, France.		Kahn-Perlès, Brigitte/M-3513-2016; Imbert, Jean/AAG-1165-2020; GHYSDAEL, Jacques/F-3377-2013; Imbert, Jean/G-3248-2013; Lecine, Patrick/H-9338-2016	Kahn-Perlès, Brigitte/0000-0001-5673-5901; Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; Lecine, Patrick/0000-0002-8091-7286; Gouilleux, Fabrice/0000-0001-6047-1718				Anderson MK, 1999, DEVELOPMENT, V126, P3131; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BHAT NK, 1989, J IMMUNOL, V142, P672; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Bucher P, 1997, IMMUNOBIOLOGY, V198, P136, DOI 10.1016/S0171-2985(97)80034-4; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; COFFER P, 1994, ONCOGENE, V9, P911; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P329; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Genuario RR, 1996, J BIOL CHEM, V271, P4388; Ghysdael J, 1997, ON COGENES TRANSCRIP, P29; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; HORI T, 1987, BLOOD, V70, P1069; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; John S, 1999, MOL CELL BIOL, V19, P1910; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KahnPerles B, 1997, J BIOL CHEM, V272, P21774, DOI 10.1074/jbc.272.35.21774; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Miyazaki T, 1996, CANCER SURV, V27, P25; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; OLIVE D, 1994, FUND CLIN IMMUNOL, V2, P185; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rabault B, 1996, ONCOGENE, V13, P877; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SOLDAINI E, 1995, J BIOL CHEM, V270, P10733, DOI 10.1074/jbc.270.18.10733; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zamorano J, 1998, J IMMUNOL, V160, P3502; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	68	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2086	2097		10.1038/sj.onc.1203542	http://dx.doi.org/10.1038/sj.onc.1203542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815800	Green Published			2022-12-28	WOS:000086728000002
J	Huang, S; Stupack, D; Liu, AH; Cheresh, D; Nemerow, GR				Huang, S; Stupack, D; Liu, AH; Cheresh, D; Nemerow, GR			Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of alpha(v) integrins	ONCOGENE			English	Article						integrins; B lymphocytes; Epstein-Barr virus	VITRONECTIN RECEPTOR; IN-VIVO; FIBRONECTIN; ALPHA-V-BETA-3; MELANOMA; ADHESION; IDENTIFICATION; PURIFICATION; ATTACHMENT; MIGRATION	alpha(v) Integrins have been shown to play an important role in epithelial-derived cell migration, cell growth and tumor invasion/metastasis, however their role on cells of hematopoietic origin is less clear. Epstein-Barr virus (EBV), a human herpesvirus associated with several lymphoproliferative disorders in man, induces expression of alpha(v) integrins on transformed B lymphocytes. In the studies reported here, we show that EBV infection increases alpha(v), beta(3) and beta(5) integrin subunit mRNAs as well as upregulates the expression of the alpha(v)beta(3) integrin protein on human B cells. Among the nine different EBV proteins expressed in latently infected B cells (nuclear and plasma membrane-associated), only LMP1, LMP2A and EBNA2 were shown to selectively transactivate the alpha(v) integrin promoter. Treatment of EBV-transformed B cells with alpha(v) antisense oligonucleotides specifically reduced cell surface expression of alpha(v) integrins, inhibited cell growth in low serum, reduced cell invasion in matrigels and decreased expression of metalloprotease, MMP9, These studies indicate that alpha(v) integrins play a significant role in EBV-induced B-lymphocyte proliferation and invasion. Strategies to interfere with alpha(v) integrin expression and/or function may therefore be of potential value in the treatment of EBV-associated lymphoproliferative disorders.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Nemerow, GR (corresponding author), Scripps Res Inst, Dept Immunol, IMM19,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054352] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54352] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DONAHUE JP, 1994, BBA-GENE STRUCT EXPR, V1219, P228, DOI 10.1016/0167-4781(94)90278-X; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; EPSTEIN MA, 1973, LANCET, V2, P836; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; HENLE W, 1967, J NATL CANCER I, V43, P1147; Huang S, 1996, J VIROL, V70, P4502, DOI 10.1128/JVI.70.7.4502-4508.1996; Huang S, 1997, P NATL ACAD SCI USA, V94, P8156, DOI 10.1073/pnas.94.15.8156; HUANG SA, 1995, J VIROL, V69, P2257, DOI 10.1128/JVI.69.4.2257-2263.1995; HUANG SA, 1994, J BIOL CHEM, V269, P28764; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; POPE JH, 1967, NATURE, V216, P810, DOI 10.1038/216810a0; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; STUPACK DG, 1992, EXP CELL RES, V203, P443, DOI 10.1016/0014-4827(92)90019-5; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WILKINS JA, 1983, J IMMUNOL, V131, P298; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	32	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1915	1923		10.1038/sj.onc.1203509	http://dx.doi.org/10.1038/sj.onc.1203509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773881				2022-12-28	WOS:000086424300007
J	Sirchia, SM; Ferguson, AT; Sironi, E; Subramanyan, S; Orlandi, R; Sukumar, S; Sacchi, N				Sirchia, SM; Ferguson, AT; Sironi, E; Subramanyan, S; Orlandi, R; Sukumar, S; Sacchi, N			Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta 2 promoter in breast cancer cells	ONCOGENE			English	Article						breast cancer; DNA methylation; chromatin remodeling; retinoic acid receptor (RAR)beta	ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE COMPLEX; EMBRYONAL CARCINOMA-CELLS; PLZF-RAR-ALPHA; DNA METHYLATION; EXPRESSION; GENE; TRANSCRIPTION; ACETYLATION; ACTIVATION	Retinoic acid (RA)-resistance in breast cancer cells has been associated with irreversible loss of retinoic acid receptor beta, RAR beta, gene expression. Search of the causes affecting RAR beta gene activity has been oriented at identifying possible differences either at the level of one of the RAR beta promoters, RAR beta 2, or at regulatory factors. We hypothesized that loss of RAR beta 2 activity occurs as a result of multiple factors, including epigenetic modifications, which can pattern RAR beta 2 chromatin state. Using methylation-specific PCR, we found hypermethylation at RAR beta 2 in a significant proportion of both breast cancer cell lines and primary breast tumors. Treatment of cells with a methylated RAR beta 2 promoter, by means of the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR), led to demethylation within RAR beta 2 and expression of RAR beta indicating that DNA methylation is at least one factor, contributing to RAR beta inactivity. However, identically methylated promoters can differentially respond to RA, suggesting that RAR beta 2 activity may be associated to different repressive chromatin states. This supposition is supported by the finding that the more stable repressive RAR beta 2 state in the RA-resistant MDA-MB-231 cell line can be alleviated by the HDAC inhibitor, trichostatin A (TSA), with restoration of RA-induced RAR beta transcription. Thus, chromatin-remodeling drugs might provide a strategy to restore RAR beta activity, and help to overcome the hurdle of RA-resistance In breast cancer.	Univ Milan, Dept Biol, I-20133 Milan, Italy; Univ Milan, Hosp San Paolo, Lab Human Genet, Milan, Italy; Johns Hopkins Univ, Ctr Oncol, Breast Canc Program, Baltimore, MD 21205 USA; Inst Nazl Studio & Cura Tumori, Milan, Italy	University of Milan; University of Milan; Johns Hopkins University; Johns Hopkins Medicine; Fondazione IRCCS Istituto Nazionale Tumori Milan	Sacchi, N (corresponding author), Univ Milan, Dept Biol, Via Celoria 26, I-20133 Milan, Italy.		Sirchia, Silvia/AAB-2620-2019; Orlandi, Rosaria/C-1182-2017	Orlandi, Rosaria/0000-0002-0533-9041; Sirchia, Silvia/0000-0002-6106-3721				Baust C, 1996, INT J CANCER, V67, P409, DOI 10.1002/(SICI)1097-0215(19960729)67:3<409::AID-IJC16>3.0.CO;2-2; Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Cote S, 1997, ANTI-CANCER DRUG, V8, P56; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961; Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200; Formantici C, 1999, J PATHOL, V187, P424, DOI 10.1002/(SICI)1096-9896(199903)187:4<424::AID-PATH259>3.0.CO;2-0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gudas Lorraine J., 1994, P443; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Minna JD, 1997, J NATL CANCER I, V89, P602, DOI 10.1093/jnci/89.9.602; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROMAN SD, 1992, CANCER RES, V52, P2236; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SHAO ZM, 1994, INT J ONCOL, V4, P849; Shen S, 1991, DNA Seq, V2, P111, DOI 10.3109/10425179109039679; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TOULOUSE A, 1997, BBA, V1309, P1; Tsou HC, 1998, EXP CELL RES, V245, P221, DOI 10.1006/excr.1998.4268; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VANDERLEEDE BM, 1992, BIOCHEM BIOPH RES CO, V188, P695, DOI 10.1016/0006-291X(92)91112-4; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WIESCHWENDTNER M, 1997, CANCER RES, V17, P4158; Xu XC, 1997, CANCER RES, V57, P4992; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	46	184	193	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1556	1563		10.1038/sj.onc.1203456	http://dx.doi.org/10.1038/sj.onc.1203456			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734315				2022-12-28	WOS:000086108100008
J	Tan, A; Bitterman, P; Sonenberg, N; Peterson, M; Polunovsky, V				Tan, A; Bitterman, P; Sonenberg, N; Peterson, M; Polunovsky, V			Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1	ONCOGENE			English	Article						Myc; eIF4E; apoptosis; cyclin D1; translation	NEURONAL CELL-DEATH; MESSENGER-RNA; GENE-EXPRESSION; C-MYC; ORNITHINE DECARBOXYLASE; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; PROTEIN-SYNTHESIS; POOR-PROGNOSIS; BREAST-CANCER	Ectopically expressed eukaryotic translation initiation factor 4E (eIF4E) stimulates cell proliferation, suppresses apoptosis in growth factor restricted cells, and induces malignant transformation in primary rodent fibroblasts when coexpressed with protooncogene myc. We report here that eIF4E rescued rat embryo fibroblasts ectopically expressing c-Myc (REF/Myc) from genotoxic and non-genotoxic cytostatic drugs and identify cyclin D1 as a downstream effector in the antiapoptotic mechanism, In clones of REF/Myc ectopically expressing eIF4E, resistance to apoptosis paralleled steady state levels of cyclin D1. Stable expression of cyclin D1 in REF/Myc inhibited apoptosis in response to a broad range of cell cycle specific cytostatic agents, Partial loss-of-cyclin D1 function in REF/Myc ectopically expressing eIF4E (REF/Myc/4E) significantly increased chemosensitivity; either soluble antisense cyclin D1 oligomers or transfection with a dominant negative cyclin D1 mutant that prevents translocation of cyclin D-dependent kinases to the nucleus, significantly blunted the antiapoptotic effect of eIF4E, These data directly link eIF4E rescue from cytostatic drugs to cyclin D1, Since overexpression of eIF4E and cyclin D1 is observed in many aggressive forms of chemoresistant cancers, these findings provide insight into possible mechanisms responsible for this biological behavior.	Univ Minnesota, Sch Med, Dept Pulm Med, Allergy & Crit Care Div, Minneapolis, MN 55255 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Minnesota System; University of Minnesota Twin Cities; McGill University	Polunovsky, V (corresponding author), Univ Minnesota Hosp & Clin, Div Pulm Allergy & Crit Care Med, Box 276,420 Delaware St SE, Minneapolis, MN 55455 USA.			BITTERMAN, PETER/0000-0002-7995-7117	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050152] Funding Source: NIH RePORTER; NHLBI NIH HHS [2P50-HL50152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Busser J, 1998, J NEUROSCI, V18, P2801; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Dang CV, 1999, MOL CELL BIOL, V19, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; de Jong JS, 1998, J CLIN PATHOL-MOL PA, V51, P30, DOI 10.1136/mp.51.1.30; delPeso L, 1997, SCIENCE, V278, P687; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DRISCOLL B, 1999, AM J PHYSIOL-LUNG C, V20, pL679; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; EVAN GI, 1992, CELL, V69, P19; Fan G, 1999, APOPTOSIS, V4, P21, DOI 10.1023/A:1009626031179; FRANKE TF, 1997, SCIENCE, V27, P655; Gansauge S, 1997, CANCER RES, V57, P1634; Giardina SF, 1998, J NEUROCHEM, V71, P1325; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Green DR, 1996, J CELL BIOCHEM, V60, P33, DOI 10.1002/(SICI)1097-4644(19960101)60:1<33::AID-JCB6>3.0.CO;2-4; Guegan C, 1997, NEUROREPORT, V8, P1003, DOI 10.1097/00001756-199703030-00037; Han EKH, 1999, APOPTOSIS, V4, P213, DOI 10.1023/A:1009618824145; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hiyama H, 1999, CELL DEATH DIFFER, V6, P565, DOI 10.1038/sj.cdd.4400524; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hung WC, 1996, BIOCHEM BIOPH RES CO, V220, P719, DOI 10.1006/bbrc.1996.0470; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Katayose Y, 1997, CANCER RES, V57, P5441; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Kotelnikov VM, 1997, CLIN CANCER RES, V3, P95; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Liu W, 1996, NEUROREPORT, V7, P2785, DOI 10.1097/00001756-199611040-00076; LUNGBERG AS, 1999, EUR J CANCER, V25, P531; Ma CY, 1998, P NATL ACAD SCI USA, V95, P9938, DOI 10.1073/pnas.95.17.9938; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mommers ECM, 1998, HUM PATHOL, V29, P1539, DOI 10.1016/S0046-8177(98)90028-4; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Packham G, 1995, Curr Top Microbiol Immunol, V194, P283; Pardo FS, 1996, SOMAT CELL MOLEC GEN, V22, P135, DOI 10.1007/BF02369903; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; POLUNOVSKY VA, 1993, J CLIN INVEST, V92, P388, DOI 10.1172/JCI116578; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Postigo JA, 1998, NEUROSCI LETT, V241, P107, DOI 10.1016/S0304-3940(97)00981-6; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; RHEE K, 1995, CANCER RES, V55, P4188; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sauter ER, 1999, CANCER RES, V59, P4876; SCHUURING E, 1992, CANCER RES, V52, P5229; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1996, CANCER RES, V56, P3265; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TAM SW, 1994, ONCOGENE, V9, P2663; Tan A, 1999, AM J RESP CRIT CARE, V159, P220, DOI 10.1164/ajrccm.159.1.9802104; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; WANG XT, 1997, ONCOGENE, V9, P2663; Warenius HM, 1996, INT J CANCER, V67, P224, DOI 10.1002/(SICI)1097-0215(19960717)67:2<224::AID-IJC13>3.3.CO;2-5; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	78	87	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1437	1447		10.1038/sj.onc.1203446	http://dx.doi.org/10.1038/sj.onc.1203446			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723135				2022-12-28	WOS:000085942700009
J	Delgado, MD; Vaque, JP; Arozarena, I; Lopez-Ilasaca, MA; Martinez, C; Crespo, P; Leon, J				Delgado, MD; Vaque, JP; Arozarena, I; Lopez-Ilasaca, MA; Martinez, C; Crespo, P; Leon, J			H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21(WAF1)-dependent mechanism	ONCOGENE			English	Article						Ras; p21(WAF1); myeloid leukemia cells	CYCLE ARREST; P53; EXPRESSION; PATHWAY; GENE; SENESCENCE; DIFFERENTIATION; P16(INK4A)/MTS1; P21(WAF1/CIP1); SUPPRESSION	Mutated ras genes are frequently found in human cancer, However, it has been shown that oncogenic ras inhibits growth of primary cells, through pathways involving p53 and the cell cycle inhibitors p16(INK4a) and p19(ARF). We have analysed the effect of the ectopic expression of the three mammalian ras genes on the proliferation of K562 leukemia cells, which are deficient for p53, p16(INK4a), p15(INK4b) and p19(ARF) genes. We have found that high expression levels of both wild-type and oncogenic H-, K- and N-ras inhibit the clonogenic growth of K562 cells, Induction of H-rasV12 expression in K562 transfectants retards growth and this effect is accompanied with an increase of p21(WAF1) mRNA and protein levels, Furthermore, p21(WAF1) promoter is activated potently by oncogenic ras and less pronounced by wild-type ras, This induction is p53-independent since a p21(WAF1) promoter devoid of the p53 responsive elements is still activated by Ras, Finally, inhibition of p21(WAF1) expression by an antisense construct partially overcomes the growth inhibitory action of oncogenic H-ras. Altogether, these results indicate that the antiproliferative effect of ras in myeloid leukemia cells is associated to the induction of p21(WAF1) expression and suggest the existence of p19(ARF) and p16(INK4a)-independent pathways for ras-mediated growth inhibition.	Univ Cantabria, Grp Biol Mol Canc, Dept Mol Biol, Fac Med, Santander 39011, Spain; Univ Cantabria, Unidad Asociada Ctr Invest Biol, CSIC, Santander 39011, Spain	Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria	Leon, J (corresponding author), Univ Cantabria, Grp Biol Mol Canc, Dept Mol Biol, Fac Med, Santander 39011, Spain.		Arozarena, Imanol/A-5981-2017; Vaqué, José P/H-8413-2015; Leon, Javier/K-4615-2014; Crespo, Piero/M-3273-2014; Delgado, M. Dolores/K-9056-2014	Arozarena, Imanol/0000-0001-6349-2442; Vaqué, José P/0000-0002-3913-2495; Crespo, Piero/0000-0003-2825-7783; Leon, Javier/0000-0001-5803-0112; Delgado, M. Dolores/0000-0003-4682-4040				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Beaupre DM, 1999, J CLIN ONCOL, V17, P1071, DOI 10.1200/JCO.1999.17.3.1071; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DELGADO MD, 1992, CANCER RES, V52, P5979; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; HAWLEY RG, 1995, ONCOGENE, V11, P1113; Juan G, 1998, LEUKEMIA, V12, P1241, DOI 10.1038/sj.leu.2401100; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; Leon J., 1993, RAS SUPERFAMILY GTPA, P3; LERGA A, 1995, BIOCHEM BIOPH RES CO, V215, P889, DOI 10.1006/bbrc.1995.2547; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Maher J, 1996, LEUKEMIA, V10, P83; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; OTSUKI T, 1995, CANCER RES, V55, P1436; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; Quincoces AF, 1997, FEBS LETT, V416, P317, DOI 10.1016/S0014-5793(97)01229-5; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; TODD AV, 1991, LEUKEMIA LYMPHOMA, V3, P293, DOI 10.3109/10428199109107917; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; WATZINGER F, 1994, CANCER RES, V54, P3934; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	40	53	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2000	19	6					783	790		10.1038/sj.onc.1203384	http://dx.doi.org/10.1038/sj.onc.1203384			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698496				2022-12-28	WOS:000085192100008
J	Scharnhorst, V; Menke, AL; Attema, J; Haneveld, JK; Riteco, N; van Steenbrugge, GJ; van der Eb, AJ; Jochemsen, AG				Scharnhorst, V; Menke, AL; Attema, J; Haneveld, JK; Riteco, N; van Steenbrugge, GJ; van der Eb, AJ; Jochemsen, AG			EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity	ONCOGENE			English	Article						Wilms' tumor 1 gene products; early growth response 1 gene product; tumorigenesis; tumor suppression; Wilms' tumor	DNA-BINDING SPECIFICITY; ZINC FINGER PROTEIN; RAT-KIDNEY-CELLS; WT1 GENE; TRANSFORMING GROWTH-FACTOR-BETA-1; SUPPRESSOR GENE; PROTOONCOGENE TRANSCRIPTION; 3T3 CELLS; EXPRESSION; P53	The Wilms' tumor 1 gene (WT1) encodes a transcription factor of the zinc-finger family and is homozygously mutated or deleted in a subset of Wilms' tumors. Through alternative mRNA splicing, the gene is expressed as four main polypeptides that differ by a stretch of 17 amino acids just N-terminal of the four zinc-fingers and three amino acids between zinc fingers 3 and 4, We have previously shown that expression of the WT1(-/-) isoform, lacking both inserts, increases the tumor growth rate of the adenovirus-transformed baby rat kidney (AdBRK) cell line 7C3H2, whereas expression of the WT1(-/+) isoform, lacking the 17aa insert, strongly suppresses the tumorigenic phenotype. In the present study we show that expression of these splice variants does not affect the tumorigenic potential of the similar AdBRK cell line, 7C1T1, In contrast to the 7C3H2 cell line, this AdBRK cell line expresses high endogenous levels of EGR-1 (early growth response-1) protein, a transcription factor structurally related to WT1, Ectopic expression of EGR-1 in the 7C3H2 AdBRK cells significantly increases their in vivo growth rate and nullifies the tumor suppressor activity of the WT1(-/+) protein. Furthermore, we find that EGR-1 levels are elevated in some Wilms' tumors. These data are the first to show that EGR-1 overexpression causes enhanced tumor growth and that WT1 and EGR-1 exert antagonizing effects on growth regulation in baby rat kidney cells, which might reflect the situation in some Wilms' tumors.	Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands; Erasmus Univ, Dept Expt Urol, NL-3000 DR Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, Dept Mol Cell Biol, POb 9503, NL-2300 RA Leiden, Netherlands.		Menke, Aswin/AAC-6809-2021	Menke, Aswin/0000-0002-0724-0897; Scharnhorst, Volkher/0000-0002-1243-9251				BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BONETTA L, 1990, SCIENCE, V250, P940; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; DEGROOT RP, 1995, CELL GROWTH DIFFER, V6, P531; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; Duarte A, 1998, BRIT J CANCER, V77, P253, DOI 10.1038/bjc.1998.41; Eid MA, 1998, CANCER RES, V58, P2461; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUANG RP, 1995, CANCER RES, V55, P5054; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Kinane TB, 1995, J BIOL CHEM, V270, P30760, DOI 10.1074/jbc.270.51.30760; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lee YI, 1996, DNA CELL BIOL, V15, P99, DOI 10.1089/dna.1996.15.99; LEVIN WJ, 1995, ONCOGENE, V11, P1261; LIM RW, 1987, ONCOGENE, V1, P263; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; LUO XN, 1995, ONCOGENE, V11, P743; MACHIN GA, 1984, HISTOPATHOLOGY, V8, P35, DOI 10.1111/j.1365-2559.1984.tb02320.x; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; Menke AL, 1996, ONCOGENE, V12, P537; Menke AL, 1998, INT REV CYTOL, V181, P151, DOI 10.1016/S0074-7696(08)60418-0; MENKE AL, 1995, INT J CANCER, V63, P76, DOI 10.1002/ijc.2910630115; MILLBRANDT J, 1987, SCIENCE, V238, P797; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; RACKLEY RR, 1995, J UROLOGY, V154, P700, DOI 10.1016/S0022-5347(01)67136-2; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Royuela M, 1998, GROWTH FACTORS, V16, P101, DOI 10.3109/08977199809002121; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; VANDENHEUVEL SJ, 1993, J VIROL, V67, P5526; WANG ZY, 1995, ONCOGENE, V10, P415; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	48	63	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					791	800		10.1038/sj.onc.1203390	http://dx.doi.org/10.1038/sj.onc.1203390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698497				2022-12-28	WOS:000085192100009
J	Liu, JB; Estes, ML; Drazba, JA; Liu, HY; Prayson, R; Kondo, S; Jacobs, BS; Barnett, GH; Barna, BP				Liu, JB; Estes, ML; Drazba, JA; Liu, HY; Prayson, R; Kondo, S; Jacobs, BS; Barnett, GH; Barna, BP			Anti-sense oligonucleotide of p21(waf1/cip1) prevents Interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells	ONCOGENE			English	Article						antisense oligonucleotide; astrocytoma; cytokine; p21(waf1/cip1)	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR; CYCLE ARREST; CDK INHIBITOR; DNA-SYNTHESIS; MICE LACKING; TGF-BETA; EXPRESSION; PROLIFERATION; P21	Elevation of the cyclin-dependent kinase (cdk) inhibitor, p27(kip1) is necessary for Interleukin (IL)-4-mediated growth arrest of human low grade astrocytoma (RTLGA) cells and occurs at 24 h of treatment. Pathways involved in IL-4 alteration of p27(kip1) are unknown, however. Here we investigated whether other cdk inhibitors contributed to the actions of IL-4 on RTLGA cells. By 12 h of IL-4 treatment, both cdk4 and cdk2 kinase activities against the retinoblastoma protein (pRb) were reduced and nuclear entry of pRb was prohibited. Twelve-hour cdk complexes contained elevated p21(waf1/cip1) but not p27(kip1), p15(ink4B) or p16(ink4A), IL-4 increased p21(waf1/cip1) but not p27(kip1) mRNA levels, and stimulated luciferase activity of a p21(waf1/cip1) promoter-luciferase reporter. In p53-mutant WITG3 cells, IL-4 did not alter p21(waf1/cip1) mRNA and promoter-luciferase activity or p27(kip1) protein, suggesting a need for functional p53. STAT6 phosphorylation by IL-4, however, occurred in both p53-mutant WITG3 and p53-functional RTLGA cells. Pre-treatment of RTLGA with anti-sense but not missense p21(waf1/cip1) oligonucleotide prior to IL-4: (a) restored cdk activities; (b) reduced cdk4-associated p21(waf1/cip1) levels; (c) prevented p27(kip1) elevation; and (d) reversed growth arrest. These results are the first to suggest that p21(waf1/cip1) is essential for IL-4-mediated elevation of p27(kip1) and growth arrest of astrocytoma cells.	Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res 653, Cleveland, OH 44109 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathol Anat, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurol Surg, Cleveland, OH 44195 USA	MetroHealth System; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Barna, BP (corresponding author), Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res 653, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.				NINDS NIH HHS [R01NS-33932] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033932] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; BARNA BP, 1995, J NEUROIMMUNOL, V60, P75, DOI 10.1016/0165-5728(95)00055-7; Benedetti S, 1999, CANCER RES, V59, P645; Blanchard DA, 1997, J IMMUNOL, V158, P3054; Brodie C, 1998, J NEUROIMMUNOL, V81, P20, DOI 10.1016/S0165-5728(97)00154-9; BRODIE C, 1994, J NEUROIMMUNOL, V55, P91, DOI 10.1016/0165-5728(94)90150-3; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DAMELL JE, 1997, SCIENCE, V277, P1630; DRAETTA G, 1996, TOPICS BIOL, P241; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ESTES ML, 1993, AM J PATHOL, V143, P337; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; HALLEVY O, 1995, SCIENCE, V267, P1018; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1997, CANCER SURV, V29, P91; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEM SE, 1992, SCIENCE, V256, P827; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Koff A, 1995, Prog Cell Cycle Res, V1, P141; Kondo S, 1996, ONCOGENE, V13, P1279; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; Kwon TK, 1997, J IMMUNOL, V158, P5642; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu JB, 1997, J IMMUNOL, V159, P812; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOIS AF, 1995, CANCER RES, V55, P4010; Lu BF, 1997, J IMMUNOL, V159, P1255; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MITCHELL LC, 1989, J IMMUNOL, V142, P1548; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Noffz G, 1998, J IMMUNOL, V160, P345; OConnor PM, 1997, CANCER RES, V57, P4285; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Paul WE, 1997, CIBA F SYMP, V204, P208; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Puri R K, 1995, Cancer Treat Res, V80, P143; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sampson JH, 1997, NEUROSURGERY, V41, P1365, DOI 10.1097/00006123-199712000-00024; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; SUZUMURA A, 1994, J NEUROIMMUNOL, V53, P209, DOI 10.1016/0165-5728(94)90031-0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, J MOL MED-JMM, V75, P317, DOI 10.1007/s001090050117; Tikoo R, 1997, J BIOL CHEM, V272, P442; Toms SA, 1998, J NEUROSURG, V88, P884, DOI 10.3171/jns.1998.88.5.0884; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Wei MX, 1998, J NEUROVIROL, V4, P237, DOI 10.3109/13550289809114523; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1996, ONCOGENE, V12, P1557	72	23	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					661	669		10.1038/sj.onc.1203373	http://dx.doi.org/10.1038/sj.onc.1203373			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698511				2022-12-28	WOS:000085192000008
J	Villalonga, P; Rius, E; Bachs, O; Agell, N				Villalonga, P; Rius, E; Bachs, O; Agell, N			[Lys(61)]N-Ras is able to induce full activation and nuclear accumulation of Cdk4 in NIH3T3 cells	ONCOGENE			English	Article						Ras; cdk4; cdk2; cell cycle; cell nucleus	CYCLIN-DEPENDENT KINASES; INHIBITOR P27(KIP1); RETINOBLASTOMA PROTEIN; SIGNAL-TRANSDUCTION; G(1) PROGRESSION; PHASE-TRANSITION; 3T3 FIBROBLASTS; RAS ACTIVITY; S-PHASE; GROWTH	The elements of the cell cycle regulatory machinery activated by the oncogenic form of Ras, [Lys(61)]N-Ras, have been analysed in NIH3T3 cells. We demonstrate that [Lys(61)]N-Ras expression is able to induce full cdk4 activation. As already reported, oncogenic Ras expression was sufficient to induce cyclin D1 and p21(cip1) expression and their association with cdk4. Furthermore, serum-starved [Lys(61)]N-Ras NIH3T3 cells showed nuclear accumulation of cyclin D1 and cdk4 not observed in serum-started NIH3T3 cells. This accumulation of cdk4 into the cell nucleus observed in serum-started [Lys(61)]N-Ras NIH3T3 cells was inhibited by a microinjection of neutralizing anti-Ras antibodies. Thus, active [Lys(61)]N-Ras was a sufficient signal to induce nuclear accumulation of cyclin D1/cdk4, leading to its full activation, Transfection of [Lys(61)]N-Ras NIH3T3 cells with an inactive form of MEK or their treatment with PD 98059, showed that nuclear translocation of cdk4 was MEK dependent. Interestingly, cells constitutively expressing [Lys(61)]N-Ras did not inactivate pRb and did not proliferate in the absence of serum. This may be due to the fact that although association of cdk2 with cyclin E and the translocation of those complexes to the nucleus were achieved, [Lys(61)]N-Ras expression was not sufficient to induce cdk2 activation. The high levels of p27(kip1) that were found in cyclin E/cdk2 complexes may be responsible for the inability of oncogenic Res to activate this kinase. In consequence, oncogenic alterations that lead to a decrease in p27(kip1) bound to cyclin E may cooperate with Ras to induce full cdk2 activation, pRb inactivation and thus cell proliferation.	Univ Barcelona, Fac Med, IDIBAPS, Dept Biol Cellular Anat Patol, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Agell, N (corresponding author), Univ Barcelona, Fac Med, IDIBAPS, Dept Biol Cellular Anat Patol, E-08036 Barcelona, Spain.		Agell, Neus/E-9640-2016; Villalonga, Priam/K-4350-2014	Agell, Neus/0000-0002-1205-6074; Villalonga, Priam/0000-0002-7190-6884				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1997, CANCER RES, V57, P1569; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BOS JL, 1989, CANCER RES, V49, P4682; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; DOU QP, 1994, J BIOL CHEM, V269, P1306; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1997, CURR BIOL, V7, P258; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Geng Y, 1996, ONCOGENE, V12, P1173; GRANA X, 1995, ONCOGENE, V11, P211; HARPER JW, 1993, CELL, V75, P805; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KEYOMARSI K, 1994, CANCER RES, V54, P380; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Peeper DS, 1997, FEBS LETT, V410, P11, DOI 10.1016/S0014-5793(97)00319-0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1995, ONCOGENE, V11, P635; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roussel ME, 1998, ADV CANCER RES, V74, P1, DOI 10.1016/S0065-230X(08)60763-0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Winston JT, 1996, ONCOGENE, V12, P127; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	71	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					690	699		10.1038/sj.onc.1203341	http://dx.doi.org/10.1038/sj.onc.1203341			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698514				2022-12-28	WOS:000085192000011
J	Krutovskikh, VA; Troyanovsky, SM; Piccoli, C; Tsuda, H; Asamoto, M; Yamasaki, H				Krutovskikh, VA; Troyanovsky, SM; Piccoli, C; Tsuda, H; Asamoto, M; Yamasaki, H			Differential effect of subcellular localization of communication impairing gap junction protein connexin43 on tumor cell growth in vivo	ONCOGENE			English	Article						connexin43; dominant negative mutants; tumor suppression	C6 GLIOMA-CELLS; INTERCELLULAR COMMUNICATION; RAT-LIVER; TRANSFORMED-CELLS; CARCINOMA-CELLS; GENE MUTATION; EXPRESSION; TRANSFECTION; CARCINOGENESIS; CDNA	There is a large body of evidence suggesting the connexin gap junction proteins appear to act as tumor suppressors, and their tumor inhibitory effect is usually attributed to their main function of cell coupling through gap junctions, However, some cancer cells (e.g. the rat bladder carcinoma BC31 cell line) are cell-cell communication proficient. Using specific site-directed mutagenesis in the third membrane-spanning (3M) domain of connexin43 (Cx43), we abolished the intrinsic gap junction intercellular communication (GJIC) in BC31 cells either by closing the gap junctional channels or by disruption of the transport of connexin complexes to the lateral membrane. Clones of BC31 cells transfected with a dominant negative Cx43 mutant giving rise to gap junctional channels, permeable only for a small tracer (neurobiotin), displayed accelerated growth rate in vivo, showing the critical role of selective gap junctional permeability in the regulation of cell growth in vivo. The use of other dominant-negative mutants of Cx43 also suggested that the effect of impaired communication on the tumorigenicity of cancer cells depends on the subcellular location of connexin, Inhibition of intrinsic GJIC in BC31 cells by sequestering of Cx protein inside the cytoplasm, due to expression of dominant-negative transport-deficient Cx43 mutants, did not significantly enhance the growth of transfectants in nude mice, but occasionally slightly retarded it. In contrast, augmentation of GJIC in BC31 cells by forced expression of wild-type Cx43, or a communication-silent mutant, fully suppressed tumorigenicity of these cells, Overall, these results show that cell coupling is a strong, but not the sole, mechanism by which Cx suppresses growth of tumorigenic cells in vivo; a GJIC-independent activity of Cx proteins should be considered as another strong tumor-suppressive factor.	Int Agcy Res Canc, Unit Multistage Carcinogenesis, F-69372 Lyon, France; Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA; Natl Canc Ctr, Res Inst, Div Expt Pathol Chemotherapy, Tokyo 1040045, Japan; Nagoya City Univ, Sch Med, Dept Pathol, Nagoya, Aichi 4678601, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Washington University (WUSTL); National Cancer Center - Japan; Nagoya City University	Krutovskikh, VA (corresponding author), Int Agcy Res Canc, Unit Multistage Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.				NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40534] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asamoto M, 1998, JPN J CANCER RES, V89, P481, DOI 10.1111/j.1349-7006.1998.tb03287.x; ASAMOTO M, 1994, CARCINOGENESIS, V15, P2163, DOI 10.1093/carcin/15.10.2163; BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; BRISSETTE JL, 1994, P NATL ACAD SCI USA, V91, P6453, DOI 10.1073/pnas.91.14.6453; BRUZZONE R, 1994, NEURON, V13, P1253, DOI 10.1016/0896-6273(94)90063-9; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; Deschenes SM, 1997, J NEUROSCI, V17, P9077; Donaldson P, 1997, HISTOL HISTOPATHOL, V12, P219; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; FITZGERALD DJ, 1994, CARCINOGENESIS, V15, P1859, DOI 10.1093/carcin/15.9.1859; FITZGERALD DJ, 1983, CANCER RES, V43, P3614; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Huang RP, 1998, CANCER RES, V58, P5089; KLANN RC, 1989, CANCER RES, V49, P699; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEUBE RE, 1995, J CELL SCI, V108, P883; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MERCHENTHALER I, 1989, J HISTOCHEM CYTOCHEM, V37, P1563, DOI 10.1177/37.10.2674275; MESNIL M, 1995, CANCER RES, V55, P629; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; NAUS CCG, 1992, CANCER RES, V52, P4208; NEVEU MJ, 1994, J CELL SCI, V107, P83; Omori Y, 1996, CARCINOGENESIS, V17, P2077, DOI 10.1093/carcin/17.9.2077; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; SAITO T, 1997, CANCER RES, V57, P376; Statuto M, 1997, J BIOL CHEM, V272, P24710, DOI 10.1074/jbc.272.39.24710; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; YAMASAKI H, 1990, CARCINOGENESIS, V11, P1051, DOI 10.1093/carcin/11.7.1051; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	44	82	95	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					505	513		10.1038/sj.onc.1203340	http://dx.doi.org/10.1038/sj.onc.1203340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698520				2022-12-28	WOS:000085104200004
J	Horstmann, S; Ferrari, S; Klempnauer, KH				Horstmann, S; Ferrari, S; Klempnauer, KH			Regulation of B-Myb activity by cyclin D1	ONCOGENE			English	Article						B-Myb; cell cycle regulation; cyclin D1; phosphorylation; trans-activation	CELL-CYCLE; A-MYB; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; DEPENDENT-KINASE; ESTROGEN-RECEPTOR; GENE ACTIVATION; DNA-BINDING; C-MYB; EXPRESSION	Evidence obtained during recent years suggests that B-Myb, a highly conserved member of the Myb transcription factor family, plays a key role in cell proliferation. We have shown previously that the activity of B-Myb is stimulated by cyclin A/Cdk2-dependent phosphorylation of the carboxyl-terminus of B-Myb, We have now investigated in more detail the effect of other cyclins on B-Myb, Here, we show that cyclin D1, in contrast to cyclin A, strongly inhibits the activity of B-Myb. This inhibitory effect does not involve increased phosphorylation of B-Myb but seems to rely on the formation of a specific complex of B-Myb and cyclin D1, Our work identifies B-Myb as an interacting partner for cyclin D1 and suggest that the activity of B-Myb during the cell cycle is controlled by the antagonistic effects of cyclin D1 and A. The results presented here suggest a more general role of cyclin D1 as regulator of transcription in addition to the known effect on RE phosphorylation.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Inst Expt Canc Res, Tumor Biol Ctr, D-79011 Freiburg, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.		Buchinger, Sebastian/M-3003-2013; Ferrari, Stefano/I-7357-2016	Buchinger, Sebastian/0000-0003-4859-8972; Ferrari, Stefano/0000-0002-6607-215X				ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MASSAGUE J, 1995, CURR OPIN CELL BIOL, V7, P769, DOI 10.1016/0955-0674(95)80059-X; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sitzmann J, 1996, ONCOGENE, V12, P1889; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	49	53	53	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					298	306		10.1038/sj.onc.1203302	http://dx.doi.org/10.1038/sj.onc.1203302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645009				2022-12-28	WOS:000084844400016
J	Lynch, DK; Ellis, CA; Edwards, PAW; Hiles, ID				Lynch, DK; Ellis, CA; Edwards, PAW; Hiles, ID			Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism	ONCOGENE			English	Article						Akt; ErbB4; integrin-linked kinase; phosphatidylinositol 3-kinase; protein kinase B; site-directed mutagenesis	GLYCOGEN-SYNTHASE KINASE-3; NATRIURETIC-PEPTIDE RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; PROMOTES CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; PHOSPHOINOSITIDE 3-KINASE; MOLECULAR-CLONING; SIGNALING PATHWAY; INDUCED APOPTOSIS	The serine threonine kinase protein kinase B regulates cellular activities as diverse as glycogen metabolism and apoptosis, Full activation of protein kinase B requires 3-phosphoinositides and dual phosphorylation on threonine-308 and serine-473, CaM-K kinase and 3-phosphoinositide dependent-kinase-l phosphorylate threonine-308, Integrin-linked kinase reportedly phophorylates serine-473, Consistent,vith this, in a model COS cell system we show that expression of wild-type integrin-linked kinase promotes the wortmannin sensitive phosphorylation of serine-473 of protein kinase B and its downstream substrates, and inhibits C-2-ceramide induced apoptosis, In contrast, integrin-linked kinase mutated in a lysine residue critical for function in protein kinases is inactive in these experiments, and furthermore, acts dominantly to block serine-473 phosphorylation induced by ErbB4, However, alignment of analogous sequences from different species demonstrates that integrin-linked kinase is not a typical protein kinase and identifies a conserved serine residue which potentially regulates kinase activity in a phosphorylation dependent manner, Mutation of this serine to aspartate or glutamate, but not alanine, in combination with the inactivating lysine mutation restores integrin-linked kinase dependent phosphorylation of serine-473 of protein kinase, These data strongly suggest that integrin-linked kinase does not possess serine-473 kinase activity but functions as an adaptor to recruit a serine-473 kinase or phosphatase.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Stevenage SG1 2NY, Herts, England	GlaxoSmithKline	Hiles, ID (corresponding author), Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Foster DC, 1998, J BIOL CHEM, V273, P16311, DOI 10.1074/jbc.273.26.16311; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; PEARSON RB, 1995, EMBO J, V14, P5278; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Sambrook J, 1987, MOL CLONING LAB MANU; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	57	177	187	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					8024	8032		10.1038/sj.onc.1203258	http://dx.doi.org/10.1038/sj.onc.1203258			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637513				2022-12-28	WOS:000084634600011
J	Vadlamudi, R; Adam, L; Talukder, A; Mendelsohn, J; Kumar, R				Vadlamudi, R; Adam, L; Talukder, A; Mendelsohn, J; Kumar, R			Serine phosphorylation of paxillin by heregulin-beta 1: role of p38 mitogen activated protein kinase	ONCOGENE			English	Article						heregulin; signaling; spreading; paxillin; motility	FOCAL ADHESION KINASE; NEU DIFFERENTIATION FACTOR; HEPATOCYTE GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; RECEPTOR INTERACTIONS; CARCINOMA-CELLS; GENE-PRODUCT; HUMAN-BREAST; CANCER	The mechanisms through which heregulin (HRG) regulates the progression of breast cancer cells to a more invasive phenotype are currently unknown, Recently we have shown that HRG treatment of breast cancer cells leads to the formation of lamellipodia/filopodia, and increased cell migration and invasiveness through the phosphatidylinositol 3-kinase (PI-3 kinase). Since the process of cell migration must involve changes in adhesion, we explored the potential HRG regulation of paxillin, a major cytoskeletal phosphoprotein of focal adhesion. We report that HRG stimulation of noninvasive breast cancer cells resulted in stimulation of p38 mitogen-activated protein kinase (p38(MAPK)), extracellular signal-regulated kinases (ERK) and PI-3K, and a concurrent unexpected increase in the level of paxillin phosphorylation on serine residue which was sensitive to protein-phosphatase 2b but not to protein tyrosine phosphatase 1, In addition, HRG triggered a rapid redistribution of paxillin to the perinuclear regions from the tyrosine-phosphorylated focal adhesions, and increased cell scattering. There was no effect of HRG on the state of phosphorylation and localization of focal adhesion kinase, The HRG-induced increase in serine phosphorylation of paxillin and cell scattering were selectively inhibited by a specific inhibitor of p38(MAPK) or a dominant-negative p38(MAPK) mutant, but not by inhibitors of p42/44(MAPK) or PI-3 kinase pathways. For the first time our results have shown that HRG, a potent migratory growth factor stimulates serine phosphorylation of paxillin. These findings suggest a role of p38(MAPK) dependent signal transduction pathway(s) in serine phosphorylation and disassembly of the paxillin from the focal complexes during HRG-induced cell shape alterations and motility.	Univ Texas, MD Anderson Canc Ctr, Cell Growth Regulat Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cell Growth Regulat Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA65746, CA80066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; KIM HH, 1994, J BIOL CHEM, V269, P24747; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KUMAR R, 1995, J CELL BIOCHEM, V62, P102; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LO L, 1999, IN PRESS MOL CARCINO; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARTE BM, 1995, ONCOGENE, V10, P167; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHLAEPFER DD, 1994, NATURE, V372, P786; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Vadlamudi R, 1999, CANCER RES, V59, P2843; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Yamaguchi R, 1997, ONCOGENE, V15, P1753, DOI 10.1038/sj.onc.1201345; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	47	62	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7253	7264		10.1038/sj.onc.1203163	http://dx.doi.org/10.1038/sj.onc.1203163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602479				2022-12-28	WOS:000084119400009
J	Barkett, M; Gilmore, TD				Barkett, M; Gilmore, TD			Control of apoptosis by Rel/NF-kappa B transcription factors	ONCOGENE			English	Review						Rel; NF-kappa B; apoptosis; transcription factor; tumor necrosis factor; IAPs; lymphocytes; neurodegenerative diseases; hepatocyte; cancer therapy	TUMOR-NECROSIS-FACTOR; MANGANESE SUPEROXIDE-DISMUTASE; ALPHA-INDUCED APOPTOSIS; ZINC-FINGER PROTEIN; INDUCED CELL-DEATH; MURINE CLONAL OSTEOBLASTS; BETA-PEPTIDE TOXICITY; CHICKEN SPLEEN-CELLS; TNF-ALPHA; CONSTITUTIVE ACTIVATION	Apoptosis is a physiological process critical for organ development, tissue homeostasis, and elimination of defective or potentially dangerous cells in complex organisms. Apoptosis can be initiated by a wide variety of stimuli, which activate a cell suicide program that is constitutively present in most vertebrate cells. In diverse cell types, Rel/NF-kappa B transcription factors have been shown to have a role in regulating the apoptotic program, either as essential for the induction of apoptosis or, perhaps more commonly, as blockers of apoptosis. Whether Rel/NF-kappa B promotes or inhibits apoptosis appears to depend on the specific cell type and the type of inducer. An understanding of the role of Rel/NF-kappa B transcription factors in controlling apoptosis may lead to the development of therapeutics for a wide variety of human diseases, including neurodegenerative and immune diseases, and cancer.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Barkett, M (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline; NIGMS NIH HHS [TG32-GM08921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; ARSURA M, 1999, UNPUB; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; Bakker TR, 1999, J IMMUNOL, V162, P3456; Bakker TR, 1999, INT J CANCER, V80, P320; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BARKETT M, 1999, UNPUB; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Batra RK, 1999, AM J RESP CELL MOL, V21, P238, DOI 10.1165/ajrcmb.21.2.3470; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; Bellas RE, 1997, AM J PATHOL, V151, P891; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Botchkina GI, 1999, MOL MED, V5, P372, DOI 10.1007/BF03402126; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Buchmann A, 1999, CELL DEATH DIFFER, V6, P190, DOI 10.1038/sj.cdd.4400475; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; CHEN C, 1999, UNPUB; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Delfino F, 1998, MOL ENDOCRINOL, V12, P1696, DOI 10.1210/me.12.11.1696; DeLuca C, 1998, VIROLOGY, V244, P27, DOI 10.1006/viro.1998.9085; DeMeester SL, 1998, CRIT CARE MED, V26, P1500, DOI 10.1097/00003246-199809000-00016; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Dong G, 1999, CANCER RES, V59, P3495; Draczynska-Lusiak B, 1998, NEUROREPORT, V9, P527, DOI 10.1097/00001756-199802160-00028; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Duffey DC, 1999, CANCER RES, V59, P3468; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; Esslinger CW, 1998, MOL IMMUNOL, V35, P847, DOI 10.1016/S0161-5890(98)00071-6; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Feinman R, 1999, BLOOD, V93, P3044; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GONDAKIS S, 1999, ONCOGENE, V18, P6888; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GROSSMAN M, 1999, IN PRESS P NATL ACAD; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Heussler VT, 1999, P NATL ACAD SCI USA, V96, P7312, DOI 10.1073/pnas.96.13.7312; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JAATTELA M, 1991, LAB INVEST, V64, P724; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Keller JN, 1998, J NEUROSCI, V18, P687; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kitajima I, 1996, J BONE MINER RES, V11, P200; Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0; Kolenko V, 1999, J IMMUNOL, V163, P590; KORNER M, 1991, BIOCHEM BIOPH RES CO, V181, P80, DOI 10.1016/S0006-291X(05)81384-1; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lee RM, 1999, GENE DEV, V13, P718, DOI 10.1101/gad.13.6.718; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liou ML, 1999, J BIOL CHEM, V274, P10145, DOI 10.1074/jbc.274.15.10145; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Manna SK, 1999, J IMMUNOL, V162, P1510; Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997; Marinovich M, 1996, EXP CELL RES, V226, P98, DOI 10.1006/excr.1996.0207; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Masdehors P, 1999, BRIT J HAEMATOL, V105, P752, DOI 10.1046/j.1365-2141.1999.01388.x; Matsui K, 1998, J IMMUNOL, V161, P3469; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Maulik N, 1999, FEBS LETT, V443, P331, DOI 10.1016/S0014-5793(98)01719-0; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; McDade TP, 1999, J SURG RES, V83, P56, DOI 10.1006/jsre.1998.5560; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; Moerman AM, 1999, MOL BRAIN RES, V67, P303, DOI 10.1016/S0169-328X(99)00091-1; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; Nakai M, 1999, MOL BRAIN RES, V64, P59, DOI 10.1016/S0169-328X(98)00310-6; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Paillard F, 1999, HUM GENE THER, V10, P1, DOI 10.1089/10430349950019138; Qin ZH, 1999, J NEUROSCI, V19, P4023; Ravi R, 1998, CANCER RES, V58, P882; Ravi R, 1998, CANCER RES, V58, P4531; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schauer SL, 1998, J IMMUNOL, V160, P4398; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schwarz EM, 1998, J VIROL, V72, P5654, DOI 10.1128/JVI.72.7.5654-5660.1998; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Sheehy AM, 1999, J BIOL CHEM, V274, P8708, DOI 10.1074/jbc.274.13.8708; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stehlik C, 1998, BIOCHEM BIOPH RES CO, V243, P827, DOI 10.1006/bbrc.1998.8185; Sumitomo M, 1999, HUM GENE THER, V10, P37, DOI 10.1089/10430349950019174; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Taub R, 1998, HEPATOLOGY, V27, P1445, DOI 10.1002/hep.510270538; Teixeiro E, 1999, EUR J IMMUNOL, V29, P745, DOI 10.1002/(SICI)1521-4141(199903)29:03<745::AID-IMMU745>3.0.CO;2-0; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Tumang JR, 1998, EUR J IMMUNOL, V28, P4299, DOI 10.1002/(SICI)1521-4141(199812)28:12<4299::AID-IMMU4299>3.0.CO;2-Y; Usami I, 1998, BIOCHEM PHARMACOL, V55, P185, DOI 10.1016/S0006-2952(97)00429-2; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; van Hogerlinden M, 1999, CANCER RES, V59, P3299; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang W, 1999, J IMMUNOL, V162, P314; Wang WX, 1999, CLIN CANCER RES, V5, P119; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Xie HJ, 1997, MOL IMMUNOL, V34, P987, DOI 10.1016/S0161-5890(97)00128-4; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	213	1035	1098	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	1999	18	49					6910	6924		10.1038/sj.onc.1203238	http://dx.doi.org/10.1038/sj.onc.1203238			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602466				2022-12-28	WOS:000083896500008
J	Pahl, HL				Pahl, HL			Activators and target genes of Rel/NF-kappa B transcription factors	ONCOGENE			English	Review						NF-kappa B; Rel; transcription factors; immune response; stress response; ER overload	TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; HUMAN ENDOTHELIAL-CELLS; STIMULATING FACTOR GENE; DNA-BINDING ACTIVITY; RESPIRATORY SYNCYTIAL VIRUS; GLYCATION END-PRODUCTS; INTERCELLULAR-ADHESION MOLECULE-1; LISTERIA-MONOCYTOGENES INFECTION	The vertebrate transcription factor NF-kappa B is induced by over 150 different stimuli. Active NF-kappa B, in turn, participates in the control of 'transcription of over 150 target genes. Because a large variety of bacteria and viruses activate NF-kappa B and because the transcription factor regulates the expression of inflammatory cytokines, chemokines, immunoreceptors, and cell adhesion molecules, NF-kappa B has often been termed a 'central mediator of the human immune response'. This article contains a complete listing of all NF-kappa B inducers and target genes described to date, The collected data argue that NF-kappa B functions more generally as a central regulator of stress responses, In addition, NF-kappa B activation blocks apoptosis in several cell types. Coupling stress responsiveness and anti-apoptotic pathways through the use of a common transcription factor may result in increased cell survival following stress insults.	Univ Freiburg, Dept Expt Anesthesiol, D-79106 Freiburg, Germany	University of Freiburg	Pahl, HL (corresponding author), Univ Freiburg, Klin Tumorbiol, Klinikum, Breisacher Str 117, D-79106 Freiburg, Germany.		Pahl, Heike/AGM-5260-2022					ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; Adolph KW, 1997, GENE, V193, P5, DOI 10.1016/S0378-1119(97)00070-X; ANDALIBI A, 1993, BIOCHEM SOC T, V21, P651, DOI 10.1042/bst0210651; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; ANISOWICZ A, 1991, J IMMUNOL, V147, P520; ARAKAWA T, 1995, FEBS LETT, V363, P105, DOI 10.1016/0014-5793(95)00293-I; Asanuma M, 1998, MOL BRAIN RES, V60, P305, DOI 10.1016/S0169-328X(98)00188-0; Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BELLAS RE, 1993, J VIROL, V67, P2908, DOI 10.1128/JVI.67.5.2908-2913.1993; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Bitko V, 1997, VIROLOGY, V232, P369, DOI 10.1006/viro.1997.8582; BLACKWELL TS, 1994, AM J RESP CELL MOL, V11, P464, DOI 10.1165/ajrcmb.11.4.7917314; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRACH MA, 1991, PATHOBIOLOGY, V59, P284, DOI 10.1159/000163664; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRESSLER P, 1991, J IMMUNOL, V147, P2290; BROOKS PA, 1995, J VIROL, V69, P6005, DOI 10.1128/JVI.69.10.6005-6009.1995; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; BUSAM K, 1992, INFECT IMMUN, V60, P2008, DOI 10.1128/IAI.60.5.2008-2015.1992; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; Cazals V, 1999, BBA-MOL CELL RES, V1448, P349, DOI 10.1016/S0167-4889(98)00095-0; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; CHEN C, 1999, UNPUB MOL CELL BIOL; CHEN F, 1995, BIOCHEM BIOPH RES CO, V214, P839, DOI 10.1006/bbrc.1995.2363; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; CHIRMULE N, 1994, BIOCHEM BIOPH RES CO, V203, P498, DOI 10.1006/bbrc.1994.2210; CHOPRA A, 1992, BIOCHEM BIOPH RES CO, V185, P489, DOI 10.1016/0006-291X(92)91651-6; Ciaccio PJ, 1996, BIOCHEM BIOPH RES CO, V228, P524, DOI 10.1006/bbrc.1996.1693; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Dehbi M, 1998, ONCOGENE, V16, P2033, DOI 10.1038/sj.onc.1201747; Delfino F, 1998, MOL ENDOCRINOL, V12, P1696, DOI 10.1210/me.12.11.1696; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DOKTER WHA, 1994, J BIOL CHEM, V269, P4201; Duyao M P, 1992, Curr Top Microbiol Immunol, V182, P421; DYER RB, 1993, INFECT IMMUN, V61, P4427, DOI 10.1128/IAI.61.10.4427-4433.1993; Eaves-Pyles T, 1999, INFECT IMMUN, V67, P800, DOI 10.1128/IAI.67.2.800-804.1999; EDBROOKE MR, 1991, CYTOKINE, V3, P380, DOI 10.1016/1043-4666(91)90041-B; ENSOLI B, 1989, EMBO J, V8, P3019, DOI 10.1002/j.1460-2075.1989.tb08452.x; Espandiari P, 1998, J BIOCHEM MOL TOXIC, V12, P339, DOI 10.1002/(SICI)1099-0461(1998)12:6<339::AID-JBT3>3.0.CO;2-N; Ferlini C, 1999, BRIT J CANCER, V79, P257, DOI 10.1038/sj.bjc.6690042; FIGUEIREDO MS, 1995, J BIOL CHEM, V270, P11828, DOI 10.1074/jbc.270.20.11828; Fong TC, 1996, J IMMUNOL, V157, P4442; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Garcia J, 1998, J BIOL CHEM, V273, P34391, DOI 10.1074/jbc.273.51.34391; Garcia-Nogales P, 1999, J NEUROCHEM, V72, P1750, DOI 10.1046/j.1471-4159.1999.721750.x; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; GOEBELER M, 1995, J IMMUNOL, V155, P2459; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Grohmann U, 1998, IMMUNITY, V9, P315, DOI 10.1016/S1074-7613(00)80614-7; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GRUSS HJ, 1992, BLOOD, V80, P2563; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Haas AF, 1998, FREE RADICAL BIO MED, V25, P998, DOI 10.1016/S0891-5849(98)00135-X; Haddad EB, 1996, FEBS LETT, V379, P265, DOI 10.1016/0014-5793(95)01524-8; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HANNINK M, 1990, ONCOGENE, V5, P1843; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Harcourt BH, 1999, J MED VIROL, V57, P9, DOI 10.1002/(SICI)1096-9071(199901)57:1<9::AID-JMV2>3.0.CO;2-2; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; Hashemi FB, 1999, J INFECT DIS, V179, P924, DOI 10.1086/314674; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAUF N, 1994, INFECT IMMUN, V62, P2740, DOI 10.1128/IAI.62.7.2740-2747.1994; Hauf N, 1997, P NATL ACAD SCI USA, V94, P9394, DOI 10.1073/pnas.94.17.9394; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; He C, 1996, CANCER LETT, V106, P185, DOI 10.1016/0304-3835(96)04318-2; Hein H, 1997, BIOCHEM BIOPH RES CO, V237, P537, DOI 10.1006/bbrc.1997.7169; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Hennig B, 1996, AM J CLIN NUTR, V63, P322, DOI 10.1093/ajcn/63.3.322; Hennig B, 1999, J BIOCHEM MOL TOXIC, V13, P83, DOI 10.1002/(SICI)1099-0461(1999)13:2<83::AID-JBT4>3.3.CO;2-Z; Hildt E, 1996, VIROLOGY, V225, P235, DOI 10.1006/viro.1996.0594; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; Hobbie S, 1997, J IMMUNOL, V159, P5550; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; Hsu DK, 1996, AM J PATHOL, V148, P1661; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Ichikawa S, 1998, BIOCHEM BIOPH RES CO, V253, P707, DOI 10.1006/bbrc.1998.9855; Iciek LA, 1997, J IMMUNOL, V158, P4769; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; IVANOV V, 1989, MOL CELL BIOL, V9, P4677, DOI 10.1128/MCB.9.11.4677; IVANOV V, 1994, J IMMUNOL, V153, P2394; JAMIESON C, 1989, J EXP MED, V170, P1737, DOI 10.1084/jem.170.5.1737; JANSSEN YMW, 1995, P NATL ACAD SCI USA, V92, P8458, DOI 10.1073/pnas.92.18.8458; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KLAMAN LD, 1995, J VIROL, V69, P871, DOI 10.1128/JVI.69.2.871-881.1995; Klebanoff SJ, 1999, J INFECT DIS, V179, P653, DOI 10.1086/314644; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Kretz-Remy C, 1998, J BIOL CHEM, V273, P3180, DOI 10.1074/jbc.273.6.3180; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Krushel LA, 1999, J BIOL CHEM, V274, P2432, DOI 10.1074/jbc.274.4.2432; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Kuprash DV, 1996, J IMMUNOL, V156, P2465; KURATA S, 1994, J BIOL CHEM, V269, P24553; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; Lang CH, 1999, AM J PHYSIOL-GASTR L, V276, pG719, DOI 10.1152/ajpgi.1999.276.3.G719; LANIADOSCHWARTZMAN M, 1994, J BIOL CHEM, V269, P24321; LASTER SM, 1988, J IMMUNOL, V141, P2629; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; LAWRENCE O, 1995, INFECT IMMUN, V63, P1040, DOI 10.1128/IAI.63.3.1040-1046.1995; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; Lee RM, 1999, GENE DEV, V13, P718, DOI 10.1101/gad.13.6.718; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Li CF, 1999, AM J PHYSIOL-HEART C, V276, pH543, DOI 10.1152/ajpheart.1999.276.2.H543; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; LI XX, 1991, J BIOL CHEM, V266, P15192; Li Y, 1996, CARCINOGENESIS, V17, P2305, DOI 10.1093/carcin/17.11.2305; Li YX, 1996, BIOCHEM BIOPH RES CO, V229, P982, DOI 10.1006/bbrc.1996.1911; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Lin SC, 1996, MOL CELL BIOL, V16, P4591; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Liu R, 1998, AIDS RES HUM RETROV, V14, P1509, DOI 10.1089/aid.1998.14.1509; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; LOPEZCABRERA M, 1995, J BIOL CHEM, V270, P21545, DOI 10.1074/jbc.270.37.21545; Lorimer DD, 1997, BIOCHEM BIOPH RES CO, V241, P558, DOI 10.1006/bbrc.1997.7838; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARCUZZI A, 1989, NUCLEIC ACIDS RES, V17, P10455, DOI 10.1093/nar/17.24.10455; MARI B, 1994, J BIOL CHEM, V269, P8517; Marie C, 1999, INFECT IMMUN, V67, P688, DOI 10.1128/IAI.67.2.688-693.1999; Mastronarde JG, 1996, J INFECT DIS, V174, P262, DOI 10.1093/infdis/174.2.262; Matsui K, 1998, J IMMUNOL, V161, P3469; Matsumoto S, 1997, BIOCHEM BIOPH RES CO, V234, P454, DOI 10.1006/bbrc.1997.6665; McCarthy GM, 1998, J BIOL CHEM, V273, P35161, DOI 10.1074/jbc.273.52.35161; McDonald PP, 1998, BLOOD, V92, P4828, DOI 10.1182/blood.V92.12.4828.424k09_4828_4835; Mejdoubi N, 1999, BIOCHEM BIOPH RES CO, V254, P93, DOI 10.1006/bbrc.1998.9903; MESSER G, 1990, Cytokine, V2, P389, DOI 10.1016/1043-4666(90)90046-V; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; Mirza A, 1997, AM J PHYSIOL-GASTR L, V272, pG281, DOI 10.1152/ajpgi.1997.272.2.G281; Misra UK, 1996, J LEUKOCYTE BIOL, V60, P784, DOI 10.1002/jlb.60.6.784; MOFFAT GJ, 1992, BIOCHEMISTRY-US, V31, P12376, DOI 10.1021/bi00164a012; Moffatt S, 1996, J VIROL, V70, P8485, DOI 10.1128/JVI.70.12.8485-8491.1996; Mohan RR, 1998, INVEST OPHTH VIS SCI, V39, P2626; MOORE NC, 1995, J IMMUNOL, V155, P4653; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621; Moriuchi H, 1997, J IMMUNOL, V158, P3483; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Munroe DG, 1995, J INFLAMM, V45, P260; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; MUROI M, 1994, J BIOL CHEM, V269, P30561; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Musso R, 1997, MOL PHARMACOL, V51, P27, DOI 10.1124/mol.51.1.27; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1137, DOI 10.1006/bbrc.1994.2784; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nagase M, 1998, J BIOL CHEM, V273, P33702, DOI 10.1074/jbc.273.50.33702; Naumann M, 1997, J EXP MED, V186, P247, DOI 10.1084/jem.186.2.247; Ni A, 1998, BBA-GENE STRUCT EXPR, V1442, P177, DOI 10.1016/S0167-4781(98)00163-8; Nie ZZ, 1998, MOL PHARMACOL, V53, P663, DOI 10.1124/mol.53.4.663; Nishikawa M, 1999, AM J RESP CELL MOL, V20, P189, DOI 10.1165/ajrcmb.20.2.3305; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; NOVAK TJ, 1990, MOL CELL BIOL, V10, P6325, DOI 10.1128/MCB.10.12.6325; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; OH CK, 1994, J IMMUNOL, V153, P325; Ohkawa T, 1999, BBA-MOL CELL RES, V1448, P416, DOI 10.1016/S0167-4889(98)00155-4; OHMORI Y, 1995, J IMMUNOL, V155, P3593; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; Ohtsuka T, 1996, J BIOL CHEM, V271, P1651, DOI 10.1074/jbc.271.3.1651; Okladnova O, 1997, GENOMICS, V42, P452, DOI 10.1006/geno.1997.4735; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; PAHL HL, 1999, IN PRESS PHYS REV; Pak J, 1996, J VIROL, V70, P4167, DOI 10.1128/JVI.70.6.4167-4172.1996; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pan ZXK, 1998, BBA-GENE STRUCT EXPR, V1443, P90, DOI 10.1016/S0167-4781(98)00198-5; PAUL NL, 1990, J VIROL, V64, P5412, DOI 10.1128/JVI.64.11.5412-5419.1990; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; Phi VL, 1996, BIOCHEMI J, V313, P39; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Post A, 1998, J NEUROSCI, V18, P8236; Pugin J, 1998, AM J PHYSIOL-LUNG C, V275, pL1040, DOI 10.1152/ajplung.1998.275.6.L1040; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; RAJAVASHISTH TB, 1995, ARTERIOSCL THROM VAS, V15, P1591, DOI 10.1161/01.ATV.15.10.1591; Ramesh GT, 1999, TOXICOL APPL PHARM, V155, P280, DOI 10.1006/taap.1999.8624; RANGANATHAN PN, 1993, NUCLEIC ACIDS RES, V21, P1959, DOI 10.1093/nar/21.8.1959; RATTNER A, 1991, MOL CELL BIOL, V11, P1017, DOI 10.1128/MCB.11.2.1017; Rawadi G, 1999, J IMMUNOL, V162, P2193; RAY A, 1995, J BIOL CHEM, V270, P29201, DOI 10.1074/jbc.270.49.29201; REIKERSTORFER A, 1995, J BIOL CHEM, V270, P17645, DOI 10.1074/jbc.270.30.17645; RENSINGEHL A, 1995, J INFLAMM, V45, P161; Richards ML, 1997, J IMMUNOL, V158, P263; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; RONG BL, 1992, VIROLOGY, V189, P750, DOI 10.1016/0042-6822(92)90599-K; Ronni T, 1997, J IMMUNOL, V158, P2363; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; Santee SM, 1996, J BIOL CHEM, V271, P21151, DOI 10.1074/jbc.271.35.21151; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; SCALA G, 1993, J VIROL, V67, P2853, DOI 10.1128/JVI.67.5.2853-2861.1993; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schanstra JP, 1998, J CLIN INVEST, V101, P2080, DOI 10.1172/JCI1359; Schmidt KN, 1996, J IMMUNOL, V156, P4514; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SCHRECK R, 1992, CLIN EXP IMMUNOL, V90, P188; Schumann R R, 1995, Prog Clin Biol Res, V392, P297; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Shea LM, 1996, J IMMUNOL, V157, P3902; Shen BJ, 1997, DNA CELL BIOL, V16, P703, DOI 10.1089/dna.1997.16.703; Shenkar R, 1997, AM J RESP CELL MOL, V16, P145, DOI 10.1165/ajrcmb.16.2.9032121; Shenkar R, 1996, AM J PHYSIOL-LUNG C, V270, pL729, DOI 10.1152/ajplung.1996.270.5.L729; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SHURMAN L, 1989, J IMMUNOL, V143, P3806; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; Simoni J, 1998, ASAIO J, V44, pM356, DOI 10.1097/00002480-199809000-00007; SMITH CS, 1994, CELL IMMUNOL, V155, P292, DOI 10.1006/cimm.1994.1123; SMITH MF, 1994, J IMMUNOL, V153, P3584; Sporn LA, 1997, INFECT IMMUN, V65, P2786, DOI 10.1128/IAI.65.7.2786-2791.1997; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; Steinle AU, 1999, GASTROENTEROLOGY, V116, P420, DOI 10.1016/S0016-5085(99)70140-X; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Sugano N, 1997, J EXP MED, V186, P731, DOI 10.1084/jem.186.5.731; Sultana C, 1999, J CELL PHYSIOL, V179, P67, DOI 10.1002/(SICI)1097-4652(199904)179:1<67::AID-JCP9>3.0.CO;2-0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suzuki K, 1999, P NATL ACAD SCI USA, V96, P2285, DOI 10.1073/pnas.96.5.2285; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; Szabo G, 1996, DNA CELL BIOL, V15, P1081, DOI 10.1089/dna.1996.15.1081; TAKEUCHI M, 1995, P NATL ACAD SCI USA, V92, P3561, DOI 10.1073/pnas.92.8.3561; TANAKA Y, 1996, J VIROL, V70, P8505; TEN RM, 1993, CR ACAD SCI III-VIE, V316, P496; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Tensen CP, 1999, BBA-GENE STRUCT EXPR, V1446, P167, DOI 10.1016/S0167-4781(99)00084-6; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THEVENIN C, 1990, New Biologist, V2, P793; THIEBLEMONT N, 1995, J IMMUNOL, V155, P4861; Tinnell SB, 1998, INT IMMUNOL, V10, P1529, DOI 10.1093/intimm/10.10.1529; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TREDE NS, 1993, J IMMUNOL, V150, P5604; Tulchinsky E, 1997, J BIOL CHEM, V272, P4828, DOI 10.1074/jbc.272.8.4828; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; UEDA A, 1994, J IMMUNOL, V153, P2052; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Vadlamudi RK, 1998, FEBS LETT, V435, P138, DOI 10.1016/S0014-5793(98)01021-7; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; Walker AK, 1996, ONCOGENE, V12, P2515; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WIDMER U, 1993, J IMMUNOL, V150, P4996; WILLIAMS JL, 1990, EMBO J, V9, P4435, DOI 10.1002/j.1460-2075.1990.tb07894.x; Wolf I, 1998, J BIOL CHEM, V273, P28831, DOI 10.1074/jbc.273.44.28831; WOOD JN, 1995, NEUROSCI LETT, V192, P41, DOI 10.1016/0304-3940(95)11603-T; Worm MM, 1998, EUR J IMMUNOL, V28, P901, DOI 10.1002/(SICI)1521-4141(199803)28:03<901::AID-IMMU901>3.0.CO;2-S; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; WU RL, 1994, J BIOL CHEM, V269, P28450; Xia CL, 1996, BIOCHEM J, V313, P155, DOI 10.1042/bj3130155; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YAN SD, 1994, J BIOL CHEM, V269, P9889; YAO KS, 1995, BIOCHEM PHARMACOL, V49, P275, DOI 10.1016/0006-2952(94)00544-V; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; YE JP, 1995, CARCINOGENESIS, V16, P2401, DOI 10.1093/carcin/16.10.2401; Ye JP, 1999, AM J PHYSIOL-LUNG C, V276, pL426, DOI 10.1152/ajplung.1999.276.3.L426; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855; Yokoyama C, 1996, GENOMICS, V36, P296, DOI 10.1006/geno.1996.0465; You LR, 1999, J VIROL, V73, P1672, DOI 10.1128/JVI.73.2.1672-1681.1999; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; YU DY, 1989, J IMMUNOL, V143, P2395; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHANG DX, 1995, BIOCHEM J, V310, P143, DOI 10.1042/bj3100143; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225; Zhao JL, 1996, J EXP MED, V183, P777, DOI 10.1084/jem.183.3.777; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhu Y, 1997, BBA-LIPID LIPID MET, V1345, P93, DOI 10.1016/S0005-2760(96)00169-5; Zhu YX, 1996, J BIOL CHEM, V271, P15815, DOI 10.1074/jbc.271.26.15815; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	345	3268	3423	2	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	1999	18	49					6853	6866		10.1038/sj.onc.1203239	http://dx.doi.org/10.1038/sj.onc.1203239			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602461				2022-12-28	WOS:000083896500003
J	Bannasch, D; Weis, I; Schwab, M				Bannasch, D; Weis, I; Schwab, M			Nmi protein interacts with regions that differ between MycN and Myc and is localized in the cytoplasm of neuroblastoma cells in contrast to nuclear MycN	ONCOGENE			English	Article						protein-protein interactions; two-hybrid; Max; immunofluorescence; Ga14 DNA binding domain; amplification	C-MYC; N-MYC; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; NEURO-BLASTOMA; IN-VIVO; MAX; GENE; EXPRESSION; AMPLIFICATION	Myc family proteins play an important role in cellular processes such as proliferation, differentiation, apoptosis and transformation. A number of interaction partners of Myc have been identified, such as Max, p107, TBP, YY1, Miz-1, AP-2 and Nmi. Both Max and Nmi also bind to MycN. In contrast to the well defined binding of Max to Myc family proteins the interaction of Nmi with Myc or MycN is only poorly characterized. By employing the yeast two-hybrid system we have mapped the regions of MycN and Myc responsible for binding to Nmi. For MycN exclusively a central region mediates binding to Nmi. In contrast, for Myc a C-terminal portion of the protein, and possibly also a central part, is involved in Nmi interaction. Nmi does not interact with Max and has no transactivation capabilities in yeast, suggesting that Nmi alone is not a transcriptional activator in mammalian cells. Immunofluorescence demonstrates that both in 293 embryonic kidney cells and in Kelly neuroblastoma cells all detectable ectopically expressed Nmi is localized in the cytoplasm, in part in a punctate, granular pattern. MycN, which is highly expressed in Kelly cells consequent to amplification, appears to be localized exclusively in the nuclei. This directly demonstrates that in the same cell at least the major proportion of MycN and Nmi is localized in different cellular compartments. This result is confirmed by the finding that endogenous Nmi, which is expressed in Kelly cells only after stimulation with interferon gamma, is detected exclusively in the cytoplasm of these cells. Therefore only a very small amount of MycN and Nmi is likely to be involved in MycN/Nmi interaction in vivo.	Deutsch Krebsforschungszentrum, Div Cytogenet H0400, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Div Cytogenet H0400, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANNASCH D, 1999, IN PRESS PLASMID, V42; Bao JX, 1996, ONCOGENE, V12, P2171; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CERNI C, 1995, ONCOGENE, V11, P587; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRANDORI C, 1998, TIBS, V22, P177; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Ingvarsson S, 1990, Semin Cancer Biol, V1, P359; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KHANNA R, 1995, MICROBIOL REV, V59, P387, DOI 10.1128/MMBR.59.3.387-405.1995; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; SCHWAB M, 1988, ONCOGENE HDB, P381; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	54	32	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6810	6817		10.1038/sj.onc.1203090	http://dx.doi.org/10.1038/sj.onc.1203090			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597290				2022-12-28	WOS:000083792000024
J	Craig, AL; Blaydes, JP; Burch, LR; Thompson, AM; Hupp, TR				Craig, AL; Blaydes, JP; Burch, LR; Thompson, AM; Hupp, TR			Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation	ONCOGENE			English	Article						p53; transcription; kinase; radiation; phosphorylation	DNA-BINDING FUNCTION; WILD-TYPE P53; PROTEIN; PHOSPHORYLATION; CELLS; DAMAGE; MDM2; TRANSCRIPTION; STABILITY; ACTIVATE	Induction of the transactivation function of p53 after cellular irradiation was studied under conditions in which upstream signaling events modulating p53 activation were uncoupled from those regulating stabilization. This investigation prompted the discovery of a novel radiation-responsive kinase pathway targeting Ser20 that results in the masking of the DO-1 epitope in undamaged cells. Unmasking of the DO-1 epitope via dephosphorylation occurs in response to low doses of nonionizing radiation. Our data show that phosphorylation at Ser20 reduces binding of the mdm2 protein, suggesting that a function of the Ser20-kinase pathway may be to produce a stable pool of inactive p53 in undamaged cells which can be readily activated after cellular injury. Phospho-specific monoclonal antibodies were used to determine whether the Ser20 signaling pathway is coupled to the Ser15 and Ser392 radiation-responsive kinase pathways. These results demonstrated that: (1) dephosphorylation at Ser20 is co-ordinated with an increased steady-state phosphorylation at Ser392 after irradiation, without p53 protein stabilization, and (2) stabilization of p53 protein can occur without Ser15 phosphorylation at higher doses of radiation. These data show that the Ser20 and Ser392 phosphorylation sites are both targeted by an integrated network of signaling pathways which is acutely sensitive to radiation injury.	Univ Dundee, Dundee Canc Res Inst, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Dundee Canc Res Inst, Dept Mol Oncol, Dundee DD1 9SY, Scotland; Univ Dundee, Dundee Canc Res Inst, Dept Surg, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Dundee Canc Res Inst, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Berns EMJJ, 1998, J CLIN ONCOL, V16, P121, DOI 10.1200/JCO.1998.16.1.121; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; BOND J, 1999, IN PRESS ONCOGENE; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; DOVER R, 1994, J CELL SCI, V107, P1181; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Oren M, 1996, BBA-REV CANCER, V1288, pR13, DOI 10.1016/S0304-419X(96)00030-3; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; THOMPSON AM, 1998, BRIT J SURG, V82, P210; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VOJTESEK B, 1995, ONCOGENE, V10, P389; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	36	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6305	6312		10.1038/sj.onc.1203085	http://dx.doi.org/10.1038/sj.onc.1203085			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597229				2022-12-28	WOS:000083934100014
J	Askham, JM; Moncur, P; Markham, AF; Morrison, EE				Askham, JM; Moncur, P; Markham, AF; Morrison, EE			Regulation and function of the interaction between the APC tumour suppressor protein and EB1	ONCOGENE			English	Article						APC; EB1; cell cycle; mitosis; phosphorylation; microtubules	BINDING PROTEIN; CELL-MIGRATION; FISSION YEAST; PHOSPHORYLATION; MICROTUBULES; P34(CDC2); DYNAMICS; PROMOTES; GENE; TAU	The interaction between the adenomatous polyposis coli (A PC) tumour suppressor and the microtubule-associated protein EB1 was examined, Immunoprecipitation suggested that APC and EB1 were not associated in cultures of HCT116 cells arrested in mitosis, The C-terminal 170 amino acids of APC, purified as a bacterial fusion protein, precipitated EB1 from cell extracts, significantly refining the location of the EB1 interaction domain in APC, In vitro phosphorylation of this fusion protein by either protein kinase A or p34(cdc2) reduced its ability to bind to EB1, Expression of GFP fusions to C-terminal APC sequences Lacking or including the APC basic domain but encompassing the EB1 binding region in SW480 cells revealed a microtubule tip association which co-localized with that of EB1, Expression of the basic domain alone revealed a non-specific microtubule localization. In vitro interaction studies confirmed that the APC basic domain did not contribute to EB1 binding. These findings strongly suggest that the interaction between APC and EB1 targets APC to microtubule tips, and that the interaction between the two proteins is down-regulated during mitosis by the previously described mitotic phosphorylation of APC.	Univ Leeds, St James Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Morrison, EE (corresponding author), Univ Leeds, St James Hosp, Mol Med Unit, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.							ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; Morrison EE, 1998, J VIROL, V72, P7108, DOI 10.1128/JVI.72.9.7108-7114.1998; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1995, CANCER RES, V55, P2972; Trzepacz C, 1997, J BIOL CHEM, V272, P21681, DOI 10.1074/jbc.272.35.21681; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588	24	104	107	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1950	1958		10.1038/sj.onc.1203498	http://dx.doi.org/10.1038/sj.onc.1203498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773885				2022-12-28	WOS:000086424300011
J	Rudolph, B; Hueber, AO; Evan, GI				Rudolph, B; Hueber, AO; Evan, GI			Reversible activation of c-Myc in thymocytes enhances positive selection and induces proliferation and apoptosis in vitro	ONCOGENE			English	Article						switchable c-myc; 4-OHT; T cell development; proliferation; apoptosis	T-CELL-RECEPTOR; TRANSGENIC MICE; CYCLE PROGRESSION; GENE-EXPRESSION; DNA-BINDING; MAX; DIFFERENTIATION; PROTEIN; DELETION; BCL-2	In order to study the effect of c-Myc activation in T lymphocytes in vivo, we generated transgenic mice that express a 4-hydroxytamoxifen (4-OHT)-dependent switchable c-myc oncoprotein under the control of the proximal lck promoter. Activation of c-MycER(TM) causes no obvious alteration in T cell ontogeny. However, using MHC class I restricted H-Y-TCR transgenic mice, we found that c-Myc activation in vivo enhances the efficiency of positive selection. Moreover, splenic T cells derived from lck-c-mycER(TM) transgenic mice in which c-Myc had been activated exhibited increased proliferation in vitro in response to activation with anti-CD3/CD28 antibody. Activation of c-MycER(TM) also promotes apoptosis in thymocytes in vitro.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Evan, GI (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields,POB 123, London WC2A 3PX, England.		Anne-Odile, Hueber/P-9860-2019; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alarcon RM, 1996, CANCER RES, V56, P4315; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BroussardDiehl C, 1996, J IMMUNOL, V156, P3141; CALNAN BJ, 1995, IMMUNITY, V3, P273; CARDING S, 1987, THYMUS, V10, P219; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Furr BJ, 1979, PHARMACOLOGICAL BIOC, V2, P355; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUCAS B, 1993, J IMMUNOL, V151, P4574; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MARRACK P, 1993, IMMUNOL REV, V131, P79, DOI 10.1111/j.1600-065X.1993.tb01531.x; Miyazaki T, 1998, J EXP MED, V188, P715, DOI 10.1084/jem.188.4.715; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; ROBEY EA, 1992, INT IMMUNOL, V4, P969, DOI 10.1093/intimm/4.9.969; Shortman K, 1990, Semin Immunol, V2, P3; SPANOPOULOU E, 1989, NATURE, V342, P185, DOI 10.1038/342185a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	45	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1891	1900		10.1038/sj.onc.1203508	http://dx.doi.org/10.1038/sj.onc.1203508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773879				2022-12-28	WOS:000086424300005
J	De Rosa, M; Fasano, C; Panariello, L; Scarano, MI; Belli, G; Iannelli, A; Ciciliano, F; Izzo, P				De Rosa, M; Fasano, C; Panariello, L; Scarano, MI; Belli, G; Iannelli, A; Ciciliano, F; Izzo, P			Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene	ONCOGENE			English	Article						Turcot syndrome; PMS2 gene; brain and colorectal tumors; microsatellite instability (MIN)	FAMILIAL ADENOMATOUS POLYPOSIS; NONPOLYPOSIS COLORECTAL-CANCER; AUTOSOMAL-DOMINANT INHERITANCE; MISMATCH REPAIR; COLON-CANCER; MUTATOR PHENOTYPE; HOMOLOG; INSTABILITY; TISSUES; TUMORS	Turcot's syndrome is a genetic disease characterized by the concurrence of primary brain tumors and colon cancers and/or multiple colorectal adenomas. We report a Turcot family with no parental consanguinity, in which two affected sisters, with no history of tumors in their parents, died of a brain tumor and of a colorectal tumor, respectively, at a very early age. The proband had a severe microsatellite instability (MIN) phenotype in both tumor and normal colon mucosa, and mutations in the TGF beta-RII and APC genes in the colorectal tumor. We identified two germline mutations within the PMS2 gene: a G deletion (1221delG) in exon 11 and a four-base-pair deletion (2361delCTTC) in exon 14, both of which were inherited from the patient's unaffected parents. These results represent the first evidence that two germline frameshift mutations in PMS2, an MMR gene which is only rarely involved in HNPCC, are not pathogenic per se, but become so when occurring together in a compound heterozygote, The compound heterozygosity for two mutations in the PMS2 gene has implications for the role of protein PMS2 in the mismatch repair mechanism, as well as for the presymptomatic molecular diagnosis of at-risk family members. Furthermore, our data support and enlarge the notion that high DNA instability in normal tissues might trigger the development of cancer in this syndrome.	Univ Naples Federico II, CEINGE Biotecnol Avanzate, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II	Izzo, P (corresponding author), Univ Naples Federico II, CEINGE Biotecnol Avanzate, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.		Fasano, Carlo/R-2913-2016; Iannelli, Antonio/E-6521-2012; De Rosa, Marina/I-5954-2012; Fasano, Carlo/Y-3954-2019	Fasano, Carlo/0000-0002-6368-1398; Fasano, Carlo/0000-0002-6368-1398; Izzo, Paola/0000-0003-1549-0615				BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CRAIL H W, 1949, U S Nav Med Bull, V49, P123; Dietmaier W, 1997, CANCER RES, V57, P4749; DUPUIS MJM, 1995, NEW ENGL J MED, V332, P1518; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; ITOH H, 1993, INT J COLORECTAL DIS, V8, P87, DOI 10.1007/BF00299334; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEWIS JH, 1983, CANCER, V51, P524, DOI 10.1002/1097-0142(19830201)51:3<524::AID-CNCR2820510326>3.0.CO;2-I; MARCOWITZ S, 1995, SCIENCE, V268, P1336; MASTRONARDI L, 1991, NEUROSURGERY, V28, P449, DOI 10.1227/00006123-199103000-00021; Matsui T, 1998, DIS COLON RECTUM, V41, P797, DOI 10.1007/BF02236273; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Panariello L, 1998, Hum Mutat, V12, P216; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Perucho M, 1996, BIOL CHEM, V377, P675; Scarano M I, 1999, Hum Mutat, V13, P256; Scarano MI, 1997, HUM MUTAT, V9, P191, DOI 10.1002/(SICI)1098-1004(1997)9:2<191::AID-HUMU16>3.0.CO;2-Y; TOPS CMJ, 1992, AM J MED GENET, V43, P888, DOI 10.1002/ajmg.1320430528; TURCOT J, 1959, Dis Colon Rectum, V2, P465, DOI 10.1007/BF02616938	28	108	114	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1719	1723		10.1038/sj.onc.1203447	http://dx.doi.org/10.1038/sj.onc.1203447			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763829				2022-12-28	WOS:000086083800012
J	Johnson, BA; Geha, M; Blackwell, TK				Johnson, BA; Geha, M; Blackwell, TK			Similar but distinct effects of the tristetraprolin/TIS11 immediate-early proteins on cell survival	ONCOGENE			English	Article						immediate-early; apoptosis; zinc finger; TNF-alpha; mRNA; growth factor	PRIMARY RESPONSE GENE; FINGER TRANSCRIPTION FACTOR; MESSENGER-RNA DEGRADATION; NECROSIS-FACTOR-ALPHA; C-MYC; YEAST HOMOLOG; DNA-SYNTHESIS; TNF-ALPHA; IN-VIVO; APOPTOSIS	The immediate early protein tristetraprolin (TTP) is required to prevent inappropriate production of the cytokine TNF-alpha, and is a member of a zinc finger protein family that is associated with RNA binding. TTP expression is induced by TNF-alpha, and evidence indicates that TTP can bind and destabilize the TNF-alpha mRNA, TTP and the closely related TIS11b and TIS11d proteins are evolutionarily conserved, however, and induced transiently in various cell types by numerous diverse stimuli, suggesting that they have additional functions. Supporting this idea, continuous expression of each TTP/TIS11 protein at physiological levels causes apoptotic cell death. By various criteria, this cell death appears analogous to apoptosis induced by certain oncoproteins. It is also dependent upon the zinc fingers, suggesting that it involves action on appropriate cellular targets. TTP but not TIS11b or TIS11d also sensitizes cells to induction of apoptosis by TNF-alpha. The data suggest that the TTP and TIS11 immediate early proteins have similar but distinct effects on growth or survival pathways, and that TTP might influence TNF-alpha regulation at multiple levels.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Blackwell, TK (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017461] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD17461] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barabino SML, 1997, GENE DEV, V11, P1703, DOI 10.1101/gad.11.13.1703; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P561; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CORPS AN, 1995, FEBS LETT, V368, P160, DOI 10.1016/0014-5793(95)00635-M; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOMPERTS M, 1992, FEBS LETT, V306, P1, DOI 10.1016/0014-5793(92)80825-2; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guedes S, 1997, DEVELOPMENT, V124, P731; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KANOH J, 1995, MOL BIOL CELL, V6, P1185, DOI 10.1091/mbc.6.9.1185; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; MA QF, 1995, ONCOGENE, V10, P487; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MESNER PW, 1995, J NEUROSCI, V15, P7357; Murray MV, 1997, MOL CELL BIOL, V17, P2291, DOI 10.1128/MCB.17.4.2291; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rudner DZ, 1998, GENE DEV, V12, P1010, DOI 10.1101/gad.12.7.1010; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Tabara H, 1999, DEVELOPMENT, V126, P1; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Thompson MJ, 1996, GENE, V174, P225, DOI 10.1016/0378-1119(96)00084-4; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WARBRICK E, 1994, GENE, V151, P243, DOI 10.1016/0378-1119(94)90664-5; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	56	65	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1657	1664		10.1038/sj.onc.1203474	http://dx.doi.org/10.1038/sj.onc.1203474			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763822				2022-12-28	WOS:000086083800005
J	Leu, CM; Chang, CM; Hu, CP				Leu, CM; Chang, CM; Hu, CP			Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway	ONCOGENE			English	Article						EGF; apoptosis; MAP kinase; Mcl-1; human esophageal carcinoma	HUMAN ESOPHAGEAL-CARCINOMA; SQUAMOUS-CELL CARCINOMAS; BREAST-CANCER-CELLS; HAMSTER OVARY CELLS; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; PROGNOSTIC-SIGNIFICANCE; SIGNAL-TRANSDUCTION; SURVIVAL FACTOR; FACTOR-ALPHA	Overexpression of epidermal growth factor receptor (EGFR) and establishment of transforming growth factor alpha (TGF alpha)/EGF autocrine system are frequently detected in tumor cells. In addition to mitogenic ability, we demonstrate in this report that EGF protects a human esophageal carcinoma (CE) cell line, CE81T/VGH, from staurosporine-induced apoptosis, The anti-apoptotic signal of EGF is alleviated by a MEK inhibitor PK98059 or an ERK2 dominant negative mutant but not by a phosphatidylinositol-3'-kinase (PI-3K) inhibitor wortmannin, Furthermore, v-raf blocks apoptosis induced by staurosporine, This evidence implies that the survival signal of EGF is mediated via the Raf-MEK-ERK pathway but not the PI3-K pathway. The survival effect of EGF is coincident with the induction of mcl-1, an anti-apoptotic gene in the bcl-2 family. PD98059 also suppresses the induction of Mcl-1 by EGF, implying that EGF may up-regulate Mcl-1 via the MAP kinase pathway. Overexpression of mcl-1 is sufficient to protect against apoptosis, while transfection of a mcl-1 antisense plasmid causes cell death. The expression of mcl-1 antisense plasmid also suppresses the anti-apoptotic effect of EGF. Taken together, these results indicate that EGF may up-regulate Mcl-1 through the MAP kinase pathway to suppress apoptosis.	Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Hlth Res Inst, Intramural Res Affairs, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan	Hu, CP (corresponding author), Vet Gen Hosp, Dept Med Res & Educ, 201 Shih Pai Rd,Sec 2, Taipei 11217, Taiwan.		Chang, Chung-Ming/E-3945-2010					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Altmeyer A, 1997, IMMUNITY, V7, P667, DOI 10.1016/S1074-7613(00)80387-8; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BASOLO F, 1992, INT J CANCER, V51, P634, DOI 10.1002/ijc.2910510421; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; CHEN SC, 1991, CANCER RES, V51, P1898; Collette Y, 1997, EUR J IMMUNOL, V27, P3283, DOI 10.1002/eji.1830271227; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dunn SE, 1997, CANCER RES, V57, P2687; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; FITZPATRICK SL, 1984, CANCER RES, V44, P3442; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; HU CP, 1984, J NATL CANCER I, V72, P577; IIHARA K, 1993, CANCER, V71, P2902, DOI 10.1002/1097-0142(19930515)71:10<2902::AID-CNCR2820711004>3.0.CO;2-J; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liu YC, 1996, EXP CELL RES, V228, P206, DOI 10.1006/excr.1996.0318; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Minshall C, 1996, J IMMUNOL, V156, P939; OMURA S, 1995, J ANTIBIOT, V48, P535, DOI 10.7164/antibiotics.48.535; OSTEROP APRM, 1994, BIOCHEMISTRY-US, V33, P7453, DOI 10.1021/bi00189a053; OZAWA S, 1987, INT J CANCER, V39, P333, DOI 10.1002/ijc.2910390311; OZAWA S, 1989, CANCER, V63, P2169, DOI 10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parrizas M, 1997, J BIOL CHEM, V272, P154; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Turner BC, 1997, CANCER RES, V57, P3079; Wang JM, 1999, MOL CELL BIOL, V19, P6195; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Wong Fen-Hwa, 1992, Chinese Journal of Microbiology and Immunology (Taipei), V25, P59; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	57	88	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1665	1675		10.1038/sj.onc.1203452	http://dx.doi.org/10.1038/sj.onc.1203452			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763823				2022-12-28	WOS:000086083800006
J	Gual, P; Giordano, S; Williams, TA; Rocchi, S; Van Obberghen, E; Comoglio, PM				Gual, P; Giordano, S; Williams, TA; Rocchi, S; Van Obberghen, E; Comoglio, PM			Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis	ONCOGENE			English	Article						PLC-gamma; Gab1; HGF; tubulogenesis	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; KIDNEY-CELLS REQUIRES; GRB2 BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RECEPTOR; EPITHELIAL-CELLS; DOCKING PROTEIN; SCATTER FACTOR; MET RECEPTOR	A distinctive property of Hepatocyte Growth Factor (HGF) is its ability to induce differentiation of tubular structures from epithelial and endothelial cells (branching tubulogenesis), The HGF receptor directly activates PI3 kinase, Ras and STAT signalling pathways and phosphorylates the adaptator GRB2 Associated Binder-1 (Gab1), Gab1 is also phosphorylated in response to Epidermal Growth Factor (EGF) but is unable to induce tubule formation. Comparison of P-32-peptide maps of Gab1 from EGF- versus HGF-treated cells, demonstrates that the same sites are phosphorylated in vivo. However, while both EGF and HGF induce rapid tyrosine phosphorylation of Gab1 with a peak at 15 min, the phosphorylation persists for over 1 h, only in response to HGF. Nine tyrosines are phosphorylated by both receptors, Three of them (Y307, Y373, Y407) bind phospholipase C-gamma (PLC-gamma), Interestingly, the overexpression of a Gab1 mutant unable to bind PLC-gamma (Gab1 Y307/373/407F) did not alter HGF-stimulated cell scattering, only partially reduced the growth stimulation but completely abolished HGF-mediated tubulogenesis, It is concluded that sustained recruitment of PLC gamma to Gab1 plays an important role in branching tubulogenesis.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Fac Med, INSERM, U145, F-06107 Nice 2, France	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Gual, P (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Comoglio, Paolo/G-6323-2011; Rocchi, Stephane/O-4152-2016; Gual, Philippe/M-8787-2017; Williams, Tracy/K-5604-2013; Giordano, Silvia/J-9858-2018; Gual, Philippe/P-9833-2019	Rocchi, Stephane/0000-0002-0943-1304; Gual, Philippe/0000-0001-7393-8356; Giordano, Silvia/0000-0003-1854-1086; Gual, Philippe/0000-0001-7393-8356; Williams, Tracy Ann/0000-0002-2388-6444; Comoglio, Paolo/0000-0002-7056-5328				AHARONOV A, 1978, J SUPRAMOL STR CELL, V9, P41, DOI 10.1002/jss.400090105; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HELIN K, 1991, J BIOL CHEM, V266, P8363; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kozu A, 1997, PHARMACEUT RES, V14, P1228, DOI 10.1023/A:1012167126364; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCINTYRE BS, 1995, CELL PROLIFERAT, V28, P45, DOI 10.1111/j.1365-2184.1995.tb00038.x; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; MIZUNO K, 1993, J BIOCHEM-TOKYO, V114, P96, DOI 10.1093/oxfordjournals.jbchem.a124147; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1993, FEBS LETT, V329, P147, DOI 10.1016/0014-5793(93)80212-D; NALDINI L, 1991, ONCOGENE, V6, P501; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P1; Porter VA, 1998, AM J PHYSIOL-CELL PH, V274, pC1346; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TAKAISHI K, 1994, ONCOGENE, V9, P273; Thackeray JR, 1998, DEVELOPMENT, V125, P5033; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	63	140	150	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1509	1518		10.1038/sj.onc.1203514	http://dx.doi.org/10.1038/sj.onc.1203514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734310				2022-12-28	WOS:000086108100003
J	Alimov, A; Kost-Alimova, M; Liu, J; Li, CD; Bergerheim, U; Imreh, S; Klein, G; Zabarovsky, ER				Alimov, A; Kost-Alimova, M; Liu, J; Li, CD; Bergerheim, U; Imreh, S; Klein, G; Zabarovsky, ER			Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma	ONCOGENE			English	Article						tumor suppressor genes; allele titration assay; deletion mapping; human chromosome 3	TUMOR-SUPPRESSOR GENE; COMPARATIVE GENOMIC HYBRIDIZATION; LUNG-CANCER; HOMOZYGOUS DELETION; SHORT ARM; T(3-8) BREAKPOINT; LINKING CLONES; SOLID TUMORS; REGION; CHROMOSOME-3	We have recently developed an allele titration assay (ATA) to assess the sensitivity and influence of normal cell admixture in loss of heterozygosity (LOH) studies based on CA-repeat, The assay showed that these studies are biased by the size-dependent differential sensitivity of allele detection. Based on these data, we have set up new criteria for evaluation of LOH, By combining these new rules with comparative genome hybridization (CGH) we have shown the presence of interstitial deletions in renal cell carcinoma (RCC) biopsies and cell lines, At least three out of 11 analysed RCC cell lines and three out of 37 biopsies contain interstitial deletions on chromosome 3, Our study suggests the presence of several regions on human chromosome 3 that might contribute to tumor development by their loss: (i) 3p25-p26, around the VHL gene (D3S1317); (ii) 3p21.3-p22 (between D3S1260 and D3S1611); (iii) 3p21.2 (around D3S1235 and D3S1289); (iv) 3p13-p14 (around D3S1312 and D3S1285), For the first time, AP20 region (3p21.3-p22) was carefully tested for LOH in RCC, It was found that the AP20 region is the most frequently affected area. Our data also suggest that another tumor suppressor gene is located near the VHL gene in 3p25-p26.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Russian Acad Sci, Engellhardt Inst Mol Biol, Moscow 117984, Russia; Karolinska Hosp, Dept Urol, S-17176 Stockholm, Sweden; Karolinska Inst, Ctr Genom Res, S-17177 Stockholm, Sweden	Karolinska Institutet; Russian Academy of Sciences; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Zabarovsky, ER (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Alimov, Andrei/J-7358-2018; Zabarovsky, Eugene R/A-6645-2010	Li, Chunde/0000-0003-4331-079X; Alimov, Andrei/0000-0002-8495-7728				BEAR A, 1987, CANCER RES, V47, P3856; BERGERHEIM U, 1989, CANCER RES, V49, P1390; Bergerheim USR, 1996, CANCER GENET CYTOGEN, V86, P95, DOI 10.1016/0165-4608(95)00201-4; Chudek J, 1997, INT J CANCER, V73, P225, DOI 10.1002/(SICI)1097-0215(19971009)73:2<225::AID-IJC11>3.3.CO;2-N; DALY MC, 1993, ONCOGENE, V8, P1721; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; GEMMILL RM, 1995, NATURE, V377, P299; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hu LF, 1996, GENE CHROMOSOME CANC, V17, P118, DOI 10.1002/(SICI)1098-2264(199610)17:2<118::AID-GCC7>3.0.CO;2-8; IMREH S, 1994, GENE CHROMOSOME CANC, V11, P237, DOI 10.1002/gcc.2870110406; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; KHOLODNYUK I, 1996, GENE CHROMOSOME CANC, V18, P1; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; LUBINSKI J, 1994, CANCER RES, V54, P3710; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PRESTI JC, 1993, CANCER RES, V53, P5780; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Roche J, 1996, ONCOGENE, V12, P1289; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329; Tomita Y, 1996, INT J CANCER, V66, P322, DOI 10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; vandenBerg A, 1996, CYTOGENET CELL GENET, V72, P225, DOI 10.1159/000134196; vandenBerg A, 1996, GENE CHROMOSOME CANC, V15, P64, DOI 10.1002/(SICI)1098-2264(199601)15:1<64::AID-GCC9>3.0.CO;2-2; VANDENBERG A, 1995, CYTOGENET CELL GENET, V68, P91; VANDERHOUT AH, 1991, GENOMICS, V11, P537, DOI 10.1016/0888-7543(91)90060-R; VANDERHOUT AH, 1993, INT J CANCER, V53, P353; WANG JY, 1994, GENOMICS, V20, P105, DOI 10.1006/geno.1994.1133; Wei MH, 1996, CANCER RES, V56, P1487; WILHELM M, 1995, CANCER RES, V55, P5383; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YANO H, 1988, IN VITRO CELL DEV B, V24, P9	40	72	78	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1392	1399		10.1038/sj.onc.1203449	http://dx.doi.org/10.1038/sj.onc.1203449			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723130				2022-12-28	WOS:000085942700004
J	North, S; El-Ghissassi, F; Pluquet, O; Verhaegh, G; Hainaut, P				North, S; El-Ghissassi, F; Pluquet, O; Verhaegh, G; Hainaut, P			The cytoprotective aminothiol WR1065 activates p21(waf-1) and down regulates cell cycle progression through a p53-dependent pathway	ONCOGENE			English	Article						WR1065; p53; redox control; cell cycle; radioprotection	DNA-BINDING ACTIVITY; P53 PROTEIN; RADIOPROTECTOR WR1065; AMIFOSTINE; WR-1065; MUTATIONS; EXPRESSION; PROTECTION; MODULATION; APOPTOSIS	The phosphoaminothiol WR1065, the active metabolite of the pro-drug amifostine (WR2721), protects cultured cells and tissues against cytotoxic exposure to radiation or chemotherapeutic agents. We show here that WR1065 and the pro-drug WR2721 activate the p53 tumor suppressor protein and induce the expression of the cyclin-dependent kinase inhibitor p21(waf-1) in the breast cancer cell line MCF-7, and in the mouse fibroblast cell line balb/c 3T3, Using two MCF-7 derived cell lines, MN1 and MDD2, we show that induction of p21(waf-1) is detectable in MN1 (expressing a functional p53) but not in MDD2 (p53 disabled). These effects are observed at concentrations of WR1065 (0.5 to 1 mM) identical to those required to protect against cytotoxicity by hydrogen peroxide. Induction of p53 is not prevented by addition of aminoguanidine, an inhibitor of Cu-dependent amine-oxidases which blocks the extra-cellular degradation of WR1065 into toxic metabolites. Moreover, spermidine, a natural polyamine structurally related to amifostine, does not activate p53. Induction of p53 by WR1065 results in a delay in the G1/S transition in MCF-7 and MN-1 cells, but not in the p53 disabled cells MDD2. These data indicate that WR1065, a polyamine analog with thiol anti-oxidant properties, activates a cell cycle check-point involving p53.	Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, F-69372 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.		Verhaegh, Gerald/L-4708-2015; Hainaut, Pierre/B-6018-2012	Verhaegh, Gerald/0000-0003-0227-2280; Hainaut, Pierre/0000-0002-1303-1610				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bacus SS, 1996, ONCOGENE, V12, P2535; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; CALABROJONES PM, 1988, CANCER RES, V48, P3634; Capizzi RL, 1996, EUR J CANCER, V32A, pS5, DOI 10.1016/S0959-8049(96)00333-4; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Clark LS, 1996, CARCINOGENESIS, V17, P2647, DOI 10.1093/carcin/17.12.2647; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRDINA DJ, 1995, CARCINOGENESIS, V16, P767, DOI 10.1093/carcin/16.4.767; GRDINA DJ, 1985, CARCINOGENESIS, V6, P929, DOI 10.1093/carcin/6.6.929; GRDINA DJ, 1994, RADIAT RES, V138, P44, DOI 10.2307/3578845; GRDINA DJ, 1992, CELL PROLIFERAT, V25, P23, DOI 10.1111/j.1365-2184.1992.tb01434.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; KASTAN MB, 1991, CANCER RES, V51, P6304; Korst AEC, 1997, BRIT J CANCER, V75, P1439, DOI 10.1038/bjc.1997.247; Korst AEC, 1998, EUR J CANCER, V34, P412, DOI 10.1016/S0959-8049(97)10012-0; Kramer DL, 1999, CANCER RES, V59, P1278; Leroy D, 1997, J BIOL CHEM, V272, P20820, DOI 10.1074/jbc.272.33.20820; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; List AF, 1998, LEUKEMIA, V12, P1596, DOI 10.1038/sj.leu.2401151; Liu SC, 1997, CARCINOGENESIS, V18, P2457, DOI 10.1093/carcin/18.12.2457; Loignon M, 1997, CANCER RES, V57, P3390; Martinez JD, 1997, CELL GROWTH DIFFER, V8, P941; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEIER T, 1995, BIOCHEM PHARMACOL, V50, P489, DOI 10.1016/0006-2952(95)00164-U; Milligan JR, 1997, RADIAT RES, V148, P325, DOI 10.2307/3579517; Mitchell JLA, 1998, BIOCHEM J, V335, P329, DOI 10.1042/bj3350329; Murley JS, 1997, CELL PROLIFERAT, V30, P283, DOI 10.1046/j.1365-2184.1997.00092.x; Piette J, 1997, BIOL CHEM, V378, P1237; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Schiller JH, 1996, J CLIN ONCOL, V14, P1913, DOI 10.1200/JCO.1996.14.6.1913; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SMOLUK GD, 1988, CANCER RES, V48, P3641; TRESKES M, 1994, EUR J CANCER, V30A, P183, DOI 10.1016/0959-8049(94)90084-1; TRESKES M, 1992, CANCER RES, V52, P2257; VAUGHAN ATM, 1989, BRIT J CANCER, V60, P893, DOI 10.1038/bjc.1989.386; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; WOLOSCHAK GE, 1995, CANCER RES, V55, P4788; WYATT I, 1989, INT J RADIAT BIOL, V55, P463, DOI 10.1080/09553008914550491; YUHAS JM, 1980, CANCER RES, V40, P1519; ZHANG X, 1992, INT J RADIAT ONCOL, V42, P713	47	61	64	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1206	1214		10.1038/sj.onc.1203413	http://dx.doi.org/10.1038/sj.onc.1203413			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713709				2022-12-28	WOS:000085567800011
J	Shao, J; Fujiwara, T; Kadowaki, Y; Fukazawa, T; Waku, T; Itoshima, T; Yamatsuji, T; Nishizaki, M; Roth, JA; Tanaka, N				Shao, J; Fujiwara, T; Kadowaki, Y; Fukazawa, T; Waku, T; Itoshima, T; Yamatsuji, T; Nishizaki, M; Roth, JA; Tanaka, N			Overexpression of the wild-type p53 gene inhibits NF-kappa B activity and synergizes with aspirin to induce apoptosis in human colon cancer cells	ONCOGENE			English	Article						adenovirus vector; p53; NF-kappa B; aspirin; colon cancer	TUMOR-NECROSIS-FACTOR; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; SODIUM-SALICYLATE; EXPRESSION; ALPHA; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; RESISTANCE; PROTEINS	The tumor suppressor gene p53 is a potent transcriptional regulator of genes which are involved in many cellular activities including cell cycle arrest, apoptosis, and angiogenesis, Recent studies have demonstrated that the activation of the transcriptional factor nuclear factor kappa B (NF-kappa B) plays an essential role in preventing apoptotic cell death. In this study, to better understand the mechanism reponsible for the p53-mediated apoptosis, the effect of wild-type p53 (wt-p53) gene transfer on nuclear expression of NF-kappa B was determined in human colon cancer cell lines, A Western blot analysis of nuclear extracts demonstrated that NF-kappa B protein levels in the nuclei were suppressed by the transient expression of the wt-p53 in a dose-dependent manner. Transduced wt-p53 expression increased the cytoplasmic expression of I kappa B alpha as well as its binding ability to NF-kappa B, thus markedly reducing the amount of NF-kappa B that translocated to the nucleus, The decrease in nuclear NF-kappa B protein correlated with the decreased NF-kappa B constitutive activity measured by electrophoretic mobility shift assay. Furthermore, parental cells transfected with NF-kappa B were better protected from cell death induced by the wt-p53 gene transfer. We also found that the wt-p53 gene transfer was synergistic with aspirin (acetylsalicylic acid) in inhibiting NF-kappa B constitutive activity, resulting in enhanced apoptotic cell death. These results suggest that the inhibition of NF-kappa B activity is a plausible mechanism for apoptosis induced by the wt-p53 gene transfer in human colon cancer cells and that anti-NF-kappa B reagent aspirin could make these cells more susceptible to apoptosis.	Okayama Univ, Sch Med, Dept Surg 1, Okayama 7008558, Japan; Okayama Univ, Sch Med, Sect Mol Oncol, Okayama 7008558, Japan; Shiga Univ Med Sci, Dept Surg 1, Shiga 5202192, Japan; Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA	Okayama University; Okayama University; Shiga University of Medical Science; University of Texas System; UTMD Anderson Cancer Center	Fujiwara, T (corresponding author), Okayama Univ, Sch Med, Dept Surg 1, 2-5-1 Shikata Cho, Okayama 7008558, Japan.		Fukazawa, Takuya/GLR-7099-2022					AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bellas RE, 1997, AM J PATHOL, V151, P891; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; FUJIWARA T, 1994, CANCER RES, V54, P2287; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; INSEL PA, 1990, PHARMACOL BASIS THER, P638; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Kochetkova M, 1997, J CLIN INVEST, V99, P3000, DOI 10.1172/JCI119495; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ogawa N, 1997, INT J CANCER, V73, P367, DOI 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A; Ravi R, 1998, CANCER RES, V58, P4531; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wong HR, 1997, J CLIN INVEST, V99, P2423, DOI 10.1172/JCI119425; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374	38	116	121	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					726	736		10.1038/sj.onc.1203383	http://dx.doi.org/10.1038/sj.onc.1203383			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698490				2022-12-28	WOS:000085192100002
J	Nam, SW; Clair, T; Campo, CK; Lee, HY; Liotta, LA; Stracke, ML				Nam, SW; Clair, T; Campo, CK; Lee, HY; Liotta, LA; Stracke, ML			Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells	ONCOGENE			English	Article						autotaxin; invasion; metastasis; motility; ras	MOTILITY-STIMULATING PROTEIN; SURFACE-ANTIGENS; EXPRESSION; CLONING; GROWTH; BRAIN; SITE	Autotaxin (ATX), an exo-nucleotide pyrophosphatase and phosphodiesterase, was originally isolated as a potent stimulator of tumor cell motility. In order to study whether ATX expression affects motility-dependent processes such as invasion and metastasis, we stably transfected full-length ATX cDNA into two nonexpressing cell lines, parental and ras-transformed NIH3T3 (clone7) cells. The effect of ATX secretion on in vitro cell motility was variable, The ras-transformed, ATX-secreting subclones had enhanced motility to ATX as chemoattractant, but there was little difference in the motility responses of NIH3T3 cells transfected with atx, an inactive mutant gene, or empty vector, In MatrigelTM invasion assays, all subclones, which secreted enzymatically active ATX, demonstrated greater spontaneous and ATX-stimulated invasion than appropriate controls. This difference in invasiveness was not caused by differences in gelatinase production, which was constant within each group of transfectants, In vivo studies with athymic nude mice demonstrated that injection of atx-transfected NIH3T3 cells resulted in a weak tumorigenic capacity with few experimental metastases. Combination of ATX expression with ras transformation produced cells with greatly amplified tumorigenesis and metastatic potential compared to ras-transformed controls, Thus, ATX appears to augment cellular characteristics necessary for tumor aggressiveness.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nam, SW (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Room 2A33, Bethesda, MD 20892 USA.			Alewine, Christine/0000-0003-1661-0957				Aznavoorian S, 1996, J BIOL CHEM, V271, P3247, DOI 10.1074/jbc.271.6.3247; Bachner D, 1998, DEV DYNAM, V213, P398; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Deissler H, 1999, FASEB J, V13, P657, DOI 10.1096/fasebj.13.6.657; Deterre P, 1996, J IMMUNOL, V157, P1381; Fuss B, 1997, J NEUROSCI, V17, P9095; Huang RP, 1998, INT J CANCER, V77, P880, DOI 10.1002/(SICI)1097-0215(19980911)77:6<880::AID-IJC14>3.0.CO;2-5; JU WD, 1991, NEW BIOL, V3, P380; Kawagoe H, 1997, CANCER RES, V57, P2516; KINDLERROHRBORN A, 1985, DIFFERENTIATION, V30, P53, DOI 10.1111/j.1432-0436.1985.tb00513.x; KINDLERROHRBORN A, 1994, DIFFERENTIATION, V57, P215, DOI 10.1007/s002580050057; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; Mulvaney PT, 1998, INT J CANCER, V78, P46, DOI 10.1002/(SICI)1097-0215(19980925)78:1<46::AID-IJC9>3.0.CO;2-X; MURATA J, 1994, J BIOL CHEM, V269, P30479; Stefan C, 1999, BBA-MOL CELL RES, V1450, P45, DOI 10.1016/S0167-4889(99)00031-2; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAKAHASHI T, 1970, J EXP MED, V132, P1181, DOI 10.1084/jem.132.6.1181; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	23	152	155	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					241	247		10.1038/sj.onc.1203263	http://dx.doi.org/10.1038/sj.onc.1203263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645002				2022-12-28	WOS:000084844400009
J	Brown, LA; Yang, SH; Hair, A; Galanis, A; Sharrocks, AD				Brown, LA; Yang, SH; Hair, A; Galanis, A; Sharrocks, AD			Molecular characterization of a zebrafish TCF ETS-domain transcription factor	ONCOGENE			English	Article						ETS-domain; ternary complex factor; transcription factors; zebrafish	ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX FACTORS; DNA-BINDING SPECIFICITIES; SERUM RESPONSE ELEMENT; SIGNAL-TRANSDUCTION; FACTORS ELK-1; C-FOS; MAP KINASES; PATHWAYS; P38	The ternary complex factor (TCF) subfamily of ETS-transcription factors represent key nuclear targets of the MAP kinase pathways. Members of this subfamily are classified by the presence of several conserved domains for DNA binding, interaction with SRF, interaction with MAP kinases and transcriptional activation. In this study we have isolated a further member of this subfamily (TCF-1) from zebrafish, The protein product of zebrafish TCF-1 (zTCF-1), shares sequence similarity with the mammalian TCFs in all four conserved domains, with highest overall similarity to SAP-1. Zebrafish TCF-1 is expressed throughout zebrafish embryonic development and exhibits typical TCF DNA binding characteristics, with the B-box being required for interaction with SRF, Of the mammalian TCFs, its DNA binding specificity resembles Elk-1. zTCF-1 is a target for both the growth factor/mitogen-activated and stress-activated MAP kinase cascades in vitro and in vivo. However, differential targeting occurs, with the profile of its activation closely resembling that of mammalian SAP-1, Together, our results demonstrate that the TCFs have been functionally conserved during vertebrate development.	Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Sharrocks, AD (corresponding author), Univ Manchester, Sch Biol Sci, Stoppard Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Galanis, Alex/ABF-4762-2020	Galanis, Alex/0000-0001-9991-3173	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWN AL, 1998, UNPUB MECH DEV; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CANO E, 1995, J CELL SCI, V108, P3599; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GILLE H, 1992, NATURE, V358, P415; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Plant KE, 1996, NUCLEIC ACIDS RES, V24, P3514, DOI 10.1093/nar/24.18.3514; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO VN, 1994, ONCOGENE, V9, P1855; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SETH A, 1992, J BIOL CHEM, V267, P24796; Sgambato V, 1998, J NEUROSCI, V18, P214; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHARROCKS AD, 1995, FEBS LETT, V368, P77, DOI 10.1016/0014-5793(95)00604-8; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHAO LJ, 1993, GENE, V137, P345, DOI 10.1016/0378-1119(93)90032-X	43	11	12	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7985	7993		10.1038/sj.onc.1203197	http://dx.doi.org/10.1038/sj.onc.1203197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637509				2022-12-28	WOS:000084634600007
J	Dermott, JM; Reddy, MVR; Onesime, D; Reddy, EP; Dhanasekaran, N				Dermott, JM; Reddy, MVR; Onesime, D; Reddy, EP; Dhanasekaran, N			Oncogenic mutant of G alpha(12) stimulates cell proliferation through cycloxygenase-2 signaling pathway	ONCOGENE			English	Article						G protein; G alpha(12); oncogene; transformation; signal transduction; COX-2, celebrex, celecoxib	CYTOSOLIC PHOSPHOLIPASE A(2); G-PROTEINS; COOPERATIVE TRANSFORMATION; NIH3T3 CELLS; 3T3 CELLS; EXPRESSION; KINASE; CYCLOOXYGENASE-2; GENE; FIBROBLASTS	Expression of the GTPase-deficient, activated mutant alpha-subunit of the heterotrimeric G protein G12 (G alpha(12)QL) leads to the neoplastic transformation of fibroblast cell lines. The mitogenic pathway regulated by G alpha(12)QL includes an extensive signaling network involving several small GTPases and various kinases. In addition, G alpha(12)QL has been shown to potentiate the serum-induced phospholipase-A(2) activity in NIH3T3 cells. In the present study, we demonstrate that cycloxygenase-2 (COX-2) pathway is involved in the mitogenic pathway activated by G alpha(12)QL Expression of G alpha(12)QL and not G alpha(13)QL, stimulates the serum-induced release of arachidonic acid in NIH3T3 cells. Furthermore, expression of G alpha(12)QL or the stimulation of wild-type G alpha(12) induces the expression of COX-2. Our results also indicate that the COX-2 inhibitor acutely disrupts the DNA-synthesis stimulated by G alpha(12)QL in NIH3T3 cells. These studies, for the first time, identify the crucial role of COX-2 in Gait-mediated regulation of cell proliferation and suggest a role for prostaglandin-derived autocrine loop in G alpha(12)-mediated signaling pathways.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Dennis M, 1997, CEREBROVASC DIS, V7, P22, DOI 10.1159/000108159; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gebauer G, 1999, J CELL BIOCHEM, V75, P547, DOI 10.1002/(SICI)1097-4644(19991215)75:4<547::AID-JCB1>3.3.CO;2-X; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; JIANG H, 1993, FEBS LETT, V3, P319; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Zhang YH, 1996, ONCOGENE, V12, P2377	30	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7185	7189		10.1038/sj.onc.1203345	http://dx.doi.org/10.1038/sj.onc.1203345			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602471				2022-12-28	WOS:000084119400001
J	Allemand, I; Anglo, A; Jeantet, AY; Cerutti, I; May, E				Allemand, I; Anglo, A; Jeantet, AY; Cerutti, I; May, E			Testicular wild-type p53 expression in transgenic mice induces spermiogenesis alterations ranging from differentiation defects to apoptosis	ONCOGENE			English	Article						p53; transgenic mice; spermatogenesis; apoptosis	TUMOR-SUPPRESSOR P53; GERM-CELL DEATH; DNA-DAMAGE; TERATOCARCINOMA CELLS; FUNCTIONAL DOMAIN; DEFICIENT MICE; IRRADIATED RAT; IN-VIVO; SPERMATOGENESIS; RADIATION	While p53 is dispensable for development, an excess of p53 has dramatic consequences on the embryogenesis and on the cell differentiation. In an attempt to analyse in vivo the effects of p53 activity, we have generated transgenic mice expressing the wild-type p53 under the control of the metallothionein I promoter. In the three transgenic lines established, exogenous p53 is expressed constitutively in the postmeiotic cells of transgenic males and two lines are subfertile, Transgenic males expressing the upper level of p53 produce few spermatozoa since the majority of developing spermatids undergo apoptosis, In the subfertile males exhibiting an intermediate amount of p53, teratozoospermia is obvious suggesting an altered terminal differentiation of postmeiotic cells. In contrast lower level of p53 does not lead the third line to sterility. These results suggest that the activity of p53 is dependent irt vivo on the amount of p53 present within cells, as it has been already demonstrated in vitro.	CEA, DSV, DRR, Lab Cancerogenese Mol,UMR 217,CNRS, F-92265 Fontenay Aux Roses, France; Univ Paris 06, Lab Cytophysiol Analyt, F-75006 Paris, France; Inst Rech Sci Canc, SEAT, F-94801 Villejuif, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Allemand, I (corresponding author), CEA, DSV, DRR, Lab Radiobiol Cellules Germinales, BP6, F-92265 Fontenay Aux Roses, France.			allemand, isabelle/0000-0002-8861-7632				Adachi J, 1998, CELL DEATH DIFFER, V5, P148, DOI 10.1038/sj.cdd.4400325; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Beumer TL, 1997, MOL REPROD DEV, V47, P240, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;240::AID-MRD2&gt;3.0.CO;2-L; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; BlancoRodriguez J, 1996, CELL PROLIFERAT, V29, P13, DOI 10.1046/j.1365-2184.1996.d01-5.x; BRAUN RE, 1989, NATURE, V337, P373, DOI 10.1038/337373a0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chresta CM, 1996, CANCER RES, V56, P1834; DE SK, 1991, MOL ENDOCRINOL, V5, P628, DOI 10.1210/mend-5-5-628; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERSTEN K, 1997, NAT GENET, V378, P378; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gromoll J, 1997, BIOL REPROD, V57, P1312, DOI 10.1095/biolreprod57.6.1312; HALL PA, 1997, CURR BIOL, V7, P144; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hendry JH, 1996, INT J RADIAT BIOL, V70, P677, DOI 10.1080/095530096144563; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MacCallum DE, 1996, ONCOGENE, V13, P2575; MIYASHITA T, 1995, CELL, V80, P293; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Odorisio T, 1998, NAT GENET, V18, P257, DOI 10.1038/ng0398-257; Orlovskaya EI, 1997, MOL BIOL+, V31, P184; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PENG HQ, 1993, CANCER RES, V53, P3574; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; RHEE K, 1995, DEV DYNAM, V204, P406, DOI 10.1002/aja.1002040407; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SassoneCorsi P, 1997, CELL, V88, P163, DOI 10.1016/S0092-8674(00)81834-6; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; Sjoblom T, 1996, ONCOGENE, V12, P2499; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; West A, 1997, INT J RADIAT BIOL, V71, P283, DOI 10.1080/095530097144166; WILLIE AH, 1992, CANCER METAST REV, V11, P95; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zheng H, 1997, INT J RADIAT BIOL, V71, P275, DOI 10.1080/095530097144157; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	61	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6521	6530		10.1038/sj.onc.1203052	http://dx.doi.org/10.1038/sj.onc.1203052			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597255				2022-12-28	WOS:000083709200015
J	Yang, XH; He, ZM; Xin, BZ; Cao, L				Yang, XH; He, ZM; Xin, BZ; Cao, L			LMP1 of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16(INK4a) expression	ONCOGENE			English	Article						EBV/LMP1; senescense; p16(INK4a); p21(WAF1)	LYMPHOCYTE GROWTH TRANSFORMATION; LATENT MEMBRANE PROTEIN-1; NF-KAPPA-B; HUMAN-DIPLOID FIBROBLASTS; REPLICATIVE SENESCENCE; NASOPHARYNGEAL CARCINOMAS; TUMOR-SUPPRESSOR; POINT MUTATION; P53 GENE; CELLS	Epstein-Barr virus is associated with a number of human proliferative and malignant diseases. It is capable of immortalizing human primary B-lymphocytes in vitro. Studies indicate that latent membrane protein LMP1 is one of the viral proteins essential for this process. In this report, LMP1 was shown to prevent primary mouse embryonic fibroblasts from entering into replicative senescence in vitro. It further suppresses the senescence-associated induction of p16(INK4a), commonly believed to be a key regulator of replicative senescence. In addition, LMP1 was shown to prevent premature senescence provoked by oncogenic ras in mouse embryonic fibroblasts, and to inhibit the oncogene ras-mediated induction of p16(INK4a) and p21(WAF1). In parallel, LMP1 also prevents ras-induced premature senescence in rat embryonic fibroblasts REF52 and human diploid fibroblasts IMR90. Moreover, LMP1 is capable of suppressing the p16(INK4a) promoter in REF52 and Saos-2 cells in a promoter reporter assay. Our findings suggest that with the expression of p16(INK4a) and replicative senescence being suppressed, LMP1 may play a key role in Epstein-Barr virus-associated proliferative diseases, and it may further contribute to cancer development by preventing premature senescence induced by mitogenic oncogenes.	Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Cao, L (corresponding author), Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.		Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BAICHWAL VR, 1989, ONCOGENE, V4, P67; Bond J, 1996, ONCOGENE, V13, P2097; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; Gulley ML, 1998, AM J PATHOL, V152, P865; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARVEY M, 1993, ONCOGENE, V8, P2457; HAUSEN HZ, 1970, NATURE, V227, P245, DOI 10.1038/227245a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENLE G, 1969, J NATL CANCER I, V43, P1147; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JARRETT RF, 1991, J CLIN PATHOL, V44, P844, DOI 10.1136/jcp.44.10.844; Kaye KM, 1999, J VIROL, V73, P10525, DOI 10.1128/JVI.73.12.10525-10530.1999; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PURTILO DT, 1975, LANCET, V1, P936; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SPRUCK CH, 1992, CANCER RES, V52, P4787; Stein GH, 1999, MOL CELL BIOL, V19, P2109; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1995, ONCOGENE, V10, P785; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Yang XH, 2000, J VIROL, V74, P883, DOI 10.1128/JVI.74.2.883-891.2000; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	70	58	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2000	19	16					2002	2013		10.1038/sj.onc.1203515	http://dx.doi.org/10.1038/sj.onc.1203515			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803461				2022-12-28	WOS:000086613200004
J	Roth, J; Koch, P; Contente, A; Dobbelstein, M				Roth, J; Koch, P; Contente, A; Dobbelstein, M			Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain	ONCOGENE			English	Article						p53; apoptosis; transcriptional activation; protein-DNA-interaction; p73	FUNCTIONAL DOMAINS; GROWTH SUPPRESSION; CRYSTAL-STRUCTURE; CERVICAL-CANCER; WILD-TYPE; APOPTOSIS; PROTEIN; GENE; POLYMORPHISM; REGION	The p53 tumor suppressor protein induces apoptosis through a mechanism that may involve the transcriptional activation of cellular genes, including the PIG3 gene. A p53 protein lacking the proline-rich region (p53 Delta 62-91) induces many p53-responsive genes but not PIG3, In parallel, this mutant induces growth arrest but not apoptosis, We show here that the replacement of the N-terminal (amino acids 1-80) or C-terminal (amino acids 344-393) domains of p53 with heterologous domains does not interfere with transcription from the PIG3 promoter, but these chimeras still require the proline-rich region for PIG3 activation. The p53-homolog p73 beta also activated the PIG3 promoter, but in contrast to p53, the proline-rich domain of p73 beta (residues 81-113) was dispensable to induce the PIG3 promoter, Some tumor-derived p53-mutants, especially M246I, retained the ability to activate transcription of mdm2 but specifically failed to induce the PIG3 promoter, thus resembling p53 Delta 62-91. Further, p53 Delta 62-91 and p53M246I were defective for induction of apoptosis, Finally, p53 Delta 62-91 and p53M246I both showed reduced binding to the DNA of the PIG3 promoter and also to the DNA of the mdm2 and p21 promoters in vitro. Correspondingly, at low expression levels, p53 Delta 62-91 and p53M246I poorly activated the mdm2 promoter when compared to wild type p53. Our results suggest that the proline-rich domain of p53 affects the ability of the central domain to bind DNA, Moreover, some tumor-derived mutations within the central DNA binding domain of p53 mimic the loss of the proline-rich domain.	Univ Marburg, Inst Virol, Zentrum Mikrobiol & Hyge, D-35037 Marburg, Germany; Univ Marburg, Zentrum Innere Med, Abt Gastroenterol & Stoffwechsel, Fachbereich Med, D-35043 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Zentrum Mikrobiol & Hyge, Robert Koch Str 17, D-35037 Marburg, Germany.		Koch, Philipp/AAZ-3751-2020	Dobbelstein, Matthias/0000-0001-5052-3967; Koch, Philipp/0000-0003-3713-8786				Agami R, 1999, NATURE, V399, P809; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Dobbelstein M, 1996, J VIROL, V70, P6479, DOI 10.1128/JVI.70.9.6479-6485.1996; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; Gong JG, 1999, NATURE, V399, P806; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON P, 1993, ONCOGENE, V8, P589; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Konig C, 1999, J VIROL, V73, P2253; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Minaguchi T, 1998, CANCER RES, V58, P4585; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rosenthal AN, 1998, LANCET, V352, P871, DOI 10.1016/S0140-6736(98)07357-7; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Sun XF, 1996, ONCOGENE, V13, P407; Taylor JA, 1996, CANCER RES, V56, P294; Thomas M, 1999, MOL CELL BIOL, V19, P1092; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	44	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1834	1842		10.1038/sj.onc.1203500	http://dx.doi.org/10.1038/sj.onc.1203500			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777217				2022-12-28	WOS:000086292500011
J	Kratzer, F; Rosorius, O; Heger, P; Hirschmann, N; Dobner, T; Hauber, J; Stauber, RH				Kratzer, F; Rosorius, O; Heger, P; Hirschmann, N; Dobner, T; Hauber, J; Stauber, RH			The adenovirus type 5 E1B-55K oncoprotein is a highly active shuttle protein and shuttling is independent of E4orf6, p53 and Mdm2	ONCOGENE			English	Article						adenovirus; nucleo-cytoplasmic transport; oncoproteins; GFP	REGION-4 34-KILODALTON PROTEIN; NUCLEAR EXPORT; 55-KILODALTON PROTEIN; MESSENGER-RNAS; INFECTED-CELLS; TRANSFORMED-CELLS; TUMOR-ANTIGEN; LIVING CELLS; REV PROTEIN; SEQUENCE	The E1B-55K and E4orf6 oncoproteins of adenovirus type 5 are involved in the export of viral mRNAs, Previously, it cr as suggested that a complex composed of E1B-55K and E4orf6 serves as a nucleocytoplasmic transporter for viral mRNAs in which the E4orf6 protein directs both nuclear import and export, We now demonstrate that the E1B-55K protein itself shuttles efficiently in the absence of E4orf6, In addition, E1B-55K trafficking was independent of the defined shuttle proteins Mdm2 or p53, which interacts with E1B-55K, The identified N-terminal E1B-55K leucine-rich nuclear-export signal (NES) conferred rapid nuclear export even in a heterologous system in contrast to the postulated E4orf6NES, Interestingly, although shuttling was blocked by inhibitors of the CRM1 mediated export pathway, E1B-55K inhibited neither the activity nor the trafficking of the retroviral shuttle proteins HIV-1 Rev and HTLV-1 Rex, In contrast, Rev or Rex blocked the nuclear export of E1B-55K, most likely by competing for essential export factors, Our results provide new insights into the regulation of the adenovirus mRNA export system and the processes of adenovirus mediated transformation.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany	University of Erlangen Nuremberg; University of Regensburg	Stauber, RH (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.			Stauber, Roland/0000-0002-1341-4523; Heger, Peter/0000-0003-2583-2981				Aranda M, 1998, VIROLOGY, V243, P261, DOI 10.1006/viro.1998.9032; BABICH A, 1983, MOL CELL BIOL, V3, P1212, DOI 10.1128/MCB.3.7.1212; Bevec D, 1997, BIOL SIGNAL, V6, P124; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DIX I, 1993, J VIROL, V67, P3226, DOI 10.1128/JVI.67.6.3226-3231.1993; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Felber BK, 1997, MOD CELL B, V17, P323; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FUJITA A, 1995, J VIROL, V69, P6180, DOI 10.1128/JVI.69.10.6180-6190.1995; Ginsberg HS, 1999, P NATL ACAD SCI USA, V96, P10409, DOI 10.1073/pnas.96.18.10409; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heger P, 1999, ONCOGENE, V18, P4080, DOI 10.1038/sj.onc.1202762; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; Horridge JJ, 1998, J VIROL, V72, P9374, DOI 10.1128/JVI.72.11.9374-9379.1998; Huang W, 1998, J VIROL, V72, P225, DOI 10.1128/JVI.72.1.225-235.1998; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; Kirn D, 1999, NAT MED, V5, P991, DOI 10.1038/12426; Konig C, 1999, J VIROL, V73, P2253; Leppard KN, 1998, SEMIN VIROL, V8, P301, DOI 10.1006/smvy.1997.0132; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; LEPPARD KN, 1993, J GEN VIROL, V74, P575, DOI 10.1099/0022-1317-74-4-575; Liao DQ, 1999, VIROLOGY, V254, P11, DOI 10.1006/viro.1998.9512; Logan J, 1984, CANCER CELL, V2, P527; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NORDQVIST K, 1994, MOL CELL BIOL, V14, P437, DOI 10.1128/MCB.14.1.437; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Rosorius O, 1999, J CELL SCI, V112, P2369; Rosorius O, 1999, BIOTECHNIQUES, V27, P350, DOI 10.2144/99272rr02; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHENK T, 1996, VIROLOGY, P2111; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Stewart AK, 1999, GENE THER, V6, P350, DOI 10.1038/sj.gt.3300833; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Yang UC, 1996, J VIROL, V70, P4071, DOI 10.1128/JVI.70.6.4071-4080.1996; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	60	84	85	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					850	857		10.1038/sj.onc.1203395	http://dx.doi.org/10.1038/sj.onc.1203395			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702793				2022-12-28	WOS:000085567700002
J	Manganini, M; Maier, JAM				Manganini, M; Maier, JAM			Transforming growth factor beta(2) inhibition of hepatocyte growth factor-induced endothelial proliferation and migration	ONCOGENE			English	Article						Hepatocyte Growth Factor; Met; signal transduction; endothelial cells	BLOOD-VESSEL FORMATION; KINASE IN-VITRO; TYROSINE KINASE; SCATTER FACTOR; MET RECEPTOR; C-MET; CELLS; PROTEIN; PHOSPHORYLATION; ACTIVATION	Angiogenesis is a highly controlled event,which depends on the proper equilibrium of activators and inhibitors present within the microenvironment, Hepatocyte Growth Factor (HGF) activates migration and proliferation of endothelial cells and is angiogenic, acting through the tyrosine kinase receptor encoded by the Met protooncogene. To get insights into the molecular mechanisms involved in HGF-induced angiogenesis, we searched for cDNAs differentially expressed in human endothelial cells exposed to HGF, a potent angiogenic factor. We found that HGF-treated endothelial cells upregulated the expression of Transforming Growth Factor (TGF) beta(2). To understand the significance of this finding, we cultured endothelial cells with HGF and TGF pi simultaneously. We found that TGF beta(2) impairs HGF-dependent proliferative and migratory responses, TGF Pt did not prevent the tyrosine phosphorylation of R-let, but it inhibited some signalling pathways activated by HGF. We show that endothelial proliferation induced by HGF required the activation of the MAPK cascade, while HGF-induced endothelial migration,vas dependent on the tyrosine phosphorylation of Src. Indeed, TGF beta(2), inhibited HGF effects because it prevented HGF-induced MAP kinase activation and tyrosine phosphorylation of Src. We suggest that the induction of TGF beta(2), by HGF in endothelial cells may represent a physiologic mechanism to counterbalance HGF angiogenic activity.	Univ Milan, Dept Biomed Sci & Technol, I-20133 Milan, Italy	University of Milan	Maier, JAM (corresponding author), Univ Milan, Dept Biomed Sci & Technol, Via Olgettina 60, I-20133 Milan, Italy.		Maier, Jeanette AM/H-4820-2012	Maier, Jeanette AM/0000-0002-6326-9221				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ATFI A, 1994, J BIOL CHEM, V269, P30688; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cary LA, 1996, J CELL SCI, V109, P1787; Consalez GG, 1996, TRENDS GENET, V12, P455; Dragoni I, 1998, J BIOL CHEM, V273, P31119, DOI 10.1074/jbc.273.47.31119; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fukuda K, 1998, ONCOGENE, V16, P3349, DOI 10.1038/sj.onc.1201896; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Maier JAM, 1996, ONCOGENE, V13, P1009; Maniatis T., 1982, MOL CLONING LAB MANU; MCCARTHY SA, 1991, TRENDS PHARMACOL SCI, V12, P462, DOI 10.1016/0165-6147(91)90637-8; MERWIN JR, 1991, AM J PATHOL, V138, P37; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PAZDRAK K, 1995, J IMMUNOL, V155, P4454; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wu ZH, 1998, AM J PATHOL, V152, P1599; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	36	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					124	133		10.1038/sj.onc.1203225	http://dx.doi.org/10.1038/sj.onc.1203225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644987				2022-12-28	WOS:000084844300014
J	Massimi, P; Pim, D; Bertoli, C; Bouvard, V; Banks, L				Massimi, P; Pim, D; Bertoli, C; Bouvard, V; Banks, L			Interaction between the HPV-16 E2 transcriptional activator and p53	ONCOGENE			English	Article						HPV; E2; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; ONCOGENIC HUMAN PAPILLOMAVIRUSES; ADENOVIRUS-INFECTED CELLS; DNA-REPLICATION; ESTROGEN-RECEPTOR; VIRAL REPLICATION; PROTEIN; BINDING; TRANSACTIVATION; EXPRESSION	The HPV-16 E2 protein is a major regulator of viral DNA replication and gene expression. Through interactions with the viral origin binding protein, El, it localizes El to the origin of replication and stimulates the initiation of viral DNA replication. However, several recent reports have described a number of diverse activities of E2 relating to the induction of apoptosis through both p53 dependent and independent mechanisms, and to induction of growth arrest in both the G1 and G2M phases of the cell cycle. Recent studies have also shown that p53 can specifically inhibit HPV DNA replication, albeit through an unknown mechanism. Since p53 has been described in the replication centres of Herpes Viruses, Adenovirus and SV40 we decided to investigate whether any of the above activities of E2 may be related to an association with p53. We show, in a series of in vitro assays, specific interaction between p53 and HPV-16 E2 via residues in the carboxy terminal half of the E2 protein. Mutational analysis of p53 indicates that sequences in both the DIVA binding and oligomerization domains are essential for the interaction, and a mutant of p53 which is unable to bind E2 is also unable to inhibit HPV DNA replication. Finally, using an inducible system of p53 expression we also show that E2 will complex with p53 in vivo. These results raise the intriguing possibility that p53 may also be involved in HPV DNA replication centres, and also provides explanations for some of the diverse activities reported for the HPV E2 proteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; CEA, Ctr Etude Nucl, DSV, DRR,UMR 217 CNRS,Lab Cancerogenese Mol, F-92265 Fontenay Aux Roses, France	International Center for Genetic Engineering & Biotechnology (ICGEB); CEA	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; HEDGE RS, 1992, NATURE, V359, P505; Hwang ES, 1996, ONCOGENE, V12, P795; Konig C, 1999, J VIROL, V73, P2253; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Piccini A, 1997, J GEN VIROL, V78, P1963, DOI 10.1099/0022-1317-78-8-1963; PICCINI A, 1995, J GEN VIROL, V61, P1630; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, P69; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; REMM M, 1992, NUCLEIC ACIDS RES, V20, P6015, DOI 10.1093/nar/20.22.6015; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; TARUNINA M, 1993, ONCOGENE, V8, P3165; Thomas M, 1996, ONCOGENE, V13, P471; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhong L, 1997, J VIROL, V71, P3146, DOI 10.1128/JVI.71.4.3146-3160.1997	43	66	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7748	7754		10.1038/sj.onc.1203208	http://dx.doi.org/10.1038/sj.onc.1203208			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618715				2022-12-28	WOS:000084256900004
J	Kriebel, P; Patel, BKR; Nelson, SA; Grusby, MJ; LaRochelle, WJ				Kriebel, P; Patel, BKR; Nelson, SA; Grusby, MJ; LaRochelle, WJ			Consequences of Stat6 deletion on Sis/PDGF- and IL-4-induced proliferation and transcriptional activation in murine fibroblasts	ONCOGENE			English	Article						PDGF; IL-4; Stat-6; transcriptional activation	SIMIAN SARCOMA-VIRUS; HUMAN RECOMBINANT INTERLEUKIN-4; GROWTH-FACTOR RECEPTORS; JAK-3 JANUS KINASE; NF-KAPPA-B; TYROSINE PHOSPHORYLATION; FACTOR-I; HEMATOPOIETIC-CELLS; MYELOID CELLS; GENE	Aberrant communication among growth factors and cytokines that regulate tissue homeostasis often results in malignancy. Among the many cell types that participate in this process, stromal fibroblasts communicate in a paracrine and juxtracrine manner with cells of epithelial, endothelial, and hematopoietic origin. For fibroblasts, platelet-derived growth factor (PDGF) is a major proliferative and differentiation agent, Interleukin-4 (IL-4), however, possesses only modulating functions in this cell type. Here, we investigated the consequences of deleting Stat6 on PDGF and IL-4 signaling, proliferation, and transcriptional activation by establishing and characterizing early passage fibroblasts from wild-type and Stat6 null mice. Both wild-type and Stat6(-/-) fibroblasts showed nearly identical PDGFR and IL-4R activation, gross substrate tyrosine phosphorylation, PI 3-kinase activation, as well as Stat1, 3 and 5 DNA binding activities. Unexpectedly, IL-4's enhancement of PDGF-induced [H-3]thymidine incorporation was greatly diminished in Stat6(-/-), but not wild-type fibroblasts, PDGF-induced [H-3]thymidine uptake was largely unaffected. Strikingly, IL-3, but not PDGF induction of the proinflammatory gene products, IL-6 and MCP-1 was markedly reduced in Stat6(-/-) fibroblasts. Thus, Stat6 is an important and specific mediator of IL-1-enhanced PDGF-induced proliferation as well as IL-4's transcriptional activation of IL-6 and MCP-1.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health	LaRochelle, WJ (corresponding author), NCI, Cellular & Mol Biol Lab, Bldg 37,Room 1E24, Bethesda, MD 20892 USA.		Nelson, Stefanie/GRN-7686-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040171, R01AI040171] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40171] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Betsholtz C, 1997, KIDNEY INT, V51, P1361, DOI 10.1038/ki.1997.186; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; Dirks RPH, 1996, MOL BIOL REP, V22, P1, DOI 10.1007/BF00996300; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; FEGHALI CA, 1992, CLIN IMMUNOL IMMUNOP, V63, P182, DOI 10.1016/0090-1229(92)90011-C; FLEMING TP, 1992, CANCER RES, V52, P4550; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HONDA M, 1992, J IMMUNOL, V148, P2175; HOU J, 1994, SCIENCE, V165, P1701; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAPLAN MH, 1996, IMMUNITY, V4, P1; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LEEK RD, 1994, J LEUKOCYTE BIOL, V56, P423, DOI 10.1002/jlb.56.4.423; NEEDLEMAN BW, 1992, ARTHRITIS RHEUM, V35, P67, DOI 10.1002/art.1780350111; NELSON SA, 1999, SOURCEBOOK ASBESTOS, V19, P291; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; OHARA J, 1988, P NATL ACAD SCI USA, V85, P8221, DOI 10.1073/pnas.85.21.8221; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; OWEN AJ, 1982, P NATL ACAD SCI-BIOL, V79, P3203, DOI 10.1073/pnas.79.10.3203; Paquet P, 1996, INT ARCH ALLERGY IMM, V109, P308, DOI 10.1159/000237257; Patel BKR, 1998, GENOMICS, V52, P192, DOI 10.1006/geno.1998.5436; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Paul WE, 1997, CIBA F SYMP, V204, P208; Peden K, 1987, Prog Clin Biol Res, V253, P101; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROTH M, 1995, P NATL ACAD SCI USA, V92, P1312, DOI 10.1073/pnas.92.5.1312; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takemura H, 1998, J RHEUMATOL, V25, P1534; Trautmann A, 1998, J IMMUNOL, V160, P5053; VANDERMEEREN A, 1993, AM J RESP CELL MOL, V8, P214, DOI 10.1165/ajrcmb/8.2.214; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VIGNAUD JM, 1994, CANCER RES, V54, P5455; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	65	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7294	7302		10.1038/sj.onc.1203148	http://dx.doi.org/10.1038/sj.onc.1203148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602484				2022-12-28	WOS:000084119400014
J	Chen, FE; Ghosh, G				Chen, FE; Ghosh, G			Regulation of DNA binding by Rel/NF-kappa B transcription factors: structural views	ONCOGENE			English	Review						Rel; NF-kappa B; I kappa B; DNA; structure; transcription	FACTOR NF-KAPPA; V-REL; DIMERIZATION DOMAINS; CRYSTAL-STRUCTURE; C-REL; P65; ACTIVATION; HOMODIMER; COMPLEX; P50	Rel/NF-kappa B transcription factors form homo- and heterodimers with different DNA binding site specificities and DNA binding affinities. Several intracellular pathways evoked by a wide range of biological factors and environmental conditions can lead to the activation of Rel/NF-kappa B dimers by signaling degradation of the inhibitory I kappa B protein. In the nucleus Rel/NF-kappa B dimers modulate the expression of a variety of genes including those encoding cytokines, growth factors, acute phase response proteins, immunoreceptors, other transcription factors, cell adhesion molecules, viral proteins and regulators of apoptosis, The primary focus of this review is on structural and functional aspects of Rel/NF kappa B:DNA complexes and their formation. The salient features of the Rel/NF-kappa B dimer:DNA structure are described, as are modes of transcriptional regulation by phosphorylation, altered DNA binding properties, varying protein conformations, and interactions with I kappa B proteins.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr,MC 0359, La Jolla, CA 92093 USA.				NCI NIH HHS [CA71871] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071871] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; COLEMAN TA, 1993, MOL CELL BIOL, V13, P3850, DOI 10.1128/MCB.13.7.3850; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HRDLICKOVA R, 1995, J VIROL, V69, P3369; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tisne C, 1998, J MOL BIOL, V279, P127, DOI 10.1006/jmbi.1998.1757; Tisne C, 1999, BIOCHEMISTRY-US, V38, P3883, DOI 10.1021/bi982402d; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; ZABEL U, 1991, J BIOL CHEM, V266, P252; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	38	251	258	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6845	6852		10.1038/sj.onc.1203224	http://dx.doi.org/10.1038/sj.onc.1203224			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602460				2022-12-28	WOS:000083896500002
J	Wang, YZ; Wharton, W; Garcia, R; Kraker, A; Jove, R; Pledger, WU				Wang, YZ; Wharton, W; Garcia, R; Kraker, A; Jove, R; Pledger, WU			Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity	ONCOGENE			English	Article						PDGF; STATs; Src	PROTEIN-TYROSINE KINASE; STIMULATING FACTOR-RECEPTOR; FACTOR-ALPHA RECEPTOR; CELL-PROLIFERATION; PDGF RECEPTOR; C-SRC; PHOSPHORYLATION SITES; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC REGION	Members of the STAT family of transcriptional regulators modulate the expression of a variety of gene products that promote cell proliferation, survival and transformation. Although initially identified as mediators of cytokine signaling, the STAT proteins are also activated by, and thus mag contribute to the actions of, polypeptide growth factors. To define the mechanism by which these factors activate STATs, me examined the process of Stat3 activation in Balb/c-3T3 fibroblasts treated with platelet-derived growth factor (PDGF), As STATs are activated by tyrosine phosphorylation, and as PDGF receptors are ligand-activated tyrosine kinases, we considered the possibility that Stat3 interacts with and is phosphorylated by PDGF receptors, We find that Stat3 associates with PDGF beta receptors in both the presence and, surprisingly, the absence of PDGF, Moreover, Stat3 was phosphorylated on tyrosine in PDGF beta receptor immunoprecipitates of PDGF-treated but not untreated cells. Although required, receptor activation was insufficient for Stat3 activation. When added to cells in combination with a pharmacologic agent (PD180970) that specifically inhibits the activity of Src family tyrosine kinases, PDGF did not activate Stat3 as monitored by electrophoretic mobility shift assay. PD180970 did not affect MAPK activation by PDGF or the JAK-dependent activation of Stat3 by interleukin-6, The necessity of Src activity for Stat3 activation by PDGF was further evidenced by data showing the presence of Src in complexes containing both Stat3 and PDGF beta receptors in PDGF-treated cells. These results suggest a novel mechanism of STAT activation in which inactive Stat3 pre-assembles with inactive PDGF receptors, and in response to ligand binding and in a manner dependent on Src kinase activity, is rapidly phosphorylated and activated. Additional data demonstrate that Src kinase activity is also required for PDGF stimulation of DNA synthesis in density-arrested cells.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Med Chem, Ann Arbor, MI 48105 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pfizer	Pledger, WU (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA67360, CA55652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067360, R01CA055652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choudhury GG, 1996, KIDNEY INT, V49, P19, DOI 10.1038/ki.1996.3; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; COATS SR, 1994, BIOCHEM J, V297, P379, DOI 10.1042/bj2970379; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GarciaOlivares A, 1997, ENVIRONMETRICS, V8, P1, DOI 10.1002/(SICI)1099-095X(199701)8:1<1::AID-ENV230>3.3.CO;2-2; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HARRINGTON MA, 1985, J CELL BIOCHEM, V27, P67, DOI 10.1002/jcb.240270202; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; Heldin CH, 1996, CANCER SURV, V27, P7; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Marais R, 1996, CANCER SURV, V27, P101; MARENGERE LEM, 1994, J CELL SCI, P97; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; OLASHAW NE, 1991, J BIOL CHEM, V266, P10234; OLASHAW NE, 1983, NATURE, V306, P272, DOI 10.1038/306272a0; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; Roginskaya V, 1999, LEUKEMIA, V13, P855, DOI 10.1038/sj.leu.2401429; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	63	100	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2075	2085		10.1038/sj.onc.1203548	http://dx.doi.org/10.1038/sj.onc.1203548			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815799				2022-12-28	WOS:000086728000001
J	Alevizopoulos, K; Sanchez, B; Amati, B				Alevizopoulos, K; Sanchez, B; Amati, B			Conserved region 2 of adenovirus E1A has a function distinct from pRb binding required to prevent cell cycle arrest by p16(INK4a) or p27(Kip1)	ONCOGENE			English	Article						E1A; p27; p16; pRb; E2F	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR PROTEIN; S-PHASE ENTRY; HISTONE DEACETYLASE; GROWTH SUPPRESSION; REPRESS TRANSCRIPTION; NEGATIVE MODULATION; FAMILY PROTEINS; DROSOPHILA CTBP	Ectopic expression of the CDK inhibitors (CKIs) p16(INK4a) and p27(Kip1) in Rat1 fibroblasts induces dephosphorylation and activation of Retinoblastoma-family proteins (pRb, p107 and p130), their association with E2F proteins, and cell cycle arrest in G1, The growth-inhibitory action of p16, in particular, is believed to be mediated essentially via pRb activation. The 12S E1A protein of human Adenovirus 5 associates with pRb-family proteins via residues in its Conserved Regions (CR) 1 and 2, in particular through the motif LXCXE in CR2. These interactions are required for E1A to prevent G1 arrest upon co-expression of CKIs, We show here that mutating either of two conserved motifs adjacent to LXCXE in CR2, GFP and SDDEDEE, also impairs the ability of E1A to overcome G1 arrest by p16 or p27, Strikingly, however, these mutations affect neither the association of E1A with pRb, p07 and p130, nor its ability to derepress E2F-1 transcriptional activity in transient transfection assays. One of the E1A mutants, however, is defective in derepressing several endogenous E2F target genes in the presence of p16 or p27, Thus, CR2 possesses an essential function besides pRb-binding, We speculate that this function might be required for the full derepression of E2F-regulated genes in their natural chromatin context.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Amati, B (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BARBEAU D, 1994, ONCOGENE, V9, P359; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eckner R, 1996, BIOL CHEM, V377, P685; EGAN C, 1989, ONCOGENE, V4, P383; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Geng Y, 1996, ONCOGENE, V12, P1173; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NEVINS JR, 1992, SCIENCE, V258, P424; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Putzer BM, 1997, J VIROL, V71, P9538; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUELLE DE, 1995, ONCOGENE, V11, P635; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Whalen SG, 1996, J VIROL, V70, P5373, DOI 10.1128/JVI.70.8.5373-5383.1996; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	76	13	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2067	2074		10.1038/sj.onc.1203534	http://dx.doi.org/10.1038/sj.onc.1203534			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803468				2022-12-28	WOS:000086613200011
J	Vial, E; Castellazzi, M				Vial, E; Castellazzi, M			Down-regulation of the extracellular matrix protein SPARC in vSrc- and vJun-transformed chick embryo fibroblasts contributes to tumor formation in vivo	ONCOGENE			English	Article						vSrc; vJun; AP1; SPARC; chick embryo fibroblasts; cell transformation; tumorigenesis	ENDOTHELIAL GROWTH-FACTOR; C-JUN; CELLULAR-TRANSFORMATION; NEOPLASTIC PROGRESSION; AP-1 FUNCTION; V-JUN; EXPRESSION; CELLS; OSTEONECTIN; OVEREXPRESSION	In vitro transformation of primary cultures of chick embryo fibroblasts by the membrane-bound vSrc or the nuclear vJun oncoproteins is correlated with a downregulation of the secreted glycoprotein SPARC (also called BM-40 or osteonectin). This protein is a nonstructural component of the extracellular matrix that is thought to regulate cell-matrix interaction during development, wound repair, and carcinogenesis. Its precise function remains unclear. To estimate the contribution of SPARC down-regulation to the major aspects of the transformed phenotype, we have reexpressed this protein from a self-replicating retrovirus Rcas, designated R-SPARC, in the transformed cultures. These R-SPARC-infected cultures display the following main properties: (i) they accumulate the SPARC protein to a level identical to or only slightly higher than the level in normal chick embryo fibroblasts; (ii) they retain the main phenotypic properties characteristic of in vitro transformed cells, that is, altered morphology, capacity to grow in a reduced amount of serum, and capacity to develop colonies from single cells in agar; (iii) they display a clearly reduced capacity to develop local fibrosarcomas in vivo. Taken together, these data strongly suggest that down-regulation of SPARC contributes to the transformed phenotype triggered by vSrc and vJun in primary avian fibroblasts, by facilitating in vivo tumorigenesis.	Ecole Normale Super Lyon, INSERM U412, Inst Natl Sante & Rech Med, Unite Virol Humaine, F-69364 Lyon 07, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM U412, Inst Natl Sante & Rech Med, Unite Virol Humaine, 46 Allee Italie, F-69364 Lyon 07, France.							Akamatsu H, 1996, CANCER RES, V56, P4541; BASSUK JA, 1993, EUR J BIOCHEM, V218, P117, DOI 10.1111/j.1432-1033.1993.tb18358.x; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; COLOMBO MP, 1991, EUR J CANCER, V27, P58, DOI 10.1016/0277-5379(91)90062-I; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; EVERITT EA, 1992, EXP CELL RES, V199, P134, DOI 10.1016/0014-4827(92)90471-J; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GIVOL I, 1992, ONCOGENE, V7, P141; HONENESTER E, 1997, EMBO J, V16, P3778; HUGUES SH, 1987, J VIROL, V61, P3004; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANKATBUTTGEREI.B, 1998, FEBS LETT, V236, P352; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; MORGAN IM, 1994, ONCOGENE, V9, P2793; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; PIU F, 1993, CR ACAD SCI III-VIE, V316, P772; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Reed KL, 1996, ULTRASOUND OBST GYN, V8, P1, DOI 10.1046/j.1469-0705.1996.08010001.x; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TIMPL R, 1993, MOL CELLULAR ASPECTS, P211; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VOGT PK, 1994, FOS JUN FAMILIES TRA, P203; YOUNG MF, 1986, NUCLEIC ACIDS RES, V14, P4483, DOI 10.1093/nar/14.11.4483	46	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1772	1782		10.1038/sj.onc.1203493	http://dx.doi.org/10.1038/sj.onc.1203493			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777211				2022-12-28	WOS:000086292500005
J	Neve, RM; Sutterluty, H; Pullen, N; Lane, HA; Daly, JM; Krek, W; Hynes, NE				Neve, RM; Sutterluty, H; Pullen, N; Lane, HA; Daly, JM; Krek, W; Hynes, NE			Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells	ONCOGENE			English	Article						single chain antibody; p27(kip1); c-Myc; PI3 kinase; MAP kinase	NEU DIFFERENTIATION FACTOR; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; INTRACELLULAR EXPRESSION; SIGNAL-TRANSDUCTION; INHIBITOR P27(KIP1); KINASE-ACTIVITY; OVARIAN-CANCER; CDK INHIBITOR; GROWTH	The ErbB2 receptor tyrosine kinase is overexpressed in a variety of human tumours. In order to understand the mechanism by which ErbB2 mediates tumour proliferation we have functionally inactivated the receptor using an intracellularly expressed, ER-targeted single-chain antibody (scFV-5R), Inducible expression of scFv-5R in the ErbB2-overexpressing SKBr3 breast tumour cell line leads to loss of plasma membrane localized ErbB2, Simultaneously, the activity of ErbB3, MAP kinase and PKB/Akt decreased dramatically, suggesting that active ErbB2/ErbB3 dimers are necessary for sustained activity of these kinases. Loss of functional ErbB2 caused the SKBr3 tumour cells to accumulate in the G1 phase of the cell cycle, This was a result of reduction in CDK2 activity, which was mediated by a re-distribution of p27(Kip1) from sequestering complexes to cyclin E/CDK2 complexes. The level of c-Myc and D-cyclins, proteins involved in p27(Kip1) sequestration, decreased in the absence of functional ErbB2. Ectopic expression of c-Myc led to an increase in D cyclin levels, CDK2 activity and resulted in a partial G1 rescue. We propose that c-Myc is a primary effector of ErbB2-mediated oncogenicity and functions to prevent normal p27(Kip1) control of cyclinE/CDR2.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst, R-1066-206,Maulbeerstr 66, CH-4058 Basel, Switzerland.			Sutterluty-Fall, Hedwig/0000-0001-9249-9299; Pullen, Nicholas/0000-0002-4014-9278				ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BERGER MS, 1988, CANCER RES, V48, P1238; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Czubayko F, 1997, GENE THER, V4, P943, DOI 10.1038/sj.gt.3300483; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; EBBINGHAUS SW, 1993, J CLIN INVEST, V92, P2433, DOI 10.1172/JCI116850; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jannot CB, 1996, ONCOGENE, V13, P275; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; SCHUURING E, 1992, ONCOGENE, V7, P355; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; Zhang K, 1996, J BIOL CHEM, V271, P3884	60	121	128	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2000	19	13					1647	1656		10.1038/sj.onc.1203470	http://dx.doi.org/10.1038/sj.onc.1203470			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763821				2022-12-28	WOS:000086083800004
J	Ren, SR; Smith, MJ; Louro, ID; McKie-Bell, P; Bani, MR; Wagner, M; Zochodne, B; Redden, DT; Grizzle, WE; Wang, ND; Smith, DI; Herbst, RA; Bardenheuer, W; Opalka, B; Schutte, J; Trent, JM; Ben-David, Y; Ruppert, JM				Ren, SR; Smith, MJ; Louro, ID; McKie-Bell, P; Bani, MR; Wagner, M; Zochodne, B; Redden, DT; Grizzle, WE; Wang, ND; Smith, DI; Herbst, RA; Bardenheuer, W; Opalka, B; Schutte, J; Trent, JM; Ben-David, Y; Ruppert, JM			The p44(S10) locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma	ONCOGENE			English	Article						proteasome; regulatory particle; p44(S10); gene amplification; melanoma	COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; BREAST-CANCER; CELL-LINES; DNA; COMPLEX; DEGRADATION	Gene amplification is frequently present in human tumors, although specific target genes relevant to many amplified loci remain unidentified. An expression cloning assay enabled identification of a candidate oncogene derived from human chromosome 3p14.1, The cDNA retrieved from morphologically transformed cells contained the full-length protein coding region and detected an abundant transcript in the same cells. Sequence analysis revealed identity with the wild-type sequence of p44(S10), a highly conserved subunit of the 26S proteasome that exhibits similarity to the Arabidopsis fus6/cop11 family of signaling molecules. p44(S10) gene copy number and mRNA expression were increased in association with segmental 1.8-11-fold chromosomal gains in cutaneous malignant melanoma cell lines (5/13; 40%) and tumors (2/40; 5%), and in breast cancer MCF-7 cells. Likewise, malignant progression of human radial growth phase WM35 melanoma cells was associated with amplification and increased expression of endogenous p44(S10), and increased expression of p44(S10) was sufficient to induce proliferation of WM35 cells in vivo. The results demonstrate segmental copy number gains within chromosome 3p in cutaneous malignant melanoma and suggest that deregulation of a proteasome regulatory particle subunit may contribute to the malignant phenotype.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA; Univ Alabama, Dept Med, Div Hematol Oncol, Birmingham, AL USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA; Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Hannover Med Sch, Dept Dermatol, D-30449 Hannover, Germany; Univ Essen Gesamthsch, Sch Med, Dept Med Oncol Canc Res, W German Canc Ctr Essen, D-45122 Essen, Germany; Natl Human Genome Res Inst, NIH, Bethesda, MD USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Alabama System; University of Alabama Birmingham; Mayo Clinic; Hannover Medical School; University of Duisburg Essen; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Ruppert, JM (corresponding author), Room 570 WTI,1824 6th Ave S, Birmingham, AL 35294 USA.		Bani, Maria Rosa/AAB-3397-2020; Louro, Iuri D/I-8641-2012	Bani, Maria Rosa/0000-0001-8178-1432; Louro, Iuri/0000-0001-5160-9615	NATIONAL CANCER INSTITUTE [R29CA065686, R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA65686, CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bani MR, 1996, CANCER RES, V56, P3075; Bardenheuer W, 1996, GENOME RES, V6, P176, DOI 10.1101/gr.6.3.176; Barks JH, 1997, GENE CHROMOSOME CANC, V19, P278, DOI 10.1002/(SICI)1098-2264(199708)19:4<278::AID-GCC11>3.3.CO;2-9; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bastian BC, 1998, CANCER RES, V58, P2170; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DESHANE J, 1994, GENE THER, V1, P332; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Montgomery D.C., 2005, DESIGN ANAL EXPT, V6th; NEUBAUER A, 1992, ONCOGENE, V7, P1019; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Sozzi G, 1998, ADV CANCER RES, V74, P141, DOI 10.1016/S0065-230X(08)60766-6; VOGELSTEIN B, 1998, GENETIC BIASIS HUMAN; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	31	24	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1419	1427		10.1038/sj.onc.1203462	http://dx.doi.org/10.1038/sj.onc.1203462			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723133				2022-12-28	WOS:000085942700007
J	Calin, GA; di Iasio, MG; Caprini, E; Vorechovsky, I; Natali, PG; Sozzi, G; Croce, CM; Barbanti-Brodano, G; Russo, G; Negrini, M				Calin, GA; di Iasio, MG; Caprini, E; Vorechovsky, I; Natali, PG; Sozzi, G; Croce, CM; Barbanti-Brodano, G; Russo, G; Negrini, M			Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms	ONCOGENE			English	Article						PPP2R1A; PPP2R1B; mutations; human neoplasms	TUMOR-SUPPRESSOR GENE; PROTEIN PHOSPHATASE-2A; ATAXIA-TELANGIECTASIA; OVARIAN-CANCER; BREAST-CANCER; ATM GENE; HETEROZYGOSITY; REGIONS; REFINEMENT; LEUKEMIA	The phosphatase 2A (PP2A) is one of the major cellular serine-threonine phosphatases, It was recently shown that the gene encoding for the beta isoform of its subunit A, PPP2R1B, is altered in human lung and colorectal carcinomas, suggesting a role in human tumorigenesis, Here, we report the detection of mutations in breast, lung carcinomas and melanomas in the genes of both alpha (PPP2R1A) and beta isoforms, Mutations affecting PPP2R1B were found in four breast carcinomas, while mutations in PPP2R1A were found in carcinomas of the breast and of the lung and in one melanoma. Most of the mutations affecting PPP2R1B were exons deletions, suggesting abnormal splicing. These splicing abnormalities were detected in tumor samples in the absence of the normal splicing product, and were not found in several normal controls. In one case, a homozygous deletion present in tumor DNA, and not in the matched normal control was demonstrated. Mutations affecting the PPP2R1A gene were nucleotide substitutions changing highly conserved amino acids and one frame-shift. Although the frequency of alterations is low, the inclusion of both isoforms of subunit A in the genes mutated in human cancer and the addition of breast cancer to the list of neoplasms in which PPP2R1B is altered, strengthen the potential role of PP2A in human tumorogenesis.	Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, I-44100 Ferrara, Italy; Ist Dermopat Immacolata, I-00167 Rome, Italy; Novum, Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Ist Nazl Tumori, I-23133 Milan, Italy; Regina Elena Canc Inst, Immunol Lab, I-00158 Rome, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Kimmel Canc Inst, Philadelphia, PA 19107 USA	University of Ferrara; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Karolinska Institutet; Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Negrini, M (corresponding author), Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Russo, Giandomenico/K-9566-2016; Negrini, Massimo/J-2377-2016; Calin, George/E-9390-2011; Young, Richard A/F-6495-2012; sozzi, gabriella/G-8259-2011	Russo, Giandomenico/0000-0002-7718-9687; Negrini, Massimo/0000-0002-0007-1920; Young, Richard A/0000-0001-8855-8647; sozzi, gabriella/0000-0001-9360-6914; Calin, George/0000-0001-6704-5615				Baysal BE, 1998, GENE, V217, P107, DOI 10.1016/S0378-1119(98)00350-3; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Davis M, 1996, CANCER RES, V56, P741; di Iasio MG, 1999, ONCOGENE, V18, P1635, DOI 10.1038/sj.onc.1202453; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; Gabra H, 1996, CANCER RES, V56, P950; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; Hayashi K, 1996, LABORATORY PROTOCOLS FOR MUTATION DETECTION, P14; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERBST RA, 1995, CANCER RES, V55, P2494; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Maniatis T., 1982, MOL CLONING LAB MANU; NEGRINI M, 1995, CANCER RES, V55, P3003; RASIO D, 1995, CANCER RES, V55, P3988; Rosenberg JE, 1996, ONCOGENE, V13, P2483; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sparks AB, 1998, CANCER RES, V58, P1130; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Vorechovsky I, 1996, CANCER RES, V56, P2726; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	30	178	186	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1191	1195		10.1038/sj.onc.1203389	http://dx.doi.org/10.1038/sj.onc.1203389			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713707				2022-12-28	WOS:000085567800009
J	Wennbo, H; Tornell, J				Wennbo, H; Tornell, J			The role of prolactin and growth hormone in breast cancer	ONCOGENE			English	Article						prolactin; growth hormone; transgenic mice; mammary cancer; auto/paracrine	MESSENGER-RIBONUCLEIC-ACID; MAMMARY-GLAND DEVELOPMENT; RECEPTOR GENE; TRANSGENIC MICE; PROGESTERONE RECEPTORS; EXPRESSION; RAT; TUMORS; ACTIVATION; PITUITARY	This review will focus on the role for prolactin (PRL) and growth hormone (GH) in mammary tumor formation. Much attention has previously been focused on circulating levels of GH/PRL in relation to mammary tumor formation. We will review data demonstrating that these ligands also could be produced locally in different organs, including the mammary gland and mammary tumors, and suggest that this local production may be of importance for pathological conditions. We will also discuss mechanisms for crosstalk between steroids and GH/PRL. A crosstalk between GH- and PRL response is possible at multiple levels. In the human, GH can activate both the prolactin receptor (PRLR) and the growth hormone receptor (GHR), We have demonstrated that activation of the PRLR, but not the GHR, is inducing mammary tumors in transgenic mice. Furthermore, the elevated levels of insulin-like growth factor 1 (IGF-I) seen in the GHR activating transgenic mice is not sufficient for tumor induction. The induced tumors express functionally active prolactin that could be of importance for the tumor formation. Paracrine/aurocrine stimulation by PRL may be more important than PRL transported via the circulation. In women, the role for stimulation of the PRLR and/or the GHR in mammary tumor formation has not been proven, although experiments from primates suggest that the PRLR could be of importance.	Univ Gothenburg, Dept Physiol, Gothenburg, Sweden; Astra Transgen Ctr, Molndal, Sweden	University of Gothenburg	Tornell, J (corresponding author), Univ Gothenburg, Dept Physiol, Gothenburg, Sweden.							ADLER RA, 1986, ENDOCR REV, V7, P302, DOI 10.1210/edrv-7-3-302; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; BONNETERRE J, 1987, CANCER RES, V47, P4724; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BURROW GN, 1981, NEW ENGL J MED, V304, P156, DOI 10.1056/NEJM198101153040306; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; DECOUVELAERE C, 1995, CELL GROWTH DIFFER, V6, P477; EMERMAN JT, 1985, HORM METAB RES, V17, P421, DOI 10.1055/s-2007-1013563; FELDMAN M, 1993, ENDOCRINOLOGY, V133, P1602, DOI 10.1210/en.133.4.1602; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; GINSBURG E, 1995, CANCER RES, V55, P2591; GINSBURG E, 1996, BIOL SIGNALING MAMMA; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; HOLTKAMP W, 1984, INT J CANCER, V34, P323, DOI 10.1002/ijc.2910340307; Humphreys RC, 1997, MOL ENDOCRINOL, V11, P801, DOI 10.1210/me.11.6.801; HUSEBY RA, 1985, ENDOCRINOLOGY, V116, P1440, DOI 10.1210/endo-116-4-1440; ITUARTE EA, 1984, ANN INTERN MED, V101, P627, DOI 10.7326/0003-4819-101-5-627; JAHN GA, 1991, ENDOCRINOLOGY, V128, P2976, DOI 10.1210/endo-128-6-2976; KLEINBERG DL, 1990, ENDOCRINOLOGY, V126, P3274, DOI 10.1210/endo-126-6-3274; KURTZ A, 1993, BIOL REPROD, V48, P1095, DOI 10.1095/biolreprod48.5.1095; KWA HG, 1974, LANCET, V1, P433; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LUENG DD, 1987, NATURE, V330, P1782; MATSUZAWA A, 1986, INT REV CYTOL, V103, P303, DOI 10.1016/S0074-7696(08)60839-6; Medina D., 1982, MOUSE BIOMEDICAL RES, VIV, P373; MERSHON J, 1995, ENDOCRINOLOGY, V136, P3619, DOI 10.1210/en.136.8.3619; Mertani HC, 1998, INT J CANCER, V79, P202; MOL JA, 1995, J CLIN ENDOCR METAB, V80, P3094, DOI 10.1210/jc.80.10.3094; MOL JA, 1995, J CLIN INVEST, V95, P2028, DOI 10.1172/JCI117888; MURPHY LJ, 1984, CANCER RES, V44, P1963; MUSEY VC, 1987, NEW ENGL J MED, V316, P229, DOI 10.1056/NEJM198701293160501; NABARRO JD, 1987, CLIN ENDOCRINOL, V26, P327; NAGASAWA H, 1979, EUR J CANCER, V15, P267, DOI 10.1016/0014-2964(79)90037-9; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; RUAN WF, 1995, ENDOCRINOLOGY, V136, P1296, DOI 10.1210/en.136.3.1296; SCHMITT-NEY M, 1992, MOL ENDOCRINOL, V6, P1988, DOI 10.1210/me.6.12.1988; SELMAN PJ, 1994, ENDOCRINOLOGY, V134, P287, DOI 10.1210/en.134.1.287; SILBERSTEIN GB, 1994, ENDOCRINOLOGY, V134, P84, DOI 10.1210/en.134.1.84; STEINMETZ RW, 1993, J ENDOCRINOL, V136, P271, DOI 10.1677/joe.0.1360271; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TORNELL J, 1992, J STEROID BIOCHEM, V43, P237, DOI 10.1016/0960-0760(92)90213-3; TORNELL J, 1991, INT J CANCER, V49, P114, DOI 10.1002/ijc.2910490121; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANGILDER JC, 1975, ARCH SURG-CHICAGO, V110, P293; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yang XF, 1996, CANCER RES, V56, P1509; ZUMOFF B, 1988, ANTICANCER RES, V8, P627	56	88	93	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1072	1076		10.1038/sj.onc.1203349	http://dx.doi.org/10.1038/sj.onc.1203349			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713692				2022-12-28	WOS:000085796400014
J	Willers, H; McCarthy, EE; Wu, B; Wunsch, H; Tang, W; Taghian, DG; Xia, F; Powell, SN				Willers, H; McCarthy, EE; Wu, B; Wunsch, H; Tang, W; Taghian, DG; Xia, F; Powell, SN			Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control	ONCOGENE			English	Article						p53; homologous recombination; G1/S cell cycle checkpoint; genomic stability	TEMPERATURE-SENSITIVE MUTANT; WILD-TYPE P53; DNA-BINDING; NUCLEAR-LOCALIZATION; GAMMA-IRRADIATION; TERMINAL DOMAIN; MAMMALIAN-CELLS; PROTEIN; EXPRESSION; GROWTH	The tumor suppressor p53 is considered as the guardian of the genome which is activated following genotoxic stress. In many cell types, p53 mediates G1 cell cycle arrest as the predominant cellular response. Inactivation of wild-type p53 leads to loss of G1/S checkpoint control and to genomic instability, including increased spontaneous homologous recombination (HR), To determine whether regulation of the G1/S checkpoint is required for suppression of HR, we assessed recombination events using a plasmid substrate that stably integrated into the genome of p53-null mouse fibroblasts. Exogenous expression of a temperature-sensitive p53 protein (Ala135 to Val), which had lost trans-activation function and could not regulate G1/S transition,when in mutant conformation, reduced HR rates to the same extent as wild-type p53. Furthermore, a p53 construct with an alternatively-spliced carboxy terminus also retained this ability in the absence of both activities, G1/S control and non-sequence specific DNA binding as mediated by the carboxy terminus. Our data dissociate regulation of HR by p53 from its role as a cell cycle checkpoint protein. The results support a model which extends p53's role as a guardian of the genome to include transactivation-independent regulatory functions in DNA repair, replication and recombination.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Lab Mol & Cellulare Radiat Biol, Charlestown, MA 02129 USA; Univ Hamburg, Hosp Eppendorf, Dept Radiat Oncol, D-20246 Hamburg, Germany; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Harvard University; Massachusetts General Hospital; University of Hamburg; Eli Lilly	Powell, SN (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Dept Radiat Oncol, Cox 3,100 Blossom St, Boston, MA 02114 USA.		Xia, Fen/G-3708-2013		NCI NIH HHS [CA 58985] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EYFJORD JE, 1995, CANCER RES, V55, P646; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HIRANO Y, 1995, ONCOGENE, V10, P1879; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Isaacs JS, 1997, CANCER RES, V57, P2986; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Leiter LM, 1996, ONCOGENE, V12, P2661; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; PARDO FS, 1994, RADIAT RES, V140, P180, DOI 10.2307/3578901; POWELL SN, 1995, CANCER RES, V55, P1643; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STEWART N, 1995, ONCOGENE, V10, P109; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tang W, 1999, CANCER RES, V59, P2562; Wiesmuller L, 1996, J VIROL, V70, P737; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	53	86	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					632	639		10.1038/sj.onc.1203142	http://dx.doi.org/10.1038/sj.onc.1203142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698508				2022-12-28	WOS:000085192000005
J	Cleverley, SC; Costello, PS; Henning, SW; Cantrell, DA				Cleverley, SC; Costello, PS; Henning, SW; Cantrell, DA			Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma	ONCOGENE			English	Article						Rho; lymphoma; thymus; transformation; C3-transferase	RAS TRANSFORMATION; TRANSGENIC MICE; GTPASES; COOPERATION; BOTULINUM; PROTEIN; TUMORS; MYB	In situ studies in model cell lines have implicated the GTPase Rho in the control of diverse cellular responses including the control of the actin cytoskeleton and the regulation of cell cycle progression. It is also reported that the transformation of fibroblasts via oncogenic Ras requires intact Rho signalling. An invaluable tool used to investigate Rho function is the bacterial toxin C3 transferase derived from Clostridium hotulinum. C3 transferase ribosylates Rho in its effector domain thereby abolishing interaction with downstream effecters. We have previously reported the use of C3 transferase under the control of the thymocyte specific Ick promoter to explore the role of Rho in T cell biology. Strikingly, Ick-C3 mice develop aggressive malignant thymic lymphoblastic lymphomas between 4 and 8 months of age. These studies reveal that loss of Rho function is associated with prediposition to lymphoid cell transformation. Inhibition of Rho function has been suggested as a therapeutic strategy for treatment of Ras-transformed tumours, The development of lymphomas in mice devoid of functional Rho in their T cell compartment shows that such a strategy would need to be used with caution.	Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England	Cancer Research UK	Cantrell, DA (corresponding author), Imperial Canc Res Fund, Lymphocyte Activat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.							ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Badiani PA, 1996, ONCOGENE, V13, P2205; Bronson R., 1990, GENETIC EFFECTS AGIN, VII, P279; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GALLANDRINI R, 1997, IMMUNITY, V7, P163; Henning SW, 1998, CURR OPIN IMMUNOL, V10, P322, DOI 10.1016/S0952-7915(98)80171-4; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Owen MJ, 1996, CURR OPIN IMMUNOL, V8, P191, DOI 10.1016/S0952-7915(96)80057-4; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	23	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					13	20		10.1038/sj.onc.1203259	http://dx.doi.org/10.1038/sj.onc.1203259			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644975				2022-12-28	WOS:000084844300002
J	Takahashi, T; Suwabe, N; Dai, P; Yamamoto, M; Ishii, S; Nakano, T				Takahashi, T; Suwabe, N; Dai, P; Yamamoto, M; Ishii, S; Nakano, T			Inhibitory interaction of c-Myb and GATA-1 via transcriptional co-activator CBP	ONCOGENE			English	Article						c-Myb; GATA-1; CBP; cell differentiation; hematopoiesis	MURINE HEMATOPOIETIC-CELLS; EMBRYONIC STEM-CELLS; NUCLEAR-PROTEIN CBP; ERYTHROID-DIFFERENTIATION; ONCOGENE PRODUCT; COACTIVATOR CBP; GENE; EXPRESSION; BINDING; PROMOTER	Gene targeting experiments have revealed that transcription factors such as c-Myb and GATA-1 play crucial roles during hematopoietic differentiation. c-Myb is necessary in the immature cells of almost every hematopoietic lineage and GATA-1 is essential for the development of the ervthroid lineage. In addition, CREB-binding protein (CBP) acts as a transcriptional adapter for various transcription factors, including c-Myc and GATA-1. In this paper,,ve show that the transcription factors c-Myb and GATA-1 each inhibit the transcriptional activity of the other and that any possible bipartite complexes c-Myb, GATA-1, and CBP could be formed, but the tripartite complex was hardly formed, The exclusive binding of GATA-1 and c-Myb to CBP is probably the molecular basis for the mutual inhibition of their transcriptional activity. Our data suggest that cross-talk between these three factors might be important for hematopoietic differentiation and that CBP functions as a hey molecule during the process.	Osaka Univ, Dept Mol Cell Biol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan	Osaka University; University of Tsukuba; University of Tsukuba; RIKEN	Nakano, T (corresponding author), Osaka Univ, Dept Mol Cell Biol, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		Yamamoto, Masayuki/A-4873-2010; Ishii, Shunsuke/A-5271-2016	Yamamoto, Masayuki/0000-0002-9073-9436; Ishii, Shunsuke/0000-0002-6530-2478				Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cross MA, 1997, CIBA F SYMP, V204, P3; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; FERRAO P, 1995, ONCOGENE, V11, P1631; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; Lipsick JS, 1996, ONCOGENE, V13, P223; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V9, P1123; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Orita T, 1997, J BIOL CHEM, V272, P23216, DOI 10.1074/jbc.272.37.23216; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	43	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					134	140		10.1038/sj.onc.1203228	http://dx.doi.org/10.1038/sj.onc.1203228			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644988				2022-12-28	WOS:000084844300015
J	Yoshida, S; Kaneita, Y; Aoki, Y; Seto, M; Mori, S; Moriyama, M				Yoshida, S; Kaneita, Y; Aoki, Y; Seto, M; Mori, S; Moriyama, M			Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5 '-RACE and LA-PCR analyses of biopsy samples	ONCOGENE			English	Article						BCL6; translocation; hypermutation; lymphoma	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; SOMATIC HYPERMUTATION; BURKITT-LYMPHOMA; CHROMOSOMAL BREAKPOINT; 3Q27 TRANSLOCATION; MOLECULAR-CLONING; ONCOGENE; LOCUS; PROTEIN	In order to elucidate the molecular mechanism(s) for BCL6 translocation, we identified translocational partner genes by subjecting clinical biopsy samples from patients with non-Hodgkin's lymphoma to 5'-rapid amplification of cDNA ends (5'-RACE). Sequence analysis of the 5'-RACE product revealed that the BCL6 gene was fused to the J segment of the immunoglobulin heavy chain (IgH) gene in about half of the cases, but in the other half, it was fused to heterologous partners, including the MHC class II transactivator (CIITA), pim-1, eukaryotic initiation factor 4AII (ejf4AII), transferrin receptor (TFRR) and ikaros genes, Since analyses using genomic long and accurate (LA)-PCR revealed that the breakpoints in the partner gene mere confined to the first intron or the second exon in all cases, the promoter and the first exon of the BCL6 gene mere replaced by the promoter and the first or both the first and second exon of the partner gene, The breakpoint Banking sequences had no recombination signal sequences (RSSs) or chi sequences and were homologous with the switch region only when the BCL6 gene was fused to the IgH gene, suggesting that BCL6 translocation cannot be explained solely by mistakes of V(D)J, or chi-mediated or class-switch recombination, but rather another mechanism may also be required to explain the molecular mechanism for the promiscuous BCL6 translocation.	Univ Tokyo, Inst Med Sci, Dept Pathol, Tokyo, Japan; Aichi Canc Inst, Lab Chemotherapy, Nagoya, Aichi, Japan; Tottori Univ, Fac Med, Sch Life Sci, Dept Mol Biol, Tottori 6838503, Japan	University of Tokyo; Aichi Cancer Center; Tottori University	Moriyama, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol Biol, 86 Nishimachi, Tottori 6838503, Japan.							Akasaka T, 1997, CANCER RES, V57, P7; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1994, BLOOD, V83, P2423; BENARDIN F, 1997, ONCOGENE, V14, P849; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1993, CAUSES CONSEQUENCES, P313; DALLERY E, 1995, ONCOGENE, V10, P2171; GAIDANO G, 1998, BIOL HIGH GRADE MALI, P353; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; HARRIS NL, 1994, BLOOD, V84, P1361; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Klein U, 1998, IMMUNOL REV, V162, P261; MIKI T, 1994, BLOOD, V83, P217; MIKI T, 1994, BLOOD, V83, P26; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SUZUKI K, 1994, JPN J CANCER RES, V85, P911, DOI 10.1111/j.1349-7006.1994.tb02968.x; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1993, HUMAN B CELL NEOPLAS, P333; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZUTTER MM, 1998, BIOL LOW GRADE MALIG, P337	33	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7994	7999		10.1038/sj.onc.1203293	http://dx.doi.org/10.1038/sj.onc.1203293			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637510				2022-12-28	WOS:000084634600008
J	DeCristofaro, MF; Betz, BL; Wang, WD; Weissman, BE				DeCristofaro, MF; Betz, BL; Wang, WD; Weissman, BE			Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors	ONCOGENE			English	Article						BAF47; SWI/SNF; rhabdomyosarcomas; rhabdoid; tumor suppressor genes	TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; SWI/SNF COMPLEX; HUMAN HOMOLOG; YEAST; BINDING; SNF5; STIMULATION; SWI2/SNF2; COOPERATE	The organization of genomic DNA into chromatin aids in the regulation of gene expression by limiting the access of transcriptional binding domains. The SWI/SNF family of chromatin-remodeling complexes, which are conserved from yeast to humans, open the chromatin to facilitate the transcriptional machinery to access their targets. The gene encoding the BAF47/hSNF5 subunit of the complex has been found mutated in both rhabdoid cell lines and in primary rhabdoid tumors. Since the pediatric tumors rhabdomyosarcoma (RMS) and Wilms' tumor (WT) share a similar genetic link with rhabdoid tumors, it was hypothesized that they may also show alterations of the BAF47 gene. Using primary tumors, the BAF47 protein was detected in all WT but less than 75% of the RMS tested, In cell lines, the BAF47 protein was missing in all rhabdoid cell lines and one RMS cell Line. Analysis of sample DNA displayed either a mutation or deletion of the BAF47 gene in all samples negative for the protein. Several other subunits of the human SWI/SNF complex, including BRG1 which is the subunit directly interacting with the Rb tumor suppressor gene, were detected in all tumor samples. Alteration of BAF47 may be a genetic marker associated with the poor prognosis seen in all rhabdoid tumors but only some RMS.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; NIA, Gerontol Res Ctr, Genet Lab, NIH, Baltimore, MD 21224 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Weissman, BE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295,Rm 32-062, Chapel Hill, NC 27599 USA.		Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928	NATIONAL CANCER INSTITUTE [R01CA063176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008581] Funding Source: NIH RePORTER; NCI NIH HHS [CA63176] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM08581] Funding Source: Medline; PHS HHS [5-T32-WS07017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIEGEL JA, 1990, CANCER RES, V59, P74; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Charles AK, 1998, AM J PATHOL, V153, P991, DOI 10.1016/S0002-9440(10)65641-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Green Daniel M., 1997, P733; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Parham D, 1996, PEDIAT NEOPLASIA MOR, P87; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Pogacnik A, 1997, ACTA CYTOL, V41, P539, DOI 10.1159/000332553; Rosty C, 1998, GENE CHROMOSOME CANC, V21, P82, DOI 10.1002/(SICI)1098-2264(199802)21:2<82::AID-GCC2>3.0.CO;2-3; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	29	74	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7559	7565		10.1038/sj.onc.1203168	http://dx.doi.org/10.1038/sj.onc.1203168			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602515				2022-12-28	WOS:000084119600017
J	Epinat, JC; Gilmore, TD				Epinat, JC; Gilmore, TD			Diverse agents act at multiple levels to inhibit the Rel/NF-kappa B signal transduction pathway	ONCOGENE			English	Review						Rel; NF-kappa B; I kappa B signal transduction; NF-kappa B inhibition; IKK	NITRIC-OXIDE SYNTHASE; DNA-BINDING ACTIVITY; GLUCOCORTICOID-MEDIATED REPRESSION; ADHESION MOLECULE EXPRESSION; FACTOR-INDUCED APOPTOSIS; ACID PHENETHYL ESTER; CD4(+) T-LYMPHOCYTES; N-TERMINAL KINASE; ALPHA-LIPOIC ACID; TRANSCRIPTION FACTOR	Rel/NF-kappa B transcription factors regulate several important physiological processes, including developmental processes, inflammation and immune responses, cell growth, cancer, apoptosis, and the expression of certain viral genes. Therefore, they have also been sought-after molecular targets for pharmacological intervention. As details of the Rel/NF-kappa B signal transduction pathway are revealed, it is clear that modulators of this pathway can act at several levels. Inhibitors of the Rel/NF-kappa B pathway include a variety of natural and designed molecules, including anti-oxidants, proteasome inhibitors, peptides, small molecules, and dominant-negative or constitutively active polypeptides in the pathway. Several of these molecules act as general inhibitors of Rel/NF-kappa B induction, whereas others inhibit specific pathways of induction. Inhibitors of Rel/NF-kappa B are likely to gain stature as treatments for certain cancers and neurodegenerative and inflammatory diseases.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Epinat, JC (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.							Arbault S, 1997, BIOMED PHARMACOTHER, V51, P430, DOI 10.1016/S0753-3322(97)82321-9; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; BISWAS DK, 1993, J ACQ IMMUN DEF SYND, V6, P778; Bork PM, 1999, PLANTA MED, V65, P297, DOI 10.1055/s-1999-13989; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; Brennan P, 1998, BIOCHEM PHARMACOL, V55, P965, DOI 10.1016/S0006-2952(97)00535-2; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Cho S, 1998, BIOCHEM BIOPH RES CO, V253, P104, DOI 10.1006/bbrc.1998.9697; Cominacini L, 1997, J HYPERTENS, V15, P1633, DOI 10.1097/00004872-199715120-00065; D'Acquisto F, 1998, FEBS LETT, V440, P76, DOI 10.1016/S0014-5793(98)01407-0; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Duffey DC, 1999, CANCER RES, V59, P3468; Egan L J, 1998, Gastroenterology, V115, P1295, DOI 10.1016/S0016-5085(98)70106-4; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Ehrlich LC, 1998, NEUROREPORT, V9, P1723, DOI 10.1097/00001756-199806010-00010; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fiedler MA, 1996, J VIROL, V70, P9079, DOI 10.1128/JVI.70.12.9079-9082.1996; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gehrt A, 1998, J ANTIBIOT, V51, P455, DOI 10.7164/antibiotics.51.455; Geng ZH, 1997, FREE RADICAL BIO MED, V23, P345, DOI 10.1016/S0891-5849(97)00006-3; Gerbes AL, 1998, HEPATOLOGY, V28, P1309, DOI 10.1002/hep.510280520; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; GRUNBERGER D, 1988, EXPERIENTIA, V44, P230, DOI 10.1007/BF01941717; Harant H, 1998, FEBS LETT, V436, P329, DOI 10.1016/S0014-5793(98)01153-3; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hernandez-Presa MA, 1998, AM J PATHOL, V153, P1825, DOI 10.1016/S0002-9440(10)65697-0; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; Hiramoto M, 1998, J IMMUNOL, V160, P810; Hirano F, 1998, IMMUNOPHARMACOLOGY, V39, P31, DOI 10.1016/S0162-3109(97)00095-7; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; IQBAL M, 1995, J MED CHEM, V38, P2276, DOI 10.1021/jm00013a002; Islam KN, 1998, CIRCULATION, V98, P2255, DOI 10.1161/01.CIR.98.21.2255; ISRAEL N, 1992, J IMMUNOL, V149, P3386; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; Janssen YMW, 1999, METHOD ENZYMOL, V300, P363; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Jobin C, 1998, J IMMUNOL, V160, P410; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Katsuyama K, 1998, ARTERIOSCL THROM VAS, V18, P1796, DOI 10.1161/01.ATV.18.11.1796; Kawashima S, 1998, J INTERF CYTOK RES, V18, P423, DOI 10.1089/jir.1998.18.423; KAZMI SMI, 1995, J CELL BIOCHEM, V57, P299, DOI 10.1002/jcb.240570214; Kim CH, 1999, BIOCHEM BIOPH RES CO, V259, P505, DOI 10.1006/bbrc.1999.0814; Kimura T, 1997, BIOCHEM BIOPH RES CO, V231, P557, DOI 10.1006/bbrc.1997.6135; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kotake Y, 1998, BBA-MOL CELL RES, V1448, P77, DOI 10.1016/S0167-4889(98)00126-8; Kumar A, 1998, ONCOGENE, V17, P913, DOI 10.1038/sj.onc.1201998; KUNZ D, 1995, BIOCHEM BIOPH RES CO, V216, P438, DOI 10.1006/bbrc.1995.2642; Lauzurica P, 1999, EUR J IMMUNOL, V29, P1890, DOI 10.1002/(SICI)1521-4141(199906)29:06<1890::AID-IMMU1890>3.0.CO;2-F; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Mahboubi K, 1998, J PHARMACOL EXP THER, V285, P862; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Manna SK, 1999, BIOCHEM PHARMACOL, V57, P763, DOI 10.1016/S0006-2952(98)00354-2; Manna SK, 1998, J IMMUNOL, V161, P2863; Manna SK, 1999, J IMMUNOL, V162, P2095; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; MANNA SK, 1998, J IMMUNOL, V161, P2773; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MCCAFFREY PG, 1994, NUCLEIC ACIDS RES, V22, P2134, DOI 10.1093/nar/22.11.2134; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Musonda CA, 1998, CARCINOGENESIS, V19, P1583, DOI 10.1093/carcin/19.9.1583; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Oyama T, 1998, J IMMUNOL, V160, P1224; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palayoor ST, 1998, CLIN CANCER RES, V4, P763; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pierce JW, 1996, J IMMUNOL, V156, P3961; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Pyatt DW, 1998, TOXICOL APPL PHARM, V149, P178, DOI 10.1006/taap.1998.8369; Pyatt DW, 1998, TOXICOLOGY, V128, P83, DOI 10.1016/S0300-483X(98)00047-X; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Revilla Y, 1998, J BIOL CHEM, V273, P5405, DOI 10.1074/jbc.273.9.5405; RITCHIE DM, 1995, INT J IMMUNOPHARMACO, V17, P805, DOI 10.1016/0192-0561(95)00072-A; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Saliou C, 1998, FEBS LETT, V440, P8, DOI 10.1016/S0014-5793(98)01409-4; SAPPEY C, 1995, AIDS RES HUM RETROV, V11, P1049, DOI 10.1089/aid.1995.11.1049; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sen CK, 1998, BIOCHEM BIOPH RES CO, V247, P223, DOI 10.1006/bbrc.1998.8764; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; SEN J, 1995, J IMMUNOL, V154, P3213; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; Shoji S, 1998, BIOCHEM BIOPH RES CO, V249, P745, DOI 10.1006/bbrc.1998.9221; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Shumilla JA, 1998, ARCH BIOCHEM BIOPHYS, V349, P356, DOI 10.1006/abbi.1997.0470; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Simpson CS, 1999, J NEUROCHEM, V73, P353, DOI 10.1046/j.1471-4159.1999.0730353.x; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; Singh S, 1996, J IMMUNOL, V157, P4412; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Spiecker M, 1999, METHOD ENZYMOL, V300, P374; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; Sueoka E, 1998, BIOCHEM BIOPH RES CO, V252, P566, DOI 10.1006/bbrc.1998.9695; Sugano N, 1998, BIOCHEM BIOPH RES CO, V252, P25, DOI 10.1006/bbrc.1998.9599; Sun WH, 1998, BIOCHEM BIOPH RES CO, V244, P691, DOI 10.1006/bbrc.1998.8324; SUZUKI YJ, 1994, BIOCHEM MOL BIOL INT, V32, P299; Suzuki YJ, 1995, BIOCHEM MOL BIOL INT, V36, P241; SUZUKI YJ, 1993, BIOCHEM BIOPH RES CO, V193, P277, DOI 10.1006/bbrc.1993.1620; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; SUZUKI YJ, 1993, BIOCHEM MOL BIOL INT, V31, P693; TEPPER MA, 1995, J IMMUNOL, V155, P2427; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Trepicchio WL, 1998, ANN NY ACAD SCI, V856, P12, DOI 10.1111/j.1749-6632.1998.tb08308.x; Umansky V, 1996, INT IMMUNOL, V8, P491, DOI 10.1093/intimm/8.4.491; van Hogerlinden M, 1999, CANCER RES, V59, P3299; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Venkataraman L, 1996, J IMMUNOL, V157, P1149; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JY, 1998, LIVER, V18, P180; Wang WH, 1997, IMMUNITY, V6, P165, DOI 10.1016/S1074-7613(00)80423-9; WECHSLER AS, 1994, J IMMUNOL, V153, P2515; WEISSMANN G, 1991, HOSP PRACT, V26, P60; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334; YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	187	183	205	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	1999	18	49					6896	6909		10.1038/sj.onc.1203218	http://dx.doi.org/10.1038/sj.onc.1203218			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602465				2022-12-28	WOS:000083896500007
J	Tejpar, S; Nollet, F; Li, C; Wunder, JS; Michils, G; dal Cin, P; Van Cutsem, E; Bapat, B; van Roy, F; Cassiman, JJ; Alman, BA				Tejpar, S; Nollet, F; Li, C; Wunder, JS; Michils, G; dal Cin, P; Van Cutsem, E; Bapat, B; van Roy, F; Cassiman, JJ; Alman, BA			Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)	ONCOGENE			English	Article						beta-catenin; aggressive fibromatosis; mutational analysis; immunohistochemistry; tyrosine phosphorylation	ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; HEPATOCELLULAR CARCINOMAS; FUNCTIONAL INTERACTION; APC GENE; PHOSPHORYLATION; ACTIVATION; RECEPTOR; UNCOMMON; PROTEIN	Aggressive fibromatosis (also called desmoid tumor) occurs as a sporadic lesion or as part of Familial Adenomatous Polyposis, which is caused by germ line mutations in the Adenomatous polyposis Coli (APC) gene. APC is involved in the regulation of the cellular level of beta-catenin, which is a mediator in Wnt signaling, Mutational analysis of the beta-catenin and APC genes was performed in 42 sporadic aggressive fibromatoses. Nine tumors had mutations in APC, and 22 had a point mutation in beta-catenin at either codon 45 or codon 41 (producing a stabilized beta-catenin protein product). Immunohistochemistry showed an elevated beta-catenin protein level in all tumors, regardless of mutational status. Beta-catenin localized to the nucleus, and was not tyrosine phosphorylated in the six tumors in which this was tested. The demonstration of mutations in two mediators in the Wnt-APC-beta-catenin pathway implicates beta-catenin stabilization as the key factor in the pathogenesis of aggressive fibromatosis. This is the first demonstration of somatic beta-catenin mutations in a locally invasive, but non metastatic lesion composed of spindle cells, illustrating the importance of beta-catenin stabilization in a variety of cell types and neoplastic processes. Moreover, this tumor has one of the highest reported frequencies of beta-catenin mutations of any tumor type.	Hosp Sick Children, Div Orthopaed Surg, Programme Dev Biol, Toronto, ON M5G 1X8, Canada; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; VIB Univ Ghent, Dept Mol Biol, Mol Cell Biol Unit, B-9000 Ghent, Belgium; Mt Sinai Hosp, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON M5G 1X5, Canada; Katholieke Univ Leuven, Dept Gastroenterol, B-3000 Louvain, Belgium; Mt Sinai Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; KU Leuven; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Alman, BA (corresponding author), Hosp Sick Children, Div Orthopaed Surg, Programme Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Van+Cutsem, Eric/ABE-1762-2021; Bapat, Bharati/B-5839-2014; van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039				Alman BA, 1997, AM J PATHOL, V151, P329; Alman BA, 1997, DIAGN MOL PATHOL, V6, P98, DOI 10.1097/00019606-199704000-00005; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOSMAN FT, 1992, J CLIN PATHOL, V45, P120, DOI 10.1136/jcp.45.2.120; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Fukuchi T, 1998, CANCER RES, V58, P3526; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Giarola M, 1998, BRIT J CANCER, V78, P582, DOI 10.1038/bjc.1998.544; Iwao K, 1998, CANCER RES, V58, P1021; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitaeva MN, 1997, CANCER RES, V57, P4478; Koch A, 1999, CANCER RES, V59, P269; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Li MM, 1996, HUM PATHOL, V27, P939, DOI 10.1016/S0046-8177(96)90221-X; Liu D, 1997, LAB INVEST, V77, P557; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PLUKKER JT, 1995, BRIT J SURG, V82, P510, DOI 10.1002/bjs.1800820424; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; Takayama T, 1998, BRIT J CANCER, V77, P605, DOI 10.1038/bjc.1998.97; vanDiest PJ, 1997, J CLIN PATHOL, V50, P801, DOI 10.1136/jcp.50.10.801; vanDiest PJ, 1996, ANAL QUANT CYTOL, V18, P351; Voeller HJ, 1998, CANCER RES, V58, P2520; Zurawel RH, 1998, CANCER RES, V58, P896	33	237	248	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6615	6620		10.1038/sj.onc.1203041	http://dx.doi.org/10.1038/sj.onc.1203041			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597266				2022-12-28	WOS:000083709200026
J	Lai, HK; Borden, KLB				Lai, HK; Borden, KLB			The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA	ONCOGENE			English	Article						PML; nuclear bodies; APL; RING; RNA transport	INITIATION-FACTOR 4E; RING FINGER DOMAIN; TRANSLATION INITIATION; BINDING-PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ONCOPROTEIN PML; MESSENGER-RNA; GENE-PRODUCT; CELL-DEATH; BODIES	The majority of the promyelocytic leukemia (PML) protein is present in nuclear bodies which are altered in several pathogenic conditions including acute promyelocytic leukemia. PML nuclear bodies are found in nearly all cells yet their function remains unknown. Here, we demonstrate that PML and the eukaryotic initiation factor 4E (eIF-4E) co-localize and co-immunopurify. eIF-4E is involved in nucleocytoplasmic transport of specific mRNAs including cyclin D1, eIF-4E overexpression leads to increased cyclin D1 protein levels;,whereas, overexpression of PML leads to decreased cyclin D1 le,els. Neither PML nor eIF-4E cause significant changes in cyclin D1 mRNA levels. The association with eIF-4E led us to investigate if PML could alter mRNA distribution as a possible post-transcriptional mechanism for suppressing cyclin D1 production. We show that overexpression of PML results in nuclear retention of cyclin D1 mRNA and that intact PR-IL nuclear bodies are required. Addition of eIF-4E overcomes PML induced retention and alters the morphology of PML bodies suggesting a mechanism by which eIF-4E can modulate PML function. These results raise the possibility that PML nuclear bodies may participate in the regulation of nucleocytoplasmic transport of specific mRNAs.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Borden, KLB (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1218, New York, NY 10029 USA.				NCI NIH HHS [R01 CA80728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Boddy MN, 1996, ONCOGENE, V13, P971; Boddy MN, 1997, J CELL SCI, V110, P2197; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1998, J VIROL, V72, P3819, DOI 10.1128/JVI.72.5.3819-3826.1998; CAMPBELL DE, 2000, IN PRESS J VIROL; Carlile GW, 1998, BIOCHEM J, V335, P691, DOI 10.1042/bj3350691; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KENTSIS A, 2000, IN PRESS CURR OPIN P; Knudsen KE, 1999, CANCER RES, V59, P2297; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Mayfield S, 1996, CHEM BIOL, V3, P415, DOI 10.1016/S1074-5521(96)90088-5; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; STUURMAN N, 1992, J CELL SCI, V101, P773; STUURMAN N, 1997, CELL MOL BIOL LETT, V2, P137; TERRIS B, 1995, CANCER RES, V55, P1590; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yacoub A, 1996, NUCLEIC ACIDS RES, V24, P4298, DOI 10.1093/nar/24.21.4298; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	42	81	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1623	1634		10.1038/sj.onc.1203473	http://dx.doi.org/10.1038/sj.onc.1203473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763819				2022-12-28	WOS:000086083800002
J	Luque, I; Zong, WX; Chen, CL; Gelinas, C				Luque, I; Zong, WX; Chen, CL; Gelinas, C			N-terminal determinants of I kappa B alpha necessary for the cytoplasmic regulation of c-Rel	ONCOGENE			English	Article						I kappa B alpha; c-Rel; NF-kappa B	DNA-BINDING; NUCLEAR-LOCALIZATION; MEDIATED INHIBITION; ANKYRIN REPEATS; SEQUENCES; COMPLEX; DOMAIN; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION	I kappa-B alpha is a dual regulator of Rel/NF-kappa B transcription factors. I kappa B alpha retains inactive NF-kappa B dimers in the cytoplasm, and inhibits their DNA-binding and transcriptional activities in the nucleus. Our previous studies identified discrete functional domains in I kappa B alpha responsible for the cytoplasmic and nuclear regulation of c-Rel, Determinants necessary for regulating c-Rel in the nucleus mapped to the central ankyrin domain of I kappa-B alpha and a fen negatively-charged amino acids that follow in the C-terminal PEST region. In contrast, sequences involved in the cytoplasmic regulation of c-Rel reside in the N-terminal and central ankyrin domains of I kappa B alpha. Here, we present a refined mapping of the N-terminal determinants of I kappa B alpha necessary for the cytoplasmic regulation of c-Rel homodimers, We demonstrate that amino acids 48-58 in p40/I kappa-B alpha are essential to block the nuclear localization of c-Rel dimers, These data define a region of I kappa B alpha that may be required for optimal masking of the c-Rel NLS, or for the nuclear export of c-Rel/I kappa B alpha complexes. These findings highlight a novel function for the N-terminus of I kappa B alpha in the control of the subcellular localization of Rel/NF-kappa B dimers, Given the implication of deregulated NF-kappa B activity in hematopoietic and solid tumors, our findings predict that certain alterations in this domain of I kappa B alpha may have severe biological repercussions.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gelinas, C (corresponding author), CABM, 679 Hoes Lane, Piscataway, NJ 08854 USA.		Luque, Ignacio/D-5060-2009; Luque, Inmaculada/K-9464-2014	Luque, Ignacio/0000-0002-0336-5094; Luque, Inmaculada/0000-0003-1838-2636	NATIONAL CANCER INSTITUTE [R29CA054999, R01CA054999] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; RAYETB, 1999, ONCOGENE, V18, P6938; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SACHDEV S, 1995, ONCOGENE, V11, P811; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Xu X, 1997, ONCOGENE, V14, P1521, DOI 10.1038/sj.onc.1200985; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	41	7	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1239	1244		10.1038/sj.onc.1203400	http://dx.doi.org/10.1038/sj.onc.1203400			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713713				2022-12-28	WOS:000085567800015
J	Ciesielski, MJ; Fenstermaker, RA				Ciesielski, MJ; Fenstermaker, RA			Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function	ONCOGENE			English	Article						epidermal growth factor receptor; glioma; intron; oncogene; phosphorylation; recombination	HUMAN GLIOBLASTOMA CELLS; CONFERS ENHANCED TUMORIGENICITY; EGF-RECEPTOR; TYROSINE KINASE; HUMAN GLIOMAS; MALIGNANT GLIOMAS; FACTOR-ALPHA; EXPRESSION; TRANSFORMATION; AMPLIFICATION	A number of epidermal growth factor receptor (EGFR) deletion mutants have been identified in gliomas, in which the EGFR gene is frequently amplified and rearranged. We have previously characterized the structure of a gene in A-172 human glioma cells that encodes a 190-kDa EGFR mutant with tandem duplication of the tyrosine kinase (TK) and calcium-mediated internalization (CAIN) domains, Here we describe a 185-kDa tandem duplication mutant (TDM) that is expressed in KE and A-1235 glioma cells, along with certain functional characteristics of the mutants. The corresponding transcripts in KE and A-1235 cells contain 1053 additional nucleotides representing an in-frame duplication of exons 18 through 25 which encode the entire TK region and a portion of the CAIN domain. As with duplication of the entire TK/CAIN region (exons 18-26) in A-172 cells, duplication of exons 18-25 is associated with a specific genomic rearrangement between flanking introns, Involved introns contain homology to recombination signal sequence (RSS) heptamers present in the V(D)J region of the T lymphocyte receptor gene. In defined medium, both oncogenic TDM are constitutively autophosphorylated and inefficiently downregulated, High-affinity binding is reduced in EGFR.TDM/18-26, although the t1/2 of receptor internalization is not prolonged.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Neurosurg, Buffalo, NY 14263 USA; SUNY Buffalo, Dept Neurosurg, Sch Med & Biomed Sci, Buffalo, NY 14260 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Fenstermaker, RA (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Neurosurg, Elm & Carlton St, Buffalo, NY 14263 USA.				NCI NIH HHS [CA 16056-22] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Etienne MC, 1998, CLIN CANCER RES, V4, P2383; Fenstermaker RA, 1998, ONCOGENE, V16, P3435, DOI 10.1038/sj.onc.1202156; Frisa PS, 1996, CELL GROWTH DIFFER, V7, P223; HALEY JD, 1989, ONCOGENE, V4, P273; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; HUMPHREY PA, 1988, CANCER RES, V48, P2231; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1996, ONCOGENE, V13, P85; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PANNEERSELVAM K, 1995, EUR J BIOCHEM, V230, P951, DOI 10.1111/j.1432-1033.1995.tb20641.x; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; Roth DB, 1998, CELL, V94, P411, DOI 10.1016/S0092-8674(00)81580-9; SCHLEGEL J, 1994, INT J CANCER, V56, P72; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	37	35	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					810	820		10.1038/sj.onc.1203409	http://dx.doi.org/10.1038/sj.onc.1203409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698499				2022-12-28	WOS:000085192100011
J	Pim, D; Thomas, M; Javier, R; Gardiol, D; Banks, L				Pim, D; Thomas, M; Javier, R; Gardiol, D; Banks, L			HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase	ONCOGENE			English	Article						HPV E6; DLG; ubiquitin	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; P53 IN-VITRO; CERVICAL-CANCER; HUMAN HOMOLOG; PROGNOSTIC-SIGNIFICANCE; MUTATIONAL ANALYSIS; PDZ DOMAINS; CELLS; ONCOPROTEIN	The Discs Large (DLG) tumour suppressor protein is targeted for ubiquitin mediated degradation by the high risk human papillomavirus (HPV) E6 proteins. In this study we have used a mutational analysis of E6 in order to investigate the mechanism by which this occurs. We first show that the differences in the affinities of HPV-16 and of HPV-18 E6 proteins for binding DLG is reflected in their respective abilities to target DLG for degradation. A mutational analysis of HPV-18 E6 has enabled us to define regions within the carboxy terminal half of the protein which are essential for the ability of E6 to direct the degradation of DLG. Mutants within the amino terminal portion of E6 which have lost the ability to bind the E6-AP ubiquitin ligase, as measured by their ability to degrade p53, nonetheless retain the ability to degrade DLG. Significant levels of DLG degradation are also obtained using wheat germ extracts which lack E6-AP. Finally, we show that the transfer of the DLG binding domain onto the low risk HPV-6 E6 confers DLG binding activity to that protein and, most significantly, allows HPV-6 E6 to target DLG for degradation. These results indicate that E6 mediated degradation of DLG does not involve the EB-AP ubiquitin ligase and, in addition, shows that the high and low risk HPV E6 proteins most likely share a common cellular intermediary in the ubiquitin pathway.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA; Fac Ciencias Bioquim, Inst Mol & Cellular Biol, Dept Microbiol, RA-2000 Rosario, Argentina	International Center for Genetic Engineering & Biotechnology (ICGEB); Baylor College of Medicine	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.				NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA58541, R01 CA058541] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BARNES W, 1988, GYNECOL ONCOL, V29, P267, DOI 10.1016/0090-8258(88)90225-9; BURNETT AF, 1992, GYNECOL ONCOL, V47, P343, DOI 10.1016/0090-8258(92)90137-8; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HIRAIWA A, 1993, VIROLOGY, V192, P102, DOI 10.1006/viro.1993.1012; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Inoue T, 1998, MOL CARCINOGEN, V21, P215; ISHIWATARI H, 1994, J MED VIROL, V44, P243, DOI 10.1002/jmv.1890440306; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; THOMAS M, 1995, ONCOGENE, V10, P261; VILLA LL, 1991, VIROLOGY, V181, P374; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; ZHANG JW, 1995, GYNECOL ONCOL, V57, P170, DOI 10.1006/gyno.1995.1120; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	47	80	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2000	19	6					719	725		10.1038/sj.onc.1203374	http://dx.doi.org/10.1038/sj.onc.1203374			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698489				2022-12-28	WOS:000085192100001
J	Gryz, EA; Meakin, SO				Gryz, EA; Meakin, SO			Acidic substitution of the activation loop tyrosines in TrkA supports nerve growth factor-independent cell survival and neuronal differentiation	ONCOGENE			English	Article						nerve growth factor; TrkA; tyrosine kinase receptor; kinase activation; activation loop; neurotrophins	MAP KINASE KINASE; FACTOR-I RECEPTOR; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MAMMALIAN-CELLS; PC12 CELLS; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; BINDING-SITES	TrkA is the receptor tyrosine kinase (RTK) for nerve growth factor (NGF) and stimulates NGF-dependent cell survival and differentiation in primary neurons. TrkA expression in neuronal tumors also supports NGF-dependent differentiation of neuroblastomas and apoptosis of medulloblastomas. Phosphorylation of the activation loop tyrosines in RTK's are essential to activation as well as allosteric changes that facilitate substrate interaction and phosphorylation. Acidic amino acid substitution of the activation loop tyrosines in TrkA, Tyr(683)Tyr(684), was performed to mimic the negative charges normally induced by ligand activation and receptor phosphorylation. A total of eight independent mutants containing single or double substitutions were generated for comparison. Herein, we demonstrate that acidic substitution of the activation loop tyrosines is sufficient to induce allosteric changes required for constitutive TrkA kinase activity as well as phosphorylation of TrkA signaling proteins such as Shc, PLC gamma-1, FRS-2 and erk1/2. The strongest constitutively active TrkA mutants, GluAsp and AspGlu, support NGF-independent neuritogenesis and cell survival to levels approximately 65 and 80-100%, respectively, of NGF-activated wild type TrkA. Thus, constitutively active TrkA may provide a useful strategy in future therapeutic approaches to limit the development and progression of neuronal tumors.	John P Robarts Res Inst, Neurodegenerat Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Neurodegenerat Grp, 100 Perth Dr, London, ON N6A 5K8, Canada.		Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; Goldsmith BA, 1997, J NEUROCHEM, V69, P1014; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GREEN SH, 1986, J BIOL CHEM, V261, P5316; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LONGATI P, 1994, ONCOGENE, V9, P49; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; McCarty JH, 1998, ONCOGENE, V16, P1691, DOI 10.1038/sj.onc.1201688; Meakin SO, 1997, J NEUROCHEM, V69, P954; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1991, P NATL ACAD SCI USA, V88, P5862, DOI 10.1073/pnas.88.13.5862; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Muragaki Y, 1997, J NEUROSCI, V17, P530; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; POLUHA W, 1995, ONCOGENE, V10, P185; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Raffioni S, 1998, J BIOL CHEM, V273, P35250, DOI 10.1074/jbc.273.52.35250; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHILLING P, 1991, J HYPERTENS, V9, P3; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHANG B, 1991, J BIOL CHEM, V266, P990	56	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					417	430		10.1038/sj.onc.1203330	http://dx.doi.org/10.1038/sj.onc.1203330			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656690				2022-12-28	WOS:000084873700013
J	Shirasaki, F; Makhluf, HA; LeRoy, C; Watson, DK; Trojanowska, M				Shirasaki, F; Makhluf, HA; LeRoy, C; Watson, DK; Trojanowska, M			Ets transcription factors cooperate with Sp1 to activate the human Tenascin-C promoter	ONCOGENE			English	Article						Tenascin-C; transcriptional regulation; Fli1; GABP; Sp1	EXTRACELLULAR-MATRIX PROTEIN; ALPHA-2(I) COLLAGEN GENE; BINDING-SITES; DNA-BINDING; MONOCLONAL-ANTIBODIES; HUMAN FIBROBLASTS; TISSUE INHIBITOR; MOUSE TENASCIN; GROWTH-FACTORS; FAMILY MEMBER	Tenascin-C (TN-C), an extracellular matrix glycoprotein is expressed during embryonic development, but is present only at low levels in normal adult tissues. TN-C is re-expressed during wound healing, fibrotic diseases and in cancer. To better understand the mechanisms that control TN-C gene expression, we examined the regulation of the human TN-C promoter in human fibroblasts. We demonstrate that a short segment of the TN-C promoter between bp -133 and -27 contains three evolutionarily conserved Ets binding sites (EBS). These three EBSs bind in vitro expressed Fli1 protein and mediate transactivation of the TN-C gene by Fli1. Furthermore, two proximal EBSs contribute significantly to basal activity of the TN-C promoter. GABP, which is present in human fibroblast nuclear extracts, interacts with the two proximal EBSs, In addition, several Spl and Sp3 binding sites have been located in close proximity to the EBSs within this promoter region. The studies performed in Drosophila cells demonstrate that either Fli1 or GABP alpha + beta 1 functionally interact with Spl resulting in a synergistic stimulation of the TN-C promoter activity. In conclusion, this study shows for the first time that the TN-C gene is regulated by Ets proteins, which together with Spl act as potent activators of TN-C expression.	Med Univ S Carolina, Hollings Canc Ctr, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Trojanowska, M (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA.			Trojanowska, Maria/0000-0001-9550-7178	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042334] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42334] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; CHIQUETEHRISMANN R, 1995, BIOESSAYS, V17, P873, DOI 10.1002/bies.950171009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPERTINO DW, 1995, P NATL ACAD SCI USA, V92, P2131, DOI 10.1073/pnas.92.6.2131; Copertino DW, 1997, P NATL ACAD SCI USA, V94, P1846, DOI 10.1073/pnas.94.5.1846; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crossin KL, 1996, J CELL BIOCHEM, V61, P592; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FUJIWARA S, 1990, HYBRIDOMA, V9, P559, DOI 10.1089/hyb.1990.9.559; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHERZI R, 1995, FEBS LETT, V369, P335, DOI 10.1016/0014-5793(95)00778-8; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Gherzi R, 1997, DNA CELL BIOL, V16, P559, DOI 10.1089/dna.1997.16.559; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; Hodge DR, 1996, ONCOGENE, V12, P11; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KOIZUMI S, 1990, ONCOGENE, V5, P675; Kusagawa H, 1998, BRIT J CANCER, V77, P98, DOI 10.1038/bjc.1998.15; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Mackie EJ, 1997, INT J BIOCHEM CELL B, V29, P1133, DOI 10.1016/S1357-2725(97)00031-9; Mager AM, 1998, INT J DEV BIOL, V42, P561; Makhluf HA, 1996, J INVEST DERMATOL, V107, P856, DOI 10.1111/1523-1747.ep12331160; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Meyer D, 1995, INT J DEV BIOL, V39, P909; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RAO VN, 1993, ONCOGENE, V8, P2167; RETTIG WJ, 1994, J CELL SCI, V107, P487; SAKAI T, 1993, BRIT J CANCER, V67, P1058, DOI 10.1038/bjc.1993.194; SETH A, 1993, ONCOGENE, V8, P1783; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHOJI T, 1992, VIRCHOWS ARCH A, V421, P53, DOI 10.1007/BF01607139; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; YAMADA S, 1992, LIVER, V12, P10; Yoshida T, 1997, J PATHOL, V182, P421; YOSHIDA T, 1995, CANCER LETT, V90, P65, DOI 10.1016/0304-3835(94)03679-D; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zhang XK, 1995, HYBRIDOMA, V14, P563, DOI 10.1089/hyb.1995.14.563	59	79	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7755	7764		10.1038/sj.onc.1203360	http://dx.doi.org/10.1038/sj.onc.1203360			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618716	Bronze			2022-12-28	WOS:000084256900005
J	Hans, MA; Muller, M; Meyer-Ficca, M; Burkle, A; Kupper, JH				Hans, MA; Muller, M; Meyer-Ficca, M; Burkle, A; Kupper, JH			Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: Evidence for increased tumor cell apoptosis in vivo	ONCOGENE			English	Article						apoptosis; DNA damage; PARP; transfection; tumorigenesis	HUMAN POLY(ADP-RIBOSE) POLYMERASE; DNA-BINDING DOMAIN; TRANSDOMINANT INHIBITION; GAMMA-IRRADIATION; MAMMALIAN-CELLS; HAMSTER-CELLS; CLEAVAGE; PROTEASE; REPAIR; MUTANT	Poly(ADP-ribose) polymerase (PARP(4)) catalyzes the formation of ADP-ribose polymers covalently attached to proteins by using NAD(+) as substrate. PARP is strongly activated by DNA single- or double-strand breaks and is thought to be involved in cellular responses to DNA damage. We characterized a dominant negative PARP mutant, i.e, the DNA-binding domain of this enzyme, whose overexpression in cells leads to increased genetic instability following DNA damage. In order to study whether PARP activity is also implicated in the process of tumorigenesis, me generated stably transfected HeLa cell clones with constitutive overexpression of dominant negative PARP and investigated tumor formation of these clones in nude mice. We found that inhibition of PARP activity dramatically reduces tumor forming ability of HeLa cells. Moreover, me provide strong evidence that the observed reduction in tumor forming ability is due to increased tumor cell apoptosis in viva. Viewed together, our data and those from other groups show that inhibition of PARP enzyme activity interferes with DNA base excision repair and leads to increased genetic instability and recombination but, on the other hand, can sensitize cells to apoptotic stimuli and by this mechanism may prevent tumor formation.	Univ Tubingen, Dept Mol Pathol, D-72076 Tubingen, Germany; German Canc Res Ctr, Dept Tumorvirol, D-69120 Heidelberg, Germany	Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ)	Kupper, JH (corresponding author), Univ Tubingen, Dept Mol Pathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.		Meyer-Ficca, Mirella/P-1771-2014	Meyer-Ficca, Mirella/0000-0002-9949-8157				Butler AJ, 1999, MOL CELL BIOL, V19, P296; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawamitsu H, 1983, Princess Takamatsu Symp, V13, P41; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kupper JH, 1996, CANCER RES, V56, P2715; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; Kupper JH, 1996, CYTOTECHNOLOGY, V21, P225, DOI 10.1007/BF00365345; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VanGool L, 1997, EUR J BIOCHEM, V244, P15; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X	24	20	23	2	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7010	7015		10.1038/sj.onc.1203178	http://dx.doi.org/10.1038/sj.onc.1203178			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597301	Bronze			2022-12-28	WOS:000083901900007
J	Lu, YL; Lin, YZ; LaPushin, R; Cuevas, B; Fang, XJ; Yu, SX; Davies, MA; Khan, H; Furui, T; Mao, ML; Zinner, R; Hung, MC; Steck, P; Siminovitch, K; Mills, GB				Lu, YL; Lin, YZ; LaPushin, R; Cuevas, B; Fang, XJ; Yu, SX; Davies, MA; Khan, H; Furui, T; Mao, ML; Zinner, R; Hung, MC; Steck, P; Siminovitch, K; Mills, GB			The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells	ONCOGENE			English	Article						PTEN/MMAC1; PI3-K (phosphatidylinositol 3-kinase); breast cancer; apoptosis; anoikis; cell cycle arrest	GLYCOGEN-SYNTHASE KINASE-3; IN-VITRO; PHOSPHATASE-ACTIVITY; GLIOBLASTOMA CELLS; GLIOMA-CELLS; PTEN; PHOSPHORYLATION; ACTIVATION; SURVIVAL; DEATH	The PTEN/MMAC1/TEP (PTEN) tumor suppressor gene at 10q23.3 is mutated in multiple types of sporadic tumors including breast cancers and also in the germline of patients with the Cowden's breast cancer predisposition syndrome. The PTEN gene encodes a multifunctional phosphatase capable of dephosphorylating the same sites in membrane phosphatidylinositols phosphorylated by phosphatidylinositol 3'-kinase (PI3K). We demonstrate herein that loss of PTEN function in breast cancer cells results in an increase in basal levels of phosphorylation of multiple components of the PI3K signaling cascade as web as an increase in duration of ligand-induced signaling through the PI3K cascade. These alterations are reversed by wild-type but not phosphatase inactive PTEN. In the presence of high concentrations of serum, enforced expression of PTEN induces a predominant G1 arrest consistent with the capacity of PTEN to evoke increases in the expression of the p27Kip1 cyclin dependent kinase inhibitor. In the presence of low concentrations of serum, enforced PTEN expression results in a marked increase in cellular apoptosis, a finding which is consistent with the capacity of PTEN to alter the phosphorylation, and presumably function, of the AKT, BAD, p70S6 kinase and GSK3 alpha apoptosis regulators. Under anchorage-independent conditions, PTEN also induces anoikis, a form of apoptosis that occurs when cells are dissociated from the extracellular matrix, which is enhanced in conjunction with low serum culture conditions. Together, these data suggest that PTEN effects on the PI3K signaling cascade are influenced by the cell stimulatory context, and that depending on the exposure to growth factors and other exogenous stimuli such as integrin ligation, PTEN can induce cell cycle arrest, apoptosis or anoikis in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Toronto, Dept Med Immunol & Mol & Med Genet, Toronto, ON M5G 1X5, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Toronto	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Div Med, 1515 Holcombe Blvd,Box 092, Houston, TX 77030 USA.		Siminovitch, Katherine/K-1475-2013; Hung, Mien-Chie/ABD-5911-2021; Davies, Michael/GWV-2527-2022	Hung, Mien-Chie/0000-0003-4317-4740; 	NATIONAL CANCER INSTITUTE [R01CA071418] Funding Source: NIH RePORTER; NCI NIH HHS [CA71418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheney IW, 1998, CANCER RES, V58, P2331; Cheyney IW, 1999, CANCER RES, V59, P2318; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DICRISTOFANO A, 1998, LEUKEMIA, V12, P1277; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Furnari FB, 1998, CANCER RES, V58, P5002; FURNARI FB, 1997, CANCER RES, V57, P4997; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Koester SK, 1997, CYTOMETRY, V29, P306; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1998, CANCER RES, V58, P5667; LI J, 1997, NAT GENET, V15, P356; LIAW D, 1997, CANCER RES, V57, P2124; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARSH DJ, 1997, HUM MOL GENET, V6, P1383; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PARSONS R, 1998, ONCOGENE, V16, P89; Pepper C, 1998, LEUKEMIA RES, V22, P439, DOI 10.1016/S0145-2126(98)00013-7; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; SCHULTZ RM, 1995, ANTICANCER RES, V15, P1135; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SHI YF, 1995, CANCER RES, V55, P1982; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STECK PA, 1997, NAT GENET, V16, P64; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1999, CANCER RES, V59, P442; TAMURA M, 1998, CANCER RES, V58, P2331; Teng DHF, 1997, CANCER RES, V57, P5221; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	51	260	289	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7034	7045		10.1038/sj.onc.1203183	http://dx.doi.org/10.1038/sj.onc.1203183			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597304				2022-12-28	WOS:000083901900010
J	Qiu, SG; Krishnan, S; El-Guendy, N; Rangnekar, VM				Qiu, SG; Krishnan, S; El-Guendy, N; Rangnekar, VM			Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation	ONCOGENE			English	Article						Ras; Par-4; ERK; transformation	PROTEIN-KINASE-C; MAMMALIAN-CELL; GROWTH ARREST; GENE; PHOSPHORYLATION; APOPTOSIS; ACTIVATION; SURVIVAL; INHIBITION; EXPRESSION	Oncogenic variants of the cellular Ras protein are often associated with different types of human cancers. However, the mechanisms by which oncogenic Ras induces transformation are not fully established. Expression of the transcriptional repressor Par-4 was downregulated by oncogenic Ras via the Raf-MEK-ERK pathway. Restoration of Par-4 levels by abrogation of the Raf-MEK-ERK pathway with the MEK-inhibitor PD98059 or by ectopic Par-4, that acted to inhibit ERK expression and activation, was sufficient to suppress oncogenic Ras-induced transformation. These findings identify Par-4 as a novel target that has to be downmodulated by oncogenic Ras for successful transformation.	Univ Kentucky, Dept Surg, Lexington, KY 40536 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Combs Res Bldg,Room 303,800 Rose St, Lexington, KY 40536 USA.			El-Guendy, Nadia/0000-0002-0770-3740	NCI NIH HHS [R01 CA60872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; BOS JL, 1989, CANCER RES, V49, P4682; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GALANG CK, 1994, ONCOGENE, V9, P2913; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KISS Z, 1995, FEBS LETT, V357, P279, DOI 10.1016/0014-5793(94)01371-7; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Muthukkumar S, 1996, J BIOL CHEM, V271, P5733, DOI 10.1074/jbc.271.10.5733; PARK M, 1998, GENETIC BASIS HUMAN, P205; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	35	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7115	7123		10.1038/sj.onc.1203199	http://dx.doi.org/10.1038/sj.onc.1203199			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597313				2022-12-28	WOS:000083901900019
J	Yoon, Y; Ao, ZH; Cheng, Y; Schlossman, SF; Prasad, KVS				Yoon, Y; Ao, ZH; Cheng, Y; Schlossman, SF; Prasad, KVS			Murine Siva-1 and Siva-2, alternate splice forms of the mouse Siva gene, both bind to CD27 but differentially transduce apoptosis	ONCOGENE			English	Article						Siva; CD27; apoptosis; alternate splice forms; murine Siva gene; TNFR family	NECROSIS-FACTOR RECEPTOR; NF-KAPPA-B; DOMAIN-CONTAINING RECEPTOR; T-CELL ACTIVATION; RING FINGER PROTEIN; DEATH-DOMAIN; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; KINASE RIP; FAMILY	CD27, a member of the TNFR family known to provide essential co-stimulatory signals for T cell growth and B cell Ig synthesis, can also mediate cell death. Using the CD27 cytoplasmic tail as the bait in yeast two hybrid assay, me previously cloned human Siva, a pro-apoptotic molecule. Here me report the characterization of the mouse Siva gene as a 4 kb sequence containing 4 exons and 3 introns. RT-PCR has revealed the presence of two forms of mouse Siva mRNA, the longer full length form Siva-1 and the shorter Siva-2 lacking the sequence coded by exon 2. Immunoblotting with anti-Siva (human) antibodies clearly demonstrate the presence of both Siva-1 and Siva-2. Cotransfection experiments in 293T cells reveal that mouse CD27 receptor can interact with both forms of Siva. Although mouse Siva-1 can trigger apoptosis in Rat-1 cells and in some of the mouse cell lines in transient transfection experiments, similar to the observation made with human Siva, intriguingly its alternate splice form, Siva-2 appears to be much less toxic. It is therefore likely that Siva-2 could regulate the function of Siva-1.	Dana Farber Canc Inst, Div Tumor Immunol, Dept Canc Immunol & Aids, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Prasad, KVS (corresponding author), Dana Farber Canc Inst, Div Tumor Immunol, Dept Canc Immunol & Aids, M552,44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056706] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56706] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGEMATSU K, 1994, J IMMUNOL, V153, P1421; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Baker SJ, 1996, ONCOGENE, V12, P1; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; GRAVESTEIN LA, 1993, EUR J IMMUNOL, V23, P943, DOI 10.1002/eji.1830230427; HINTZEN RQ, 1995, J IMMUNOL, V154, P2612; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jacquot S, 1997, J IMMUNOL, V159, P2652; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KOBATA T, 1995, P NATL ACAD SCI USA, V92, P11249, DOI 10.1073/pnas.92.24.11249; KOBATA T, 1994, J IMMUNOL, V153, P5422; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Padanilam BJ, 1998, KIDNEY INT, V54, P1967, DOI 10.1046/j.1523-1755.1998.00197.x; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	49	42	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7174	7179		10.1038/sj.onc.1203144	http://dx.doi.org/10.1038/sj.onc.1203144			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597319				2022-12-28	WOS:000083901900025
J	Furth, PA; Bar-Peled, U; Li, ML; Lewis, A; Laucirica, R; Jager, R; Weiher, H; Russell, RG				Furth, PA; Bar-Peled, U; Li, ML; Lewis, A; Laucirica, R; Jager, R; Weiher, H; Russell, RG			Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model	ONCOGENE			English	Article						Bcl-2; cancer progression; mitosis; apoptosis; mouse model	DEPENDENT PROTEIN-KINASES; CELL-CYCLE PROGRESSION; LYMPH-NODE METASTASES; LARGE-T-ANTIGEN; BREAST-CANCER; MAMMARY-GLAND; REDUCES PROLIFERATION; TRANSGENE EXPRESSION; SUPPRESSION; FAMILY	Bcl-2 is an anti-apoptotic and anti-proliferative protein over-expressed in several different human cancers including breast, Gain of Bcl-2 function in mammary epithelial cells was superimposed on the WAP-TAg transgenic mouse model of breast cancer progression to determine its effect on epithelial cell survival and proliferation at three key stages in oncogenesis: the initial proliferative process, hyperplasia, and cancer. During the initial proliferative process, Bcl-2 strongly inhibited both apoptosis and mitotic activity. However as tumorigenesis progressed to hyperplasia and adenocarcinoma, the inhibitory effects on mitotic activity were lost. In contrast, anti-apoptotic activity persisted in both hyperplasias and adenocarcinomas. These results demonstrate that the inhibitory effect of Bcl-2 on epithelial cell proliferation and apoptosis can separate during cancer progression. In this model, retention of anti-apoptotic activity with loss of anti-proliferative action resulted in earlier tumor presentation.	Univ Maryland, Ctr Med Biotechnol, Inst Human Virol, Sch Med,Dept Med,Div Infect Dis, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Baylor Coll Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Inst Diabet Forsch, D-80804 Munich, Germany	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Helmholtz Association; Karlsruhe Institute of Technology	Furth, PA (corresponding author), Univ Maryland, Ctr Med Biotechnol, Inst Human Virol, Sch Med,Dept Med,Div Infect Dis, 725 W Lombard St,Room N545, Baltimore, MD 21201 USA.		Jager, Richard/B-9478-2009	Jager, Richard/0000-0002-1623-1917	NATIONAL CANCER INSTITUTE [R29CA068033] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; Bonetti A, 1998, CLIN CANCER RES, V4, P2331; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bottinger EP, 1997, CANCER RES, V57, P5564; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DEMERIL D, 1996, CANCER, V77, P1494; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; Frankfurt OS, 1997, CLIN CANCER RES, V3, P465; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Kitada S, 1998, AM J PATHOL, V152, P51; KORSMEYER SJ, 1992, BLOOD, V80, P879; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lind EF, 1999, J IMMUNOL, V162, P5374; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; OReilly LA, 1997, J IMMUNOL, V159, P2301; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Pillai MR, 1996, CANCER EPIDEM BIOMAR, V5, P329; Ravaioli A, 1998, CELL PROLIFERAT, V31, P113; SAEGUSA M, 1995, CANCER, V76, P2297, DOI 10.1002/1097-0142(19951201)76:11<2297::AID-CNCR2820761118>3.0.CO;2-B; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHANKEY TV, 1993, CYTOMETRY, V14, P472, DOI 10.1002/cyto.990140503; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Sierra A, 1996, CLIN CANCER RES, V2, P1887; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Theodorakis P, 1996, ONCOGENE, V12, P1707; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TZENG YJ, 1993, ONCOGENE, V8, P1965; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zhang GJ, 1998, ONCOL REP, V5, P1211	48	42	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6589	6596		10.1038/sj.onc.1203073	http://dx.doi.org/10.1038/sj.onc.1203073			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597263				2022-12-28	WOS:000083709200023
J	Manna, SK; Aggarwal, BB				Manna, SK; Aggarwal, BB			All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kappa B, activated protein-1 and apoptosis in human lung cancer cells	ONCOGENE			English	Article						ATRA; TNF; NF-kappa B; AP-1; apoptosis	TUMOR-NECROSIS-FACTOR; LYMPHOMA U-937 CELLS; FACTOR-ALPHA; SURFACE EXPRESSION; CELLULAR-RESPONSE; GROWTH-INHIBITION; INTERFERON-GAMMA; HL-60 CELLS; LINE HL-60; DIFFERENTIATION	Retinoids modulate the growth and differentiation effects of TNF but the mechanism is not understood. In this study, we investigated the effect of all-tr all-trans-retinoic acid (ATRA) on the cell surface expression of TNF receptors and receptor-mediated signaling in various human lung cancer cell lines. ATRA treatment of cells that express wild-type p53 (A549 and H460), or null p53 (H1299), or mutant p53 (H596) increased the number of TNF receptors, as determined by the specific binding of I-125-labeled TNF to these cells, in a dose- and time-dependent manner. Treatment with 2 mu M ATRA for 24 h at 37 degrees C produced the maximal increase. Scatchard analysis indicated that the increase inducted by ATRA was due to an increase in receptor number and not to an increase in affinity. The upmodulation of TNF receptors nas also confirmed by covalent receptor-ligand cross-linking studies. The increase in TNF receptors sensitized H596 cells to TNF-induced activation of NF-kappa B, AP-1 and apoptosis, A549 cells, however, were completely resistant to TNF-induced activation of NF-kappa B, AP-1 and apoptosis, Treatment of these cells with as little as 0.5 mu M ATRA was effective in converting TNF-resistant cells to TNF-sensitive. Overall our results indicate that ATRA induces the TNF receptors in human lung cancer cells, which sensitizes them to TNF-induced signaling leading to activation of NF-kappa B, AP-1 and apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; AGGARWAL BB, 1987, J BIOL CHEM, V262, P10000; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1992, TUMOR NECROSIS FACTO, P624; AMOS B, 1989, PHARM RETINOIDS SKIN, P26; BEAUPAIN R, 1990, ANTICANCER RES, V10, P1061; Benner S E, 1995, Oncology (Williston Park), V9, P205; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHAMBAUTGUERIN AM, 1995, J NEUROCHEM, V65, P537; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAN H, 1994, J BIOL CHEM, V269, P31424; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; DE LUCA LM, 1991, FASEB J, V5, P2924; DRACH J, 1993, CANCER RES, V53, P2100; FALK LA, 1991, BLOOD, V77, P1248; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gridley DS, 1996, ONCOL RES, V8, P485; HAN SK, 1994, AM J RESP CELL MOL, V11, P270, DOI 10.1165/ajrcmb.11.3.8086165; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Haridas V, 1998, J IMMUNOL, V160, P3152; HASS PE, 1985, J BIOL CHEM, V260, P2214; HEMMI H, 1987, BLOOD, V69, P501; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; JETTEN AM, 1980, NATURE, V284, P626, DOI 10.1038/284626a0; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KILIAN PL, 1988, MONOKINES OTHER NONL, P203; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; LOTAN R, 1992, CANCER RES, V52, P4878; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MEHTA K, 1994, J LEUKOCYTE BIOL, V55, P336, DOI 10.1002/jlb.55.3.336; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; Oridate N, 1995, J CELL BIOCHEM, P80; PANDITA R, 1992, FEBS LETT, V312, P87, DOI 10.1016/0014-5793(92)81416-J; PECK R, 1991, EUR J CANCER, V27, P53, DOI 10.1016/0277-5379(91)90061-H; Pestana ES, 1996, ACTA ONCOL, V35, P473, DOI 10.3109/02841869609109925; POGREBNIAK HW, 1991, J THORAC CARDIOV SUR, V102, P904, DOI 10.1016/S0022-5223(19)33941-8; PREWITT TW, 1994, J THORAC CARDIOV SUR, V107, P43; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; Sheski FD, 1999, J LAB CLIN MED, V133, P265, DOI 10.1016/S0022-2143(99)90083-5; SIDELL N, 1991, J IMMUNOL, V146, P3809; SIDELL N, 1988, CELL IMMUNOL, V115, P299, DOI 10.1016/0008-8749(88)90183-9; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1999, CANCER RES, V59, P2829; TOBLER A, 1987, BLOOD, V70, P1940; TOTPAL K, 1995, BLOOD, V85, P3547, DOI 10.1182/blood.V85.12.3547.bloodjournal85123547; TRINCHIERI G, 1987, BLOOD, V69, P1218; WINZEN R, 1992, J IMMUNOL, V148, P3454; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; ZHENG ZS, 1990, CANCER RES, V50, P1201; Zou CP, 1998, CLIN CANCER RES, V4, P1345	57	50	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2110	2119		10.1038/sj.onc.1203547	http://dx.doi.org/10.1038/sj.onc.1203547			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815802				2022-12-28	WOS:000086728000004
J	Raouf, A; Li, V; Kola, I; Watson, DK; Seth, A				Raouf, A; Li, V; Kola, I; Watson, DK; Seth, A			The Ets1 proto-oncogene is upregulated by retinoic acid: characterization of a functional retinoic acid response element in the Ets1 promoter	ONCOGENE			English	Article						Ets1 promoter; retinoic acid; osteoblast; transcription factor	MURINE LEUKEMIA-VIRUS; C-MYC; C-ETS-1 PROTOONCOGENE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; MESSENGER-RNA; CELL-LINES; GROWTH; DIFFERENTIATION; PROTEINS	The v-ets oncoprotein and its progenitor Ets1 belong to a family of transcription factors that are related by an 85 amino acid conserved DNA binding domain, the ets domain. Ets1 plays important role(s) in control of cell proliferation, differentiation and apoptosis. Abnormal expression of Ets1 could lead to disruption of these processes and contribute to development of malignancy, Retinoic acid (RA) inhibits proliferation, induces differentiation and regulates apoptosis in many different cell types. Here, we demonstrate that RA treatment increases the expression of Ets1 mRNA, but not that of Ets2, Elk1 or Fli1 in MC3T3-E1 cells. Ets1 induction is detectable after 4 h, can be maintained for at least 14 days, and is inhibited by Actinomycin D, which suggests that RA regulation of Ets1 occurs at the transcriptional level. The promoter region of Ets1 contains four retinoic acid response element (RARE) half sites located at -94, - 152, - 1765 and - 2252 from the translation start site. We show that RAR beta is expressed by MC3T3-E1 cells in the presence of RA and demonstrate that it binds to the - 94 RARE half site. Furthermore, RA induces transcription of Ets1 promoter-reporter constructs containing this RARE half site.	Univ Toronto, Dept Lab Med & Pathobiol, MRC Grp Periodontal Physiol, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Monash Univ, Mol Genet & Dev Grp, Melbourne, Vic 3004, Australia; Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC USA	University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Monash University; Medical University of South Carolina	Seth, A (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, MRC Grp Periodontal Physiol, Toronto, ON, Canada.		Kola, Ismail/C-5254-2013					BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; Chen ZQ, 1997, CANCER RES, V57, P2013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDOFF AN, 1994, ANTICANCER RES, V14, P1199; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HART AH, 1995, ONCOGENE, V10, P1423; HOOSEIN NM, 1988, CANCER LETT, V40, P219, DOI 10.1016/0304-3835(88)90014-6; Inoue A, 1996, BIOCHEM BIOPH RES CO, V228, P182, DOI 10.1006/bbrc.1996.1636; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JORCYK CL, 1991, ONCOGENE, V6, P523; Jorcyk CL, 1997, CELL MOL BIOL, V43, P211; KARPERIEN M, 1997, MOL ENDOCRINOL, V11, P1434; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; LOHNES D, 1994, DEVELOPMENT, V120, P2723; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; NILES RM, 1988, CANCER INVEST, V6, P39, DOI 10.3109/07357908809077027; OKA T, 1991, ONCOGENE, V6, P2077; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; SUVA LJ, 1994, MOL ENDOCRINOL, V8, P1507, DOI 10.1210/me.8.11.1507; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; THIELE CJ, 1988, ONCOGENE, V3, P281; Wang DY, 1997, IN VITRO CELL DEV-AN, V33, P248; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409	41	25	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1969	1974		10.1038/sj.onc.1203505	http://dx.doi.org/10.1038/sj.onc.1203505			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773887				2022-12-28	WOS:000086424300013
J	Fuxe, J; Raschperger, E; Pettersson, RF				Fuxe, J; Raschperger, E; Pettersson, RF			Translation of p15.5(INK4B), an N-terminally extended and fully active form of p15(INK4B), is initiated from an upstream GUG codon	ONCOGENE			English	Article						cell cycle control; cell cycle inhibitors; replicative senescence; non-AUG translation initiation	DEPENDENT KINASE INHIBITORS; FIBROBLAST GROWTH-FACTOR; CELL-CYCLE ARREST; NUCLEAR-LOCALIZATION; CDK INHIBITORS; SUBCELLULAR-LOCALIZATION; TGF-BETA; IN-VIVO; CANCER; P15	The expression of the cyclin-dependent kinase inhibitor p15(INK4B) in normal cells after induction with TGF-beta 1, or following overexpression from an adenovirus-encoded cDNA, appears on an SDS-polyacrylamide gel as a doublet. Here, the underlying mechanism behind the synthesis of the two species has been studied. By expressing cDNAs truncated at their 5' end, we found that the synthesis of the more slowly migrating form, called p15.5(INK4B), is dependent on a sequence upstream of the first AUG codon thought to initiate translation of p15(INK4B). Two potential, in frame, alternative upstream initiation codons, AUG and GUG, were individually changed to GCA encoding alanine, Analysis by in vitro translation, or immunoblotting of lysates from transfected 293 cells, showed that translation of p15.5(INK4B) is initiated at the GUG located 13 codons upstream of the first AUG. When this AUG was mutated, p15(INK4B) was no longer made. Instead, a shorter form, initiated at an in frame AUG located seven codons downstream was synthesized. Finally, when both these AUGs were mutated, only p15.5(INK4B) was generated. Both p15(INK4B) and p15.5(INK4B) bound to CDK4 and CDK6, inhibited DNA synthesis, and caused replicative senescence of a human glioma cell line. We thus conclude that p15(INK4B) and p15.5(INK4B), encoded by the CDKN2B gene, are functionally indistinguishable as based on these assays.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Pettersson, RF (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.		Fuxe, Jonas/T-4433-2017	Fuxe, Jonas/0000-0003-4576-9377				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CAO YH, 1993, GROWTH FACTORS, V8, P277, DOI 10.3109/08977199308991573; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Nister M, 1994, ATLAS HUMAN TUMOR CE, P17, DOI [10.1016/B978-0-12-333530-2.50005-8, DOI 10.1016/B978-0-12-333530-2.50005-8]; Parry D, 1996, MOL CELL BIOL, V16, P3844; QUELLE DE, 1995, ONCOGENE, V11, P635; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, ONCOGENE, V11, P987; Tsubari M, 1997, CANCER RES, V57, P2966; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391	28	18	18	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1724	1728		10.1038/sj.onc.1203496	http://dx.doi.org/10.1038/sj.onc.1203496			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763830				2022-12-28	WOS:000086083800013
J	Bullock, AN; Henckel, J; Fersht, AR				Bullock, AN; Henckel, J; Fersht, AR			Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy	ONCOGENE			English	Article						tumour suppressor; stability; denaturation; activity; protein	TUMOR-SUPPRESSOR P53; WILD-TYPE; PROTEIN STABILITY; TEMPERATURE SENSITIVITY; M-VALUES; IN-VIVO; APOPTOSIS; TRANSACTIVATION; BARNASE; CELLS	The tumour suppressor p53 is mutated in half of all human cancers, most frequently with missense substitutions in its core domain. We present a new assessment of the mutation database based on quantitative folding and DNA-binding studies of the isolated core domain. Our data identify five distinct mutant classes that correlate with four well-defined regions of the core domain structure. On extrapolation to 37 degrees C the wild-type protein has a stability of 3.0 kcal/mol, This also emerges as an oncogenic threshold: all beta-sandwich mutants destabilized by this amount (50% denatured) are expected to promote cancer. Other weakly destabilizing mutations are restricted to loop 3 in the DNA-binding region, Drugs that stabilize mutant p53 folding have the potential to reactivate apoptotic signalling pathways in tumour cells either by transactivation-dependent or independent pathways. Using an affinity ligand as a proof of principle we have recovered the thermodynamic stability of the hotspot G245S. With reference states for the five mutant classes as a guide, future therapeutic strategies may similarly stabilize partially structured or binding states of mutant p53 that restore limited p53 pathways to tumour suppression.	Univ Cambridge, Chem Lab, Cambridge CB2 2QH, England; MRC Ctr, Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, Chem Lab, Hills Rd, Cambridge CB2 2QH, England.		Fersht, Alan R/B-2189-2008					BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; Chene P, 1999, J MOL BIOL, V286, P1269, DOI 10.1006/jmbi.1999.2563; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; Dalby PA, 1998, J MOL BIOL, V276, P625, DOI 10.1006/jmbi.1997.1546; Di Como CJ, 1998, ONCOGENE, V16, P2527; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Fahraeus R, 1999, J PATHOL, V187, P138; Fersht A., 1999, STRUCTURE MECH PROTE; FERSHT AR, 1993, CURR OPIN STRUC BIOL, V3, P75, DOI 10.1016/0959-440X(93)90205-Y; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guillouf C, 1998, INT J ONCOL, V13, P107; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; KASTAN MB, 1991, CANCER RES, V51, P6304; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Munoz V, 1996, FOLD DES, V1, pR71, DOI 10.1016/S1359-0278(96)00036-3; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Pace C N, 1986, Methods Enzymol, V131, P266; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ponchel F, 1998, BRIT J CANCER, V77, P1555, DOI 10.1038/bjc.1998.256; Radford SE, 1999, CELL, V97, P291, DOI 10.1016/S0092-8674(00)80739-4; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROLLEY N, 1995, ONCOGENE, V11, P763; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SAUER RT, 1992, CURR OPIN STRUC BIOL, V2, P46; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Wacey AI, 1999, HUM GENET, V104, P15, DOI 10.1007/s004390050904; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wiman KG, 1998, MED ONCOL, V15, P222, DOI 10.1007/BF02787204; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Yaffe MB, 1999, NATURE, V402, P30; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	70	310	320	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1245	1256		10.1038/sj.onc.1203434	http://dx.doi.org/10.1038/sj.onc.1203434			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713666				2022-12-28	WOS:000085743800001
J	Kristensen, VN; Harada, N; Yoshimura, N; Haraldsen, E; Lonning, P; Erikstein, B; Karesen, R; Kristensen, T; Borresen-Dale, AL				Kristensen, VN; Harada, N; Yoshimura, N; Haraldsen, E; Lonning, P; Erikstein, B; Karesen, R; Kristensen, T; Borresen-Dale, AL			Genetic variants of CYP19 (aromatase) and breast cancer risk	ONCOGENE			English	Article						CYP19 (aromatase); estrogen metabolism; polymorphism; breast cancer risk	CYTOCHROME-P450 GENE; EXPRESSION; PROMOTERS; TISSUE; CELLS; WOMEN	The effect of a SNP in exon 10 of CYP19 on tumor mRNA levels and splice variants were studied and correlated with clinical parameters and risk of breast cancer. In the vast majority of breast cancers, the estrogen levels modulate the tumor growth and depend on the activity of CYP19, Patients (n=481) and controls (n=236) were genotyped by T-tracks in a single sequencing reaction (SSR), The frequency of TT genotypes was significantly higher in patients versus controls (P=0.007) particularly among those with stage III and IV disease (P=0.004) and with tumors larger than 5 cm (P=0.001), A significant association between presence of the T allele and the level of aromatase mRNA in the tumors was observed (P=0.018), as well as with a switch from adipose promoter to ovary promoter (P=0.004). Previously, we reported a rare polymorphic allele of CYP19 (repeat (TTTA)(12)) to be significantly more frequent in breast cancer patients than in controls, Here we describe another polymorphism, a C-T substitution in exon 10 of the CYP19 gene which is in strong linkage disequilibrium with the (TTTA)n polymorphism but with higher frequency of the variant allele, Our data suggest that the T-allele of the CYP19 gene is associated with a 'high activity' phenotype.	Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway; Fujita Hlth Univ, Sch Med, Dept Biochem, Toyoake, Aichi 47011, Japan; Norwegian Radium Hosp, Inst Canc Res, Dept Oncol, N-0310 Oslo, Norway; Univ Bergen, Haukeland Hosp, Dept Oncol, N-5020 Bergen, Norway; Univ Oslo, Ullevaal Hosp, Dept Oncol, N-0407 Oslo, Norway; Univ Oslo, Dept Biochem, N-0316 Oslo, Norway	University of Oslo; Fujita Health University; University of Oslo; University of Bergen; Haukeland University Hospital; University of Oslo; University of Oslo	Borresen-Dale, AL (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.		Kristensen, Tom/C-5873-2019	Kristensen, Tom/0000-0002-2131-4469; Lonning, Per Eystein/0000-0002-8890-6303				Burak WE, 1997, BREAST CANCER RES TR, V44, P57, DOI 10.1023/A:1005782311558; DURGAM VR, 1995, BBA-GENE STRUCT EXPR, V1263, P89, DOI 10.1016/0167-4781(95)00093-V; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HARADA N, 1992, AM J HUM GENET, V51, P666; HARADA N, 1995, PHARMACOGENETICS, V5, P59; Kristensen T, 1998, BIOTECHNIQUES, V24, P832, DOI 10.2144/98245dt04; Kristensen VN, 1998, PHARMACOGENETICS, V8, P43, DOI 10.1097/00008571-199802000-00006; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MEANS GD, 1989, J BIOL CHEM, V264, P19386; Michael MD, 1997, MOL CELL ENDOCRINOL, V134, P147, DOI 10.1016/S0303-7207(97)00178-0; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Simpson E R, 1994, Int J Fertil Menopausal Stud, V39 Suppl 2, P75; SOURDAINE P, 1994, J MOL ENDOCRINOL, V13, P331, DOI 10.1677/jme.0.0130331; Thomas HV, 1997, BRIT J CANCER, V75, P1075, DOI 10.1038/bjc.1997.183; TODA K, 1989, FEBS LETT, V247, P371, DOI 10.1016/0014-5793(89)81373-0; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Zhao Y, 1997, J STEROID BIOCHEM, V61, P203, DOI 10.1016/S0960-0760(97)80013-1	19	148	155	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1329	1333		10.1038/sj.onc.1203425	http://dx.doi.org/10.1038/sj.onc.1203425			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713674				2022-12-28	WOS:000085743800009
J	Gire, V; Wynford-Thomas, D				Gire, V; Wynford-Thomas, D			RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation	ONCOGENE			English	Article						differentiation; thyroid; epithelial; oncogene; RAS	PROTEIN-KINASE-A; THYROGLOBULIN GENE; MUTANT RAS; EXPRESSION; GROWTH; TRANSFORMATION; PHOSPHORYLATION; INTERFERENCE; PATHWAYS; TTF-1	Neoplastic transformation of rodent thyroid epithelial cell lines by mutant RAS genes has been widely studied as an experimental model of oncogene-induced loss of tissue-specific differentiation. However, separate evidence strongly implicates RAS mutation as an early event in human thyroid tumour development at a stage prior to loss of differentiation. To resolve this controversy we examined the short- and long-term responses of normal human thyroid epithelial cells to mutant RAS introduced by micro-injection and retroviral transduction respectively. In both cases, expression of RAS at a level sufficient to induce rapid proliferation did not lead to loss of differentiation as shown by expression of cytokeratin 18, E-cadherin, thyroglobulin, TTF-1 and Pax-8 proteins. Indeed, RAS was able to prevent, and to reverse, the loss of thyroglobulin expression which occurs normally in TSH-deficient culture medium. These responses were partially mimicked by activation of RAF, a major RAS effector, indicating involvement of the MAP Kinase signal pathway. The striking contrast between the effect of mutant RAS on differentiation in primary human, compared to immortalized rodent, epithelial cultures is most likely explained by the influence of additional co-operating abnormalities in the latter, and highlights the need for caution in extrapolating from cell line data.	Univ Wales Coll Med, Canc Res Campaign Labs, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Canc Res Campaign Labs, Dept Pathol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.		Gire, Veronique/N-7553-2017; Gire, Véronique/AAC-2218-2020	Gire, Veronique/0000-0002-9009-2185				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AVVEDIMENTO VE, 1988, P NATL ACAD SCI USA, V85, P1744, DOI 10.1073/pnas.85.6.1744; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; BROCAS H, 1982, FEBS LETT, V137, P189, DOI 10.1016/0014-5793(82)80346-3; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; FABBRO D, 1994, CANCER RES, V54, P4744; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gallagher AP, 1998, CANCER RES, V58, P2029; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LIBERT F, 1987, NUCLEIC ACIDS RES, V15, P6735, DOI 10.1093/nar/15.16.6735; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; POHL V, 1990, J CELL BIOL, V111, P663, DOI 10.1083/jcb.111.2.663; Roger PP, 1997, EUR J ENDOCRINOL, V137, P579, DOI 10.1530/eje.0.1370579; SUAREZ HG, 1990, ONCOGENE, V5, P565; VANRENTERGHEM P, 1993, BIOCHIM BIOPHYS ACTA, V1307, P97; VANRENTGERHEM P, 1995, MOL CELL ENDOCRINOL, V112, P83; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	30	37	38	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					737	744		10.1038/sj.onc.1203399	http://dx.doi.org/10.1038/sj.onc.1203399			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698491				2022-12-28	WOS:000085192100003
J	May, P; May, E				May, P; May, E			Twenty years of p53 research: structural and functional aspects of the p53 protein	ONCOGENE			English	Review						p53 protein; tumour suppressor; transactivator; DNA damage; cell growth arrest; apoptosis	WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; DNA-BINDING FUNCTION; TEMPERATURE-SENSITIVE MUTANT; P53-DEPENDENT G(1) ARREST; CYCLIN-DEPENDENT KINASES; HEAT-SHOCK PROTEINS; VIRUS-40 T-ANTIGEN; HUMAN CANCER-CELLS; C-TERMINAL DOMAIN		CEA, Lab Cancerogenese Mol, UMR 217, CEA CNRS,DRR,DSV, F-92265 Fontenay Aux Roses, France	CEA	May, P (corresponding author), CEA, Lab Cancerogenese Mol, UMR 217, CEA CNRS,DRR,DSV, 60-68 Av Div Leclerc,BP 6, F-92265 Fontenay Aux Roses, France.							Abarzua P, 1996, ONCOGENE, V13, P2477; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ANGELOPOULOU K, 1994, INT J CANCER, V58, P480, DOI 10.1002/ijc.2910580404; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Beaudry GA, 1996, CURR OPIN BIOTECH, V7, P592, DOI 10.1016/S0958-1669(96)80069-3; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; BENCHIMOL S, 1985, SOMAT CELL MOLEC GEN, V11, P505, DOI 10.1007/BF01534845; Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y; Bouck N, 1996, BBA-REV CANCER, V1287, P63, DOI 10.1016/0304-419X(96)00005-4; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BRAIN R, 1994, ONCOGENE, V9, P1775; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman C E, 1997, Adv Pharmacol, V41, P429, DOI 10.1016/S1054-3589(08)61068-6; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CANNON JV, 1990, EMBO J, V9, P1595; CHANG C, 1979, J VIROL, V31, P463, DOI 10.1128/JVI.31.2.463-471.1979; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVID YB, 1988, ONCOGENE, V3, P179; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EHRHART JC, 1988, ONCOGENE, V3, P595; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1994, ONCOGENE, V9, P3249; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HANAWALT PC, 1987, ENVIRON HEALTH PERSP, V76, P9, DOI 10.2307/3430458; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1996, AM J PATHOL, V148, P1113; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lohrum M, 1996, ONCOGENE, V13, P2527; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MAYR GA, 1995, CANCER RES, V55, P2410; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MELERO JA, 1979, VIROLOGY, V93, P466, DOI 10.1016/0042-6822(79)90250-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PURDIE CA, 1994, ONCOGENE, V9, P603; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Reznikov M V, 1989, Mol Biol (Mosk), V23, P1692; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROVINSKY B, 1987, MOL CELL BIOL, V7, P853; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Scolnick DM, 1997, CANCER RES, V57, P3693; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shaw P, 1996, ONCOGENE, V12, P921; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHOHAT O, 1987, ONCOGENE, V1, P277; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Slebos RJC, 1998, CANCER RES, V58, P5333; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOUSSI T, 1987, ONCOGENE, V1, P71; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1990, ONCOGENE, V5, P945; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEWART N, 1995, ONCOGENE, V10, P109; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VOTJA PJ, 1995, BIOCHIM BIOPHYS ACTA, V1242, P29; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wynford-Thomas D, 1999, J PATHOL, V187, P100; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHAN QM, 1994, CANCER RES, V54, P2755; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	269	508	536	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	1999	18	53					7621	7636		10.1038/sj.onc.1203285	http://dx.doi.org/10.1038/sj.onc.1203285			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618702				2022-12-28	WOS:000084634500001
J	Ananthaswamy, HN; Ouhtit, A; Evans, RL; Gorny, A; Khaskina, P; Sands, AT; Conti, CJ				Ananthaswamy, HN; Ouhtit, A; Evans, RL; Gorny, A; Khaskina, P; Sands, AT; Conti, CJ			Persistence of p53 mutations and resistance of keratinocytes to apoptosis are associated with the increased susceptibility of mice lacking the XPC gene to UV carcinogenesis	ONCOGENE			English	Article						sunlight; skin cancer; p53; apoptosis; DNA repair	INDUCED SKIN TUMORS; NUCLEOTIDE EXCISION-REPAIR; SQUAMOUS-CELL CARCINOMAS; GROUP-C FIBROBLASTS; XERODERMA-PIGMENTOSUM; ULTRAVIOLET-B; DNA-DAMAGE; HAIRLESS MICE; MOUSE SKIN; SUPPRESSOR GENE	Like xeroderma pigmentosum (XP) patients, transgenic mice lacking nucleotide excision repair (NER) genes such as XPA and XPC are extremely susceptible to ultraviolet (UV)-induced skin cancer, Because the p53 gene is an important target for UV carcinogenesis and because the p53 protein modulates NER, we investigated the consequences of NER deficiency on UV-induced p53 mutations in XPC-/- mouse skin tumors. Thirty-eight (76%) of 50 UV-induced XPC-/- skin tumor analysed displayed C --> T or CC --> TT transitions at dipyrimidine sites on the untranscribed strand of the p53 gene. A major hot spot for p53 mutation occurred at codon 270, which is also a hot spot in UV-induced skin tumors from NER-proficient C3H and SKH-hr 1 mice. Interestingly, codon 270 mutations were induced in both XPC-/- and +/+ mouse skin after 1 week of UV irradiation, but the mutations persisted only in XPC-/- mouse skin after 3-4 weeks of chronic UV, The persistence of UV-induced p53 mutations in XPC-/- mouse skin was associated with decreased apoptosis and increased proliferation of keratinocytes, suggesting that these events may contribute to the accelerated development of UV-induced skin tumors in XPC-/- mice.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Lexicon Genet, The Woodlands, TX 77381 USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center; Lexicon Pharmaceuticals; University of Texas System; UTMD Anderson Cancer Center	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA046523, P30CA016672, R01CA042157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42157, CA 46523, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Berg RJW, 1997, CANCER RES, V57, P581; Berg RJW, 1998, J INVEST DERMATOL, V110, P405, DOI 10.1111/j.1523-1747.1998.00173.x; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; Cheo DL, 1996, CURR BIOL, V6, P1691, DOI 10.1016/S0960-9822(02)70794-X; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1989, CARCINOGENESIS, V10, P1691, DOI 10.1093/carcin/10.9.1691; de Vries A, 1998, ONCOGENE, V16, P2205, DOI 10.1038/sj.onc.1201744; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; EVANS MK, 1993, CANCER RES, V53, P5377; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FORD JM, 1994, MOL CARCINOGEN, V10, P105, DOI 10.1002/mc.2940100208; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; KANJILAL S, 1993, CANCER RES, V53, P2961; KRESS S, 1992, CANCER RES, V52, P6400; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li G, 1996, AM J PATHOL, V148, P1113; Li G, 1997, AM J PATHOL, V150, P1457; Ljungman M, 1996, ONCOGENE, V13, P823; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nataraj AJ, 1996, P NATL ACAD SCI USA, V93, P7961, DOI 10.1073/pnas.93.15.7961; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; ROBBINS JH, 1988, JAMA-J AM MED ASSOC, V260, P384; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; SETLOW RB, 1969, P NATL ACAD SCI USA, V64, P1035, DOI 10.1073/pnas.64.3.1035; SMITH ML, 1995, ONCOGENE, V10, P1053; Takeuchi S, 1998, CANCER RES, V58, P641; VANKRANEN HJ, 1995, CARCINOGENESIS, V16, P1141; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	39	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7395	7398		10.1038/sj.onc.1203147	http://dx.doi.org/10.1038/sj.onc.1203147			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602497				2022-12-28	WOS:000084119400027
J	Kiermaier, A; Gawn, JM; Desbarats, L; Saffrich, R; Ansorge, W; Farrell, PJ; Eilers, M; Packham, G				Kiermaier, A; Gawn, JM; Desbarats, L; Saffrich, R; Ansorge, W; Farrell, PJ; Eilers, M; Packham, G			DNA binding of USF is required for specific E-box dependent gene activation in vivo	ONCOGENE			English	Article						Myc; Max; USF; prothymosin-alpha; IgH enhancer; EBV	HEAVY-CHAIN ENHANCER; C-MYC; TRANSCRIPTION FACTOR; COOPERATIVE INTERACTION; HISTONE DEACETYLASE; TARGET GENE; CELL-GROWTH; PROTEINS; TRANSFORMATION; RECOGNITION	Although USF-1 and -2 are the major proteins that bind to Myc-regulated E-box (CACGTG) elements in many cells, there is no clear role for USF during Myc-dependent gene regulation. Using dominant negative alleles of USF-1 we now show that DNA binding by USF at a MSc-regulated E-box limits the ability of another E-box binding factor, TFE-3, to activate a target gene of Myc in vivo and to stimulate S phase entry in resting fibroblasts, Similarly, dominant negative alleles of USF-1 relieve the restriction that presents activation of the IgH enhancer by TFE-3 in non B-cells, DNA binding activity of USF complexes is abundant in primary human B-cells and is significantly downregulated during B-cell immortalization, Re-expression of USF-1 in immortalized B-cells retards proliferation. Our data establish an essential role for USF in restricting E-box dependent gene activation in vivo and suggest that this control is relaxed during cellular immortalization.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Microbiol, London W2 1PG, England; EMBL, Biochem Instrumentat Programme, D-69117 Heidelberg, Germany; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ Marburg, Inst Mol Biol & Tumour Res, D-35033 Marburg, Germany	Imperial College London; European Molecular Biology Laboratory (EMBL); Imperial College London; Ludwig Institute for Cancer Research; Philipps University Marburg	Packham, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Microbiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Ansorge, Wilhelm/AAN-8780-2020	Saffrich, Rainer/0000-0002-0547-4550; Eilers, Martin/0000-0002-0376-6533				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Aperlo C, 1996, EUR J BIOCHEM, V241, P249, DOI 10.1111/j.1432-1033.1996.0249t.x; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Berger A, 1998, BBA-LIPID LIPID MET, V1390, P225, DOI 10.1016/S0005-2760(97)00180-X; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; DAMARE ARF, 1994, EMBO J, V13, P180; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Galibert MD, 1997, J IMMUNOL, V159, P6176; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MAEKAWA T, 1991, NUCLEIC ACIDS RES, V19, P4689, DOI 10.1093/nar/19.17.4689; Merrell K, 1997, MOL CELL BIOL, V17, P3335, DOI 10.1128/MCB.17.6.3335; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sinclair Alison J., 1995, V7, P89; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; TOBIAS KE, 1995, ONCOGENE, V11, P1721; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	34	23	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7200	7211		10.1038/sj.onc.1203166	http://dx.doi.org/10.1038/sj.onc.1203166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602473				2022-12-28	WOS:000084119400003
J	Kogel, D; Bierbaum, H; Preuss, U; Scheidtmann, KH				Kogel, D; Bierbaum, H; Preuss, U; Scheidtmann, KH			C-terminal truncation of Dlk/ZIP kinase leads to abrogation of nuclear transport and high apoptotic activity	ONCOGENE			English	Article						Dlk/ZIP kinase; nuclear transport; PML bodies; actin filaments; apoptosis	PROTEIN-KINASE; CELL-DEATH; SERINE/THREONINE KINASE; SIGNAL-TRANSDUCTION; NASCENT RNA; PATHWAYS; PML; IDENTIFICATION; BODIES	Dlk (also termed ZIP kinase) is a novel serine/threonine kinase with a unique C-terminal domain that is rich in arginine and contains three putative NLS motifs and a functional lecuine zipper. Dlk is indeed localized in the nucleus where it shows a speckled distribution, To elucidate the biological functions of Dlk, we wanted to identify the signals relevant for nuclear transport and further the nuclear structures which Dlk binds to. Expression of various deletion and point mutations of Dlk as GFP fusion proteins revealed that the leucine zipper is required for association with speckles and the most C-terminal NLS is necessary and sufficient for nuclear transport. Interestingly, a C-terminal deletion mutant defective for nuclear transport exhibited a pronounced colocalization with actin filaments and, even more strikingly, was a very potent inducer of apoptosis, This apoptotic activity was abrogated, however, when this mutant was retargeted to the nucleus via a heterologous NLS from large T, indicating that Dlk only exerts an apoptotic activity in the cytoplasm, To identify the speckle like structures to which Dlk binds we performed immunofluorescence analyses with antibodies directed against representative marker proteins of replication, transcription, or splicing centers. None of these marker proteins revealed a colocalization with Dlk. Instead, we found a partial colocalization with PML bodies which seem to play a key role in regulation of apoptosis, Taken together, these data strongly suggest a functional role for Dlk in control of cell survival which is dependent on its subcellular localization.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany	University of Bonn	Scheidtmann, KH (corresponding author), Univ Bonn, Inst Genet, Roemerstr 164, D-53117 Bonn, Germany.			Kogel, Donat/0000-0003-1209-0210				Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HOZAK P, 1994, J CELL SCI, V107, P2191; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STUURMAN N, 1992, J CELL SCI, V101, P773; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	36	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7212	7218		10.1038/sj.onc.1203169	http://dx.doi.org/10.1038/sj.onc.1203169			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602474				2022-12-28	WOS:000084119400004
J	Tchou, WW; Yie, TA; Tan, TH; Rom, WN; Tchou-Wong, KM				Tchou, WW; Yie, TA; Tan, TH; Rom, WN; Tchou-Wong, KM			Role of c-Jun N-terminal kinase 1 (JNK1) in cell cycle checkpoint activated by the protease inhibitor N-acetyl-leucinyl-leucinyl-norleucinal	ONCOGENE			English	Article						JNK; LLnL; cell cycle arrest	SPINDLE ASSEMBLY CHECKPOINT; MAP KINASE; INDUCED APOPTOSIS; GAMMA-RADIATION; MAMMALIAN-CELLS; ARREST; PATHWAY; REQUIREMENT; DEGRADATION; INDUCTION	The cysteine protease inhibitor N-acetyl-leucinyl-leucinyl-norleucinal (LLnL) inhibited the growth of the Calu-1 lung carcinoma cells and induced a prolonged cell cycle arrest in the S phase, c-Jun N-terminal kinases (JNKs) participate in cellular responses to mitogenic stimuli, environmental stresses, and apoptotic signals but its role in cell cycle checkpoint control has not been elucidated. In this report, me examined the role of JNK in LLnL-induced S phase checkpoint by overexpression of a dominant-negative mutant of JNK1 (JNK1-APF) in Calu-1 cells. Expression of high levels of JNK1-APF blocked the growth-inhibitory effects of LLnL and abrogated S phase arrest induced by LLnL. These results support the role of JNK in the activation of cell cycle checkpoint induced by LLnL.	NYU, Med Ctr, Div Hematol & Oncol, New York, NY 10016 USA; NYU, Med Ctr, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Microbiol, New York, NY 10016 USA; NYU, Med Ctr, Dept Environm Med, New York, NY 10016 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	New York University; New York University; New York University; New York University; New York University; Baylor College of Medicine	Tchou-Wong, KM (corresponding author), NYU, Med Ctr, Div Hematol & Oncol, 550 1st Ave,MSB 147, New York, NY 10016 USA.		Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Rom, William/0000-0002-8793-7028	NHLBI NIH HHS [R01 HL59832] Funding Source: Medline; NIAID NIH HHS [R01 AI38649] Funding Source: Medline; PHS HHS [M0100096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Patel R, 1998, J CELL SCI, V111, P2247; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VISNITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	32	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6974	6980		10.1038/sj.onc.1203195	http://dx.doi.org/10.1038/sj.onc.1203195			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597296				2022-12-28	WOS:000083901900002
J	Govind, S				Govind, S			Control of development and immunity by Rel transcription factors in Drosophila	ONCOGENE			English	Review						dorsal-ventral polarity; immunity; hematopoiesis; muscle; Drosophila; dorsal	DORSAL-VENTRAL POLARITY; NF-KAPPA-B; EMBRYONIC DORSOVENTRAL POLARITY; SIGNAL-TRANSDUCTION PATHWAY; REGULATED NUCLEAR IMPORT; PROTEIN DORSAL; TRANSMEMBRANE PROTEIN; FUNCTIONAL DOMAINS; PATTERN-FORMATION; MORPHOGEN DORSAL	The Drosophila Rel/NF-kappa B transcription factors-Dorsal, Dif, and Relish - control several biological processes, including embryonic pattern formation, muscle development, immunity, and hematopoiesis. Molecular-genetic analysis of 12 mutations that cause embryonic dorsal/ventral patterning defects has defined the steps that control the formation of this axis. Regulated activation of the Toll receptor leads to the establishment of a gradient of nuclear Dorsal protein, which in turn governs the subdivision of the axis and specification of ventral, lateral and dorsal fates. Phenotypic analysis of dorsal-ventral embryonic mutants and the characterization of the two other fly Rel proteins, Dif and Relish, have shown that the intracellular portion of the Toll to Cactus pathway also controls the innate immune response in Drosophila. Innate immunity and hematopoiesis are regulated by analogous Rel/NF-kappa B-family pathways in mammals. The elucidation of the complex regulation and diverse functions of Drosophila Rel proteins underscores the relevance of basic studies in Drosophila.	CUNY City Coll, Dept Biol, New York, NY 10031 USA; CUNY, Grad Ctr, New York, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System	Govind, S (corresponding author), Novartis Inst Biomed Res, 133-2028A,556 Morris Ave, Summit, NJ USA.			Govind, Shubha/0000-0002-6436-639X				Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Anderson KV, 1998, CELL, V95, P439, DOI 10.1016/S0092-8674(00)81610-4; ANDRESON KV, 1986, GAMETOGENESIS EARLY, P177; BarillasMury C, 1996, EMBO J, V15, P4691, DOI 10.1002/j.1460-2075.1996.tb00846.x; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; Cantera R, 1999, J NEUROBIOL, V38, P16, DOI 10.1002/(SICI)1097-4695(199901)38:1<16::AID-NEU2>3.0.CO;2-0; Cantera R, 1999, MOL CELL NEUROSCI, V13, P131, DOI 10.1006/mcne.1999.0739; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; Drier EA, 1997, SEMIN CANCER BIOL, V8, P83, DOI 10.1006/scbi.1997.0059; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; Edwards DN, 1997, DEVELOPMENT, V124, P3855; ENGSTROM T, 1993, PRODUCTIVITY QUALITY, V1, P333; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GERTTULA S, 1988, GENETICS, V119, P123; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GONZALEZCRESPO S, 1993, GENE DEV, V7, P1703, DOI 10.1101/gad.7.9.1703; GOVIND S, 1992, P NATL ACAD SCI USA, V89, P7861, DOI 10.1073/pnas.89.17.7861; Govind S, 1996, BIOCHEM SOC T, V24, P39, DOI 10.1042/bst0240039; Govind S, 1996, MOL CELL BIOL, V16, P1103; GOVIND S, 1993, DEVELOPMENT, V117, P135; Gross I, 1999, GENE, V228, P233, DOI 10.1016/S0378-1119(98)00595-2; GROSS I, 1996, NUCLEIC ACIDS RES, V89, P7861; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HALFON M, 1995, DEV BIOL, V196, P151; Halfon MS, 1998, DEV BIOL, V199, P164, DOI 10.1006/dbio.1998.8915; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT PM, 1993, GENETICS, V135, P405; HEDENGREN M, 1999, IN PRESS MOL CELL; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; HONG CC, 1995, CELL, V82, P785, DOI 10.1016/0092-8674(95)90475-1; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; Huguet C, 1997, ONCOGENE, V15, P2965, DOI 10.1038/sj.onc.1201471; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ISODA K, 1994, P NATL ACAD SCI USA, V91, P5350, DOI 10.1073/pnas.91.12.5350; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1992, EMBO J, V11, P3147, DOI 10.1002/j.1460-2075.1992.tb05387.x; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAMENS J, 1991, NEW BIOL, V3, P1005; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIROV N, 1994, MOL CELL BIOL, V14, P713, DOI 10.1128/MCB.14.1.713; Konrad KD, 1998, P NATL ACAD SCI USA, V95, P6819, DOI 10.1073/pnas.95.12.6819; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LeMosy EK, 1999, TRENDS CELL BIOL, V9, P102, DOI 10.1016/S0962-8924(98)01494-9; LeMosy EK, 1998, DEVELOPMENT, V125, P4045; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MEISTER M, 1994, EMBO J, V13, P5958, DOI 10.1002/j.1460-2075.1994.tb06941.x; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; Nicolas E, 1998, J BIOL CHEM, V273, P10463, DOI 10.1074/jbc.273.17.10463; Nilson LA, 1998, CELL, V93, P253, DOI 10.1016/S0092-8674(00)81576-7; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAN D, 1992, EMBO J, V11, P1837, DOI 10.1002/j.1460-2075.1992.tb05235.x; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; Pancer Z, 1999, IMMUNOGENETICS, V49, P773, DOI 10.1007/s002510050551; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; Qiu P, 1998, DEVELOPMENT, V125, P1909; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; REICHHART JM, 1993, CR ACAD SCI III-VIE, V316, P1218; Rizki T.M., 1984, P579; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Rose D, 1997, DEVELOPMENT, V124, P1561; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; Roth S, 1998, CURR BIOL, V8, pR906, DOI 10.1016/S0960-9822(98)00006-2; Rusch J, 1996, CURR OPIN GENET DEV, V6, P416, DOI 10.1016/S0959-437X(96)80062-1; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Shirokawa JM, 1997, MOL CELL BIOL, V17, P3345, DOI 10.1128/MCB.17.6.3345; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; STEWARD R, 1993, CURR OPIN GENET DEV, V3, P556, DOI 10.1016/0959-437X(93)90090-C; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; TATEI K, 1995, MOL CELL BIOL, V15, P3627; THISSE B, 1987, GENE DEV, V5, P1285; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; Towb P, 1998, DEVELOPMENT, V125, P2443; TRYSELIUS Y, 1992, EUR J BIOCHEM, V204, P395, DOI 10.1111/j.1432-1033.1992.tb16648.x; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; WILSON I, 1997, CURR BIOL, V7, P175; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; Yang J, 1997, P NATL ACAD SCI USA, V94, P14524, DOI 10.1073/pnas.94.26.14524; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	139	87	89	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6875	6887		10.1038/sj.onc.1203223	http://dx.doi.org/10.1038/sj.onc.1203223			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602463				2022-12-28	WOS:000083896500005
J	Duval, A; Iacopetta, B; Ranzani, GN; Lothe, RA; Thomas, G; Hamelin, R				Duval, A; Iacopetta, B; Ranzani, GN; Lothe, RA; Thomas, G; Hamelin, R			Variable mutation frequencies in coding repeats of TCF-4 and other target genes in colon, gastric and endometrial carcinoma showing microsatellite instability	ONCOGENE			English	Article						TCF-4; coding repeat; stomach; endometrium; colon; microsatellite instability	REPLICATION ERROR PHENOTYPE; II RECEPTOR GENE; BETA-CATENIN; COLORECTAL-CANCER; SOMATIC MUTATIONS; HOMOLOG; APC; ACTIVATION; TUMORS; DNA	Frameshift mutations in genes containing mononucleotide repeats are often observed in cancers exhibiting a high frequency of microsatellite instability (MSI-H). Several tumor types, including colorectal, gastric, and endometrial carcinomas, display this phenotype in a significant proportion of cases. We recently showed in a large series of MSI-H colorectal tumors that approximately 40% of them exhibited frameshift mutations in an (A)9 tract within the coding region of the TCF-4 gene, a crucial member of the APC/beta-catenin/TCF pathway. In the present study, we have examined MSI-H cancers from other primary tumor sites for mutations in this new target gene. Two of 22 (9%) MSI-H primary gastric cancers and none of 23 MSI-H endometrial primary tumors and cell lines were found to have a 1 bp deletion in the TCF-4 repeat. In the same series of tumors we also looked for frameshift mutations in other coding repeats localized within the TGF beta-RII, BAX, IGFIIR, hMSH3 and hMSH6 genes. Our results suggest that the TCF-4 gene, in a similar manner to some of these latter genes, is differentially altered in MSI-H tumors from different primary sites.	INSERM, U434, CEPH, F-75010 Paris, France; Univ Western Australia, Dept Surg, Nedlands, WA 6009, Australia; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo, Norway	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Western Australia; University of Pavia; University of Oslo	Hamelin, R (corresponding author), INSERM, U434, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.			Lothe, Ragnhild A./0000-0002-1693-1032; Ranzani, Guglielmina/0000-0002-3080-6473				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Candidus S, 1996, CANCER RES, V56, P49; Duval A, 1999, CANCER RES, V59, P4213; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fukuchi T, 1998, CANCER RES, V58, P3526; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoang JM, 1997, CANCER RES, V57, P300; HORII A, 1992, CANCER RES, V52, P5231; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MYEROFF LL, 1995, CANCER RES, V55, P5545; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; TAMURA G, 1994, CANCER RES, V54, P1149; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Wu MS, 1998, CANCER RES, V58, P1494; Yamamoto H, 1997, CANCER RES, V57, P4420; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	26	55	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6806	6809		10.1038/sj.onc.1203287	http://dx.doi.org/10.1038/sj.onc.1203287			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597289				2022-12-28	WOS:000083792000023
J	Jordan, P; Brazao, R; Boavida, MG; Gespach, C; Chastre, E				Jordan, P; Brazao, R; Boavida, MG; Gespach, C; Chastre, E			Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors	ONCOGENE			English	Article						Rac1; Ras; GTPase; colorectal cancer; alternative splicing	CELL-CELL ADHESION; SMALL GTPASES; CRYSTAL-STRUCTURE; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; SIGNALING PATHWAY; GTP ANALOG; RHO; CDC42; PROTEINS	Rac1 is a member of the Ras superfamily of small GTPases involved in signal transduction pathways that induce the formation of lamellipodia, stimulate cell proliferation and activate the JNK/SAPK protein kinase cascade, Here we describe that amplification by RT-PCR of the entire Rac1 coding sequence from a series of human adult and fetal tissues revealed beside the expected Rac1 cDNA, a variant product which contained additional 57 nucleotides between codons 75 and 76. This variant resulted in an in-frame insertion of 19 new amino acids immediately behind the switch II region, including two potential threonine phosphorylation sites for casein kinase II and protein kinase C, Primers designed within and downstream of the inserted nucleotide sequence allowed isolation of a genomic clone with intronic consensus sequences demonstrating that the insertion corresponds to a novel, yet undescribed exon 3b, This Rac1 splice variant, designated Rac1b, was predominantly identified in skin and epithelial tissues from the intestinal tract. Most notably, the expression of rac1b versus rad was found to be elevated in colorectal tumors at various stages of neoplastic progression, as compared to their respective adjacent tissues. We suggest that the 19 amino acid-insertion following the switch II region may create a novel effector binding site in rac1b, and thus participate in signaling pathways related to the normal or neoplastic growth of the intestinal mucosa.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Lab Oncobiol, P-1649 Lisbon, Portugal; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Instituto Nacional de Saude Dr. Ricardo Jorge; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Lab Oncobiol, Ave Padre Cruz, P-1649 Lisbon, Portugal.		Jordan, Peter/G-9335-2012; CHASTRE, Eric/L-8446-2018	Jordan, Peter/0000-0002-1425-9211; CHASTRE, Eric/0000-0002-8993-1228				Allen WE, 1997, J CELL SCI, V110, P707; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Courjal F, 1997, GENOMICS, V44, P242, DOI 10.1006/geno.1997.4871; Gayther SA, 1998, CANCER RES, V58, P4086; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schneider TD, 1997, NUCLEIC ACIDS RES, V25, P4408, DOI 10.1093/nar/25.21.4408; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Vider BZ, 1996, ONCOGENE, V12, P153; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	184	188	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6835	6839		10.1038/sj.onc.1203233	http://dx.doi.org/10.1038/sj.onc.1203233			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597294				2022-12-28	WOS:000083792000028
J	Hansen, GM; Justice, MJ				Hansen, GM; Justice, MJ			Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia	ONCOGENE			English	Article						leukemia or lymphoma; hematopoiesis; homeobox; mouse; retrovirus	ACUTE MYELOGENOUS LEUKEMIAS; PROTEIN-CODING REGIONS; HOMEOBOX GENE PRH; INSITU HYBRIDIZATION; MYELOID-LEUKEMIA; MULTIPLE GENES; LYMPHOMAS; IDENTIFICATION; DNA; LOCUS	AKXD recombinant inbred mice develop a variety of leukemias and lymphomas due to retrovirally mediated insertional activation of cellular proto-oncogenes. We describe a new retroviral insertion site that is the most frequent genetic alteration in AKXD B-cell leukemias. Multiple genes flank the site of viral insertion, but the expression of just two, Hex and mEg5, is significantly upregulated. Hex is a divergent homeobox gene that is transiently expressed in many hematopoietic lineages, suggesting an involvement in cellular differentiation. mEp5 is a member of the bim-C subfamily of kinesin related proteins that are necessary for spindle formation and stabilization during mitosis. Our data provide the first genetic evidence for the activation of these genes in leukemia, and suggest that unscheduled expression of Hex and mEg5 contributes to the development of B-cell leukemia. In addition, this work highlights the use of genomic approaches for the study of position effect mutations.	Baylor Coll Med, Dept Mol & Hum Genet, Houston, TX 77030 USA	Baylor College of Medicine	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Hum Genet, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA063229] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA63229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Beeman RW, 1997, INSECT MOL BIOL, V6, P83, DOI 10.1046/j.1365-2583.1997.00159.x; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; CHATTOPADHYAY SK, 1980, P NATL ACAD SCI-BIOL, V77, P5774, DOI 10.1073/pnas.77.10.5774; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAVERIE JM, 1994, GENOMICS, V23, P575, DOI 10.1006/geno.1994.1545; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DUBE ID, 1991, BLOOD, V78, P2996; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Hansen GM, 1999, GENOMICS, V56, P228, DOI 10.1006/geno.1998.5708; Hawley RG, 1997, CANCER RES, V57, P337; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Heng H H, 1994, Methods Mol Biol, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; IHLE JN, 1990, PROG CLIN BIOL RES, V352, P329; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LEVY ER, 1994, BLOOD, V83, P1348; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; MONK RJ, 1981, CELL, V24, P301, DOI 10.1016/0092-8674(81)90319-6; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; *MOUS GEN DAT, 1999, MOUS GEN INF; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sarkar G, 1993, PCR Methods Appl, V2, P318; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; SUZUKAWA K, 1994, BLOOD, V84, P2681; TSICHLIS PN, 1990, J VIROL, V64, P2236, DOI 10.1128/JVI.64.5.2236-2244.1990; TSICHLIS PN, 1989, P NATL ACAD SCI USA, V86, P5487, DOI 10.1073/pnas.86.14.5487; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; White JA, 1998, GENOMICS, V48, P270, DOI 10.1006/geno.1997.5157	54	50	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6531	6539		10.1038/sj.onc.1203023	http://dx.doi.org/10.1038/sj.onc.1203023			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597256				2022-12-28	WOS:000083709200016
J	Campbell, IG; Manolitsas, T				Campbell, IG; Manolitsas, T			Absence of PPP2R1B gene alterations in primary ovarian cancers	ONCOGENE			English	Article						ovarian cancer; PPP2R1B; loss of heterozygosity; chromosome 11q23; mutation analysis	MOLECULAR-CLONING; REGION; HETEROZYGOSITY; FREQUENT; PROTEIN; TUMORS; REFINEMENT; CARCINOMA; DELETIONS; 11Q23	The PPP2R1B gene has recently been implicated as a tumor suppressor based on the finding of somatic alterations in lung and colon cancers. PPP2R1B is located on chromosome 11q22-24 which coincides with the site of frequent loss of heterozygosity (LOH) in ovarian cancer. We investigated if the PPP2R1B gene was inactivated in ovarian cancer by single strand conformational polymorphism (SSCP) and heteroduplex (HD) analysis of 99% of the coding region. LOH at the PPP2R1B locus was detected in 32% of the malignant tumors but no somatic alterations were detected in any of 65 malignant, five borderline or six benign tumors. A germline G>A transition (GGC>GAC) in codon 90 was detected in 4/76 tumors. This alteration has previously been described as a mutation but on further investigation we found that the frequency of this variant among 167 ovarian cancers (4.2%) was not statistically significantly different from that observed in 247 noncancer random controls (2.4%). We conclude that the PPP2R1B gene is not involved in the pathogenesis of ovarian cancer. The codon 90 Gly>Asp alteration may represent a non-pathological polymorphism and consequently the mutation frequency reported in lung cancers may have been overstated and the designation of PPP2R1B as a tumor suppressor gene should be regarded with caution.	Univ Southampton, Princess Anne Hosp, Dept Obstet & Gynaecol, Southampton SO16 5YA, Hants, England; Peter MacCallum Canc Inst, E Melbourne, Vic 3002, Australia	University of Southampton; Peter Maccallum Cancer Center	Campbell, IG (corresponding author), Peter MacCallum Canc Inst, Sir Donald & Lady Trescowthick Res Labs, Locked Bag 1,A Beckett St, Melbourne, Vic 3000, Australia.		campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				Baysal BE, 1998, GENE, V217, P107, DOI 10.1016/S0378-1119(98)00350-3; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Davis M, 1996, CANCER RES, V56, P741; Evans MF, 1998, ONCOGENE, V16, P2557, DOI 10.1038/sj.onc.1202039; Gabra H, 1996, CANCER RES, V56, P950; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Herbst RA, 1999, INT J CANCER, V80, P205, DOI 10.1002/(SICI)1097-0215(19990118)80:2<205::AID-IJC8>3.0.CO;2-J; Hui ABY, 1996, CANCER RES, V56, P3225; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; Monaco C, 1998, GENOMICS, V52, P358, DOI 10.1006/geno.1998.5419; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Obata K, 1998, CANCER RES, V58, P2095; Skomedal H, 1997, J PATHOL, V181, P158; Wang L, 1998, ONCOGENE, V16, P635, DOI 10.1038/sj.onc.1201576; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284	16	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6367	6369		10.1038/sj.onc.1203070	http://dx.doi.org/10.1038/sj.onc.1203070			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597236				2022-12-28	WOS:000083934100021
J	Veal, E; Groisman, R; Eisenstein, M; Gill, G				Veal, E; Groisman, R; Eisenstein, M; Gill, G			The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells	ONCOGENE			English	Article						differentiation; mouse embryonic stem cell; NTERA-2 embryonal carcinoma cells; secreted glycoprotein	HEXAMETHYLENE BISACETAMIDE HMBA; RETINOIC ACID; MONOCLONAL-ANTIBODY; TGF-ALPHA; LINE; EXPRESSION; GROWTH; TERATOCARCINOMAS; ACTIVATION; INDUCTION	Differentiation of the human embryonal carcinoma cell Line NTERA-2 is characterized by changes in morphology, altered patterns of gene expression, reduced proliferative potential, and a loss of tumorigenicity. The cellular repressor of E1A-stimulated genes, CREG, was previously shown to antagonize transcriptional activation and cellular transformation by the Adenovirus EIA oncoprotein. These properties suggested that CREG may function to inhibit cell growth and/or promote differentiation, Here we show that CREG is a secreted glycoprotein which enhances differentiation of NTERA-2 cells. Northern blot analysis reveals that, although CREG mRNA is widely expressed in adult tissues, CREG mRNA is not significantly expressed in pluripotent mouse embryonic stem cells or NTERA-2 embryonal carcinoma cells. CREG mRNA is rapidly induced upon in vitro differentiation of both mouse embryonic stem cells and human NTERA-2 cells, We show that constitutive expression of CREG in NTERA-2 cells enhances neuronal differentiation upon treatment with retinoic acid. Media enriched in CREG was also found to promote NTERA-2 differentiation in the absence of an inducer such as retinoic acid. These studies suggest that secreted CREG protein participates in a signaling cascade important for differentiation of pluripotent stem cells such as those found in teratocarcinomas.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Gill, G (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Veal, Elizabeth/0000-0002-1152-5473; Groisman, Sonia/0000-0003-1153-3841; Groisman, Regina/0000-0003-3990-7622				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANDREWS PW, 1994, LAB INVEST, V71, P243; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Baldassarre G, 1996, INT J CANCER, V66, P538, DOI 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3; BASELGA J, 1993, ONCOGENE, V8, P3257; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; KURIE JM, 1993, DIFFERENTIATION, V54, P115; Maerz WJ, 1998, ONCOGENE, V17, P761, DOI 10.1038/sj.onc.1201992; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942	25	76	96	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2120	2128		10.1038/sj.onc.1203529	http://dx.doi.org/10.1038/sj.onc.1203529			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815803				2022-12-28	WOS:000086728000005
J	Cardiff, RD; Anver, MR; Gusterson, BA; Hennighausen, L; Jensen, RA; Merino, MJ; Rehm, S; Russo, J; Tavassoli, FA; Wakefield, LM; Ward, JM; Green, JE				Cardiff, RD; Anver, MR; Gusterson, BA; Hennighausen, L; Jensen, RA; Merino, MJ; Rehm, S; Russo, J; Tavassoli, FA; Wakefield, LM; Ward, JM; Green, JE			The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting	ONCOGENE			English	Article						genetically engineered mice; mouse mammary models; breast tumor classifications	MYC-INDUCED TUMORIGENESIS; SCARFF-BLOOM-RICHARDSON; ALPHA TRANSGENIC MICE; TRUNCATED INT3 GENE; GROWTH-FACTOR-ALPHA; TGF-ALPHA; HISTOLOGICAL GRADES; METASTATIC DISEASE; BREAST CARCINOMAS; GLAND INVOLUTION	NIH sponsored a meeting of medical and veterinary pathologists with mammary gland expertise in Annapolis in March 1999, Rapid development of mouse mammary models has accentuated the need for definitions of the mammary lesions in genetically engineered mice (GEM) and to assess their usefulness as models of human breast disease. The panel of nine pathologists independently reviewed material representing over 90% of the published systems, The GEM tumors were found to have: (1) phenotypes similar to those of non-GEM; (2) signature phenotypes specific to the transgene; and (3) some morphological similarities to the human disease. The current mouse mammary and human breast tumor classifications describe the majority of GEM lesions but unique morphologic lesions are found in many GEM. Since little information is available on the natural history of GEM lesions, a simple morphologic nomenclature is proposed that allows direct comparisons between models. Future progress requires rigorous application of guidelines covering pathologic examination of the mammary gland and the whole animal. Since the phenotype of the lesions is an essential component of their molecular pathology, funding agencies should adopt policies ensuring careful morphological evaluation of any funded research involving animal models. A pathologist should be part of each research team.	Univ Calif Davis, UCD Ctr Comparat Med, Davis, CA 95616 USA; NCI, Pathol Histotechnol Lab, SAIC Frederick, FCRDC, Frederick, MD 21702 USA; Inst Canc Res, Breakthrough toby Robins Breast Canc Res Ctr, London SW3 6JB, England; NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA; Armed Forces Inst Pathol, Dept Gynecol & Breast Pathol, Washington, DC 20306 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; NCI, Vet & Tumor Pathol Sect, Off Lab Anim Resources, Frederick, MD 21702 USA	University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fox Chase Cancer Center; GlaxoSmithKline; United States Department of Defense; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cardiff, RD (corresponding author), Univ Calif Davis, UCD Ctr Comparat Med, Cty Rd 98 & Hutchison Dr, Davis, CA 95616 USA.		Jensen, Roy A/B-9739-2011; gusterson, barry a/D-3752-2009	Jensen, Roy A/0000-0003-4430-2281; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.3.CO;2-E; BARNES DM, 1993, J CELL BIOCHEM, P132; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; Cardiff RD, 1998, ADV ONCOBIOL, V2, P177; CARDIFF RD, 1984, ADV CANCER RES, V42, P167, DOI 10.1016/S0065-230X(08)60458-3; Cardiff RD, 1998, J MAMMARY GLAND BIOL, V3, P3, DOI 10.1023/A:1018714016205; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; Charpin C, 1995, ANTICANCER RES, V15, P2611; Cheung ATW, 1997, INT J ONCOL, V11, P69; COFFEY RJ, 1994, CANCER RES, V54, P1678; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUNN TB, 1959, PHYSIOPATHOLOGY CANC, V2, P38; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Gallahan D, 1996, CANCER RES, V56, P1775; Genestie C, 1998, ANTICANCER RES, V18, P571; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HUSEBY RA, 1985, ENDOCRINOLOGY, V116, P1440, DOI 10.1210/endo-116-4-1440; Husler MR, 1998, TRANSGENIC RES, V7, P253, DOI 10.1023/A:1008865911660; IWAMOTO T, 1990, ONCOGENE, V5, P535; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JENSEN RA, 1993, J CELL BIOCHEM, P59; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Joseph H, 1999, MOL BIOL CELL, V10, P1221, DOI 10.1091/mbc.10.4.1221; Kitsberg DI, 1996, ONCOGENE, V13, P2507; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Krane IM, 1996, ONCOGENE, V12, P1781; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LEDOUSSAL V, 1989, CANCER, V64, P1914, DOI 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Medina D, 1996, Cancer Treat Res, V83, P37; MEDINA D, 1976, CANCER RES, V36, P2589; MEDINA D, 1988, CARCINOGENESIS, V9, P1113, DOI 10.1093/carcin/9.7.1113; MEDINA D, 1976, J NATL CANCER I, V57, P331, DOI 10.1093/jnci/57.2.331; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; MORRIS DW, 1990, J VIROL, V64, P1794, DOI 10.1128/JVI.64.4.1794-1802.1990; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Page DL, 1998, BREAST CANCER RES TR, V51, P195, DOI 10.1023/A:1006122716137; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; REHM S, 1990, AM J PATHOL, V136, P575; Rehm S, 1996, PATHOBIOLOGY AGING M, V2, P381; RUSSO J, 1990, LAB INVEST, V62, P244; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SASS B, 1979, J NATL CANCER I, V62, P1287; Shibata MA, 1996, CANCER RES, V56, P2998; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tavassoli FA, 1998, MODERN PATHOL, V11, P140; TAVASSOLI FA, 1990, CANCER, V65, P518, DOI 10.1002/1097-0142(19900201)65:3<518::AID-CNCR2820650324>3.0.CO;2-O; Tavassoli FA, 1997, BREAST J, V3, P48, DOI [10.1111/j.1524-4741.1997.tb00139.x, DOI 10.1111/J.1524-4741.1997.TB00139.X]; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Tzeng YJ, 1996, FEBS LETT, V380, P215, DOI 10.1016/0014-5793(96)00021-X; TZENG YJ, 1993, ONCOGENE, V8, P1965; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WELLINGS SR, 1976, EXPERIENTIA, V32, P1463, DOI 10.1007/BF01937436	68	381	390	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		968	988		10.1038/sj.onc.1203277	http://dx.doi.org/10.1038/sj.onc.1203277			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713680				2022-12-28	WOS:000085796400002
J	Murphy, KL; Rosen, JM				Murphy, KL; Rosen, JM			Mutant p53 and genomic instability in a transgenic mouse model of breast cancer	ONCOGENE			English	Article						mutant p53; mammary tumorigenesis; DMBA; transgenic mice; review	MAMMARY TUMORIGENESIS; DNA-BINDING; CENTROSOME AMPLIFICATION; GENETIC INSTABILITY; SPINDLE CHECKPOINT; CELL-PROLIFERATION; MICE; MUTATIONS; PROTEIN; EXPRESSION		Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Mol & Cellular Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA 16303] Funding Source: Medline; NIGMS NIH HHS [GM08231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen JJ, 1999, CANCER RES, V59, p1752S; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gretarsdottir S, 1998, CANCER RES, V58, P859; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Liu PK, 1996, ONCOGENE, V12, P2267; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Ritland SR, 1997, CANCER RES, V57, P3520; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STEWART N, 1995, ONCOGENE, V10, P109; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; TISTY TD, 1995, MUTAT RES, V337, P1; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	54	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1045	1051		10.1038/sj.onc.1203274	http://dx.doi.org/10.1038/sj.onc.1203274			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713688				2022-12-28	WOS:000085796400010
J	Coutts, M; Zou, XM; Calame, K				Coutts, M; Zou, XM; Calame, K			v-Abl utilizes multiple mechanisms to drive G1/S progression in fibroblasts	ONCOGENE			English	Article						v-Abl; cell cycle; p27; E2F	CDK INHIBITOR P27(KIP1); CELL-CYCLE PROGRESSION; C-MYC TRANSCRIPTION; RESTRICTION POINT; TYROSINE KINASE; DEPENDENT KINASES; GROWTH; PROTEIN; ARREST; PHOSPHORYLATION	Transformation of 3T3 fibroblasts by the v-Abl tyrosine kinase replaces mitogenic and adhesion signals normally required for cell cycle progression. A 3T3 cell line conditionally transformed with v-Abl has been used to study v-Abl's effects on cell cycle in the context of either serum depletion or absence of adhesion signals. We show that E2F-dependent mRNAs, encoding proteins required for cell cycle progression, are induced by v-Abl, In addition, we identify two previously unknown targets of v-Abl signaling: (1) cyclin D1 and D2 mRNAs are induced upon v-Abl activation; and (2) the CDK inhibitor p27 is decreased upon v-Abl activation.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Columbia University	Calame, K (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St,HHSC 1202, New York, NY 10032 USA.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BirchenallRoberts MC, 1997, J BIOL CHEM, V272, P8905; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DelSal G, 1996, CRIT REV ONCOGENESIS, V7, P127, DOI 10.1615/CritRevOncog.v7.i1-2.80; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Harper JW, 1997, CANCER SURV, V29, P91; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; QUELLE DE, 1995, ONCOGENE, V11, P635; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sheaff RJ, 1997, METHOD ENZYMOL, V283, P173; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	42	5	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					801	809		10.1038/sj.onc.1203398	http://dx.doi.org/10.1038/sj.onc.1203398			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698498				2022-12-28	WOS:000085192100010
J	Schor, NF; Rudin, CM; Hartman, AR; Thompson, CB; Tyurina, YY; Kagan, VE				Schor, NF; Rudin, CM; Hartman, AR; Thompson, CB; Tyurina, YY; Kagan, VE			Cell line dependence of Bcl-2-induced alteration of glutathione handling	ONCOGENE			English	Article						oxidative stress; apoptosis; glutathione	NEOCARZINOSTATIN CYTO-TOXICITY; CHEMOTHERAPY-INDUCED APOPTOSIS; NEUROBLASTOMA-CELLS; NERVOUS-SYSTEM; FREE-RADICALS; CYTOCHROME-C; BCL-2; DEATH; DIFFERENTIATION; POTENTIATION	Bcl-2 has been associated with both oxidative and antioxidative effects in vivo. Moreover, despite evidence that Bcl-2 is antiapoptotic by virtue of its effect on reactive oxygen species and their scavengers, BcI-2 exerts its antiapoptotic effects even under anaerobic conditions. The reasons for the variable relationship between Bcl-2 and reactive oxygen species are not clear. The present studies demonstrate that the impact of Bcl-2 on glutathione (GSH) metabolism is cell line-dependent. Bcl-2 overproduction in PC12 cells is associated with increased functional thiol reserves, increased reductive activation of chemotherapeutic prodrugs, and GSH accumulation after treatment with N-acetlcysteine. In contrast, Bcl-2-overproducing MCF-7 breast cancer cells demonstrate neither altered GSH handling nor potentiation of chemotherapeutic prodrug reduction. These findings indicate that the effects of Bcl-2 on GSH handling are millieu-dependent. This could account for the variable effects of Bcl-2 in in vivo systems. Furthermore, since our previous studies have demonstrated that reduction-dependent prodrugs may be useful chemotherapeutic agents against tumors that demonstrate altered GSH handling, screening in vitro for alteration of GSH handling may predict responsiveness of such tumors to these reduction-dependent agents.	Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Chicago	Schor, NF (corresponding author), Childrens Hosp Pittsburgh, Div Child Neurol, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Tyurina, Yulia/0000-0003-0287-2091; Schor, Nina/0000-0002-3817-7376	NCI NIH HHS [CA74289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074289, R55CA074289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; BEERMAN TA, 1977, BIOCHIM BIOPHYS ACTA, V475, P294, DOI 10.1016/0005-2787(77)90020-X; Beham A. W., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P224; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonetti A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P192; CAMPOS L, 1993, BLOOD, V81, P3091; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHIN DH, 1988, BIOCHEMISTRY-US, V27, P8106, DOI 10.1021/bi00421a020; Cortazzo M, 1996, CANCER RES, V56, P1199; DEGRAFF WG, 1985, CANCER RES, V45, P4760; DEGRAFF WG, 1985, J BIOL CHEM, V260, P8312; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; Gelbard HA, 1997, PEDIATR NEUROL, V16, P93, DOI 10.1016/S0887-8994(96)00258-5; HALLIWELL B, 1985, TINS             JAN, P22; Hartsell TL, 1996, J PHARMACOL EXP THER, V277, P1158; HARTSELL TL, 1995, J PHARMACOL EXP THER, V275, P479; HUBEL CA, 1997, FREE RADICAL BIO MED, V23, P596; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Langmuir ME, 1996, FLUORESCENCE MICROSCOPY AND FLUORESCENT PROBES, P229; MAEDA H, 1994, ENEDIYNE ANTIBIOTICS, P363; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; Reber U, 1998, BIOCHEM PHARMACOL, V55, P349, DOI 10.1016/S0006-2952(97)00480-2; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; SCHOR NF, 1992, J CLIN INVEST, V89, P774, DOI 10.1172/JCI115655; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; Smith TK, 1998, DEV BRAIN RES, V105, P175, DOI 10.1016/S0165-3806(97)00168-5; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; Stoyanovsky DA, 1996, ARCH BIOCHEM BIOPHYS, V330, P3, DOI 10.1006/abbi.1996.0219; TEIXEIRA C, 1995, CANCER RES, V55, P3902; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TYURINA YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P412; WOOD KA, 1994, ANN NY ACAD SCI, V738, P400; WOOD KA, 1995, J NEUROSCI, V15, P5851; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	37	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					472	476		10.1038/sj.onc.1203324	http://dx.doi.org/10.1038/sj.onc.1203324			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656697				2022-12-28	WOS:000084873700020
J	Todd, MC; Sclafani, RA; Langan, TA				Todd, MC; Sclafani, RA; Langan, TA			Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein	ONCOGENE			English	Article						adenovirus; cell cycle; cyclin D1; ovarian tumors; p16; Rb	RETINOBLASTOMA PROTEIN; P16(INK4A) EXPRESSION; PRODUCT P16(INK4A); MOLECULAR ANALYSIS; HIGH-FREQUENCY; BREAST-CANCER; CYCLE ARREST; GENE-PRODUCT; TUMORS; LINES	Defects of the 'Rb/cyclin D1/p16 pathway' have been shown to play a critical role in the development of virtually all human malignancies assessed. To determine the contribution of G1 phase cell cycle defects to ovarian tumorigenesis, we have examined a panel of normal and tumor ovarian tissues and ovarian cancer cell lines for the expression of Rb, p16 and cyclin D1 proteins. Unlike most types of human cancer whose development involves the loss of either Rb or p16 expression, we observed the coexpression of Rb, p16 and cyclin D1 in 82% of ovarian cancer tissues and cell lines, Furthermore, the growth and cell cycle distribution profiles of three ovarian cancer cell lines (ES-2, PA-1 and NIH OVCAR-3) that coexpressed Rb and p16, were found to be unaffected by adenoviral-mediated overexpression of functional p16 protein, indicating the existence of a defect(s) downstream from p16 in these cells. By contrast overexpression of ectopic p16 in the one ovarian cancer cell line (SK-OV3) that expressed Rb but lacked p16 protein, resulted in a G1 growth arrest. These data suggest that defects of the 'Rb/cyclin D1/p16 pathway', other than the loss of Rb or p16, may play a major role in the development of ovarian cancer.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Todd, MC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave,Box B121, Denver, CO 80262 USA.			Sclafani, Robert/0000-0002-1100-6489				Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Dong Y, 1997, INT J CANCER, V74, P57, DOI 10.1002/(SICI)1097-0215(19970220)74:1<57::AID-IJC10>3.0.CO;2-F; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2; Geradts J, 1996, AM J PATHOL, V149, P15; GERADTS J, 1995, CANCER RES, V55, P6006; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; HE J, 1995, CANCER RES, V55, P4833; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hung WC, 1996, HUM PATHOL, V27, P1324, DOI 10.1016/S0046-8177(96)90345-7; JIN XM, 1995, CANCER RES, V55, P3250; Kanuma T, 1997, MOL CARCINOGEN, V18, P134, DOI 10.1002/(SICI)1098-2744(199703)18:3<134::AID-MC2>3.0.CO;2-F; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; LIU Y, 1994, INT J CANCER, V58, P663, DOI 10.1002/ijc.2910580508; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; McCluskey LL, 1999, GYNECOL ONCOL, V72, P87, DOI 10.1006/gyno.1998.5235; Milde-Langosch K, 1998, INT J CANCER, V79, P61, DOI 10.1002/(SICI)1097-0215(19980220)79:1<61::AID-IJC12>3.0.CO;2-K; Niemann TH, 1998, GYNECOL ONCOL, V69, P214, DOI 10.1006/gyno.1998.5015; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Palmero I, 1996, CANCER SURV, V27, P351; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; Ryan A, 1998, GYNECOL ONCOL, V68, P14, DOI 10.1006/gyno.1997.4881; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SCHULTZ DC, 1995, CANCER RES, V55, P2150; Schuyer M, 1996, BRIT J CANCER, V74, P1069, DOI 10.1038/bjc.1996.491; Sclafani RA, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P123; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shih YC, 1997, INT J CANCER, V70, P508, DOI 10.1002/(SICI)1097-0215(19970304)70:5<508::AID-IJC3>3.3.CO;2-6; Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373; TAYLOR RR, 1995, GYNECOL ONCOL, V58, P307, DOI 10.1006/gyno.1995.1235; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wolf JK, 1999, GYNECOL ONCOL, V73, P27, DOI 10.1006/gyno.1998.5259; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	46	25	27	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					258	264		10.1038/sj.onc.1203289	http://dx.doi.org/10.1038/sj.onc.1203289			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645004				2022-12-28	WOS:000084844400011
J	Esteller, M; Avizienyte, E; Corn, PG; Lothe, RA; Baylin, SB; Aaltonen, LA; Herman, JG				Esteller, M; Avizienyte, E; Corn, PG; Lothe, RA; Baylin, SB; Aaltonen, LA; Herman, JG			Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome	ONCOGENE			English	Article						LKB1; hypermethylation; Peutz-Jeghers; human cancer	PROMOTER HYPERMETHYLATION; SOMATIC MUTATIONS; COLON-CANCER; CELL-LINES; METHYLATION; GENE; NEOPLASIA; KINASE; HMLH1	Germ-Line mutations of the LKB1 gene cause Peutz-Jeghers syndrome (PJS) characterized by mucocutaneous pigmentation, predisposition to benign hamartomas of the gastrointestinal tract and also to several types of tumors. However, somatic mutations of this gene are, very rare. To examine inactivation of LKB1 by epigenetic mechanisms,,ve investigated a series of primary tumors and canter cell lines, for hg permethylation affecting the CpG island located in the 5' region of the LKB1 gene using Methylation-specific PCR (MSP). First, we screened 51 cancer cell lines. Only three colorectal and one cervical carcinoma cell lines were methylated at LKB1, and loss of the LKB1 transcript was demonstrated. Treatment with the demethylating agent 5-aza-2'-deoxycytidine restored LKB1 expression, To address the incidence of LKB1 epigenetic inactivation in primary tumors, we analysed colorectal, breast, gastric, pancreatic, thyroid, bladder and testicular carcinomas (n = 195), Normal tissues from the mentioned organs were unmethylated in this region. Among the described tumors, only one colorectal carcinoma and three testicular tumors displayed LKB1 promoter hypermethylation. Further study of those histological types more commonly associated with PJS, demonstrated that LKB1 promoter hypermethylation was present in five of 11 (45%) papillary breast carcinomas, Finally, in three patients with a strong family story suggestive of PJS disease, abnormal LKB1 methylation was found in four of 22 (18%) hamartomatous polyps lesions. Our findings provide an alternative pathway for inactivation of the LKB1 tumor suppressor gene involving promoter hypermethylation.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway	Johns Hopkins University; Johns Hopkins Medicine; University of Helsinki; University of Oslo	Herman, JG (corresponding author), Johns Hopkins Oncol Ctr, 424 N Bond St, Baltimore, MD 21231 USA.		Esteller, Manel/L-5956-2014; Aaltonen, Lauri/A-5375-2010	Esteller, Manel/0000-0003-4490-6093; Aaltonen, Lauri/0000-0001-6839-4286; Lothe, Ragnhild A./0000-0002-1693-1032				Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bignell GR, 1998, CANCER RES, V58, P1384; Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004; Dong SM, 1998, CANCER RES, V58, P3787; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 1999, AM J CLIN PATHOL, V111, P336; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gruber SB, 1998, CANCER RES, V58, P5267; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; JONES HW, 1971, OBSTET GYNECOL, V38, P945; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kane MF, 1997, CANCER RES, V57, P808; Lee JY, 1998, CANCER RES, V58, P1140; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Resta N, 1998, CANCER RES, V58, P4799; RILEY E, 1980, CANCER, V46, P815, DOI 10.1002/1097-0142(19800815)46:4<815::AID-CNCR2820460428>3.0.CO;2-V; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; TOMPKINS WA, 1974, J NATL CANCER I, V52, P1101, DOI 10.1093/jnci/52.4.1101; Vermeulen SJ, 1998, CANCER GENET CYTOGEN, V107, P76, DOI 10.1016/S0165-4608(98)00081-8; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45	29	146	152	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					164	168		10.1038/sj.onc.1203227	http://dx.doi.org/10.1038/sj.onc.1203227			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644993				2022-12-28	WOS:000084844300020
J	Tamura, K; Rice, RL; Wipf, P; Lazo, JS				Tamura, K; Rice, RL; Wipf, P; Lazo, JS			Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor	ONCOGENE			English	Article						Cdc25 phosphatase inhibitor; cell cycle arrest; Cdc2; Cdk2; Cdk4; tsFT210	CELL-CYCLE; SMALL-MOLECULE; C-MYC; TYROSINE PHOSPHATASE; PROTEIN-KINASE; PHOSPHORYLATION; ACTIVATION; MITOSIS; LIBRARY; OVEREXPRESSION	The Cdc25 dual specificity phosphatase family has a central role in controlling cell cycle progression and has been implicated in the etiology of cancer. One compound, 4-(benzyl-(2-[(2, 5-diphenyl-oxazole-4-carbonyl)-amino]-ethyl)-carbamoyl) -2-decanoylamino butyric acid (SC-alpha alpha delta 9), was previously identified as the most potent reported synthetic inhibitor of Cdc25 phosphatases in vitro. In the present study, we demonstrate that SC-alpha alpha delta 9 inhibited Cdc25-dependent cell cycle progression at both G1 and G2/M phase using tsFT210 cells, which express a temperature-sensitive Cdc2 mutant, SC-alpha alpha delta 9 blocked both G2/M transition and dephosphorylation of Cdc2 in a concentration-dependent manner. SC-alpha alpha delta 9 also enhanced tyrosine phosphorylation of both Cdk2 and Cdk4, and decreased Cdk4 kinase activity. Both of the kinases are potent regulators of G1 transition. Furthermore, closely related chemical analogs that lacked Cdc25 inhibitory activity failed to block cell cycle progression at both G1 and G2/M, and did not affect Cdc2 phosphorylation or Cdk4 kinase activity. SC-alpha alpha delta 9 did not alter p53, p21 or p16 levels, Our results support the hypothesis that the disruption in cell cycle transition caused by SC-alpha alpha delta 9 was due to intracellular Cdc25 inhibition. We propose that the SC-alpha alpha delta 9 pharmacophore could be useful in further clarifying the role of Cdc25 phosphatase-dependent pathways in checkpoint control, oncogenesis, and apoptosis.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15261 USA; Hiroshima Univ, Sch Med, Dept Internal Med 2, Minami Ku, Hiroshima 734, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hiroshima University	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, Biomed Sci Tower E-1340, Pittsburgh, PA 15261 USA.		Wipf, Peter/AAG-1771-2021	Wipf, Peter/0000-0001-7693-5863	NATIONAL CANCER INSTITUTE [P01CA078039, R01CA039745] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78039, CA-39745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARATTE B, 1992, ANTICANCER RES, V12, P873; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Gasparotto D, 1997, CANCER RES, V57, P2366; Gunasekera SP, 1996, J AM CHEM SOC, V118, P8759, DOI 10.1021/ja961961+; HAMAGUCHI T, 1995, FEBS LETT, V372, P54, DOI 10.1016/0014-5793(95)00953-7; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernandez S, 1998, CANCER RES, V58, P1762; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HORIGUCHI T, 1994, BIOCHEM PHARMACOL, V48, P2139, DOI 10.1016/0006-2952(94)90516-9; HUNTER T, 1994, CELL, V79, P537; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Kakeya H, 1998, CANCER RES, V58, P704; Lammer C, 1998, J CELL SCI, V111, P2445; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; NAGATA A, 1991, NEW BIOL, V3, P959; Peng HR, 1998, J MED CHEM, V41, P4677, DOI 10.1021/jm980500r; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; RICE RL, 1998, P AM ASSOC CANC RES, V39, P1208; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Vogt A, 1998, J PHARMACOL EXP THER, V287, P806; Wipf P, 1997, BIOORGAN MED CHEM, V5, P165, DOI 10.1016/S0968-0896(96)00199-X; Wu WG, 1998, CANCER RES, V58, P4082	33	25	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6989	6996		10.1038/sj.onc.1203179	http://dx.doi.org/10.1038/sj.onc.1203179			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597298				2022-12-28	WOS:000083901900004
J	Gerondakis, S; Grossmann, M; Nakamura, Y; Pohl, T; Grumont, R				Gerondakis, S; Grossmann, M; Nakamura, Y; Pohl, T; Grumont, R			Genetic approaches in mice to understand Rel/NF-kappa B and I kappa B function: transgenics and knockouts	ONCOGENE			English	Review						NF-kappa B; Rel; I kappa B; IKK; knockout mice; transgenic mice; mouse genetics	TRANSCRIPTION FACTORS; IMMUNE-RESPONSES; T-CELLS; SPLENIC MICROARCHITECTURE; PROLIFERATIVE RESPONSES; TARGETED DISRUPTION; MULTIFOCAL DEFECTS; ONCOPROTEIN BCL-3; INHIBITOR PROTEIN; EXHIBIT DEFECTS	Rel/NF-kappa B transcription factors have been implicated in regulating a wide variety of genes important in cellular processes that include cell division, cell survival, differentiation and immunity. Here genetic models in which various Rel/NF-kappa B and I kappa B proteins have either been over-expressed or deleted in mice will be reviewed. Although expressed fairly ubiquitously, homozygous disruption of individual Rel/NF-kappa B genes generally affects the development of proper immune cell function. One exception is rela, which is essential for embryonic liver development. The disruption of genes encoding the individual subunits of the I kappa B kinase, namely IKK alpha and IKK beta, has demonstrated that IKK beta transmits the response to most common NF-kappa B inducing agents, whereas IKK alpha has an unexpected role in keratinocyte differentiation. Future studies will no doubt focus on the effect of multiple gene disruptions of members of this signaling pathway, on tissue-specific disruptions of these genes, and on the use of these mice as models for human diseases.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Gerondakis, S (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, PO, Parkville, Vic 3050, Australia.		Nakamura, Yukio/A-5263-2016	Nakamura, Yukio/0000-0001-8056-4946				Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; Attar RM, 1997, SEMIN CANCER BIOL, V8, P93, DOI 10.1006/scbi.1997.0060; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; CAAMANO JH, 1999, IN PRESS J IMMUNOL; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; GROSSMANN M, 1999, IN PRESS P NATL ACAD; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Harling-McNabb L, 1999, INT IMMUNOL, V11, P1431, DOI 10.1093/intimm/11.9.1431; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Horwitz BH, 1999, J IMMUNOL, V162, P1941; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; MEMET S, 1999, IN PRESS J IMMUNOL; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Snapper CM, 1996, J IMMUNOL, V156, P183; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weih F, 1997, J IMMUNOL, V158, P5211; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; Weih F, 1996, ONCOGENE, V12, P445; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	62	254	258	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6888	6895		10.1038/sj.onc.1203236	http://dx.doi.org/10.1038/sj.onc.1203236			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602464				2022-12-28	WOS:000083896500006
J	Karin, M				Karin, M			How NF-kappa B is activated: the role of the I kappa B kinase (IKK) complex	ONCOGENE			English	Review						NF-kappa B; Rel; I kappa B; IKK; kinase; phosphorylation; proteasome; signal transduction	UBIQUITIN-PROTEASOME PATHWAY; F-BOX; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; CELL-DEATH; ALPHA; PHOSPHORYLATION; DEGRADATION; PROTEIN	Rel/NF-kappa B transcription factors are primarily regulated by association with inhibitor I kappa B proteins. Thus, in most cells NF-kappa B exists in the cytoplasm in an inactive complex bound to I kappa B. Most agents that activate NF-kappa B do so through a common pathway based on phosphorylation-induced, proteasome-mediated degradation of I kappa B. The key regulatory step in this pathway involves activation of a high molecular weight I kappa B kinase (IKK) complex, whose catalysis is generally carried out by a heterodimeric kinase consisting of IKK alpha and IKK beta subunits. This review describes the identification of proteins in the IKK complex, and the regulation and physiological functions of IKK.	Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Gilmore TD, 1997, J CLIN INVEST, V100, P2935, DOI 10.1172/JCI119843; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REYAT B, 1999, ONCOGENE, V18, P6938; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	72	958	992	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	1999	18	49					6867	6874		10.1038/sj.onc.1203219	http://dx.doi.org/10.1038/sj.onc.1203219			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602462				2022-12-28	WOS:000083896500004
J	Konishi, Y; Tominaga, M; Watanabe, Y; Imamura, F; Goldfarb, A; Maki, R; Blum, H; De Robertis, EM; Tominaga, A				Konishi, Y; Tominaga, M; Watanabe, Y; Imamura, F; Goldfarb, A; Maki, R; Blum, H; De Robertis, EM; Tominaga, A			GOOSECOID inhibits erythrocyte differentiation by competing with Rb for PU.1 binding in murine cells	ONCOGENE			English	Article						goosecoid; PU.1; Rb	TRANSCRIPTION FACTOR PU.1; RETINOBLASTOMA PROTEIN; ERYTHROLEUKEMIA-CELLS; POSITIVE REGULATOR; GENE-PRODUCT; ETS ONCOGENE; LEUKEMIA; EXPRESSION; SCL; HEMATOPOIESIS	Misexpression of the dorsal mesodermal patterning factor goosecoid on the ventral side of amphibian embryos results in inhibition of blood formation in early embryogenesis, To investigate the mechanism of this inhibition, we ectopically expressed goosecoid in erythroleukemia cells. While erythroid differentiation of these cells can be induced by activin, goosecoid expressing cells were unresponsive to activin, We demonstrate an in vitro interaction between the oncogene PU.1, an ets family transcription factor thought to play a role in erythropoiesis, and the goosecoid protein (GSC). Interaction with PU.1 was specific as GSC did not bind to the ets family members, Fli-1 or Ets-2, The ability of goosecoid expressing erythroleukemia cells to differentiate in response to activin was rescued by coexpression of the GSC-binding N-terminal portion of PU.1. The N-terminal portion of PU.1 was coimmunoprecipitated with anti-GSC antibodies as well. The N-terminal domain of PU.1 is the region recognized by the retinoblastoma protein (Rb), a tumor suppressor gene presumably involved in erythroid differentiation. We show that GSC competitively inhibits binding of Rb to PU.1, Our data suggest that the suppression of blood formation by GSC could, at least in part, be mediated by binding to PU.1.	Kochi Med Sch, Med Res Ctr, Nankoku, Kochi 7838505, Japan; Kumamoto City Hosp, Div Pulm Dis, Kumamoto 8620808, Japan; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Burnham Inst, La Jolla, CA 92037 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Calif Los Angeles, Sch Med, HHMI, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	Kochi University; University of Virginia; Sanford Burnham Prebys Medical Discovery Institute; Helmholtz Association; Karlsruhe Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tominaga, A (corresponding author), Kochi Med Sch, Med Res Ctr, Okoh Cho, Nankoku, Kochi 7838505, Japan.							APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEROBERTIS EM, 1992, DEVELOPMENT, P167; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; GOLDFARB AN, 1992, BLOOD, V80, P2858; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HROMAS R, 1993, BLOOD, V82, P2998; IKAWA Y, 1976, GANN, V67, P767; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Spemann H., 1924, FDN EXPT EMBRYOLOGY, P144; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	42	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6795	6805		10.1038/sj.onc.1203118	http://dx.doi.org/10.1038/sj.onc.1203118			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597288				2022-12-28	WOS:000083792000022
J	Schulz, RA; Gajewski, K				Schulz, RA; Gajewski, K			Ventral neuroblasts and the Heartless FGF receptor are required for muscle founder cell specification in Drosophila	ONCOGENE			English	Article						D-mef2; heartless; muscle founder cells; signal transduction; ventral neuroblasts	GROWTH-FACTOR RECEPTOR; CENTRAL-NERVOUS-SYSTEM; SINGLE-MINDED GENE; MESODERM; EXPRESSION; MIGRATION; HOMOLOG; EMBRYO; TINMAN; BREATHLESS	Muscle founder cells are uniquely specified cells that fuse with neighboring myoblasts to generate the complex pattern of body wall muscles in the Drosophila embryo. We have investigated the positional specification of founder cells for ventral oblique muscles, marked by the restricted expression of tinman RNA and the activity of a D-mef2 enhancer. The formation of these ventral myoblasts requires the function of the Heartless FGF receptor in the mesoderm and the presence of ventral neuroblasts in the central nervous system. Overproduction of ventral neuroblasts due to the forced expression of the homeodomain protein Vnd leads to increased numbers of founder cells. These results suggest the use of a neuroectoderm-to-mesoderm signaling pathway in the specification of ventral muscle precursors.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Schulz, RA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NHLBI NIH HHS [HL59151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BAKER R, 1995, DEVELOPMENT, V121, P1387; Bate M, 1996, SEMIN CELL DEV BIOL, V7, P103, DOI 10.1006/scdb.1996.0015; Bate Michael, 1993, P1013; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Baylies MK, 1998, CELL, V93, P921, DOI 10.1016/S0092-8674(00)81198-8; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAND AH, 1993, DEVELOPMENT, V118, P401; Buff E, 1998, DEVELOPMENT, V125, P2075; Chu H, 1998, GENE DEV, V12, P3613, DOI 10.1101/gad.12.22.3613; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; Gajewski K, 1998, DEV GENES EVOL, V208, P382, DOI 10.1007/s004270050194; Gisselbrecht S, 1996, GENE DEV, V10, P3003, DOI 10.1101/gad.10.23.3003; Grass S, 1996, DEVELOPMENT, V122, P141; HILLIKER AJ, 1981, DROS INFORM SERV, V56, P65; Ingham P. W., 1997, The molecular biology of insect disease vectors: a methods manual., P268; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; LEWIS JO, 1994, MECH DEVELOP, V48, P81, DOI 10.1016/0925-4773(94)90018-3; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; McDonald JA, 1998, GENE DEV, V12, P3603, DOI 10.1101/gad.12.22.3603; Michelson AM, 1998, DEV GENET, V22, P212, DOI 10.1002/(SICI)1520-6408(1998)22:3<212::AID-DVG4>3.0.CO;2-9; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; Nguyen HT, 1998, DEV BIOL, V204, P550, DOI 10.1006/dbio.1998.9081; Ranganayakulu G, 1996, DEV BIOL, V176, P143, DOI 10.1006/dbio.1996.9987; REICHMANFRIED M, 1995, MECH DEVELOP, V52, P265, DOI 10.1016/0925-4773(95)00407-R; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Shishido E, 1997, DEVELOPMENT, V124, P2119; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; VOLK T, 1994, DEVELOPMENT, V120, P59; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354	34	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6818	6823		10.1038/sj.onc.1203081	http://dx.doi.org/10.1038/sj.onc.1203081			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597291				2022-12-28	WOS:000083792000025
J	Wouters, BG; Denko, NC; Giaccia, AJ; Brown, JM				Wouters, BG; Denko, NC; Giaccia, AJ; Brown, JM			A p53 and apoptotic independent role for p21(waf1) in tumour response to radiation therapy	ONCOGENE			English	Article						apoptosis; cancer-therapy; radiosensitivity; cyclin-dependent; kinase inhibitor; xenografts	CYCLIN-DEPENDENT KINASE; CLONOGENIC SURVIVAL; CANCER-THERAPY; CELL-DEATH; IONIZING-RADIATION; SOLID TUMORS; BCL-2; P21; DELAYS; RESISTANCE	Loss of p21 in human cancer cells results in checkpoint failure, induction of polyploidy and subsequent apoptosis following DNA damage. Tumours in immunodeficient mice derived from cells lacking p21 are also more sensitive to ionizing radiation than their wild-type counterparts. Abrogation of p53 in the p21(+/+) parental cells results in an in vitro phenotype that is indistinguishable from that of the p21 knockout cells. Thus, the in vitro phenotype resulting from loss of p21 is consistent with its well-established role in the p53/p21 damage response pathway. However, despite the similar in vitro phenotype, p21(+/+) cells with abrogated p53 show no evidence of the sensitivity observed in the p21(-/-) cells when grown as tumours in immunodeficient mice. The increased radio-sensitization stabilization of p21(-/-) tumours is also unrelated to the increase in apoptosis observed in these tumours following radiation treatment. Apoptosis in the p21(-/-) tumours was significantly reduced by expression of bcl-2 without any corresponding change in the overall response of the tumour. Similarly, abrogation of p53 in the p21(+/+) tumours substantially increased radiation-induced apoptosis within the tumours without increasing their radiation sensitivity. Dissociation of these in vivo and in vitro phenotypes indicates that p21 participates in a novel in vivo specific damage response pathway that is distinct from its role in the p53 pathway, and therefore that it may be an effective therapeutic target for cancer therapy.	Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA	Stanford University	Wouters, BG (corresponding author), Ottawa Reg Canc Ctr, Canc Res Grp, 3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Wouters, Bradly/T-1525-2017; denko, nicholas/F-8444-2010	Wouters, Bradly/0000-0002-8187-592X; 	NATIONAL CANCER INSTITUTE [R01CA064489, R01CA015201] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA15201, CA 64489, CA 09302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA K, 1995, CANCER RES, V55, P1431; BIGGS JR, 1995, J MOL MED-JMM, V73, P509; Brizel DM, 1996, CANCER RES, V56, P941; Brown JM, 1996, NAT MED, V2, P1055, DOI 10.1038/nm1096-1055b; Brown JM, 1998, CANCER RES, V58, P1408; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GJERSET RA, 1997, ENCY CANC, P1785; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Han JW, 1997, CANCER RES, V57, P176; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hockel M, 1996, CANCER RES, V56, P4509; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang H, 1996, INT J RADIAT BIOL, V70, P151, DOI 10.1080/095530096145148; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Lock RB, 1996, CANCER RES, V56, P4006; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wouters BG, 1997, CANCER RES, V57, P4703; YIN DX, 1995, CANCER RES, V55, P4922	26	43	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6540	6545		10.1038/sj.onc.1203053	http://dx.doi.org/10.1038/sj.onc.1203053			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597257				2022-12-28	WOS:000083709200017
J	Zhan, Y; van de Water, B; Wang, YP; Stevens, JL				Zhan, Y; van de Water, B; Wang, YP; Stevens, JL			The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells	ONCOGENE			English	Article						kidney; bcl-2; apoptosis; caspase; glutathione	C-MYC; OXIDATIVE STRESS; CATHEPSIN-B; GRANZYME-B; DEATH; PROTEASE; ACTIVATION; EXPRESSION; MECHANISM; CA2+	The kidney is a target for toxicants including cisplatin and S-(1,2-dichlorovinyl)-L-cysteine (DCVC), a metabolite of the environmental contaminant, trichloroethylene. Necrosis is well characterized in kidney cells, but pathways leading to apoptosis are less clear. Cysteine conjugates are useful toxicants because they induce either necrosis or apoptosis depending on chemical structure or antioxidant status. Herein, we show that in the renal epithelial cell line LLC-PK1, activation of caspase3 (CPP32/Yama/apopain) is crucial for apoptosis, but not necrosis. Apoptosis was blocked by zVAD.fmk, and partially by a cathepsin inhibitor. Caspase-3 activity and cleavage of poly(ADP-ribose) polymerase (PARP) was detected only during apoptosis. S-(1,1,2,2-Tetrafluoroethyl)-1-cysteine (TFEC), a metabolite of tetrafluoroethylene, kills cells only by necrosis, and did not activate caspases under any conditions. Apoptosis and activation of caspase3 by cisplatin, but not DCVC, was prevented by bcl-2. Thus, caspase-3 activation by bcl-2-dependent and -independent mechanisms is a terminal event in chemical-apoptosis of renal epithelial cells.	Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Adirondack Biomed Res Inst, New York, NY 12946 USA	University of Vermont	Stevens, JL (corresponding author), Univ Vermont, Coll Med, Dept Pathol, A249 Med Alumni Bldg, Burlington, VT 05405 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007847] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46267] Funding Source: Medline; NIEHS NIH HHS [ES07847] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHEN Q, 1990, J BIOL CHEM, V265, P21603; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CRONIN RE, 1995, KIDNEY, P1680; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183; Eguchi Y, 1997, CANCER RES, V57, P1835; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GOLDSTEIN RS, 1996, TOXICOLOGY, P417; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; GUENETTE RS, 1994, EUR J BIOCHEM, V226, P311, DOI 10.1111/j.1432-1033.1994.tb20055.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; LOCK EA, 1989, TOXICOL LETT, V46, P93, DOI 10.1016/0378-4274(89)90120-3; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; MAJNO G, 1995, AM J PATHOL, V146, P3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; MOALLEM SA, 1995, TERATOLOGY, V52, P3, DOI 10.1002/tera.1420520103; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; Shimizu S, 1996, ONCOGENE, V12, P2251; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; VAMVAKAS S, 1989, MUTAT RES, V222, P329, DOI 10.1016/0165-1218(89)90108-0; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; VanDeWater B, 1996, AM J PHYSIOL-RENAL, V270, pF593, DOI 10.1152/ajprenal.1996.270.4.F593; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; ZORNIG M, 1995, ONCOGENE, V11, P2165	56	66	74	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6505	6512		10.1038/sj.onc.1203060	http://dx.doi.org/10.1038/sj.onc.1203060			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597253				2022-12-28	WOS:000083709200013
J	Echlin, DR; Tae, HJ; Mitin, N; Taparowsky, EJ				Echlin, DR; Tae, HJ; Mitin, N; Taparowsky, EJ			B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos	ONCOGENE			English	Article						AP-1; transcription regulation; protein; DNA interactions; transformation	C-JUN; DNA-BINDING; C3H10T1/2 CELLS; V-MYC; ACTIVATION; PROTEIN; EXPRESSION; ONCOGENE; MUTANT; MAF	B-ATF is a nuclear basic Leucine zipper protein that belongs to the AP-1/ATF superfamily of transcription factors. Northern blot analysis reveals that the human B-ATF gene is expressed most highly in hematopoietic tissues. Interaction studies in vitro and in vivo show that the leucine zipper of B-ATF mediates dimerization with members of the Jun family of proteins. Chimeric proteins consisting of portions of B-ATF and the DNA binding domain of the yeast activator GAL4 do not stimulate reporter gene expression in mammalian cells, indicating that B-ATF does not contain a conventional transcription activation domain. Jun/B-ATF dimers display similar DNA binding profiles as Jun/Fos dimers, with a bias toward binding TRE (12-O-tetradecanolyphorbol-13-acetate-response element) over CRE (cyclic AMP-response element) DNA sites. B-ATF inhibits transcriptional activation of a reporter gene containing TRE sites in a dose-dependent manner, presumably by competing with Fos for Jun and forming transcriptionally inert Jun/B-ATF heterodimers, Stable expression of B-ATF in C3H10T1/2 cells does not reduce cell viability, but does result in a reduced cellular growth rate when compared to controls, This effect is dominant in the presence of the growth promoting effects of the H-Ras or the v-Fos oncoproteins, since expression of B-ATF restricts the efficiency of focus formation by these transforming agents. These findings demonstrate that B-ATF is a tissue-specific transcription factor with the potential to function as a dominant-negative to AP-1.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Taparowsky, EJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.		Mitin, Natalia/E-8043-2012		NATIONAL CANCER INSTITUTE [R01CA078264] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Carrozza ML, 1997, ONCOGENE, V14, P1083, DOI 10.1038/sj.onc.1200921; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVENPORT EA, 1992, EXP CELL RES, V202, P532, DOI 10.1016/0014-4827(92)90108-K; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Dorsey MJ, 1995, ONCOGENE, V11, P2255; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hasegawa H, 1996, BIOCHEM BIOPH RES CO, V222, P164, DOI 10.1006/bbrc.1996.0700; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; Lemercier C, 1997, DEV BIOL, V182, P101, DOI 10.1006/dbio.1996.8454; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Meyer NP, 1998, MAMM GENOME, V9, P849, DOI 10.1007/s003359900881; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MIN SY, 1994, CELL GROWTH DIFFER, V5, P563; MIN SY, 1992, ONCOGENE, V7, P1531; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; WANG S, 1994, APPL LASER, V14, P1; Wang XY, 1999, MOL ENDOCRINOL, V13, P254, DOI 10.1210/me.13.2.254; WICK M, 1992, ONCOGENE, V7, P859; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XANTHOUDAKIS S, 1996, BIOL REACTIVE INTERM, V5	53	83	88	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1752	1763		10.1038/sj.onc.1203491	http://dx.doi.org/10.1038/sj.onc.1203491			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777209				2022-12-28	WOS:000086292500003
J	Ji, QS; Carpenter, G				Ji, QS; Carpenter, G			Role of basal calcium in the EGF activation of MAP kinases	ONCOGENE			English	Article						calcium; MAP kinase; EGF	PROTEIN-TYROSINE PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; TRANSCRIPTION; BMK1/ERK5	The role of intracellular Ca2+ pools in the regulation of growth factor signal transduction pathways and mitogenesis is not well understood. We have examined the roles of basal and transiently mobilized Ca2+ in the regulation of MAP kinases by EGF, To assess the influence of Ca2+ transients we utilized Plcg1(-/-) and Plcg1(+/+) mouse embryonic fibroblasts, while BAPTA/AM was employed to chelate total intracellular Ca2+ in the same cell lines, The MAP kinases erk-1, erk-2 and erk-5 exhibited similar patterns of activation in wild-type and Plcg1(-/-) cells treated with EGF, However, pretreatment with BAPTA/AM significantly increased and prolonged erk-1 and erk-2 activation in both cell types, In contrast, BAPTA/AM prevented the EGF activation of erk-5 in wild-type and Plcg1(-/-) cells. These data indicate that basal Ca2+, but not growth factor provoked Ca2+ transients, has a significant influence on the activation of these MAP kinases, AG1478, a specific EGF receptor kinase inhibitor, abolished the prolonged erk-1 and erk-2 activation produced by EGF in cells pretreated with BAPTA/AM, This indicates that the prolonged activation of erk-1 and erk-2 produced in the presence of BAPTA/AM requires continuous signaling from the EGF receptor kinase.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA075195] Funding Source: NIH RePORTER; NCI NIH HHS [CA75195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BOHMER FD, 1995, ANAL BIOCHEM, V228, P267, DOI 10.1006/abio.1995.1349; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; STOSCHECK CM, 1983, ARCH BIOCHEM BIOPHYS, V227, P457, DOI 10.1016/0003-9861(83)90476-9; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	30	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1853	1856		10.1038/sj.onc.1203517	http://dx.doi.org/10.1038/sj.onc.1203517			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777220				2022-12-28	WOS:000086292500014
J	Suzuki, A; Ito, T; Kawano, H; Hayashida, M; Hayasaki, Y; Tsutomi, Y; Akahane, K; Nakano, T; Miura, M; Shiraki, K				Suzuki, A; Ito, T; Kawano, H; Hayashida, M; Hayasaki, Y; Tsutomi, Y; Akahane, K; Nakano, T; Miura, M; Shiraki, K			Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death	ONCOGENE			English	Article						Survivin; Cdk4; procaspase 3/p21 complex; Fas-mediated cell death; cell survival	ANTI-APOPTOSIS GENE; RETINOBLASTOMA PROTEIN; ICE/CED-3 PROTEASE; ICE CASCADE; GRANZYME-B; CYCLE; ACTIVATION; INVOLVEMENT; EXPRESSION; CASPASE-3	Caspase 3 is ran essential death factor for the Fas-mediated cell death, and its inactivation in cells is initiated by an interaction with p21 on mitochondria or with PAP family member ILP, Survivin is also a member of HAP family and is specifically expressed during embryogenesis and in tumor cells and suppresses cell death signaling, In our current study, we demonstrated that Survivin translocation into the nucleus is dependent on Fas stimulation and cell proliferation. Survivin also interacts with the cell cycle regulator Cdk4, leading to Cdk2/Cyclin E activation and Rb phosphorylation, As a result of Survivin/Cdk4 complex formation, p21 is released from its complex with Cdk4 and interacts with mitochondrial procaspase 3 to suppress Fas-mediated cell death, Here, we propose that Survivin supports procaspase 3/p21 complex formation as a result of interaction with Cdk4 resulting in suppression of cell death signaling.	Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, Basic Technol Res Lab, Project Cell Death Res,Edogawa Ku, Tokyo 1348630, Japan; Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan; Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, Drug Safety Res Lab, Edogawa Ku, Tokyo 1348630, Japan; Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, New Prod Res Lab 4, Edogawa Ku, Tokyo 1348630, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Suita, Osaka 565, Japan	Daiichi Sankyo Company Limited; Mie University; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Osaka University	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, Basic Technol Res Lab, Project Cell Death Res,Edogawa Ku, Kitakasai 1-16-13, Tokyo 1348630, Japan.							Adida C, 1998, AM J PATHOL, V152, P43; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fleischer S, 1974, Methods Enzymol, V31, P6; Hasegawa J, 1996, CANCER RES, V56, P1713; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu S, 1996, ONCOGENE, V12, P2251; SMITH PK, 1985, ANAL BIOCHEM, V170, P203; Suzuki A, 1997, EXP CELL RES, V233, P48, DOI 10.1006/excr.1997.3546; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1997, EXP CELL RES, V234, P507, DOI 10.1006/excr.1997.3639; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016/S0014-2999(97)01520-3; Tamm I, 1998, CANCER RES, V58, P5315; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	39	215	379	2	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1346	1353		10.1038/sj.onc.1203429	http://dx.doi.org/10.1038/sj.onc.1203429			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713676				2022-12-28	WOS:000085743800011
J	Pao, MM; Liang, GN; Tsai, YC; Xiong, ZG; Laird, PW; Jones, PA				Pao, MM; Liang, GN; Tsai, YC; Xiong, ZG; Laird, PW; Jones, PA			DNA methylator and mismatch repair phenotypes are not mutually exclusive in colorectal cancer cell lines	ONCOGENE			English	Article						DNA mismatch repair; DNA methylation; colorectal cancer; retrovirus	NONPOLYPOSIS COLON-CANCER; GENETIC INSTABILITY; CPG ISLAND; MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; DENOVO METHYLATION; HMLH1; EXPRESSION; MUTATIONS; CLONING	A potential link between DNA repair and de novo methylation of exogenous sequences in colorectal cancer cell lines suggested that cells deficient in mismatch repair (MMR-) had an increased ability to silence the introduced virus promoter by DIVA methylation due to the presence of a methylator phenotype (MET+) (Lengauer et al., 1997a), We explored this relationship in more detail and found that although there was a clear difference in the abilities of MMR cells to express the viral promoter compared to their MMR- counterparts, this difference was not consistently explained by levels of methylation in the viral promoter. Furthermore, we were unable to distinguish differences between the levels of methylation of six endogenous known CpG islands or 100 random DNA fragments containing CCGG sites within the cells. No consistent differences between the abilities of the cells to methylate the CpG island in exon 2 of the p16 gene were observed after transient demethylation by 5-aza-2'-deoxycytidine nor in the levels of expression of three human methyltransferase enzymes. Our results do not therefore support the existence of mutually exclusive DNA methylation (MET) and DNA repair (MMR) phenotypes.	Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Dept Surg, Norris Comprehens Canc Ctr, Urol Canc Res Lab, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Jones, PA (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, MS73,1441 Eastlake Ave, Los Angeles, CA 90033 USA.		Laird, Peter W/G-8683-2012	Laird, Peter W/0000-0001-9117-3641; Liang, Gangning/0000-0001-8664-922X	NCI NIH HHS [R01-CA75090-01, R01 CA075090, R35 CA 49758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075090, R35CA049758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahuja N, 1997, CANCER RES, V57, P3370; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Boland CR, 1998, CANCER RES, V58, P5248; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; delaChapelle A, 1995, ANNU REV GENET, V29, P329, DOI 10.1146/annurev.ge.29.120195.001553; Deng GR, 1999, CANCER RES, V59, P2029; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUJII H, 1989, J BIOL CHEM, V264, P10057; Goggins M, 1998, AM J PATHOL, V152, P1501; Gonzalgo ML, 1997, CANCER RES, V57, P594; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAN HJ, 1993, CANCER RES, V53, P5087; Her C, 1998, GENOMICS, V52, P50, DOI 10.1006/geno.1998.5374; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HORII A, 1994, BIOCHEM BIOPH RES CO, V204, P1257, DOI 10.1006/bbrc.1994.2598; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; Kane MF, 1997, CANCER RES, V57, P808; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Myohanen SK, 1998, CANCER RES, V58, P591; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Nelson JB, 1997, CANCER RES, V57, P35; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RADMAN M, 1986, ANNU REV GENET, V20, P523, DOI 10.1146/annurev.ge.20.120186.002515; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Watanabe A, 1996, GENOMICS, V31, P311, DOI 10.1006/geno.1996.0053; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	55	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					943	952		10.1038/sj.onc.1203414	http://dx.doi.org/10.1038/sj.onc.1203414			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702803				2022-12-28	WOS:000085567700012
J	Schnabel, CA; Jacobs, Y; Cleary, ML				Schnabel, CA; Jacobs, Y; Cleary, ML			HoxA9-mediated immortalization of myeloid progenitors requires functional interactions with TALE cofactors Pbx and Meis	ONCOGENE			English	Article						Hox; Pbx; Meis; homeodomain; DNA binding; hematopoietic	COOPERATIVE DNA-BINDING; HOX HOMEOBOX GENES; PROTEINS; HOMEODOMAIN; LEUKEMIA; T(7-11)(P15-P15); TRANSFORMATION; TRANSLOCATION; EXPRESSION; PARTNERS	Specific Hox genes are implicated in leukemic transformation, and their selective genetic collaboration with TALE homeobox genes, Pbx and Meis, accentuates their oncogenic potential. The molecular mechanisms under-lying these coordinate functions, however, have not been characterized. In this study, we demonstrate that HoxA9 requires its Pbx interaction motif as well as its amino terminus to enhance the clonogenic potential of myeloid progenitors in vitro. We further show that HoxA9 forms functional trimeric DNA binding complexes with Pbx and Meis-like proteins on a modified enhancer. DNA binding complexes containing HoxA9 and TALE homeoproteins display cooperative transcriptional activity and are present in leukemic cells. Trimeric complex formation on its own, however, is not sufficient for HoxA9-mediated immortalization. Rather, structure-function analyses demonstrate that domains of HoxA9 which are necessary for cellular transformation are coincident with those required for trimer-mediated transcriptional activation. Furthermore, the amino terminus of HoxA9 provides essential transcriptional effector properties and its requirement for myeloid transformation can be functionally replaced by the VP16 activation domain. These data suggest that biochemical interactions between HoxA9 and TALE homeoproteins mediate cellular transformation in hematopoietic cells, and that their transcriptional activity in higher order DNA binding complexes provides a molecular basis for their collaborative roles in leukemo-genesis.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Cleary, ML (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [T32CA009151, R37CA042971, R01CA042971] Funding Source: NIH RePORTER; NCI NIH HHS [CA42971, CA09151] Funding Source: Medline; NIAID NIH HHS [AI-07290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; HAWLEY RG, 1994, GENE THER, V1, P136; JACOBS Y, 1999, IN PRESS MOL CELL BI; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; LU QA, 1995, MOL CELL BIOL, V15, P3786; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109	36	105	107	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					608	616		10.1038/sj.onc.1203371	http://dx.doi.org/10.1038/sj.onc.1203371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698505				2022-12-28	WOS:000085192000002
J	Mizuno, T; Iwamoto, KS; Kyoizumi, S; Nagamura, H; Shinohara, T; Koyama, K; Seyama, T; Hamatani, K				Mizuno, T; Iwamoto, KS; Kyoizumi, S; Nagamura, H; Shinohara, T; Koyama, K; Seyama, T; Hamatani, K			Preferential induction of RET/PTC1 rearrangement by X-ray irradiation	ONCOGENE			English	Article						thyroid; radiation; RET/PTC; scid mice	PAPILLARY THYROID CARCINOMAS; RET TYROSINE KINASE; EXTERNAL RADIATION; MOLECULAR CHARACTERIZATION; ONCOGENE REARRANGEMENTS; HIGH PREVALENCE; CHERNOBYL; PROTOONCOGENE; CHILDREN; EXPRESSION	Ionizing radiation is a well known risk factor of thyroid cancer development, but the mechanism of radiation induced carcinogenesis is not clear. The RET/PTC oncogene, an activated form of the RET proto-oncogene, is frequently observed in papillary thyroid carcinoma (PTC); RET/PTC1, -2 and -3 are known to be the three major forms, High frequencies of RET/PTC rearrangements have been observed in radiation-associated PTC, such as those appearing post-Chernobyl or post-radiotherapy, but the rearrangement types differ between these two populations. We investigated whether a specific type of RET/PTC rearrangement was induced by X-rays in vivo and in vitro. ln human normal thyroid tissues transplanted in scid mice, the RET/PTC1 rearrangement was predominantly detected throughout the observation period (up to 60 days) after X-ray exposure of 50 Gy, On the other hand, RET/PTC3 was detected only 7 days after X-irradiation, and no transcript of RET/PTC2 was detected. These results are supported by the results of an in vitro study, The RET/PTC1 rearrangement was preferentially induced in a dose-dependent manner by X-rays within a high dose range (10, 50 and 100 Gy) in four cell lines. On the other hand, RET/PTC3 was induced at a much lower frequency, and no induction of RET/PTC2 was observed. These results suggest that the preferential induction of the RET/PTC1 rearrangement may play an important role in the early steps of thyroid carcinogenesis induced by acute X-irradiation.	Radiat Effects Res Fdn, Dept Radiobiol, Hiroshima 7320815, Japan	Radiation Effects Research Foundation - Japan	Mizuno, T (corresponding author), Radiat Effects Res Fdn, Dept Radiobiol, Hiroshima 7320815, Japan.							BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANCOCK SL, 1995, INT J RADIAT ONCOL, V31, P1165, DOI 10.1016/0360-3016(95)00019-U; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ITO T, 1993, JPN J CANCER RES, V84, P105, DOI 10.1111/j.1349-7006.1993.tb02840.x; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; Kitamura Y, 1999, J HUM GENET, V44, P96, DOI 10.1007/s100380050117; Klugbauer S, 1995, ONCOGENE, V11, P2459; Learoyd DL, 1998, J CLIN ENDOCR METAB, V83, P3631, DOI 10.1210/jc.83.10.3631; Mayr B, 1998, BRIT J CANCER, V77, P903, DOI 10.1038/bjc.1998.149; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; MORRIS CM, 1991, BLOOD, V78, P1078; Motomura T, 1998, THYROID, V8, P485, DOI 10.1089/thy.1998.8.485; Murnane JP, 1996, MUTAT RES-GENET TOX, V367, P11, DOI 10.1016/S0165-1218(96)90017-8; Nikiforov YE, 1997, CANCER RES, V57, P1690; Pisarchik AV, 1998, THYROID, V8, P1003, DOI 10.1089/thy.1998.8.1003; Preston DL, 1994, RADIAT RES, V137, P68; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SANTORO M, 1994, ONCOGENE, V9, P509; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.3.CO;2-C; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; THOMPSON DE, 1994, RAD RES S, V137, P17; TUCKER MA, 1991, CANCER RES, V51, P2885; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0	34	75	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					438	443		10.1038/sj.onc.1203343	http://dx.doi.org/10.1038/sj.onc.1203343			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656692				2022-12-28	WOS:000084873700015
J	Chang, J; Lee, C; Hahm, KB; Yi, Y; Choi, SG; Kim, SJ				Chang, J; Lee, C; Hahm, KB; Yi, Y; Choi, SG; Kim, SJ			Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells	ONCOGENE			English	Article						transcription factor; cancer; TGF-beta; tumorigenicity	GROWTH-FACTOR-BETA; MICROSATELLITE INSTABILITY; DOMAIN PROTEIN; GENE; FAMILY; INHIBITION; MEMBER; COLON; CDNA	The epithelium-specific transcription factor, ERT/ESX/ ESE-1/ELF3, binds to the TGF-beta RII promoter in a sequence specific manner and regulates its expression, In this study, we investigated whether ERT could regulate endogenous TGF-beta RII expression in Hs578t breast cancer cells. Analyses of the Hs578t parental cell line revealed ion RII mRNA expression and resistance to the growth inhibitory effects of TGF-beta. Infection of this cell Line with a retroviral construct expressing ERT induced higher levels of endogenous RII mRNA expression and protein expression relative to cells infected with chloramphenicol acetyltransferase (CATneo) as a control. Relative to control cells, the ERTneo-expressing Hs578t cells show approximately a 50% reduction in cell growth in the presence of exogenous TGF-beta 1, as well as a fourfold higher induction of activation in transient transfection assays using the 3TP-luciferase reporter construct. When transplanted into athymic mice, ERT-expressing Hs578t cells showed decreased and delayed tumorigenicity compared with control cells. This data strongly suggests that ERT plays an important role as a transcriptional activator of TGF-P RII expression, and that deregulated ERT expression may play a critical role in rendering Hs578t human breast cancer cells insensitive to TGF-beta's growth inhibitory effects.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.							CAPOCASALE RJ, 1995, P NATL ACAD SCI USA, V92, P5501, DOI 10.1073/pnas.92.12.5501; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 1997, CANCER RES, V57, P2856; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim IY, 1996, CANCER RES, V56, P44; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MYEROFF LL, 1995, CANCER RES, V55, P5545; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	25	44	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					151	154		10.1038/sj.onc.1203252	http://dx.doi.org/10.1038/sj.onc.1203252			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644990				2022-12-28	WOS:000084844300017
J	Rubbi, CP; Milner, J				Rubbi, CP; Milner, J			Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus	ONCOGENE			English	Article						latent p53; transcription sites; nucleolus; confocal microscopy; hdm-2	RNA-POLYMERASE-II; WILD-TYPE P53; NASCENT RNA; INDUCED APOPTOSIS; CONFOCAL IMAGES; NUCLEAR MATRIX; DNA-DAMAGE; CELL-CYCLE; PROTEIN; MICROSCOPY	The p53 tumour suppressor functions as a sensor of genotoxic stress and, once activated, induces cell growth arrest or apoptosis, The precise intranuclear localization of latent p53 protein in non-stressed cells is unknown, Such information is essential in order to understand how relatively few molecules of p53 can detect and respond to DNA damage. Here we present the first detailed supramolecular localization of p53 in the nuclei of cells under normal conditions of growth, We show that soluble, non-bound p53 is released by permeabilization, leaving structurally bound p53 in both the nucleus and nucleolus. ln situ biochemical studies reveal (i) that nuclear-bound p53 is tethered by RNA (directly or indirectly) and (ii) that a sub-population of nuclear-bound p53 co-localizes with sites of RNA synthesis. Transcriptional co-localization appeared to be independent of p53 conformation but dependent upon its quaternary structure. In the nucleolus p53 was observed at sites of rRNA synthesis and also adjacent to such sites. In contrast, nucleolar hdm-2 (shown by others to complex p53 and 5S RNA) was excluded from sites of rRNA synthesis. Our discovery that p53 is physically linked with sites of transcription may explain how relatively few p53 protein molecules can monitor genetic stress and respond preferentially to damage of actively transcribed genes.	Univ York, Dept Biol, YCR P53 Res Grp, York YO1 5DD, N Yorkshire, England	University of York - UK	Milner, J (corresponding author), Univ York, Dept Biol, YCR P53 Res Grp, York YO1 5DD, N Yorkshire, England.							ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BARBARESE E, 1995, J CELL SCI, V108, P2781; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CONCHELLO JA, 1994, APPL OPTICS, V33, P3740, DOI 10.1364/AO.33.003740; Fay FS, 1997, EXP CELL RES, V231, P27, DOI 10.1006/excr.1996.3460; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; GIBSON SF, 1991, J OPT SOC AM A, V8, P1601, DOI 10.1364/JOSAA.8.001601; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Gonzalez R.C., 1993, DIGITAL IMAGE PROCES, P583; Grande MA, 1997, J CELL SCI, V110, P1781; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane DP, 1996, ONCOGENE, V12, P2461; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; MILNER J, 1993, ONCOGENE, V8, P2001; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; Pombo A, 1996, EXP CELL RES, V229, P201, DOI 10.1006/excr.1996.0360; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Stenoien D, 1998, J CELL BIOCHEM, V70, P213, DOI 10.1002/(SICI)1097-4644(19980801)70:2<213::AID-JCB7>3.0.CO;2-R; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; TEPOELE RH, 1999, IN PRESS ONCOGENE; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEBER J, 1977, CELL, V10, P611, DOI 10.1016/0092-8674(77)90093-9; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZERRAHN J, 1992, ONCOGENE, V7, P1371	43	69	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					85	96		10.1038/sj.onc.1203378	http://dx.doi.org/10.1038/sj.onc.1203378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644983				2022-12-28	WOS:000084844300010
J	Georgiades, IB; Curtis, LJ; Morris, RM; Bird, CC; Wyllie, AH				Georgiades, IB; Curtis, LJ; Morris, RM; Bird, CC; Wyllie, AH			Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability	ONCOGENE			English	Article						colorectal cancer; chromosomal instability; genomic instability; microsatellite instability; RER	ANEUPLOID CLONAL DIVERGENCE; NONPOLYPOSIS COLON-CANCER; DNA-REPLICATION ERRORS; MISMATCH REPAIR GENES; GENOMIC INSTABILITY; SOMATIC MUTATIONS; MUTATOR PHENOTYPE; TUMORS; P53; CARCINOGENESIS	Two apparently independent mechanisms of instability are recognized in colorectal cancer, microsatellite instability and chromosomal instability. Evidence from colorectal cancer cell lines indicates the presence of either, or both, types of instability in the vast majority, Here, we sought to determine the prevalence of such instability in primary sporadic colorectal cancers. Microsatellite instability was established by demonstration of ovel clonal, nongerm-line alleles in at least two of four tested loci. Chromosomal abnormalities were identified by comparative genomic hybridization (CGH) and flow cytometric analysis of nuclear DNA content. Tumours harbouring chromosomal instability were distinguished from those with stable but aneuploid karyotypes by comparing chromosomal defects at multiple sites throughout each cancer. This analysis allowed assessment of both the number of chromosomal abnormalities and their heterogeneity throughout the tumour. The results confirm that microsatellite instability is consistently associated with multiple, repeated changes in microsatellites throughout the growth of the affected colorectal carcinomas, There were also several carcinomas in which major structural or numerical abnormalities in chromosomes had clearly continued to arise during tumour growth, However, a substantial subset of tumours shelved neither microsatellite instability nor multiple, major chromosomal abnormalities. We suggest that the development of a proportion of colorectal cancers proceeds via a different pathway of carcinogenesis not associated with either of the currently recognized forms of genomic instability.	Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Curtis, LJ (corresponding author), Gen Infirm Leeds, Dept Histopathol, Great George St, Leeds LS1 3CX, W Yorkshire, England.							AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, CANCER RES, V57, P3920; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Bubb VJ, 1996, ONCOGENE, V12, P2641; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARDER P, 1993, ONCOGENE, V8, P1397; CARDER PJ, 1995, BRIT J CANCER, V71, P215, DOI 10.1038/bjc.1995.46; Eshleman JR, 1996, ONCOGENE, V12, P1425; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KIM HG, 1994, AM J PATHOL, V145, P148; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MCQUEEN HA, 1991, BRIT J CANCER, V63, P94, DOI 10.1038/bjc.1991.19; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PURDIE CA, 1991, AM J PATHOL, V138, P807; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Senba S, 1998, CANCER, V82, P279, DOI 10.1002/(SICI)1097-0142(19980115)82:2<279::AID-CNCR6>3.3.CO;2-D; Thibodeau SN, 1998, CANCER RES, V58, P1713; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Togo G, 1996, CANCER RES, V56, P5620; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WU C, 1994, ONCOGENE, V9, P991; Yao J, 1999, INT J CANCER, V80, P667, DOI 10.1002/(SICI)1097-0215(19990301)80:5<667::AID-IJC6>3.0.CO;2-0	43	103	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7933	7940		10.1038/sj.onc.1203368	http://dx.doi.org/10.1038/sj.onc.1203368			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637503				2022-12-28	WOS:000084634600001
J	Miller, JR; Hocking, AM; Brown, JD; Moon, RT				Miller, JR; Hocking, AM; Brown, JD; Moon, RT			Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways	ONCOGENE			English	Review						Wnt; beta-catenin; cancer; signal transduction	ADENOMATOUS POLYPOSIS-COLI; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR PROTEIN; MAMMARY ONCOGENE INT-1; SITE-SPECIFIC PHOSPHORYLATION; INTEGRIN-LINKED KINASE; TISSUE POLARITY GENE; EPITHELIAL-CELL LINE; KAPPA-B-ALPHA; BETA-CATENIN	Communication between cells is often mediated by secreted signaling molecules that bind cell surface receptors and modulate the activity of specific intracellular effecters. The Wnt family of secreted glycoproteins is one group of signaling molecules that has been shown to control a variety of developmental processes including cell fate specification, cell proliferation, cell polarity and cell migration. In addition, mis-regulation of Wnt signaling can cause developmental defects and is implicated in the genesis of several human cancers. The importance of Wnt signaling in development and in clinical pathologies is underscored by the large number of primary research papers examining various aspects of Wnt signaling that have been published in the past several years. In this review, we will present a synopsis of current research with particular attention paid to molecular mechanism of Wnt signal transduction and how the mis-regulation of Wnt signaling leads to cancer.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Ctr Dev Biol, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Miller, JR (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.		Moon, Randall T/B-1743-2014	Moon, Randall T/0000-0002-9352-1408; Hocking, Anne/0000-0003-2130-3732				ADLER PN, 1990, GENETICS, V126, P401; Alman BA, 1997, AM J PATHOL, V151, P329; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Barnes MR, 1998, TRENDS PHARMACOL SCI, V19, P399, DOI 10.1016/S0165-6147(98)01246-2; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Bilger A, 1996, SEMIN CANCER BIOL, V7, P249, DOI 10.1006/scbi.1996.0033; Binari RC, 1997, DEVELOPMENT, V124, P2623; Blaker H, 1999, GENE CHROMOSOME CANC, V25, P399; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Bui TD, 1997, BIOCHEM BIOPH RES CO, V239, P911, DOI 10.1006/bbrc.1997.7530; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Cox RT, 1999, GENETICS, V153, P319; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fan MJ, 1998, P NATL ACAD SCI USA, V95, P5626, DOI 10.1073/pnas.95.10.5626; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fukuchi T, 1998, CANCER RES, V58, P3526; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; IOZZO RV, 1995, CANCER RES, V55, P3495; ISHITANI T, 1999, NATURE, V399, P795; ITOH K, 1994, DEVELOPMENT, V120, P2703; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Iwao K, 1999, JPN J CANCER RES, V90, P205, DOI 10.1111/j.1349-7006.1999.tb00734.x; Iwao K, 1998, CANCER RES, V58, P1021; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kang DE, 1999, J NEUROSCI, V19, P4229; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; Koesters R, 1999, CANCER RES, V59, P3880; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lagna G, 1999, MECH DEVELOP, V80, P101, DOI 10.1016/S0925-4773(98)00208-1; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Laurent MN, 1997, DEVELOPMENT, V124, P4905; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miller JR, 1999, J CELL BIOL, V146, P427, DOI 10.1083/jcb.146.2.427; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Miyoshi Y, 1998, CANCER RES, V58, P2524; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; Muller HAJ, 1999, DEVELOPMENT, V126, P577; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Olson DJ, 1998, TUMOR BIOL, V19, P244, DOI 10.1159/000030014; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; Olson DJ, 1998, EXP CELL RES, V241, P134, DOI 10.1006/excr.1998.4030; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pai LM, 1997, DEVELOPMENT, V124, P2255; Palacios J, 1998, CANCER RES, V58, P1344; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; PEIFER M, 1994, DEVELOPMENT, V120, P369; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Redston M, 1998, NAT GENET, V20, P13, DOI 10.1038/1666; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Sagae S, 1999, JPN J CANCER RES, V90, P510, DOI 10.1111/j.1349-7006.1999.tb00777.x; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Samowitz WS, 1999, CANCER RES, V59, P1442; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Sparks AB, 1998, CANCER RES, V58, P1130; Steiner P, 1996, Prog Cell Cycle Res, V2, P73; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tesco G, 1998, J BIOL CHEM, V273, P33909, DOI 10.1074/jbc.273.51.33909; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; Voeller HJ, 1998, CANCER RES, V58, P2520; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Willert K, 1999, DEVELOPMENT, V126, P4165; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wright K, 1999, INT J CANCER, V82, P625, DOI 10.1002/(SICI)1097-0215(19990827)82:5<625::AID-IJC1>3.0.CO;2-2; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zurawel RH, 1998, CANCER RES, V58, P896	174	596	657	0	38	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 20	1999	18	55					7860	7872		10.1038/sj.onc.1203245	http://dx.doi.org/10.1038/sj.onc.1203245			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630639				2022-12-28	WOS:000084405900003
J	Tallquist, MD; Soriano, P; Klinghoffer, RA				Tallquist, MD; Soriano, P; Klinghoffer, RA			Growth factor signaling pathways in vascular development	ONCOGENE			English	Review						receptor tyrosine kinases; endothelial cells; vascular smooth muscle cells	RECEPTOR TYROSINE KINASE; FOCAL ADHESION KINASE; ENDOTHELIAL-CELL SURVIVAL; NEURAL CREST MIGRATION; MAJOR BINDING-SITE; PDGF-BETA-RECEPTOR; SRC-FAMILY KINASES; LIGAND-BINDING; EPH-FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE	Recent research on the formation and maintenance of the vasculature in the embryo and in the adult has provided a greater understanding of the cellular signals involved in these processes, With this understanding comes the potential means of controlling vascularization in pathological situations such as tumorigenesis and wounding. For the purpose of this review, we will discuss the key receptor tyrosine kinases involved in vascular function and the molecules which relay signals downstream of receptor activation. The receptor tyrosine kinases discussed include the vascular endothelial cell growth factor receptors, Eph receptors, Tie1, and Tie2, all of which: are expressed on vascular endothelial cells. We also discuss the roles of the platelet derived growth factor receptors which are expressed on vascular smooth muscle cells.: While all of these receptor tyrosine kinases activate many similar effector molecules, some of the signals initiated appear to be distinct. This may explain, at least in part, how different receptor tyrosine kinases expressed in overlapping patterns on the developing vasculature, direct unique biological functions.	Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Tallquist, MD (corresponding author), Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA.		Tallquist, Michelle/AAU-5277-2021; Soriano, Philippe M/E-5797-2015	Tallquist, Michelle/0000-0002-1383-144X; Soriano, Philippe M/0000-0002-0427-926X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025326, R37HD025326, R01HD024875] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24875, HD25326, HD08412] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Barleon B, 1997, J BIOL CHEM, V272, P10382; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; BREIER G, 1992, DEVELOPMENT, V114, P521; BROCK TA, 1991, AM J PATHOL, V138, P213; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen J, 1996, ONCOGENE, V12, P979; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Crosby JR, 1998, NAT GENET, V18, P385, DOI 10.1038/ng0498-385; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; D'Angelo G, 1999, MOL ENDOCRINOL, V13, P692, DOI 10.1210/me.13.5.692; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; Desai J, 1999, BIOL REPROD, V60, P887, DOI 10.1095/biolreprod60.4.887; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Ellis C, 1996, ONCOGENE, V12, P1727; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Esser S, 1998, J CELL SCI, V111, P1853; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HEUCHEL R, 1999, IN PRESS P NATL ACAD; Hidaka M, 1999, P NATL ACAD SCI USA, V96, P7370, DOI 10.1073/pnas.96.13.7370; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; HUANG LW, 1995, ONCOGENE, V11, P2097; Hughes AD, 1996, GEN PHARMACOL-VASC S, V27, P1079, DOI 10.1016/S0306-3623(96)00060-2; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; INUI H, 1994, J BIOL CHEM, V269, P30546; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; KORHONEN J, 1994, ONCOGENE, V9, P395; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1997, DEVELOPMENT, V124, P3943; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Partanen J, 1996, DEVELOPMENT, V122, P3013; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Risau W, 1998, KIDNEY INT, V54, pS3, DOI 10.1046/j.1523-1755.1998.06701.x; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Rodewald HR, 1996, ONCOGENE, V12, P397; ROSS R, 1990, PHILOS T ROY SOC B, V327, P155, DOI 10.1098/rstb.1990.0051; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SEETHARAM L, 1995, ONCOGENE, V10, P135; Seifert RA, 1998, KIDNEY INT, V54, P731, DOI 10.1046/j.1523-1755.1998.00046.x; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; TANAKA S, 1993, MOL CELL BIOL, V14, P5495; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zent R, 1998, EXP CELL RES, V240, P134, DOI 10.1006/excr.1998.4008; ZIEGLER SF, 1993, ONCOGENE, V8, P663; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	193	88	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7917	7932		10.1038/sj.onc.1203216	http://dx.doi.org/10.1038/sj.onc.1203216			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630644				2022-12-28	WOS:000084405900008
J	Garcia-Guzman, M; Dolfi, F; Zeh, K; Vuori, K				Garcia-Guzman, M; Dolfi, F; Zeh, K; Vuori, K			Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation	ONCOGENE			English	Article						kinase; oncogenesis; signal transduction; tyrosine phosphorylation	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NECROSIS-FACTOR-ALPHA; GRB2 BINDING-SITE; INVASIVE-GROWTH; DOCKING PROTEIN; V-CRK; PROLONGED ACTIVATION; CELL-TRANSFORMATION; CARBOXY-TERMINUS	Constitutive activation of the Met tyrosine kinase results in transformation of cells of diverse origin. Recent studies have demonstrated a role for the c-Jun N-terminal kinase (JNK) in Met-induced transformation, but little is known about the molecular mechanisms that connect Met to JNK activation. Our studies show that activated Met associates with, and phosphorylates, the docking protein Gab1, which in turn binds to the src homology 2 (SH2)-domain of the adapter protein Crk and recruits Crk to the Met signaling complex. Formation of the Gab1-Crk complex correlates with Met-induced JNK activation, and mutant forms of Met that fail to induce the complex formation also fail to activate JNK. Importantly, expression of a loss-of-function mutant of Crk severely impairs activation of the JNK pathway by Met. We also show here that Met controls the transcription of the matrix metalloproteinase-l (MMP-1) gene in carcinoma cells and that this transcriptional regulation occurs in a Crk-JNK-dependent manner through an AP-1 element in the MMP-1 promoter. Taken together, our data implicate the Gab1-Crk signaling complex in Met-induced JNK activation and suggest that the Gab1-Crk complex formation may be an important event in regulating the tumorigenic phenotype of Met-transformed cells.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA071560, R01CA076037] Funding Source: NIH RePORTER; NCI NIH HHS [CA71560, CA76037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BARDELLI A, 1994, J BIOTECHNOL, V37, P109, DOI 10.1016/0168-1656(94)90002-7; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FELLER SM, 1995, ONCOGENE, V10, P1465; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keegan K, 1996, ONCOGENE, V12, P1537; Khwaja A, 1996, ONCOGENE, V12, P2491; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LONGATI P, 1994, ONCOGENE, V9, P49; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; PATCH LA, 1995, J CELL SCI, V108, P1371; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	63	73	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7775	7786		10.1038/sj.onc.1203198	http://dx.doi.org/10.1038/sj.onc.1203198			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618718				2022-12-28	WOS:000084256900007
J	Maul, RS; Chang, DD				Maul, RS; Chang, DD			EPLIN, Epithelial protein lost in neoplasm	ONCOGENE			English	Article						breast; prostate; cancer; EPLIN	CANCER-CELLS; LIM DOMAINS; ADHESION; BINDING	We have identified a novel cytoskeletal protein, EPLIN (Epithelial Protein Lost In Neoplasm), that is preferentially er;pressed in human epithelial cells. Two EPLIN isoforms, a 600 amino acid EPLIN-alpha and a 759 amino acid EPLIN-beta, are detected in primary epithelial cells of oral mucosa, prostate and mammary glands. The expression of EPLIN-alpha is either down-regulated or lost in the majority of oral cancer cell lines (8/8), prostate cancer cell lines (4/4) and xenograft tumors (3/3), and breast cancer cell lines (5/6), The amino acid sequence of EPLIN is characterized by the presence of a single centrally located LIM domain. Both EPLIN isoforms localize to filamentous actin and suppress cell proliferation when overexpressed. These findings indicate that the loss of EPLIN seen in cancer cells may play a role in cancer progression.	Univ Calif Los Angeles, Sch Med, Div Hemeonc,Jonnson Comprehens Canc Ctr, Dept Med & Microbiol Immunol & Mol Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hemeonc,Jonnson Comprehens Canc Ctr, Dept Med & Microbiol Immunol & Mol Mol Genet, Factor 10-240,10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NCI NIH HHS [TF32CA75956] Funding Source: Medline; NIGMS NIH HHS [GM58215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA075956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM058215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BALTZ R, 1992, PLANT J, V2, P713, DOI 10.1046/j.1365-313X.1992.t01-13-00999.x; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	16	71	74	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7838	7841		10.1038/sj.onc.1203206	http://dx.doi.org/10.1038/sj.onc.1203206			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618726				2022-12-28	WOS:000084256900015
J	Kikyo, M; Tanaka, K; Kamei, T; Ozaki, K; Fujiwara, T; Inoue, E; Takita, Y; Ohya, Y; Takai, Y				Kikyo, M; Tanaka, K; Kamei, T; Ozaki, K; Fujiwara, T; Inoue, E; Takita, Y; Ohya, Y; Takai, Y			An FH domain-containing Bnr1p is a multifunctional protein interacting with a variety of cytoskeletal proteins in Saccharomyces cerevisiae	ONCOGENE			English	Article						Rho; formin-like protein; septins	GTP-BINDING PROTEIN; ACTIN CYTOSKELETON; EXCHANGE PROTEINS; ESCHERICHIA-COLI; SHUTTLE VECTORS; CELL DIVISION; BUD SITE; YEAST; BNI1P; CYTOKINESIS	Proteins containing formin homology domains, FH1 and FH2, are involved in cytokinesis or establishment of cell polarity in a variety of organisms. Bni1p and Bnr1p are FPF proteins and potential targets of the Rho family small GTP-binding proteins in S. cerevisiae. We have shown that Bnr1p is localized at the bud neck to interact with Hof1p, involved in cytokinesis. We report here that the overexpression of BNR1 causes a cytokinesis deficiency which is similar to the phenotypes of the septin mutants, including cdc3, cdc10, cdc11, and cdc12. The region required for the septin mutant phenotypes was mapped to Bnr1p (35-500), which coincided,vith the region required for the bud-neck localization. To further isolate a gene interacting with BNI1 or BNR1, a multicopy suppressor of the bni1 bnr1 mutant was isolated. This gene encoded Smy1p, a kinesin-related protein. Bnr1p, but not Bni1p, directly interacted with the C-terminal region of Smy1p. The Smy1p-interacting region of Bnr1p was mapped to a region containing the FH2 domain. Bnr1p also directly interacted with Bud6p, a novel actin-binding protein. Bnr1p is thus a multifunctional protein which interacts with the septin system, a microtubule-dependent motor protein, and the actin system, to regulate cytoskeletal functions in S. cerevisiae.	Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1130033, Japan	Osaka University; University of Tokyo	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kuroda, Kumi O/A-3312-2013; Yashiroda, Yoko/C-8769-2014	Kuroda, Kumi O./0000-0001-7037-1753				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FRAZIER JA, 1997, CURR BIOL, V7, P414; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Giot L, 1997, MOL BIOL CELL, V8, P987, DOI 10.1091/mbc.8.6.987; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lillie SH, 1998, J CELL BIOL, V140, P873, DOI 10.1083/jcb.140.4.873; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Mino A, 1998, BIOCHEM BIOPH RES CO, V251, P732, DOI 10.1006/bbrc.1998.9541; NAKATSURU S, 1994, BIOCHEM BIOPH RES CO, V202, P82, DOI 10.1006/bbrc.1994.1896; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; Umikawa M, 1998, ONCOGENE, V16, P2011, DOI 10.1038/sj.onc.1201724; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	39	47	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7046	7054		10.1038/sj.onc.1203184	http://dx.doi.org/10.1038/sj.onc.1203184			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597305				2022-12-28	WOS:000083901900011
J	Crusius, K; Kaszkin, M; Kinzel, V; Alonso, A				Crusius, K; Kaszkin, M; Kinzel, V; Alonso, A			The human papillomavirus type 16 E5 protein modulates phospholipase C-gamma-1 activity and phosphatidyl inositol turnover in mouse fibroblasts	ONCOGENE			English	Article						phospholipids; phospholipases; membranes; kinases	EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-CELL LINE; KINASE-C ACTIVATION; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; A431 CELLS; KERATINOCYTES; HYDROLYSIS; GENE; COMMUNICATION	The human papillomavirus type 16 E5 (HPV16-E5) protein is a membrane protein that has been associated with malignant growth. The protein affects growth factor-mediated signal transduction in a ligand-dependent manner. We show now that E5 expression in A31 fibroblasts results in an increased level of diacylglycerol (DAG) and inositol phosphates. Immunoprecipitation of phospholipase C-gamma-1 (PLC-gamma-1) with specific antibodies and immunoblotting with anti-phosphotyrosine antibodies reveal a large increase in tyrosine phosphorylation of the enzyme in ES-expressing cells compared to control vector-transfected cells. This activation of tyrosine phosphorylation is growth factor independent. In addition, an enhanced formation of phosphatidic acid (PA) was observed in E5 cells. This increase did not result from activation of phospholipase D (PLD), although the enzyme was activatable by treatment with phorbol ester. Thus, a phosphohydrolase-mediated DAG synthesis from PLD-produced PA can be excluded. The observed effects were not further enhanced by EGF showing that the presence of the growth factor is not necessary for maintaining permanent activation of PLC-gamma-1 in E5-expressing cells. The DAG- and inositol phosphate-mediated signal cascade within the cells is thus effectively uncoupled from external control via EGF and its receptor in the presence of E5 protein.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Alonso, A (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							Auvinen E, 1997, INT J ONCOL, V11, P1297; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; Homma MK, 1996, CELL GROWTH DIFFER, V7, P281; Kaszkin M, 1996, BIOCHEM J, V314, P129, DOI 10.1042/bj3140129; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; Katan M, 1996, CANCER SURV, V27, P199; Khare S, 1997, J CLIN INVEST, V99, P1831, DOI 10.1172/JCI119350; Kiss Z, 1998, BBA-LIPID LIPID MET, V1392, P109, DOI 10.1016/S0005-2760(98)00030-7; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; Lambeth JD., 1996, NEW COMPREHENSIVE BI, P237; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Liscovitch M, 1996, J LIPID MEDIAT CELL, V14, P215, DOI 10.1016/0929-7855(96)00528-7; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; REYNOLDS NJ, 1993, BIOCHEM J, V294, P535, DOI 10.1042/bj2940535; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; WAGNER H, 1962, J LIPID RES, V3, P177; WAHL M, 1988, J BIOL CHEM, V263, P7581; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	36	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6714	6718		10.1038/sj.onc.1203075	http://dx.doi.org/10.1038/sj.onc.1203075			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597278				2022-12-28	WOS:000083792000012
J	Hori, T; Osaka, F; Chiba, T; Miyamoto, C; Okabayashi, K; Shimbara, N; Kato, S; Tanaka, K				Hori, T; Osaka, F; Chiba, T; Miyamoto, C; Okabayashi, K; Shimbara, N; Kato, S; Tanaka, K			Covalent modification of all members of human cullin family proteins by NEDD8	ONCOGENE			English	Article						cullin; NEDD8; SCF; ubiquitin; ubiquitin-like protein	UBIQUITIN-LIKE PROTEIN; F-BOX PROTEIN; CELL-CYCLE; LIGASE COMPLEX; HUMAN CUL-1; PATHWAY; GENE; PROTEOLYSIS; SUMO-1; SYSTEM	Recently we found that NEDD8, a ubiquitin-like protein, was linked covalently to human cullin-4A (abbreviated Cul-4A) by a new ubiquitin-related pathway that is analogous to but distinct from the ligating system for SUMO1, another ubiquitin-like protein. However, it remained unknown whether the other five members of the family of human cullin/Cdc53 proteins are modified by NEDD8, Here we report that all Hs-Cul family proteins, such as Cul-1, Cul-2, Cul-3, Cul-4B, and Cul-5, in addition to Cul-4A, were modified by covalent attachment of NEDD8 in rabbit reticulocyte lysates, Moreover, by comprehensive Northern-blot analyses, we examined multiple tissue distributions of the messages for all Cul-family proteins, NEDD8, and the NEDD8-ligating system consisting of APP-BP1/hUba3, and hUbc12, which function as E1- and E2-like enzymes, respectively, The expressions of Cul-1, Cul-2, and Cul-3 resembled each other and were apparently correlated to those of NEDD8 and the NEDD8-ligating system in various human cells and tissues. However, the mRNA levels of Cul-4A, Cul-4B, and Cul-5 differed considerably from each other as well as from other Cul-family proteins. The enhanced expression of all Cul-family proteins except Cul-5 was observed in a variety of tumor cell lines.	Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1130021, Japan; Hoffmann La Roche Inc, Nutley, NJ 07110 USA; Japan Sci & Technol Corp, Sagami Chem Res Ctr, ERATO, Kato Cytoprot Network Project, Kanagawa 2290012, Japan; Sumitomo Elect Ind Ltd, Biomed R&D Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan	Tokyo Metropolitan Institute of Medical Science; Roche Holding; Japan Science & Technology Agency (JST); Sumitomo Electric Industries	Tanaka, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1130021, Japan.							Chen LC, 1998, CANCER RES, V58, P3677; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Du M, 1998, J BIOL CHEM, V273, P24289, DOI 10.1074/jbc.273.38.24289; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tanaka K, 1998, MOL CELLS, V8, P503; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	40	242	257	2	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6829	6834		10.1038/sj.onc.1203093	http://dx.doi.org/10.1038/sj.onc.1203093			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597293				2022-12-28	WOS:000083792000027
J	Kamei, T; Matozaki, T; Sakisaka, T; Kodama, A; Yokoyama, S; Peng, YF; Nakano, K; Takaishi, K; Takai, Y				Kamei, T; Matozaki, T; Sakisaka, T; Kodama, A; Yokoyama, S; Peng, YF; Nakano, K; Takaishi, K; Takai, Y			Coendocytosis of cadherin and c-Met coupled to disruption of cell-cell adhesion in MDCK cells - regulation by Rho, Rac and Rab small G proteins	ONCOGENE			English	Article						c-Met; E-cadherin; endocytosis; small G proteins	EPIDERMAL GROWTH-FACTOR; CANINE KIDNEY-CELLS; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOCYTIC PATHWAY; KINASE; ACTIVATION; TRANSPORT; SITES; MORPHOGENESIS	Both E-cadherin, a cell-cell adhesion molecule, and c-Met, the hepatocyte growth factor (HGF)/scatter factor (SF) receptor, were colocalized at cell-cell adhesion sites of MDCK cells. HGF/SF or a phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), induced disruption of cell-cell adhesion, which was accompanied by endocytosis of both E-cadherin and c-Met. Reduction of medium Ca2+ to a micromolar range showed the same effects. Re-increase in medium Ca2+ to a millimolar range formed cell-cell adhesion, which was accompanied by exocytosis of E-cadherin and c-Met, followed by their re-colocalization at the cell-cell adhesion sites. These results suggest that E-cadherin and c-Met are colocalized at cell-cell adhesion sites and undergo co-endo-exocytosis. We have previously shown that TPA does not induce disruption of cell-cell adhesion and subsequent scattering of MDCK cells stably expressing a dominant active mutant of RhoA or Rac1 small G protein or a dominant negative mutant of Rab5 small G protein. In these cell lines, the HGF- or TPA-induced coendocytosis of E-cadherin and c-Met was inhibited, but the coendocytosis of E-cadherin and c-Met in response to reduction of medium Ca2+ was not affected. Wortmannin, an inhibitor of phosphoinositide (PI) 3-kinase, inhibited the HGF-induced disruption of cell-cell junction and endocytosis of E-cadherin and c-Met, but not the TPA-induced ones. These results suggest that disruption of cell-cell adhesion is involved in the HGF- or TPA-induced coendocytosis of E-cadherin and c-Met in MDCK cells, and that the Rho and Rab family members indirectly regulate this coendocytosis. In addition, coendocytosis of E-cadherin and c-Met in response to HGF is partly mediated by PI 3-kinase. The cross-talk between cell-cell and cell-matrix adherens junctions is discussed.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O	37	171	178	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6776	6784		10.1038/sj.onc.1203114	http://dx.doi.org/10.1038/sj.onc.1203114			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597286				2022-12-28	WOS:000083792000020
J	Abdollahi, A; Bao, R; Hamilton, TC				Abdollahi, A; Bao, R; Hamilton, TC			LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein	ONCOGENE			English	Article						LOT1; ovary; epidermal growth factor; EGFR; TGF-alpha; cancer	SURFACE EPITHELIAL-CELLS; HUMAN-BREAST-CANCER; OVARIAN-CANCER; OKADAIC ACID; TRANSCRIPTIONAL ACTIVATION; SPONTANEOUS TRANSFORMATION; TYROSINE PHOSPHORYLATION; MYELOID DIFFERENTIATION; INCESSANT OVULATION; SIGNAL-TRANSDUCTION	We previously reported cloning the rLot1 gene, and its human homolog (hLOT1), through analysis of differential gene expression in normal and malignant rat ovarian surface epithelial cells. Both human and rat ovarian carcinoma cell lines exhibited lost or decreased expression of this gene. Interestingly, the LOT1 gene localized at band q25 of human chromosome 6 which is a frequent site for LOH in many solid tumors including ovarian cancer. In this report we have further characterized the potential role of LOT1 in malignant transformation and developed evidence that the gene is a novel target of growth factor signaling pathway. Assays using transient transfections showed that LOT1 is a nuclear protein and may act as a transcription factor. In vitro and lit vivo studies involving ovarian cancer cell lines revealed that expression of LOT1 is directly associated with inhibition of cellular proliferation and induction of morphological transformations. Additionally, we show that in normal rat ovarian surface epithelial cells Lot1 gene expression is responsive to growth factor stimulation. Its mRNA is strongly down-regulated by epidermal growth factor receptor (EGFR) ligands, namely EGF and TGF-alpha. Blocking the ligand-activated EGFR signal transduction pathway by the specific EGF receptor inhibitor, tyrphostin AG1478, and the MEK inhibitor, PD098059, restores the normal level of Lot1 gene expression. It appears that the regulation of Lot1 gene is unique to these ligands, as well as the growth promoting agent TPA, since other factors either did not affect Lot1 expression, or the effect was modest and transient. Altogether, the results suggest that Lot1 expression is primarily mediated via EGF receptor or a related pathway and it may regulate the growth promoting signals as a zinc-finger motif containing nuclear transcription factor.	Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Abdollahi, A (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA56916] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1999, J SOC GYNECOL INVEST, V6, P32, DOI 10.1016/S1071-5576(98)00048-3; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; AHARONOV A, 1978, J BIOL CHEM, V253, P3970; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; BAUKNECHT T, 1986, CANCER RES, V46, P2614; BERCHUCK A, 1990, OBSTET GYNECOL, V75, P255; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CARPENTER G, 1981, HDB EXPT PHARM, V57, P90; CASAGRANDE JT, 1979, LANCET, V2, P170; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; Cheng AY, 1998, CANCER RES, V58, P3611; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; COURNEY A, 1988, CELL, V55, P741; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; ESKRAND A, 1994, ONCOGENE, V9, P2313; FATHALLA MF, 1971, LANCET, V2, P163; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1984, NATURE, V311, P414, DOI 10.1038/311414a0; Ilekis JV, 1997, GYNECOL ONCOL, V65, P36, DOI 10.1006/gyno.1996.4526; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; KOMMOSS F, 1990, J PATHOL, V162, P223, DOI 10.1002/path.1711620308; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MELLON K, 1995, J UROLOGY, V153, P919, DOI 10.1016/S0022-5347(01)67604-3; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOON SO, 1984, P NATL ACAD SCI-BIOL, V81, P2298, DOI 10.1073/pnas.81.8.2298; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORISHIGE KI, 1991, CANCER RES, V51, P5322; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; Rani CSS, 1997, J BIOL CHEM, V272, P10777; ROBERTS D, 1999, UNPUB; RODRIGUEZ GC, 1991, AM J OBSTET GYNECOL, V164, P745, DOI 10.1016/0002-9378(91)90508-O; SAINSBURY JRC, 1985, LANCET, V1, P364; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SCAMBIA G, 1992, J CLIN ONCOL, V10, P529, DOI 10.1200/JCO.1992.10.4.529; SHECHTER Y, 1978, P NATL ACAD SCI USA, V75, P5788, DOI 10.1073/pnas.75.12.5788; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TANAKA K, 1989, CANCER GENET CYTOGEN, V43, P1, DOI 10.1016/0165-4608(89)90122-2; TESTA JR, 1994, CANCER RES, V54, P2778; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMAMOTO T, 1986, CANCER RES, V46, P414; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU L, 1988, CELL, V55, P1005	85	47	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6477	6487		10.1038/sj.onc.1203067	http://dx.doi.org/10.1038/sj.onc.1203067			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597250				2022-12-28	WOS:000083709200010
J	Eggert, A; Ikegaki, N; Liu, XG; Chou, TT; Lee, VM; Trojanowski, JQ; Brodeur, GM				Eggert, A; Ikegaki, N; Liu, XG; Chou, TT; Lee, VM; Trojanowski, JQ; Brodeur, GM			Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; tyrosine kinase receptors; neurotrophins; signal transduction; differentiation	NERVE GROWTH-FACTOR; NGF RECEPTOR; TYROSINE KINASES; IN-VITRO; ACTIVATION; EXPRESSION; ASSOCIATION; PROTEIN; PROTOONCOGENE; TRANSFECTION	Activation of the neurotrophin receptor TrkA by its ligand nerve growth factor (NGF) initiates a cascade of signaling events leading to neuronal differentiation in vitro and might play an important role in the differentiation of favorable neuroblastomas (NB) in vivo. To study TrkA signal transduction pathways and their effects on differentiation in NE, we stably expressed wild-type TrkA and five different TrkA mutants in the NGF unresponsive human NE cell line SH-SY5Y. Resulting clones were characterized by TrkA mRNA and protein expression, and by autophosphorylation of the receptor. Introduction of wild-type TrkA restored NGF responsiveness of SH-SY5Y cells, as demonstrated by morphological differentiation, activation of mitogen-activated protein kinases (MAPK) and induction of immediate-early genes, Expression of TrkA in the absence of NGF resulted in growth inhibition of transfectants compared to parental cells, whereas NGF-treatment increased their proliferation rate, Analysis of downstream signal transduction pathways indicated that NGF-induced differentiation was dependent on TrkA kinase activity, Our data suggest that several redundant pathways are present further downstream but activation of the RAS/MAPK signaling pathway seems to be of major importance for NGF mediated differentiation of NE cells. Our results also show that the signaling effector SH2-B is a substrate of NGF-mediated Trk signaling in NE, whereas it is not activated by NGF in rat pheochromocytoma PC12 cells, This might explain the differences we observed in TrkA signaling between neuroblastoma and PC12 cells. Further insight into TrkA signaling may suggest new options for the treatment of NB.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Brodeur, GM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, ARC Rm 902-D 3516 Civic Ctr Blvd, Philadelphia, PA 19104 USA.		Eggert, Angelika/AAE-6907-2022	Eggert, Angelika/0000-0003-3476-8184	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034514] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 34514] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRODEUR GM, 1993, J NATL CANCER I, V85, P344, DOI 10.1093/jnci/85.5.344; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EGGERT A, 2000, IN PRESS BIOTECHNIQU, V28; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1997, CULTURING NERVE CELL; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOGNER P, 1993, CANCER RES, V53, P2044; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOEB DM, 1993, J NEUROSCI, V13, P2919; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muragaki Y, 1997, J NEUROSCI, V17, P530; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PELLICI G, 1992, CELL, V70, P93; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; POLUHA W, 1995, ONCOGENE, V10, P185; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STEPHENS RM, 1994, NEURON, V12, P1; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	39	73	79	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2043	2051		10.1038/sj.onc.1203518	http://dx.doi.org/10.1038/sj.onc.1203518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803465				2022-12-28	WOS:000086613200008
J	Kataoka, M; Wiehle, S; Spitz, F; Schumacher, G; Roth, JA; Cristiano, RJ				Kataoka, M; Wiehle, S; Spitz, F; Schumacher, G; Roth, JA; Cristiano, RJ			Down-regulation of bcl-2 is associated with p16(INK4)-mediated apoptosis in non-small cell lung cancer cells	ONCOGENE			English	Article						apoptosis; adenovirus; p16; p53; non-small cell lung cancer	WILD-TYPE P53; MYOCYTE DIFFERENTIATION; CYCLE CONTROL; GENE-PRODUCT; RB; TUMOR; EXPRESSION; PROTEIN; DEATH; LINES	We introduced a functional p16 cDNA into non-small cell lung cancer (NSCLC) cell lines expressing different combinations of normal and mutated p16, p53, and Rb genes via a recombinant adenovirus to determine the effect of exogenous p16 expression on cell growth. Analysis of p16-deficient cells infected with Adv/p16 identified growth arrest of the cells in the G(0)-G(1) phase early on, Apoptosis was identified to occur by the 5th day after infection which corresponded with increased p16 expression, reduced Rb expression, and increased Rb hypophosphorylation, but only occurred in cells expressing functional p53. Further analysis indicated that the expression of the anti-apoptotic protein bcl-2 was greatly reduced in the NSCLC cell lines H460 and A549 (both -p16, +p53, +Rb), again only by the 5th day after Adv/p16 infection, but no affect on Bar expression was observed, H1299 cells (-p16, -p53, +Rb) infected with Adv/p16 only exhibited apoptosis by an additional infection with Adv/p53 which also corresponded with a down-regulation of bcl-2, In addition, the infection of A549 cells with Adv/p16 followed by a subsequent infection with Adv/Rb lead to a significant decrease in apoptosis which correlated with an increase in bcl-2 expression. These studies suggest that p16 is capable of mediating apoptosis in NSCLC cell lines expressing wild-type p53, through a direct down-regulation of Rb and an indirect down-regulation of the anti-apoptotic protein bcl-2.	Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Cardiovasc & Thorac Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Cristiano, RJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd,Box 13, Houston, TX 77030 USA.				PHS HHS [T3209599-08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORCZYCA W, 1993, CANCER RES, V53, P1945; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; JIN XM, 1995, CANCER RES, V55, P3250; Kataoka A, 1996, ONCOL REP, V3, P111; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; McConkey DJ, 1996, ONCOGENE, V13, P1693; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Naruse I, 1998, ANTICANCER RES, V18, P4275; NOBLE JR, 1992, EXP CELL RES, V203, P297, DOI 10.1016/0014-4827(92)90002-P; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Spitz FR, 1996, CLIN CANCER RES, V2, P1665; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZHANG WW, 1994, CANCER GENE THER, V1, P5	28	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	2000	19	12					1589	1595		10.1038/sj.onc.1203466	http://dx.doi.org/10.1038/sj.onc.1203466			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734319				2022-12-28	WOS:000086108100012
J	Olivo, C; Vanni, C; Mancini, P; Silengo, L; Torrisi, MR; Tarone, G; Defilippi, P; Eva, A				Olivo, C; Vanni, C; Mancini, P; Silengo, L; Torrisi, MR; Tarone, G; Defilippi, P; Eva, A			Distinct involvement of Cdc42 and RhoA GTPases in actin organization and cell shape in untransformed and Dbl oncogene transformed NIH3T3 cells	ONCOGENE			English	Article						Cdc42; RhoA; Dbl oncogene; actin cytoskeleton organization	GUANINE-NUCLEOTIDE EXCHANGE; RAS TRANSFORMATION; SIGNALING PATHWAY; PROTEIN-KINASE; ACTIVATION; FAMILY; CYTOSKELETON; FIBROBLASTS; DOWNSTREAM; ADHESION	The Dbl oncogene is a putative exchange factor for the small GTPases RhoA and Cdc42, which are involved in actin polymerization into stress fibers and filopodia, respectively. We report here that, upon adhesion to fibronectin, Dbl-transformed NIH3T3 cells display a contracted, polygonal shape with a high number of short stress fibers. In contrast, untransformed NIH3T3 cells acquire the characteristic fibroblast morphology and organize a regular mesh of long stress fibers. We show that in Dbl-transformed and in untransformed NIH3T3 cells the different shape and actin cytoskeleton organization observed in the early steps of adhesion involves activation of distinct GTPases, Upon adhesion to fibronectin, cell morphology of Dbl-transformed NIH3T3 cells depends on activation of RhoA and not of Cdc42, In contrast Cdc42 activation is necessary to untransfected NIH3T3 cells to acquire their fibroblast shape. In both Dbl-transformed and in untransformed NIH3T3 cells a basal Rac activation is necessary to support stress fiber organization, while constitutive Rac activation promotes ruffles and lamellipodia formation. As a consequence of RhoA activation, Dbl-transformed cells show high activity of ROCK-alpha and CRIK kinases, two known RhoA effecters. In addition Dbl-transformed and NIH3T3 cells expressing the constitutive active form of RhoA are less motile on fibronectin than cells expressing constitutive active Cdc42, We conclude that in NIH3T3 cells in response to fibronectin the expression of the Dbl oncogene leads to a predominant activation of RhoA which both supports the peculiar cell shape and actin cytoskeleton organization in stress fibers and regulates cell motility.	Univ Turin, Dipartimento Genet Biol & Biochim, I-10126 Turin, Italy; Ist Giannina Gaslini, Mol Biol Lab, I-16148 Genoa, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy	University of Turin; University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome	Defilippi, P (corresponding author), Univ Turin, Dipartimento Genet Biol & Biochim, Via Santena 5bis, I-10126 Turin, Italy.		DEFILIPPI, Paola/L-2232-2014; Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; Tarone, Guido/0000-0003-4805-086X; Defilippi, Paola/0000-0001-6427-4906; mancini, patrizia/0000-0003-0556-2056				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DARTSCH PC, 1994, EUR J CELL BIOL, V63, P316; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKADA CY, 1982, CELL, V29, P33, DOI 10.1016/0092-8674(82)90087-3; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; TARONE G, 1982, J CELL BIOL, V94, P179, DOI 10.1083/jcb.94.1.179; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388; ZANGRILLI D, 1995, METHOD ENZYMOL, V256, P347; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	46	22	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1428	1436		10.1038/sj.onc.1203440	http://dx.doi.org/10.1038/sj.onc.1203440			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723134				2022-12-28	WOS:000085942700008
J	Li, RZ; Pei, HP; Watson, DK; Papas, TS				Li, RZ; Pei, HP; Watson, DK; Papas, TS			EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes	ONCOGENE			English	Article						ETS1; EAP1/Daxx; protein interaction; transcriptional repression; DID motif	MATRIX METALLOPROTEINASE-1; ONCOGENIC ACTIVITY; BINDING PROTEIN; EXPRESSION; PROMOTER; CELLS; PROTOONCOGENE; FAMILY; FORM; DAXX	ETS1 is a member of the evolutionarily conserved family of ets genes, which are transcription factors that bind to unique DNA sequences, either alone or by association with other proteins. In this study, we have used the yeast two-hybrid system to identify an ETS1 interacting protein. The ETS1 N-terminal amino acid region was used as bait and an interaction was identified with the Daxx protein, referred to as EAP1 (ETS1 Associated Protein 1)/Daxx. This interactin has been shown to exist in yeast and in vitro. EAP1/Daxx and ETS1 are colocalized in the nucleus of mammalian cells. The region in EAP1/Daxx which specifically binds to ETS1 is located within its carboxy terminal 173 amino acid region. The ETS1 interaction region is located within its N-terminal 139 amino acids and is referred as the Daxx Interaction Domain (DID). The DID appears to be conserved in several other ets family members, as well as in other proteins known to interact with Daxx. The EAP1/Daxx interacts with both isoforms of ETS1, p51-ETS1 and p42-ETS1. Interaction of EAP1/Daxx with ETS1 causes the repression of transcriptional activation of the MMP1 and BCL2 genes. The interaction domains of both ETS1 and EAP1/Daxx are required for this repression and deletion of either domain abolishes this activity.	Med Univ S Carolina, Hollings Canc Ctr, CMSB, Charleston, SC 29425 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Li, RZ (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, CMSB, Romm 334,86 Jonathan Lucas St, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [R01CA076231, P01CA078582] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA76231, P01CA78582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; Bhat NK, 1996, INT J ONCOL, V8, P841; BHAT NK, 1994, CHALLENGES MODERN ME, V5, P63; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Herberg JA, 1998, J MOL BIOL, V277, P839, DOI 10.1006/jmbi.1998.1637; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; JORCYK CL, 1991, ONCOGENE, V6, P523; Kiriakidou M, 1997, DNA CELL BIOL, V16, P1289, DOI 10.1089/dna.1997.16.1289; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Moore DD, 1995, GLOB MOB SURV; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Pluta AF, 1998, J CELL SCI, V111, P2029; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; Rutter JL, 1998, CANCER RES, V58, P5321; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	43	155	162	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					745	753		10.1038/sj.onc.1203385	http://dx.doi.org/10.1038/sj.onc.1203385			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698492				2022-12-28	WOS:000085192100004
J	Lu, WG; Pochampally, R; Chen, LH; Traidej, M; Wang, YL; Chen, JD				Lu, WG; Pochampally, R; Chen, LH; Traidej, M; Wang, YL; Chen, JD			Nuclear exclusion of p53 in a subset of tumors requires MDM2 function	ONCOGENE			English	Article						MDM2; p53; ARF; antisense oligodeoxynucleotide; leptomycin B; tumor suppressor	DNA-DAMAGE; CELL-CYCLE; CYTOPLASMIC SEQUESTRATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; TERMINAL DOMAIN; BREAST-CANCER; FEEDBACK LOOP; PROTEIN	Wild type p53 accumulates in the cytoplasm in a subset of tumors such as neuroblastomas and breast carcinomas through an unknown mechanism. Exclusion of p53 from the nucleus may lead to inactivation of p53 during tumor development. We present evidence that MDM2 plays a significant role in promoting the degradation of nuclear p53 in tumor cells with a cytoplasmic p53 phenotype, Inhibition of MDM2 expression using antisense oligonucleotide, inhibition of MDM2 function by the tumor suppressor ARF or a MDM2 deletion mutant result in the accumulation of nuclear p53, p53 point mutants deficient in MDM2 binding have increased nuclear localization. Inhibition of nuclear export by leptomycin B also results in retention of nascent p53 in the nucleus, suggesting that cytoplasmic distribution of p53 results from efficient export of nuclear p53 in combination with MDM2-mediated degradation, These results suggest that MDM2 is an important determinant of p53 subcellular distribution and may contribute to p53 inactivation without overexpression.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Louisiana State Univ, Med Ctr, Dept Microbiol, New Orleans, LA 70112 USA	H Lee Moffitt Cancer Center & Research Institute; Louisiana State University System	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.			Chomnawang, Mullika/0000-0002-3200-9259; Pochampally, Radhika/0000-0002-4263-0364				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CORDONCARDO C, 1994, CANCER RES, V54, P794; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GANNON JV, 1991, NATURE, V349, P802; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Isaacs JS, 1998, CELL GROWTH DIFFER, V9, P545; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zariwala M, 1996, ONCOGENE, V13, P2033; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	52	66	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					232	240		10.1038/sj.onc.1203262	http://dx.doi.org/10.1038/sj.onc.1203262			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645001	Bronze			2022-12-28	WOS:000084844400008
J	McCullagh, P; Chaplin, T; Meerabux, J; Grenzelias, D; Lillington, D; Poulsom, R; Gregorini, A; Saha, V; Young, BD				McCullagh, P; Chaplin, T; Meerabux, J; Grenzelias, D; Lillington, D; Poulsom, R; Gregorini, A; Saha, V; Young, BD			The cloning, mapping and expression of a novel gene, BRL, related to the AF10 leukaemia gene	ONCOGENE			English	Article						chromosome translocation; leukaemia; MLL; AF10	HISTONE ACETYLTRANSFERASE ACTIVITY; ACUTE MONOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NUCLEAR-PROTEIN CBP; TRANSCRIPTIONAL ACTIVATION; T(10-11) TRANSLOCATION; BINDING-PROTEIN; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MOLECULAR-CLONING	The MLL gene is reciprocally translocated with one of a number of different partner genes in a proportion of human acute leukaemias. The precise mechanism of oncogenic transformation is unclear since most of the partner genes encode unrelated proteins, However, two partner genes, AF10 and AF17 are related through the presence of a cysteine rich region and a leucine zipper. The identification of other proteins with these structures will aid our understanding of their role in normal and leukaemic cells. We report the cloning of a novel human gene (BRL) which encodes a protein containing a cysteine rich region related to that of AF10 and AF17 and is overall most closely related to the previously known protein BR140, BRL maps to chromosome 22q13 and shows high levels of expression in testis and several cell lines. The deduced protein sequence also contains a bromodomain, four potential LXXLL motifs and four predicted nuclear localization signals. A monoclonal antibody raised to a BRL peptide sequence confirmed its widespread expression as a 120 Kd protein and demonstrated localization to the nucleus within spermatocytes.	St Bartholomews & Royal London Sch Med & Dent, Dept Med Oncol, Imperial Canc Res Fund, London EC1M 6BQ, England; Imperial Canc Res Fund, In Situ Hybridizat Serv, London WC2A 3PX, England	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK	Young, BD (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Med Oncol, Imperial Canc Res Fund, Charterhouse Sq, London EC1M 6BQ, England.			Saha, Vaskar/0000-0002-2916-9649				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BEVERLOO HB, 1995, CANCER RES, V55, P4220; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, MOL CELL BIOL, V16, P593; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gregorini A, 1996, GENE CHROMOSOME CANC, V17, P269; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Harlow E, 1998, ANTIBODIES LAB MANUA; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAI JL, 1992, CANCER GENET CYTOGEN, V60, P180, DOI 10.1016/0165-4608(92)90013-X; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEBEAU MM, 1985, LEUKEMIA RES, V9, P605, DOI 10.1016/0145-2126(85)90140-7; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACCOLLIN M, 1993, GENOMICS, V15, P680, DOI 10.1006/geno.1993.1125; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nicolas RH, 1996, GENE, V175, P233, DOI 10.1016/0378-1119(96)82845-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Rinderle C, 1999, HUM MOL GENET, V8, P277, DOI 10.1093/hmg/8.2.277; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Soenen V, 1996, GENE CHROMOSOME CANC, V15, P191, DOI 10.1002/(SICI)1098-2264(199603)15:3<191::AID-GCC9>3.0.CO;2-Y; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tanabe S, 1996, BLOOD, V88, P3535; THOMPSON KA, 1994, BIOCHEM BIOPH RES CO, V198, P1143, DOI 10.1006/bbrc.1994.1162; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TROFATTER JA, 1995, GENOME RES, V5, P214, DOI 10.1101/gr.5.3.214; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	57	19	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7442	7452		10.1038/sj.onc.1203117	http://dx.doi.org/10.1038/sj.onc.1203117			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602503				2022-12-28	WOS:000084119600005
J	Sabourin, LA; Rudnicki, MA				Sabourin, LA; Rudnicki, MA			Induction of apoptosis by SLK, a Ste20-related kinase	ONCOGENE			English	Article						Ste20 kinase; apoptosis; JNK1	STE20-LIKE PROTEIN-KINASE; SIGNAL-TRANSDUCTION; BINDING PROTEIN; CELL-DEATH; CLONING; DOMAIN; SAPK/JNK; CDC42P; SYSTEM; YEAST	We have cloned and characterized a novel murine Ste20-related kinase designated SLK, SLK displays high homology to the Ste20-related kinase LOK, and is more distantly related to MST1 and 2, both Ste20-like kinases, In addition, SLK displays high homology to microtubule and nuclear associated protein (M-NAP) and AT1-46, both of unknown function. SLK is ubiquitously expressed as multiple mRNAs in tissues and cell lines and is downregulated by mitogen depletion in differentiating myoblasts, Biochemical characterization showed that SLK overexpression activates c-Jun amino-terminal kinase 1 (JNK1), However, in vitro kinase assays indicated that SLK was not activated in response to various growth factors or stress-inducing agents. Immunofluorescence studies revealed that SLK colocalized to distinct cytosolic domains, preferentially at the periphery of the cells. In addition, prolonged overexpression of SLK in cultured fibroblasts resulted in apoptosis as demonstrated by annexin-V and TUNEL staining. Our results suggest that SLK belongs to a new family of protein kinases, mediating activation of the stress response pathway through a novel signaling cascade.	McMaster Univ, MOBIX, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada	McMaster University	Rudnicki, MA (corresponding author), McMaster Univ, MOBIX, Inst Mol Biol & Biotechnol, Life Sci Bldg,Room 437,1280 Main St W, Hamilton, ON L8S 4K1, Canada.							Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUGHES DA, 1995, SEMIN CELL BIOL, V6, P89, DOI 10.1016/1043-4682(95)90005-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Itoh S, 1997, ARCH BIOCHEM BIOPHYS, V340, P201, DOI 10.1006/abbi.1997.9893; KATOH M, 1995, ONCOGENE, V10, P1447; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Sambrook J., 2002, MOL CLONING LAB MANU; Schaar DG, 1996, BRAIN RES, V721, P217, DOI 10.1016/0006-8993(96)00176-X; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	27	66	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7566	7575		10.1038/sj.onc.1203119	http://dx.doi.org/10.1038/sj.onc.1203119			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602516				2022-12-28	WOS:000084119600018
J	Kongkanuntn, R; Bubb, VJ; Sansom, OJ; Wyllie, AH; Harrison, DJ; Clarke, AR				Kongkanuntn, R; Bubb, VJ; Sansom, OJ; Wyllie, AH; Harrison, DJ; Clarke, AR			Dysregulated expression of beta-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice	ONCOGENE			English	Article						beta-catenin; Apc; p53; Msh2; intestine; pancreas	WNT SIGNALING PATHWAY; INTESTINAL ADENOMAS; NEGATIVE REGULATOR; COLORECTAL-CANCER; SOMATIC MUTATIONS; DESMOID TUMORS; GENE; CARCINOMA; COMPLEX; AXIN	We have analysed the pattern of beta-catenin expression by immunohistochemistry in mice singly or multiply mutant for Ape, p53 and Msh2. We observed increased expression of beta-catenin in all intestinal lesions arising on an Apc(Min) +/- background. In all categories of lesion studied mosaic patterns of beta-catenin expression were observed, with the proportion of cells showing enhanced expression decreasing with increasing lesion size. p53 statics did not alter these patterns. We also show that beta-catenin dysregulation marks pancreatic abnormalities occurring in Apc(Min) +/- and (Apc(Min) +/-, p53-/-) mice. In these mice both adenomas and adenocarcinomas of the pancreas arose and were characterized by increased expression of beta-catenin, We have extended these analyses to intestinal lesions arising in mice mutant for the mismatch repair gene Msh2, In these mice, increased expression of beta-catenin was again observed. However, in contrast with Apc(Min) +/- mice, a subset of lesions retained normal expression. Taken together, these findings show that increased expression of beta-catenin is an efficient marker of early neoplastic change in both murine intestine and pancreas in Ape mutant mice. However, we also show that dysregulation of beta-catenin is not an obligate step in the development of intestinal lesions, and therefore that genetic events other than the loss of Ape function may initiate the transition from normal to neoplastic epithelium.	Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Clarke, AR (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010				Alman BA, 1997, AM J PATHOL, V151, P329; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P1; Chen HY, 1997, J CELL SCI, V110, P345; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Going JJ, 1996, J PATHOL, V179, P121; HORII A, 1992, CANCER RES, V52, P6696; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Inomata M, 1996, CANCER RES, V56, P2213; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LUONGO C, 1994, CANCER RES, V54, P5947; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Reitmair AH, 1996, CANCER RES, V56, P2922; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sheng HM, 1998, CARCINOGENESIS, V19, P543, DOI 10.1093/carcin/19.4.543; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shoemaker AR, 1997, BIOCHIM BIOPHYS ACTA, V1332, P25; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takayama T, 1996, AM J PATHOL, V148, P39; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; vanOordt CWV, 1997, CARCINOGENESIS, V18, P2197, DOI 10.1093/carcin/18.11.2197	43	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7219	7225		10.1038/sj.onc.1203181	http://dx.doi.org/10.1038/sj.onc.1203181			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602475				2022-12-28	WOS:000084119400005
J	Ito, K; Okamoto, I; Araki, N; Kawano, Y; Nakao, M; Fujiyama, S; Tomita, K; Mimori, T; Saya, H				Ito, K; Okamoto, I; Araki, N; Kawano, Y; Nakao, M; Fujiyama, S; Tomita, K; Mimori, T; Saya, H			Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from cell-cell contacts	ONCOGENE			English	Article						metalloprotease; mechanical stimulation; calcium ionophore; E-cadherin; beta-catenin	BREAST-CARCINOMA CELLS; SOLUBLE E-CADHERIN; CANCER-PATIENTS; ADHESION; RECEPTORS; CLEAVAGE; TISSUE; GROWTH; METALLOPROTEINASES; IDENTIFICATION	Cadherins are major cell-cell adhesion molecules in both tumor and normal tissues. Although serum levels of soluble E-cadherin have been shown to be higher in the cancer patients than in healthy volunteers, the detail mechanism regulating release of soluble E-cadherin remains to be elucidated. Here we show that the ectodomain of E-cadherin is proteolytically cleaved from some cancer cells by a membrane-bound metalloprotease to yield soluble form, and the residual membrane-tethered cleavage product is subsequently degraded by intracellular proteolytic pathway. Futhermore, we show that extracellular calcium influx, that is induced by mechanical scraping of cells or ionomycin treatment, enhances the metalloprotease-mediated E-cadherin cleavage and the subsequent degradation of the cytoplasmic domain. Immunocytochemical analysis demonstrates that the sequential proteolysis of E-cadherin triggered by the calcium influx results in translocation of beta-catenin from the cell-cell contacts to cytoplasm. Our data suggest that calcium influx-induced proteolysis of E-cadherin not only disrupts the cell-cell adhesion but also activates beta-catenin-mediated intracellular signaling pathway, potentially leading to alterations in motility and proliferation activity of cells.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 3, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					ABERLE H, 1994, J CELL SCI, V107, P3655; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Codony-Servat J, 1999, CANCER RES, V59, P1196; COOMBER BL, 1990, ARTERIOSCLEROSIS, V10, P215, DOI 10.1161/01.ATV.10.2.215; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; Gofuku J, 1998, BRIT J CANCER, V78, P1095, DOI 10.1038/bjc.1998.634; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; ITO A, 1995, BRIT J CANCER, V71, P1039, DOI 10.1038/bjc.1995.200; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KATAYAMA M, 1994, BRIT J CANCER, V69, P580, DOI 10.1038/bjc.1994.106; LIN YZJ, 1991, ONCOGENE, V6, P639; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lombard MA, 1998, CANCER RES, V58, P4001; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; REIDY MA, 1990, TOXICOL PATHOL, V18, P547; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SATO H, 1992, ONCOGENE, V7, P77; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Talbot DC, 1996, EUR J CANCER, V32A, P2528; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; Tran POT, 1999, EXP CELL RES, V246, P319, DOI 10.1006/excr.1998.4239; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	39	111	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7080	7090		10.1038/sj.onc.1203191	http://dx.doi.org/10.1038/sj.onc.1203191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597309				2022-12-28	WOS:000083901900015
J	Rayet, B; Gelinas, C				Rayet, B; Gelinas, C			Aberrant rel/nfkb genes and activity in human cancer	ONCOGENE			English	Review						cancer; I kappa B; NF-kappa B; oncogenesis; Rel; transcription	NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; GERMINAL CENTER REACTIONS; TRANSCRIPTION FACTOR-IIB; TATA-BINDING PROTEIN; C-REL PROTOONCOGENE; CELL LUNG-CARCINOMA; V-REL; BREAST-CANCER; MICE LACKING	Rel/NF-kappa B transcription factors are key regulators of immune, inflammatory and acute phase responses and are also implicated in the control of cell proliferation and apoptosis. Remarkable progress has been made in understanding the signal transduction pathways that lead to the activation of Rel/NF-kappa B factors and the consequent induction of gene expression. Evidence linking deregulated Rel/NF-kappa B activity to oncogenesis in mammalian systems has emerged in recent years, consistent with the acute oncogenicity of the viral oncoprotein v-Rel in animal models. Chromosomal amplification, overexpression and rearrangement Of genes coding for Rel/NF-kappa B factors have been noted in many human hematopoietic and solid tumors. Persistent nuclear NF-kappa B activity was also described in several human cancer cell types, as a result of constitutive activation of upstream signaling kinases or mutations inactivating inhibitory I kappa B subunits. Studies point to a correlation between the activation of cellular gene expression by Rel/NF-kappa B factors and their participation in the malignant process. Experiments implicating NF-kappa B in the control of the apoptotic response also support a role in oncogenesis and in the resistance of tumor cells to chemotherapy, This review focuses on the status of the rel, nfkb and ikb genes and their activity in human tumors and their association with the onset or progression of malignancies.	Univ Med & Dent New Jersey, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Gelinas, C (corresponding author), Univ Med & Dent New Jersey, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.				NATIONAL CANCER INSTITUTE [R01CA054999, R29CA054999] Funding Source: NIH RePORTER; NCI NIH HHS [CA54999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bentires-Alj M, 1999, CANCER RES, V59, P811; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWNELL E, 1988, ONCOGENE, V2, P527; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHANG CC, 1994, ONCOGENE, V9, P923; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dejardin E, 1998, ONCOGENE, V16, P3299, DOI 10.1038/sj.onc.1201879; Devalaraja MN, 1999, CANCER RES, V59, P1372; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; EPINAT JC, 1999, IN PRESS ONCOGENE; Ferrier R, 1999, ONCOGENE, V18, P995, DOI 10.1038/sj.onc.1202374; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1999, DNA ALTERATIONS CANC; GRIMM S, 1994, ONCOGENE, V9, P2391; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huguet C, 1997, CELL DEATH DIFFER, V4, P413, DOI 10.1038/sj.cdd.4400259; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Khaled Z, 1996, NUCLEIC ACIDS RES, V24, P737, DOI 10.1093/nar/24.4.737; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KODURU PRK, 1993, AM J HEMATOL, V44, P117, DOI 10.1002/ajh.2830440209; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LAI JL, 1995, BLOOD, V85, P2490, DOI 10.1182/blood.V85.9.2490.bloodjournal8592490; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LENARDO M, 1994, IMMUNOL TODAY, V15, P145, DOI 10.1016/0167-5699(94)90308-5; Ling WJ, 1998, BLOOD, V92, P1334, DOI 10.1182/blood.V92.4.1334.416k25_1334_1341; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MATHEW S, 1993, ONCOGENE, V8, P191; Maxwell SA, 1995, GENE, V166, P339, DOI 10.1016/0378-1119(95)00578-1; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; Michaux L, 1997, CANCER GENET CYTOGEN, V94, P36, DOI 10.1016/S0165-4608(96)00247-6; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Mori N, 1999, BLOOD, V93, P2360; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; NERI A, 1995, BLOOD, V86, P3160, DOI 10.1182/blood.V86.8.3160.bloodjournal8683160; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OHNO H, 1993, LEUKEMIA, V7, P2057; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perletti L, 1997, GENOMICS, V46, P251, DOI 10.1006/geno.1997.5022; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sheehy AM, 1999, J BIOL CHEM, V274, P8708, DOI 10.1074/jbc.274.13.8708; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; SUMITOMO M, 1999, HUM GENE THER, V161, P674; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; THAKUR S, 1994, ONCOGENE, V9, P2335; Trecca D, 1997, ONCOGENE, V14, P791, DOI 10.1038/sj.onc.1200895; Tumang JR, 1998, EUR J IMMUNOL, V28, P4299, DOI 10.1002/(SICI)1521-4141(199812)28:12<4299::AID-IMMU4299>3.0.CO;2-Y; Uzzo RG, 1999, J NATL CANCER I, V91, P718, DOI 10.1093/jnci/91.8.718; VANDENBERGHE H, 1979, CANCER, V44, P188, DOI 10.1002/1097-0142(197907)44:1<188::AID-CNCR2820440131>3.0.CO;2-F; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang WX, 1999, CLIN CANCER RES, V5, P119; WHITE DW, 1995, ONCOGENE, V10, P857; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; ZHANG JD, 1994, ONCOGENE, V9, P1931; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zong WX, 1997, ONCOGENE, V15, P971, DOI 10.1038/sj.onc.1201266; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	128	957	1003	0	58	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6938	6947		10.1038/sj.onc.1203221	http://dx.doi.org/10.1038/sj.onc.1203221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602468				2022-12-28	WOS:000083896500010
J	Balana, ME; Lupu, R; Labriola, L; Charreau, EH; Elizalde, PV				Balana, ME; Lupu, R; Labriola, L; Charreau, EH; Elizalde, PV			Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas	ONCOGENE			English	Article						progestin; heregulin; mouse mammary tumors; type I insulin-like growth factor receptor	BREAST-CANCER CELLS; NEU DIFFERENTIATION FACTOR; EPIDERMAL GROWTH-FACTOR; FACTOR-I RECEPTOR; MEDROXYPROGESTERONE ACETATE; TRANSDUCTION PATHWAYS; ESTROGEN-RECEPTOR; EPITHELIAL-CELLS; TUMOR-CELLS; EXPRESSION	The present study addressed links between progestin and heregulin (HRG) signaling pathways in mammary tumors. An experimental model of hormonal carcinogenesis, in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in female Balb/c mice, was used. MPA induced an in vivo up-regulation of HRG mRNA expression in progestin-dependent (HD) tumor lines. Mammary tumor progression to a progestin-independent (HI) phenotype was accompanied by a high constitutive expression of HRG. The HRG message arose from the tumor epithelial cells. Primary cultures of malignant epithelial cells from a HD tumor line were used to investigate HRG involvement on cell proliferation. HRG induced a potent proliferative effect on these cells and potentiated MPA mitogenic effects. Blocking endogenous HRG synthesis by antisense oligodeoxynucleotides (ASODNs) to HRG mRNA inhibited MPA-induced cell growth, indicating that HRG acts as a mediator of MPA-induced growth. High levels of ErbB-2 and ErbB-3 expression and low ErbB-4 levels mere found in HD cells. Treatment of these cells with either MPA or HRG resulted in tyrosine phosphorylation of both ErbB-2 and ErbB-3. Furthermore, both HRG and MPA proliferative effects mere abolished when cells were treated with ASODNs to ErbB-2 mRNA, providing evidence for a critical role of ErbB-2 in HRG-induced growth. Finally, blocking type I insulin-like growth factor receptor (IGF-IR) expression with ASODN resulted in the complete inhibition of HRG proliferative effect, demonstrating that a functional IGF-IR is required for HRG mitogenic activity. These results provide the first evidence of interactions between progestins and HRB/ErbB signal transduction pathways in mammary cancer and the first demonstration that IGF-IR is required for HRG proliferative effects.	Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Calif Berkeley, Lawrence Berkeley Natl Labs, Berkeley, CA 94710 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Elizalde, PV (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Labriola, Leticia/E-9059-2012; Labriola, Leticia/ABF-9079-2020	Labriola, Leticia/0000-0003-3899-6088; Labriola, Leticia/0000-0003-3899-6088; Elizalde, Patricia V./0000-0002-5923-9898				Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BACUS SS, 1993, CANCER RES, V53, P5251; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERLII R, 1995, MOL CELL BIOL, V15, P6496; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DRAN G, 1995, BREAST CANCER RES TR, V35, P173, DOI 10.1007/BF00668207; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Guerra FK, 1996, INT J CANCER, V65, P812, DOI 10.1002/(SICI)1097-0215(19960315)65:6<812::AID-IJC18>3.3.CO;2-5; HAMBURGER AW, 1997, MOL CELL ENDOCRINOL, V138, P163; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Krane IM, 1996, ONCOGENE, V12, P1781; LANARI C, 1989, INT J CANCER, V43, P845, DOI 10.1002/ijc.2910430518; Lewis GD, 1996, CANCER RES, V56, P1457; Lowe WL, 1997, ENDOCRINOLOGY, V138, P2219, DOI 10.1210/en.138.6.2219; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MOLINOLO AA, 1987, J NATL CANCER I, V79, P1341; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; NORMANNO N, 1993, INT J ONCOL, V2, P903; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Tang CK, 1996, CANCER RES, V56, P3350; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; YOUNG JAT, 1985, NUCLEIC ACIDS RES, V13, P8883, DOI 10.1093/nar/13.24.8883	43	50	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6370	6379		10.1038/sj.onc.1203028	http://dx.doi.org/10.1038/sj.onc.1203028			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597237				2022-12-28	WOS:000083934100022
J	Challier, C; Cocault, L; Flon, M; Pauchard, M; Porteu, F; Gisselbrecht, S; Souyri, M				Challier, C; Cocault, L; Flon, M; Pauchard, M; Porteu, F; Gisselbrecht, S; Souyri, M			A new feature of Mpl receptor: ligand-induced transforming activity in FRE rat fibroblasts	ONCOGENE			English	Article						Mpl; transformation; fibroblasts; MAPK; Shc	PROTEIN-TYROSINE PHOSPHORYLATION; HUMAN BLOOD-PLATELETS; C-MPL; MEGAKARYOCYTIC DIFFERENTIATION; CYTOPLASMIC DOMAIN; CYTOKINE RECEPTOR; SHC PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PRIMARY REGULATOR	Mpl is the receptor for thrombopoietin, the primary regulator of platelet production by megakaryocytes. Upon stimulation by its ligand, Mpl receptor induces proliferation and differentiation of hematopoietic cell lines of various origins. In this paper, we show that Mpl is also able to transform FRE rat fibroblasts in the presence of MGDF (pegylated Megakaryocyte Growth and Development Factor), a modified form of its ligand. We also demonstrate that upon MGDF stimulation Mpl receptor activates the classical transduction pathways described for hematopoietic cell lines in FRE cells. Introduction of Mpl deletion mutants in FRE cells allowed us to demonstrate that the C-terminal region of the Mpl intracytoplasmic domain, which is involved in hematopoietic differentiation, is necessary for the transformation process. Within that region, site-directed mutagenesis showed that the Y112 residue, which is required for She phosphorylation, is essential for rat fibroblast transformation by Mpl/MGDF, suggesting the involvement of She in Mpl-mediated transformation. Interestingly, we showed that transformation correlated with strong and sustained MAPK activation. Neither Jak2 Stat3 nor Stat5 phosphorylation was sufficient to induce the transformation process. Taken altogether, our results suggest the oncogenicity of Mpl in fibroblastic cells in the presence of its ligand.	Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France; Hop Cochin, Inst Cochin Genet Mol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Souyri, M (corresponding author), Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France.		Souyri, Michele/L-5845-2017; PORTEU, Françoise/I-8445-2016	PORTEU, Françoise/0000-0002-2403-4163; PETIT, Laurence/0000-0002-2475-9367				Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Cocault L, 1996, BLOOD, V88, P1656; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eaton DL, 1997, EXP HEMATOL, V25, P1; Fichelson S, 1999, BLOOD, V94, P1601, DOI 10.1182/blood.V94.5.1601.417k19_1601_1613; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HAWLEY RG, 1994, GENE THER, V1, P136; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kimura S, 1998, P NATL ACAD SCI USA, V95, P1195, DOI 10.1073/pnas.95.3.1195; Ljungdahl S, 1998, CELL GROWTH DIFFER, V9, P565; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; OLIFF AI, 1980, J VIROL, V33, P475, DOI 10.1128/JVI.33.1.475-486.1980; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SOUYRI M, 1987, VIROLOGY, V158, P69, DOI 10.1016/0042-6822(87)90239-X; Takatoku M, 1997, J BIOL CHEM, V272, P7259, DOI 10.1074/jbc.272.11.7259; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947	44	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2000	19	16					2033	2042		10.1038/sj.onc.1203472	http://dx.doi.org/10.1038/sj.onc.1203472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803464				2022-12-28	WOS:000086613200007
J	Yeh, JJ; Lunetta, KL; van Orsouw, NJ; Moore, FD; Mutter, GL; Vijg, J; Dahia, PLM; Eng, C				Yeh, JJ; Lunetta, KL; van Orsouw, NJ; Moore, FD; Mutter, GL; Vijg, J; Dahia, PLM; Eng, C			Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours	ONCOGENE			English	Article						mitochondria; thyroid tumours; sequence variants; mutations	TUMORS; APOPTOSIS; CANCER	Somatic mutations in mtDNA have recently been identified in colorectal tumours, Studies of oncocytic tumours have led to hypotheses which propose that defects in oxidative phosphorylation may result in a compensatory increase in mitochondrial replication and/or gene expression. Mutational analysis of mtDNA in thyroid neoplasia, which is characterised by increased numbers of mitochondria and is also one of the most common sites of oncocytic tumours, has been limited to date. Using the recently developed technique of two-dimensional gene scanning, me have successfully examined 21 cases of thyroid tumours, six cases of nonneoplastic thyroid pathology, 30 population controls, nine foetal thyroid tissues and nine foetal tissues of nonthyroid origin, either kidney or liver. We have identified three different somatic mutations (23%) in papillary thyroid carcinomas. In addition, we have found significant differential distributions of mtDNA sequence variants between thyroid carcinomas and controls. Interestingly, these variants appear to be more frequent in the genes which encode complex I of the mitochondrial electron transport chain compared to normal population controls, These findings suggest first, that somatic mtDNA mutations may be involved in thyroid tumorigenesis and second, that the accumulation of certain non-somatic variants may be related to tumour progression in the thyroid.	Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet & Human Canc Genet Program, Med Res Facil 690C, Columbus, OH 43210 USA; Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA; San Antonio Canc Inst, Inst Drug Dev, San Antonio, TX USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Surg, Boston, MA 02114 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Boston University	Eng, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet & Human Canc Genet Program, Med Res Facil 690C, 420 W 12th Ave, Columbus, OH 43210 USA.		Mutter, George L/C-5819-2009	Lunetta, Kathryn/0000-0002-9268-810X; Eng, Charis/0000-0002-3693-5145	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BIANCHI MS, 1995, CYTOGENET CELL GENET, V71, P99, DOI 10.1159/000134072; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Cavalli LR, 1998, MUTAT RES-FUND MOL M, V398, P19, DOI 10.1016/S0027-5107(97)00223-6; Dhanda RK, 1998, BIOTECHNIQUES, V25, P664, DOI 10.2144/98254dt06; EBNER D, 1991, VIRCHOWS ARCH B, V60, P139, DOI 10.1007/BF02899539; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; JOHNSON D, 1996, AM J PATHOL, V149, P1786; Muller-Hocker J, 1998, ULTRASTRUCT PATHOL, V22, P91; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; SIGEL S, 1998, NONPARAMETRIC STAT B; Simon DK, 1999, ANNU REV MED, V50, P111; Stefaneanu L, 1979, Endocrinologie, V17, P233; TALLINI G, 1994, CYTOGENET CELL GENET, V66, P253, DOI 10.1159/000133706; van Orsouw NJ, 1998, GENOMICS, V52, P27, DOI 10.1006/geno.1998.5410; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WELTER C, 1989, GENE CHROMOSOME CANC, V1, P79, DOI 10.1002/gcc.2870010112	22	145	162	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2060	2066		10.1038/sj.onc.1203537	http://dx.doi.org/10.1038/sj.onc.1203537			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803467				2022-12-28	WOS:000086613200010
J	Atlas, E; Stramwasser, M; Whiskin, K; Mueller, CR				Atlas, E; Stramwasser, M; Whiskin, K; Mueller, CR			GA-binding protein alpha/beta is a critical regulator of the BRCA1 promoter	ONCOGENE			English	Article						BRCA1; expression; GABP alpha/beta; breast cancer	SPORADIC BREAST-CANCER; MESSENGER-RNA; GENE; EXPRESSION; METHYLATION; MUTATIONS; CELLS; SITE; REGION; DIFFERENTIATION	Decreased expression of BRCA1 may play a role in the etiology of sporadic breast cancer. Deletion and point mutant analysis of proximal promoter elements in the BRCA1 1a promoter revealed a 22 bp region which was critical for the expression of the promoter in MCF-7 cells, but had a much reduced effect in T47D cells, The main transcription factor interacting with this site was identified as GABP alpha/beta, and a discrete DNA binding complex was only observed in nuclear extracts from MCF-7 cells, Cotransfection experiments with GABP alpha and beta 1 expression vectors produced transactivation of this element in both lines, These results suggest that GABP alpha/beta is a critical activator of BRCA1 expression, and that its activity may differ in human breast cell lines.	Queens Univ, Dept Biochem, Can Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Mueller, CR (corresponding author), Queens Univ, Dept Biochem, Can Res Labs, Kingston, ON K7L 3N6, Canada.							Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Boccia LM, 1996, MOL CELL BIOL, V16, P1929; Brown MA, 1996, ONCOGENE, V12, P2507; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Dobrovic A, 1997, CANCER RES, V57, P3347; Favy DA, 1999, BIOCHEM BIOPH RES CO, V258, P284, DOI 10.1006/bbrc.1999.0602; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hoare S, 1999, ENDOCRINOLOGY, V140, P2268, DOI 10.1210/en.140.5.2268; Jarvis EM, 1998, CANCER GENET CYTOGEN, V101, P109, DOI 10.1016/S0165-4608(97)00267-7; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Ozcelik H, 1998, INT J CANCER, V77, P1; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yokomori N, 1998, MOL ENDOCRINOL, V12, P1241, DOI 10.1210/me.12.8.1241	42	41	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1933	1940		10.1038/sj.onc.1203516	http://dx.doi.org/10.1038/sj.onc.1203516			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773883				2022-12-28	WOS:000086424300009
J	Machida, K; Matsuda, S; Yamaki, K; Senga, T; Thant, AA; Kurata, H; Miyazaki, K; Hayashi, K; Okuda, T; Kitamura, T; Hayakawa, T; Hamaguchi, M				Machida, K; Matsuda, S; Yamaki, K; Senga, T; Thant, AA; Kurata, H; Miyazaki, K; Hayashi, K; Okuda, T; Kitamura, T; Hayakawa, T; Hamaguchi, M			v-Src suppresses SHPS-1 expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells	ONCOGENE			English	Article						SHPS-1; SIRP; v-Src; transformation; tumor suppressor; signal transduction	CHICKEN-EMBRYO FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; PLASMA-MEMBRANE MATRIX; MORPHOLOGICAL TRANSFORMATION; TYROSINE PHOSPHORYLATION; C-RAS; PROTEIN; ADHESION; P60SRC; ASSOCIATION	We investigated the effect of cell transformation by v-src on the expression and tyrosine phosphorylation of SHPS-1, a putative docking protein for SHP-1 and SHP-2. We found that transformation by v-sle virtually inhibited the SHPS-1 expression at mRNA level. While nontransforming Src kinases including c-Src, nonmyristoylated forms of v-Src had no inhibitory effect on SHPS-1 expression, transforming Src kinases including wild-type v-Src and chimeric mutant of c-Src bearing v-Src SH3 substantially suppressed the SHPS-1 expression. In cells expressing temperature sensitive mutant of v-Src, suppression of the SHPS-1 expression was temperature-dependent. In contrast, tyrosine phosphorylation of SHPS-1 was rather activated in cells expressing c-Src or nonmyristoylated forms of v-Src, SHPS-1 expression in SR3Y1 was restored by treatment with herbimycin A, a potent inhibitor of tyrosine kinase, or by the expression of dominant negative form of Ras. Contrary, active form of Mek1 markedly suppressed SHPS-1 expression. Finally, overexpression of SHPS-1 in SR3Y1 led to the drastic reduction of anchorage independent growth of the cells. Taken together, our results suggest that the suppression of SHPS-1 expression is a pivotal event for cell transformation by v-src, and the Ras-MAP kinase cascade plays a critical role in the suppression.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 2, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Surg 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1080071, Japan	Nagoya University; Nagoya University; Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kitamura, Toshio/AAA-2071-2021					Comu S, 1997, J NEUROSCI, V17, P8702; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROW DS, 1992, ONCOGENE, V7, P999; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GOTOH Y, 1994, ONCOGENE, V9, P1891; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KOZUMA LM, 1990, MOL CELL BIOL, V10, P837; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Lin XY, 1997, CANCER RES, V57, P2304; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; Miyazaki K, 1999, BIOCHEM BIOPH RES CO, V263, P759, DOI 10.1006/bbrc.1999.1464; OZAKI T, 1994, CANCER RES, V54, P646; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Senga T, 2000, ONCOGENE, V19, P273, DOI 10.1038/sj.onc.1203296; Shibata K, 1998, CANCER RES, V58, P900; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; ZHANG M, 1995, CANCER RES, V55, P2537; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	40	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1710	1718		10.1038/sj.onc.1203497	http://dx.doi.org/10.1038/sj.onc.1203497			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763828				2022-12-28	WOS:000086083800011
J	Mils, V; Baldin, V; Goubin, F; Pinta, I; Papin, C; Waye, M; Eychene, A; Ducommun, B				Mils, V; Baldin, V; Goubin, F; Pinta, I; Papin, C; Waye, M; Eychene, A; Ducommun, B			Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase	ONCOGENE			English	Article						cell cycle; CDC25B phosphatase; 14-3-3 proteins; checkpoint	XENOPUS EGG EXTRACTS; DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; CELL-CYCLE; FISSION YEAST; TYROSINE PHOSPHATASE; MITOTIC INDUCER; ACTIVATION; PHOSPHORYLATION; REGULATORS	CDC25 dual-specificity phosphatases are essential regulators that activate cyclin-dependent kinases (CDKs) at critical stages of the cell cycle. In human cells, CDC25A and C are involved in the control of G1/S and G2/M respectively, whereas CDC25B is proposed to act both in S phase and G2/M. Evidence for an interaction between CDC25 phosphatases and members of the 14-3-3 protein family has been obtained in vitro and in vivo in several organisms. On the basis of the work performed with CDC25C, it has been proposed that phosphorylation is required to mediate the interaction with 14-3-3. Here we have examined the molecular basis of the interaction between CDC25B phosphatases and 14-3-3 proteins. We show that in the two-hybrid assay all three splice variants of CDC25B interact similarly and strongly with 14-3-3 eta, beta and zeta proteins, but poorly with epsilon and theta. In vitro, CDC25B interacts at a low level with 14-3-3 beta, epsilon, zeta, eta, and theta isoforms. This interaction is not increased upon phosphorylation of CDC25B by CHK1 and is not abolished by dephosphorylation. In contrast, a specific, strong interaction between CDC25B and 14-3-3 zeta and eta isoforms is revealed by a deletion of 288 residues in the amino-terminal region of CDC25B. This interaction requires the integrity of Ser 323, although it is independent of phosphorylation. Thus, interaction between 14-3-3 proteins and CDC25B is regulated in a manner that is different from that with CDC25C. We propose that, in addition to a low affinity binding site that is available for all 14-3-3 isoforms, post-translational modification of CDC25B in vivo exposes a high-affinity binding site that is specific for the zeta and eta 14-3-3 isoforms.	Univ Toulouse 3, CNRS, LBCMCP, F-31062 Toulouse, France; Ctr Univ Orsay, Inst Curie Rech, Lab Oncogenese REtrovirale & Mol, CNRS,UMR 146, F-91405 Orsay, France; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Chinese University of Hong Kong	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, LBCMCP, 118 Route Narbonne, F-31062 Toulouse, France.		BALDIN, Véronique/Y-8397-2019; Eychene, Alain/M-8838-2017; 韋妙宜教授, Mary Miu Yee Waye/A-9674-2008; DUCOMMUN, Bernard/B-3208-2008	BALDIN, Véronique/0000-0001-8523-0494; 韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917; EYCHENE, Alain/0000-0002-6818-7225; DUCOMMUN, Bernard/0000-0002-7126-8368				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; BALDIN V, 1999, PROGR CYCLE RES, V4; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lammer C, 1998, J CELL SCI, V111, P2445; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NAGATA A, 1991, NEW BIOL, V3, P959; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5144; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Xu X, 1996, J BIOL CHEM, V271, P5118; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	43	92	93	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1257	1265		10.1038/sj.onc.1203419	http://dx.doi.org/10.1038/sj.onc.1203419			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713667				2022-12-28	WOS:000085743800002
J	Seol, DW; Chen, QY; Zarnegar, R				Seol, DW; Chen, QY; Zarnegar, R			Transcriptional activation of the Hepatocyte Growth Factor receptor (c-met) gene by its ligand (Hepatocyte Growth Factor) is mediated through AP-1	ONCOGENE			English	Article						c-Met; AP-1; SP-1; hepatocyte growth factor	FUNCTIONAL-CHARACTERIZATION; EARLY RESPONSE; SCATTER FACTOR; EXPRESSION; PROTEIN-1; BINDING; HGF; JUN; MORPHOGENESIS; INDUCTION	Hepatocyte Growth Factor (HGF) exerts its biological effects via binding and activating a transmembrane protein tyrosine kinase receptor known as c-Met. Previous studies from our laboratory demonstrated that c-met gene expression is inducible by its own ligand (HGF), However, the molecular mechanism(s) involved in this process are unknown. The present study,vas carried out to address this question. Transfection of various c-met-CAT promoter constructs into the mouse hepatocellular carcinoma cell line Hepa 1-6 in combination with electrophoretic mobility shift assays (EMSA) identified the responsive element as an activated protein-1 (AP-1) binding site (TGAGTCA) within the c-mct core promoter region at position -158 to -152. The c-met AP-I element binds specifically to AP-I protein as, verified by supershift assays. EMSA studies and mutational analyses of the promoter region also revealed that the members of the Sp family of transcription factors (Sp-1 and Sp-3) bind to the c-met Sp-1 element (located at position -124) which is adjacent to the AP-1 site. We show that Sp binding dampens binding of AP-1 to its cognate site in the c-met promoter region. Stimulation of Hepa 1-6 cells with HGF resulted in a rapid and dramatic enhancement of the AP-1 binding activity as well as an overall increase in the le,el of AP-I protein. Cotransfection of AP-1 expression vectors (c-Fos plus c-Jun) with c-met promoter constructs resulted in stimulation of c-met promoter activity. We found that transactivation of the c-met promoter by AP-1 can be blocked by Curcumin, an inhibitor of AP-I, Moreover, we found that the induction of the endogenous c-met gene by HGF is inhibited by the addition of Curcumin, The results demonstrate that the HGF-induced transcription of the c-met gene by HGF is, at least in part, due to activation of the AP-1 pathway.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Room S-411A,BST S, Pittsburgh, PA 15261 USA.							Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Bell A, 1999, ONCOGENE, V18, P887, DOI 10.1038/sj.onc.1202379; BLADT F, 1995, NATURE, V373, P702; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Chen QY, 1997, HEPATOLOGY, V26, P59; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Gambarotta G, 1996, ONCOGENE, V13, P1911; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; JANSON L, 1991, GENE, V109, P297, DOI 10.1016/0378-1119(91)90625-L; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, CELL GROWTH DIFFER, V7, P1805; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kida M, 1999, J BIOL CHEM, V274, P6138, DOI 10.1074/jbc.274.10.6138; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEIDEN JM, 1989, J AUTOIMMUN, V2, P67, DOI 10.1016/0896-8411(89)90118-2; LIU YH, 1994, J BIOL CHEM, V269, P4152; Maffe A, 1998, EUR J MORPHOL, V36, P74; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIR E, 1994, HEPATOLOGY, V20, P955, DOI 10.1002/hep.1840200426; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	33	63	66	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1132	1137		10.1038/sj.onc.1203404	http://dx.doi.org/10.1038/sj.onc.1203404			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713700				2022-12-28	WOS:000085567800002
J	Evans, JA; Wagner, U; Santos, CM; Hennighausen, L				Evans, JA; Wagner, U; Santos, CM; Hennighausen, L			The interactive web-based histology atlas system	ONCOGENE			English	Article						histology; internet; breast; carcinogenesis; mouse models		Molecular pathways and mechanisms underlying human cancer are frequently investigated in animal models. Studies to identify and dissect molecular pathways include the discovery of genes and their subsequent analysis in transgenic and 'knock-out' mice. A critical aspect in such investigations is the evaluation of organ integrity and histology upon the alteration or inactivation of specific genes. Results from such studies are usually published in scientific journals. However, due to print space and costs the display of large high quality images is limited, Furthermore, the printed media does not permit an easy comparison of histological images published in different journals and different years; The Internet provides a tool for the timely and inexpensive dissemination of scientific data to the research community. However, its potential for the analysis of histological images has not been explored. Here we present a web-based interactive histology atlas (http://histology,nih,gov) that permits the retrieval of annotated, high-resolution histology images via the Internet, This histology atlas also takes advantage of the interactive nature of the Internet to support the communication between different research groups. As an outline forum this atlas provides the framework to evaluate and understand cancer pathology, and to develop a consensus between veterinary and human pathologists.	NIH, Ctr Informat Technol, Div Computat Biosci, Bethesda, MD 20892 USA; NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Evans, JA (corresponding author), NIH, Ctr Informat Technol, Div Computat Biosci, Bldg 12A,Room 1018, Bethesda, MD 20892 USA.			Wagner, Ulrike/0000-0002-3230-5058; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))			0	7	9	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		989	991		10.1038/sj.onc.1203279	http://dx.doi.org/10.1038/sj.onc.1203279			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713681				2022-12-28	WOS:000085796400003
J	Rose-Hellekant, TA; Sandgren, EP				Rose-Hellekant, TA; Sandgren, EP			Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice	ONCOGENE			English	Article						c-myc; mammary cancer; transforming growth factor alpha; transgenic mice	ACIDIC PROTEIN GENE; TGF-ALPHA; EPITHELIAL-CELLS; MOUSE MAMMARY; SYNERGISTIC INTERACTION; INDUCED TUMORIGENESIS; HA-RAS; EXPRESSION; GLAND; BREAST	The growth factor transforming growth factor alpha (TGF alpha) and the nuclear transcription factor c-myc often are overexpressed by human breast canter cells. To produce models of breast disease with these etiologies, mice were generated that carried TGF-alpha- or c-myc-encoding transgenes. Transgene targeting employed the whey acidic protein (WAP) gene promoter, which is expressed in pregnant and lactating mammary epithelial cells. Non-virgin WAP-TGF alpha transgenic mice displayed accelerated mammary development during pregnancy, delayed post-parturient mammary involution, a progressive increase in the number of hyperplastic alveolar nodules (HANs), and development of mammary carcinoma with a mean latency of 9 months. Non-virgin WAP-c-myc transgenic mice displayed accelerated mammary gland development during pregnancy and development of mammary carcinomas with a latency of 8 months, Bitransgenic mice carrying both WAP-TGF alpha and WAP-c-myc displayed a dramatic acceleration of tumor development. These models identify the overexpression of TGF alpha or c-myc as etiological factors in the development of mammary neoplasia and demonstrate the increased severity of disease when both molecular alterations are present in the same cell.	Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sandgren, EP (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, 2015 Linden Dr W, Madison, WI 53706 USA.				NCI NIH HHS [R01-CA64843] Funding Source: Medline; NCRR NIH HHS [K01-RR00145] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000145] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; Berns EMJJ, 1996, GENE CHROMOSOME CANC, V16, P170, DOI 10.1002/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.0.CO;2-W; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Christensen ME, 1996, HISTOCHEM CELL BIOL, V105, P391, DOI 10.1007/BF01463660; Davies BR, 1999, AM J PATHOL, V155, P303, DOI 10.1016/S0002-9440(10)65124-3; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DUBIK D, 1996, MAMMARY TUMOR CELL C, P171; HALTER SA, 1992, AM J PATHOL, V140, P1131; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JHAPPAN C, 1990, CELL, V61, P1121; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lee D C, 1992, Cancer Treat Res, V63, P233; LEE DC, 1995, PHARMACOL REV, V47, P51; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Robinson GW, 1996, DEV DYNAM, V206, P159, DOI 10.1002/(SICI)1097-0177(199606)206:2<159::AID-AJA5>3.0.CO;2-H; Rudland PS, 1995, BIOMED PHARMACOTHER, V49, P389, DOI 10.1016/0753-3322(96)82676-X; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Santarelli R, 1996, ONCOGENE, V12, P495; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH GH, 1995, AM J PATHOL, V147, P1081; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	34	35	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1092	1096		10.1038/sj.onc.1203350	http://dx.doi.org/10.1038/sj.onc.1203350			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713695				2022-12-28	WOS:000085796400017
J	Ishidate, T; Matsumine, A; Toyoshima, K; Akiyama, T				Ishidate, T; Matsumine, A; Toyoshima, K; Akiyama, T			The APC-hDLG complex negatively regulates cell cycle progression from the G0/G1 to S phase	ONCOGENE			English	Article						APC; hDLG; cell cycle; tumor suppressor	TUMOR-SUPPRESSOR PROTEIN; WNT SIGNALING PATHWAY; ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; HUMAN HOMOLOG; DISCS LARGE; POSTSYNAPTIC DENSITY; GENE-PRODUCT; INTERACTS; AXIN	The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis and in many sporadic colorectal tumors. The carboxyl-terminal S/TXV motif of the APC gene product interacts with the PDZ domain of hDLG, the human homolog of the Drosophila lethal (I) discs large-1 (dlg) tumor suppressor. In the present study, we found that overexpression of hDLG suppresses cell proliferation by blocking cell cycle progression from the G0/G1 to S phase. This inhibition of cell cycle progression was abolished when the PDZ, SH3 or guanylate kinase-like domain of hDLG was mutated. Moreover, overexpression of these mutant hDLGs partially interfered with the cell cycle blocking activity of APC. Consistent with this result, mutant APC lacking the S/TXV motif exhibited weaker cell cycle blocking activity than the intact APC, These results suggest that APC-hDLG complex formation plays an important role in transducing the APC cell cycle blocking signal.	Univ Tokyo, Dept Mol & Genet Informat, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan; Osaka Univ, Dept Oncogene Res, Inst Microbial Dis, Suita, Osaka 565, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari Ku, Osaka 537, Japan	University of Tokyo; Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases	Akiyama, T (corresponding author), Univ Tokyo, Dept Mol & Genet Informat, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pedemonte S, 1998, GENE CHROMOSOME CANC, V22, P257, DOI 10.1002/(SICI)1098-2264(199808)22:4<257::AID-GCC1>3.0.CO;2-U; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867	36	155	158	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					365	372		10.1038/sj.onc.1203309	http://dx.doi.org/10.1038/sj.onc.1203309			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656683				2022-12-28	WOS:000084873700006
J	Lee, SG; Rho, HM				Lee, SG; Rho, HM			Transcriptional repression of the human p53 gene by hepatitis B viral X protein	ONCOGENE			English	Article						HBx; repression; human p53 promoter; E-box element; c-Myc	HELIX-LOOP-HELIX; TUMOR-SUPPRESSOR GENE; PROMOTER ACTIVITY; VIRUS; BINDING; ELEMENT; LIVER; REPLICATION; EXPRESSION; SEQUENCE	Hepatitis B viral X protein (HBx) and the human p53 protein (p53) have been known as a transactivator and as a tumor suppressor, respectively, These two proteins have also been known to interact with each other to neutralize their authentic functions and the p53 represses the E-IBV enhancer/X promoter activity. Here we report that the promoter activity of the human p53 gene was strongly repressed by the HBx using the chloramphenicol acetyl transferase (CAT) assay, Analyses of serial deletion, site-directed mutagenesis and the heterologous promoter system showed that the site responsible for the repression was the E-box element in the promoter of the p53 gene, In addition, HBx as expected also repressed the activation of the p53 promoter by c-Myc through the E-box element, Northern blot analyses also showed that the expression of the p53 gene in the HepG2-K8 cell line, which expresses HBV genes including HBx, was much more repressed than that of the control cell HepG2. These results with previous data suggest that the shift of the reciprocal inhibitory activities at the levels of protein-protein interaction and transcription between HBx and p53 may play a decisive role in the HBV-related hepatocarcinogenesis.	Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Cell Differentiat, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Rho, HM (corresponding author), Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea.		Lee, Seok-Geun/B-3408-2011	Lee, Seok-Geun/0000-0002-0060-5777				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; CASELMANN WH, 1996, ADV VIRUS RES, V47, P303; Choi BH, 1999, J BIOL CHEM, V274, P2858, DOI 10.1074/jbc.274.5.2858; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM SH, 1992, J GEN VIROL, V73, P2421, DOI 10.1099/0022-1317-73-9-2421; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Ray RB, 1997, J BIOL CHEM, V272, P10983; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	32	105	122	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					468	471		10.1038/sj.onc.1203312	http://dx.doi.org/10.1038/sj.onc.1203312			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656696				2022-12-28	WOS:000084873700019
J	Micouin, A; Wietzerbin, J; Steunou, V; Martyre, MC				Micouin, A; Wietzerbin, J; Steunou, V; Martyre, MC			p95(vav) associates with the type I interferon (IFN) receptor and contributes to the antiproliferative effect of IFN-alpha in megakaryocytic cell lines	ONCOGENE			English	Article						vav; type IIFN receptor; megakaryocytic cells; IFN antiproliferative effect	VAV PROTOONCOGENE PRODUCT; PROTEIN-TYROSINE KINASE; HEMATOPOIETIC-CELLS; T-CELL; MYELOID METAPLASIA; BETA RECEPTOR; STEEL FACTOR; B-CELLS; PHOSPHORYLATION; EXPRESSION	The vav proto-oncogene product is a 95 kDa protein predominantly expressed in hematopoietic cells. Vav presents a wide range of functional domains, including structural domains known to be involved in signal transduction, Triggering of various cytokine receptors among which type I interferon receptor induces a rapid and transient tyrosine phosphorylation of p95(vav). Nevertheless, the biological functions of p95(vav) are still unclear, This report is the first documentation on the physical association of p95(vav) With both alpha and beta type I interferon receptor chains, as demonstrated by co-immunoprecipitation and Western blot analysis in megakaryocytic cells (Dami and UT7), This interaction is increased by interferon-alpha/beta stimulation, Moreover, p95(vav) phosphorylated subsequently to type I interferon treatment, is translocated in the nucleus; a concomitant increase of its association with the regulatory subunit of the nuclear DNA-dependent protein kinase, KU-70 is observed in the nucleus. To determine whether p95(vav) participates in the biological response to type I interferons, we studied the effects of non modified Vav oligodeoxynucleotides on the antiproliferative effect of interferon-alpha on megakaryocytic cells, By this oligodeoxynucleotide strategy, we show that p95(vav) contributes greatly to the cell proliferation inhibition induced by type I IFN.	Inst Curie, U365 INSERM, Sect Rech, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Micouin, A (corresponding author), Inst Curie, U365 INSERM, Sect Rech, 26 Rue Ulm, F-75231 Paris, France.							ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CARLOSTELLA C, 1987, BLOOD, V70, P1014; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COHEN B, 1995, MOL CELL BIOL, V15, P4208; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; GREENBERG SM, 1988, BLOOD, V72, P1968; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HU P, 1993, BIOESSAYS, V15, P179, DOI 10.1002/bies.950150306; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1995, CRIT REV ONCOGEN, V6, P82; KOMATSU N, 1991, CANCER RES, V51, P341; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Luger SM, 1996, BLOOD, V87, P1326, DOI 10.1182/blood.V87.4.1326.bloodjournal8741326; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MARTYRE MC, 1994, BRIT J HAEMATOL, V86, P244, DOI 10.1111/j.1365-2141.1994.tb04722.x; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; REEVES WH, 1994, MANUAL BIOL MARKERS; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Romero F, 1996, MOL CELL BIOL, V16, P37; Romero F, 1998, J BIOL CHEM, V273, P5923, DOI 10.1074/jbc.273.10.5923; SACCHI S, 1995, LEUKEMIA LYMPHOMA, V19, P13, DOI 10.3109/10428199509059658; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Williams EA, 1997, J CHEM TECHNOL BIOT, V70, P9; WU J, 1995, MOL CELL BIOL, V15, P4337; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	43	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					387	394		10.1038/sj.onc.1203314	http://dx.doi.org/10.1038/sj.onc.1203314			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656686				2022-12-28	WOS:000084873700009
J	Martinez, LA; Chen, Y; Pavone, A; Fischer, SM; Conti, CJ				Martinez, LA; Chen, Y; Pavone, A; Fischer, SM; Conti, CJ			Deregulated expression of cyclin D1 overrides antimitogenic signals	ONCOGENE			English	Article						cell cycle; cyclin D1; keratinocytes; transforming growth factor beta 1	MOUSE SKIN CARCINOGENESIS; EPITHELIAL-CELL LINE; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; RETINOBLASTOMA PROTEIN; GROWTH-INHIBITION; BREAST-CANCER; ECTOPIC EXPRESSION; P27(KIP1) PROTEIN; DEPENDENT KINASES	Several types of epithelial neoplasms exhibit high expression of transforming growth factor beta 1 (TGF(beta)-1), indicating that they have acquired tolerance to this normally growth inhibitory cytokine, Since cyclin D1 is expressed at high levels in murine skin tumors coincident with high levels of TGF(beta)-1 expression, we hypothesized that cyclin D1 may override TGF(beta)-1 induced growth arrest, We observed that in primary murine keratinocytes treated with TGF(beta)-1, cyclin D1 is quickly suppressed at both the mRNA and protein level. Since changes in other cell cycle proteins occur at a later time during TGF,-1 treatment, the early suppression of cyclin D1 suggests that this gene is a critical target for TGF(beta)-1 growth suppression, Using primary keratinocytes from transgenic mice that overexpress cyclin D1 (K5-D1 mice), we observed partial resistance to TGF(beta)-1 growth inhibition. This resistance involves changes in the cyclin/ cdk/inhibitor complexes rather than differences in expression of the TGF(beta) receptors or signaling. Comparison of cdk associated kinase activity between wild-type and K5-D1 cells shows differential regulation, We conclude that deregulated cyclin D1 and subsequent alterations in cell cycle machinery provides keratinocytes the ability to at least partially override growth inhibitory signals.	Univ Texas, MD Andersn Canc Res Ctr, Pk Res Div, Smithville, TX 78957 USA; Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29425 USA	University of Texas System; UTMD Anderson Cancer Center; Medical University of South Carolina	Conti, CJ (corresponding author), Univ Texas, MD Andersn Canc Res Ctr, Pk Res Div, Pk Rd 1-C, Smithville, TX 78957 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, R01CA042157, R01CA034443] Funding Source: NIH RePORTER; NCI NIH HHS [CA42157, CA34443, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; Arber N, 1996, ONCOGENE, V12, P1903; BIANCHI AB, 1993, ONCOGENE, V8, P1127; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Ciaparrone M, 1998, CANCER RES, V58, P114; Doki Y, 1997, CARCINOGENESIS, V18, P1139, DOI 10.1093/carcin/18.6.1139; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILMUS J, 1994, ONCOGENE, V9, P3627; Fowlis DJ, 1996, CELL GROWTH DIFFER, V7, P679; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; JIANG W, 1993, ONCOGENE, V8, P3447; KO TC, 1995, ONCOGENE, V10, P177; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PATAMALAI B, 1994, MOL CARCINOGEN, V9, P220, DOI 10.1002/mc.2940090406; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rundhaug JE, 1997, MOL CARCINOGEN, V19, P122, DOI 10.1002/(SICI)1098-2744(199707)19:2<122::AID-MC7>3.0.CO;2-H; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572	40	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					315	322		10.1038/sj.onc.1203301	http://dx.doi.org/10.1038/sj.onc.1203301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645011				2022-12-28	WOS:000084844400018
J	Lakin, ND; Jackson, SP				Lakin, ND; Jackson, SP			Regulation of p53 in response to DNA damage	ONCOGENE			English	Review						p53; DNA damage; checkpoints; phosphorylation; acetylation; PI-3 kinases	NIJMEGEN BREAKAGE SYNDROME; DEPENDENT PROTEIN-KINASE; CYCLE CHECKPOINT PATHWAY; TUMOR-SUPPRESSOR PROTEIN; C-TERMINAL DOMAIN; ATAXIA-TELANGIECTASIA GENE; P53-DEPENDENT G(1) ARREST; IONIZING-RADIATION; TRANSCRIPTIONAL ACTIVATION; BINDING FUNCTION	Activation of p53 can occur in response to a number of cellular stresses, including DNA damage, hypoxia and nucleotide deprivation. Several forms of DNA damage have been shown to activate p53, including those generated by ionising radiation (IR), radio-mimetic drugs, ultraviolet Light (UV) and chemicals such as methyl methane sulfonate (MMS). Under normal conditions, p53 levels are maintained at a low state by virtue of the extremely short-half life of the polypeptide. In addition to this, p53 normally exists in an largely inactive state that is relatively inefficient at binding to DNA and activating transcription. Activation of p53 in response to DNA damage is associated with a rapid increase in its levels and with an increased ability of p53 to bind DNA and mediate transcriptional activation. This then leads to the activation of a number of genes whose products trigger cell-cycle arrest, apoptosis, or DNA repair. Recent work has suggested that this regulation is brought about largely through DNA damage triggering a series of phosphorylation, dephosphorylation and acetylation events on the p53 polypeptide, Here, we discuss the nature of these modifications, the enzymes that bring them about, and how changes in p53 modification lead to p53 activation.	Univ Cambridge, Wellcome Trust Canc Res Campaign, Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	Jackson, SP (corresponding author), Univ Cambridge, Wellcome Trust Canc Res Campaign, Inst Canc & Dev Biol, Tennis Court Rd, Cambridge CB2 1QR, England.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; AJIMURA M, 1993, GENETICS, V133, P51; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Candeias SM, 1997, BIOCHIMIE, V79, P607, DOI 10.1016/S0300-9084(97)82010-X; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen P, 1999, ONCOGENE, V18, P249, DOI 10.1038/sj.onc.1202257; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DVIR A, 1993, J BIOL CHEM, V268, P10440; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goldman SC, 1996, AM J PATHOL, V148, P1381; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang LC, 1996, CANCER RES, V56, P2940; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jackson SP, 1996, CANCER SURV, V28, P261; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jongmans W, 1996, ONCOGENE, V13, P1133; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LAKIN ND, 1999, IN PRESS ONCOGENE; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuura K, 1998, BIOCHEM BIOPH RES CO, V242, P602, DOI 10.1006/bbrc.1997.7924; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Price BD, 1996, CANCER RES, V56, P246; PRICE BD, 1995, ONCOGENE, V11, P73; PRICE BD, 1993, ONCOGENE, V8, P3055; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rathmell WK, 1997, CANCER RES, V57, P68; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scolnick DM, 1997, CANCER RES, V57, P3693; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; Stumm M, 1997, AM J HUM GENET, V60, P1246; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yamazaki V, 1998, CANCER RES, V58, P2316; ZHANG W, 1994, CANCER RES, V54, P4448	141	737	758	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	1999	18	53					7644	7655		10.1038/sj.onc.1203015	http://dx.doi.org/10.1038/sj.onc.1203015			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618704				2022-12-28	WOS:000084634500003
J	Vrana, JA; Decker, RH; Johnson, CR; Wang, Z; Jarvis, WD; Richon, VM; Ehinger, M; Fisher, PB; Grant, S				Vrana, JA; Decker, RH; Johnson, CR; Wang, Z; Jarvis, WD; Richon, VM; Ehinger, M; Fisher, PB; Grant, S			Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-X-L, c-Jun, and p21(CIP1), but independent of p53	ONCOGENE			English	Article						SAHA; HMBA; apoptosis; differentiation; leukemia; p53	HISTONE DEACETYLASE INHIBITORS; DOMINANT-NEGATIVE MUTANT; RETINOBLASTOMA PROTEIN; TRICHOSTATIN-A; CYCLE ARREST; HL-60 CELLS; DNA-DAMAGE; DIFFERENTIATION; KINASE; EXPRESSION	Determinants of differentiation and apoptosis in myelomonocytic leukemia cells (U937) exposed to the novel hybrid polar compound SAHA. (suberoylanilide hydroxamic acid) have been examined, In contrast to hexamethylenbisacetamide (HMBA), SAHA-related maturation was limited and accompanied by marked cytoxicity. SAHA-mediated apoptosis occurred within the G(0)G(1) and S phase populations, and,vas associated with decreased mitochondrial membrane potential, caspase-3 activation, PARP degradation, hypophosphorylation/cleavage of pRB, and down-regulation of c-Myc, c-Myb, and B-Myb. Enforced expression of Bcl-2 or Bcl-x(L), inhibited SAHA-induced apoptosis, but only modestly potentiated differentiation. While SAHA induced the cyclin-dependent kinase inhibitor p21(CIP1), antisense ablation of this CDKI increased, rather than decreased, SAHA-related lethality, In contrast, conditional expression of mild-type p53 failed to modify SAHA actions, but markedly potentiated HMBA-induced apoptosis. Finally, SAHA modestly increased expression/activation of the stress-activated protein kinase (SAPK/JNK); moreover, SAHA-related lethality was partially attenuated by a dominant-negative c-jun mutant protein (TAM67). SAHA did not stimulate mitogen-activated protein kinase (MAPK), nor was Lethality diminished by the specific MEK/MAPK inhibitor PD98059. These findings indicate that SAHA potently induces apoptosis in human leukemia cells via a pathway that is p53-independent but at least partially regulated by Bcl-2/Bcl-x(L), p21(CIP1), and the c-Jun/AP-1 signaling cascade.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol, Richmond, VA 23298 USA; Mem Sloan Kettering Canc Ctr, Dept Dev Cell Biol & Genet, New York, NY 10021 USA; Univ Lund Hosp, Res Dept 2, S-22185 Lund, Sweden; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Memorial Sloan Kettering Cancer Center; Lund University; Skane University Hospital; Columbia University; Columbia University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.		Ehinger, Mats/H-8457-2016	Ehinger, Mats/0000-0003-2342-1679	NATIONAL CANCER INSTITUTE [R03CA077141, R01CA063753, P01CA072955] Funding Source: NIH RePORTER; NCI NIH HHS [CA77141, CA72955, CA63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREEFF M, 1992, BLOOD, V80, P2604; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; BROWN PH, 1994, ONCOGENE, V9, P791; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Ehinger M, 1996, BLOOD, V87, P1064, DOI 10.1182/blood.V87.3.1064.bloodjournal8731064; Franklin CC, 1995, ONCOGENE, V11, P2365; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Grant S, 1996, EXP CELL RES, V228, P65, DOI 10.1006/excr.1996.0300; Grant S, 1996, CELL GROWTH DIFFER, V7, P603; HASS R, 1991, CELL GROWTH DIFFER, V2, P541; JIANG HP, 1994, ONCOGENE, V9, P3397; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; Medina V, 1997, CANCER RES, V57, P3697; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NAUMOVSKI L, 1994, BLOOD, V83, P2261; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; OHTA H, 1995, CANCER RES, V55, P691; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; SELVAKUMARAN M, 1994, BLOOD, V84, P1036; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Thompson MA, 1998, CANCER RES, V58, P5168; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vrana JA, 1998, DIFFERENTIATION, V63, P33, DOI 10.1046/j.1432-0436.1998.6310033.x; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang SJ, 1997, MOL PHARMACOL, V52, P1000, DOI 10.1124/mol.52.6.1000; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen A, 1998, CANCER RES, V58, P3163	42	255	284	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7016	7025		10.1038/sj.onc.1203176	http://dx.doi.org/10.1038/sj.onc.1203176			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597302				2022-12-28	WOS:000083901900008
J	Okada-Ban, M; Moens, G; Thiery, JP; Jouanneau, J				Okada-Ban, M; Moens, G; Thiery, JP; Jouanneau, J			Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells	ONCOGENE			English	Article						FGF-2; nuclear localization; tumor progression; lung metastasis	MOLECULAR-WEIGHT FORMS; IN-VIVO; TRANSCRIPTION; PROLIFERATION; TRANSLATION; TRANSITION; EXPRESSION; PHENOTYPE; BINDING; FAMILY	The tumorigenic and metastatic properties of rat bladder carcinoma NET-II cells transfected with a cDNA encoding the 24 kD nuclear isoform of human fibroblast growth factor-2 (FGF-2) were analysed and compared with those cells producing the 18 kD cytoplasmic isoform FGF-2. In transfected clones, 24 kD FGF-2 was found in the nucleus, and no FGF-2 was secreted. RT-PCR analysis shelved no upregulation of FGF-2-specific receptor FGFR2c expression in these proliferating transfected cells. A shorter latency period for in vivo tumor formation and abundant spontaneous lung metastases were only seen if nuclear FGF-2-producing cells were injected subcutaneously into nude mice. Intravenous injection of 24 kD FGF-2-producing cells led to extensive experimental lung metastases whereas injection of control NET-II cells or 18 kD FGF-a-producing cells did not. As FGF-2-producing cells have no specific FGF-2 receptors, our results suggest that the 24 kD FGF-2 has nuclear targets, and activates metastatic property of carcinoma cells via a mechanism other than the conventional FGF receptor-mediated signaling pathway.	Inst Curie, CNRS, UMR144, Sect Rech, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Okada-Ban, M (corresponding author), Inst Curie, CNRS, UMR144, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COLTRINI D, 1995, CANCER RES, V55, P4729; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; ESTIVAL A, 1993, CANCER RES, V53, P1182; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALANDRIS A, 1993, GROWTH FACTORS, V8, P49, DOI 10.3109/08977199309029134; Hill DJ, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046926; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Levine JE, 1995, NEUROIMMUNOMODULAT, V2, P290, DOI 10.1159/000097208; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; PASUMARTHI K, 1995, CIRC RES, V78, P126; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENCO M, 1990, J CELL PHYSL, V144, P108; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; TOSHIMA K, 1971, J NATL CANCER I, V47, P979	33	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6719	6724		10.1038/sj.onc.1203092	http://dx.doi.org/10.1038/sj.onc.1203092			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597279				2022-12-28	WOS:000083792000013
J	Murphy, KL; Kittrell, FS; Gay, JP; Jager, R; Medina, D; Rosen, JM				Murphy, KL; Kittrell, FS; Gay, JP; Jager, R; Medina, D; Rosen, JM			Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice	ONCOGENE			English	Article						Bcl-2; mammary tumorigenesis; DMBA; transgenic mice	CELL-DEATH; EPITHELIAL-CELLS; DNA-DAMAGE; MUTANT P53; APOPTOSIS; TUMORIGENESIS; OVEREXPRESSION; GLAND; PROLIFERATION; MORPHOGENESIS	Bcl-2 is known to have dual antiproliferative and antiapoptotic roles. Overexpression of Bcl-2 in the mammary gland using a whey acidic protein (WAP) promoter-driven Bcl-2 transgene inhibits apoptosis in the mammary gland during pregnancy, lactation, and involution, and also counteracts apoptosis induced by overexpression of a mutant p53 transgene (WAP-p53 172 R-L), WAP-Bcl-2 mice and nontransgenic controls were treated with the carcinogen dimethylbenz(a)anthracene (DMBA), Surprisingly, the nontransgenic mice developed mammary tumors with decreased latency. Tumors arising in WAP-Bcl-2 mice displayed substantially reduced levels of proliferation relative to those seen in nontransgenic mice (P<0.015), perhaps resulting in the observed increase in tumor latency following carcinogen treatment. This WAP-Bcl-2 mouse tumor model reflects the situation seen in some human breast cancers overexpressing Bcl-2, where expression of Bcl-2 has been shown to correlate with a lower proliferative index in tumors.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Baylor College of Medicine; Baylor College of Medicine; Helmholtz Association; Karlsruhe Institute of Technology	Rosen, JM (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Jager, Richard/B-9478-2009	Jager, Richard/0000-0002-1623-1917	NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline; NIGMS NIH HHS [GM08231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; Friedrich K, 1995, PATHOL RES PRACT, V191, P1114, DOI 10.1016/S0344-0338(11)80656-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; LunaMore S, 1996, PATHOL RES PRACT, V192, P27, DOI 10.1016/S0344-0338(96)80126-9; MARIN MC, 1994, ONCOGENE, V9, P3107; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; Merlo GR, 1997, CELL GROWTH DIFFER, V8, P251; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Siziopikou KP, 1996, CANCER, V77, P499, DOI 10.1002/(SICI)1097-0142(19960201)77:3<499::AID-CNCR11>3.0.CO;2-#; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TEIXEIRA C, 1995, CANCER RES, V55, P3902	23	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6597	6604		10.1038/sj.onc.1203099	http://dx.doi.org/10.1038/sj.onc.1203099			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597264				2022-12-28	WOS:000083709200024
J	Tamura, T; Mancini, A; Joos, H; Koch, A; Hakim, C; Dumanski, J; Weidner, KM; Niemann, H				Tamura, T; Mancini, A; Joos, H; Koch, A; Hakim, C; Dumanski, J; Weidner, KM; Niemann, H			FMIP, a novel Fms-interacting protein, affects granulocyte/macrophage differentiation	ONCOGENE			English	Article						novel c-Fms-interacting protein; M-CSF-receptor; granulocyte/macrophage differentiation; lineage control	COLONY-STIMULATING FACTOR; M-CSF RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; ONCOGENE PRODUCT; PROGENITOR CELLS; BINDING-SITE; SH2 DOMAINS; GM-CSF; ACTIVATION	Hematopoietic cell growth, differentiation, and commitment to a restricted lineage are guided by a set of cytokines acting exclusively on cells expressing the corresponding cytokine receptor. The macrophage colony stimulating factor (M-CSF, also termed CSF-1) and its cognate receptor, the tyrosine kinase c-Fms, are essential for monocyte and macrophage development. The underlying molecular mechanism, however, is poorly understood. Here we identified a novel Fms-interacting protein (FMIP, MW 78 kDa) which binds transiently via its N-terminal 144 residues to the cytoplasmic domain of activated Fms-molecules. Binding of FMIP was paralleled by rapid tyrosine phosphorylation within the binding domain which drastically reduced its ability to associate with Fms. Binding was specific as evidenced by co-immunoprecipitation and association with recombinant GST-Fms fusion proteins. No binding was observed with the tyrosine phosphorylated cytoplasmic domains of c-Kit, TrkA, c-Met, and the insulin receptor. The role of FMIP in hematopoietic differentiation was studied in the bipotential myeloid progenitor cell line, FDC-P1Mac11. Overexpression of FMIP prevented M-CSF induced macrophage differentiation. Instead, cells differentiated into granulocytes. Our data suggest that the level of FMIP expression could form a threshold that decides about differentiation either into macrophages or into granulocytes.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Karolinska Inst, Dept Mol Med, S-17176 Stockholm, Sweden; Roche Pharma Res Werk Penzberg, D-82372 Penzberg, Germany	Hannover Medical School; Karolinska Institutet	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl-Neuberg-Str 1, D-30623 Hannover, Germany.			Dumanski, Jan Piotr/0000-0002-1489-1452				Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CROSS MA, 1997, CIBA F SYMP, P3; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; Helftenbein G, 1996, ONCOGENE, V12, P931; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; JUST U, 1993, GROWTH FACTORS, V9, P291, DOI 10.3109/08977199308991589; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Novak U, 1996, ONCOGENE, V13, P2607; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WHETTON AD, 1994, J CELL BIOL, V125, P651, DOI 10.1083/jcb.125.3.651; XIE YG, 1993, HUM MOL GENET, V2, P1361; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	41	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6488	6495		10.1038/sj.onc.1203062	http://dx.doi.org/10.1038/sj.onc.1203062			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597251				2022-12-28	WOS:000083709200011
J	Kimmelman, AC; Osada, M; Chan, AML				Kimmelman, AC; Osada, M; Chan, AML			R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells	ONCOGENE			English	Article						R-Ras3; M-Ras; PI3-K; Akt; survival	NERVE GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; NEURONAL SURVIVAL; NEURITE OUTGROWTH; ONCOGENIC RAS; R-RAS; TRANSFORMATION; KINASE; TARGET	The GTP-binding protein, R-Ras3/M-Ras, is a novel member of the Ras subfamily of GTPases which shows highest sequence similarity to the TC21 gene. R-Ras3 is highly expressed in both human and mouse brain and ectopic expression of a constitutively active mutant of R-Ras3 induces cellular transformation in NIH3T3 cells. To gain further insight into the normal cellular function of R-Ras3, we examined the ability of R-Ras3 in activating several known intracellular signaling cascades. We observed that R-Ras3 is a relatively weak activator of the mitogen-activated protein kinase/extracellular-signal-regulated kinases (MAPK/ERKs) when compared to the EI-Ras oncogene. On the contrary, both R-Ras3 and H-Ras activated the Jun N-terminal kinase (JNK) to a similar extent, Under similar experimental conditions, R-Ras3 significantly stimulated one of the phosphatidylinositol 3-kinase (PI3-K) downstream substrates, Akt/PKB/RAC (Akt), which has been extensively implicated in mediating cell survival signaling. The activation of Akt by R-Ras3 was most likely to be PI3-K-dependent since this biochemical event was blocked by the pharmacological inhibitors, Wortmannin and LY294002, as well as by a dominant negative mutant of PI3-K. More importantly, R-Ras3 affinity-precipitated PI3-K from cell extracts in a GTP-dependent manner, and associated lipid kinase activity,vas readily detectable in R-Ras3 immune complexes. The biological significance of R-Ras3 in inducing Akt kinase activity is evidenced by the ability of an activated R-Ras3 to confer cell survival in the rat pheochromocytoma cell line, PC12, As expected, this biological activity of R-Ras3 was also abrogated by the addition of LY294002. Thus, R-Ras3 represents a novel G-protein which may play a role in cell survival of neural-derived cells.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Chan, AML (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.		Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464	NATIONAL CANCER INSTITUTE [R01CA066654, R29CA078509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059771] Funding Source: NIH RePORTER; NCI NIH HHS [CA78509, CA66654] Funding Source: Medline; NIMH NIH HHS [MH59771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; BOS JL, 1989, CANCER RES, V49, P4682; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAN AML, 1994, P NATL ACAD SCI USA, V82, P2394; COLLINS F, 1991, J NEUROSCI, V11, P2582; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, ONCOGENE, V9, P3281; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Deshmukh M, 1997, MOL PHARMACOL, V51, P897, DOI 10.1124/mol.51.6.897; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HUANG Y, 1995, ONCOGENE, V11, P1255; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LACAL JC, 1986, MOL CELL BIOL, V6, P1002, DOI 10.1128/MCB.6.4.1002; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SAEZ R, 1994, ONCOGENE, V9, P2977; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	48	41	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2014	2022		10.1038/sj.onc.1203530	http://dx.doi.org/10.1038/sj.onc.1203530			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803462				2022-12-28	WOS:000086613200005
J	Brembeck, FH; Opitz, OG; Libermann, TA; Rustgi, AK				Brembeck, FH; Opitz, OG; Libermann, TA; Rustgi, AK			Dual function of the epithelial specific ets transcription factor, ELF3, in modulating differentiation	ONCOGENE			English	Article						ets transcription factors; epithelial cell; differentiation	DNA-BINDING; PROTEIN DOMAINS; GENE-EXPRESSION; FAMILY PROTEINS; ACTIVATION; PROMOTER; MEMBER; PHOSPHORYLATION; PROTOONCOGENE; KERATIN-4	The ets family of transcription factors comprises many members which contribute to diverse cellular functions that vary depending upon the cell- and tissue-type context, Recently, different groups have identified a novel member of the ets family that is epithelial-specific. Variably called ESE-1, ERT, jen, ESX, this gene is designated currently as ELF3, In order to understand transcriptional regulatory mechanisms mediated by ELF3, we investigated its effect on the human keratin 4 gene promoter based upon the role of keratin 4 in early differentiation of the esophageal squamous epithelium, Interestingly, ELF3 suppressed basal keratin 4 promoter activity in both esophageal and cervical epithelial cancer cell Lines, a novel result, while simultaneously activating the late-differentiation linked SPRR2A promoter. Furthermore, serial deletion constructs of the keratin 4 promoter continued to be suppressed by ELF3, a phenomenon that was only partially rescued by ELF3 ets domain mutants, but completely abrogated by deletion of the ELF3 pointed domain. These results suggest that ELF3 may have dual functions in the transcriptional regulation of genes involved in squamous epithelial differentiation. One of these functions may not be exclusively mediated through DNA binding in the context of transcriptional suppression of the keratin 4 promoter.	Univ Penn, Div Gastroenterol, Philadelphia, PA 19014 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19014 USA; Univ Penn, Dept Genet, Philadelphia, PA 19014 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rustgi, AK (corresponding author), Univ Penn, Div Gastroenterol, 415 Curie Blvd,600A CRB, Philadelphia, PA 19014 USA.		Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179	NIDCR NIH HHS [P01-DE12467] Funding Source: Medline; NIDDK NIH HHS [R01-DK53377, P30 DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053377, P30DK050306] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Arlotta P, 1997, J BIOL CHEM, V272, P29904, DOI 10.1074/jbc.272.47.29904; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Buttice G, 1996, ONCOGENE, V13, P2297; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; Ness SL, 1998, J BIOL CHEM, V273, P23904, DOI 10.1074/jbc.273.37.23904; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; Opitz OG, 1998, J BIOL CHEM, V273, P23912, DOI 10.1074/jbc.273.37.23912; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REEVES R, 1990, J BIOL CHEM, V265, P8573; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WERNERT N, 1992, AM J PATHOL, V140, P119	33	46	49	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1941	1949		10.1038/sj.onc.1203441	http://dx.doi.org/10.1038/sj.onc.1203441			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773884				2022-12-28	WOS:000086424300010
J	Ng, SW; Yiu, GK; Liu, Y; Huang, LW; Palnati, M; Jun, SH; Berkowitz, RS; Mok, SC				Ng, SW; Yiu, GK; Liu, Y; Huang, LW; Palnati, M; Jun, SH; Berkowitz, RS; Mok, SC			Analysis of p73 in human borderline and invasive ovarian tumor	ONCOGENE			English	Article						p53-related gene; tumor suppressor; gene expression; ovarian carcinoma; loss of heterozygosity	P53 HOMOLOG; EPITHELIAL TUMORS; CELL-LINES; GENE; MUTATION; EXPRESSION; PROTEIN; CARCINOMA; CANCER; NEUROBLASTOMA	p73 is a novel gene that has high sequence homology and similar gene structure to the tumor suppressor gene p53, We analysed p73 in seven ovarian carcinoma cell Lines and a total of 63 human borderline and invasive ovarian tumor samples. Loss of heterozygosity at this locus was observed in 50% of invasive tumors but in none of the borderline tumors. Biallelic expression of the gene was observed in the heterozygous tumor tissues. Direct sequencing and single-strand conformation polymorphism analyses of the p73 cDNA sequence homologous to the highly mutatable region of p53 did not reveal any mutations. When compared to the primary cultures of normal human ovarian surface epithelial cells and immortalized cell lines, four of the seven ovarian carcinoma cell lines, 71% of the invasive tumors, and 92% of the borderline tumor tissues express elevated levels of p73 transcript. Except for the OVCA3 cell line, Western blot analysis of the nuclear extracts prepared from the cell lines showed concordant levels of p73 protein. Our analysis also demonstrated the expression of a spliced variant of p73 transcript with the omission of exon 2 solely in the cancer cell lines and invasive tumor tissues. This exon 2-spliced transcript would give rise to a truncated p73 protein without the N-terminal transactivation domain. In reminiscence of the dominant negative phenotype of the N-terminal truncated variants of another p53-related gene, p63, the expression of the truncated p73 variant form in ovarian tumors may play an important role in the pathogenesis of ovarian cancer.	Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Ng, SW (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, 221 Longwood Ave, Boston, MA 02115 USA.		Yiu, Glenn/AAF-2858-2020		NCI NIH HHS [CA70216, R01CA69453, R01CA69291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070216, R01CA069291, R01CA069453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; FAJAC A, 1995, INT J CANCER, V64, P146, DOI 10.1002/ijc.2910640213; FRANKEL RH, 1992, CANCER RES, V52, P1427; GOLENBERG EM, 1993, MOL PHYLOGENET EVOL, V2, P52, DOI 10.1006/mpev.1993.1006; Hagiwara K, 1999, CANCER RES, V59, P4165; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MOK SC, 1995, GYNECOL ONCOL, V57, P299, DOI 10.1006/gyno.1995.1146; MOK SCH, 1993, CANCER RES, V53, P1489; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PEJOVIC T, 1995, ANN MED, V27, P73, DOI 10.3109/07853899509031940; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Shimada A, 1999, CANCER RES, V59, P2781; Takahashi H, 1998, CANCER RES, V58, P2076; Thompson FH, 1997, CANCER GENET CYTOGEN, V96, P106, DOI 10.1016/S0165-4608(96)00307-X; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	30	55	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1885	1890		10.1038/sj.onc.1203512	http://dx.doi.org/10.1038/sj.onc.1203512			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773878				2022-12-28	WOS:000086424300004
J	Garcia-Cuellar, MP; Schreiner, SA; Birke, M; Hamacher, M; Fey, GH; Slany, RK				Garcia-Cuellar, MP; Schreiner, SA; Birke, M; Hamacher, M; Fey, GH; Slany, RK			ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)(+)	ONCOGENE			English	Article						leukemia; MLL; translocation; ENL; ABI1	ACUTE MYELOID-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTION FACTORS; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MUTANT MICE; HRX-ENL; GENE; CLONING; ALL-1	Translocations of the chromosomal locus 11q23 that disrupt the MLL gene (alternatively ALL-I or HRX) are frequently found in children's leukemias. These events fuse the MLL amino terminus in frame with a variety of unrelated proteins, Up to date, 16 different fusion partners have been characterized and more are likely to exist. No general unifying property could yet be detected amongst these proteins. We show here that the frequent MLL fusion partner ENL at 19p13.1 interacts with the human homologue of the mouse Abl-Interactor 1 (ABI1) protein. ABI1 in turn, is fused to MLL in the t(10:ll)(p11.2;q23) translocation, ABI1 was identified as an ENL binding protein by a yeast two-hybrid screen. The interaction of ENL and ABI1 could be verified in vitro by far-Western blot assays and GST-pulldown studies as well as in vivo by co-immunoprecipitation experiments. A structure-function analysis identified an internal region of ENL and a composite motif of ABI1 including an SH3 domain as mutual binding partners. These data introduce novel aspects that might contribute to the understanding of the process of leukemogenesis by MLL fusion proteins.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERNARD OA, 1994, ONCOGENE, V9, P1039; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; James P, 1996, GENETICS, V144, P1425; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; PRASAD R, 1993, CANCER RES, V53, P5624; Rogaia D, 1997, CANCER RES, V57, P799; RUBNITZ JE, 1994, BLOOD, V84, P1747; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Taki T, 1998, BLOOD, V92, P1125, DOI 10.1182/blood.V92.4.1125.416k40_1125_1130; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681	38	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1744	1751		10.1038/sj.onc.1203506	http://dx.doi.org/10.1038/sj.onc.1203506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777208				2022-12-28	WOS:000086292500002
J	Kojima, M; Morisaki, T; Izuhara, K; Uchiyama, A; Matsunari, Y; Katano, M; Tanaka, M				Kojima, M; Morisaki, T; Izuhara, K; Uchiyama, A; Matsunari, Y; Katano, M; Tanaka, M			Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation	ONCOGENE			English	Article						colon carcinoma; LPS; PGE2; COX-2; NF-kappa B	CYCLOOXYGENASE-2 GENE-EXPRESSION; EPITHELIAL-CELLS; INDUCIBLE CYCLOOXYGENASE; GASTRIC-CARCINOMA; MESSENGER-RNA; UP-REGULATION; CANCER CELLS; MACROPHAGES; PROTEIN; INDUCTION	Both nonneoplastic colon epithelium and colon carcinoma cells in situ are continuously exposed to lipopolysaccharide (LPS), Few reports have addressed possible direct effects of LPS in promotion of colon carcinoma and underlying mechanisms. We found evidence that LPS directly stimulated growth of the human colon carcinoma cell line CE-1 through an increase in the production of prostaglandin E-2 (PGE(2)) as a result of cyclo-oxygenase-2 (COX-2) expression. LPS induced significant increases in PGE(2) production in CE-1 cells, which were found to express a high-affinity LPS receptor, CD14, Positive correlations were found between PGE(2) production and activation of nuclear factor (NF)-kappa B as well as expression of both COX-2 mRNA and protein in LPS-stimnlated CE-I cells. When CE-1 cells were exposed to exogenous PGE(2), DNA synthesis increased. These results indicate that LPS may stimulate DNA synthesis in certain colon carcinoma cells as a result of PGE(2) production involving increased COX-2 expression that might result in turn from activation of NF-kappa B by LPS, Further investigation of the pathways mediating LPS-induced stimulation of colon carcinoma cells may provide insights into LPS effects in in vivo tumor biology.	Kyushu Univ, Grad Sch Med Sci, Fac Med, Dept Clin Chem & Lab Med,Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Surg 1, Div Clin Immunol,Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Kyushu University	Morisaki, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Fac Med, Dept Clin Chem & Lab Med,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bellezzo JM, 1998, J LAB CLIN MED, V131, P36, DOI 10.1016/S0022-2143(98)90075-0; Brophy VH, 1998, IMMUNOGENETICS, V47, P196; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DuBois RN, 1996, CANCER RES, V56, P733; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GustafsonSvard C, 1996, GUT, V38, P79, DOI 10.1136/gut.38.1.79; Hida T, 1998, CANCER RES, V58, P3761; Huang M, 1998, CANCER RES, V58, P1208; Huang M, 1996, J IMMUNOL, V157, P5512; Ikebe T, 1998, INT J CANCER, V77, P578; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kirkevold M, 1997, SCAND J CARING SCI, V11, P65, DOI 10.1111/j.1471-6712.1997.tb00434.x; Kucharzik T, 1997, CLIN EXP IMMUNOL, V110, P296; LEE SH, 1992, J BIOL CHEM, V267, P25934; MASTINO A, 1993, CELL IMMUNOL, V152, P120, DOI 10.1006/cimm.1993.1272; MAXWELL WJ, 1990, DIGESTION, V47, P160, DOI 10.1159/000200492; Mayeux PR, 1997, J TOXICOL ENV HEALTH, V51, P415, DOI 10.1080/00984109708984034; MORISAKI T, 1992, CANCER RES, V52, P6059; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; Reddy BS, 1996, CANCER RES, V56, P4566; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Ristimaki A, 1997, CANCER RES, V57, P1276; SANO H, 1995, CANCER RES, V55, P3785; SATO H, 1993, ONCOGENE, V8, P395; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Suh N, 1998, CANCER RES, V58, P717; Tanaka C, 1997, BIOCHEM BIOPH RES CO, V232, P568, DOI 10.1006/bbrc.1997.6264; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wolff H, 1998, CANCER RES, V58, P4997; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	52	144	156	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1225	1231		10.1038/sj.onc.1203427	http://dx.doi.org/10.1038/sj.onc.1203427			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713711				2022-12-28	WOS:000085567800013
J	Callahan, R; Smith, GH				Callahan, R; Smith, GH			MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways	ONCOGENE			English	Review						MMTV; Wnt; Fgf; notch; elF3p48/INT6	HUMAN BREAST-CANCER; TUMOR VIRUS-DNA; TRANSGENIC MICE; PROVIRAL INSERTION; EPITHELIAL-CELLS; GROWTH-FACTORS; NOTCH-GENE; IN-VIVO; MOUSE DEVELOPMENT; STEM-CELL	The study of the mouse mammary tumor virus (MMTV) has provided important insights into the mechanisms of gene transcription regulation by steroid hormones, the mode of action of heritable super antigens and the progressive nature of neoplastic transformation in the mammary gland, Here we describe the current situation with respect to the latter aspect of MMTV biology and the prospects for further advance in our understanding of breast cancer in humans that may be expected from a continued study of MMTV-induced mammary neoplasia, MMTV is a heritable somatic mutagen whose target range is limited, Commonly, the tumorigenic capacity of MMTV is restricted to mammary gland, whereas infection is found in a variety of cell types, In order to replicate, proviral DNA must be inserted into the cell DNA and cell division is required to fix the mutation. Yet only in the mammary epithelium does this lead to neoplastic transformation. This suggests a unique relationship between MMTV and mammary epithelium. In evaluating this relationship, we and others have discovered genes and potential gene pathways that are pertinent in mammary differentiation and neoplasia, In addition, the clonal nature of these progressive events from normal to malignant phenotype has become increasingly clear, The weight of these observations compel us to conclude that mammary neoplasms arise from multipotent mammary epithelial cells through a process of acquired mutations that are reflected in the increasingly malignant nature of the population of progeny produced by these damaged stem cells.	NCI, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Callahan, R (corresponding author), NCI, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA.							ANDERVONT HB, 1952, ANN NY ACAD SCI, V54, P1004, DOI 10.1111/j.1749-6632.1952.tb39975.x; ANDERVONT HB, 1962, J NATL CANCER I, V28, P1153; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bittner JJ, 1936, SCIENCE, V84, P162, DOI 10.1126/science.84.2172.162; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; CALLAHAN R, 1986, CURR TOP MICROBIOL, V127, P362; CALLAHAN R, 1982, P NATL ACAD SCI-BIOL, V79, P4113, DOI 10.1073/pnas.79.13.4113; CARDIFF RD, 1983, J NATL CANCER I, V71, P1011; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; COHEN JC, 1979, CELL, V16, P333; COHEN JC, 1979, J VIROL, V32, P483, DOI 10.1128/JVI.32.2.483-496.1979; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; DANIEL CW, 1971, EXP GERONTOL, V6, P95, DOI 10.1016/0531-5565(71)90053-2; DANIEL CW, 1971, EXP CELL RES, V65, P27, DOI 10.1016/S0014-4827(71)80046-0; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DEOME K.B., 1959, JNCI-J NATL CANCER I, V78, P751; DEOME KB, 1978, CANCER RES, V38, P2103; DEOME KB, 1978, CANCER RES, V38, P4050; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; Diella F, 1997, DNA CELL BIOL, V16, P839, DOI 10.1089/dna.1997.16.839; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; DIEVART A, 1999, IN PRESS ONCOGENE; ESCOT C, 1986, J VIROL, V58, P619, DOI 10.1128/JVI.58.2.619-625.1986; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FELLUGA B, 1969, J NATL CANCER I, V43, P319; FOULDS L, 1956, J NATL CANCER I, V17, P713; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; Golovkina TV, 1998, J VIROL, V72, P3066, DOI 10.1128/JVI.72.4.3066-3071.1998; HELD W, 1994, IMMUNOL TODAY, V15, P184, DOI 10.1016/0167-5699(94)90317-4; HILGERS J, 1981, MAMMARY TUMORS MOUSE; HILKENS J, 1983, J VIROL, V45, P140, DOI 10.1128/JVI.45.1.140-147.1983; HUGUET EL, 1994, CANCER RES, V54, P2615; IMAI S, 1994, J VIROL, V68, P3437, DOI 10.1128/JVI.68.5.3437-3442.1994; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Kordon EC, 1998, DEVELOPMENT, V125, P1921; KORDON EC, 1995, J VIROL, V69, P8066, DOI 10.1128/JVI.69.12.8066-8069.1995; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE AE, 1968, BRIT J CANCER, V22, P77, DOI 10.1038/bjc.1968.11; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MARCHETTI A, 1991, J VIROL, V65, P4550, DOI 10.1128/JVI.65.8.4550-4554.1991; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; MEDINA D, 1990, PROTOPLASMA, V159, P77, DOI 10.1007/BF01322591; MEDINA D, 1973, METHOD CANCER RES, V7, P3; MICHALIDES R, 1981, CELL, V23, P165, DOI 10.1016/0092-8674(81)90281-6; MICHALIDES R, 1985, VIROLOGY, V142, P278, DOI 10.1016/0042-6822(85)90336-8; Miyazaki S, 1999, GENE, V233, P241, DOI 10.1016/S0378-1119(99)00130-4; Morimoto Y, 1985, Crit Rev Ther Drug Carrier Syst, V2, P19; Morse H., 1978, ORIGINS INBRED MICE; MUHLBOCK O, 1950, J NATL CANCER I, V10, P861; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; NICOLL CHARLES S., 1965, LIFE SCI, V4, P993, DOI 10.1016/0024-3205(65)90203-1; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; Qin W, 1999, J VIROL, V73, P368, DOI 10.1128/JVI.73.1.368-376.1999; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RINGOLD GM, 1979, P NATL ACAD SCI USA, V76, P665, DOI 10.1073/pnas.76.2.665; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; RONGEY RW, 1973, J NATL CANCER I, V50, P1581, DOI 10.1093/jnci/50.6.1581; Rosenberg CL, 1997, HUM PATHOL, V28, P214, DOI 10.1016/S0046-8177(97)90109-X; Ross SR, 1998, IMMUNOL RES, V17, P209, DOI 10.1007/BF02786445; ROUBINIAN JR, 1980, J NATL CANCER I, V65, P795, DOI 10.1093/jnci/65.4.795; SARKAR NH, 1994, VIROLOGY, V203, P52, DOI 10.1006/viro.1994.1454; SCHLOM J, 1978, JNCI-J NATL CANCER I, V61, P66; SCHWARTZ MS, 1992, INT J CANCER, V51, P805, DOI 10.1002/ijc.2910510523; SELL S, 1994, LAB INVEST, V70, P6; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SIRACUSA LD, 1991, GENOMICS, V10, P313, DOI 10.1016/0888-7543(91)90314-5; SMITH GH, 1991, J VIROL, V65, P6365, DOI 10.1128/JVI.65.11.6365-6370.1991; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; SMITH GH, 1982, INT J CANCER, V29, P587, DOI 10.1002/ijc.2910290516; SMITH GH, 1984, CANCER RES, V44, P3426; SMITH GH, 1966, JNCI-J NATL CANCER I, V36, P685, DOI 10.1093/jnci/36.4.685; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; SMITH GH, 1967, CANCER RES, V27, P2179; SMITH GH, 1988, J CELL SCI, V90, P173; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; SQUARTINI F, 1961, J NATL CANCER I, V26, P813; SQUARTINI F, 1963, NATURE, V197, P505, DOI 10.1038/197505a0; SQUARTINI F, 1983, CANCER RES, V43, P5879; Squartini F, 1979, IARC Sci Publ, V23, P43; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; TERAMOTO YA, 1980, J NATL CANCER I, V64, P967; Tsai YC, 1996, CANCER RES, V56, P402; TSUBURA Y, 1981, GANN, V72, P424; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; VANDEVIJVER MJ, 1989, MOL DIAGNOSTICS HUMA; VANNIE R, 1975, INT J CANCER, V16, P922, DOI 10.1002/ijc.2910160606; VANNIE R, 1977, INT J CANCER, V19, P383, DOI 10.1002/ijc.2910190316; VARMUS HE, 1982, CANCER SURV, V1, P309; VLAHAKIS G, 1970, SCIENCE, V170, P185, DOI 10.1126/science.170.3954.185; WAINSCOAT JS, 1990, CANCER RES, V50, P1355; Wang Y, 1998, CLIN CANCER RES, V4, P2565; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WELLINGS SR, 1980, PATHOL RES PRACT, V166, P515, DOI 10.1016/S0344-0338(80)80248-2; Wesley CS, 1999, MOL CELL BIOL, V19, P5743; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOUNG LJT, 1971, EXP GERONTOL, V6, P49, DOI 10.1016/0531-5565(71)90048-9	123	138	142	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		992	1001		10.1038/sj.onc.1203276	http://dx.doi.org/10.1038/sj.onc.1203276			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713682				2022-12-28	WOS:000085796400004
J	Dickson, C; Creer, A; Fantl, V				Dickson, C; Creer, A; Fantl, V			Mammary gland oncogenes as indicators of pathways important in mammary gland development	ONCOGENE			English	Article						mammary gland; cyclin D1; fibroblast growth factor; dominant negative Fgf-receptor	GROWTH-FACTOR FAMILY; TRANSGENIC MICE; TUMOR VIRUS; CYCLIN D1; BREAST-CANCER; EXPRESSION; MOUSE; INT-2; GENE; ACTIVATION	The identification of dominant acting proto-oncogenes in mammary tumors from mice and humans has highlighted a number of signal transduction pathways that have subsequently been shown to have a role in normal mammary growth and differentiation. Here we describe the use of two different transgenic mouse strategies to investigate the function of two of these signalling pathways in the normal growth and differentiation of the mouse mammary gland during pregnancy.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Dickson, C (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.							BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON C, 1991, ANN NY ACAD SCI, V638, P18, DOI 10.1111/j.1749-6632.1991.tb49014.x; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Gallahan D, 1996, CANCER RES, V56, P1775; GILLETT C, 1994, CANCER RES, V54, P1812; Jackson D, 1997, J CELL SCI, V110, P1261; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAMMIE GA, 1991, CANCER CELL, V3, P1; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1991, CURR TOP MICROBIOL, V171, P44; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1991, SEMIN VIROL, V2, P319; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	33	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1097	1101		10.1038/sj.onc.1203267	http://dx.doi.org/10.1038/sj.onc.1203267			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713696				2022-12-28	WOS:000085796400018
J	Sternlicht, MD; Bissell, MJ; Werb, Z				Sternlicht, MD; Bissell, MJ; Werb, Z			The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter	ONCOGENE			English	Article						matrix metalloproteinases; stromelysin; TIMP; mammary carcinogenesis; epithelial-to-mesenchymal conversion	HUMAN BREAST-CANCER; ERYTHROID-POTENTIATING ACTIVITY; MESSENGER-RNA EXPRESSION; TIMP-1 TRANSGENIC MICE; TISSUE INHIBITOR; GROWTH-FACTOR; EPITHELIAL-CELLS; IN-VIVO; INTESTINAL TUMORIGENESIS; DISTANT METASTASES	Extracellular matrix-degrading matrix metalloproteinases (MMPs) ape invariably upregulated in epithelial cancers and are key agonists in angiogenesis, invasion and metastasis. Yet most MMPs are secreted not by the cancer cells themselves, but by stromal cells within and around the tumor mass. Because the stromal environment can influence tumor formation, and because MMPs can alter this environment, MMPs may also contribute to the initial stages of cancer development. Several recent studies in MMP-overexpressing and MMP-deficient mice support this possibility, but have required carcinogens or pre-existing oncogenic mutations to initiate tumorigenesis. Here we review the spontaneous development of premalignant and malignant lesions in the mammary glands of transgenic mice that express an autoactivating form of MMP3/stromelysin-1 under the control of the whey acidic protein gene promoter. These changes were absent in nontransgenic littermates and were quenched by co-expression of a human tissue inhibitor of metalloproteinases-1 (TIMP-1) transgene, Thus by altering the cellular microenvironment, stromelysin-l can act res a natural tumor promoter and enhance cancer susceptibility.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Sternlicht, MD (corresponding author), Univ Calif San Francisco, Dept Anat, 513 Parnassus Ave,HSW-1301, San Francisco, CA 94143 USA.				NCI NIH HHS [R01 CA057621-07, CA72006, R01 CA057621, P01 CA072006, CA57621, P01 CA072006-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057621, P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad A, 1998, AM J PATHOL, V152, P721; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bachman KE, 1999, CANCER RES, V59, P798; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; Birchmeier C, 1996, ACTA ANAT, V156, P217; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Castagnino P, 1998, ONCOGENE, V17, P481, DOI 10.1038/sj.onc.1201957; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Codony-Servat J, 1999, CANCER RES, V59, P1196; Cool M, 1999, CANCER RES, V59, P2438; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GACK S, 1994, J BIOL CHEM, V269, P10363; Gilles C, 1996, BREAST JOURNAL, VOL 2, NO 1, JANUARY/FEBRUARY 1996, P83; Goss KJH, 1998, INT J CANCER, V78, P629; Grant GM, 1999, MATRIX BIOL, V18, P145, DOI 10.1016/S0945-053X(99)00003-7; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Imren S, 1996, CANCER RES, V56, P2891; Jacobs TW, 1999, NEW ENGL J MED, V340, P430, DOI 10.1056/NEJM199902113400604; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Jung K, 1997, INT J CANCER, V74, P220, DOI 10.1002/(SICI)1097-0215(19970422)74:2<220::AID-IJC14>3.0.CO;2-H; Kataoka H, 1999, AM J PATHOL, V154, P457, DOI 10.1016/S0002-9440(10)65292-3; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kossakowska AE, 1996, BRIT J CANCER, V73, P1401, DOI 10.1038/bjc.1996.266; Kruger A, 1997, BLOOD, V90, P1993, DOI 10.1182/blood.V90.5.1993; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Lindsay CK, 1997, HUM PATHOL, V28, P359, DOI 10.1016/S0046-8177(97)90136-2; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; LU XQ, 1991, CANCER RES, V51, P6231; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Lund LR, 1996, DEVELOPMENT, V122, P181; Martin DC, 1999, LAB INVEST, V79, P225; Martin DC, 1996, ONCOGENE, V13, P569; Martorana AM, 1998, CANCER RES, V58, P4970; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.3.CO;2-G; Mimori K, 1997, BRIT J CANCER, V76, P531, DOI 10.1038/bjc.1997.420; Mitsiades N., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P722; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; Nemeth JA, 1996, EXP CELL RES, V224, P110, DOI 10.1006/excr.1996.0117; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Ritland SR, 1997, CANCER RES, V57, P3520; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; Shoji A, 1997, CARCINOGENESIS, V18, P2093, DOI 10.1093/carcin/18.11.2093; Soloway PD, 1996, ONCOGENE, V13, P2307; STASKUS PW, 1991, J BIOL CHEM, V266, P449; Sternlicht M., 1999, GUIDEBOOK EXTRACELLU, P503; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; URIA JA, 1994, CANCER RES, V54, P2091; Vallorosi C. J., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P721; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Willenbucher RF, 1999, AM J PATHOL, V154, P1825, DOI 10.1016/S0002-9440(10)65438-7; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; WRIGHT JH, 1994, MOL CARCINOGEN, V10, P207, DOI 10.1002/mc.2940100405; Yoshiji H, 1998, INT J CANCER, V75, P81, DOI 10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.3.CO;2-J; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; Zeng ZS, 1995, CLIN CANCER RES, V1, P899	98	206	214	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1102	1113		10.1038/sj.onc.1203347	http://dx.doi.org/10.1038/sj.onc.1203347			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713697	Green Submitted, Green Accepted			2022-12-28	WOS:000085796400019
J	Costantini, P; Belzacq, AS; La Vieira, H; Larochette, N; de Pablo, MA; Zamzami, N; Susin, SA; Brenner, C; Kroemer, G				Costantini, P; Belzacq, AS; La Vieira, H; Larochette, N; de Pablo, MA; Zamzami, N; Susin, SA; Brenner, C; Kroemer, G			Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis	ONCOGENE			English	Article						ADP/ATP carrier; Bcl-2; cell death; mitochondria; permeability transition	MITOCHONDRIAL BENZODIAZEPINE RECEPTOR; DEPENDENT ANION CHANNEL; CYTOCHROME-C; ADP/ATP CARRIER; BCL-2; MEMBRANE; RELEASE; INDUCTION; PROTEIN; PHENANTHROLINE	Mitochondrial membrane permeabilization is a critical event in the process leading to physiological or chemotherapy-induced apoptosis. This permeabilization event is at least in part under the control of the permeability transition pore complex (PTPC), which interacts with oncoproteins from the Bcl-2 family as well as with tumor suppressor proteins from the Bar family, which inhibit or facilitate membrane permeabilization, respectively. Here we show that thiol crosslinking agents including diazenedicarboxylic acid bis SN,N-dimethylamide (diamide), dithiodipyridine (DTDP), or bis-maleimido-hexane (BMH) can act on the adenine nucleotide translocator (ANT), one of the proteins within the PTPC. ANT alone reconstituted into artificial lipid bilayers suffices to confer a membrane permeabilization response to thiol crosslinking agents. Diamide, DTDP, and BMH but not tert-butylhydroperoxide or arsenite cause the oxidation of a critical cysteine residue (Cys 56) of ANT. Thiol modification within ANT is observed in intact cells, isolated mitochondria, and purified ANT. Recombinant Bcl-2 fails to prevent thiol modification of ANT. Concomitantly, a series of different thiol crosslinking agents (diamide, DTDP, and BMH, phenylarsine oxide) but not tert-butylhydroperoxide or arsenite induce mitochondrial membrane permeabilization and cell death irrespective of the expression level of Bcl-2. These data indicate that thiol crosslinkers cause a covalent modification of ANT which, beyond any control by Bcl-2, leads to mitochondrial membrane permeabilization and cell death.	CNRS, ERS 1984, F-94801 Villejuif, France; Univ Technol Compiegne, CNRS, UPRES A6022, F-60205 Compiegne, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Kroemer, G (corresponding author), CNRS, ERS 1984, 19 Rue Guy Moquet, F-94801 Villejuif, France.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Susin, Santos A/Q-6754-2017; LAROCHETTE, Nathanael/R-4298-2017	KROEMER, Guido/0000-0002-9334-4405; Susin, Santos A/0000-0002-3366-1628; LAROCHETTE, Nathanael/0000-0002-7936-678X; Vieira, Helena/0000-0001-9415-3742				Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; BRENNER C, 1999, IN PRESS ONCOGENE; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Costantini P, 1998, BBA-BIOENERGETICS, V1365, P385, DOI 10.1016/S0005-2728(98)00090-5; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUSIN SA, 1999, IN PRESS METH ENZYMO; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864	45	237	247	0	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					307	314		10.1038/sj.onc.1203299	http://dx.doi.org/10.1038/sj.onc.1203299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645010				2022-12-28	WOS:000084844400017
J	Namba, K; Abe, M; Saito, S; Satake, M; Ohmoto, T; Watanabe, T; Sato, Y				Namba, K; Abe, M; Saito, S; Satake, M; Ohmoto, T; Watanabe, T; Sato, Y			Indispensable role of the transcription factor PEBP2/CBF in angiogenic activity of a murine endothelial cell MSS31	ONCOGENE			English	Article						PEBP2/CBF; transcription factor; angiogenesis	ACUTE MYELOID-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; RECEPTOR TYROSINE KINASE; MYOSIN HEAVY-CHAIN; DEFINITIVE HEMATOPOIESIS; PLASMINOGEN-ACTIVATOR; GROWTH-FACTOR; DNA-BINDING; PROTOONCOGENE PRODUCT; VASCULAR DEVELOPMENT	Mice lacking the AML1/PEBP2 alpha B/CBFa2 gene or PEBP2 beta/CBFb gene exhibit a defect in definitive hematopoiesis and die in utero because of hemorrhage in the central nervous system. Hematopoiesis in the embryo is considered to be tightly associated with vascular development, Here ive examined whether PEBP2/CBF plays any role in angiogenesis besides that in definitive hematopoiesis, We found that AML1/ PEBP2 alpha B/CBFa2, PEBP2 alpha A/CBFa1, and PEBP2 beta/ CBFb were expressed in a murine endothelial cell Line MISS31, The expression of these molecules as cell as the DNA binding activity of PEBP2/CBF were augmented by angiogenic growth factors such as bFGF and VEGF. Moreover, the expression of PEBP2 alpha/CBFa protein in endothelial tells was confirmed at the site of angiogenesis in vivo, To further clarify the role of PEBP2/CF in angiogenesis, we established permanent transfectants of PEBP2 beta-MYH11 gene, one that interacts with the runt domain of the alpha subunit and deregulates PEBP2/CBF in a dominant interfering manner. Proliferation, migration, and tube formation of the PEBP2 beta-MYH11 transfectants were significantly reduced in comparison with those activities of the mock transfectants. These results suggest that transcription factor PEBP2/CBF plays an important role in angiogenesis.	Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 7008558, Japan	Tohoku University; Tohoku University; Okayama University	Sato, Y (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.							BAE SC, 1993, ONCOGENE, V8, P809; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; CLAXTON DF, 1994, BLOOD, V83, P1850; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DICKSON MC, 1995, DEVELOPMENT, V121, P1945; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nishikawa S, 1998, IMMUNITY, V8, P761, DOI 10.1016/S1074-7613(00)80581-6; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SATO Y, 1993, EXP CELL RES, V204, P223, DOI 10.1006/excr.1993.1028; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Tanaka Y, 1998, ONCOGENE, V17, P699, DOI 10.1038/sj.onc.1201985; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; WOTTON D, 1993, LEUKEMIA S, V2, pS55; YANAI N, 1991, CELL STRUCT FUNCT, V16, P87, DOI 10.1247/csf.16.87; YANG JT, 1993, DEVELOPMENT, V119, P1093	48	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					106	114		10.1038/sj.onc.1203257	http://dx.doi.org/10.1038/sj.onc.1203257			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644985				2022-12-28	WOS:000084844300012
J	Riedel, H; Yousaf, N; Zhao, YY; Dai, HP; Deng, YP; Wang, J				Riedel, H; Yousaf, N; Zhao, YY; Dai, HP; Deng, YP; Wang, J			PSM, a mediator of PDGF-BB-, IGF-I-, and insulin-stimulated mitogenesis	ONCOGENE			English	Article						SH2-B; growth factor; receptor tyrosine kinase; adapter; trojan peptide; malignant cell transformation	GROWTH-FACTOR-I; SH2 DOMAIN; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASE; TRK RECEPTORS; PROTEINS; SYSTEM; CELLS; PHOSPHORYLATION	PSM/SH2-B has been described as a cellular partner of the Fc epsilon RI receptor, insulin receptor (IR), insulin-like growth factor-I (IGF-I) receptor (IGF-IR), and nerve growth factor receptor (TrkA). A function has been proposed in neuronal differentiation and development but its role in other signaling pathways is still unclear. To further elucidate the physiologic role of PSM we have identified additional mitogenic receptor tyrosine kinases as putative PSM partners including platelet-derived growth factor (PDGF) receptor (PDGFR) beta, hepatocyte growth factor receptor (Met), and fibroblast growth factor receptor. We have mapped Y740 as a site of PDGFR beta that is involved in the association with PSM. We have further investigated the putative role of PSM in mitogenesis with three independent experimental strategies and found that all consistently suggested a role as a positive, stimulatory signaling adapter in normal NIH3T3 and baby hamster kidney fibroblasts, (1) PSM expression from cDNA using an ecdysone-regulated transient expression system stimulated PDGF-BB-, IGF-I-, and insulin- but not EGF-induced DNA synthesis in an ecdysone dose-responsive fashion; (2) Microinjection of the (dominant negative) PSM SH2 domain interfered with PDGF-BB- and insulin-induced DNA synthesis; and (3) A peptide mimetic of the PSM Pro-rich putative SH3 domain-binding region interfered with PDGF-BB-, IGF-I-, and insulin- but not with EGF-induced DNA synthesis in NIH3T3 fibroblasts. This experiment was based on cell-permeable fusion peptides with the Drosophila antennapedia homeodomain which effectively traverse the plasma membrane of cultured cells, These experimental strategies independently suggest that PSM functions as a positive, stimulatory, mitogenic signaling mediator in PDGF-BB, IGF-I, and insulin but not in EGF action. This function appears to involve the PSM SH2 domain as well as the Pro-rich putative SH3 domain binding region. Our findings support the model that PSM participates as an adapter in carious mitogenic signaling mechanisms by linking an activated (receptor) phospho-tyrosine to the SH3 domain of an unknown cellular partner.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Riedel, H (corresponding author), Wayne State Univ, Dept Biol Sci, 2171 BSB, Detroit, MI 48202 USA.			Deng, Youping/0000-0002-5951-8213	NCI NIH HHS [R01 CA77873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed Z, 1999, BIOCHEM J, V341, P665, DOI 10.1042/0264-6021:3410665; BASERGA R, 1995, CANCER RES, V55, P249; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; BROWN SAN, 1993, BIOCHEM BIOPH RES CO, V193, P1116, DOI 10.1006/bbrc.1993.1741; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; COOPER J, 1993, BIOL PLATELET DERIVE, P44; DeMali KA, 1997, J BIOL CHEM, V272, P9011; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Gotoh N, 1995, ONCOGENE, V11, P2525; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1993, BIOL PLATELET DERIVE, P1; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; Hughes AD, 1996, GEN PHARMACOL-VASC S, V27, P1079, DOI 10.1016/S0306-3623(96)00060-2; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Moodie SA, 1999, J BIOL CHEM, V274, P11186, DOI 10.1074/jbc.274.16.11186; MURAGAKI Y, 1995, J COMP NEUROL, V356, P387, DOI 10.1002/cne.903560306; MYERS MG, 1991, J BIOL CHEM, V266, P10616; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; OOI J, 1995, ONCOGENE, V10, P1621; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1999, J BIOL CHEM, V274, P26485, DOI 10.1074/jbc.274.37.26485; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WENNSTROM S, 1994, ONCOGENE, V9, P651; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; ZVIBEL I, 1985, INT J CANCER, V36, P261, DOI 10.1002/ijc.2910360220	53	35	36	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					39	50		10.1038/sj.onc.1203253	http://dx.doi.org/10.1038/sj.onc.1203253			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644978				2022-12-28	WOS:000084844300005
J	Snouwaert, JN; Gowen, LC; Latour, AM; Mohn, AR; Xiao, A; DiBiase, L; Koller, BH				Snouwaert, JN; Gowen, LC; Latour, AM; Mohn, AR; Xiao, A; DiBiase, L; Koller, BH			BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a Brca1 transgene	ONCOGENE			English	Article						BRCA1 proteins; homologous recombination; ES cells; DNA repair; non-homologous recombination	DOUBLE-STRAND BREAK; MURINE BRCA1; TRANSCRIPTIONAL ACTIVATION; NUCLEAR PHOSPHOPROTEIN; OVARIAN-CANCER; MEIOTIC CELLS; DNA-DAMAGE; GENE BRCA1; MOUSE; REPAIR	BRCA1 is a nuclear phosphoprotein that has been classified as a tumor suppressor based on the fact that women carrying a mutated copy of the BRCA1 gene are at increased risk of developing breast and ovarian cancer. The association of BRCA1 with RAD51 has led to the hypothesis that BRCA1 is involved in DNA repair. We describe here the generation and analysis of murine embryonic stem (ES) cell lines in which both copies of the murine homologue of the human BRCA1 gene have been disrupted by gene targeting. We show that exogenous DNA introduced into these BRCA1 deficient cells by electroporation is randomly integrated into the genome at a significantly higher rate than in wild type ES cells. In contrast, integration of exogenous DNA by homologous recombination occurs in BRCA1 deficient cells at a significantly lower rate than in wild type controls. When BRCA1 expression is re-established at 5-10% of normal levels by introduction of a Brca1 transgene into BRCA1 deficient ES cells, the frequency of random integration is reduced to wild type levels, although the frequency of homologous recombination is not significantly improved. These results suggest that BRCA1 plays a role in determining the response of cells to double stranded DNA breaks.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Koller, BH (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.			Morton, Lori/0000-0002-5214-5784; Ramsey, Amy/0000-0002-2717-5279	NCI NIH HHS [CA82423] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082423] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; EASTON DF, 1993, AM J HUM GENET, V52, P678; Game J., 1983, YEAST GENETICS FUNDA, P109; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Larson JS, 1997, CANCER RES, V57, P3351; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOHN A, 1995, DNA CLONING, V4, P143; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Snouwaert JN, 1998, CURRENT TOPICS ON BRCA1, P33, DOI 10.3233/BD-1998-101-206; Templeton NS, 1997, GENE THER, V4, P700, DOI 10.1038/sj.gt.3300457; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zabludoff SD, 1996, ONCOGENE, V13, P649; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	49	164	165	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7900	7907		10.1038/sj.onc.1203334	http://dx.doi.org/10.1038/sj.onc.1203334			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630642				2022-12-28	WOS:000084405900006
J	Lo, PK; Chen, JY; Lo, WC; Chen, BF; Hsin, JP; Tang, PP; Wang, FF				Lo, PK; Chen, JY; Lo, WC; Chen, BF; Hsin, JP; Tang, PP; Wang, FF			Identification of a novel mouse p53 target gene DDA3	ONCOGENE			English	Article						p53; growth suppression; DDA3	WILD-TYPE P53; DNA-DAMAGE; P53-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAIN; PROTEIN; INHIBITOR; GROWTH; CELLS; CHECKPOINT	We have identified a novel p53 regulated gene designated DDA3 through differential mRNA display on IW32 erythroleukemia cells containing a temperature sensitive p53 allele, tsp53val-135. DDA3 mRNA induction could be observed in all sublines expressing tsp53val-135 cultured at permissive temperature as well as in NIH3T3 cells undergoing DNA damage. Upregulation of DDA3 could be detected within 2 h after down-shifting the temperature to 32.5 degrees C; upon shifting back to 38.5 degrees C, DDA3 mRNA rapidly degraded with a half-life of less than 2 h. Actinomycin D, but not cycloheximide, inhibited the p53 dependent DDA3 induction, suggesting that the activation is through transcriptional regulation and does not require de novo protein synthesis. DDA3 was expressed in multiple mouse tissues including brain, spleen, lung, kidney and testis. Full-length DDA3 cDNA was cloned and it contained an open reading frame predicted to encode a proline rich protein of 329 amino acids. Overexpression of DDA3 in H1299 lung carcinoma cells suppressed colony formation. These results suggest that DDA3 is a p53-regulated gene that might participate in the p53-mediated growth suppression.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Mackay Mem Hosp, Dept Pathol, Taipei 104, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Mackay Memorial Hospital	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.		Chen, Joanne Jeou-Yuan/S-7022-2018					Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHOPPIN J, 1984, BLOOD, V64, P341; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISRAELI D, 1997, EMBO J, V16, P4382; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405	48	37	41	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7765	7774		10.1038/sj.onc.1203167	http://dx.doi.org/10.1038/sj.onc.1203167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618717				2022-12-28	WOS:000084256900006
J	Budunova, IV; Perez, P; Vaden, VR; Spiegelman, VS; Slaga, TJ; Jorcano, JL				Budunova, IV; Perez, P; Vaden, VR; Spiegelman, VS; Slaga, TJ; Jorcano, JL			Increased expression of p50-NF-kappa B and constitutive activation of NF-kappa B transcription factors during mouse skin carcinogenesis	ONCOGENE			English	Article						NF-kappa B factors; I kappa B proteins; skin carcinogenesis	DNA-BINDING; ONCOPROTEIN BCL-3; P50 HOMODIMERS; PRECURSOR P105; REL-FAMILY; NUCLEAR-LOCALIZATION; P65 SUBUNIT; PROTEINS; CELLS; ALPHA	To elucidate the possible role of NF-kappa B in mouse skin carcinogenesis we studied the expression of p50 (NF-kappa B1), p52 (NF-kappa B2), p65 (ReIA) and I kappa B-alpha inhibitor as well as kappa B-binding activity in adult SENCAR mouse skin, skin papillomas, and squamous cell carcinomas (SCC) generated by a two-stage carcinogenesis protocol. We found that in normal epidermis all of the above proteins were mostly expressed in the cytoplasm of basal cells. Western blot analysis revealed a dramatic increase of p50 and p52 expression in mouse skin tumors starting from the middle stage of promotion. We also found that the level of I kappa B-alpha protein in many late papillomas and see was lower than in normal epidermis, Results of EMSA showed an increase in kappa B-binding activity in mouse skin tumors and suggested that p50 is the major component of constitutive kappa B-binding complexes in normal epidermis and in tumors. It has been shown that nuclear I kappa B protein Bcl-3 is able to increase p50/p50 homodimer binding to the different kappa B sites in mouse thymocytes. Our finding on Bcl-3 overexpression in late papillomas and SCC could explain the selective increase of p50-related kappa B-binding in mouse skin tumors, Thus, our results strongly suggest the important role of p50 in skin carcinogenesis.	AMC Canc Res Ctr, Denver, CO 80214 USA; CIEMAT, Dept Mol & Cell Biol, E-28040 Madrid, Spain	AMC Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Budunova, IV (corresponding author), AMC Canc Res Ctr, 1600 Pierce St, Denver, CO 80214 USA.		Perez, Paloma/K-8841-2017	Perez, Paloma/0000-0002-7166-2824; Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA79065-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALMAIN A, 1982, NUCLEIC ACIDS RES, V10, P4259, DOI 10.1093/nar/10.14.4259; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Binder RL, 1998, CANCER RES, V58, P4314; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gilmore TD, 1996, ONCOGENE, V13, P1367; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE J, 1993, ONCOGENE, V8, P2067; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Karin M, 1998, CANCER J SCI AM, V4, pS92; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KOONG AC, 1994, CANCER RES, V54, P5273; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Leveillard Thierry, 1993, Gene Expression, V3, P135; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Slaga T J, 1995, Prog Clin Biol Res, V391, P1; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Tobin D, 1996, ONCOGENE, V12, P785; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WATANABE M, 1993, ONCOGENE, V8, P2949; WEIH F, 1994, ONCOGENE, V9, P3289; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058	53	110	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7423	7431		10.1038/sj.onc.1203104	http://dx.doi.org/10.1038/sj.onc.1203104			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602501				2022-12-28	WOS:000084119600003
J	Gavine, PR; Neil, JC; Crouch, DH				Gavine, PR; Neil, JC; Crouch, DH			Protein stabilization: a common consequence of mutations in independently derived v-Myc alleles	ONCOGENE			English	Article						Myc; viral mutations; stabilization	ALPHA IN-VIVO; C-MYC; TRANSFORMING ACTIVITY; INDUCED DEGRADATION; PROTEASOME PATHWAY; TERMINAL REGION; PHOSPHORYLATION; DOMAIN; MYOD; FOS	Myc is overexpressed in many cancers as a result of gene rearrangement or amplification, but coding sequence changes which cluster in the N-terminal transactivation domain also appear to play a role in tumour progression. The prototypic v-Myc gene of MC29 virus differs from avian c-Myc by a series of mutations, including a change at a regulatory phosphorylation site within the mutational hotspot (thr-61) which is known to potentiate transformation in vitro. We now show that the mutation at thr-61 stabilizes the v-Myc protein (turnover difference) and that this single mutation is both necessary and sufficient for the phenotype. A major involvement of the proteasome in Myc degradation was confirmed, but surprisingly, a dilysine motif adjacent to thr-61 proved not to be the ubiquitin target. Two other v-Myc genes which carry a mutation at thr-61 (avian MH2) or a large deletion encompassing this domain (feline T17) were found to be stabilized to a similar extent as MC29, showing that stabilization is a common feature of independently derived Myc oncogenes, These results suggest a common selective process in the genesis of these three viral oncoproteins and a mechanistic link with Jun, Fos and Myb oncoproteins which are also stabilized relative to their cellular counterparts.	Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland; Univ Glasgow, Sch Vet, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland	University of Dundee; University of Glasgow	Crouch, DH (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland.							Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Chen RH, 1996, ONCOGENE, V12, P1493; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COLL J, 1983, EMBO J, V12, P2189; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; CROUCH DH, 1990, ONCOGENE, V5, P683; CROUCH DH, 1993, ONCOGENE, V8, P1849; CURRAN T, 1984, CELL, V36, P259; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; FULTON R, 1996, J VIROL, V170, P1154; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; Kilbey A, 1996, ONCOGENE, V12, P2409; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PULVERER BJ, 1994, ONCOGENE, V9, P59; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	37	16	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7552	7558		10.1038/sj.onc.1203102	http://dx.doi.org/10.1038/sj.onc.1203102			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602514				2022-12-28	WOS:000084119600016
J	Rey, O; Lee, S; Park, NH				Rey, O; Lee, S; Park, NH			Impaired nucleotide excision repair in UV-irradiated human oral keratinocytes immortalized with type 16 human papillomavirus genome	ONCOGENE			English	Article						HPV; p53; oral cancer; DNA repair	TRANSCRIPTION-COUPLED REPAIR; HUMAN FIBROBLASTS; MOUSE CELLS; DNA-BINDING; P53; PROTEIN; E6; DEGRADATION; INTEGRITY; DEFICIENT	We previously reported that 'high risk' human papillomaviruses (HPV) induce genetic instability in human oral keratinocytes. To understand the mechanisms of HPV-induced genetic instability, we determined the nucleotide excision repair (NER) capacity of normal (NHOK) and human papillomavirus type-16 immortalized oral keratinocytes HOK-16B) by strand-specific removal of UV-induced cyclobutane pyrimidine diners (CPDs) from a 16 Kb fragment of the p53 gene. In NHOK the NER activity was initiated in both DNA strands immediately, although the process in the non-transcribed strand was notably slower than that of the transcribed strand. In HOK-16B cells the initiation of CPDs removal was delayed for at least 8h in both DNA strands, and the process was significantly slower than that in NHOK. UV-irradiation enhanced the p53 protein level more than 30-fold in NHOK(, but it did not significantly alter the protein level in the HOK-16B cells. UV-irradiation also increased the p21(WAF1/CIP1) protein level only in NHOK. These data indicate that 'high risk' HPV induces genetic instability by impairing NER capacity of cells. Impaired NER activity of HOK-16B cells may be implicated with their inability to enhance active p53 when challenged by genotoxic stress.	Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; Inst Dent Res, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Park, NH (corresponding author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.			Rey, Osvaldo/0000-0003-1575-9864	NIDCR NIH HHS [DE11229, DE10598] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010598, P20DE010598, R01DE011229] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FRITSCHE M, 1993, ONCOGENE, V8, P307; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; Liu X, 1997, ONCOGENE, V14, P2347, DOI 10.1038/sj.onc.1201078; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; REY O, 1992, J VIROL, V66, P5815, DOI 10.1128/JVI.66.10.5815-5824.1992; Rey O, 1999, ONCOGENE, V18, P827, DOI 10.1038/sj.onc.1202328; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shin KH, 1996, ONCOGENE, V12, P1089; TOMMASINO M, 1993, ONCOGENE, V8, P195; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	29	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					6997	7001		10.1038/sj.onc.1203180	http://dx.doi.org/10.1038/sj.onc.1203180			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597299				2022-12-28	WOS:000083901900005
J	Siegel, J; Li, Y; Whyte, P				Siegel, J; Li, Y; Whyte, P			SHIP-mediated inhibition of K562 erythroid differentiation requires an intact catalytic domain and Shc binding site	ONCOGENE			English	Article						SHIP; erythroid differentiation; K562 cells	INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; TYROSINE-PHOSPHORYLATED PROTEIN; FULL-LENGTH CDNA; CELL-LINE K562; FC-GAMMA-RIIB; PHOSPHATASE SHIP; MEGAKARYOCYTIC DIFFERENTIATION; ERYTHROLEUKEMIA-CELLS; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION	Growing evidence supports a role for the SHIP inositol 5'-phosphatase in the negative regulation of a variety of receptor-mediated signaling pathways in hematopoietic cells. SHIP expression among cultured cell lines was examined and found to be restricted to cells of hematopoietic origin, with the exception of the K562 erythroleukemia cell line, in which SHIP protein and mRNA were undetectable. The absence of endogenous SHIP in K562 cells provided a useful system to study the role of SHIP in growth and differentiation. When stably expressed in K562 cells, SHIP was found to be constitutively tyrosine phosphorylated and associated with endogenous Shc and Grb-2. Stable expression of SHIP did not affect growth of the cells but resulted in decreased synthesis of hemoglobin protein and E-globin mRNA in response to hemin, an inducer of erythroid differentiation. This effect was not due to increased cell death in the SHIP-expressing lines following hemin stimulation, but was likely the result of an impaired differentiation program in these cells. Mutational analysis indicated that SHIP must retain both an intact catalytic domain and Shc binding site to efficiently inhibit K562 erythroid differentiation.	McMaster Univ, Inst Mol Biol & Biotechnol, Ctr Hlth Sci, Dept Pathol, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Whyte, P (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Ctr Hlth Sci, Dept Pathol, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							BARALLE FE, 1980, CELL, V21, P621, DOI 10.1016/0092-8674(80)90425-0; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harlow E., 1988, ANTIBODIES LAB MANUA; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HENSOLD JO, 1991, BLOOD, V77, P1362; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kubota Y, 1996, LEUKEMIA, V10, P720; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; LEIBOWITZ D, 1991, LEUKEMIA RES, V15, P65, DOI 10.1016/0145-2126(91)90146-K; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1998, BLOOD, V91, P2753, DOI 10.1182/blood.V91.8.2753.2753_2753_2759; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MASONGARCIA M, 1991, FASEB J, V5, P2958, DOI 10.1096/fasebj.5.14.1752362; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; NISHIMURA J, 1988, LEUKEMIA RES, V12, P875, DOI 10.1016/0145-2126(88)90014-8; OKABEKADO J, 1986, CANCER RES, V46, P1239; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rivero JA, 1996, BIOCHEM BIOPH RES CO, V224, P796, DOI 10.1006/bbrc.1996.1102; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; SAXTON TM, 1994, J IMMUNOL, V153, P623; Schaefer A, 1997, CELL SIGNAL, V9, P483, DOI 10.1016/S0898-6568(97)00094-6; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; TORTI M, 1992, J BIOL CHEM, V267, P8293; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	54	10	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7135	7148		10.1038/sj.onc.1203212	http://dx.doi.org/10.1038/sj.onc.1203212			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597315				2022-12-28	WOS:000083901900021
J	Takao, N; Kato, H; Mori, R; Morrison, C; Sonada, E; Sun, XG; Shimizu, H; Yoshioka, K; Takeda, S; Yamamoto, K				Takao, N; Kato, H; Mori, R; Morrison, C; Sonada, E; Sun, XG; Shimizu, H; Yoshioka, K; Takeda, S; Yamamoto, K			Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation	ONCOGENE			English	Article						ATM disruption; p53; cell cycle checkpoint; DNA repair	ATAXIA-TELANGIECTASIA GENE; STRAND-BREAK REPAIR; CYCLE CHECKPOINTS; HOMOLOGOUS RECOMBINATION; VERTEBRATE CELLS; DNA-DAMAGE; NUCLEOTIDE-SEQUENCE; DEFICIENT MICE; P53; DEFECTS	ATM is a member of the large phosphatidylinositol-3 kinase family and plays an important role in cellular response to DNA damage. To further define the physiological roles of ATM at the cellular level, me created an isogenic set of stable cell lines differing only in their ATM status from the chicken B cell line DT40 by targeted integration. These stable DT40 cell lines, as most of transformed chicken cell lines, do not express p53. However, ATM(-/-) DT40 cells displayed retarded cellular proliferation, defective G(2)/M checkpoint control and radio-resistant DNA synthesis. Furthermore, ATM(-/-) DT40 cells were sensitive to ionizing radiation and showed highly elevated frequencies of both spontaneous and radiation-induced chromosomal aberrations. In addition, a slight but significant reduction in targeted integration frequency was observed in,ATM(-/-) DT40 cells. These results suggest that ATM has multiple p53-independent functions in cell cycle checkpoint control and in maintenance of chromosomal DNA. These ATM deficient DT40 clones therefore provide a useful model system for analysing p53-independent ATM functions.	Kanazawa Univ, Fac Med, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Fac Med, Kanazawa, Ishikawa 9200934, Japan; Kyoto Univ, Fac Med, Dept Radiat Genet, Kyoto 6068501, Japan	Kanazawa University; Kanazawa University; Kyoto University	Yamamoto, K (corresponding author), Kanazawa Univ, Fac Med, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan.		Morrison, Ciaran/B-6568-2008; Morrison, Ciaran/AAH-2034-2019	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029; Mori, Ryoichi/0000-0002-7596-9620; Takeda, Shunichi/0000-0002-7924-7991				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BUERSTEDDE JM, 1991, CELL, V82, P685; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CORNFORTH MN, 1987, RADIAT RES, V111, P385, DOI 10.2307/3576926; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; *ISCN1985, 1985, REP STAND COMM HUM C; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; Laderoute MP, 1996, ANTICANCER RES, V16, P2825; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEHMANN AR, 1995, TRENDS GENET, V11, P375, DOI 10.1016/S0168-9525(00)89112-X; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MEYN MS, 1995, CANCER RES, V55, P5991; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULES RS, 1995, CANCER RES, V55, P1763; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11383, DOI 10.1093/nar/16.23.11383; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TAYLOR AMR, 1976, NATURE, V260, P441, DOI 10.1038/260441a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WESTPHAL CH, 1997, CANCER RES, V57, P164; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	46	92	95	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7002	7009		10.1038/sj.onc.1203172	http://dx.doi.org/10.1038/sj.onc.1203172			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597300				2022-12-28	WOS:000083901900006
J	Ohta, T; Michel, JJ; Xiong, Y				Ohta, T; Michel, JJ; Xiong, Y			Association with cullin partners protects ROC proteins from proteasome-dependent degradation	ONCOGENE			English	Article						ROC family; cullins; proteasome-dependent degradation	CELL-CYCLE; UBIQUITIN-LIGASE; S-PHASE; F-BOX; COMPLEX; PROTEOLYSIS; FAMILY; KINASE; IDENTIFICATION; CONJUGATION	Cullin 1/CDC53 represents a multigene family and has been linked to the ubiquitin-mediated proteolysis of several different proteins. We recently identified two closely related RING finger proteins, ROC1 and ROC2, that share considerable sequence similarity to an APC subunit, APC11, and demonstrated ROC1 as an essential subunit of CUL1 and CDC53 ubiquitin ligases. We report here that the expression of ROC1, ROC2 and APC11 genes are induced by mitogens and remain constant during the cell cycle. Unlike other subunits of SCF and APC E3 ligases, ectopically expressed ROC family proteins are degraded by a proteasome-inhibitor sensitive pathway and are stabilized by associating with cullins. Mutations at the conserved Phe79 and His80 residues in the RING finger of ROC1 diminish its binding with cullins, resulting in a loss of cullin protection and ubiquitin ligase activity. These results suggest a potential mechanism for regulating the activity of ROC-cullin ligases through complex assembly and ROC/APC11 subunit ubiquitination.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.			Ohta, Tomohiko/0000-0002-9700-7342	NCI NIH HHS [CA68377, CA65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068377, R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LI Y, 1994, ONCOGENE, V9, P2261; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Mathias N, 1999, MOL CELL BIOL, V19, P1759; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	33	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6758	6766		10.1038/sj.onc.1203115	http://dx.doi.org/10.1038/sj.onc.1203115			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597284				2022-12-28	WOS:000083792000018
J	Liu, JF; Chevet, E; Kebache, S; Lemaitre, G; Barritault, D; Larose, L; Crepin, M				Liu, JF; Chevet, E; Kebache, S; Lemaitre, G; Barritault, D; Larose, L; Crepin, M			Functional Rac-1 and Nck signaling networks are required for FGF-2-induced DNA synthesis in MCF-7 cells	ONCOGENE			English	Article						FGF-2; MCF-7; DNA synthesis	FIBROBLAST-GROWTH-FACTOR; BREAST-CANCER CELLS; PROTEIN-KINASE PATHWAY; TYROSINE PHOSPHATASE; RECEPTOR ACTIVATION; STIMULATED CELLS; FACTOR FAMILY; MAP KINASE; RAS; SHC	The effects of Fibroblast Growth Factor-2 (FGF-2) on breast cancer cell DNA synthesis are controversial. To elucidate the mechanisms by which FGF-2 stimulates or inhibits DNA synthesis, we analysed FGF-2 signaling pathways in breast cancer MCF-7 and MCF-7 cells overexpressing Ha-Ras (MCF-7ras), We found that FGF-2-induction of DNA synthesis correlates with Ras transient activation, FRS-2 tyrosine phosphorylation and low level of expression of p66(She). In addition, Nck-associated proteins are highly tyrosine phosphorylated and JNK reaches a higher level of activation when FGF-2 triggers DNA synthesis. Interestingly upon FGF-2 treatment, JNK activation and DNA synthesis are dependent on Rac-1 activity. These results confirm that in MCF-7 cells, induction of DNA synthesis by FGF-2 requires a transient activation of the Ras/MAPK cascade and demonstrates for the first time that intact Rac-1 and Nck signaling networks are required.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B2, Canada; Univ Paris 13, UFR Leonard de Vinci, Lab Rech Oncol Mol Humaine, EA 445, F-93012 Bobigny, France; Univ Paris 13, Lab CRRET, F-94010 Creteil, France	McGill University; McGill University; Universite Paris 13; Universite Paris 13; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Chevet, E (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.		Liu, Jianfeng/E-2786-2012; chevet, eric/E-4992-2016; Lemaître, Gilles/AAL-5889-2021	chevet, eric/0000-0001-5855-4522; Lemaitre, Gilles/0000-0002-0898-1582				Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Cantrell D, 1998, TRENDS CELL BIOL, V8, P180, DOI 10.1016/S0962-8924(98)01264-1; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Fenig E, 1997, CLIN CANCER RES, V3, P135; GELMANN EP, 1992, INT J CANCER, V50, P665, DOI 10.1002/ijc.2910500431; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GOMM JJ, 1991, CANCER RES, V51, P4685; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KAREY KP, 1988, CANCER RES, V48, P4083; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JF, 1998, EUR J BIOCHEM, V258, P271, DOI 10.1046/j.1432-1327.1998.2580271.x; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCLESKEY SW, 1994, CANCER RES, V54, P523; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Rockow S, 1996, ONCOGENE, V12, P2351; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; SOMMERS CL, 1990, CANCER RES, V50, P67; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Wang HS, 1997, CANCER RES, V57, P1750; Wang JK, 1996, ONCOGENE, V13, P721; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	47	29	31	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6425	6433		10.1038/sj.onc.1203027	http://dx.doi.org/10.1038/sj.onc.1203027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597244				2022-12-28	WOS:000083709200004
J	Barnouin, K; Fredersdorf, S; Eddaoudi, A; Mittnacht, S; Pan, LX; Du, MQ; Lu, X				Barnouin, K; Fredersdorf, S; Eddaoudi, A; Mittnacht, S; Pan, LX; Du, MQ; Lu, X			Antiproliferative function of p27(kip1) is frequently inhibited in highly malignant Burkitt's lymphoma cells	ONCOGENE			English	Article						D-type cyclin; cyclin dependant kinase; p27(kip1); cell cycle; Birkitt's lymphoma	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; CDK INHIBITORS; MICE LACKING; CYCLE ARREST; TGF-BETA; INACTIVATION; EXPRESSION; GROWTH; HYPERPLASIA	Lack of detectable expression of p27(kip1) cyclin dependent kinase inhibitor has previously been correlated with high degree of malignancy in human breast, colorectal, gastric and smalt cell lung carcinomas. Here me demonstrate that an inverse correlation between p27(kip1) expression and tumour malignancy also exists in most types of human B cell lymphomas examined. A clear exception was Burkitt's lymphoma (BL), a highly malignant tumour which often expresses high levels of p27(kip1). Analysis of p27(kip1) derived from Burkitt's lymphoma cell lines expressing high levels of p27(kip1), BL40 and BL41, in a cyclin E/cdk2 kinase inhibition assay demonstrated that p27(kip1) is not permanently inactivated since heat treatment can restore the inhibitory activity of p27(kip1). However, p27(kip1) expressed in these two cell lines is largely sequestered in inactive complexes and me have no evidence that c-myc or Epstein-Barr virus are responsible for the sequestration of p27(kip1) in these two cell lines although c-myc and EBV are two oncogenic agents often associated with Burkitt's lymphomas. Interestingly, we observed that high level p27(kip1) expression often correlated,vith cyclin D3 overexpression both in vivo and in BL cell lines. The majority of p27(kip1) in BL40 cells was complexed with cyclin D3 indicating that overexpressed cyclin D3 may at least be part of the sequestering activity for the inhibitory function of p27(kip1). Furthermore, cyclinD3/cdk4 complex could sequester p27(kip1) in a cyclin E/cdk2 kinase assay in vitro. Finally, me show that cyclin D3 transfected into an inducible p27(kip1) cell line could overcome the G1 arrest mediated by p27(kip1). These results argue that in addition to down-regulation of p27(kip1) expression, some tumour cells can sequester and tolerate the antiproliferative function of p27(kip1), They also suggest a novel role for the overexpression of D-type cyclins as one pathway allowing tumour cells to overcome the antiproliferative function of p27(kip1).	St Marys Hosp, Imperial Coll, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; UCL, Sch Med, Dept Histopathol, London WC1E 6JJ, England; Inst Canc Res, London SW3 6JB, England; St Marys Hosp, Imperial Coll, Sch Med, Dept Med Microbiol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Lu, X (corresponding author), St Marys Hosp, Imperial Coll, Sch Med, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.			Lu, Xin/0000-0002-6587-1152; Du, Ming-Qing/0000-0002-1017-5045; Eddaoudi, Ayad/0000-0001-5272-6426				Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Harlow E., 1988, ANTIBODIES LAB MANUA; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SanchezBeato M, 1997, AM J PATHOL, V151, P151; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SINCLAIR AJ, 1995, METH MOL G, V7, P89; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZerfassThome K, 1996, ONCOGENE, V13, P2323	28	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6388	6397		10.1038/sj.onc.1203162	http://dx.doi.org/10.1038/sj.onc.1203162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597239				2022-12-28	WOS:000083934100024
J	Corre, I; Baumann, H; Hermouet, S				Corre, I; Baumann, H; Hermouet, S			Regulation by G(i2) proteins of v-fms-induced proliferation and transformation via Src-kinase and STAT3	ONCOGENE			English	Article						CSF-1R; receptor tyrosine-kinases; G(i2); Src-kinase; ERK-MAPK; STAT3	TYROSINE KINASES; COUPLED RECEPTORS; PERTUSSIS TOXIN; CELL-PROLIFERATION; MEDIATED ACTIVATION; DIRECT STIMULATION; BINDING-PROTEIN; GROWTH-FACTORS; ALPHA-SUBUNIT; TGF-BETA	We previously showed that G(i2) proteins interfere with the transduction of CSF-1 receptor (CSF-1R) proliferation signals (Corre and Hermouet, 1995). To identify CSF-1R pathways controlled by G(i2), we transfected nu-fms, the oncogenic equivalent of CSF-IR, in NIH3T3 cells in which G(i2) proteins were inactivated by stably expressing a dominant negative mutant form of the alpha subunit of G(i2) (alpha(i2)-G204A). Expression of alpha(i2)-G204A resulted in decreased Src-kinase activity, delayed activation of p42 ERK-MAPK, decreased cyclin D1 expression and reduced proliferation in response to serum. In alpha(i2)-G204A cells transfected with nu-fms, Src-kinase activity remained deficient but p42 MAPK activity and cyclin D1 expression were similar to those of vector/nu-fms cells, suggesting that nu-fms bypasses Src to activate the ERK-MAPK cascade. However, DNA synthesis and focus formation were inhibited by up to 80% in alpha(i2)-G204A/nu-fms cells compared to vector/nu-fms cells. We found that tyrosine phosphorylation of STAT3, also activated by CSP-1R/nu-fms, was inhibited in alpha(i2)-G204A/nu-fms cells; in addition, expression of an 85 kDa, C-terminal truncated form of STAT3 (STAT3 Delta) was constitutively increased. Both the inhibition of v-fms-induced STAT3 tyrosine phosphorylation and the increased expression of STAT3 Delta were reproduced by transfecting a dominant negative mutant of Src. Last, we show that expression of STAT3 Delta 55C, a mutant form of STAT3 lacking the last 55 C-terminal amino acids, is sufficient to inhibit DNA synthesis and nu-fms-induced transformation in NIH3T3 cells. In summary, adequate regulation by G(i2) proteins of the activity of both Src-kinase and STAT3 is required for optimal cell proliferation in response to CSF-1R/nu-fms.	Inst Biol, INSERM, U463, Grp Cytokines Recepteurs & Transduct Signal, F-44093 Nantes, France; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Roswell Park Cancer Institute	Hermouet, S (corresponding author), Inst Biol, INSERM, U463, Grp Cytokines Recepteurs & Transduct Signal, 9 Quai Moncousu, F-44093 Nantes, France.		Corre, Isabelle/L-2583-2015	CORRE, Isabelle/0000-0001-6444-1145				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BELKA C, 1995, LEUKEMIA, V9, P754; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Corre I, 1999, EXP HEMATOL, V27, P28, DOI 10.1016/S0301-472X(98)00032-0; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HE YX, 1988, BLOOD, V71, P1187; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; KOYASU S, 1989, CELL STRUCT FUNCT, V14, P459; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAESTRONI GJM, 1994, EXP HEMATOL, V22, P313; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MAYANI H, 1995, EXP HEMATOL, V23, P422; MILLER BA, 1991, BLOOD, V77, P486; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1994, J CELL SCI, P105; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; WANG Y, IN PRESS HEPATOLOGY; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YEUNG YG, 1992, J BIOL CHEM, V267, P23447	41	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6335	6342		10.1038/sj.onc.1203010	http://dx.doi.org/10.1038/sj.onc.1203010			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597233				2022-12-28	WOS:000083934100018
J	Darbinian, N; Gallia, GL; Kundu, M; Shcherbik, N; Tretiakova, A; Giordano, A; Khalili, K				Darbinian, N; Gallia, GL; Kundu, M; Shcherbik, N; Tretiakova, A; Giordano, A; Khalili, K			Association of Pur alpha and E2F-1 suppresses transcriptional activity of E2F-1	ONCOGENE			English	Article						single-stranded DNA binding protein; Pur alpha; E2F-1; protein-protein interaction	SINGLE-STRANDED-DNA; CELLULAR PROTEINS YB-1; BINDING PROTEIN; RETINOBLASTOMA PROTEIN; CONTROL ELEMENT; TUMOR-ANTIGEN; CYCLE CONTROL; GENE; REPLICATION; COMPONENTS	Protein-protein interaction can play an important role in the control of several biological events including gene transcription, replication and cell proliferation. E2F-1 is a DNA-binding transcription factor which, upon interaction with its target DNA sequence, induces expression of several S phase specific genes allowing progression of the cell cycle. Evidently, the activity of this protein is modulated by its cellular partner, pRb, which in the hypophosphorylated form, binds to E2F-1 and inactivates its transcriptional ability. In this study, we have demonstrated that expression of a sequence-specific single-stranded DNA binding protein, Pur alpha, in cells decreases the ability of E2F-1 to exert its transcriptional activity upon the responsive promoter derived from DHFR, Results from band shift experiments revealed that while Pur alpha does not recognize the double-stranded DNA fragment containing the E2F-1 binding site, it has the ability to inhibit E2F-1 interaction with its target DNA sequence. Results from GST pull-down assays and the combined immunoprecipitation/Western blot analysis of nuclear extracts revealed a direct association of E2F-1 with Pur alpha in the absence of the DNA molecule containing the E2F-1 binding site, The association of Pur alpha with E2F-1 may increase the stability of E2F-1, as a higher level of E2F-1 was detected in cells coexpressing Pur alpha and E2F-1, The importance of these observations with respect to the role of Pur alpha in the control of cell cycle progression is discussed.	Med Coll Penn & Hahnemann Univ, Sch Med, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sbarro Inst Canc Res, Philadelphia, PA 19107 USA	Drexel University; Jefferson University	Khalili, K (corresponding author), Med Coll Penn & Hahnemann Univ, Sch Med, Ctr Neurovirol & Neurooncol, 245 N 15th St,MS 406, Philadelphia, PA 19102 USA.		Kundu, Mondira/N-8139-2018; Giordano, Antonio/F-1927-2010	Kundu, Mondira/0000-0001-9946-2472; Giordano, Antonio/0000-0002-5959-016X				BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; NEVINS JR, 1992, SCIENCE, V258, P424; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	17	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6398	6402		10.1038/sj.onc.1203011	http://dx.doi.org/10.1038/sj.onc.1203011			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597240				2022-12-28	WOS:000083934100025
J	Masselink, H; Bernards, R				Masselink, H; Bernards, R			The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR	ONCOGENE			English	Article						BS69; BRAM1; N-CoR; E1A; MYND; repression	HISTONE DEACETYLASE COMPLEX; ACUTE MYELOID-LEUKEMIA; ACTIVATES TRANSCRIPTION; REPRESSES TRANSCRIPTION; INSITU HYBRIDIZATION; BASAL TRANSCRIPTION; MOLECULAR-CLONING; TERMINAL DOMAIN; FUSION PARTNER; INTERACTS	BS69 was first identified as a protein that interacts directly with the transactivation domain (conserved region 3) of the 289R adenovirus type 5 E1A protein. We show here that BS69 is a potent repressor of transcription, BS69 mediates repression, at least in part, through interaction with the co-repressor N-CoR, BS69 interacts with N-CoR through a MYND domain in its carboxyl terminus, A recently cloned splice variant of BS69, designated BRAM1, is also capable of interacting with N-CoR and E1A. but unlike BS69. is not able to repress transcription, indicating that N-CoR interaction is necessary but not sufficient for BS69 repression, Expression of E1A inhibits repression mediated by BS69, Our data suggest that BS69 participates in transcriptional repressor complexes and that E1A can modulate these complexes through interaction with BS69.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Mymryk JS, 1997, BIOCHEM CELL BIOL, V75, P95, DOI 10.1139/bcb-75-2-95; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VOUSDEN KH, 1989, ONCOGENE, V4, P153; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WINSTON CW, 1999, MOL CELL BIOL, V6, P601; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	59	68	72	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1538	1546		10.1038/sj.onc.1203421	http://dx.doi.org/10.1038/sj.onc.1203421			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734313	Green Published			2022-12-28	WOS:000086108100006
J	Matsuzaki, T; Aisaki, K; Yamamura, Y; Noda, M; Ikawa, Y				Matsuzaki, T; Aisaki, K; Yamamura, Y; Noda, M; Ikawa, Y			Induction of erythroid differentiation by inhibition of Ras/ERK pathway in a Friend murine leukemia cell line	ONCOGENE			English	Article						Friend leukemia cell; EPO-induced differentiation; Ras/ERK pathway	MOUSE ERYTHROLEUKEMIA-CELLS; SIGNAL-TRANSDUCTION PATHWAY; PROTEIN-KINASE CASCADE; P38 MAP KINASE; ERYTHROPOIETIN RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; ACTIVATION; JAK2	The role of Ras and MAP kinases (MAPKs) in the regulation of erythroid differentiation was studied using a cell line (SKT6) derived from Friend virus (Anemic strain)-induced murine erythroleukemia. This cell line undergoes differentiation in vitro in response to erythropoietin (EPO) or other chemical inducers such as dimethylsulfoxide (DMSO), When a constitutively active ras mutant (ras12V) was expressed in SKT6 cells, EPO-induced differentiation was inhibited. Conversely, a dominant negative I au mutant (ras17N) induced differentiation even in the absence of EPO, suggesting that the basal Ras activity is essential for the maintenance of the undifferentiated phenotype and proliferative potential in this cell line. Rapid inactivation of ERK was observed after expression of ras17N. Slow but significant inactivation of ERR was also observed during EPO-induced differentiation. Furthermore, overexpression of a constitutively active mutant of ERK-activating kinase (MAPKK) was found to suppress erythroid differentiation, while pharmacological inhibition of MAPKK induced differentiation. These findings suggest that down-regulation of Ras/ERK signaling pathway may be an essential event in EPO-induced erythroid differentiation in this system.	Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Bunkyo Ku, Tokyo 1138519, Japan; Japan Sci & Technol Corp, CREST, Honcho, Saitama 3320012, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Kyoto University	Ikawa, Y (corresponding author), Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.			Matsuzaki, Tomoko/0000-0002-9878-0433				Aisaki K, 1999, JPN J CANCER RES, V90, P171, DOI 10.1111/j.1349-7006.1999.tb00730.x; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dumont FJ, 1998, J IMMUNOL, V160, P2579; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kang CD, 1999, EXP MOL MED, V31, P76, DOI 10.1038/emm.1999.13; Kato MV, 1997, BLOOD, V90, P1373, DOI 10.1182/blood.V90.4.1373.1373_1373_1378; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; Kume T, 1996, J BIOL CHEM, V271, P30916, DOI 10.1074/jbc.271.48.30916; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; KURAMOCHI S, 1990, EUR J BIOCHEM, V193, P163, DOI 10.1111/j.1432-1033.1990.tb19318.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu Q, 1998, MOL CELL BIOL, V18, P3257, DOI 10.1128/MCB.18.6.3257; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; Sharlow ER, 1997, BLOOD, V90, P2175, DOI 10.1182/blood.V90.6.2175.2175_2175_2187; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Tilbrook PA, 1996, CELL GROWTH DIFFER, V7, P511; TODOKORO K, 1994, BIOCHEM BIOPH RES CO, V203, P1912, DOI 10.1006/bbrc.1994.2411; TODOKORO K, 1988, BIOCHIM BIOPHYS ACTA, V943, P326, DOI 10.1016/0005-2736(88)90564-0; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126; TORTI M, 1992, J BIOL CHEM, V267, P8293; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Wakao H, 1997, BIOCHEM BIOPH RES CO, V234, P198, DOI 10.1006/bbrc.1997.6486; WATANABE T, 1992, J BIOL CHEM, V267, P17116; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; XU X, 1995, JPN J CANCER RES, V86, P284, DOI 10.1111/j.1349-7006.1995.tb03052.x; Yamamura Y, 1998, MOL CELL BIOL, V18, P1172, DOI 10.1128/MCB.18.3.1172	52	32	33	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1500	1508		10.1038/sj.onc.1203461	http://dx.doi.org/10.1038/sj.onc.1203461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734309				2022-12-28	WOS:000086108100002
J	Dion, F; Mes-Masson, AM; Seymour, RJ; Provencher, D; Tonin, PN				Dion, F; Mes-Masson, AM; Seymour, RJ; Provencher, D; Tonin, PN			Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers	ONCOGENE			English	Article						ovary; cancer; chromosome 17q35; loss of heterozygosity; tumor suppressor	ALLELIC LOSS; P53 GENE; BREAST CARCINOMAS; NM23 EXPRESSION; TUMORS DISTAL; DELETION UNIT; FREQUENT LOSS; HUMAN GENOME; HETEROZYGOSITY; MUTATIONS	Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis, To further define the pattern of allelic imbalance in epithelial ovarian tumors of different histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25, LOH was observed for at Least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25, Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion defined by D17S795 and D17S801, One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap defined by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors.	Montreal Gen Hosp, Inst Res, Montreal, PQ H3G 1A4, Canada; Univ Montreal, Notre Dame Hosp, Ctr Hosp, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J2, Canada; Montreal Gen Hosp, Dept Obstet & Gynecol, Montreal, PQ H3G 1A4, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J2, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1B1, Canada	McGill University; Universite de Montreal; Universite de Montreal; McGill University; Universite de Montreal; McGill University; McGill University	Tonin, PN (corresponding author), Montreal Gen Hosp, Inst Res, Room L10-120,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.			Mes-Masson, Anne-Marie/0000-0002-6498-266X				BERCHUCK A, 1994, GYNECOL ONCOL, V52, P232, DOI 10.1006/gyno.1994.1037; BORROW J, 1991, GENOMICS, V10, P477, DOI 10.1016/0888-7543(91)90335-C; CORNELIS RS, 1993, ONCOGENE, V8, P781; CROPP CS, 1993, CANCER RES, V53, P5617; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; ECCLES DM, 1990, ONCOGENE, V5, P1599; ECCLES DM, 1992, BRIT J CANCER, V65, P40, DOI 10.1038/bjc.1992.8; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; GODWIN AK, 1994, AM J HUM GENET, V55, P666; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAHN M, 1993, CLIN CHEM, V39, P549; Harlozinska A, 1996, INT J CANCER, V69, P415, DOI 10.1002/(SICI)1097-0215(19961021)69:5<415::AID-IJC11>3.0.CO;2-1; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOBS IJ, 1993, CANCER RES, V53, P1218; Kalikin LM, 1999, GENOMICS, V57, P36, DOI 10.1006/geno.1998.5740; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; LEE JH, 1990, CANCER RES, V50, P2724; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; MANDAI M, 1995, BRIT J CANCER, V72, P691, DOI 10.1038/bjc.1995.395; MARKS JR, 1991, CANCER RES, V51, P2979; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Mertens F, 1997, CANCER RES, V57, P2765; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILNER BJ, 1993, CANCER RES, V53, P2128; OKAMOTO A, 1991, CANCER RES, V51, P5171; Papp J, 1996, BRIT J CANCER, V74, P1592, DOI 10.1038/bjc.1996.594; Phelan CM, 1998, CANCER RES, V58, P1004; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; Phillips NJ, 1996, CANCER RES, V56, P606; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; Plummer SJ, 1997, GENOMICS, V45, P140, DOI 10.1006/geno.1997.4906; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; Risk JM, 1999, GENOMICS, V59, P234, DOI 10.1006/geno.1999.5857; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Sakamoto T, 1996, GYNECOL ONCOL, V63, P173, DOI 10.1006/gyno.1996.0302; SATO T, 1991, CANCER RES, V51, P5118; Scambia G, 1996, J CLIN ONCOL, V14, P334, DOI 10.1200/JCO.1996.14.2.334; Schneider J, 1996, ANTICANCER RES, V16, P1197; Schultz DC, 1996, CANCER RES, V56, P1997; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tangir J, 1996, ONCOGENE, V12, P735; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; TSAO SW, 1991, ANTICANCER RES, V11, P1975; VIEL A, 1995, CANCER RES, V55, P2645; von Brevern M, 1998, ONCOGENE, V17, P2101, DOI 10.1038/sj.onc.1202139; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wertheim I, 1996, ONCOGENE, V12, P2147; Wiper DW, 1998, GYNECOL ONCOL, V71, P77, DOI 10.1006/gyno.1998.5110; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405	54	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1466	1472		10.1038/sj.onc.1203463	http://dx.doi.org/10.1038/sj.onc.1203463			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723138				2022-12-28	WOS:000085942700012
J	Le, Q; Dawson, MI; Soprano, DR; Soprano, KJ				Le, Q; Dawson, MI; Soprano, DR; Soprano, KJ			Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids	ONCOGENE			English	Article						SCC cells; retinoic acid receptors; RAR agonists; RAR antagonists; conformationally restricted retinoids	OVARIAN ADENOCARCINOMA CELLS; BREAST-CANCER CELLS; SQUAMOUS CARCINOMA-CELLS; TERMINAL DIFFERENTIATION; SYNTHETIC RETINOIDS; SELECTIVE RETINOIDS; HUMAN KERATINOCYTES; DIMETHYL-SULFOXIDE; RETROVIRAL VECTORS; CYCLE PROGRESSION	Retinoids have been shown to inhibit the growth of many human tumor cells including breast, ovarian and squamous cell carcinoma (SCC), While the exact mechanism of retinoid mediated growth suppression is not known, a role for the retinoic acid receptors (RARs) and retinoid X receptors (RXRs) has been established in both the breast and ovarian tumor cell models. We set out to determine if modulation of RAR/RXR function would alter the retinoid sensitivity of oral SCC cells. We found that the growth of SCC cells was significantly inhibited by treatment with either all-trans-retinoic acid (trans-RA) or the synthetic, conformationally restricted RAR gamma selective retinoids MM11254 and MM11389. In order to demonstrate a role for RAR/RXR function in this process, stable oral SCC cell clones constitutively overexpressing the dominant negative mutant RAR beta 2 (R269Q) were prepared and shown to exhibit reduced RAR/RXR transcriptional transactivation activity. We found that oral SCC cells exhibiting reduced RAR/RXR function became resistant to growth inhibition by all-trans-RA, MM11254 and MM11389. Likewise, treatment of oral SCC cells with the RAR gamma antagonist MM11253 was found to block the ability of MM11254 and MM11389 to inhibit SCC cell growth. Thus, modulation of RAR function through the use of RAR-gamma selective agonists, an RAR-gamma selective antagonist or a pan-RAR dominant negative mutant significantly alters the growth inhibitory response of oral SCC cells to retinoids.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Mol Med Res Inst, Dept Med Chem, Mt View, CA 94043 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL CANCER INSTITUTE [R01CA064945, P01CA051993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049045] Funding Source: NIH RePORTER; NCI NIH HHS [CA51993, CA64945] Funding Source: Medline; NIDDK NIH HHS [DK49045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYLSWORTH CF, 1986, J NATL CANCER I, V76, P339; BENNER SE, 1994, J NATL CANCER I, V86, P140, DOI 10.1093/jnci/86.2.140; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CARMICHAEL J, 1987, CANCER RES, V47, P936; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; CLINE PR, 1983, CANCER RES, V43, P3203; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; Crowe DL, 1998, CANCER RES, V58, P142; DARWICHE N, 1995, CANCER RES, V55, P2774; Dawson MI, 1998, CANCER LETT, V133, P1, DOI 10.1016/S0304-3835(98)00147-5; DAWSON MI, 1995, J MED CHEM, V38, P3368, DOI 10.1021/jm00017a021; DE LUCA LM, 1991, FASEB J, V5, P2924; GRUNT TW, 1991, J CELL SCI, V100, P657; GRUNT TW, 1992, J CELL SCI, V103, P501; Gudas Lorraine J., 1994, P443; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; HARNISH DC, 1992, DEV DYNAM, V194, P239, DOI 10.1002/aja.1001940309; HAWLEY RG, 1994, GENE THER, V1, P136; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hong Waun Ki, 1994, P597; HU L, 1991, CANCER RES, V51, P3972; KIM KH, 1984, P NATL ACAD SCI-BIOL, V81, P4280, DOI 10.1073/pnas.81.14.4280; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1994, CANCER RES, V54, pS1987; LOTAN R, 1990, METHOD ENZYMOL, V190, P100; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LOTAN R, 1987, INT J CANCER, V40, P224, DOI 10.1002/ijc.2910400217; LOTAN R, 1992, J CELL PHYSIOL, V151, P94, DOI 10.1002/jcp.1041510114; Mangelsdorf David J., 1994, P319; Monzon RI, 1997, MOL PHARMACOL, V51, P377; Moon Richard C., 1994, P573; MUNKER M, 1987, CANCER RES, V47, P4081; Oridate N, 1996, ONCOGENE, V12, P2019; OWEN TA, 1987, J BIOL CHEM, V262, P15111; OWEN TA, 1989, J CELL PHYSIOL, V139, P424, DOI 10.1002/jcp.1041390227; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REISS M, 1985, J NATL CANCER I, V74, P1015; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RUBIN AL, 1986, CANCER RES, V46, P2356; SAKAR R, 1988, CANC LET, V41, P225; SAUNDERS DE, 1993, ANTI-CANCER DRUG, V4, P201, DOI 10.1097/00001813-199304000-00012; SHAO ZM, 1995, ONCOGENE, V11, P493; SOMAY C, 1992, BRIT J CANCER, V66, P93, DOI 10.1038/bjc.1992.223; SOMAY C, 1991, J CELL SCI, V100, P657; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Soprano DR, 1996, ONCOGENE, V12, P577; Sun SY, 1997, CANCER RES, V57, P4931; TAIRIS N, 1995, J BIOL CHEM, V270, P18380, DOI 10.1074/jbc.270.31.18380; THATCHER SM, 1985, DIFFERENTIATION, V29, P82; TOSCANI A, 1988, ONCOGENE RES, V3, P223; TOSCANI A, 1987, ANAL BIOCHEM, V165, P309, DOI 10.1016/0003-2697(87)90274-0; VOLKES EE, 1993, NEW ENGL J MED, V328, P184; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Wu SJ, 1998, ONCOGENE, V17, P2839, DOI 10.1038/sj.onc.1202208; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; XU XC, 1994, CANCER RES, V54, P3580	66	36	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1457	1465		10.1038/sj.onc.1203436	http://dx.doi.org/10.1038/sj.onc.1203436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723137				2022-12-28	WOS:000085942700011
J	Takakura, S; Kohno, T; Shimizu, K; Ohwada, S; Okamoto, A; Yokota, J				Takakura, S; Kohno, T; Shimizu, K; Ohwada, S; Okamoto, A; Yokota, J			Somatic mutations and genetic polymorphisms of the PPP1R3 gene in patients with several types of cancers	ONCOGENE			English	Article						protein phosphatase 1; PPP1R3; mutation; single nucleotide polymorphism; tumor suppressor gene	TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; COWDEN-DISEASE; PROTEIN-PHOSPHORYLATION; REGULATORY SUBUNIT; INSULIN-RESISTANCE; PTEN/MMAC1 GENE; CODING REGION; FREQUENT LOSS; HUMAN-LUNG	Recently, we found nonsense and missense mutations of the PPP1R3 (protein phosphatase 1, regulatory submit 3) gene in diverse human cancer cell lines and primary lung carcinomas, indicating that PPP1R3 functions as a tumor suppressor in human carcinogenesis. In this study, to assess the prevalence of PPP1R3 mutations in human primary cancers and the genetic diversity of the PPP1R3 gene in the human population, somatic mutations and genetic polymorphisms in the PPP1R3 gene were examined in 137 pairs of cancerous and non-cancerous tissues of patients with cancers of colon, ovary, and liver. Five somatic mutations including two missense mutations were detected in three cancerous tissues consisting of two colorectal carcinomas and one ovarian carcinoma, Five novel single nucleotide polymorphisms (SNPs) associated with the substitution of amino acids were also identified in cancer patients, in addition to five known nonsynonymous SNPs, including three previously reported ones as having an impact on the susceptibility to insulin resistant disorders. Differences in the activities and properties of multiple PPP1R3 proteins, which are produced in human cells due to variable somatic mutations and genetic polymorphisms in the PPP1R3 gene, can be involved in human carcinogenesis and susceptibility to diseases.	Natl Canc Ctr, Div Biol, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Jikei Univ, Dept Obstet & Gynecol, Sch Med, Minato Ku, Tokyo 1058461, Japan; Gunma Univ, Dept Surg 2, Sch Med, Maebashi, Gumma 3718511, Japan	National Cancer Center - Japan; Jikei University; Gunma University	Yokota, J (corresponding author), Natl Canc Ctr, Div Biol, Res Inst, Chuo Ku, 1-1 Tsukiji 5-Chome, Tokyo 1040045, Japan.							CHEN YH, 1994, DIABETES, V43, P1234, DOI 10.2337/diabetes.43.10.1234; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Eng C, 1998, INT J ONCOL, V12, P701; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; HANSEN L, 1995, HUM MOL GENET, V4, P1313, DOI 10.1093/hmg/4.8.1313; ISACCHI A, 1989, GENE, V81, P129, DOI 10.1016/0378-1119(89)90343-0; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kohno T, 1998, JPN J CANCER RES, V89, P471, DOI 10.1111/j.1349-7006.1998.tb03285.x; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kohno T, 1999, CANCER RES, V59, P4170; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liang H, 1998, P NATL ACAD SCI USA, V95, P3781, DOI 10.1073/pnas.95.7.3781; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Milland J, 1996, EUR J BIOCHEM, V238, P221, DOI 10.1111/j.1432-1033.1996.0221q.x; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; Rubin Ethel, 1998, Frontiers in Bioscience, V3, pD1209; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Strauss BS, 1998, SEMIN CANCER BIOL, V8, P431, DOI 10.1006/scbi.1998.0092; Takenoshita S, 1998, CARCINOGENESIS, V19, P803, DOI 10.1093/carcin/19.5.803; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Xia J, 1998, DIABETES, V47, P1519, DOI 10.2337/diabetes.47.9.1519; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen Jean C., 1999, Neoplasia (New York), V1, P16, DOI 10.1038/sj.neo.7900011	31	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2000	19	6					836	840		10.1038/sj.onc.1203388	http://dx.doi.org/10.1038/sj.onc.1203388			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698503				2022-12-28	WOS:000085192100015
J	Blalock, WL; Pearce, M; Steelman, LS; Franklin, RA; McCarthy, SA; Cherwinski, H; McMahon, M; McCubrey, JA				Blalock, WL; Pearce, M; Steelman, LS; Franklin, RA; McCarthy, SA; Cherwinski, H; McMahon, M; McCubrey, JA			A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells	ONCOGENE			English	Article						MEK1; signal transduction; oncogenes; cytokines	MAP KINASE KINASE; NIH 3T3 CELLS; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MALIGNANT TRANSFORMATION; INTERLEUKIN-3 RECEPTOR; CYTOKINE RECEPTORS; INTERFERON-GAMMA; DEPENDENT CELLS; GENE-EXPRESSION	The Raf/MEK/MAP kinase cascade plays a critical role in transducing growth signals from activated cell surface receptors, Using Delta MEK1:ER, a conditionally-active form of MEK1, we demonstrate the ability of this dual specificity protein kinase to abrogate the cytokine-dependency of the human rand murine hematopoietic cells lines TF-1, FDC-P1 and FL5.12. Cytokine-independent cells were obtained from TF-1, FDC-P1 and FL5.12 cells at frequencies of 2.5 x 10(-3), 5 x 10(-5) and 10(-7) respectively, indicating that not all cells expressing Delta MEK1:ER were factor-independent. In general, cells that were converted to a cytokine-independent phenotype displayed a higher level of MAP kinase activity in response to Delta MEK1:ER activation than those that remained cytokine-dependent, Delta ME K1:ER-responsive cells could be maintained long-term in the presence of beta-estradiol as well as the estrogen-receptor antagonist 4-Hydroxy-Tamoxifen and the antiestrogen ICI 164383, Removal of hormone led to the rapid cessation of cell growth in a manner similar to that observed when cytokine is withdrawn from the parental cells. Treatment of Delta MEK1:ER-responsive cells with a specific and selective inhibitor, PD98059, prevented growth in response to beta-estradiol. GM-CSF mRNA transcripts were detected in the MEK1-responsive cells indicating that the activated Delta MEK1:ER may induce a pathway leading to autocrine proliferation. Treatment of MEK1-responsive cells with an anti-GM-CSF antibody, but not a control antibody, suppressed cell growth. The cell. lines described here will be useful for elaborating the ability of the MAP kinase pathway to regulate cell proliferation in hematopoietic cells.	E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	McCubrey, JA (corresponding author), E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Brody Bldg 5N98C, Greenville, NC 27858 USA.		McCarthy, Sarah/HCI-8963-2022; McMahon, Martin/L-3303-2013; Blalock, William L/C-6959-2019	McMahon, Martin/0000-0003-2812-1042; Blalock, William L/0000-0002-8045-4840; Franklin, Richard A./0000-0003-0299-9578; McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01CA15025] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGATE PA, 1994, BLOOD, V83, P2459; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRUNET A, 1994, ONCOGENE, V9, P3379; Cleveland JL, 1994, ONCOGENE, V9, P2227; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; delPeso L, 1997, SCIENCE, V278, P687; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; DENT P, 1995, MOL CELL BIOL, V15, P4125; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Hanazono Y, 1996, ACTA HAEMATOL-BASEL, V95, P236; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; HUANG W, 1994, MOL CELL BIOL, V6, P237; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KINOSHITA T, 1995, EMBO J, V14, P265; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MAY WS, 1994, J BIOL CHEM, V269, P26865; MAYO MW, 1995, BLOOD, V86, P3139; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; MCCUBREY JA, 1995, INT J ONCOL, V7, P573; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mufson RA, 1997, FASEB J, V11, P37, DOI 10.1096/fasebj.11.1.9034164; OADI H, 1997, BLOOD, V89, P2745; OADI H, 1995, J BIOL CHEM, V270, P10800; OADI H, 1997, LEUKEMIA S3, V11, P405; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P9430; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Shelly C, 1998, LEUKEMIA, V12, P1951, DOI 10.1038/sj.leu.2401221; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Steelman LS, 1996, LEUKEMIA, V10, P528; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XY, 1997, LEUKEMIA, V11, P1711, DOI 10.1038/sj.leu.2400793; Wang XY, 1997, CYTOKINES CELL MOL T, V3, P3; Wang XY, 1996, CELL GROWTH DIFFER, V7, P487; Wang XY, 1997, INT J ONCOL, V10, P989; Wang XY, 1998, LEUKEMIA, V12, P520, DOI 10.1038/sj.leu.2400975; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	67	74	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					526	536		10.1038/sj.onc.1203337	http://dx.doi.org/10.1038/sj.onc.1203337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698522	Bronze			2022-12-28	WOS:000085104200006
J	Ala-aho, R; Johansson, N; Grenman, R; Fusenig, NE; Lopez-Otin, C; Kahari, VM				Ala-aho, R; Johansson, N; Grenman, R; Fusenig, NE; Lopez-Otin, C; Kahari, VM			Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1	ONCOGENE			English	Article						interferon-gamma; collagenase; squamous cell carcinoma; mitogen activated protein kinase; matrix metalloproteinase	NECROSIS-FACTOR-ALPHA; SQUAMOUS-CELL CARCINOMAS; GENE-EXPRESSION; MATRIX METALLOPROTEINASE-13; TISSUE INHIBITOR; MESSENGER-RNA; FIBROBLAST COLLAGENASE; RHEUMATOID-ARTHRITIS; BREAST CARCINOMAS; III PROCOLLAGENS	Collagenase-3 (MMP-13) is characterized by an exceptionally wide substrate specificity and restricted expression, MMP-13 is specifically expressed by transformed human keratinocytes in squamous cell carcinomas in who and its expression correlates with their invasion capacity. Here, we show, that interferon-gamma (IFN-gamma) markedly inhibits expression of MMP-13 by human cutaneous SCC cells (UT-SCC-7) and by ras-transformed human epidermal keratinocytes (A-5 cells) at the transcriptional level. In addition, IFN-gamma inhibits collagenase-1 (MMP-1) expression in these cells, IFN-gamma, abolished the enhancement of MMP-13 and MMP-1 expression by transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha), and inhibited invasion of A-5 cells through type I collagen. IFN-gamma also rapidly and transiently activates extracellular signal-regulated kinase 1,2 (ERK1,2) and blocking ERK1,2 pathway (Raf/MEK1,2/ERK1,2) by specific MEK1,2 inhibitor PD98059 partially (by 50%) prevents Ser-727 phosphorylation of STAT1 and suppression of MMP-13 expression by IFN-gamma, Furthermore, Ser-727 phosphorylation of STAT1 by ERK1,2, or independently of ERK1,2 activation is associated with marked reduction in MMP-13 expression. These observations identify a novel role for IFN-gamma as a potent inhibitor of collagenolytic activity and invasion of transformed squamous epithelial cells, and show that inhibition of MMP-13 expression by IFN-gamma involves activation of ERK1,2 and STAT1.	Univ Turku, Medicity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Biochem Med, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Dermatol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Turku Univ, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Turku; University of Turku; University of Turku; Abo Akademi University; University of Turku; University of Turku; Helmholtz Association; German Cancer Research Center (DKFZ); University of Oviedo	Kahari, VM (corresponding author), Univ Turku, Medicity Res Lab, Tykistokatu 6, FIN-20520 Turku, Finland.		Kahari, Veli-Matti/T-4925-2019; López-Otín, Carlos/AAB-2106-2020; Kähäri, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368; López-Otín, Carlos/0000-0001-6964-1904; Kähäri, Veli-Matti/0000-0003-2421-9368				Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Arany I, 1998, CANCER LETT, V123, P173, DOI 10.1016/S0304-3835(97)00432-1; BOUKAMP P, 1990, CANCER RES, V50, P2840; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Heppner KJ, 1996, AM J PATHOL, V149, P273; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kauppila S, 1996, AM J PATHOL, V148, P539; KIM J, 1995, J IMMUNOL, V155, P2240; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Krane SM, 1996, J BIOL CHEM, V271, P28509, DOI 10.1074/jbc.271.45.28509; Lee SH, 1998, BRIT J DERMATOL, V139, P186; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; Makela M, 1998, BIOCHEM BIOPH RES CO, V253, P325, DOI 10.1006/bbrc.1998.9641; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Moers C, 1999, INT J CANCER, V80, P564, DOI 10.1002/(SICI)1097-0215(19990209)80:4<564::AID-IJC14>3.0.CO;2-X; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; PYKE C, 1992, CANCER RES, V52, P1336; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; SCHUGER L, 1990, PATHOBIOLOGY, V58, P279, DOI 10.1159/000163597; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TAMAI K, 1995, J INVEST DERMATOL, V104, P384, DOI 10.1111/1523-1747.ep12665857; Tartour E, 1998, J NATL CANCER I, V90, P287, DOI 10.1093/jnci/90.4.287; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Uria JA, 1997, CANCER RES, V57, P4882; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; VARGA J, 1995, J CLIN INVEST, V96, P475, DOI 10.1172/JCI118058; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wernicke D, 1996, J RHEUMATOL, V23, P590; WESTERMARCK J, 1995, J INVEST DERMATOL, V105, P197, DOI 10.1111/1523-1747.ep12317114; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Xu XL, 1998, CANCER RES, V58, P2832; ZHU GG, 1993, CANCER RES, V53, P5028	63	50	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					248	257		10.1038/sj.onc.1203306	http://dx.doi.org/10.1038/sj.onc.1203306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645003				2022-12-28	WOS:000084844400010
J	Shi, YJ; Pin, OY; Sugrue, SP				Shi, YJ; Pin, OY; Sugrue, SP			Characterization of the gene encoding pinin/DRS/memA and evidence for its potential tumor suppressor function	ONCOGENE			English	Article						pinin; tumor suppressor; 14q13; desmosome; DNA methylation; TCC	E-CADHERIN; CELL-LINES; DNA METHYLATION; PROSTATE-CANCER; ADHESION SYSTEM; ALPHA-CATENIN; BREAST-CANCER; LUNG CANCERS; EXPRESSION; CARCINOMA	Several cell adhesion-related proteins have been shown to act as tumor-suppressors (TS) in the neoplastic progression of epithelial-derived tumors. Pinin/DRS/memA was first identified in our laboratory and it was shown to be a cell adhesion-related molecule. Our previous study demonstrated that restoration of pinin expression in transformed cells not only positively influenced cellular adhesive properties but also reversed the transformed phenotype to more epithelial-like. Here, we show by FISH analysis that the gene locus for pinin is within 14q13. The alignment of the pinin gene with STS markers localized the gene to the previously identified TS Locus D14S75-D14S288. Northern analyses revealed diminished pinin mRNA in renal cell carcinomas (RCC) and certain cancer cell lines. Immunohistochemical examination of tumor samples demonstrated absent or greatly reduced pinin in transitional cell carcinoma (TCC) and RCC tumors, TCC-derived J82 cells as well as EcR-293 cells transfected with full-length pinin cDNA demonstrated inhibition of anchorage-independent growth of cells in soft agar. Furthermore, methylation analyses revealed that aberrant methylation of pinin CpG islands was correlated with decreased/absent pinin expression in a subset of tumor tissues. These data lend significant support to the hypothesis that pinin/DRS/memA may act as a tumor suppressor in certain types of cancers.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Chang Gung Univ, Coll Med, Tau Yuan, Taiwan	State University System of Florida; University of Florida; Chang Gung University	Sugrue, SP (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.				NEI NIH HHS [EY07883] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007883] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bandera CA, 1997, CANCER RES, V57, P513; Baylin SB, 1998, ADV CANCER RES, V72, P141; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Beroud C, 1996, GENE CHROMOSOME CANC, V17, P215, DOI 10.1002/(SICI)1098-2264(199612)17:4<215::AID-GCC3>3.0.CO;2-6; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; Brandner JM, 1997, DIFFERENTIATION, V62, P119, DOI 10.1046/j.1432-0436.1997.6230119.x; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; CAVENEE WK, 1993, J CLIN INVEST, V91, P3, DOI 10.1172/JCI116185; CHANG WYH, 1995, CANCER RES, V55, P3246; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Clurman B, 1997, NATURE, V389, P122, DOI 10.1038/38116; CONN IG, 1990, BRIT J UROL, V65, P176, DOI 10.1111/j.1464-410X.1990.tb14694.x; Davies G, 1998, ONCOL REP, V5, P1567; Degen WGJ, 1999, BBA-GENE STRUCT EXPR, V1444, P384, DOI 10.1016/S0167-4781(99)00012-3; Doki Y, 1997, CARCINOGENESIS, V18, P1139, DOI 10.1093/carcin/18.6.1139; Emig R, 1998, BRIT J CANCER, V78, P1661, DOI 10.1038/bjc.1998.739; EWING CM, 1995, CANCER RES, V55, P4813; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; GARROD DR, 1995, CANCER SURV, V24, P97; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; HSIEH JT, 1995, CANCER RES, V55, P190; Kane MF, 1997, CANCER RES, V57, P808; Kashiwabara K, 1998, INT J CANCER, V79, P215, DOI 10.1002/(SICI)1097-0215(19980619)79:3<215::AID-IJC1>3.0.CO;2-S; Kaur J, 1998, INT J CANCER, V79, P370, DOI 10.1002/(SICI)1097-0215(19980821)79:4&lt;370::AID-IJC11&gt;3.0.CO;2-9; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LICHTER P, 1992, HUMAN CYTOGENETICS P; MARSHALL CJ, 1977, J NATL CANCER I, V58, P1743, DOI 10.1093/jnci/58.6.1743; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mutirangura A, 1998, INT J CANCER, V78, P153, DOI 10.1002/(SICI)1097-0215(19981005)78:2<153::AID-IJC5>3.0.CO;2-Y; OUYANG P, 1992, J CELL BIOL, V118, P1477, DOI 10.1083/jcb.118.6.1477; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pin OY, 1999, BIOCHEM BIOPH RES CO, V263, P192, DOI 10.1006/bbrc.1999.1353; Pin OY, 1996, J CELL BIOL, V135, P1027, DOI 10.1083/jcb.135.4.1027; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Taverna D, 1998, CANCER RES, V58, P848; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; Weaver DA, 1997, CARCINOGENESIS, V18, P1251, DOI 10.1093/carcin/18.6.1251; Wong MKK, 1997, MOL BIOL CELL, V8, P1441; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474	54	43	48	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					289	297		10.1038/sj.onc.1203328	http://dx.doi.org/10.1038/sj.onc.1203328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645008				2022-12-28	WOS:000084844400015
J	Zong, S; Hu, P; Ye, TZ; Stan, R; Ellis, NA; Pandolfi, PP				Zong, S; Hu, P; Ye, TZ; Stan, R; Ellis, NA; Pandolfi, PP			A role for PML and the nuclear body in genomic stability	ONCOGENE			English	Article						PML; BLM; APL; Bloom syndrome; nuclear body; sister-chromatid exchange	ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; TRANSGENIC MICE; BLOOMS-SYNDROME; GENE; TRANSLOCATION; INTERFERON; T(15-17); PATHWAYS; PROTEIN	The PML gene of acute promyelocytic leukemia (APL) encodes a cell-growth and tumor suppressor. PML to discrete nuclear bodies (NBs) that are disrupted in APL cells. The Bloom syndrome gene BLM encodes a RecQ DNA helicase, whose absence from the cell results in genomic instability epitomized by high levels of sister-chromatid exchange (SCE) and cancer predisposition, We show here that BLM colocalizes with PML to the NB. In cells from persons with Bloom syndrome the localization of PML is unperturbed, whereas in APL cells carrying the PML-RAR alpha oncoprotein, both PML and BLM are delocalized from the NE into microspeckled nuclear regions. Treatment with retinoic acid (RA) induces the relocalization of both proteins to the NE. In primary PML-/- cells, BLM fails to accumulate in the NE. Strikingly, in PML-/- cells the frequency of SCEs is increased relative to PML +/+ cells. These data demonstrate that BLM is a constituent of the NE and that PML is required for its accumulation in these nuclear domains and for the normal function of BLM. Thus, our findings suggest a role for BLM in APL pathogenesis and implicate the PRL NE in the maintenance of genomic stability.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, Mol & Dev Biol Lab, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, Lab Canc Susceptibil, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Human Genet, Mol & Dev Biol Lab, Program Mol Biol, 1275 York Ave,Box 110, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA071692, R37CA071692, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748, CA71692] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beresten SF, 1999, PROTEIN EXPRES PURIF, V17, P239, DOI 10.1006/prep.1999.1135; Boddy MN, 1996, ONCOGENE, V13, P971; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; GERMAN J, 1977, AM J HUM GENET, V29, P248; German J, 1998, GENETIC BASIS HUMAN, P301; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	32	188	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7941	7947		10.1038/sj.onc.1203367	http://dx.doi.org/10.1038/sj.onc.1203367			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637504				2022-12-28	WOS:000084634600002
J	Lipinski, MM; Jacks, T				Lipinski, MM; Jacks, T			The retinoblastoma gene family in differentiation and development	ONCOGENE			English	Article						retinoblastoma family; differentiation; transcriptional regulation; cell-cycle exit	CELL-GROWTH CONTROL; S-PHASE ENTRY; SKELETAL-MUSCLE; ADIPOCYTE DIFFERENTIATION; NEURONAL DIFFERENTIATION; HISTONE DEACETYLASE; E2F FAMILY; TRANSCRIPTIONAL REPRESSOR; TERMINAL DIFFERENTIATION; REGULATED EXPRESSION	The retinoblastoma (Rb) tumor suppressor gene and its close relatives p107 and p130 are best known for their function in the control of cell cycle progression. In recent years, however, a new role for these proteins has been emerging as they have been linked with regulation of terminal differentiation of many tissues and cell types. In fact, Rb and its family members have been shown to be involved in multiple stages of the differentiation process including irreversible exit from the cell cycle, protection from apoptosis, induction of cell type specific gene expression and-maintenance of the post-mitotic state. They also play a critical role in assuring the orderly progression through all these stages of differentiation.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Ctr Canc Res, Dept Biol, 40 Ames St, Cambridge, MA 02139 USA.			Lipinski, Marta/0000-0002-7537-9014				Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Borycki AG, 1997, CURR BIOL, V7, pR620, DOI 10.1016/S0960-9822(06)00317-4; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Calof Anne L., 1995, Current Opinion in Neurobiology, V5, P19, DOI 10.1016/0959-4388(95)80082-4; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chitnis AB, 1999, CURR OPIN NEUROBIOL, V9, P18, DOI 10.1016/S0959-4388(99)80003-8; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CONDORELLI GL, 1995, P NATL ACAD SCI USA, V92, P4808, DOI 10.1073/pnas.92.11.4808; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; FEDDERSEN RM, 1995, MOL CELL NEUROSCI, V6, P153, DOI 10.1006/mcne.1995.1014; FIELD S, 1996, CELL, V85, P548; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee JE, 1997, DEV NEUROSCI-BASEL, V19, P27, DOI 10.1159/000111182; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARTELLI F, 1994, ONCOGENE, V9, P3579; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; SLACK RS, 1993, ONCOGENE, V8, P1585; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Stiegler P, 1998, CANCER RES, V58, P5049; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Walsh K, 1997, Prog Cell Cycle Res, V3, P53; Wang J, 1997, CANCER RES, V57, P351; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WU X, 1994, P NATL ACAD SCI USA, V91, P3802; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	84	330	341	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 20	1999	18	55					7873	7882		10.1038/sj.onc.1203244	http://dx.doi.org/10.1038/sj.onc.1203244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630640	Bronze			2022-12-28	WOS:000084405900004
J	Fiers, W; Beyaert, R; Declercq, W; Vandenabeele, P				Fiers, W; Beyaert, R; Declercq, W; Vandenabeele, P			More than one way to die: apoptosis, necrosis and reactive oxygen damage	ONCOGENE			English	Review						apoptosis; necrosis; reactive oxygen; cell death	PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; NF-KAPPA-B; INTERLEUKIN-1-BETA CONVERTING-ENZYME; APO-1/FAS LIGAND EXPRESSION; FACTOR-INDUCED CYTOTOXICITY; BCL-X-L; FACTOR-ALPHA; SUPEROXIDE-DISMUTASE; L929 CELLS	Cell death is an essential phenomenon in normal development and homeostasis, but also plays a crucial role in various pathologies. Our understanding of the molecular mechanisms involved has increased exponentially, although it is still far from complete. The morphological features of a cell dying either by apoptosis or by necrosis are remarkably conserved for quite different cell types derived from lower or higher organisms. At the molecular level, several gene products play a similar, crucial role in a major cell death pathway in a worm and in man. However, one should not oversimplify. It is now evident that there are multiple pathways leading to cell death, and some cells may have the required components for one pathway, but not for another, or contain endogenous inhibitors which preclude a particular pathway. Furthermore, different pathways can co-exist in the same cell and are switched on by specific stimuli. Apoptotic cell death, reported to be noninflammatory, and necrotic cell death, which may be inflammatory, are two extremes, while the real situation is usually more complex. We here review the distinguishing features of the various cell death pathways: caspases (cysteine proteases cleaving after particular aspartate residues), mitochondria and/or reactive oxygen species are often, but not always, key components. As these various caspase-dependent and caspase-independent cell death pathways are becoming better characterized, we may learn to differentiate them, fill in the many gaps in our understanding, and perhaps exploit the knowledge acquired for clinical benefit.	Univ Ghent, Dept Biol Mol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium	Ghent University	Fiers, W (corresponding author), Univ Ghent, Dept Biol Mol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009; Beyaert, Rudi/B-2589-2009	Vandenabeele, Peter/0000-0002-6669-8822; Beyaert, Rudi/0000-0002-5704-582X				AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Baker A, 1997, CANCER RES, V57, P5162; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Banki K, 1999, J IMMUNOL, V162, P1466; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Belaud-Rotureau MA, 1999, CELL DEATH DIFFER, V6, P788, DOI 10.1038/sj.cdd.4400552; BERKOW RL, 1987, J IMMUNOL, V139, P3783; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BREKKE OL, 1992, CYTOKINE, V4, P269, DOI 10.1016/1043-4666(92)90067-2; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Castagne V, 1996, P ROY SOC B-BIOL SCI, V263, P1193, DOI 10.1098/rspb.1996.0175; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; De Valck D, 1998, J CELL BIOCHEM, V71, P392, DOI 10.1002/(SICI)1097-4644(19981201)71:3<392::AID-JCB8>3.0.CO;2-N; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Dusi S, 1996, J IMMUNOL, V157, P4615; EDDY LJ, 1992, BIOCHEM BIOPH RES CO, V184, P1056, DOI 10.1016/0006-291X(92)90698-K; Eguchi Y, 1997, CANCER RES, V57, P1835; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Faris M, 1998, J IMMUNOL, V160, P134; FIERS W, 1986, COLD SPRING HARB SYM, V51, P587, DOI 10.1101/SQB.1986.051.01.071; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GOOSSENS V, 1999, IN PRESS BIOFACTORS, V10; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hall S. S., 1997, COMMOTION BLOOD; Hammond EM, 1998, FEBS LETT, V425, P391, DOI 10.1016/S0014-5793(98)00266-X; Hampton MB, 1998, TOXICOL LETT, V103, P355, DOI 10.1016/S0378-4274(98)00333-6; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Hotta M, 1998, J EXP MED, V188, P1445, DOI 10.1084/jem.188.8.1445; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KAWAGUCHI T, 1990, BIOCHEM BIOPH RES CO, V171, P1378, DOI 10.1016/0006-291X(90)90838-E; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Koonin EV, 1999, NATURE, V401, P662, DOI 10.1038/44317; Krammer P H, 1999, Adv Immunol, V71, P163; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li JJ, 1997, CANCER RES, V57, P1991; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Manna SK, 1999, J IMMUNOL, V162, P1510; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; MATTHEWS N, 1983, BRIT J CANCER, V48, P405, DOI 10.1038/bjc.1983.205; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEALE ML, 1988, IMMUNOLOGY, V64, P81; Nishina H, 1998, J IMMUNOL, V161, P3416; Nishina H, 1999, DEVELOPMENT, V126, P505; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PARK YMK, 1992, RADIAT RES, V131, P162, DOI 10.2307/3578437; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Peppelenbosch M, 1999, J IMMUNOL, V162, P837; Prins JB, 1998, BIOSCIENCE REP, V18, P329, DOI 10.1023/A:1020261316486; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SanchezAlcazar JA, 1997, J BIOL CHEM, V272, P30167, DOI 10.1074/jbc.272.48.30167; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shinoura N, 1999, ONCOGENE, V18, P5703, DOI 10.1038/sj.onc.1202966; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Simm A, 1997, J CELL SCI, V110, P819; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Steemans M, 1998, J EXP MED, V188, P2193, DOI 10.1084/jem.188.11.2193; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Taniguchi S, 1996, J DERMATOL SCI, V12, P44, DOI 10.1016/0923-1811(95)00463-7; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Ueda S, 1998, J IMMUNOL, V161, P6689; VANDECRAEN M, 1999, IN PRESS CELL DEATH, V6; Vander Heiden MG, 1999, MOL CELL, V3, P159; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; VANHAESEBROECK B, 1991, CANCER RES, V51, P2229; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Wallach D, 1998, CURR OPIN IMMUNOL, V10, P131, DOI 10.1016/S0952-7915(98)80240-9; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; WONG GHW, 1995, BBA-MOL BASIS DIS, V1271, P205, DOI 10.1016/0925-4439(95)00029-4; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	164	701	728	2	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7719	7730		10.1038/sj.onc.1203249	http://dx.doi.org/10.1038/sj.onc.1203249			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618712				2022-12-28	WOS:000084256900001
J	Lee, AWM; Nambirajan, S; Moffat, JG				Lee, AWM; Nambirajan, S; Moffat, JG			CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells	ONCOGENE			English	Article						colony-stimulating factor-1 receptor; p31Waf1/Cip1; cyclin D1; MAP kinase; breast cancer; estrogen	COLONY-STIMULATING FACTOR; CYCLIN D1 EXPRESSION; FACTOR-I; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CDK INHIBITORS; INDEPENDENT GROWTH; CARCINOMA CELLS; GENE-EXPRESSION; DNA-DAMAGE	The CSF-1 receptor (CSF-1R) is expressed in >50% of human breast cancers. To investigate the consequence of CSF-1R expression, hormone-dependent human breast cancer cell lines, MCF-7 and T-47D, were transfected with CSF-1R, Unexpectedly, CSF-1 substantially inhibited estradiol (E-2) and insulin-dependent proliferation of MCF-7 transfectants (MCF-7fms) and prevented cyclin E/cdk2 and cyclin A/cdk2 activation, consistent with a G(1) arrest. In contrast, CSF-1 increased DNA synthesis in T-47D transfectants (T-47Dfms) alone and with E-2 or insulin. In response to CSF-1, there was a marked and sustained upregulation of the cyclin-dependent kinase inhibitor, p21(Waf1/Cip1), in MCF-7fms but not T-47Dfms, CSF-1 also markedly upregulated cyclin D1 in MCF-7fms, The coordinate increase in cyclin D1 and p21 had the effect of decreasing the specific but not absolute activity of cyclin D1/cdk4, p53 was not involved since CSF-I induction of p21 was unaffected by dominant-negative p53 expression. ERK activation by CSF-1 was robust and sustained in MCF-7fms and to a much lesser extent in T-47Dfms. Using pharmacological and transient transfection approaches, we showed that ERK activation was necessary and sufficient for p21 induction in MCF-7fms, Moreover, activated MEK inhibited E-2-stimulated cdk2 activity. Our findings indicate that the consequence of CSF-1R-mediated signals in human breast cancer cells is dependent on the genetic background of the particular tumor.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Lee, AWM (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.				NIDDK NIH HHS [R01 DK48929] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048929] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Bacus SS, 1996, ONCOGENE, V12, P2535; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; CASEY G, 1991, ONCOGENE, V6, P1791; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FILDERMAN AE, 1992, CANCER RES, V52, P3661; Flick MB, 1997, ONCOGENE, V14, P2553, DOI 10.1038/sj.onc.1201092; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Iavarone A, 1997, NATURE, V387, P417; JIANG HP, 1994, ONCOGENE, V9, P3397; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; KACINSKI BM, 1991, ONCOGENE, V6, P941; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee AW, 1999, BLOOD, V93, P537, DOI 10.1182/blood.V93.2.537.402k30_537_553; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LEE AWM, 1992, CURR TOP CELL REGUL, V32, P73; LI Y, 1994, ONCOGENE, V9, P2261; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; MUSGROVE EA, 1993, EUR J CANCER, V29A, P2273, DOI 10.1016/0959-8049(93)90221-Z; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Parry D, 1999, MOL CELL BIOL, V19, P1775; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROUSSEL MF, 1994, J CELL SCI, P105; RUDEN TV, 1991, LEUKEMIA, V5, P3; Sapi E, 1998, CANCER RES, V58, P1027; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STANLEY E, 1981, J IMMUNOL METHODS, V264, P1694; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; Tombes RM, 1998, BIOCHEM J, V330, P1451; Wang HS, 1997, CANCER RES, V57, P1750; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAN GZ, 1995, J NEUROSCI, V15, P6200; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	70	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7477	7494		10.1038/sj.onc.1203123	http://dx.doi.org/10.1038/sj.onc.1203123			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602507				2022-12-28	WOS:000084119600009
J	Kim, E; Rohaly, G; Heinrichs, S; Gimnopoulos, D; Meissner, H; Deppert, W				Kim, E; Rohaly, G; Heinrichs, S; Gimnopoulos, D; Meissner, H; Deppert, W			Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53	ONCOGENE			English	Article						p53; mdm2; DNA conformation; non-B-DNA; sequence-specific DNA binding; transcriptional activation	MDM2 GENE; CELL-GROWTH; EXPRESSION; ACTIVATION; PROTEIN; P21; IDENTIFICATION; MODULATION; RADIATION; TERMINUS	Transcriptional activation by the tumor suppressor p53 is regulated at multiple levels, including posttranslational modifications of the p53 protein, interaction of p53 with various regulatory proteins, or at the level of sequence-specific DNA binding to the response elements in p53's target genes. We here propose as an additional regulatory mechanism that the DNA topology of p53-responsive promoters may determine the interaction of p53 with its target genes. We demonstrate that sequence-specific DNA binding (SSDB) and transcriptional activation by p53 of the mdm2 promoter is inhibited when this promoter is present in supercoiled DNA, where it forms a non-B-DNA structure which spans the p53-responsive elements. Relaxation of the supercoiled DNA in vitro resulted in conversion of the non-B-DNA to a B-DNA conformation within the mdm2 promoter, and correlated with an enhanced SSDB of p53 and an elevated expression of a reporter gene. In contrast, sequence specific UNA binding and transcriptional activation of the p21 promoter were not inhibited by DNA supercoiling, We propose that conformational alterations within p53-responsive sites, which either promote or prohibit sequence specific DNA binding of p53, are an important feature in orchestrating the activation of different p53 responsive promoters.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Hamburg, Klinikum Eppendorf, Abt Neurochirurg, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; Di Como CJ, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garcia JF, 1997, HISTOPATHOLOGY, V30, P120, DOI 10.1046/j.1365-2559.1997.d01-577.x; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GELLERT M, 1983, P NATL ACAD SCI-BIOL, V80, P5545, DOI 10.1073/pnas.80.18.5545; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Luna RMD, 1997, NAT GENET, V16, P336; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Shaw P, 1996, ONCOGENE, V12, P921; SINDEN RR, 1983, P NATL ACAD SCI-BIOL, V80, P1797, DOI 10.1073/pnas.80.7.1797; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	31	43	43	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7310	7318		10.1038/sj.onc.1203139	http://dx.doi.org/10.1038/sj.onc.1203139			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602486				2022-12-28	WOS:000084119400016
J	Knecht, H; Berger, C; McQuain, C; Rothenberger, S; Bachmann, E; Martin, J; Esslinger, C; Drexler, HG; Cai, YC; Quesenberry, PJ; Odermatt, BF				Knecht, H; Berger, C; McQuain, C; Rothenberger, S; Bachmann, E; Martin, J; Esslinger, C; Drexler, HG; Cai, YC; Quesenberry, PJ; Odermatt, BF			Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease	ONCOGENE			English	Article						LMP1; Reed-Sternberg cells; TRAF2; JNK pathway	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; REED-STERNBERG CELLS; TERMINAL KINASE; MEDIATED TRANSCRIPTION; TRANSFORMING PROTEIN; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; LMP1 ONCOGENE; ACTIVATION	The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus (EBV) is selectively expressed in the Reed-Sternberg (RS) cells of EBV-associated Hodgkin's disease (HD). However, no differences in clinical presentation and course are found between EBV positive and EBV negative forms of HD suggesting a common pathogenetic mechanism. We have studied the LMP1 associated signaling pathways and their dominant negative inhibition in the myelomonocytic HD-MyZ and the B-lymphoid L-428 HD cell lines. In both EBV negative cell lines expression of LMP1 is associated with the formation of multinuclear RS cells. Dominant negative inhibition of NF-kappa B mediated signaling at the step of I kappa B-alpha phosphorylation results in increased cell death with only a few typical RS cells resistant to overexpression of the dominant negative inhibitor I kappa B-alpha-N Delta 54. However, dominant negative inhibition of NF-kappa B mediated signaling at the early step of TRAF2 interaction results in the formation of multinuclear cells in both cell lines and, in addition, in clusters of small mononuclear cells in the HD-MyZ cell line. In HD-MyZ cells overexpression of the powerful JBD-inhibitor of the JNK signal transduction pathway is restricted to small cells and never observed in RS cells. These small cells undergo apoptosis as shown by the TUNEL technique. Apoptosis of small cells is still observed after cotransfection of JBD and LMP1 but in addition a few apoptotic HD-MyZ cells with large fused nuclear masses are identified suggesting that specific inhibition of JNK leads also to apoptosis of LMP1. induced RS cells. Thus, activation of the JNK signaling pathway is also important in the formation of Reed-Sternberg cells. Our findings are consistent with a model where all three LMP1 associated functions, i.e. NF-kappa B mediated transcription, TRAF2 dependent signaling, and c-Jun activation act as a common pathogenetic denominator of both EBV negative and EBV positive HD.	Univ Massachusetts, Ctr Canc, LIMK Labs, Worcester, MA 01605 USA; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1015 Lausanne, Switzerland; Univ Colorado, MCD Biol, Boulder, CO 80309 USA; LICR, Lausanne, Switzerland; DSMZ, Braunschweig, Germany; Univ Zurich Hosp, Lab Immunohistochem, CH-8091 Zurich, Switzerland	University of Massachusetts System; University of Massachusetts Worcester; University of Lausanne; University of Colorado System; University of Colorado Boulder; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); University of Zurich; University Zurich Hospital	Knecht, H (corresponding author), Viollier Inst, Div Hematol, Spalenring 145, CH-4002 Basel, Switzerland.			Rothenberger, Sylvia/0000-0001-8633-2994				Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Baker SJ, 1996, ONCOGENE, V12, P1; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BARGOU RC, 1993, J EXP MED, V177, P1257, DOI 10.1084/jem.177.5.1257; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CARBONE A, 1995, BLOOD, V85, P780, DOI 10.1182/blood.V85.3.780.bloodjournal853780; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DREXLER HG, 1994, LEUKEMIA LYMPHOMA, V3, P201; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; HALUSKA FG, 1994, BLOOD, V84, P1005, DOI 10.1182/blood.V84.4.1005.bloodjournal8441005; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JOSKE DJL, 1992, BLOOD, V80, P2610; Kadin Marshall E., 1994, Current Opinion in Oncology, V6, P456, DOI 10.1097/00001622-199409000-00002; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KNECHT H, 1993, BLOOD, V82, P2937; Knecht H, 1996, ONCOGENE, V13, P947; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; Messineo C, 1998, BLOOD, V91, P2443, DOI 10.1182/blood.V91.7.2443.2443_2443_2451; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothenberger S, 1997, ONCOGENE, V14, P2123, DOI 10.1038/sj.onc.1201032; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHAADT M, 1979, BLUT, V38, P185, DOI 10.1007/BF01007965; STEIN H, 1985, BLOOD, V66, P848; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; URBA WJ, 1992, NEW ENGL J MED, V326, P678, DOI 10.1056/NEJM199203053261006; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	60	17	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7161	7167		10.1038/sj.onc.1203177	http://dx.doi.org/10.1038/sj.onc.1203177			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597317				2022-12-28	WOS:000083901900023
J	Blagosklonny, MV; An, WG; Melillo, G; Nguyen, P; Trepel, JB; Neckers, LM				Blagosklonny, MV; An, WG; Melillo, G; Nguyen, P; Trepel, JB; Neckers, LM			Regulation of BRCA1 by protein degradation	ONCOGENE			English	Article						BRCA1; protein degradation; proteasome; acidic proteases; cathepsin; calpain	SUSCEPTIBILITY GENE-PRODUCT; BREAST-CANCER CELLS; NUCLEAR EXPORT; P53 PROTEIN; TRANSCRIPTIONAL ACTIVATION; PROTEOLYTIC CLEAVAGE; MUTATED P53; DNA-DAMAGE; IN-VIVO; EXPRESSION	BRCA1, a tumor suppressor protein implicated in hereditary forms of breast and ovarian cancer, is transcriptionally regulated in a proliferation-dependent manner. In this study, we demonstrate a substantial role for proteolysis in regulating the BRCA1 steady-state protein level in several cell lines. N-acetyl-leu-leu-norleucinal (ALLN), an inhibitor of the proteasome, calpain, and cathepsins, caused BRCA1 protein to accumulate in the nucleus of several human breast, prostate, and melanoma cell lines which express low or undetectable basal levels of BRCA1 protein, but not in cells with high basal expression of BRCA1. Protease inhibition did not increase BRCA1 synthesis, nor change its mRNA level, but it dramatically prolonged the protein's half-life. In contrast to ALLN, lactacystin and PS341, two specific proteasome inhibitors, as well as calpastatin peptide and PD150606, two selective calpain inhibitors, had no effect on BRCA1 stability, whereas ALLM, an effective calpain and cathepsin inhibitor but weak proteasome inhibitor, did stimulate accumulation of BRCA1. Moreover, three inhibitors of acidic cysteine proteases, chloroquine, ammonium chloride and bafilomycin, were as effective as ALLN. These results demonstrate that degradation by a cathepsin-like protease in fine balance with BRCA1 transcription is responsible for maintaining the low steady-state level of BRCA1 protein seen in many cancer cells.	NCI, Med Branch, Dept Therapeut, NIH, Rockville, MD 20850 USA; NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Neckers, LM (corresponding author), NCI, Med Branch, Dept Therapeut, NIH, 9610 Med Ctr Dr,Suite 300, Rockville, MD 20850 USA.				NATIONAL CANCER INSTITUTE [ZIASC010074, Z01SC010074] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Aprelikova O, 1996, ONCOGENE, V13, P2487; Bishop DT, 1997, SEMIN CANCER BIOL, V8, P45, DOI 10.1006/scbi.1997.0053; Blackwood MA, 1998, J CLIN ONCOL, V16, P1969, DOI 10.1200/JCO.1998.16.5.1969; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fu YHF, 1998, FEBS LETT, V421, P89, DOI 10.1016/S0014-5793(97)01541-X; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Holaska JM, 1998, P NATL ACAD SCI USA, V95, P14739, DOI 10.1073/pnas.95.25.14739; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Maki CG, 1996, CANCER RES, V56, P2649; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nagaya T, 1998, J BIOL CHEM, V273, P33166, DOI 10.1074/jbc.273.50.33166; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Paoletti F, 1997, J CELL PHYSIOL, V172, P63, DOI 10.1002/(SICI)1097-4652(199707)172:1<63::AID-JCP7>3.3.CO;2-F; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	54	58	59	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6460	6468		10.1038/sj.onc.1203068	http://dx.doi.org/10.1038/sj.onc.1203068			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597248				2022-12-28	WOS:000083709200008
J	Li, WQ; Zhang, JC; Flechner, L; Hyun, T; Yam, A; Franke, TF; Pierce, JH				Li, WQ; Zhang, JC; Flechner, L; Hyun, T; Yam, A; Franke, TF; Pierce, JH			Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal	ONCOGENE			English	Article						apoptosis; Akt/protein kinase B; protein; kinase C-alpha	MYC-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEOLYTIC ACTIVATION; MOLECULAR-CLONING; LEUKEMIA-CELLS; BETA-II; DELTA; FAMILY; TARGET	To investigate the role of protein kinase C (PKC) in apoptotic signaling induced by cytokine withdrawal, we expressed PKC-alpha, -delta and -epsilon individually in the 32D myeloid progenitor cells. The parental and PKC-delta- and PKC-epsilon- transfected 32D cells underwent apoptosis within 24 h in the absence of interleukin 3. In contrast, expression of PKC-alpha inhibited the onset of apoptosis as determined by genomic DNA fragmentation and flow cytometric analysis. Correlating with the inhibition of apoptosis, PKC-alpha transfectants exhibited increased activity of the endogenous Akt serine/threonine kinase. Furthermore, PKC-alpha, but not PKC-delta or -epsilon, specifically activated overexpressed Akt. PKC-alpha-induced Akt activity was partially dependent on phosphoinositol 3' kinase (PI 3'K) since a PI 3'K inhibitor was able to suppress PKC-alpha-induced Akt activation. Both basal and interleukin 3-stimulated phosphorylation of Akt on serine 473 was enhanced in the PKC-alpha and Akt contransfectants. Coexpression of wild type Akt and PKC-alpha resulted in greater suppression of apoptosis than PKC-alpha expression alone. Together, our results demonstrate that suppression of apoptosis by PKC-alpha correlates with its ability of activating endogenous Akt. Furthermore, activation of overexpressed Akt by PKC-alpha is consistent with their synergistic effect on suppressing apoptosis, providing the strong evidence of cross talk between Akt and PKC-alpha.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Stem Cell Res Lab, 3970 Reservoir Rd NW,NRB W309, Washington, DC 20007 USA.		Roszak, Joanna/F-4003-2010	Hyun, Teresa/0000-0002-9350-2733				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; delPeso L, 1997, SCIENCE, V278, P687; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Brian CA, 1998, ONCOL REP, V5, P305; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Saini KS, 1998, MOL CELL BIOCHEM, V178, P9, DOI 10.1023/A:1006891430596; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Whitman SP, 1997, J BIOL CHEM, V272, P23481, DOI 10.1074/jbc.272.38.23481; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	45	93	94	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6564	6572		10.1038/sj.onc.1203065	http://dx.doi.org/10.1038/sj.onc.1203065			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597260				2022-12-28	WOS:000083709200020
J	Tian, EM; Sawyer, JR; Largaespada, DA; Jenkins, NA; Copeland, NG; Shaughnessy, JD				Tian, EM; Sawyer, JR; Largaespada, DA; Jenkins, NA; Copeland, NG; Shaughnessy, JD			Evi27 encodes a novel membrane protein with homology to the IL17 receptor	ONCOGENE			English	Article						insertional mutagenesis; novel cytokine receptor; IL-17R related gene; myeloid leukemia	MYELOPROLIFERATIVE LEUKEMIA-VIRUS; MYELOID-LEUKEMIA; CHROMOSOME-TRANSLOCATION; CYTOKINE RECEPTOR; INTEGRATION SITE; CELL-LINES; T-CELL; GENE; MOUSE; EXPRESSION	Evi27 is a common site of retroviral integration in BXH2 murine myeloid leukemias. Here me show that integration at Evi27 occurs in a CpG island similar to 6 kb upstream from a novel gene (designated Evi27) with homology to the IL17 receptor (Il17r) and that proviral integrations result in increased expression of the Evi27 protein on the cell surface. The human EVI27 homology was also cloned and mapped to chromosome 3p21, Multiple Evi27 isoforms were detected at the RNA and protein level in both human and mouse, indicating that Evi27 expression is complex. Some of the isoforms are shown to likely represent secreted soluble forms of the protein produced by intron incorporation or by proteolytic cleavage. In the mouse, highest Evi27 expression occurs in liver and testes with lower expression in kidney and lung, In humans, EVI27 is expressed at high levels in the kidney, with moderate levels in the liver, brain, and testes. Within hematopoietic cells, Evi27 expression is restricted. Northern and Western analysis showed that Evi27 is expressed in selected T-cell B-cell and myeloid cell lines. These results suggest that Evi27 expression is tightly regulated during hematopoietic differentiation. Collectively, these studies identify a nea member of the cytokine receptor family whose increased and uncoordinated expression may lead to myeloid leukemia by altering Evi27's normal ability to control the growth and/or differentiation of hematopoietic cells.	Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Little Rock, AR 72205 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Ctr Canc, Minneapolis, MN 55455 USA; NCI, Frederick Canc Res & Dev Ctr, Mouse Canc Genet Program, Frederick, MD 21702 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shaughnessy, JD (corresponding author), Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Little Rock, AR 72205 USA.		Largaespada, David/C-9832-2014					Bagby G.C.J., 1994, MOL BASIS BLOOD DIS, P71; BAUMBACH WR, 1988, J VIROL, V62, P3151, DOI 10.1128/JVI.62.9.3151-3155.1988; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; CHRETIEN S, 1994, BLOOD, V83, P1813; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COPELAND NG, 1999, ANIMAL MODELS CANC P, P53; FLUBACHER MM, 1994, J VIROL, V68, P7709, DOI 10.1128/JVI.68.12.7709-7716.1994; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; Johansson B, 1997, LEUKEMIA, V11, P1207, DOI 10.1038/sj.leu.2400718; Kennedy J, 1996, J INTERF CYTOK RES, V16, P611, DOI 10.1089/jir.1996.16.611; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Liao XB, 1997, ONCOGENE, V14, P1023, DOI 10.1038/sj.onc.1200929; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Ogawa S, 1996, ONCOGENE, V13, P183; PENCIOLELLI JF, 1987, J VIROL, V61, P579, DOI 10.1128/JVI.61.2.579-583.1987; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schwarzenberger P, 1998, J IMMUNOL, V161, P6383; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; Shi G, 1996, CYTOGENET CELL GENET, V74, P295, DOI 10.1159/000134439; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P228, DOI 10.1002/(SICI)1098-2264(199708)19:4<228::AID-GCC4>3.0.CO;2-Z; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yao ZB, 1997, CYTOKINE, V9, P794, DOI 10.1006/cyto.1997.0240; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YOO ZB, 1995, J IMMUNOL, V155, P5483; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	45	56	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2098	2109		10.1038/sj.onc.1203577	http://dx.doi.org/10.1038/sj.onc.1203577			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815801				2022-12-28	WOS:000086728000003
J	Kasus-Jacobi, A; Bereziat, V; Perdereau, D; Girard, J; Burnol, AF				Kasus-Jacobi, A; Bereziat, V; Perdereau, D; Girard, J; Burnol, AF			Evidence for an interaction between the insulin receptor and Grb7. A role for two of its binding domains, PIR and SH2	ONCOGENE			English	Article						Grb7; SH2 domain; PIR/BPS; signal transduction; adapter protein; insulin receptor	ADAPTER PROTEIN GRB10; TYROSINE KINASE; I RECEPTOR; GROWTH; CLONING; FAMILY; ASSOCIATION; EXPRESSION; SUBSTRATE; REVEALS	The molecular adapter Grb7 is likely to be implicated in the development of certain cancer types. In this study we show that Grb7 binds the insulin receptors, when they are activated and tyrosine phosphorylated. This interaction is documented by two-hybrid experiments, GST pull-down assays and in vivo coimmunoprecipitations. In addition, our results argue in favor of a preferential association between Grb7 and the insulin receptors when compared to other tyrosine kinase receptors like the EGF receptor, the FGF receptor and Ret, Interestingly, Grb7 is not a substrate of the insulin receptor tyrosine kinase activity. Grb7 binds the activated tyrosine kinase loop of the insulin receptors. Two domains of Grb7 are implicated in the insulin receptor binding: the SH2 domain and the PIR (phosphotyrosine interacting region). The role of these two domains in the interaction,vith the insulin receptor was already reported for Grb10 and Grb14, the other members of the Grb7 family of proteins. However, the relative importance of these domains varies, considering the receptor and the Grb protein. These differences should be a determinant of the specificity of the receptor tyrosine kinase-Grbs binding, and thus of the implication of Grb7/10/14 in signal transduction.	CNRS, UPR 1524, F-92190 Meudon, France	Centre National de la Recherche Scientifique (CNRS)	Burnol, AF (corresponding author), CNRS, UPR 1524, 9 Rue Jules Hetzel, F-92190 Meudon, France.		Burnol, Anne-Francoise/P-2181-2017; KASUS-JACOBI, Anne/V-7799-2019	KASUS-JACOBI, Anne/0000-0003-3844-0450; BEREZIAT, Veronique/0000-0002-9795-549X				Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Leavey SF, 1998, AM J PHYSIOL-RENAL, V275, pF770, DOI 10.1152/ajprenal.1998.275.5.F770; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MORRIONE A, 1997, J BIOL CHEM, V272, P26282; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang J, 1999, MOL CELL BIOL, V19, P6217; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942	36	45	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2052	2059		10.1038/sj.onc.1203469	http://dx.doi.org/10.1038/sj.onc.1203469			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803466				2022-12-28	WOS:000086613200009
J	Schroter, M; Peli, J; Hahne, M; Tschopp, J; Reichmann, E				Schroter, M; Peli, J; Hahne, M; Tschopp, J; Reichmann, E			Fas-dependent tissue turnover is implicated in tumor cell clearance	ONCOGENE			English	Article						tumorigenesis; Fas-signaling; caspase activity; apoptosis; immune response; tissue turnover	LIGAND EXPRESSION; INDUCED APOPTOSIS; IMMUNE ESCAPE; DEATH FACTOR; CD95; INHIBITION; CASPASE-8; MICE	The apoptosis-inducing Fas receptor has been shown to be down-regulated in various types of tumors, while its ligand (FasL) appears to be frequently up-regulated. Here we provide evidence that there is a strong selective pressure in vivo against Fas-expressing, tumorigenic NIH3T3 cells, favoring survival, proliferation and eventually tumor formation by Fas-negative tells. Importantly, re-expression of Fas in these cells results in either the complete abolishment of tumor development, or in a significant extenuation of the latency period of tumor outgrowth. In addition, we found that environmental conditions which prevail during tumorigenesis, such as limiting amounts of survival factors and the lack of cell adhesion, are markedly sensitizing tumor cells to Fas-mediated suicide. Our data suggest that in addition to T cell-mediated immune responses, mechanisms of Fas-dependent tissue turnover are also centrally implicated in tumor cell clearance.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research; University of Lausanne	Reichmann, E (corresponding author), Swiss Inst Expt Canc Res, Chem Boveresses 155, CH-1066 Epalinges, Switzerland.							Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Butler LM, 1998, BRIT J CANCER, V77, P1454, DOI 10.1038/bjc.1998.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Faris M, 1998, J IMMUNOL, V160, P134; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Lebel M, 1996, ONCOGENE, V12, P1127; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; ROBERTSON MJ, 1995, LEUKEMIA LYMPHOMA, V17, P51, DOI 10.3109/10428199509051703; Shinoura N, 1999, CANCER RES, V59, P4119; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ungefroren H, 1998, CANCER RES, V58, P1741; Walker PR, 1997, J IMMUNOL, V158, P4521; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	27	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1794	1800		10.1038/sj.onc.1203499	http://dx.doi.org/10.1038/sj.onc.1203499			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777213				2022-12-28	WOS:000086292500007
J	Gu, Z; Thomas, G; Yamashiro, J; Shintaku, IP; Dorey, F; Raitano, A; Witte, ON; Said, JW; Loda, M; Reiter, RE				Gu, Z; Thomas, G; Yamashiro, J; Shintaku, IP; Dorey, F; Raitano, A; Witte, ON; Said, JW; Loda, M; Reiter, RE			Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer	ONCOGENE			English	Article						prostate; neoplasm; prostate stem cell antigen (PSCA); antibody	IN-SITU HYBRIDIZATION; GPI-ANCHORED PROTEINS; MEMBRANE ANTIGEN; INTRAEPITHELIAL NEOPLASIA; CHROMOSOMAL-ANOMALIES; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; CARCINOMA; SURFACE; ADENOCARCINOMA	Prostate stem cell antigen (PSCA) is a recently defined homologue of the Thy-1/Ly-6 family of glycosylphosphatidylinositol (GPI)-anchored cell surface antigens, PSCA mRNA is expressed in the basal cells of normal prostate and in more than 80% of prostate cancers, The purpose of the present study was to examine PSCA protein expression in clinical specimens of human prostate cancer, Five monoclonal antibodies were raised against a PSCA-GST fusion protein and screened for their ability to recognize PSCA on the cell surface of human prostate cancer cells. Immunohistochemical analysis of PSCA expression was performed on paraffin-embedded sections from 25 normal tissues, 112 primary prostate cancers and nine prostate cancers metastatic to bone. The level of PSCA expression in prostate tumors was quantified and compared with expression in adjacent normal glands, The antibodies detect PSCA expression on the cell surface of normal and malignant prostate cells and distinguish three extracellular epitopes on PSCA, Prostate and transitional epithelium reacted strongly with PSCA, PSCA staining was also seen in placental trophoblasts, renal collecting duets and neuroendocrine cells in the stomach and colon, All other normal tissues tested were negative. PSCA protein expression was identified in 105/112 (94%) primary prostate tumors and 9/9 (100%) bone metastases, The level of PSCA expression increased with higher Gleason score (P = 0.016), higher tumor stage (P = 0.010) and progression to androgen-independence (P = 0.021). Intense, homogeneous staining was seen in all nine bone metastases. PSCA is a cell surface protein with limited expression in extraprostatic normal tissues, PSCA expression correlates with tumor stage, grade and androgen independence and may have prognostic utility. Because expression on the surface of prostate cancer cells increases with tumor progression, PSCA may be a useful molecular target in advanced prostate cancer.	Univ Calif Los Angeles, Dept Urol, Ctr Hlth Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Orthoped, Los Angeles, CA 90095 USA; Urogenesys Inc, Santa Monica, CA 90404 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Harvard University; Dana-Farber Cancer Institute	Reiter, RE (corresponding author), Univ Calif Los Angeles, Dept Urol, Ctr Hlth Sci, 10833 Conte Ave, Los Angeles, CA 90095 USA.			Thomas, George V/0000-0001-7416-8840	NCI NIH HHS [K08 CA74169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA074169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alers JC, 1997, LAB INVEST, V77, P437; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Antica M, 1997, IMMUNOL LETT, V55, P47, DOI 10.1016/S0165-2478(96)02682-X; Arienti G, 1997, BBA-GEN SUBJECTS, V1336, P533, DOI 10.1016/S0304-4165(97)00071-8; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CLASSON BJ, 1994, P NATL ACAD SCI USA, V91, P5296, DOI 10.1073/pnas.91.12.5296; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Disis ML, 1997, ADV CANCER RES, V71, P343, DOI 10.1016/S0065-230X(08)60103-7; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Fair WR, 1997, PROSTATE, V32, P140; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Hanas JS, 1999, CANCER-AM CANCER SOC, V86, P756, DOI 10.1002/(SICI)1097-0142(19990901)86:5<756::AID-CNCR9>3.0.CO;2-X; Hoessli DC, 1998, TRENDS CELL BIOL, V8, P87, DOI 10.1016/S0962-8924(98)80018-4; Jenkins RB, 1997, CANCER RES, V57, P524; Kawakami M, 1997, CANCER RES, V57, P2321; KOKONTIS J, 1994, CANCER RES, V54, P1566; Lalani EN, 1997, CANCER METAST REV, V16, P29, DOI 10.1023/A:1005792206377; Liu H, 1997, CANCER RES, V57, P3629; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MagiGalluzzi C, 1997, MODERN PATHOL, V10, P839; MagiGalluzzi C, 1996, EUR UROL, V30, P167; MCNEAL JE, 1986, CANCER, V58, P1714, DOI 10.1002/1097-0142(19861015)58:8<1714::AID-CNCR2820580823>3.0.CO;2-M; Murphy GP, 1998, CANCER-AM CANCER SOC, V83, P2259, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.0.CO;2-T; Murphy GP, 1998, J UROLOGY, V160, P2396, DOI 10.1016/S0022-5347(01)62198-0; OMALLEY FP, 1990, VIRCHOWS ARCH A, V417, P191, DOI 10.1007/BF01600133; Qian JQ, 1997, MODERN PATHOL, V10, P1113; Reiter RE, 2000, GENE CHROMOSOME CANC, V27, P95, DOI 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Rubin MA, 1998, AM J SURG PATHOL, V22, P840, DOI 10.1097/00000478-199807000-00006; Said JW, 1998, MODERN PATHOL, V11, P1; SATO K, 1999, J UROLOGY, V161, pA60; Sauvageot J, 1998, PROSTATE, V34, P29, DOI 10.1002/(SICI)1097-0045(19980101)34:1<29::AID-PROS4>3.0.CO;2-F; Silver DA, 1997, CLIN CANCER RES, V3, P81; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4	38	310	389	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1288	1296		10.1038/sj.onc.1203426	http://dx.doi.org/10.1038/sj.onc.1203426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713670				2022-12-28	WOS:000085743800005
J	Bishay, K; Ory, K; Lebeau, J; Levalois, C; Olivier, MF; Chevillard, S				Bishay, K; Ory, K; Lebeau, J; Levalois, C; Olivier, MF; Chevillard, S			DNA damage-related gene expression as biomarkers to assess cellular response after gamma irradiation of a human lymphoblastoid cell line	ONCOGENE			English	Article						irradiation; DNA damage-related genes; apoptosis; cell cycle; micronucleus assay	WILD-TYPE P53; POLYMERASE-DELTA; GROWTH-ARREST; PCNA; REPLICATION; APOPTOSIS; DEATH; REPAIR; P21; RADIATION	Since defects in molecular mechanisms controlling DNA repair, cell cycle checkpoint and apoptosis could modify cellular sensitivity to DNA damaging agents, we have conducted a multiparametric molecular analysis for better understanding the regulation pathways leading to cell survival or cell death after irradiation, Using a human lymphoblastoid cell line, we have analysed, following gamma irradiation (0.5, 1, 2, 4, 8, 16 and 32 Gy, at 0.5, 24, 48 and 72 h after treatment), the correlation between proliferation, cell cycle analysis, apoptosis and micronuclei frequency with the expression of TP53, WAF1, DNA LIGASE 1, PCNA, BAX, BLC-2, BAK, DAD1, ICH1-Long and -Short forms mRNAs. We have found that whereas TP53, BAK, ICH1-Short form, and DAD1 were expressed at constant levels, WAF1, PCNA, BAX were up-regulated, ICH1-Long form, DNA LIGASE 1, and BCL-2 were downregulated. These modifications of expression were significantly correlated with doses, survival, proliferation, cell cycle delays, and apoptosis, A positive correlation of WAF1 and BAX, and a borderline negative correlation with BCL-2 expressions were observed with micronuclei frequency for doses ranging from 0.5 to 4 Gy, In conclusion, our data clearly demonstrate that gene expression profiling, which is easier and more rapid to conduct than the assessments of classical phenotypic responses, could be useful to improve knowledge concerning pathways in involved in cellular response to irradiation, knowing that such biomarkers could constitute tools to assess radio-sensitivity/radio-resistance.	CEA, DSV, DRR, Expt Cancerol Lab, F-92265 Fontenay Aux Roses, France	CEA	Chevillard, S (corresponding author), CEA, DSV, DRR, Expt Cancerol Lab, 60-68 Ave Gen Leclerc,BP6, F-92265 Fontenay Aux Roses, France.			Chevillard, Sylvie/0000-0001-5889-4041				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chevillard S, 1997, LEUKEMIA, V11, P1095, DOI 10.1038/sj.leu.2400657; Chevillard S, 1996, CANCER, V77, P292, DOI 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Fenech M, 1997, MUTAT RES-GEN TOX EN, V392, P11, DOI 10.1016/S0165-1218(97)00041-4; Foray N, 1997, BIOCHIMIE, V79, P567, DOI 10.1016/S0300-9084(97)82005-6; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kroemer G, 1998, CELL DEATH DIFFER, V5, P547, DOI 10.1038/sj.cdd.4400387; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LITTLEFIELD LG, 1989, MUTAGENESIS, V4, P265, DOI 10.1093/mutage/4.4.265; MIYASHITA T, 1995, CELL, V80, P293; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Oku T, 1998, GENES CELLS, V3, P357, DOI 10.1046/j.1365-2443.1998.00199.x; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Shu HKG, 1998, P NATL ACAD SCI USA, V95, P14453, DOI 10.1073/pnas.95.24.14453; TERAOKA H, 1992, BIOCHEM INT, V26, P963; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wenz F, 1998, RADIAT RES, V149, P32, DOI 10.2307/3579679; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu J, 1999, MOL CELL BIOL, V19, P12; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHAN QM, 1994, ONCOGENE, V9, P3743	40	39	43	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					916	923		10.1038/sj.onc.1203405	http://dx.doi.org/10.1038/sj.onc.1203405			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702800				2022-12-28	WOS:000085567700009
J	Kaida, A; Ariumi, Y; Ueda, Y; Lin, JY; Hijikata, M; Ikawa, S; Shimotohno, K				Kaida, A; Ariumi, Y; Ueda, Y; Lin, JY; Hijikata, M; Ikawa, S; Shimotohno, K			Functional impairment of p73 and p51, the p53-related proteins, by the human T-cell leukemia virus type 1 Tax oncoprotein	ONCOGENE			English	Article						Tax; HTLV-1; p53; p73; p51; CBP	HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; RAT FIBROBLASTS; TRANSACTIVATION; DOMAIN; INHIBITION; HOMOLOG; E6; TRANSFORMATION; INACTIVATION	We have previously demonstrated that the human T-cell leukemia virus type 1 (HTLV-1) Tax oncoprotein represses the trans-activation function of p53 tumor suppressor protein. Recently, several proteins with sequence homology to p53 have been identified. In this study, we demonstrated that Tax represses the transactivation functions of p73 alpha, p73 beta, and p51A, the p53-related proteins, as well as p53, Moreover, a mutant Tax of coactivator CBP-binding site (K88A), which activated NF-kappa B but not CREB pathway, could not repress the p73 nor p51 trans-activation functions, indicating that CBP-binding domain of Tax is essential for the suppression of their functions. Using proteins of Gal4-fused N-terminal region of p73 and p51, we showed that Tax-mediated inactivation of p73 or p51 requires for their N-terminal trans-activation domains. Furthermore, only the putative N-terminal trans-activation domains of them did not have enough transcriptional activities and their adjacent regions are essential for their full transactivation, suggesting the existence of their second transactivation subdomains. Thus, HTLV-1 Tax inactivated the p53-related proteins through their N-terminal transactivation domains.	Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Tohoku Univ, Dept Cell Biol, Inst Dev Aging & Canc, Sendai, Miyagi 9800872, Japan	Kyoto University; Tohoku University	Shimotohno, K (corresponding author), Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.		Ariumi, Yasuo/F-5804-2013; 井川, 俊太郎/L-5911-2015; Ueda, Yoshihide/S-7620-2016	Ueda, Yoshihide/0000-0003-3196-3494				Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEGAWA K, 1993, ONCOGENE, V8, P543; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	34	31	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					827	830		10.1038/sj.onc.1203387	http://dx.doi.org/10.1038/sj.onc.1203387			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698501				2022-12-28	WOS:000085192100013
J	Barrientes, S; Cooke, C; Goodrich, DW				Barrientes, S; Cooke, C; Goodrich, DW			Glutamic acid mutagenesis of retinoblastoma protein phosphorylation sites has diverse effects on function	ONCOGENE			English	Article						retinoblastoma; phosphorylation; cyclin-dependent kinase; mutagenesis	CYCLIN-DEPENDENT KINASE; GENE-PRODUCT PRB; CELL-CYCLE; S-PHASE; TRANSCRIPTIONAL REPRESSION; ECTOPIC EXPRESSION; TERMINAL REGION; T-ANTIGEN; BINDING; E2F	The retinoblastoma tumor suppressor gene (Rb) has many functions within the cell including regulation of transcription, differentiation, apoptosis, and the cell cycle. Regulation of these functions is mediated by phosphorylation at as many as 16 cyclin-dependent kinase (CDK) phosphorylation sites in vivo. The contribution of these sites to the regulation of the various Rb functions is not well understood. To characterize the effect of phosphorylation at these sites, we systematically mutagenized the serines or threonines to glutamic acid. Thirty-five mutants with different combinations of modified phosphorylation sites were assayed for their ability to arrest the cell cycle and for their potential to induce differentiation. Only the most highly substituted mutants failed to arrest cell cycle progression, However, mutants with as few as four modified phosphorylation sites were unable to promote differentiation. Other mutants had increased activity in this assay. We conclude that modification of Rb phosphorylation sites can increase or decrease protein activity, that different Rb functions can be regulated independently by distinct combinations of sites, and that the effects of modification at any one site are context dependent.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Goodrich, DW (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA070292] Funding Source: NIH RePORTER; NCI NIH HHS [CA-70292-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Brown VD, 1999, MOL CELL BIOL, V19, P3246; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Chen DS, 1999, MOL CELL BIOL, V19, P1002; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1990, CANCER SURV, V9, P529; HAMEL PA, 1992, ONCOGENE, V7, P693; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; INOUE A, 1995, J BIOL CHEM, V270, P22571, DOI 10.1074/jbc.270.38.22571; KATO J, 1993, GENE DEV, V7, P331; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Yang YD, 1998, J BIOL CHEM, V273, P15946, DOI 10.1074/jbc.273.26.15946	47	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					562	570		10.1038/sj.onc.1203332	http://dx.doi.org/10.1038/sj.onc.1203332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698526				2022-12-28	WOS:000085104200010
J	D'Errico, M; Calcagnile, A; Canzona, F; Didona, B; Posteraro, P; Cavalieri, R; Corona, R; Vorechovsky, I; Nardo, T; Stefanini, M; Dogliotti, E				D'Errico, M; Calcagnile, A; Canzona, F; Didona, B; Posteraro, P; Cavalieri, R; Corona, R; Vorechovsky, I; Nardo, T; Stefanini, M; Dogliotti, E			UV mutation signature in tumor suppressor genes involved in skin carcinogenesis in xeroderma pigmentosum patients	ONCOGENE			English	Article						skin cancer; XP; p53; PATCHED; UV light	BASAL-CELL CARCINOMAS; HUMAN HOMOLOG; P53 MUTATIONS; SONIC HEDGEHOG; NEVUS SYNDROME; PATCHED GENE; CANCER; REPAIR; SPECTRA; PTCH	Molecular analysis of p53 and patched (PTCH), two candidate tumor suppressor genes for non-melanocytic skin cancer, was performed in skin tumors from six patients affected by the cancer-prone disease xeroderma pigmentosum (XP), UV-specific p53 mutations were detected at a frequency of 38-50% in all the tumor types analysed, including melanomas, Additional analysis of PTCH mutations in the subset of eight basal call carcinomas (BCC) revealed a very high mutation frequency of this gene (90%) which exceeded that detected in the p53 gene in the same tumors (38%), PTCH mutations were predominantly UV-specific C > T transitions, This mutation pattern is different from that reported in BCC from normal donors where PTCH mutation frequency is 27% and mutations are frequently deletions and insertions. These findings suggest that PTCH mutations represent an earlier event in BCC development than p53 alterations and that the inability of XP patients to repair UV-induced PTCH mutations might significantly contribute to the early and frequent appearance of BCC observed in these patients.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy; Ist Dermopat Immacolata, I-00167 Rome, Italy; Karolinska Inst, Dept Biosci Novum, Ctr Nutr & Toxicol, S-14157 Huddinge, Sweden; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituto Dermopatico dell'Immacolata (IDI); Karolinska Institutet; Consiglio Nazionale delle Ricerche (CNR)	Dogliotti, E (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Viale Regina Elens 299, I-00161 Rome, Italy.			Didona, Biagio/0000-0001-6635-0490				Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; Chidambaram A, 1996, CANCER RES, V56, P4599; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DErrico M, 1997, CANCER RES, V57, P747; Dogliotti E, 1998, RECENT RES CANCER, V154, P97; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; Eklund LK, 1998, MOL CARCINOGEN, V21, P87, DOI 10.1002/(SICI)1098-2744(199802)21:2<87::AID-MC2>3.0.CO;2-L; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Giglia G, 1998, CANCER RES, V58, P4402; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McGregor WG, 1999, MOL CELL BIOL, V19, P147; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; Papp T, 1996, J CANCER RES CLIN, V122, P541, DOI 10.1007/BF01213550; STEFANINI M, 1993, CARCINOGENESIS, V14, P1101, DOI 10.1093/carcin/14.6.1101; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Unden AB, 1996, CANCER RES, V56, P4562; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Wicking C, 1997, AM J HUM GENET, V60, P21; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	28	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					463	467		10.1038/sj.onc.1203313	http://dx.doi.org/10.1038/sj.onc.1203313			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656695				2022-12-28	WOS:000084873700018
J	Kapoor, M; Hamm, R; Yan, W; Taya, Y; Lozano, G				Kapoor, M; Hamm, R; Yan, W; Taya, Y; Lozano, G			Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation	ONCOGENE			English	Article						phosphorylation; DNA binding; UV radiation	TUMOR-SUPPRESSOR PROTEIN-P53; DNA-BINDING; ULTRAVIOLET-RADIATION; GAMMA-RADIATION; KINASE; DAMAGE; TERMINUS; IDENTIFICATION; ACETYLATION; SERINE-389	The activity of the tumor suppressor p53 is induced in response to DNA-damaging agents such as UV and gamma radiation. Phosphorylation is one of the key regulatory steps for activating p53 function. Recent reports have shown that p53 is phosphorylated at both serines 15 and 392 in response to UV radiation, Phosphorylation at serine 15 prevents the binding of HDM2, a negative regulator of p53. Phosphorylation at serine 392 induces the DNA-binding function of p53, We examined the requirement for phosphorylation at both serines and show that both these modifications occur on the same molecule of p53, In vitro assays demonstrate that phosphorylation at either one of these sites is not sufficient to yield an active p53. Phosphorylation by DNA-PK, that modifies serines 15 and 37, inhibits HDM2 binding to p53 but does not induce the DNA-binding activity of p53, Phosphorylation at serine 392, on the other hand, stimulates the DNA-binding ability of p53 but does not make it immune to binding and inhibition by HDM2, Thus, our results demonstrate that multiple sites need to be modified to yield a functional p53.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan	University of Texas System; UTMD Anderson Cancer Center; National Cancer Center - Japan	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	33	72	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					358	364		10.1038/sj.onc.1203300	http://dx.doi.org/10.1038/sj.onc.1203300			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656682				2022-12-28	WOS:000084873700005
J	Senga, T; Miyazaki, K; Machida, K; Iwata, H; Matsuda, S; Nakashima, I; Hamaguchi, M				Senga, T; Miyazaki, K; Machida, K; Iwata, H; Matsuda, S; Nakashima, I; Hamaguchi, M			Clustered cysteine residues in the kinase domain of v-Src: critical role for protein stability, cell transformation and sensitivity to herbimycin A	ONCOGENE			English	Article						v-Src; temperature sensitive; cysteine; herbimycin A; protein stability	ROUS-SARCOMA VIRUS; TYROSINE KINASE; C-SRC; PHOSPHORYLATION; P60SRC; GENE; INACTIVATION; INHIBITION; PP60C-SRC; MECHANISM	We have previously reported the activation of Src by mercuric chloride based on the sulfhydryl modification, To evaluate the significance of cysteine residues in v-Src, we replaced each cysteine to alanine by oligonucleotide-directed mutagenesis and examined its effect on cell transformation. Of ten cysteine residues scattered over v-Src, four cysteines clustered in kinase domain, Cys483, Cys487, Cys496 and Cys498, were important for protein stability and cell transformation, whereas those in SH2 domain were dispensable. A single mutation in Cys498 yielded suppression of kinase activity and a temperature-sensitivity in anchorage independent growth, Double mutation either in Cys483/Cys487 or in Cys496/ Cys498 yielded clear temperature-sensitivity in cell transformation and in stability of Src protein. Instability of Src protein was magnified by quadruple mutation in the cysteines, which decreased the half-life of Src to be less than one quarter of that of wild-type. In addition, both Cys483/Cyr487 and Cys496/Cys498 kinases became resistant to in vitro inactivation by herbimycin A, which directly inactivates v-Src in addition to its effect on HSP90, Taken together, our results strongly suggest that the cysteine clustered motif of v-Src are critical for protein stability, cell transformation and in vitro inactivation by herbimycin A.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.							BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; FUKAZAWA H, 1990, BIOCHEM BIOPH RES CO, V173, P276, DOI 10.1016/S0006-291X(05)81053-8; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARONEY AC, 1992, ONCOGENE, V7, P1207; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Pu MY, 1996, ONCOGENE, V13, P2615; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMPSON RB, 1961, J AM CHEM SOC, V83, P4711, DOI 10.1021/ja01484a005; STRICKS W, 1953, J AM CHEM SOC, V75, P5673, DOI 10.1021/ja01118a060; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	35	50	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					273	279		10.1038/sj.onc.1203296	http://dx.doi.org/10.1038/sj.onc.1203296			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645006				2022-12-28	WOS:000084844400013
J	Weber, CK; Slupsky, JR; Herrmann, C; Schuler, M; Rapp, UR; Block, C				Weber, CK; Slupsky, JR; Herrmann, C; Schuler, M; Rapp, UR; Block, C			Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes	ONCOGENE			English	Article						Ras; Raf; mitogenic signaling	COMPLETE CODING SEQUENCE; PROTEIN-KINASE; A-RAF; PLASMA-MEMBRANE; BIOCHEMICAL-PROPERTIES; B-RAF; ACTIVATION; BINDING; DOMAIN; EXPRESSION	In the mitogenic signaling cascade interaction of Ras with Raf represents a critical step for the regulation of cell growth and differentiation. The major effector of Ras, the serine/threonine kinase Raf exists as three isoforms with different tissue distributions. We demonstrate that transient transfection of oncogenic Ha-Ras leads to a preferential activation of endogenous c-Raf-l in HEK 293 cells as opposed to A-Raf, In vitro binding studies using purified Ras binding domains of Raf as well as in vivo bindings tests with full length molecules reveals significantly lower binding affinities of A-Raf to Ha-Ras as compared to other Raf isoforms, The Ras-binding interface of c-Raf differs from A-Raf by a conservative Arg to Lys exchange at residue 59 or 22 respectively. Mutational analysis reveals that this residue represents a point of isozyme discrimination: c-Raf-R59K binds Ha-Ras weaker than the wildtype, likewise A-Raf-K22R increases its affinity to Ha-Ras in vivo and in vitro. Differential binding affinities are reflected in downstream signaling. Immunecomplex kinase assays reveal that Ha-Ras mediated Raf activation is decreased for c-Raf-R59K and increased for A-Raf-K22R when compared to the respective wildtype forms. Thus our observations introduce a new level of isoform discrimination in Ras/ Raf signaling asa functional consequence of conservative amino acid exchange in the Ras binding domains.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Max Planck Inst Mol Physiol, Abt Strukt Biol, D-44026 Dortmund, Germany	University of Wurzburg; Max Planck Society	Weber, CK (corresponding author), Univ Ulm, Innere Med Abt 1, D-89070 Ulm, Germany.		Slupsky, Joseph/H-2843-2019	Slupsky, Joseph/0000-0002-7410-9004				BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CRAVCHIK A, 1993, GENE, V137, P139, DOI 10.1016/0378-1119(93)90262-2; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jaitner BK, 1997, J BIOL CHEM, V272, P29927, DOI 10.1074/jbc.272.47.29927; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kerkhoff E, 1998, CANCER RES, V58, P1636; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MELNICK MB, 1993, DEVELOPMENT, V118, P127; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; RAPP UR, 1988, ONCOGENE HDB; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SLUPSKY JR, 1998, CELL GROWTH ONCOGENE; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STORM SM, 1990, ONCOGENE, V5, P345; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	37	57	63	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					169	176		10.1038/sj.onc.1203261	http://dx.doi.org/10.1038/sj.onc.1203261			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644994				2022-12-28	WOS:000084844400001
J	Nakajima, H; Nakajima, HO; Soonpaa, MH; Jing, SL; Field, LJ				Nakajima, H; Nakajima, HO; Soonpaa, MH; Jing, SL; Field, LJ			Heritable lympho-epithelial thymoma resulting from a transgene insertional mutation	ONCOGENE			English	Article						cancer; lymphoma; insertional mutagenesis; transgenic mice	THYMIC HYPERPLASIA; INSITU HYBRIDIZATION; MICE; ENLARGEMENT; GENES; RATS	Thymoma is the most common tumor of the anterior-superior mediastinum. We have identified a line of transgenic mice which spontaneously and heritably develop thymomas at a very high penetrance. The available data suggest that thymoma formation in these mice results as a consequence of transgene insertional mutagenesis, Immune histologic analyses indicate that the thymomas are of epithelial cell origin. Survival studies indicate that tumor progression is more aggressive in females as compared to males (73.9 vs 41.7% mortality at 20 weeks of age, respectively), Fluorescent in situ hybridizations have localized the transgene integration site to the F2-G region of mouse chromosome 2. Translocation encompassing the syntenic region in humans has been implicated in lympho-epithelial thymoma. These animals may constitute a useful resource for the identification of gene(s) which participate in thymoma progression, as well as a model system for screening anti-thymoma therapeutic agents.	Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Field, LJ (corresponding author), Herman B Wells Ctr Pediat Res, 702 Barnhill Dr,Room 2600, Indianapolis, IN 46202 USA.							BATTIFORA H, 1980, HUM PATHOL, V11, P635, DOI 10.1016/S0046-8177(80)80074-8; BLOOM W, 1986, AFS TXB HISTOLOGY; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; DEMINATTI MM, 1994, ANN GENET-PARIS, V37, P72; FENG GS, 1994, ONCOGENE, V9, P1545; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GULICK J, 1991, J BIOL CHEM, V266, P9180; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hogan B, 1994, MANIPULATING MOUSE E; LEWIS JE, 1987, CANCER, V60, P2727, DOI 10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D; MATANI A, 1973, ARCH PATHOL, V95, P90; MATSUYAMA M, 1988, JPN J CANCER RES, V79, P1031, DOI 10.1111/j.1349-7006.1988.tb00070.x; MOLL J, 1992, EUR J IMMUNOL, V22, P1587, DOI 10.1002/eji.1830220636; MURAKUMO Y, 1993, JPN J CANCER RES, V84, P838, DOI 10.1111/j.1349-7006.1993.tb02054.x; Murakumo Y, 1996, MAMM GENOME, V7, P505, DOI 10.1007/s003359900152; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Sambrook J., 1989, MOL CLONING; Seiki K, 1997, ARCH HISTOL CYTOL, V60, P29, DOI 10.1679/aohc.60.29	21	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					32	38		10.1038/sj.onc.1203266	http://dx.doi.org/10.1038/sj.onc.1203266			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644977				2022-12-28	WOS:000084844300004
J	Williams, CS; Mann, M; DuBois, RN				Williams, CS; Mann, M; DuBois, RN			The role of cyclooxygenases in inflammation, cancer, and development	ONCOGENE			English	Article						cyclooxygenase; development; cancer; inflammation	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2; HUMAN COLON-CANCER; PHORBOL ESTER; H SYNTHASE-1; COLORECTAL-CANCER; EPITHELIAL-CELLS; GENE DISRUPTION; G/H SYNTHASE-1	The cyclooxygenase (COX) enzymes catalyze a key step in the conversion of arachidonate to PGH(2), the immediate substrate for a series of cell specific prostaglandin and thromboxane synthases, Prostaglandins play critical roles in numerous biologic processes, including the regulation of immune function, kidney development, reproductive biology, and gastrointestinal integrity. There are two COX isoforms, which differ mainly in their pattern of expression. COX-1 is expressed in most tissues, whereas COX-2 usually is absent, but is induced by numerous physiologic stimuli. Surprisingly, disruption of Cox1 (Ptgs1) in the mouse did not result in gastrointestinal abnormalities. cox-2 (Ptgs2) null mice show reproductive anomalies and defects in kidney development, Epidemiologic, animal, and human data indicate that NSAIDs, inhibitors of cyclooxygenase, are chemopreventive for colon cancer. COX-2 is overexpressed in 50% of benign polyps and 80-85% of adenocarcinomas. Offspring from cox-2 null by Apc(Delta 716) matings exhibit an 86% reduction in polyp number when compared to offspring from control animals, thus providing genetic evidence that COX-2 contributes to tumor formation or growth. The irt vivo mechanism by which COX-2 affects tumor growth has not been determined. It is possible that both tumor and stromally derived COX-2 could influence tumor angiogenesis and/or immune function.	Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Vanderbilt Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vet Adm Med Ctr, Vanderbilt Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI MCN C2104, Nashville, TN 37232 USA.		Williams, christopher S/A-1186-2009; DuBois, Raymond N./AAX-8869-2020		NCI NIH HHS [P01CA-77839] Funding Source: Medline; NIDDK NIH HHS [DK 47297] Funding Source: Medline; NIEHS NIH HHS [P030 ES-00267-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297, R37DK047297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLISON MC, 1992, NEW ENGL J MED, V327, P749, DOI 10.1056/NEJM199209103271101; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; Boolbol SK, 1996, CANCER RES, V56, P2556; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; Chiu CH, 1997, CANCER RES, V57, P4267; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; COYNE DW, 1992, AM J PHYSIOL, V263, P97; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DINCHUK JE, 1995, 2 WORLD C INFL BRIGH; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FU JY, 1990, J BIOL CHEM, V265, P16737; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GENG Y, 1995, J IMMUNOL, V155, P796; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Goldman AP, 1998, CARCINOGENESIS, V19, P2195, DOI 10.1093/carcin/19.12.2195; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HIAL V, 1976, EUR J PHARMACOL, V37, P367, DOI 10.1016/0014-2999(76)90044-3; HIRST JJ, 1995, J CLIN ENDOCR METAB, V80, P517, DOI 10.1210/jc.80.2.517; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kalgutkar AS, 1998, SCIENCE, V280, P1268, DOI 10.1126/science.280.5367.1268; Kargman S, 1996, GASTROENTEROLOGY, V111, P445, DOI 10.1053/gast.1996.v111.pm8690211; KARGMAN SL, 1995, CANCER RES, V55, P2556; Karnes WE, 1998, CANCER RES, V58, P5473; KESTER M, 1994, J BIOL CHEM, V269, P22574; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KUDO T, 1980, GANN, V71, P260; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEE SH, 1992, J BIOL CHEM, V267, P25934; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MILLER TA, 1983, AM J PHYSIOL, V245, P601; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; OKA M, 1994, AM J SURG, V167, P264, DOI 10.1016/0002-9610(94)90089-2; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; PEREIRA MA, 1994, CARCINOGENESIS, V15, P1049, DOI 10.1093/carcin/15.5.1049; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; PUGH S, 1994, GUT, V35, P675, DOI 10.1136/gut.35.5.675; Riendeau D, 1997, BRIT J PHARMACOL, V121, P105, DOI 10.1038/sj.bjp.0701076; RIESE J, 1994, J LEUKOCYTE BIOL, V55, P476, DOI 10.1002/jlb.55.4.476; Rocca B, 1999, J CLIN INVEST, V103, P1469, DOI 10.1172/JCI6400; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; Samaha HS, 1997, CANCER RES, V57, P1301; SANO H, 1995, CANCER RES, V55, P3785; SCHAFER AI, 1995, J CLIN PHARMACOL, V35, P209, DOI 10.1002/j.1552-4604.1995.tb04050.x; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Shao JY, 1999, CARCINOGENESIS, V20, P185, DOI 10.1093/carcin/20.2.185; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Singh J, 1997, CANCER RES, V57, P3465; SOLL AH, 1991, ANN INTERN MED, V114, P307, DOI 10.7326/0003-4819-114-4-307; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WENNOGLE LP, 1995, FEBS LETT, V371, P315, DOI 10.1016/0014-5793(95)00930-8; Williams Christopher S., 1999, Neoplasia (New York), V1, P170, DOI 10.1038/sj.neo.7900024; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; ZAMBRASKI EJ, 1995, SEMIN NEPHROL, V15, P205	80	1174	1218	2	80	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 20	1999	18	55					7908	7916		10.1038/sj.onc.1203286	http://dx.doi.org/10.1038/sj.onc.1203286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630643				2022-12-28	WOS:000084405900007
J	Vaziri, H; Benchimol, S				Vaziri, H; Benchimol, S			Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase	ONCOGENE			English	Review						telomerase; hTERT; telomere; senescence; aging; p53; pRb; TIEL; PARP	HUMAN-DIPLOID FIBROBLASTS; CATALYTIC SUBUNIT GENE; P53 TUMOR SUPPRESSION; NORMAL HUMAN-CELLS; WILD-TYPE P53; CYCLE ARREST; DNA-DAMAGE; IN-VITRO; EPITHELIAL-CELLS; RNA COMPONENT	Telomere shortening may be one of several factors that contribute to the onset of senescence in human cells, The p53 and pRb pathways are involved in the regulation of cell cycle progression from G1 into S phase and inactivation of these pathways leads to extension of life span, Short dysfunctional telomeres may be perceived as damaged DNA and may activate these pathways, leading to prolonged arrest in G1, typical of cells in senescence. Inactivation of the p53 and pRb pathways, however, does not lead to cell immortalization, Cells that overcome senescence and have an extended life span continue to lose telomeric DNA and subsequently enter a second phase of growth arrest termed 'crisis', Forced expression of telomerase in human cells leads to the elongation of telomeres and immortalization, The development of human cancer is frequently associated with the inactivation of the pRb and p53 pathways, attesting to the importance of senescence in restricting the tumor-forming ability of human cells, Cancer cells must also maintain telomere length and, in the majority of cases, this is associated with expression of telomerase activity.	Univ Toronto, Ontario Canc Inst Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Stanford University; University of Toronto	Benchimol, S (corresponding author), Univ Toronto, Ontario Canc Inst Princess Margaret Hosp, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOND JA, 1994, ONCOGENE, V9, P1885; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Foster SA, 1996, ONCOGENE, V12, P1773; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Milas M, 1998, CLIN CANCER RES, V4, P1573; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WOLMAN S. R., 1964, CYTOGENETICS [BASEL], V3, P45, DOI 10.1159/000129797; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	70	40	41	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	1999	18	53					7676	7680		10.1038/sj.onc.1203016	http://dx.doi.org/10.1038/sj.onc.1203016			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618707				2022-12-28	WOS:000084634500006
J	Bryckaert, M; Guillonneau, X; Hecquet, C; Courtois, Y; Mascarelli, F				Bryckaert, M; Guillonneau, X; Hecquet, C; Courtois, Y; Mascarelli, F			Both FGF1 and Bcl-x synthesis are necessary for the reduction of apoptosis in retinal pigmented epithelial cells by FGF2: role of the extracellular signal-regulated kinase 2	ONCOGENE			English	Article						FGF; Bcl-x; ERK2; apoptosis; retinal pigmented epithelial cells	FIBROBLAST-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; PEROXYNITRITE-INDUCED APOPTOSIS; FACTOR-I; PHOTORECEPTOR DEGENERATION; NEUROTROPHIC ACTIVITY; PROTOONCOGENE BCL-2; ENDOGENOUS FGF1; PC12 CELLS	Retinal pigmented epithelial (RPE) cells are of central importance in the maintenance of neural retinal function. Changes in the RPE cells associated with repair activities have been described as metaplasia, while RPE cell apoptosis is responsible for the development of a variety of retinal degenerations. We investigated the regulation of the anti-apoptotic properties of the fibroblast growth factors (FGF) 2 in serum-free cultures of RPE cells, In the absence of serum, confluent stationary RPE cells died by apoptosis via a caspase 3-dependent pathway, The addition of FGF2 greatly reduced apoptosis over a 7-day culture period, We demonstrated the involvement of an autocrine loop involving endogenous FGF1 in the mechanisms that govern FGF2-induced resistance to apoptosis by showing: (1) higher levels of apoptosis in cells treated with antisense FGF1 oligonucleotide or after neutralization of excreted FGF1; (2) the long-term activation of FGFR1 and of ERK2, (3) the inhibition of FGFR1 and ERK2 activation and an increase in apoptosis if excreted FGF1 was neutralized, FGF2 also increased the de novo synthesis and the production of Bcl-xl before the onset of apoptosis, Both inhibition of ERK2 activation, which decreased Bcl-xl synthesis, and downregulation of Bcl-x by antisense oligonucleotide treatment inhibited the survival-promoting activity of FGF2, Thus, FGF2-induced cell survival is a progressive adaptive phenomenon involving ERK2 activation by excreted FGF1 and ERK2-dependent Bcl-x production.	Assoc Claude Bernard, CNRS, INSERM, U450, F-75016 Paris, France; IFR Circulat, INSERM, U348, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mascarelli, F (corresponding author), Assoc Claude Bernard, CNRS, INSERM, U450, 29 Rue Wilhem, F-75016 Paris, France.		Mascarelli, Frederic/L-8916-2018; Guillonneau, xavier/E-3995-2017; guillonneau, xavier/AAF-9495-2021	Guillonneau, xavier/0000-0001-7379-3935; guillonneau, xavier/0000-0001-7379-3935; Bryckaert, Marijke/0000-0003-3398-0976				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALTERIO J, 1988, FEBS LETT, V242, P41, DOI 10.1016/0014-5793(88)80981-5; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; CLARENC JP, 1993, J BIOL CHEM, V268, P5600; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURLIER F, 1997, J MOL EVOL, V44, P43; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; Desire L, 1998, DEV DYNAM, V212, P63, DOI 10.1002/(SICI)1097-0177(199805)212:1<63::AID-AJA6>3.0.CO;2-0; Enzmann V, 1998, OPHTHALMIC RES, V30, P189, DOI 10.1159/000055473; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; FENNEWALD SM, 1995, J BIOL CHEM, V270, P21718, DOI 10.1074/jbc.270.37.21718; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Funato N, 1997, BIOCHEM BIOPH RES CO, V240, P21, DOI 10.1006/bbrc.1997.7588; Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Garland JM, 1998, BLOOD, V92, P1235, DOI 10.1182/blood.V92.4.1235.416k18_1235_1246; GILLARDON F, 1995, J NEUROSCI RES, V41, P708, DOI 10.1002/jnr.490410517; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542; Guillonneau X, 1998, MOL BIOL CELL, V9, P2785, DOI 10.1091/mbc.9.10.2785; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; GUKOVA M, 1995, J BIOL CHEM, V270, P2620; Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; Levin LA, 1997, INVEST OPHTH VIS SCI, V38, P2545; LEZOUALCH F, 1995, J BIOL CHEM, V270, P12100, DOI 10.1074/jbc.270.20.12100; Lindenboim L, 1998, NEUROSCI LETT, V253, P37, DOI 10.1016/S0304-3940(98)00602-8; Liu JF, 1998, EUR J BIOCHEM, V258, P271, DOI 10.1046/j.1432-1327.1998.2580271.x; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; Mishima K, 1998, MODERN PATHOL, V11, P886; MONTPIED P, 1993, BIOCHEM BIOPH RES CO, V195, P623, DOI 10.1006/bbrc.1993.2091; Myoken Y, 1996, INT J CANCER, V65, P650, DOI 10.1002/(SICI)1097-0215(19960301)65:5<650::AID-IJC15>3.0.CO;2-B; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; Onal MZ, 1997, EUR NEUROL, V38, P141; Papermaster DS, 1997, CELL DEATH DIFFER, V4, P21, DOI 10.1038/sj.cdd.4400210; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SAHL B, 1999, ANTICANCER RES, V19, P731; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shin JT, 1996, ARCH BIOCHEM BIOPHYS, V335, P32, DOI 10.1006/abbi.1996.0479; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Spear N, 1998, ARCH BIOCHEM BIOPHYS, V356, P41, DOI 10.1006/abbi.1998.0741; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; VLODAVSKY I, 1982, EXP CELL RES, V140, P149, DOI 10.1016/0014-4827(82)90166-5; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; YAZOVITSKAYA EM, 1999, MOL CARCINOG, V25, P1; Yokoyama Y, 1997, J NEUROCHEM, V68, P2212	64	48	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7584	7593		10.1038/sj.onc.1203200	http://dx.doi.org/10.1038/sj.onc.1203200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602518				2022-12-28	WOS:000084119600020
J	Paramio, JM; Navarro, M; Segrelles, C; Gomez-Casero, E; Jorcano, JL				Paramio, JM; Navarro, M; Segrelles, C; Gomez-Casero, E; Jorcano, JL			PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein	ONCOGENE			English	Article						PTEN/MMAC1/TEP1; cell cycle; retinoblastoma protein; signal transduction	PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; GLIOMA-CELLS; KINASE; PHOSPHATASE; INHIBITION; EXPRESSION; G(1); GENE	The tumour suppressor PTEN, also named MMAC1 or TEP1, is associated with a number of malignancies in human populations. This protein has a dual protein phosphatase activity, being also capable to dephosphorylate phosphatidylinositol 3,4,5 triphosphate. We have studied the mechanism of growth suppression attributable to PTEN, We observed that PTEN overexpression inhibits cell growth in a variety of normal and transformed, human and murine cells. Bromodeoxyuridine (BrdU) incorporation and TUNEL labelling experiments in transiently transfected cells demonstrate that this inhibition is due to a cell cycle arrest rather than induction of apoptosis, Given that PTEN is unable to cause cell growth arrest in retinoblastoma (Rb)deficient cell lines, we have explored the possible requirement for pRb in the PTEN-induced inhibition of cell proliferation. We found that the co-expression of SV40 antigen, but not a mutant form (which binds exclusively to p53), and cyclin D1/cdk4 are able to overcome the PTEN-mediated growth suppression. In addition, the reintroduction of a functional pRb, but not its relatives p107 or p130, in Rb-deficient cells restores the sensitivity to PTEN-induced arrest. Finally, the hyperphosphorylation of transfected pRb is inhibited by PTEN co-expression and restored by PI-3K co-expression, Accordingly, PTEN gene is mostly expressed, in parallel to Akt, in mid-late G(1) phase during cell cycle progression prior to pRb hyperphosphorylation. Finally, we have studied the signal transduction pathways modulated by PTEN expression. We found that PTEN-induced growth arrest can be rescued by the co-expression of active PI-3K and downstream effecters such as Akt or PDK1, and also certain small GTPases such as Rad and Cdc42, but not by active Ha-ras, paf or RhoA, Collectively, our data link the tumour suppressor activities of PTEN to the machinery controlling cell cycle through the modulation of signalling molecules whose final target is the functional inactivation of the retinoblastoma gene product.	CIEMAT, Dept Mol & Cell Biol, E-28040 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Paramio, JM (corresponding author), CIEMAT, Dept Mol & Cell Biol, Ave Complutense 22, E-28040 Madrid, Spain.		Paramio, Jesus M/M-8482-2014; Navarro, Manuel/S-1496-2019; Gómez-Casero, Elena/A-7389-2016; Segrelles, Carmen/E-3655-2016; Esteban, Elena Gómez-Casero/AAK-3216-2020	Paramio, Jesus M/0000-0001-7520-3177; Navarro, Manuel/0000-0003-1118-8531; Gómez-Casero, Elena/0000-0002-7040-8832; Segrelles, Carmen/0000-0001-9340-2102; Esteban, Elena Gómez-Casero/0000-0002-7040-8832				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Pearson R B, 1995, Prog Cell Cycle Res, V1, P21; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PRENNAN P, 1997, IMMUNITY, V7, P679; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	104	106	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7462	7468		10.1038/sj.onc.1203151	http://dx.doi.org/10.1038/sj.onc.1203151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602505				2022-12-28	WOS:000084119600007
J	Spencer, JA; Misra, RP				Spencer, JA; Misra, RP			Expression of the SRF gene occurs through a Ras/Sp/SRF-mediated-mechanism in response to serum growth signals	ONCOGENE			English	Article						gene regulation; signal transduction; Sp1; SRF	C-FOS; TRANSCRIPTIONAL ACTIVATION; LYSOPHOSPHATIDIC ACID; BINDING; PROMOTER; ELEMENTS; CALCIUM; SEQUENCES; PATHWAYS; UPSTREAM	Serum Response Factor (SRF) plays a central role in the transcriptional response of mammalian cells to a variety of extracellular signals. It is a key regulator of many cellular early response genes which are believed to be involved in cell growth, differentiation, and development, The mechanism by which SRF activates transcription in response to mitogenic agents has been extensively studied, however, less is known about regulation of the SRF gene itself. Previously, we identified distinct regulatory elements in the SRF promoter that play a role in activation, including an ETS domain binding site, an overlapping Sp1/Egr-1 binding site, and two SRF binding sites, We further showed that serum induces the SRF gene by a mechanism that requires an intact SRF binding site, also termed a CArG box, In the present study we demonstrate that in response to stimulation by cells by lysophosphatidic acid (LPA) or whole serum, the SRF promoter is upregulated by a bipartite pathway that requires both an Spl factor binding site and the CArG motifs for maximal stimulation, The CArG box-dependent component of this pathway is targeted by Rho mediated signals, and the Spl binding site dependent component is targeted by Ras mediated signals.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Misra, RP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NIGMS NIH HHS [R55 GM/OD51856] Funding Source: Medline; NINDS NIH HHS [R29 NS36256] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS036256] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; Chen BK, 1997, BBA-LIPID LIPID MET, V1344, P270, DOI 10.1016/S0005-2760(96)00151-8; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; FUJII M, 1994, J VIROL, V68, P7275, DOI 10.1128/JVI.68.11.7275-7283.1994; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOOLENAAR WH, 1992, COLD SPRING HARB SYM, V57, P163, DOI 10.1101/SQB.1992.057.01.021; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1990, CANCER BIOL, V1, P47; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474	39	38	38	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7319	7327		10.1038/sj.onc.1203121	http://dx.doi.org/10.1038/sj.onc.1203121			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602487				2022-12-28	WOS:000084119400017
J	Gilmore, TD				Gilmore, TD			The Rel/NF-kappa B signal transduction pathway: introduction	ONCOGENE			English	Editorial Material						Rel; NF-kappa B; I kappa B; IKK; signal transduction; transcription factor			Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.							Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220	12	346	358	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	1999	18	49					6842	6844		10.1038/sj.onc.1203237	http://dx.doi.org/10.1038/sj.onc.1203237			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602459				2022-12-28	WOS:000083896500001
J	Nesbit, M; Nesbit, HKE; Bennett, J; Andl, T; Hsu, MY; Dejesus, E; McBrian, M; Gupta, AR; Eck, SL; Herlyn, M				Nesbit, M; Nesbit, HKE; Bennett, J; Andl, T; Hsu, MY; Dejesus, E; McBrian, M; Gupta, AR; Eck, SL; Herlyn, M			Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes	ONCOGENE			English	Article						melanocytes; bFGF; adenovirus; transformation	FACTOR MESSENGER-RNA; MELANOMA CELL-LINES; MALIGNANT-MELANOMA; FACTOR RECEPTORS; 3T3 CELLS; EXPRESSION; BFGF; GENE; FGF; PROLIFERATION	Basic fibroblast growth factor (bFGF or FGF-2) is produced by nearly all melanomas in vitro and in viva but not by normal melanocytes, which require exogenous bFGF for growth, In this study, we transduced normal human melanocytes to overexpress two forms of bFGF: (bFGF-Long and bFGF-Short) using replication-deficient adenovirus 5 vectors. bFGF-Long induced the 17.8, 22.5, 23.1 and 24.2 kDa forms of bFGF, whereas bFGF-Short induced only the 17.8 kDa mature form. Growth of cultured melanocytes transduced with either vector was similar to that of nevus and melanoma cells and was independent of exogenous bFGF and of insulin/insulin-like growth factor 1, and cyclic AMP enhancers, requiring only phorbol ester as an exogenous mitogen, Like primary melanoma cells, transduced normal melanocytes grew anchorage independently in soft agar, When injected into the dermis of human skin grafted to mice, bFGF-transduced melanocytes proliferated for at least 20 days, whereas cells from control cultures showed poor survival and no proliferation. These results demonstrate that bFGF upregulation is a component in melanoma progression.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.			Hsu, Mei-Yu/0000-0002-4628-0808; Andl, Thomas/0000-0002-5555-468X	NCI NIH HHS [CA25874, CA47159, CA76674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025874, R01CA047159, R01CA076674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMALEK Z, 1992, J CELL PHYSIOL, V150, P416, DOI 10.1002/jcp.1041500226; Ahmed NU, 1997, MELANOMA RES, V7, P299, DOI 10.1097/00008390-199708000-00004; AlAlousi S, 1996, J CUTAN PATHOL, V23, P506, DOI 10.1111/j.1600-0560.1996.tb01442.x; AlAlousi S, 1996, J CUTAN PATHOL, V23, P118, DOI 10.1111/j.1600-0560.1996.tb01284.x; ALBINO AP, 1991, CANCER RES, V51, P4815; AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; Care A, 1996, MOL CELL BIOL, V16, P4842; CohenJonathan E, 1997, CANCER RES, V57, P1364; Coleman AB, 1998, J INVEST DERMATOL, V110, P793, DOI 10.1046/j.1523-1747.1998.00166.x; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; DAVOL P, 1995, J INVEST DERMATOL, V104, P916, DOI 10.1111/1523-1747.ep12606193; DELUCA M, 1993, J CELL SCI, V105, P1079; deOliveira AR, 1996, BRAZ J MED BIOL RES, V29, P1743; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; HALABAN R, 1988, ONCOGENE RES, V3, P177; HERLYN M, 1988, EXP CELL RES, V179, P322, DOI 10.1016/0014-4827(88)90271-6; HERLYN M, 1994, PIGM CELL RES, V7, P81, DOI 10.1111/j.1600-0749.1994.tb00025.x; HERLYN M, 1994, CANCER RES, V45, P5670; Horikawa T, 1996, PIGM CELL RES, V9, P58, DOI 10.1111/j.1600-0749.1996.tb00089.x; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; JUHASZ I, 1993, AM J PATHOL, V143, P528; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; MANCIANTI ML, 1993, J INVEST DERMATOL, V100, pS281, DOI 10.1111/1523-1747.ep12470161; Nakazawa K, 1996, PIGM CELL RES, V9, P28, DOI 10.1111/j.1600-0749.1996.tb00083.x; Nelson JE, 1997, J VIROL, V71, P8902, DOI 10.1128/JVI.71.11.8902-8907.1997; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1989, ONCOGENE RES, V5, P101; REED JA, 1994, AM J PATHOL, V144, P329; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; SATYAMOORTHY K, 1996, IMMUNOLOGY HUMAN MEL, P71; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Seno M, 1998, CYTOKINE, V10, P290, DOI 10.1006/cyto.1997.0286; UEDA M, 1994, BRIT J DERMATOL, V130, P320, DOI 10.1111/j.1365-2133.1994.tb02927.x; VALYINAGY IT, 1993, LAB INVEST, V69, P152; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; WEITZMAN MD, 1995, CNAC THERAPEUTICS; YAN HC, 1993, J CLIN INVEST, V91, P986, DOI 10.1172/JCI116320; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159	48	95	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6469	6476		10.1038/sj.onc.1203066	http://dx.doi.org/10.1038/sj.onc.1203066			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597249				2022-12-28	WOS:000083709200009
J	Kim, KR; Yoshizaki, T; Miyamori, H; Hasegawa, K; Horikawa, T; Furukawa, M; Harada, S; Seiki, M; Sato, H				Kim, KR; Yoshizaki, T; Miyamori, H; Hasegawa, K; Horikawa, T; Furukawa, M; Harada, S; Seiki, M; Sato, H			Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth	ONCOGENE			English	Article						EB virus; LMP1; MDCK; Ets1; transformation; tubulogenesis	NF-KAPPA-B; FACTOR-RECEPTOR FAMILY; PLASMINOGEN-ACTIVATOR; TRANSCRIPTION FACTOR; CHICK-EMBRYO; LYMPHOCYTE TRANSFORMATION; MATRIX-METALLOPROTEINASE; GENE; MEMBRANE-PROTEIN-1; INDUCTION	The Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) has a significant role in initiating EBV-associated lymphoproliferative disease and EBV-related malignancies, In view of clinical features related to the type of EBV latency, LMP1 may influence invasiveness of EBV associated tumors categorized as types II and III as represented on nasopharyngeal carcinoma (NPC), To screen for genes associated with invasion of epithelial cells transformed by LIMP1, Madin-Darby canine kidney (MDCK) epithelial cells were transformed by LMP1, Stable transfection of a LMP1 gene into MDCK cells induced morphological change from cobblestone to a long spindle-shape, reduced cell-cell adhesion and caused high cell motility, Parental MDCK cells, which form spherical cysts in three-dimensional collagen gel matrix, form branching tubules following exposure to hepatocyte growth factor (HGF). MDCK cells transformed by LMP1 showed invasive growth to form branching tubules into collagen gel without HGF-treatment. mRNA differential display and Northern hybridization identified plasminogen activator inhibitor-1 (PAI-I), urokinase type plasminogen activator (uPA) and ets1 as genes upregulated during transformation by LMP1. Expression of a dominant negative type of Ets1 in LMP1-transformed cells downregulated uPA expression and cell motility, Deletion of LMP1 cytoplasmic carboxy-terminal activating region 1 (CTAR1) domain abolished transformation, but a deletion mutant lacking CTAR2 domain still retained transforming and uPA-inducing ability, Expression of Ets1 was immunolocalized in tumor cells of NPC tissue which frequently express LMP1, Taken together, it is suggested that LMP1 induces expression of Ets1 which may contribute to invasion of NPC by stimulating cell motility and uPA expression.	Kanazawa Univ, Dept Mol Virol & Oncol, Inst Canc Res, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Sch Med, Dept Otolaryngol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 108, Japan	Kanazawa University; Kanazawa University; University of Tokyo	Sato, H (corresponding author), Kanazawa Univ, Dept Mol Virol & Oncol, Inst Canc Res, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015					BAICHWAL VR, 1988, ONCOGENE, V2, P461; BARDELLI A, 1992, ONCOGENE, V7, P1973; BINDAL AK, 1994, J NEURO-ONCOL, V22, P101, DOI 10.1007/BF01052886; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; Davies G, 1999, ANTICANCER RES, V19, P547; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Devergne O, 1996, MOL CELL BIOL, V16, P7098; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Grisendi S, 1998, J CELL PHYSIOL, V176, P465, DOI 10.1002/(SICI)1097-4652(199809)176:3<465::AID-JCP3>3.0.CO;2-M; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hiscox S, 1999, ANTICANCER RES, V19, P509; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Kadono Y, 1998, CANCER RES, V58, P2240; Kadono Y, 1998, BIOCHEM BIOPH RES CO, V251, P681, DOI 10.1006/bbrc.1998.9531; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kieff E, 1996, VIROLOGY, P2343; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Liebowitz David, 1993, P107; LIOTTA LA, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0292-54; MILLER G, 1990, VIROLOGY, P1921; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nabeshima K, 1998, INT J CANCER, V78, P750, DOI 10.1002/(SICI)1097-0215(19981209)78:6<750::AID-IJC13>3.0.CO;2-#; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; Nakayama T, 1996, AM J PATHOL, V149, P1931; Noritake H, 1999, CLIN EXP METASTAS, V17, P105, DOI 10.1023/A:1006596620406; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QUEVA C, 1993, ONCOGENE, V8, P2511; Rickinson AB, 1996, VIROLOGY, P2397; SAPPINO AP, 1991, J CLIN INVEST, V88, P1073, DOI 10.1172/JCI115406; SATO H, 1992, ONCOGENE, V7, P77; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Takeshita H, 1999, J VIROL, V73, P5548, DOI 10.1128/JVI.73.7.5548-5555.1999; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Young L S, 1992, Semin Cancer Biol, V3, P273; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	54	80	88	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1764	1771		10.1038/sj.onc.1203502	http://dx.doi.org/10.1038/sj.onc.1203502			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777210				2022-12-28	WOS:000086292500004
J	Zrihan-Licht, S; Fu, YG; Settleman, H; Schinkmann, K; Shaw, L; Keydar, I; Avraham, S; Avraham, H				Zrihan-Licht, S; Fu, YG; Settleman, H; Schinkmann, K; Shaw, L; Keydar, I; Avraham, S; Avraham, H			RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion	ONCOGENE			English	Article						RAFTK; RhoGAP; RasGAP; ErbB-2; invasion	FOCAL ADHESION KINASE; GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; GROWTH-FACTOR; ACTIN CYTOSKELETON; PHOSPHORYLATION; RECEPTOR; BINDING; MEGAKARYOCYTES; STIMULATION	Focal adhesions and actin cytoskeleton are involved in cell growth, shape and movement and in tumor invasion. Mitogen-induced changes in actin cytoskeleton are accompanied by changes in the tyrosine phosphorylation of several focal adhesion proteins. in this study, we have investigated the role of RAFTK, a cytoplasmic tyrosine kinase related to focal adhesion kinase (FAK), in heregulin-mediated signal transduction in breast cancer cells. Stimulation of T47D cells with heregulin (HRG) induced the tyrosine phosphorylation of RAFTK and the formation of a multiprotein complex;, Analyses of the members of the HRG-stimulated complex revealed that RAFTK is associated with p190 RhoGAP (p190), RasGAP and ErbB-2, and plays an essential role in mediating the tyrosine phosphorylation of plop by Src, Mutation of the Src binding site within RAFTK (402) abolished the phosphorylation of p190. In addition, upon HRG stimulation of T47D cells, association of ErbB-2 with RAFTK was observed and found to be indirect and mediated by Src. Expression of wild-type RAFTK (WT) significantly increased MDA-MB-435 and MCF-7 breast cancer cell invasion, while expression of the kinase-mutated RAFTK-R457 (KM) or the Src binding site mutant RAFTM (402) did not affect this cell invasion. Furthermore, HRG leads to tbe activation of MAP kinase which is mediated by RAFTK. These findings indicate that RAFTK serves as a mediator and an integration paint between the GAP proteins and HRG-mediated signaling in breast cancer cells, and implicate RAFTK involvement in the MAP kinase pathway and in breast cancer cell invasion.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02125 USA; Harvard Univ, Sch Med, Boston, MA 02125 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tel Aviv University	Avraham, H (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.			Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55455, HL51456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chen HC, 1996, EUR J BIOCHEM, V235, P495, DOI 10.1111/j.1432-1033.1996.00495.x; CHENG JC, 1995, CELL GROWTH DIFFER, V6, P139; Cohen BM, 1996, J BIOL CHEM, V271, P4813; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kumar R, 1996, J CELL BIOCHEM, V62, P102; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, J CELL SCI, V108, P225; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AL, 1993, CELL, V70, P389; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Serpente N, 1996, MOL CELL NEUROSCI, V7, P391, DOI 10.1006/mcne.1996.0028; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063	50	90	96	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1318	1328		10.1038/sj.onc.1203422	http://dx.doi.org/10.1038/sj.onc.1203422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713673				2022-12-28	WOS:000085743800008
J	Ivanov, VN; Kehrl, JH; Ronai, Z				Ivanov, VN; Kehrl, JH; Ronai, Z			Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis	ONCOGENE			English	Article						TRAF2; GCK; NF-kappa B; melanoma; apoptosis; UV-irradiation	NF-KAPPA-B; RECEPTOR-ASSOCIATED FACTOR-2; FAS LIGAND EXPRESSION; FACTOR TNF RECEPTOR-1; TERMINAL KINASE; SIGNAL-TRANSDUCTION; INDUCED ACTIVATION; CELL-DEATH; T-CELLS; PATHWAYS	Radiation resistance is a hallmark of human melanoma, and yet mechanisms underlying this resistance are not well understood. We recently established the role of ATF2 in this process, suggesting that stress kinases, which contribute to regulation of ATF2 stability and activity, play an important role in the acquisition of such resistance. Here we demonstrate that changes in the expression and respective activities of TRAF2/GCK occur during melanoma development and regulate its sensitivity to UV-induced apoptosis, Comparing early- and late-stage melanoma cells revealed low expression of TRAF2 and GCK in early-stage melanoma, which coincided with poor resistance to UV-induced, TNF-mediated apoptosis; forced expression of GCK alone or in combination with TRAF2 efficiently increased JNK and NF-kappa B activities, which coincided with increased protection against apoptosis, Conversely, forced expression of the dominant negative form of TRAF2 or GCK in late-stage melanoma cells reduced NF-kappa B activity and decreased Fas expression, resulting in a lower degree of UV-induced, Fas-mediated cell death. Our results illustrate a mechanism in which protection from, or promotion of, UV-induced melanoma cell death depends on the nature of the apoptotic cascade (TNF or Fas) and on the availability of TRAF2/GCK, whose expression increases during melanoma progression.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; NIH, Immunoregulat Lab, Bethesda, MD 20892 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave,Room 15-20, New York, NY 10029 USA.		Ivanov, Vladimir N/A-3081-2008; Kehrl, John/AAE-6292-2019	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400; Kehrl, John/0000-0002-6526-159X	NCI NIH HHS [CA 51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051995, R29CA051995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bakker TR, 1999, INT J CANCER, V80, P320; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chaudhuri A, 1999, BIOCHEM BIOPH RES CO, V256, P620, DOI 10.1006/bbrc.1999.0385; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moretti S, 1999, INT J CANCER, V84, P160, DOI 10.1002/(SICI)1097-0215(19990420)84:2<160::AID-IJC12>3.3.CO;2-I; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Shi CS, 1999, J IMMUNOL, V163, P3279; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sprecher E, 1999, J CUTAN PATHOL, V26, P72, DOI 10.1111/j.1600-0560.1999.tb01805.x; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yang YM, 1996, ONCOGENE, V12, P2223; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	61	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					933	942		10.1038/sj.onc.1203415	http://dx.doi.org/10.1038/sj.onc.1203415			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702802	Green Published			2022-12-28	WOS:000085567700011
J	Caldeira, S; de Villiers, EM; Tommasino, M				Caldeira, S; de Villiers, EM; Tommasino, M			Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein	ONCOGENE			English	Article						human papillomaviruses; E7 proteins; pocket proteins; S phase induction	CELL-CYCLE REGULATION; TYPE-16 E7; EPIDERMODYSPLASIA VERRUCIFORMIS; TRANSFORMING ACTIVITY; RB-BINDING; IN-VIVO; GENE; ONCOPROTEIN; DNA; DIMERIZATION	Studies on human papillomavirus type 16 have demonstrated that the product of the early gene, E7, plays a key role in the immortalization and malignant transformation of the host cell. Several of the biological activities of HPV16 E7 are mediated by inactivation of the members of the pocket protein family, pRb, p107 and p130. In this study, we have characterized the in vitro properties of five E7 proteins from benign and malignant HPV types (10, 32, 48, 54, 77), We show that these E7 proteins associate with pRb and p107 with different efficiencies. All E7s increased the proliferative rate of immortalized rodent fibroblasts cultured in 10% calf serum containing medium. This property is completely independent of their ability to associate with the pocket proteins. Furthermore, all E7s, except HPV10 E7, stimulate G1/S progression and activated the cyclin E and cyclin A promoter in the absence of growth factors, This activity also does not correlate with the E7-efficiency of binding the pocket proteins. Together these data provide evidence that different E7s alter the regulation of the cell cycle by diverse mechanism(s). Finally, this comparative analysis of the different E7 proteins demonstrates that the oncogenicity of a HPV type is not determined by the ability of E7 to associate with the pocket proteins.	Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Angew Tumorvirol, INF 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019	Caldeira, Sandra/0000-0002-6057-5979				BANKS L, 1990, ONCOGENE, V5, P1383; BEAUDENON S, 1986, NATURE, V321, P246, DOI 10.1038/321246a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; CICCOLINI F, 1994, ONCOGENE, V9, P2633; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Delius H, 1998, VIROLOGY, V240, P359, DOI 10.1006/viro.1997.8943; deVilliers EM, 1997, CLIN DERMATOL, V15, P199, DOI 10.1016/S0738-081X(96)00164-2; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HU TH, 1995, INT J ONCOL, V6, P167; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; KREMSDORF D, 1983, J VIROL, V48, P340, DOI 10.1128/JVI.48.2.340-351.1983; Lavia P, 1999, BIOESSAYS, V21, P221; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER M, 1989, J VIROL, V63, P4907; ORTH G, 1978, P NATL ACAD SCI USA, V75, P1537, DOI 10.1073/pnas.75.3.1537; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; Tommasino M, 1997, PAPILLOMAVIRUSES HUM; WATANABE S, 1992, VIROLOGY, V190, P872, DOI 10.1016/0042-6822(92)90928-I; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	35	39	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2000	19	6					821	826		10.1038/sj.onc.1203375	http://dx.doi.org/10.1038/sj.onc.1203375			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698500				2022-12-28	WOS:000085192100012
J	Tolkacheva, T; Chan, AML				Tolkacheva, T; Chan, AML			Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene	ONCOGENE			English	Article						Ras; PTEN; endometrium; transformation	PHOSPHATIDYLINOSITOL 3-KINASE; ENDOMETRIAL CANCERS; GLIOBLASTOMA CELLS; SIGNALING PATHWAY; PTEN; MUTATIONS; PROTOONCOGENE; ACTIVATION; CARCINOMA; PROTEINS	The human PTEN/MMAC1/TEP1 (PTEN) tumor suppressor gene encodes a phosphatase with specificity towards the D3 phosphate of phosphatidylinositides. PTEN mutations hale been reported in the endometrioid type of uterine tumors which are associated with frequent activations of the Ras oncogenes. In this study, we report the ability of PTEN to potently inhibit H-Ras induced morphological transformation and anchorage-independent growth in NIH3T3 cells. This novel activity of PTEN was correlated more with its ability to suppress the phosphatidylinositol 3-kinase (PI3-K)-dependent signaling cascade, but not the mitogen-activated protein kinase (MAPK) pathway. To define the minimal region in PTEN protein that is responsible for this anti-oncogenic activity, a panel of carboxyl-terminal truncation mutants was generated. While deletions of 4 and 33 amino acids do not have marked effects, removal of up to 68 amino acids drastically reduced the ability of PTEN to inhibit Ras transformation. The propensity of these mutants to suppress Ras transformation is correlated with their relative ability to dephosphorylate inositol (1,3,4,5)-tetrakisphosphate in vitro, and to suppress Akt kinase activity in cultured cells. In addition, we have evidence to suggest that the C-terminal region of PTEN contributes to the stability of the encoded gene product.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Chan, AML (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave Levy Pl,Box 1130, New York, NY 10029 USA.		Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464	NATIONAL CANCER INSTITUTE [R29CA078509, R01CA066654] Funding Source: NIH RePORTER; NCI NIH HHS [CA78509, CA66654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheney IW, 1998, CANCER RES, V58, P2331; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maxwell GL, 1998, CANCER RES, V58, P2500; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Obata K, 1998, CANCER RES, V58, P2095; Osada M, 1999, MOL CELL BIOL, V19, P6333; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Risinger JI, 1998, CLIN CANCER RES, V4, P3005; Risinger JI, 1997, CANCER RES, V57, P4736; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Tashiro H, 1997, AM J PATHOL, V150, P177; Tashiro H, 1997, CANCER RES, V57, P3935; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	43	62	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					680	689		10.1038/sj.onc.1203331	http://dx.doi.org/10.1038/sj.onc.1203331			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698513				2022-12-28	WOS:000085192000010
J	Tarafa, G; Villanueva, A; Farre, L; Rodriguez, J; Musulen, E; Reyes, G; Seminago, R; Olmedo, E; Paules, AB; Peinado, MA; Bachs, O; Capella, G				Tarafa, G; Villanueva, A; Farre, L; Rodriguez, J; Musulen, E; Reyes, G; Seminago, R; Olmedo, E; Paules, AB; Peinado, MA; Bachs, O; Capella, G			DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination	ONCOGENE			English	Article						pancreatic cancer; colorectal cancer; DCC; Smad4; Smad2	SUPPRESSOR GENE; CHROMOSOME 18Q; MUTATIONAL ANALYSIS; COLON-CANCER; ALLELIC LOSS; DPC4 SMAD4; NUDE-MICE; IN-VIVO; EXPRESSION; CARCINOMA	Chromosome 18q is lost a high proportion of colorectal and pancreatic cancers. Three candidate tumor suppressor genes, DCC, Smad4 and Smad2 have been identified in this chromosome region. DCC and Smad4 aberrations have been previously identified in pancreatic and colorectal tumors. The aim of this study was to compare the presence of concurrent genetic aberrations in DCC and neighboring Smad4 and Smad2 genes during colorectal and pancreatic distal dissemination. We have used a panel of orthotopically implanted colorectal and pancreatic xenografts and corresponding metastases. We have shown that while LOH at DCC locus occurred at a similar frequency in both tumors, diminished DCC protein expression was exclusively present in colorectal tumors harboring intragenic DCC LOH, In contrast, in pancreatic xenografts loss of DCC protein and mRNA expression was restricted to metastases, Smad4 gene aberrations were detected at a similar frequency in both tumors and were selected for during distal dissemination. Acquisition of alterations in both genes occurred independently. Our results suggest that both DCC and Smad4 contribute to pancreatic and colorectal distal dissemination. However, the role of DCC may differ between both tumor types.	Hosp Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona 08025, Spain; Hosp Santa Creu & Sant Pau, S Cirurgia Vasc, Barcelona 08025, Spain; Consorci Hosp Parc Tauli, Serv Patol, Sabadell 08023, Spain; Univ Barcelona, Serv Cient Tecn, Barcelona 08028, Spain; Univ Barcelona, IDIBAPS, Inst Invest Biomed August Pi & Sunyer, Fac Med,Dept Biol Cellular, E-08036 Barcelona, Spain; Inst Recerca Oncol, Dept Canc & Metastasi, Barcelona 08907, Spain; Inst Catala Oncol, Mol Biol Lab, Barcelona 08907, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Catalan Institute of Oncology	Capella, G (corresponding author), Inst Catala Oncol, Mol Biol Lab, Av Gran Via S-N,Km 2,7, Barcelona 08907, Spain.		Tarafa, Gemma/H-2517-2013; Peinado, Miguel A./A-5591-2008; Capella, Gabriel/I-1879-2015; Musulen, Eva/AAI-9169-2020; OLMEDO, EVA/K-6810-2014	Tarafa, Gemma/0000-0003-1734-7740; Peinado, Miguel A./0000-0002-4090-793X; Capella, Gabriel/0000-0002-4669-7320; Musulen, Eva/0000-0002-9667-6464; OLMEDO, EVA/0000-0003-0558-1513; Farre, Lourdes/0000-0002-3168-1940				BUURENVANSEGGEL.VH, 1998, GENE CHROMOSOME CANC, V21, P30; CARELLA G, 1991, ENV HLTH PERSPECT, V93, P125; Chen YQ, 1999, ONCOGENE, V18, P2747, DOI 10.1038/sj.onc.1202629; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fabre M, 1999, INT J CANCER, V81, P799, DOI 10.1002/(SICI)1097-0215(19990531)81:5<799::AID-IJC22>3.3.CO;2-N; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FU XY, 1991, P NATL ACAD SCI USA, V88, P9345, DOI 10.1073/pnas.88.20.9345; Goi T, 1998, BRIT J CANCER, V77, P466, DOI 10.1038/bjc.1998.74; Gotley DC, 1996, ONCOGENE, V13, P787; Gupta PK, 1997, CANCER RES, V57, P1188; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAHN SA, 1995, CANCER RES, V55, P4670; HOHNE MW, 1992, CANCER RES, V52, P2616; Hoque ATMS, 1997, GUT, V40, P120, DOI 10.1136/gut.40.1.120; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; Kong XT, 1997, CANCER RES, V57, P3772; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Maesawa C, 1996, EUR J CANCER, V32A, P896, DOI 10.1016/0959-8049(96)00010-X; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; PARRY PJ, 1991, NUCLEIC ACIDS RES, V19, P6983, DOI 10.1093/nar/19.24.6983-a; PEINADO MA, 1993, INT J ONCOL, V2, P123; Reyes G, 1996, CANCER RES, V56, P5713; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schmitt CA, 1998, BRIT J CANCER, V77, P588, DOI 10.1038/bjc.1998.95; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; SIMON B, 1994, GASTROENTEROLOGY, V106, P1645, DOI 10.1016/0016-5085(94)90422-7; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takei K, 1998, CANCER RES, V58, P3700; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118	40	47	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2000	19	4					546	555		10.1038/sj.onc.1203353	http://dx.doi.org/10.1038/sj.onc.1203353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698524				2022-12-28	WOS:000085104200008
J	Roy, G; Horton, JK; Roy, R; Denning, T; Mitra, S; Boldogh, I				Roy, G; Horton, JK; Roy, R; Denning, T; Mitra, S; Boldogh, I			Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins	ONCOGENE			English	Article						drug resistance; apoptosis; alkylating drugs; pro- and anti-apoptotic proteins; bcl-2 family	GENE O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; BASE EXCISION-REPAIR; APURINIC/APYRIMIDINIC ENDONUCLEASE; CYTOCHROME-C; DNA; BCL-2; MITOCHONDRIA; RECOGNITION; EXPRESSION; ACTIVATION	In a systematic study to elucidate the involvement of pro-and anti-apoptotic proteins in alkylating drug resistance of tumor cells, we utilized the A2780(100) line, that was selected by repeated exposure of A2780 cell line (human ovarian carcinoma line) to chlorambucil (CBL), A2780(100) was 5-10-fold more resistant to nitrogen mustards (IC,, of 50-60 mu M) and other DNA crosslinking agents, e,g,, cisplatin, and also to DNA topoisomerase inhibitor etoposide (ETO) than A2780. CEL (125 mu M) induced extensive apoptosis in A2780 associated with mitochondrial damage but not in A2780(100). No significant differences were observed between A2780 and A2780(100) cells in the basal levels, or the enhanced levels in some cases after CBL treatment, of DNA repair proteins involved in repair of alkyl base adducts or in repair of DNA crosslinks or double strand break repair. However, the basal levels of anti-apoptotic proteins Bcl-x(L), and Mcl-1 were 4-8-fold higher in A2780(100) than in A2780 neither of which expressed Bcl-2, In contrast, the levels of pro-apoptotic Bas and Bak were 3-5-fold higher in the CBL-treated A2780 but not in A2780(100). ETO (5 mu M) induced apoptosis in A2780 without altering the levels of Bax and Bak in these cells. lit the same time, neither ol expression of Bcl-x(L), in A2780, nor its antisense expression in A2780(100), and nor overexpression of Bas in A2780(100), significantly affected drug sensitivity of either line. Our results suggest that a change in an early step in DNA damage processing which affects intracellular signaling, such as enhanced DNA double-strand break repair, could be the primary cause for development of resistance in A2780(100) cells to drugs which induce DNA crosslinks or double strand-breaks.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Route 1079, Galveston, TX 77555 USA.		Denning, Timothy/F-2271-2011	Denning, Timothy/0000-0002-1072-7444	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES007572] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07572, ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Begleiter A, 1996, LEUKEMIA LYMPHOMA, V23, P187, DOI 10.3109/10428199609054821; Boldogh I, 1998, CANCER RES, V58, P3950; Bresnahan WA, 1997, VIROLOGY, V231, P239, DOI 10.1006/viro.1997.8489; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; Chen ZF, 1998, J PHARMACOL EXP THER, V285, P608; COLVIN OM, 1993, ADV ENZYME REGUL, V33, P19; Decaudin D, 1997, CANCER RES, V57, P62; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hazra TK, 1997, BIOCHEMISTRY-US, V36, P5769, DOI 10.1021/bi963085i; Horton JK, 1999, BIOCHEM PHARMACOL, V58, P693, DOI 10.1016/S0006-2952(99)00142-2; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; KAMESAKI S, 1993, CANCER RES, V53, P4251; KOHN KW, 1966, J MOL BIOL, V19, P266, DOI 10.1016/S0022-2836(66)80004-9; Krokan HE, 1997, BIOCHEM J, V325, P1; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Stahelin BJ, 1998, J CLIN PATHOL-MOL PA, V51, P204; Tano K, 1997, J BIOL CHEM, V272, P13250, DOI 10.1074/jbc.272.20.13250; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	33	21	23	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					141	150		10.1038/sj.onc.1203318	http://dx.doi.org/10.1038/sj.onc.1203318			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644989				2022-12-28	WOS:000084844300016
J	Albrechtsen, N; Dornreiter, I; Grosse, F; Kim, E; Wiesmuller, L; Deppert, W				Albrechtsen, N; Dornreiter, I; Grosse, F; Kim, E; Wiesmuller, L; Deppert, W			Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53	ONCOGENE			English	Review						p53; DNA repair; DNA damage; DNA recombination; DNA replication; sequence-specific DNA binding	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; C-TERMINAL DOMAIN; DNA-BINDING FUNCTION; MISMATCH REPAIR DEFICIENCY; NUCLEOTIDE EXCISION-REPAIR; LI-FRAUMENI SYNDROME; CELL-CYCLE; HOMOLOGOUS RECOMBINATION; TUMOR-SUPPRESSOR	In this review we describe the multiple functions of p53 in response to DNA damage, with an emphasis on p53's role in DNA repair. We summarize data demonstrating that p53, through its various biochemical activities and via its ability to interact with components of the repair and recombination machinery, actively participates in various processes of DIVA repair and DNA recombination, An important aspect in evaluating p53 functions arises from the finding that the p53 core domain harbors two mutually exclusive biochemical activities, sequence-specific DNA binding, required for its transactivation function, and 3'->5' exonuclease activity, possibly involved in various aspects of DNA repair. As modifications of p53 that lead to activation of its sequence-specific DNA-binding activity result in inactivation of its 3'->5' exonuclease activity, we propose that p53 exerts its functions as a 'guardian of the genome' at various levels: in its non-induced state, p53 should not be regarded as a non-functional protein, but might be actively involved in prevention and repair of endogenous DNA damage, for example via its exonuclease activity. Upon induction through exogenous DNA damage, p53 will exert its well-documented functions as a superior response element in various types of cellular stress. The dual role model for p53 in maintaining genomic integrity significantly enhances p53's possibilities as a guardian of the genome.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Inst Mol Biotechnol, Biochem Abt, D-07745 Jena, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.		Holst, Jens/AAA-8022-2022	Wewer Albrechtsen, Nicolai/0000-0003-4230-5753				Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Adams PD, 1996, MOL CELL BIOL, V16, P6623; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1992, BIOCHEM SOC T, V20, P607, DOI 10.1042/bst0200607; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BODMER W, 1994, NAT GENET, V6, P217, DOI 10.1038/ng0394-217; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cheng RZ, 1997, EXP CELL RES, V234, P300, DOI 10.1006/excr.1997.3649; Cottu PH, 1996, ONCOGENE, V13, P2727; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1995, INT REV CYTOL A, V162, P486; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; DUDENHOFFER C, 1999, IN PRESS ONCOGENE; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDIERY WS, 1993, CELL, V75, P817; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRITSCHE M, 1993, ONCOGENE, V8, P307; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Goi K, 1997, CANCER RES, V57, P1895; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hall PA, 1996, J PATHOL, V180, P1; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HAVRE PA, 1995, CANCER RES, V55, P4420; Hecker D, 1996, ONCOGENE, V12, P953; HERMEKING H, 1909, MOL CELL, V1, P3; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Janus F, 1999, MOL CELL BIOL, V19, P2155; JASIN M, 1985, CELL, V43, P695, DOI 10.1016/0092-8674(85)90242-9; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAWASAKI I, 1994, MOL CELL BIOL, V14, P4173, DOI 10.1128/MCB.14.6.4173; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu L, 1999, MOL CELL BIOL, V19, P1202; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MELENDY T, 1991, J BIOL CHEM, V266, P1942; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nickerson JA, 1998, J CELL BIOCHEM, V70, P172, DOI 10.1002/(SICI)1097-4644(19980801)70:2<172::AID-JCB3>3.0.CO;2-L; Oda N, 1996, J BIOL CHEM, V271, P13816, DOI 10.1074/jbc.271.23.13816; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; RADMAN M, 1993, NATURE, V366, P722, DOI 10.1038/366722a0; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SIEGEL J, 1995, ONCOGENE, V11, P1363; SMITH ML, 1995, ONCOGENE, V10, P1053; SNAPKA RM, 1991, NUCLEIC ACIDS RES, V19, P5065, DOI 10.1093/nar/19.18.5065; STEINMEYER K, 1988, ONCOGENE, V3, P501; STEWART N, 1995, ONCOGENE, V10, P109; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; Wang WF, 1996, J MOL EVOL, V43, P384; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wiesmuller L, 1996, J VIROL, V70, P737; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu LH, 1997, GENE DEV, V11, P106, DOI 10.1101/gad.11.1.106; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	151	140	148	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	1999	18	53					7706	7717		10.1038/sj.onc.1202952	http://dx.doi.org/10.1038/sj.onc.1202952			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618711				2022-12-28	WOS:000084634500010
J	Kaelin, WG				Kaelin, WG			The p53 gene family	ONCOGENE			English	Review						p53; p73; p63; KET; p51; p40	P53-RELATED PROTEIN; P73 GENE; EXPRESSION; HOMOLOG; NEUROBLASTOMA; ONCOPROTEINS; MUTATIONS; APOPTOSIS; CANCERS; TUMORS	p73 and p63 are two recently discovered p53 homologs, Like p53, these proteins can recognize canonical p53 DNA-binding sites and, when overproduced, can activate p53-responsive target genes and induce apoptosis. Unlike p53, these genes undergo complex alternative splicing which, at least in the case of p63, yields proteins with widely divergent biological properties. In addition p73 and p63 are, in contrast to p53, rarely mutated in human cancer. Furthermore, p73 inactivation is not required for viral transformation. Thus, there is currently no firm evidence that p63 and p73 should be considered tumor suppressors, The early suggestion that monoallelic expression of p73 contributed to carcinogenesis needs to be interpreted cautiously in light of data showing interindividual and intraindividual variation with respect to monoallelic expression of p73 and the finding that p73 mRNA levels are generally increased, rather than decreased, in a host of tumors relative to normal cells.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kaelin, WG (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.							Adams PD, 1998, CURR OPIN CELL BIOL, V10, P791, DOI 10.1016/S0955-0674(98)80123-3; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kong Xiao-Tang, 1999, Neoplasia (New York), V1, P80, DOI 10.1038/sj.neo.7900010; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kroiss MM, 1998, MELANOMA RES, V8, P504, DOI 10.1097/00008390-199812000-00005; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lo Cunsolo C, 1998, CYTOGENET CELL GENET, V82, P199, DOI 10.1159/000015099; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; SHAULSKY G, 1991, CANCER RES, V51, P5232; Takahashi H, 1998, CANCER RES, V58, P2076; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Tsao H, 1999, CANCER RES, V59, P172; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	33	158	163	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	1999	18	53					7701	7705		10.1038/sj.onc.1202955	http://dx.doi.org/10.1038/sj.onc.1202955			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618710				2022-12-28	WOS:000084634500009
J	Jardine, LJ; Milne, DM; Dumaz, N; Meek, DW				Jardine, LJ; Milne, DM; Dumaz, N; Meek, DW			Phosphorylation of murine p53, but not human p53, by MAP kinase in vitro and in cultured cells highlights species-dependent variation in post-translational modification	ONCOGENE			English	Article						p53; ERK; MAP kinase; phosphorylation	ACTIVATED PROTEIN-KINASE; WILD-TYPE P53; IN-VITRO; GENE AMPLIFICATION; FUNCTIONAL DOMAIN; STRESS SIGNALS; GROWTH ARREST; T-ANTIGEN; TRANSACTIVATION; APOPTOSIS	The p53 tumour suppressor protein is tightly regulated by protein-protein association, protein turnover and a variety of post-translational modifications. Multisite phosphorylation plays a major role in activating and in finely tuning p53 function. The proline rich domain of murine p53 is a substrate for phosphorylation, lit vitro and in cultured cells, by the p42(ERK2) and p44(ERK1) mitogen-activated protein (MAP) kinases, However, to date there have been no reports of attempts to determine whether p53 from any other species is a substrate for MAP kinase, In this paper we confirm that murine p53 is targeted by recombinant MAP kinase and by MAP kinases in extracts of both murine and human cells. In contrast, human p53 is not a substrate for recombinant MAP kinase nor are there any detectable levels of protein kinase activity in stimulated human cell extracts which phosphorylate the proline rich domain of human p53 in vitro. Finally, although stimulation of murine fibroblasts with o-tetradecanolylphorbol 13-acetate (TPA), an indirect activator of the MAP kinase pathway, leads to site-specific phosphorylation of murine p53, similar treatment of human fibroblasts and epithelial cells showed no significant changes in the phosphorylation pattern. These data are consistent with accumulating evidence that significant species-dependent differences exist in the post-translational modification of p53.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.		Dumaz, Nicolas/B-5907-2008	Dumaz, Nicolas/0000-0003-3511-2160				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meek DW, 1997, PATHOL BIOL, V45, P804; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MULLER E, 1995, ONCOGENE, V10, P1175; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; Prives C, 1999, J PATHOL, V187, P112; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	36	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7602	7607		10.1038/sj.onc.1203137	http://dx.doi.org/10.1038/sj.onc.1203137			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602521	Bronze			2022-12-28	WOS:000084119600023
J	Bruzzoni-Giovanelli, H; Faille, A; Linares-Cruz, G; Nemani, M; Le Deist, F; Germani, A; Chassoux, D; Millot, G; Roperch, JP; Amson, R; Telerman, A; Calvo, F				Bruzzoni-Giovanelli, H; Faille, A; Linares-Cruz, G; Nemani, M; Le Deist, F; Germani, A; Chassoux, D; Millot, G; Roperch, JP; Amson, R; Telerman, A; Calvo, F			SIAH-1 inhibits cell growth by altering the mitotic process	ONCOGENE			English	Article						SIAH-1; mitosis; multinucleated cell; cytokinesis; apoptosis; p21	DROSOPHILA EYE DEVELOPMENT; TUMOR SUPPRESSION; DNA-REPLICATION; HUMAN HOMOLOG; SINA GENE; APOPTOSIS; ABSENTIA; P21(WAF1/CIP1); CYTOKINESIS; ACTIVATION	SIAH-1, the human homologue of the drosophila seven in absentia gene, is a p53-p21(Waf-1) inducible gene. We report that stable transfection with SIAH-1 of the epithelial breast cancer cell line MCF-7 blocks its growth process. The transfectants show a redistribution of SIAH-1 protein within the nucleus, more specifically to the nuclear matrix, associated to dramatic changes in cell morphology and defective mitosis. Multinucleated giant cells (2-12 nuclei in more than 50% cells) were a most striking observation associated with tubulin spindle disorganization and defective cytokinesis, There were also present at high frequency abortive mitotic figures, DNA bridges and persistance of intercellular bridges and midbodies, along with an increased expression of p21(Waf-1) These results indicate that the mechanism of growth arrest induced by SIAH-1 in MCF-7 cells involves disorganization of the mitotic program, mainly during nuclei separation and cytokinesis.	Hop St Louis, Inst Genet Mol, Lab Pharmacol Expt, F-75010 Paris, France; Hop St Louis, Inst Genet Mol, Clin INSERM EP 9932, F-75010 Paris, France; CEPH, Fdn Jean Dausset, Paris, France; Hop Necker Enfants Malad, INSERM Unite 429, Paris, France; Hop Cochin, INSERM Unite 363, F-75674 Paris, France; Inst Curie, INRA, Unite 806, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Foundation Jean Dausset-CEPH; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Calvo, F (corresponding author), Hop St Louis, Inst Genet Mol, Lab Pharmacol Expt, 27 Rue Juliette Dodu, F-75010 Paris, France.			calvo, fabien/0000-0002-0298-7633; VARIN-BLANK, Nadine/0000-0003-2769-018X				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Berezney R, 1996, J CELL BIOCHEM, V62, P223, DOI 10.1002/(SICI)1097-4644(199608)62:2<223::AID-JCB10>3.3.CO;2-M; BRUZZONIGIOVANE.H, 1998, ADV MOL TOXICOLOGY, P25; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTHEW RW, 1994, P NATL ACAD SCI USA, V91, P11689, DOI 10.1073/pnas.91.24.11689; DELLA NG, 1993, DEVELOPMENT, V117, P1333; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mandelkow E, 1999, CURR OPIN CELL BIOL, V11, P34, DOI 10.1016/S0955-0674(99)80005-2; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Neufeld TP, 1998, GENETICS, V148, P277; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Vitrat N, 1998, BLOOD, V91, P3711	38	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7101	7109		10.1038/sj.onc.1203187	http://dx.doi.org/10.1038/sj.onc.1203187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597311				2022-12-28	WOS:000083901900017
J	Sun, SC; Ballard, DW				Sun, SC; Ballard, DW			Persistent activation of NF-kappa B by the Tax transforming protein of HTLV-1: hijacking cellular I kappa B kinases	ONCOGENE			English	Review						HTLV-1; Tax; NF-kappa B; I kappa B; IKK; viral oncogenesis; leukemia	VIRUS TYPE-I; HUMAN T-CELLS; SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; PRIMARY HUMAN-LYMPHOCYTES; RECEPTOR GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; LEUKEMIA-VIRUS; TRANSCRIPTIONAL ACTIVATOR; TRANSACTIVATOR TAX	Biochemical coupling of transcription factor NF-kappa B to antigen and co-stimulatory receptors is required for the temporal control of T-cell proliferation. In contrast to its transitory activation during normal growth-signal transduction, NF-kappa B is Constitutively deployed in T-cells transformed by the type 1 human T-cell leukemia virus (HTLV-1). This viral/host interaction is mediated by the HTLV-1-encoded Tax protein, which has potent oncogenic properties. As reviewed here, Tax activates NF-kappa B primarily via a pathway leading to the chronic phosphorylation and degradation of I kappa B alpha, a cytoplasmic inhibitor of NF-kappa B. To access this pathway, Tax associates stably with a cytokine-inducible I kappa B kinase (IKK), which contains both catalytic (IKK alpha and IKK beta) and noncatalytic (IKK gamma) subunits. Unlike their transiently induced counterparts in cytokine-treated cells, Tax-associated forms of IKK alpha and IKK beta are persistently activated in HTLV-1-infected T cells. Acquisition of the deregulated IKK phenotype is contingent on the presence of IKK gamma, which functions as a molecular adaptor in the assembly of pathologic Tax/I kappa B kinase complexes. These findings highlight a key mechanistic role for Wt in the Tax/NF-kappa B signaling axis and define new intracellular targets for the therapeutic control HTLV-1-associated disease.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Vanderbilt University	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [R01CA082556, R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [CA82556, CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ALEXANDRE C, 1991, ONCOGENE, V6, P543; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BEIMLING P, 1989, ONCOGENE, V4, P511; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Beraud C, 1996, J ACQ IMMUN DEF SYND, V13, pS76, DOI 10.1097/00042560-199600001-00014; Bohnlein E, 1989, Haematol Blood Transfus, V32, P393; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cann A.J., 1996, FIELDS VIROLOGY, P1849; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHEN L, 1998, NATURE, V17, P292; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Cowan EP, 1997, J VIROL, V71, P6982, DOI 10.1128/JVI.71.9.6982-6989.1997; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Esslinger CW, 1997, J IMMUNOL, V158, P5075; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FELBER BK, 1985, SCIENCE, V229, P54; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Fujimoto T, 1999, CANCER GENET CYTOGEN, V109, P1, DOI 10.1016/S0165-4608(98)00141-1; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Good L, 1997, J BIOL CHEM, V272, P1425, DOI 10.1074/jbc.272.3.1425; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Higashimura N, 1996, JPN J CANCER RES, V87, P227, DOI 10.1111/j.1349-7006.1996.tb00210.x; HIMES SR, 1993, ONCOGENE, V8, P3198; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1992, ONCOGENE, V7, P1737; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KANNO T, 1995, J BIOL CHEM, V270, P11745, DOI 10.1074/jbc.270.20.11745; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; LANOIX J, 1994, ONCOGENE, V9, P841; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MAGGIRWAR SB, 1995, ONCOGENE, V11, P993; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOCH H, 1992, J VIROL, V66, P7346, DOI 10.1128/JVI.66.12.7346-7354.1992; Mori N, 1998, CANCER RES, V58, P3993; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; MORI N, 1994, BLOOD, V84, P2904; MURAKAMI T, 1995, VIROLOGY, V206, P1066, DOI 10.1006/viro.1995.1029; MURAOKA O, 1993, IMMUNOL LETT, V37, P159, DOI 10.1016/0165-2478(93)90026-X; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; Orian A, 1999, MOL CELL BIOL, V19, P3664; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAUL NL, 1993, CYTOKINE, V5, P372, DOI 10.1016/1043-4666(93)90070-L; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Petropoulos L, 1996, VIROLOGY, V225, P52, DOI 10.1006/viro.1996.0574; Petropoulos L, 1998, VIROLOGY, V252, P189, DOI 10.1006/viro.1998.9430; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SANADA I, 1986, LEUKEMIA RES, V10, P1377, DOI 10.1016/0145-2126(86)90003-2; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SHIRAISHI Y, 1985, CANCER GENET CYTOGEN, V15, P65, DOI 10.1016/0165-4608(85)90131-1; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; WACHSMAN W, 1985, SCIENCE, V228, P1534, DOI 10.1126/science.2990032; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATANABE M, 1993, ONCOGENE, V8, P2949; Weil R, 1999, J VIROL, V73, P3709, DOI 10.1128/JVI.73.5.3709-3717.1999; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	187	163	170	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6948	6958		10.1038/sj.onc.1203220	http://dx.doi.org/10.1038/sj.onc.1203220			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602469				2022-12-28	WOS:000083896500011
J	Yamaguchi, M; Hirose, F; Inoue, YH; Shiraki, M; Hayashi, Y; Nishi, Y; Matsukage, A				Yamaguchi, M; Hirose, F; Inoue, YH; Shiraki, M; Hayashi, Y; Nishi, Y; Matsukage, A			Ectopic expression of human p53 inhibits entry into S phase and induces apoptosis in the Drosophila eye imaginal disc	ONCOGENE			English	Article						p53; Drosophila; cell cycle; apoptosis; P35	PROGRAMMED CELL-DEATH; WILD-TYPE P53; BACULOVIRUS P35; DNA-DAMAGE; CAENORHABDITIS-ELEGANS; PROTEIN P35; LUNG-CANCER; GENE; CYCLE; GROWTH	Transgenic flies in which ectopic expression of human p53 was targeted to the Drosophila eye imaginal disc were established. On sectioning of adult fly eyes which displayed a severe rough eye phenotype, most ommatidia were found to be fused and irregular shapes of rabdomeres were observed. In addition, many pigment cells were lost. In the developing eye imaginal disc, photoreceptor cell differentiation was initiated normally despite the ectopic expression of p53, However, expression of p53 inhibited cell cycle progression in eye imaginal disc cells and the S phase zone (the second mitotic wave) behind the morphogenetic furrow was almost completely abolished. Furthermore, expression of p53 induced extensive apoptosis of eye imaginal disc cells, and co-expression of baculovirus P35 in the eye imaginal disc suppressed the p53-induced rough eye phenotype, These results are consistent,vith the known functions of human p53 and indicate the existence of signaling systems with elements corresponding to human p53 in Drosophila eye imaginal disc cells. Genetic crosses of transgenic flies expressing p53 to a collection of Drosophila deficiency stocks allowed us to identify several genomic regions, deletions of which caused enhancement or suppression of the p53-induced rough eye phenotype, The transgenic flies established in this study should be useful to identify novel targets of p53 and its positive or negative regulators in Drosophila.	Aichi Canc Ctr, Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Biophys Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center	Yamaguchi, M (corresponding author), Aichi Canc Ctr, Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan.			Yamaguchi, Masamitsu/0000-0002-6321-9750; Hirose, Fumiko/0000-0003-4586-4892				Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Butler SJ, 1997, DEVELOPMENT, V124, P781; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Foley K, 1998, DEVELOPMENT, V125, P1075; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1995, SCIENCE, V270, P931, DOI 10.1126/science.270.5238.931; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; ROBERTSON HM, 1988, GENETICS, V118, P461; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SOUSSI T, 1990, ONCOGENE, V5, P945; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WILDER EL, 1995, DEVELOPMENT, V121, P477; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff Tanya, 1993, P1277; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zhou XL, 1999, CANCER RES, V59, P843; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	46	46	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6767	6775		10.1038/sj.onc.1203113	http://dx.doi.org/10.1038/sj.onc.1203113			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597285				2022-12-28	WOS:000083792000019
J	Strobeck, MW; Fribourg, AF; Puga, A; Knudsen, ES				Strobeck, MW; Fribourg, AF; Puga, A; Knudsen, ES			Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest	ONCOGENE			English	Article						AHR; BRG-1; Cdk; cyclins; G1	FAMILY PROTEINS; HISTONE DEACETYLASE; GROWTH SUPPRESSION; G(1)/S TRANSITION; PHASE-TRANSITION; HUMAN CANCER; PRB-FAMILY; S-PHASE; ACTIVATION; INHIBITION	Phosphorylation/inactivation of RB is typically required for cell cycle progression. However, we have identified a tumor cell line, C33A, which progresses through the cell cycle in the presence of an active allele of RB (PSM-RB), To determine how C33A cells evade RB-mediated arrest, we compared RB signaling to downstream effecters in this resistant cell line to that of the RB-sensitive SAOS-2 cell line. Although introduction of PSM-RB repressed E2F-mediated transcription in both C33A and SAOS-2 cells, PSM-RB failed to repress Cyclin A promoter activity in C33A, Ectopic expression of PSM-RB in SAOS-2 cells resulted in a decrease in both Cyclin A and Cdk2 protein levels without affecting Cyclin E or Cdk4, In contrast, over-expression of PSM-RB in C33A cells did not alter endogenous Cyclin A, Cyclin E, or Cdk2 protein levels or impact Cdk2 kinase activity, indicating that signaling from RB to downstream targets is abrogated in this cell line. The importance of Cdk2 activity was demonstrated by p27Kip1, which attenuated Cdk2 activity and inhibited cell cycle progression in C33A cells, Since RB signaling to Cdk2 is disrupted in these tumor cells, we coexpressed two proteins that cooperate with RB transcriptional repression, AHR and BRG-1, in an attempt to correct this signaling dysfunction, Coexpression of AHR/BRG-1 with PSM-RB attenuated Cyclin A and Cdk2 expression as well as Cdk2-associated kinase activity, resulting in cell cycle inhibition of C33A cells. Importantly, ectopic expression of Cyclin A was able to reverse the arrest mediated by co-expression of AHR/BRG-1 with PSM-RB, These results indicate that down-regulation of Cdk2 activity is requisite for RB-mediated cell cycle arrest. Thus, this study reveals a new mechanism through which tumor cells evade anti-proliferative signals, and provides insight into how RB-signaling is mediated.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA.		Puga, Alvaro/B-7676-2008		NATIONAL CANCER INSTITUTE [R01CA082525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006273, R56ES006273] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA82525-01] Funding Source: Medline; NIEHS NIH HHS [ES06273] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Ciaparrone M, 1998, CANCER RES, V58, P114; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	51	65	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1857	1867		10.1038/sj.onc.1203510	http://dx.doi.org/10.1038/sj.onc.1203510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773875				2022-12-28	WOS:000086424300001
J	Teixeira, LT; Kiyokawa, H; Peng, XD; Christov, KT; Frohman, LA; Kineman, RD				Teixeira, LT; Kiyokawa, H; Peng, XD; Christov, KT; Frohman, LA; Kineman, RD			p27(Kip1)-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation	ONCOGENE			English	Article						pituitary adenoma; p27; growth hormone; IGF-I; hepatocyte hyperplasia; splenocyte hyperplasia	KINASE INHIBITOR P27(KIP1); HUMAN PITUITARY-ADENOMAS; RAT ANTERIOR-PITUITARY; HGRH TRANSGENIC MICE; GENE-EXPRESSION; CELL-CYCLE; ELEVATED LEVELS; FACTOR-I; TUMORS; HYPERPLASIA	p27(Kip1) (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases, Disruption of the p27 gene in mice (p27-/-) results in increased body growth with a disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary, The increase in pituitary size is due to selective hyperplasia of the intermediate lobe (IL) while the anterior lobe (AL) is not overtly affected. p27 heterozygous mice (p27+/-), as well as p27-/- mice, are hypersensitive to radiation- and chemical-induced tumors compared to wildtype (p27+/+) littermates. Therefore, unlike classical tumor suppressors, only a reduction in p27 levels is necessary to predispose tissues to secondary tumor promoters. Consistent with these studies is the fact that the p27 gene sequence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decreased, Therefore, a reduction in p27 levels could be sufficient to sensitize pituitary cells to tumorigenic factors, To test this hypothesis, metallothionein promoter-driven, human growth hormone-releasing hormone (MT-hGHRH) transgenic mice, that exhibit somatotrope hyperplasia before 9 months of age and subsequent adenoma formation with 30-40% penetrance, were crossbred with p27+/- mice for two successive generations to produce p27+/+, p27+/- and p27-/- mice that expressed the hGHRH At 10-12 weeks of age, p27-/- and p27+/+, hGHRH mice were larger than their p27+/+ littermates and displayed characteristic hyperplasia of the IL and AL, respectively, Expression of the hGHRH transgene in both p27+/- and p27-/- mice selectively expanded the population of somatotropes within the AL, where pituitaries of p27+/-, hGHRH and p27-/-, hGHRH mice were two- and fivefold larger than p27+/+, hGHRH pituitaries, respectively, There was also a synergistic effect of hGHRH transgene expression and p27-deficiency on liver, spleen and ovarian growth, At 6-8 months of age, 83% of p27+/-, hGHRH mice displayed macroscopic AL (>100 mg), while all pituitaries from p27+/+, hGHRH mice remained hyperplastic (<20 mg), In contrast to the dramatic effects of p27-deficiency on hGHRH-induced organ growth, elimination of p53, by crossbreeding MT-hGHRH mice to p53-deficient mice, did not augment the hyperplastic/tumorigenic effects of hGHRH transgene expression, Taken together these results demonstrate that reduction in p27 expression is sufficient to sensitize somatotropes to the proliferative actions of excess GHRH, resulting in the earlier appearance and increased penetrance of hGHRH-induced pituitary tumors.	Univ Illinois, Dept Med MC 640, Chicago, IL 60612 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60612 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kineman, RD (corresponding author), Univ Illinois, Dept Med MC 640, 1819 W Polk, Chicago, IL 60612 USA.		Kineman, Rhonda D/H-2221-2011; Peng, Xiao-ding/B-2478-2012	Kineman, Rhonda D/0000-0001-7322-1152; Peng, Xiao-ding/0000-0002-9214-0136	NIDDK NIH HHS [DK-30667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030667, R01DK030667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASA SL, 1990, P SOC EXP BIOL MED, V193, P232; Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; Bamberger AM, 1999, VIRCHOWS ARCH, V434, P423, DOI 10.1007/s004280050361; Bamberger CM, 1999, EUR J ENDOCRINOL, V140, P250, DOI 10.1530/eje.0.1400250; BILEZIKJIAN LM, 1987, MOL ENDOCRINOL, V1, P137, DOI 10.1210/mend-1-2-137; BILLESTRUP N, 1987, MOL ENDOCRINOL, V1, P300, DOI 10.1210/mend-1-4-300; BLAZAR BR, 1995, EXP HEMATOL, V23, P1397; Blevins LS, 1998, ONCOLOGY-NY, V12, P1307; BRAR AK, 1989, ENDOCRINOLOGY, V125, P801, DOI 10.1210/endo-125-2-801; BRAR AK, 1991, ENDOCRINOLOGY, V129, P3274, DOI 10.1210/endo-129-6-3274; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; Dahia PLM, 1998, ONCOGENE, V16, P69, DOI 10.1038/sj.onc.1201516; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FROHMAN LA, 1968, ENDOCRINOLOGY, V82, P1125, DOI 10.1210/endo-82-6-1125; FROHMAN LA, 1990, ENDOCRINOLOGY, V127, P2149, DOI 10.1210/endo-127-5-2149; Green VL, 1997, EUR J ENDOCRINOL, V136, P382, DOI 10.1530/eje.0.1360382; HAMMER RE, 1985, NATURE, V315, P413, DOI 10.1038/315413a0; HARWOOD JP, 1984, MOL CELL ENDOCRINOL, V37, P277, DOI 10.1016/0303-7207(84)90097-2; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; Ikeda H, 1997, BRIT J CANCER, V76, P1119, DOI 10.1038/bjc.1997.521; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jin L, 1997, AM J PATHOL, V151, P509; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lavia P, 1999, BIOESSAYS, V21, P221; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; Lidhar K, 1999, J CLIN ENDOCR METAB, V84, P3823, DOI 10.1210/jc.84.10.3823; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Lloyd RV, 1997, AM J PATHOL, V150, P401; LLOYD RV, 1992, AM J PATHOL, V141, P895; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P433, DOI 10.1210/endo-123-1-433; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Miller TL, 1999, ENDOCRINOLOGY, V140, P4152, DOI 10.1210/en.140.9.4152; MILLER TL, 1997, 79 ANN END SOC P179, P154; Mori T, 1998, LAB ANIM SCI, V48, P64; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Prives C, 1999, J PATHOL, V187, P112; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Rutanen EM, 1998, GYNECOL ENDOCRINOL, V12, P399, DOI 10.3109/09513599809012842; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiozawa T, 1998, MOL HUM REPROD, V4, P899, DOI 10.1093/molehr/4.9.899; Snibson KJ, 1999, LIVER, V19, P242, DOI 10.1111/j.1478-3231.1999.tb00042.x; Soos T J, 1998, Results Probl Cell Differ, V22, P111; SOTO JL, 1995, ENDOCRINOLOGY, V136, P3863, DOI 10.1210/en.136.9.3863; Takeuchi S, 1998, J ENDOCRINOL, V157, P337, DOI 10.1677/joe.0.1570337; Tanaka C, 1997, J CLIN ENDOCR METAB, V82, P3141, DOI 10.1210/jc.82.9.3141; THAPAR K, 1996, NEUROSURGERY, V38, P763; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Xu X, 1999, BIOCHEMISTRY-US, V38, P8713	68	28	29	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1875	1884		10.1038/sj.onc.1203490	http://dx.doi.org/10.1038/sj.onc.1203490			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773877				2022-12-28	WOS:000086424300003
J	Kashuba, E; Kashuba, V; Pokrovskaja, K; Klein, G; Szekely, L				Kashuba, E; Kashuba, V; Pokrovskaja, K; Klein, G; Szekely, L			Epstein-Barr virus encoded nuclear protein EBNA-3 binds XAP-2, a protein associated with Hepatitis B virus X antigen	ONCOGENE			English	Article						EBNA-3; Xap-2; HBV	ARYL-HYDROCARBON RECEPTOR; RBP-J-KAPPA; GROWTH TRANSFORMATION; BURKITT-LYMPHOMA; EXPRESSION; LYMPHOCYTES; INTERACT; 3A	EBNA-3 (also called EBNA-3A) is one of the EBV encoded nuclear antigens that are necessary for B-cell transformation, EBNA-3 is known to target RBPs, nuclear proteins that also interacts with EBNA-2, EBNA-4 and EBNA-6, In order to identify additional EBNA-3 targets, an EBV-transformed human lymphocyte cDNA library was screened in the yeast two-hybrid system with N-terminus truncated EBNA-3 that cannot interact with RBP-J kappa, A clone, encoding Xap-2 protein, a cellular partner of Hepatitis B virus X-antigen was isolated. This protein is also known as the p38 subunit of the aryl hydrocarbon receptor complex (ARA9), The specific binding to EBNA-3 was confirmed by showing that the GST-Xap-2 precipitated EBNA-3 from CV1 cells that were infected with recombinant vaccinia virus expressing EBNA-3, Deletion of the C-terminus of Xap-2 eliminated the binding. Fusion with green fluorescent protein showed that Xap-2 is preferentially cytoplasmic but translocates to the nucleus upon expression of EBNA-3.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Szekely, L (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Kashuba, Elena/Q-4739-2019; Kashuba, Vladimir I/N-3732-2017; Kashuba, Elena/O-5389-2015; Szekely, Laszlo/B-1268-2009; Kashuba, Vladimir/AAO-7742-2020	Kashuba, Elena/0000-0001-7001-4035; Kashuba, Vladimir I/0000-0001-9416-8282; Kashuba, Elena/0000-0001-7001-4035; Pokrovskaja Tamm, Katja/0000-0001-6359-1256; Szekely, Laszlo/0000-0001-6144-6573				ALLDAY MJ, 1993, J GEN VIROL, V74, P361, DOI 10.1099/0022-1317-74-3-361; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; GAVIOLI R, 1992, P NATL ACAD SCI USA, V89, P5862, DOI 10.1073/pnas.89.13.5862; Hahn ME, 1997, P NATL ACAD SCI USA, V94, P13743, DOI 10.1073/pnas.94.25.13743; Johannsen E, 1996, J VIROL, V70, P4179, DOI 10.1128/JVI.70.6.4179-4183.1996; KAISE C, 1994, COLD SPRING HARBOR L, P171; Kashuba E, 1999, J HUMAN VIROL, V2, P33; Kobayashi A, 1997, J BIOCHEM, V122, P703; Krauer KG, 1996, VIROLOGY, V226, P346, DOI 10.1006/viro.1996.0662; Krauer KG, 1998, VIROLOGY, V252, P418, DOI 10.1006/viro.1998.9441; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Szekely L, 1998, J GEN VIROL, V79, P1445, DOI 10.1099/0022-1317-79-6-1445; Szekely L, 1997, CELL GROWTH DIFFER, V8, P599; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; Yamaguchi K, 1997, J IMMUNOL, V158, P2165; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996	24	35	37	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1801	1806		10.1038/sj.onc.1203501	http://dx.doi.org/10.1038/sj.onc.1203501			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777214	Bronze			2022-12-28	WOS:000086292500008
J	Tremain, R; Marko, M; Kinnimulki, V; Ueno, H; Bottinger, E; Glick, A				Tremain, R; Marko, M; Kinnimulki, V; Ueno, H; Bottinger, E; Glick, A			Defects in TGF beta signaling overcome senescence of mouse keratinocytes expressing v-ras(Ha)	ONCOGENE			English	Article						TGF beta 1; keratinocytes; replicative senescence; ras oncogene	GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR GENE; SQUAMOUS CARCINOMA-CELLS; HARVEY-RAS ONCOGENE; HUMAN BREAST-CANCER; BENIGN SKIN TUMORS; II RECEPTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSGENIC MICE	Previous studies have shown that TGF beta 1 expression is upregulated in mouse keratinocytes infected with a v-ras(Ha) retrovirus, although the functional significance of this has not been clear. Here we show that v-ras(Ha) retrovirus transduced primary mouse keratinocytes undergo hyperproliferation followed by a TGF beta 1 dependent G1 growth arrest and senescence. The growth arrest is accompanied by a 15-fold increase in total TGF beta 1 secreted and a fourfold increase in secreted active TGF beta 1. When cultured in the presence of a neutralizing antibody to TGF beta 1, the senescence response is suppressed. Levels of the TGF beta 1 target p15(ink4b) increase during senescence as does association of this kinase inhibitor with cyclinD/cdk4 complexes. However, p16(ink4a), p53 and p19(ARF) expression also increase during senescence. Genetic analysis shows that TGF beta 1 null and dominant negative T beta RII expressing v-ras(Ha) keratinocytes resist the G1 growth arrest and do not senescence. This resistance is associated with low expression of p15(ink4b) and p16(ink4a), constitutive Rb phosphorylation and high levels of cdk4 and cdk2 kinase activity. In contrast, inactivation of TGF beta 1 secretion or response does not block the induction of p53 and p19(ARF), but the level of p21(waf1), a p53 target gene, is reduced in cyclin D/cdk4 and cyclin E/cdk2 complexes. Thus, although multiple senescence pathways are activated in response to a ras oncogene, inactivation of TGF beta 1 secretion or response is sufficient to block the senescence program. Since v-ras(Ha) transduced TGF beta 1-/- keratinocytes form squamous cell carcinomas following skin grafting, these results suggest that in mouse keratinocytes, defects in TGF beta 1 signaling accelerate malignant progression by overcoming oncogene induced replicative senescence.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bethesda, MD 20892 USA; Kyushu Univ, Sch Med, Dept Cardiol, Fukuoka 812, Japan; Albert Einstein Coll Med, Bronx, NY 10467 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyushu University; Yeshiva University; Albert Einstein College of Medicine	Glick, A (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bld 37 3B-19, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC010284] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALEXANDROW MG, 1995, PERSPECT CANC RES, V30, P1; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bond J, 1996, ONCOGENE, V13, P2097; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Bottinger EP, 1997, CANCER RES, V57, P5564; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; CAMPISI J, 1993, ANN NY ACAD SCI, P195; CHANG HL, 1993, CANCER RES, V53, P4391; CUI W, 1994, CANCER RES, V54, P5831; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DLUGOSZ AA, 1995, METHOD ENZYMOL, P3; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Glick AB, 1996, CANCER RES, V56, P3645; Go C, 1999, CANCER RES, V59, P2861; GORSCH SM, 1992, CANCER RES, V52, P6949; Grady WM, 1998, CANCER RES, V58, P3101; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Herman JG, 1996, CANCER RES, V56, P722; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; Iavarone A, 1997, NATURE, V387, P417; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.3.CO;2-5; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Loughran O, 1996, ONCOGENE, V13, P561; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MUNGER K, 1992, CELL GROWTH DIFFER, V3, P291; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARSONS R, 1995, CANCER RES, V55, P5548; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUELLE DE, 1995, CELL, V83, P993; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reznikoff CA, 1996, CANCER RES, V56, P2886; Riggins GJ, 1997, CANCER RES, V57, P2578; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; RUDDLE FH, 1975, ANNU REV GENET, V9, P407, DOI 10.1146/annurev.ge.09.120175.002203; Sambrook J., 2002, MOL CLONING LAB MANU; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETH P, 1994, J VIROL, V68, P933, DOI 10.1128/JVI.68.2.933-940.1994; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Yamamoto H, 1996, J BIOL CHEM, V271, P16253, DOI 10.1074/jbc.271.27.16253; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1994, CANCER RES, V54, P1178; Zariwala M, 1996, ONCOGENE, V12, P451; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	82	93	95	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1698	1709		10.1038/sj.onc.1203471	http://dx.doi.org/10.1038/sj.onc.1203471			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763827				2022-12-28	WOS:000086083800010
J	Liu, YG; Black, J; Kisiel, N; Kulesz-Martin, MF				Liu, YG; Black, J; Kisiel, N; Kulesz-Martin, MF			SPAF, a new AAA-protein specific to early spermatogenesis and malignant conversion	ONCOGENE			English	Article						SPAF; AAA-protein; spermatogenesis; carcinogenesis; mitochondria	MESSENGER-RNA; PEROXISOME BIOGENESIS; TRANSLATIONAL CONTROL; GENE-EXPRESSION; CELL-CYCLE; FAMILY; YEAST; SEQUENCE; MOUSE; P53	A novel spermatogenesis associated factor (SPAF) was found to be aberrantly expressed at the malignant conversion stage in a clonal epidermal model of chemical carcinogenesis. Sequence analysis revealed two ATPase modules, classifying this gene as a new member of the AAA-protein family (ATPase associated with diverse activities). Immunohistochemical staining of mouse testis sections with SPAE antibody localized expression to spermatogonia and early spermatocytes in the basal compartment of the seminiferous tubules, Northern and Western analysis of SPAE expression in testes of mice at different developmental stages confirmed its expression at early stages of spermatogenesis, In view of mitochondrial-localization-like signal, sequence similarities to membrane-associated proteins, ATP binding properties, and intracellular expression patterns in testis, we speculate that SPAE protein may be involved in morphological and functional mitochondrial transformations during spermatogenesis, Ectopic expression of the SPAE gene in malignant epidermal cells may signify adoption of an early germ cell-like phenotype advantageous in malignant conversion.	Roswell Pk Canc Inst, Program Biochem, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute	Kulesz-Martin, MF (corresponding author), Oregon Hlth Sci Univ, Sch Med, Dept Dermatol L468, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL CANCER INSTITUTE [R01CA031101, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA31101, CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BALMAIN A, 1982, NUCLEIC ACIDS RES, V10, P4259, DOI 10.1093/nar/10.14.4259; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Beyer A, 1997, PROTEIN SCI, V6, P2043; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEMARTINO C, 1979, CELL TISSUE RES, V196, P1; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FEILER HS, 1995, EMBO J, V14, P5626, DOI 10.1002/j.1460-2075.1995.tb00250.x; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FUKASAWA K, 1995, P NATL ACAD SCI USA, V92, P3430, DOI 10.1073/pnas.92.8.3430; HACKENBROCK CR, 1971, J CELL BIOL, V51, P123, DOI 10.1083/jcb.51.1.123; HAN KA, 1990, MOL CARCINOGEN, V3, P75, DOI 10.1002/mc.2940030205; HAN KA, 1992, CANCER RES, V52, P749; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HRUBAN Z, 1973, JNCI-J NATL CANCER I, V50, P1487, DOI 10.1093/jnci/50.6.1487; HRUBAN Z, 1966, LAB INVEST, V15, P576; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KULESZMARTIN MF, 1988, CARCINOGENESIS, V9, P171, DOI 10.1093/carcin/9.1.171; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Liu YG, 1998, CARCINOGENESIS, V19, P683, DOI 10.1093/carcin/19.4.683; MIAN IS, 1993, TRENDS BIOCHEM SCI, V18, P125; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; Nigg E A, 1991, Semin Cell Biol, V2, P261; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER BL, 1993, J INVEST DERMATOL, V101, P595, DOI 10.1111/1523-1747.ep12366051; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sjoblom T, 1996, ONCOGENE, V12, P2499; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823; WAITES GMH, 1982, PHYSIOL REV, V62, P624, DOI 10.1152/physrev.1982.62.2.624; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITE MT, 1974, J NATL CANCER I, V53, P553, DOI 10.1093/jnci/53.2.553; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; Zabludoff SD, 1996, ONCOGENE, V13, P649	44	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1579	1588		10.1038/sj.onc.1203442	http://dx.doi.org/10.1038/sj.onc.1203442			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734318				2022-12-28	WOS:000086108100011
J	Kaykas, A; Sugden, B				Kaykas, A; Sugden, B			The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation	ONCOGENE			English	Article						EBV; LMP-1; membrane-spanning domains; inhibition of proliferation	EPSTEIN-BARR-VIRUS; NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; BURKITT-LYMPHOMA LINE; GROWTH-FACTOR; LATENT MEMBRANE-PROTEIN-1; TRANSFORMING PROTEIN; CYTOPLASMIC DOMAIN; FLOW-CYTOMETRY; C-MYC	The LMP-I oncoprotein of EBV is required to maintain proliferation of infected B-cells and shares several features with CD40, TNF-R1, and related receptors, Members of this family can bind TRAF and TRADD molecules and activate NF-kappa B and AP-I, as can LMP-1, While CD40 and TNF-R1 are dependent on binding their ligands for their signaling, LMP-1 apparently is not, We have found that LMP-1 can act as a governor of cell proliferation and thereby limit its own activities, its inhibition of proliferation is not mediated by apoptosis but results in cytostasis in four cell lines tested. The structural moiety of LMP-I that distinguishes it from CD40 and TNF-R1, its amino-terminus and multiple membrane spanning segments, alone can mediate its cytostatic activity.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sugden, B (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA.				NCI NIH HHS [T32-CA-09135, CA22443, CA07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443, T32CA009135, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON MR, 1994, INT IMMUNOL, V6, P1799, DOI 10.1093/intimm/6.11.1799; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; Bloss T, 1999, J GEN VIROL, V80, P3227, DOI 10.1099/0022-1317-80-12-3227; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; CAMPLEJOHN RS, 1994, J MICROSC-OXFORD, V176, P1, DOI 10.1111/j.1365-2818.1994.tb03493.x; CUOMO L, 1992, INT J CANCER, V51, P949, DOI 10.1002/ijc.2910510619; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MARTIN J, 1991, CELL GROWTH DIFFER, V2, P653; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Puls A, 1999, J CELL SCI, V112, P2983; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHLEISS MR, 1991, J VIROL, V65, P6782, DOI 10.1128/JVI.65.12.6782-6789.1991; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SUGDEN B, 1979, J VIROL, V31, P590, DOI 10.1128/JVI.31.3.590-595.1979; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; WEIGEL R, 1983, VIROLOGY, V125, P287, DOI 10.1016/0042-6822(83)90202-7; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	49	54	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1400	1410		10.1038/sj.onc.1203365	http://dx.doi.org/10.1038/sj.onc.1203365			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723131				2022-12-28	WOS:000085942700005
J	Steiner, MS; Wang, Y; Zhang, Y; Zhang, XW; Lu, Y				Steiner, MS; Wang, Y; Zhang, Y; Zhang, XW; Lu, Y			p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways	ONCOGENE			English	Article						p16; pRb; senescence; demethylation; adenovirus	INHIBITS CELL-PROLIFERATION; P16 MTS1; MALIGNANT MESOTHELIOMA; REPLICATIVE SENESCENCE; RETINOBLASTOMA-PROTEIN; P16(INK4A) EXPRESSION; HOMOZYGOUS DELETIONS; GROWTH SUPPRESSION; KINASE INHIBITORS; INVITRO LIFESPAN	Tumor suppressor gene p16 is a cyclin-dependent kinase inhibitor and an important negative cell cycle regulator. The inactivation of p16 appears to be a common event in prostate cancer. Replacement of p16 inhibits prostate tumor cell growth, but the mechanism is not known. Human prostate cancer cell lines PPC-1, which has an inactivated p16, and DU145, which has a nonfunctional retinoblastoma Rb protein (pRb), were used to determine the possible mechanism of p16 mediated growth inhibition. PPC-1 cells treated with 5-aza-2'-deoxycytidine (5-aza-dC), a demethylating agent, induced p16 expression, inhibited cell growth, and induced senescence. Similarly, PPC-1 cells transduced by an adenoviral vector containing the p16 gene (AdRSVp16) produced a p16 protein that suppressed cellular proliferation and induced senescence. Go-staining of AdRSVp16-transduced PPC-1 cells by p16 immunohistochemistry and by beta-galactosidase substrate X-gal showed that the morphologically enlarged cells expressed both p16 and senescence-associated beta-galactosidase. In contrast, AdRSVp16 did not induce senescence in DU145 cells, but did inhibit its growth. However, when wild-type pRb was introduced in DU145 cells, AdRSVp16 was able to induce senescence. Thus, the mechanism by which p16 suppressed prostate cancer was dependent on the pRb functional status of cells whereby p16 caused pRb(+) cells to undergo inhibition by senescence, whereas pRb(-) cells were also inhibited, but not by senescence.	Univ Tennessee, Coll Med, Dept Urol, Urol Res Labs, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Lu, Y (corresponding author), Univ Tennessee, Coll Med, Dept Urol, Urol Res Labs, 956 Court Ave, Memphis, TN 38163 USA.							ARAP W, 1995, CANCER RES, V55, P1351; BANERJEE A, 1992, CANCER RES, V52, P6297; BATES S, 1994, ONCOGENE, V9, P71; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chen ZH, 1996, CANCER RES, V56, P1083; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FAIRWEATHER DS, 1987, EXP CELL RES, V168, P153, DOI 10.1016/0014-4827(87)90424-1; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Fueyo J, 1996, ONCOGENE, V12, P103; Geradts J, 1996, AM J PATHOL, V149, P15; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Hama S, 1997, ANTICANCER RES, V17, P1933; Hara E, 1996, MOL CELL BIOL, V16, P859; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Herman JG, 1996, CANCER RES, V56, P722; HOLLIDAY R, 1986, EXP CELL RES, V166, P543, DOI 10.1016/0014-4827(86)90499-4; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Itoh N, 1997, JPN J CANCER RES, V88, P229, DOI 10.1111/j.1349-7006.1997.tb00371.x; Jarrard DF, 1999, CANCER RES, V59, P2957; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; JEN J, 1994, CANCER RES, V54, P6353; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; Kratzke RA, 1996, CANCER RES, V56, P3415; LI YJ, 1995, ONCOGENE, V11, P597; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; LIU Q, 1995, ONCOGENE, V10, P1061; Loughran O, 1996, ONCOGENE, V13, P561; Lu Y, 1998, BIOL CHEM, V379, P1323, DOI 10.1515/bchm.1998.379.11.1323; Lu Y, 1998, DNA CELL BIOL, V17, P643, DOI 10.1089/dna.1998.17.643; Lu Y, 1999, CANCER GENE THER, V6, P64, DOI 10.1038/sj.cgt.7700011; Lu Yi, 1995, Molecular and Cellular Differentiation, V3, P175; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Mobley SR, 1998, ARCH OTOLARYNGOL, V124, P88, DOI 10.1001/archotol.124.1.88; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORLEW I, 1995, J INT CANC I, V87, P1524; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARK M, 1998, CURRENT PROTOCOLS CE, pCH8; Quesnel B, 1996, BRIT J HAEMATOL, V95, P291, DOI 10.1046/j.1365-2141.1996.d01-1913.x; Reznikoff CA, 1996, CANCER RES, V56, P2886; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Schrump DS, 1996, CANCER GENE THER, V3, P357; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shapiro GI, 1996, BBA-REV CANCER, V1242, P165, DOI 10.1016/0304-419X(95)00011-4; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITHSORENSON B, 1995, HUM MUTAT, V7, P294; Steiner MS, 1999, CANCER GENE THER, V6, P456, DOI 10.1038/sj.cgt.7700065; Steiner MS, 1998, HUM GENE THER, V9, P747, DOI 10.1089/hum.1998.9.5-747; Steiner MS, 1996, MOL CELL DIFFER, V4, P275; STEINER MS, 1999, IN PRESS CANC GENE T; Stone S, 1996, CANCER RES, V56, P3199; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; Talve L, 1997, INT J CANCER, V74, P255, DOI 10.1002/(SICI)1097-0215(19970620)74:3<255::AID-IJC4>3.0.CO;2-Y; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WASHIMI O, 1995, CANCER RES, V55, P514; WILSON VL, 1983, SCIENCE, V220, P1054; Wolf JK, 1999, GYNECOL ONCOL, V73, P27, DOI 10.1006/gyno.1998.5259; XIAO S, 1995, ONCOGENE, V11, P511; XIAO S, 1995, CANCER RES, V55, P2968; ZHANG XW, 1996, ANTI-CANCER DRUG, V10, P569; Zhang Y, 1999, TUMOR TARGET, V4, P158	74	30	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1297	1306		10.1038/sj.onc.1203428	http://dx.doi.org/10.1038/sj.onc.1203428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713671				2022-12-28	WOS:000085743800006
J	Stroeken, PJM; van Rijthoven, EAM; de Boer, E; Geerts, D; Roos, E				Stroeken, PJM; van Rijthoven, EAM; de Boer, E; Geerts, D; Roos, E			Cytoplasmic domain mutants of beta 1 integrin, expressed in beta 1-knockout lymphoma cells, have distinct effects on adhesion, invasion and metastasis	ONCOGENE			English	Article						integrin cytoplasmic domains; dissemination; lymphoid cells; migration	MEDIATED TYROSINE PHOSPHORYLATION; HUMAN T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; BETA(1) INTEGRIN; ACTIVATION; SUBUNIT; REQUIREMENT; MODULATION; MIGRATION; PROTEIN	Structural requirements for beta 1 integrin cytoplasmic domain functions in adhesion, migration and signaling have been studied mainly for fibroblasts in vitro. The relevance for beta 1-dependent in vivo migration of lymphoid cells has not been assessed. To study this, we transfected beta 1 mutants into beta 1-deficient double knockout (DKO) ESb lymphoma cells, and tested the capacity of the cells to metastasize to Li,er and spleen. This was compared to alpha 4 beta 1-dependent invasion into cell monolayers in vitro and Mn2+-induced adhesion to fibronectin, Deletion of the five C-terminal residues or mutation of both threonines T788 and T789 to alanines blocked invasion and metastasis and greatly reduced adhesion, in line with known in vitro effects. However, mutations of the NP motif tyrosines had unexpected consequences. A Y783F mutation had no effect at all, but a Y783,795F double mutation strongly reduced Mn2+-induced adhesion, whereas it had limited effects on invasion and metastasis. Furthermore, cells expressing a beta 1/beta 2 chimeric subunit, which contains phenylalanines in the NPXY/F motifs, adhered poorly but invasion and metastasis was fully restored to the same levels as for cells expressing wild-type beta 1. We conclude that part of the functions of the beta 1 cytoplasmic domain that are required for adhesion are not essential for beta 1-dependent invasion and metastasis.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Roos, E (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Geerts, Dirk/K-8260-2015	Geerts, Dirk/0000-0002-6386-8187				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; Driessens MHE, 1997, EXP CELL RES, V231, P242, DOI 10.1006/excr.1996.3463; Faisst AM, 1998, DEV DYNAM, V212, P293, DOI 10.1002/(SICI)1097-0177(199806)212:2<293::AID-AJA14>3.0.CO;2-5; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Finkelstein LD, 1997, J IMMUNOL, V159, P5355; Grignani F, 1998, CANCER RES, V58, P14; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; Hunter AJ, 1997, J IMMUNOL, V159, P4806; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; Mastrangelo AM, 1999, J CELL SCI, V112, P217; MICHIELS F, 2000, IN PRESS METHODS ENZ; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; PIETRANGELI CE, 1988, EUR J IMMUNOL, V18, P863, DOI 10.1002/eji.1830180606; Retta SF, 1998, MOL BIOL CELL, V9, P715, DOI 10.1091/mbc.9.4.715; Romzek NC, 1998, MOL BIOL CELL, V9, P2715, DOI 10.1091/mbc.9.10.2715; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sakai T, 1998, J BIOL CHEM, V273, P19378, DOI 10.1074/jbc.273.31.19378; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; SCHIRRMACHER V, 1979, INT J CANCER, V23, P245, DOI 10.1002/ijc.2910230216; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Stroeken PJM, 1998, CANCER RES, V58, P1569; Valmu L, 1999, BIOCHEM J, V339, P119, DOI 10.1042/0264-6021:3390119; VALMU L, 1995, J IMMUNOL, V155, P1175; Weber C, 1997, J IMMUNOL, V159, P3968; WEISS L, 1963, AM J ANAT, V113, P51, DOI 10.1002/aja.1001130106; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wennerberg K, 1998, J CELL SCI, V111, P1117; Zell T, 1996, J IMMUNOL, V156, P883; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11	40	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1232	1238		10.1038/sj.onc.1203423	http://dx.doi.org/10.1038/sj.onc.1203423			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713712				2022-12-28	WOS:000085567800014
J	Glukhova, L; Lavialle, C; Fauvet, D; Chudoba, I; Danglot, G; Angevin, E; Bernheim, A; Goguel, AF				Glukhova, L; Lavialle, C; Fauvet, D; Chudoba, I; Danglot, G; Angevin, E; Bernheim, A; Goguel, AF			Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene	ONCOGENE			English	Article						chromosome 7 polysomy; 7q31 chromosomal region; papillary renal cell carcinoma; MET receptor tyrosine kinase	TUMORS; PROTOONCOGENE; GENE; DNA; HYBRIDIZATION; CYTOGENETICS; DUPLICATION; PARAMETERS; FEATURES; ALLELE	Molecular cytogenetic analysis of several sporadic papillary renal cell carcinomas and of their xenografts in immunodeficient mice had previously allowed us to delimit a minimal overrepresented region of chromosome 7 shaped by all of them to band 7q31, We have refined the location of the overlapping region to the junction of the subbands 7q31.2 and 7q31.3 by reverse painting with two differently labelled probes prepared from the small chromosome 7 derivatives microdissected from the cells of two distinct tumours, This small region was shown to contain the MET proto-oncogene, present at three to four copies per cell as determined by Southern blot analysis, The increased copy number of the MET gene was found to be associated with its overexpression at the mRNA level. However, no change in MET copy number or expression level was observed in the cells from two xenografted tumours serially transplanted into immunodeficient mice, as compared to those from the corresponding initial tumours. Our results indicate that expression of the MET proto-oncogene above a critical threshold is required for the maintenance of the tumorigenic phenotype of at least some papillary renal cell carcinomas, but does not further increase during tumour progression.	Inst Gustave Roussy, Lab Cytogenet & Genet Oncol, UMR 1599, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, Lab Genet Oncol, UMR 1599, F-94805 Villejuif, France; Inst Gustave Roussy, Unite Immunotherapie, F-94805 Villejuif, France; Inst Human Genet & Anthropol, D-07740 Jena, Germany	UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Goguel, AF (corresponding author), Inst Gustave Roussy, Lab Cytogenet & Genet Oncol, UMR 1599, PR2,39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Lavialle, Christian/O-2329-2019; Lavialle, Christian/B-3775-2009	ANGEVIN, Eric/0000-0001-6249-7209				Amin MB, 1997, AM J SURG PATHOL, V21, P621, DOI 10.1097/00000478-199706000-00001; Angevin E, 1999, LAB INVEST, V79, P879; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bentz M, 1996, CYTOGENET CELL GENET, V75, P17, DOI 10.1159/000134448; Bernues M, 1995, CANCER GENET CYTOGEN, V84, P123, DOI 10.1016/0165-4608(95)00044-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chudoba I, 1996, ONCOL REP, V3, P829; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007; GALDEMARD C, 1995, ONCOGENE, V10, P2331; Glukhova L, 1998, GENE CHROMOSOME CANC, V22, P171, DOI 10.1002/(SICI)1098-2264(199807)22:3<171::AID-GCC2>3.3.CO;2-K; Goguel AF, 1996, ANN GENET-PARIS, V39, P64; HAAF T, 1992, CYTOGENET CELL GENET, V60, P12, DOI 10.1159/000133284; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KOVACS G, 1993, HISTOPATHOLOGY, V22, P1, DOI 10.1111/j.1365-2559.1993.tb00061.x; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; LAGER DJ, 1995, CANCER, V76, P669, DOI 10.1002/1097-0142(19950815)76:4<669::AID-CNCR2820760420>3.0.CO;2-U; Lin JC, 1998, ONCOGENE, V16, P833, DOI 10.1038/sj.onc.1201599; Lin JC, 1996, ONCOGENE, V13, P2001; MACIEIRACOELHO A, 1982, EXP CELL RES, V141, P325, DOI 10.1016/0014-4827(82)90220-8; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SLIM R, 1994, CYTOGENET CELL GENET, V65, P104, DOI 10.1159/000133611; WEISS LM, 1995, AM J CLIN PATHOL, V103, P624; WILHELM M, 1995, WORLD J UROL, V13, P143; Zbar B, 1998, ADV CANCER RES, V75, P163, DOI 10.1016/S0065-230X(08)60742-3; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	35	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					754	761		10.1038/sj.onc.1203397	http://dx.doi.org/10.1038/sj.onc.1203397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698493				2022-12-28	WOS:000085192100005
J	Epinat, JC; Kazandjian, D; Harkness, DD; Petros, S; Dave, J; White, DW; Gilmore, TD				Epinat, JC; Kazandjian, D; Harkness, DD; Petros, S; Dave, J; White, DW; Gilmore, TD			Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein	ONCOGENE			English	Article						v-Rel; retroviral oncogene; transcription factor; malignant transformation; NF-kappa B; envelope sequences	VIRUS STRAIN-T; C-REL; KAPPA-B; HOMOLOGY DOMAIN; AMINO-ACIDS; TRANSCRIPTION; ACTIVATION; TRANSFORMATION; PROTEIN; EXPRESSION	The retroviral oncoprotein v-Rel is a member of the Rel/NF-kappa B family of transcription factors. v-Rel has multiple changes as compared to the proto-oncoprotein c-Rel, and these changes render v-Rel highly oncogenic in avian lymphoid cells, Previous results have shown that three mutant residues in the eleven helper virus-derived Envelope (Env) amino acids (aa) at the N-terminus of v-Rel are required for its full oncogenicity. In this report, we show that these mutant Env aa also enable sequences in the N-terminal half of v-Rel to activate transcription in yeast and chicken cells, under conditions where the analogous sequences from c-Rel either do not or only weakly activate transcription. Removal of the Env aa from v-Rel or site-directed mutations that revert the three mutant residues to the residues present in the Rev-A helper virus Env protein abolish this transactivation ability of v-Rel, Addition of mutant Env aa onto c-Rel is not sufficient to fully restore the transactivation function; other sequences in the N-terminal half of v-Rel are needed for full transactivating ability, A C terminally-truncated form of NF-kappa B p100 (p85), produced in HUT-78 human leukemic cells, also activates transcription in yeast, under conditions where the normal p52 and p100 proteins do not. Furthermore, transcriptional activation by p85 in yeast is likely to occur through N-terminal sequences, Taken together, these results are consistent with a model in which transactivation by N-terminal Rel Homology (RH) domain sequences in oncogenic Rel family proteins is influenced by sequences outside the RH domain.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BHAT GV, 1990, ONCOGENE, V5, P625; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chen CL, 1999, MOL CELL BIOL, V19, P307; Curristin SM, 1997, J VIROL, V71, P5972, DOI 10.1128/JVI.71.8.5972-5981.1997; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HRDLICKOVA R, 1994, J VIROL, V68, P2371; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MOSIALOS G, 1993, ONCOGENE, V8, P721; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, ONCOGENE, V8, P2501; SMARDOVA J, 1995, ONCOGENE, V10, P2017; THAKUR S, 1994, ONCOGENE, V9, P2335; Wang Y, 1999, GENE, V234, P403, DOI 10.1016/S0378-1119(99)00168-7; Whitford GM, 1996, MONOGR ORAL SCI, V16, P1; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; Xu X, 1997, ONCOGENE, V14, P1521, DOI 10.1038/sj.onc.1200985	36	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					599	607		10.1038/sj.onc.1203376	http://dx.doi.org/10.1038/sj.onc.1203376			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698504				2022-12-28	WOS:000085192000001
J	Summy, JM; Guappone, AC; Sudol, M; Flynn, DC				Summy, JM; Guappone, AC; Sudol, M; Flynn, DC			The SH3 and SH2 domains are capable of directing specificity in protein interactions between the non-receptor tyrosine kinases cSrc and cYes	ONCOGENE			English	Article						Src; Yes; SH3; SH2; tyrosine phosphorylation	HUMAN-COLON-CARCINOMA; SRC FAMILY KINASES; C-SRC; BINDING-SPECIFICITY; COMPLEX-FORMATION; GENE-PRODUCT; YES; ASSOCIATION; ACTIVATION; CELLS	The c-src and eyes proto-oncogenes encode 60 000 and 62 000 Dalton non-receptor tyrosine kinases of the Src family, pp60(c-src) and pp62(c-yes), respectively. These kinases are over 80% homologous outside of their unique amino termini, yet several studies suggest that differences exist in the regulation, activation, and function of cSrc and c Yes. The determinants of specificity in signaling between these proteins, however, remain unclear, In order to investigate the roles of the Src Homology (SH) 3 and 2 domains in mediating signaling specificity between cSrc and cYes, chimeras were created in which the SH3 and/or SH2 domains of cSrc or the fully activated variant Src(527F) were replaced by the corresponding domains of cYes. These constructs were used to assess the effects of the Yes SH3 and SH2 domains on the ability of Src to form stable complexes with and induce tyrosine phosphorylation of Src SH3 and SH2 domain binding partners in vivo. Both the Yes SH3 and SH2 domains were found to alter the capacity of Src to form stable associations with heterologous proteins. The Yes SH3 domain was unable to affinity absorb the Src SN3/SH2 binding partner AFAP-110 from COS-1 cell lysates, and chimeric constructs of Src(527F) containing the cYes SH3 domain were unable to efficiently coimmunoprecipitate with AFAP-110 from chicken embryo fibroblasts. Interactions with the Src SH2 domain binding partner pp130cas were unaffected, Additionally only chimeras containing the cYes SH2 domain were able to co-immunoprecipitate with an unidentified 87 kDa tyrosine-phosphorylated protein. These results indicate that the SH3 and SH2 domains are capable of directing specificity in substrate binding between Src and Yes, suggesting potential mechanisms for generating specificity in signaling between these two highly related non-receptor tyrosine kinases.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol & Immunol, Morgantown, WV 26506 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	West Virginia University; West Virginia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Flynn, DC (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, POB 9300, Morgantown, WV 26506 USA.				NCI NIH HHS [CA60731, CA45757, CA01605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060731, R29CA045757, R01CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; GUAPPONE AC, 1996, METH CELL SCI, V18, P1; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; Sicilia RJ, 1998, J BIOL CHEM, V273, P16756, DOI 10.1074/jbc.273.27.16756; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; SUDOL M, 1994, ONCOGENE, V9, P2145; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsygankova OM, 1998, J CELL BIOCHEM, V69, P63, DOI 10.1002/(SICI)1097-4644(19980401)69:1<63::AID-JCB7>3.0.CO;2-T; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; ZHAO YH, 1993, MOL CELL BIOL, V13, P7507, DOI 10.1128/MCB.13.12.7507; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	25	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					155	160		10.1038/sj.onc.1203265	http://dx.doi.org/10.1038/sj.onc.1203265			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644991				2022-12-28	WOS:000084844300018
J	Na, SQ; Li, BY; Grewal, IS; Enslen, H; Davis, RJ; Hanke, JH; Flavell, RA				Na, SQ; Li, BY; Grewal, IS; Enslen, H; Davis, RJ; Hanke, JH; Flavell, RA			Expression of activated CDC42 induces T cell apoptosis in thymus and peripheral lymph organs via different pathways	ONCOGENE			English	Article						apoptosis; thymus; T cells; CDC42; Fas; Fas ligand	PROTEIN-KINASE ACTIVATION; NEGATIVE SELECTION; SIGNALING PATHWAY; TRANSGENIC MICE; GTPASE CDC42; FAS LIGAND; IN-VIVO; LYMPHOCYTES; RHO; DEATH	CDC42, a Ras-related small GTP binding protein, is involved in diverse cellular functions in lymphocytes. We generated transgenic mice expressing constitutively active murine CDC42 (Q61L) under the control of the human CD2 promoter. Transgenic mice showed smaller thymi with a dramatic reduction of CD4(+)CD8(+), CD4(+) and CD8(+) thymocytes and with increase of CD4(-)CD8(-) thymocytes at CD25(-)CD44(+) and CD25(+) stage. A high percentage of the transgenic thymocytes were apoptotic, explaining the reduction of cellularity and size of the thymus, Mature T cells (TCR alpha beta(+)) in peripheral lymph organs, spleen and lymph node, were also dramatically reduced, and exhibited massive apoptosis, Expression of Fas and Fas ligand on both thymocytes and peripheral T cells was upregulated in transgenic mice, but the increased apoptosis in the thymus was independent of Fas (CD95), whereas peripheral spleen and lymph node T cell apoptosis was Fas dependent. Thus, activated CDC42 triggers distinct apoptotic pathways in thymocytes and peripheral T cells.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Pfizer; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Flavell, RA (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, POB 20811, New Haven, CT 06520 USA.		Enslen, Hervé/M-3400-2017; Enslen, Hervé/AAH-4492-2021	Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; Grewal, Iqbal S/0000-0002-4775-055X	NCI NIH HHS [CA72009, CA65861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072009, R01CA065861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ALAN A, 1997, J EXP MED, V186, P1503; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Faris M, 1998, J IMMUNOL, V160, P134; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GODFREY DI, 1993, J IMMUNOL, V150, P4244; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOGAN B, 1986, MANIPULATING MOUSE E, P217; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; Kaga S, 1998, J IMMUNOL, V160, P4182; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LINETTE GP, 1994, CURR OPIN CELL BIOL, V6, P809, DOI 10.1016/0955-0674(94)90049-3; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mehal WZ, 1998, J IMMUNOL, V161, P1686; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moorman JP, 1996, J IMMUNOL, V156, P4146; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; vonFreedenJeffry U, 1997, IMMUNITY, V7, P147, DOI 10.1016/S1074-7613(00)80517-8; WEBB SR, 1994, J IMMUNOL, V152, P586; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	49	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7966	7974		10.1038/sj.onc.1203122	http://dx.doi.org/10.1038/sj.onc.1203122			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637507				2022-12-28	WOS:000084634600005
J	Yap, DBS; Hsieh, JK; Chan, FSG; Lu, X				Yap, DBS; Hsieh, JK; Chan, FSG; Lu, X			mdm2: a bridge over the two tumour suppressors, p53 and Rb	ONCOGENE			English	Review						regulation of mdm2; transactivation; transrepression; apoptosis; p53 stability; E2F1	WILD-TYPE P53; RETINOBLASTOMA GENE-PRODUCT; ABL TYROSINE KINASE; S-PHASE ENTRY; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; SV40-TRANSFORMED CELLS	The inactivation of the p53 and Rb pathways would account for the majority of human tumours. There are many levels of cross talk between p53 and Rb that have been identified. However, the identification of the mdm2-Rb interaction established a closer link between the two most well studied tumour suppressors, p53 and Rb. Recent studies of the novel trimeric complex Rb-mdm2-p53 provided us with a functional insight of how the two tumour suppressors can act together in regulating p53 induced apoptosis. Beginning with the properties of the Rb-mdm2-p53 trimeric complex, we shall review the propounding evidence suggesting that the apoptotic function of p53 is linked to its transrepression function. The uncoupling of the apoptotic function and transactivation function of p53 will also be discussed.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Lu, X (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.			Yap, Damian/0000-0002-5370-4592; Lu, Xin/0000-0002-6587-1152				Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CordonCardo C, 1997, CANCER RES, V57, P1217; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOGA A, 1995, ONCOGENE, V11, P791; Harbour JW, 1998, OPHTHALMOLOGY, V105, P1442, DOI 10.1016/S0161-6420(98)98025-3; HARPER JW, 1993, CELL, V75, P805; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, BIOESSAYS, V12, P62; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lohmann DR, 1996, AM J HUM GENET, V58, P940; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumoto R, 1998, CANCER RES, V58, P609; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NEVINS JR, 1992, SCIENCE, V258, P424; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WADAYAMA B, 1994, CANCER RES, V54, P3042; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	105	70	74	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	1999	18	53					7681	7689		10.1038/sj.onc.1202954	http://dx.doi.org/10.1038/sj.onc.1202954			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618708				2022-12-28	WOS:000084634500007
J	Elson, A				Elson, A			Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice	ONCOGENE			English	Article						breast cancer; adenocarcinoma; sarcoma	SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; GROWTH-FACTOR; HA-RAS; CARCINOMA CELLS; NEU ONCOGENE; EXPRESSION; BREAST; GENE; TRANSFORMATION	Accurate phosphorylation of tyrosine residues in proteins plays a central role in regulation of cellular function. Although connections between aberrant tyrosine kinase activity and malignancy are well-established, significantly less Is known about the roles of protein tyrosine phosphatases (PTPases) in tumorigenesis. We have previously shown that the transmembranal form of PTPase Epsilon (PTP epsilon) is upregulated in mouse mammary tumors initiated specifically by ras or neu, suggesting that PTP epsilon may play a role in transformation by these two oncogenes, In order to test this notion lit vivo, we created transgenic mice that express elevated le, els of PTP epsilon in their mammary epithelium by use of the MMTV promoter/enhancer, Following several cycles of pregnancy female MMTV-PTP epsilon mice uniformly de, eloped pronounced and persistent mammary hyperplasia which was accompanied by residual milk production. Solitary mammary tumors were often detected secondary to mammary hyperplasia. The sporadic nature of the tumors, the long latency period prior to their development, and low levels of transgene expression in the tumors indicate that PTP epsilon provides a necessary, but insufficient, signal for oncogenesis. The results provide genetic evidence that PTP epsilon plays an accessory role in production of mammary tumors in a manner consistent with its upregulation in mammary tumors induced by ras or neu.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Elson, Ari/0000-0001-9808-9135				Ahmad A, 1998, AM J PATHOL, V152, P721; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Birchmeier C, 1996, ACTA ANAT, V156, P217; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao LG, 1998, J BIOL CHEM, V273, P21077, DOI 10.1074/jbc.273.33.21077; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; FAERMAN A, 1995, J HISTOCHEM CYTOCHEM, V43, P461, DOI 10.1177/43.5.7730585; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; HAO L, 1997, J BIOL CHEM, V272, P29332; Harlow E., 1988, ANTIBODIES LAB MANUA; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; LEDER A, 1992, DEVELOPMENT, V116, P1041; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Quarrie LH, 1996, J CELL PHYSIOL, V168, P559, DOI 10.1002/(SICI)1097-4652(199609)168:3<559::AID-JCP8>3.0.CO;2-O; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TOLEDANOKATCHAL.H, IN PRESS ONCOGENE; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	45	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7535	7542		10.1038/sj.onc.1203098	http://dx.doi.org/10.1038/sj.onc.1203098			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602512				2022-12-28	WOS:000084119600014
J	Ikematsu, N; Yoshida, Y; Kawamura-Tsuzuku, J; Ohsugi, M; Onda, M; Hirai, M; Fujimoto, J; Yamamoto, T				Ikematsu, N; Yoshida, Y; Kawamura-Tsuzuku, J; Ohsugi, M; Onda, M; Hirai, M; Fujimoto, J; Yamamoto, T			Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases	ONCOGENE			English	Article						Tob family; anti-proliferation; CDKs; CCR4 transcription factor; cell cycle	NERVE GROWTH-FACTOR; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MESSENGER-RNA; PROTEIN; IDENTIFICATION; OVEREXPRESSION; PRODUCT; CLONING	Human cDNAs encoding a novel member of Tob/BTG1 anti-proliferative family proteins were cloned. The putative protein product termed Tob2 consisted of 344 amino acids with high similarity to the Tob protein, The tob2 mRNA was 4.1 kb long and was ubiquitously expressed in human adult tissues, as was revealed by Northern blot hybridization, However, further in situ hybridization analysis showed a characteristic expression of the tob2 mRNA in oocytes, suggesting a unique role of Tob2 in oogenesis, Like the Tob protein, Tob2 inhibited cell cycle progression from the G0/G1 to S phases. Intriguingly, the amino-terminal half of Tob2 as well as that of Tob was associated with a human homologue of yeast Caf1, a component of the CCR4 transcription factor complex, Moreover, Caf1 was associated with cyclin dependent kinases, These data suggested that both Tob and Tob2 were involved in cell cycle regulation through their interaction with Caf1, Finally, the tob2 gene was mapped to human chromosome 22q13.1-q13.31.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan.		Ohsugi, Miho/AAY-9339-2020	Ohsugi, Miho/0000-0003-0288-3428				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; HARPER JW, 1993, CELL, V75, P805; Hirai M, 1996, GENOMICS, V34, P263, DOI 10.1006/geno.1996.0283; Iida A, 1998, GENE CHROMOSOME CANC, V21, P108, DOI 10.1002/(SICI)1098-2264(199802)21:2<108::AID-GCC5>3.0.CO;2-4; KIM M, 1999, IN PRESS GENE; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; Matsuda S, 1996, ONCOGENE, V12, P705; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; RABURN DJ, 1995, ENDOCRINOLOGY, V136, P5769, DOI 10.1210/en.136.12.5769; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SCHILD D, 1995, GENETICS, V140, P115; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; Walden PD, 1998, EXP CELL RES, V245, P19, DOI 10.1006/excr.1998.4237; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805	28	122	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7432	7441		10.1038/sj.onc.1203193	http://dx.doi.org/10.1038/sj.onc.1203193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602502				2022-12-28	WOS:000084119600004
J	Palayoor, ST; Youmell, MY; Calderwood, SK; Coleman, CN; Price, BD				Palayoor, ST; Youmell, MY; Calderwood, SK; Coleman, CN; Price, BD			Constitutive activation of I kappa B kinase alpha and NF-kappa B in prostate cancer cells is inhibited by ibuprofen	ONCOGENE			English	Article						NF-kappa B; ibuprofen; prostate; tumor; IKK alpha; androgen	ANDROGEN RECEPTOR GENE; IKK-ALPHA; PHOSPHORYLATION; PROTEIN; BETA; SALICYLATE; EXPRESSION; APOPTOSIS; ASPIRIN; STIMULI	Apoptotic pathways controlled by the Rel/NF-kappa B family of transcription factors may regulate the response of cells to DNA damage. Here, we have examined the NF-kappa B status Of several prostate tumor cell lines. In the androgen-independent prostate tumor cells PC-3 and DU-145, the DNA-binding activity of NF-kappa B was constitutively activated and I kappa B-alpha levels were decreased, In contrast, the androgen-sensitive prostate tumor cell line LNCaP had low levels of NF-kappa B which were upregulated following exposure to cytokines or DNA damage, The activity of the I kappa B-alpha kinase, IKK alpha, which mediates NF-kappa B activation, was also measured. In PC-3 cells, IKK alpha activity was constitutively active, whereas LNCaP cells had minimal IKK alpha activity that was activated by cytokines. The anti-inflammatory agent ibuprofen inhibited the constitutive activation of NF-kappa B and IKK alpha in PC-3 and DU-145 cells, and blocked stimulated activation of NF-kappa B in LNCaP cells. However, ibuprofen did not directly inhibit I kappa B-alpha kinase, The results demonstrate that NF-kappa B is constitutively activated in the hormone-insensitive prostate tumor cell lines PC-3 and DU-145, but not in the hormone responsive LNCaP cell line. The constitutive activation of NF-kappa B in prostate tumor cells may increase expression of anti-apoptotic proteins, thereby decreasing the effectiveness of anti-tumor therapy and contributing to the development of the malignant phenotype.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Joint Ctr Radiat Therapy,Dept Adult Oncol, Boston, MA 02115 USA; NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Joint Ctr Radiat Therapy,Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [CA64585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apakama I, 1996, BRIT J CANCER, V74, P1258, DOI 10.1038/bjc.1996.526; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LASKA EM, 1986, CLIN PHARMACOL THER, V40, P1, DOI 10.1038/clpt.1986.129; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nakajima Y, 1996, PROSTATE, V29, P296; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Palayoor ST, 1998, CLIN CANCER RES, V4, P763; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Soncin F, 1996, BIOCHEM BIOPH RES CO, V229, P479, DOI 10.1006/bbrc.1996.1829; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; TEICHER BA, 1996, RADIAT ONCOL INVEST, V4, P221; TILLEY WD, 1990, CANCER RES, V50, P5382; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	31	276	292	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7389	7394		10.1038/sj.onc.1203160	http://dx.doi.org/10.1038/sj.onc.1203160			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602496				2022-12-28	WOS:000084119400026
J	Takeuchi, S; Cho, SK; Seriu, T; Koike, M; Bartram, CR; Reiter, A; Schrappe, M; Takeuchi, C; Taguchi, H; Koeffler, HP				Takeuchi, S; Cho, SK; Seriu, T; Koike, M; Bartram, CR; Reiter, A; Schrappe, M; Takeuchi, C; Taguchi, H; Koeffler, HP			Identification of three distinct regions of deletion on the long arm of chromosome 11 in childhood acute lymphoblastic leukemia	ONCOGENE			English	Article						LOH; ALL; 11q; MLL; ATM	ATM GENE; SUSCEPTIBILITY; MAP	Cytogenetic analysis of childhood acute lymphoblastic leukemia (ALL) identified deletions of chromosome arm 11q, These observations led us to analyse the loss of heterozygosity (LOH) of chromosome arm 11q in 113 primary childhood ALL samples using 14 microsatellite markers. LOH was found in 18 (16%) patients. Detailed examination identified three distinct regions of deletion. The first region is flanked by D11S901 and D11S1391 at 11q22-23 containing the A TM gene. Mutational analysis suggested that the altered gene in this region is not the ATM gene. The second region is flanked by D11S614 and D11S924 at 11q23 containing the MLL gene, The third region is flanked by D11S1356 and D11S614 at 11q23 containing the MLL gene. All the cases with LOH at MLL locus lacked detectable MLL gene rearrangements. In addition, 20 children have been studied both at initial diagnosis and relapse; none of the individuals who relapsed acquired LOH of 11q, suggesting that 11q deletions were infrequently involved in the progression of childhood ALL. Children with 11q LOH had a good response to induction chemotherapy (P=0.015), These data suggest that alterations of putative tumor suppressor genes on 11q are important events in development of childhood ALL. Our map provides important information toward cloning putative tumor suppressor genes associated with childhood ALL.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany; Hannover Med Sch, Dept Pediat 4, Hannover, Germany; Kochi Med Sch, Dept Med, Kochi 7838505, Japan	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ruprecht Karls University Heidelberg; Hannover Medical School; Kochi University	Takeuchi, S (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA.		Schrappe, Martin/A-8109-2010; Schrappe, Martin/ABA-6144-2020	Cho, Steve Kyungrae/0000-0001-8547-8430				JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; JOHANSSON B, 1993, GENE CHROMOSOME CANC, V8, P205, DOI 10.1002/gcc.2870080402; RAIMONDI SC, 1995, BLOOD, V86, P1881, DOI 10.1182/blood.V86.5.1881.bloodjournal8651881; RAIMONDI SC, 1993, BLOOD, V81, P2237; TAKEUCHI S, 1995, CANCER RES, V55, P5377; Takeuchi S, 1998, BRIT J HAEMATOL, V103, P536, DOI 10.1046/j.1365-2141.1998.00993.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Vorechovsky I, 1996, CANCER RES, V56, P2726; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	9	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7387	7388		10.1038/sj.onc.1203145	http://dx.doi.org/10.1038/sj.onc.1203145			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602495				2022-12-28	WOS:000084119400025
J	Veldhoen, N; Metcalfe, S; Milner, J				Veldhoen, N; Metcalfe, S; Milner, J			A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein	ONCOGENE			English	Article						mdm2; p53; regulatory exon; alternative splicing	P53 PROTEIN; ONCOPROTEIN MDM2; MESSENGER-RNAS; EXPRESSION; CELLS; TRANSCRIPTS; EFFICIENCY; MICE; TRANSACTIVATION; AMPLIFICATION	The mdm2 protein interacts with a number of proteins involved in cell growth control. Such interactions favour cell proliferation and may explain the oncogenic potential of mdm2 when over-expressed in cells. Interaction with the tumour suppressor p53 involves the N-terminus of mdm2 and targets p53 for rapid degradation by the ubiquitin pathway, We now describe a novel, highly conserved exon of mdm2 (exon alpha) which includes an in-frame UGA stop codon. Expression of exon alpha disrupts in vitro translation of the p53 binding domain of mdm2. We propose that exon alpha induces translation re-initiation at an internal AUG codon within the mdm2 alpha mRNA isoform. The putative mdm2 alpha protein lacks the N-terminus of mdm2 and shows little, if any, binding capacity for p53. Mdm2 alpha mRNA is expressed in a tissue-specific manner and is observed predominantly in testis and peripheral blood lymphocytes. We propose that mdm2 alpha expression may provide a mechanism for uncoupling mdm2-p53 interaction in certain cell types and/or under specific conditions of cell growth.	Univ York, Dept Biol, YCR Res Grp P53, York YO10 5DD, N Yorkshire, England; Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England	University of York - UK; Addenbrooke's Hospital; University of Cambridge	Milner, J (corresponding author), Univ York, Dept Biol, YCR Res Grp P53, York YO10 5DD, N Yorkshire, England.							ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; GUDAS JM, 1995, CLIN CANCER RES, V1, P71; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jones SN, 1996, GENE, V175, P209, DOI 10.1016/0378-1119(96)00151-5; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LENG P, 1995, ONCOGENE, V10, P1275; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumoto R, 1998, CANCER RES, V58, P609; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Shick L, 1997, CELL GROWTH DIFFER, V8, P121; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Veldhoen N, 1998, ONCOGENE, V16, P1077, DOI 10.1038/sj.onc.1201863; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	52	10	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7026	7033		10.1038/sj.onc.1203182	http://dx.doi.org/10.1038/sj.onc.1203182			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597303				2022-12-28	WOS:000083901900009
J	Voss, J; Posern, G; Hannemann, JR; Wiedemann, LM; Turhan, AG; Poirel, H; Bernard, OA; Adermann, K; Kardinal, C; Feller, SM				Voss, J; Posern, G; Hannemann, JR; Wiedemann, LM; Turhan, AG; Poirel, H; Bernard, OA; Adermann, K; Kardinal, C; Feller, SM			The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways	ONCOGENE			English	Article						kinase specificity; Crk; CRKL; Ras; MAPK/Erk; Akt/PKB	CHRONIC MYELOGENOUS LEUKEMIA; PROTEIN-TYROSINE KINASES; FAMILY ADAPTER PROTEINS; HEMATOPOIETIC-CELLS; C-ABL; BINDING ACTIVITY; CRK; DOMAIN; PHOSPHORYLATION; ONCOGENE	Inappropriate activation of Abl family kinases plays a crucial role in different human leukaemias, In addition to the well known oncoproteins p190Bcr-Abl and p210Bcr-Abl, Tel-Abl, a novel fusion protein resulting from a different chromosomal translocation, has recently been described. In this study, the kinase specificities of the Bcr-Abl and Tel-Abl proteins were compared to the physiological Abl family kinases c-Abl and Arg (nhl related gene). Using short peptides which correspond to the target epitopes in known substrate proteins of Abl family kinases, we found a higher catalytic promiscuity of Bcr-Abl and Tel-Abl. Similar to Bcr-Abl, Tel-Abl was found in complexes with the adapter protein CRKL. In addition, c-Crk II and CRKL are tyrosine phosphorylated and complexed with numerous other tyrosine phosphorylated proteins in Tel-Abl expressing Ba/F3 cells. GTPase analysis with a Ras GTP-specific precipitation assay showed constitutive elevation of GTP-loaded Ras in cells expressing the leukaemic Abl proteins. The mitogenic MAPK/Erk kinases as well as Akt/PKB, a kinase implicated to negatively regulate apoptosis, were also constitutively activated by both Bcr-Abl and Tel-Abl, The results indicate that the leukaemic Abl-fusion proteins have catalytic specificities different from the normal kinases c-Abl and Arg and that Tel-Abl is capable to activate at least some pathways which are also upregulated by Bcr-Abl.	Inst Med Strahlenkunde & Zellforsch, Oncol Mol Lab, D-97078 Wurzburg, Germany; CellTec GmbH, Strathmann AG, D-22459 Hamburg, Germany; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; CEPH, INSERM, U434, F-75010 Paris, France; Niedersachs Inst Peptidforsch, D-30625 Hannover, Germany	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm)	Feller, SM (corresponding author), Inst Med Strahlenkunde & Zellforsch, Oncol Mol Lab, Versbacher Str 5, D-97078 Wurzburg, Germany.		Wiedemann, Leanne/E-3316-2010; Bernard, Olivier A./E-5721-2016	TURHAN, Ali/0000-0002-4861-0137; Wiedemann, Leanne/0000-0002-0964-4676; Bernard, Olivier/0000-0002-0463-9747				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; ANAFI M, 1992, J BIOL CHEM, V267, P4518; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Hannemann JR, 1998, BRIT J HAEMATOL, V102, P475, DOI 10.1046/j.1365-2141.1998.00803.x; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; NICHOLS GL, 1994, BLOOD, V84, P2912; Nilsson T, 1998, LEUKEMIA, V12, P1167, DOI 10.1038/sj.leu.2401091; ODA T, 1994, J BIOL CHEM, V269, P22925; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Okuda K, 1996, ONCOGENE, V13, P1147; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Sattler M, 1996, ONCOGENE, V12, P839; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tauchi T, 1998, INT J ONCOL, V12, P1269; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TENHOEVE J, 1994, BLOOD, V84, P1731; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	64	67	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2000	19	13					1684	1690		10.1038/sj.onc.1203467	http://dx.doi.org/10.1038/sj.onc.1203467			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763825				2022-12-28	WOS:000086083800008
J	Kanamori, M; Kon, H; Nobukuni, T; Nomura, S; Sugano, K; Mashiyama, S; Kumabe, T; Yoshimoto, T; Meuth, M; Sekiya, T; Murakami, Y				Kanamori, M; Kon, H; Nobukuni, T; Nomura, S; Sugano, K; Mashiyama, S; Kumabe, T; Yoshimoto, T; Meuth, M; Sekiya, T; Murakami, Y			Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene	ONCOGENE			English	Article						glioma; the hMLH1 gene; microsatellite instability; Turcot's syndrome; promotor methylation; the PTEN1 gene	POLYMERASE CHAIN-REACTION; CONFORMATION POLYMORPHISM ANALYSIS; COLORECTAL-CANCER; RECEPTOR GENE; COLON-CANCER; BRAIN-TUMORS; CELL-LINES; HYPERMETHYLATION; AMPLIFICATION; INACTIVATION	High-frequent microsatellite instability (MSI-H) was detected in two of the 80 gliomas examined, while the other 78 gliomas showed microsatellite stable (MSS) phenotype. Both of the two MSI-H tumors were glioblastomas which developed in teenage patients. One of the patient was diagnosed as having Turcot's syndrome and had a germline mutation in the hMLH1 gene. Loss of expression due to promoter methylation was selectively observed in the mild type allele of the hMLH1 gene in the tumor of this patient. The other patient had neither a family history nor a past personal history of malignancy. Although no mutation in the mismatch repair genes was detected in the tumor of this patient, the level of expression of the RMLH1 gene,vas markedly decreased and the promoter sequence of the gene was highly methylated. In the tumor of this patient, the PTEN1 gene, one of the genes carrying microsatellite sequences in their coding regions, was altered by a slippage mutation within five adenine repeat sequences, These findings indicate that the genetic or epigenentic inactivation of the hMLH1 gene is involved in a subset of early-onset gliomas and the PTEN1 gene could be a downstream target for mutation as observed in glioblastoma without MST.	Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, Tokyo 1040045, Japan; Tohoku Univ, Sch Med, Div Neurosurg, Sendai, Miyagi 9808575, Japan; Natl Canc Ctr Hosp, Clin Lab, Tokyo 1040045, Japan; Iwaki Kyoritu Hosp, Iwaki, Fukushima, Japan; Univ Sheffield, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England	National Cancer Center - Japan; Tohoku University; National Cancer Center - Japan; University of Sheffield	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.		Nomura, Sachio/GYU-4930-2022	Nomura, Sachio/0000-0001-9214-4041				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Chan TL, 1999, GENE CHROMOSOME CANC, V25, P75, DOI 10.1002/(SICI)1098-2264(199906)25:2<75::AID-GCC1>3.0.CO;2-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; Cunningham JM, 1998, CANCER RES, V58, P3455; Dietmaier W, 1997, CANCER RES, V57, P4749; Esteller M, 1999, CANCER RES, V59, P67; FULTS D, 1990, CANCER RES, V50, P5784; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kane MF, 1997, CANCER RES, V57, P808; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kuchiki H, 2000, INT J CANCER, V85, P113, DOI 10.1002/(SICI)1097-0215(20000101)85:1<113::AID-IJC20>3.0.CO;2-3; KUMABE T, 1992, ONCOGENE, V7, P627; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; Leung SY, 1999, CANCER RES, V59, P159; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; MURAKAMI Y, 1991, ONCOGENE, V6, P37; Myohanen SK, 1998, CANCER RES, V58, P591; Nelen MR, 1999, EUR J HUM GENET, V7, P267, DOI 10.1038/sj.ejhg.5200289; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schutte M, 1997, CANCER RES, V57, P3126; SONODA Y, 1995, CANCER RES, V55, P2166; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; SONODA Y, 1995, ONCOGENE, V11, P2145; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544	42	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1564	1571		10.1038/sj.onc.1203454	http://dx.doi.org/10.1038/sj.onc.1203454			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734316				2022-12-28	WOS:000086108100009
J	Humphreys, RC; Hennighausen, L				Humphreys, RC; Hennighausen, L			Transforming growth factor alpha and mouse models of human breast cancer	ONCOGENE			English	Article						TGF alpha; mammary gland; transformation; cancer; mouse models; transgenic	MAMMARY EPITHELIAL-CELLS; PROTEIN-KINASE-A; TRANSGENIC MICE; TGF-ALPHA; FACTOR RECEPTOR; C-MYC; NEU PROTOONCOGENE; CYCLIN D1; CONSTITUTIVE ACTIVATION; SYNERGISTIC INTERACTION	Transforming growth factor alpha (TGF alpha) is a principal molecule in the normal and neoplastic development of the mammary gland. Binding of TGF alpha to the epidermal growth factor receptor (EGFR), activates the EGFRs' endogenous tyrosine kinase activity and stimulates growth of the epithelium in the virgin and pregnant mouse mammary gland. TGF alpha expression can be detected in breast cancer cells in vivo and in vitro and overexpression can elicit partial transformation or immortalized human and rodent mammary epithelial cells. Despite evidence implicating TGF alpha in the development of mammary neoplasia, the actual mechanism of TGF alpha-induced transformation is unclear. Transgenic mouse models targeting heterologous TGF alpha to the mammary gland have established TGF alpha overexpression can induce hyperproliferation, hyperplasia and occasional carcinoma. These transgenic studies demonstrated a facilitating, proliferative role for TGF alpha in the development of neoplasia and implicated several oncogenes that can cooperate with TGF alpha to transform the mammary epithelium. From studies of EGFR signaling pathways, inhibitory and modulating agents such as anti-ECFR antibodies and specific kinases inhibitors have been used to block the action of this pathway and prevent the development of TGF alpha-induced neoplasia and tumor formation, Studies in Stat5a knockout mice have established that the JAK2/Stat5a pathway can facilitate the survival of the mammary epithelium and can impact the progression of TGF alpha-mandated mammary tumorigenesis, Together these experiments indicate that TGF alpha and the EGFR signaling pathway are potentially amenable to therapies for treatment of human breast disease.	NIDDKD, NIH, Lab Genet & Physiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Humphreys, RC (corresponding author), NIDDKD, NIH, Lab Genet & Physiol, Bldg 8,Room 111, Bethesda, MD 20892 USA.			Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; ARTEAGA CL, 1988, CANCER RES, V48, P5023; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Bianco C, 1997, CLIN CANCER RES, V3, P439; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BORELLINI F, 1989, ENVIRON HEALTH PERSP, V80, P85, DOI 10.2307/3430734; Brenner T L, 1999, J Am Pharm Assoc (Wash), V39, P236; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Ciardiello F, 1996, JNCI-J NATL CANCER I, V88, P1770, DOI 10.1093/jnci/88.23.1770; Ciardiello F, 1998, CLIN CANCER RES, V4, P821; CLARK AJL, 1989, J MOL ENDOCRINOL, V2, P3, DOI 10.1677/jme.0.0020003; COFFEY RJ, 1994, CANCER RES, V54, P1678; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; DANIEL CW, 1985, MAMMARY GLAND DEV RE, V1, P3; De Jong JS, 1998, J PATHOL, V184, P44; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; EDERY M, 1985, ENDOCRINOLOGY, V117, P405, DOI 10.1210/endo-117-1-405; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Gillett CE, 1999, J PATHOL, V187, P200, DOI 10.1002/(SICI)1096-9896(199901)187:2<200::AID-PATH228>3.0.CO;2-M; Gullick WJ, 1998, BREAST CANCER RES TR, V52, P43, DOI 10.1023/A:1006107016969; GULLICK WJ, 1999, WOMEN CANC, V1, P29; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HALTER SA, 1992, AM J PATHOL, V140, P1131; Hanna W, 1999, MODERN PATHOL, V12, P827; Hayakawa F, 1998, BRIT J HAEMATOL, V101, P521, DOI 10.1046/j.1365-2141.1998.00720.x; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KENNEY NJ, 1993, J CELL PHYSIOL, V156, P497, DOI 10.1002/jcp.1041560309; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LISCIA DS, 1990, DEV BIOL, V140, P123, DOI 10.1016/0012-1606(90)90059-R; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MARIANICOSTANTINI R, 1989, TUMORI J, V75, P311, DOI 10.1177/030089168907500404; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; PETERS GN, 1983, CANCER, V52, P680, DOI 10.1002/1097-0142(19830815)52:4<680::AID-CNCR2820520420>3.0.CO;2-E; Pilichowska M, 1997, MODERN PATHOL, V10, P969; Pircher TJ, 1999, MOL ENDOCRINOL, V13, P555, DOI 10.1210/mend.13.4.0263; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Robertson D, 1998, NAT BIOTECHNOL, V16, P615, DOI 10.1038/nbt0798-615; Robertson KW, 1996, CANCER RES, V56, P3823; Ross, 1998, Oncologist, V3, P237; SALOMON DS, 1984, CANCER RES, V44, P4069; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH GH, 1995, AM J PATHOL, V147, P1081; SMITH JA, 1989, J CELL PHYSIOL, V141, P362, DOI 10.1002/jcp.1041410218; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TELANG NT, 1990, CELL REGUL, V1, P863, DOI 10.1091/mbc.1.11.863; TODARO GJ, 1980, PROC R SOC SER B-BIO, V210, P367, DOI 10.1098/rspb.1980.0140; UMEKITA Y, 1992, VIRCHOWS ARCH A, V420, P345, DOI 10.1007/BF01600214; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VONDERHAAR BK, 1987, J CELL PHYSIOL, V132, P581, DOI 10.1002/jcp.1041320324; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wiesen JF, 1999, DEVELOPMENT, V126, P335; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Yu CL, 1997, J IMMUNOL, V159, P5206; ZAICHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148	75	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1085	1091		10.1038/sj.onc.1203278	http://dx.doi.org/10.1038/sj.onc.1203278			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713694				2022-12-28	WOS:000085796400016
J	Pettiford, SM; Herbst, R				Pettiford, SM; Herbst, R			The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP	ONCOGENE			English	Article						signal transduction; phosphatase; HePTP; MAP-kinase	MEGAKARYOCYTIC DIFFERENTIATION; K562 CELLS; LC-PTP; SUSTAINED ACTIVATION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; EXPRESSION; CLONING; BRAIN; GENE	HePTP is a tyrosine specific protein phosphatase that is strongly expressed in activated T-cells, It was recently demonstrated that in transfected T-cells HePTP impairs TCR-mediated activation of the MAP-kinase family members ERK2 and p38 and it was suggested that both ERK and p38 MAP-kinases are substrates of HePTP, The HePTP gene has been mapped to human chromosome 1q32.1, Abnormalities in this region are frequently found in various hematopoietic malignancies. HePTP is highly expressed in acute myeloid leukemia and its expression in fibroblasts resulted in transformation. To address a possible involvement of HePTP in hematopoietic malignancies we sought to identify HePTP substrate(s) in leukemic cells. Using substrate trapping mutants we have identified the MAP-kinase ERK2 as a specific target of HePTP in the myelogenous leukemia cell line K562, Tyrosine phosphorylated ERK2, but not ERK1, p38, or JNK1, efficiently bound to catalytically inactive HePTP mutants in which the active site cysteine (HePTP-C/S) or the conserved aspartic acid residue (HePTP-D/A) had been exchanged for serine and alanine, respectively. Moreover, the interaction of ERK2 with HePTP trapping mutants,vas dependent on ERK2 tyrosine phosphorylation, indicating that HePTP is specifically targeted to activated ERK2, Using a deletion mutant of HePTP (HePTP-dLD), in which 14 amino acid residues within the N-terminus are missing, rye show that regions outside the catalytic domain are also required for the interaction. Furthermore, overexpression of HePTP in K562 cells and fibroblasts interfered with PMA or growth factor induced MAP-kinase activation and HePTP efficiently dephosphorylated active ERK2 on the tyrosine residue in the activation loop in vitro. Together, these data identify ERK2 as a specific and direct target of HePTP and are consistent with a model in which HePTP negatively regulates ERK2 activity as part of a feedback mechanism.	DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Herbst, R (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADACHI M, 1995, FEBS LETT, V372, P113, DOI 10.1016/0014-5793(95)00952-6; ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ADACHI M, 1994, FEBS LETT, V338, P47, DOI 10.1016/0014-5793(94)80114-2; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bult A, 1997, EUR J CELL BIOL, V72, P337; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; FAUMAN EB, 1996, TIBS, P413; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GAITS F, 1994, CELL MOL BIOL, V40, P677; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENDRIKS W, 1995, BIOCHEM J, V305, P499, DOI 10.1042/bj3050499; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KELLY K, 1995, CURR OPIN IMMUNOL, V7, P327, DOI 10.1016/0952-7915(95)80106-5; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Lewis M, 1998, MT SINAI J MED, V65, P139; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MITELMAN F, 1990, CYTOGENET CELL GENET, V55, P358, DOI 10.1159/000133022; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Patarca R, 1996, CRIT REV ONCOGENESIS, V7, P343, DOI 10.1615/CritRevOncog.v7.i5-6.20; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Radha V, 1997, FEBS LETT, V409, P33, DOI 10.1016/S0014-5793(97)00471-7; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rosson D, 1998, ARCH BIOCHEM BIOPHYS, V352, P298, DOI 10.1006/abbi.1998.0597; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHARMA E, 1995, MOL BRAIN RES, V32, P87, DOI 10.1016/0169-328X(95)00066-2; SHIOZUKA K, 1995, GENE, V162, P279, DOI 10.1016/0378-1119(95)00306-Q; TAKEKAWA M, 1994, FEBS LETT, V339, P222, DOI 10.1016/0014-5793(94)80420-6; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Urushibara N, 1998, INT J ONCOL, V12, P603; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; van Huijsduijnen RH, 1998, GENE, V225, P1; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; ZANKE B, 1994, LEUKEMIA, V8, P236; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161	48	36	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					858	869		10.1038/sj.onc.1203408	http://dx.doi.org/10.1038/sj.onc.1203408			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702794				2022-12-28	WOS:000085567700003
J	Wei, Y; Fabre, M; Branchereau, S; Gauthier, F; Perilongo, G; Buendia, MA				Wei, Y; Fabre, M; Branchereau, S; Gauthier, F; Perilongo, G; Buendia, MA			Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas	ONCOGENE			English	Article						beta-catenin; nuclear/cytoplasmic staining; liver; hepatoblastoma; APC; E-cadherin	FAMILIAL ADENOMATOUS POLYPOSIS; APC GENE; HEPATOCELLULAR CARCINOMAS; SOMATIC MUTATIONS; COLORECTAL-CANCER; CADHERIN; COMPLEX; PATHWAY; EXON-3; MOUSE	Wnt/beta-catenin signaling is frequently activated in cancer cells by stabilizing mutations of beta-catenin or loss-of-function mutations of the APC tumor suppressor gene. We have analysed the role of beta-catenin in the pathogenesis of hepatoblastoma (HB), an embryonic liver tumor occurring mainly in children under 2 years of age. Sequence analysis of the beta-catenin NH2-terminal domain in 18 epithelial and mixed HBs revealed missense mutations in the GSK3 beta phosphorylation motif or interstitial deletions in 12 tumors (67%), In the remaining cases, no truncating mutation of APC could be evidenced. Immunohistochemical analysis of beta-catenin in 11 HBs demonstrated nuclear/cytoplasmic accumulation of the protein in all tumors analysed, with predominant nuclear beta-catenin immunostaining in undifferentiated cells, Membranous beta-catenin localization was preserved only in fetal-type tumoral hepatocytes and was associated with E-cadherin expression. Moreover, are show that beta-catenin is aberrantly overexpressed in a large spectrum of tumor components, including hepatocyte-like cells at various differentiation stages and heterologous elements such as squamous, osteoid and chrondroid tissues, and in occasional other mesenchymally-derived cells. These data strongly suggest that activation of beta-catenin signaling is an obligatory step in HE pathogenesis, and raise the possibility that it interferes with developmental signals that specify different tissue types at early stages of hepatic differentiation.	Inst Pasteur, Unite Recombinaison & Express Genet, INSERM U163, F-75724 Paris 15, France; Hop Bicetre, Lab Anat & Cytol Pathol, Le Kremlin Bicetre, France; Hop Bicetre, Serv Chirurg Pediat, Le Kremlin Bicetre, France; Univ Padua, Dipartimento Pediat, I-35128 Padua, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; University of Padua	Buendia, MA (corresponding author), Inst Pasteur, Unite Recombinaison & Express Genet, INSERM U163, 28 Rue Dr Roux, F-75724 Paris 15, France.		Wei, Yu/A-7289-2016	PERILONGO, GIORGIO/0000-0002-3712-0386				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Blaker H, 1999, GENE CHROMOSOME CANC, V25, P399; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESDOUETS C, 1995, J HEPATOL, V23, P569, DOI 10.1016/0168-8278(95)80064-6; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Giardiello FM, 1996, GUT, V39, P867, DOI 10.1136/gut.39.6.867; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Iwao K, 1998, CANCER RES, V58, P1021; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koch A, 1999, CANCER RES, V59, P269; Koesters R, 1999, CANCER RES, V59, P3880; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KURAHASHI H, 1995, CANCER RES, V55, P5007; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Miyoshi Y, 1998, CANCER RES, V58, P2524; Oda H, 1996, CANCER RES, V56, P3320; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Sparks AB, 1998, CANCER RES, V58, P1130; STOCKER JT, 1997, LIVER CANC; VANTHIEU JT, 1999, AM J PATHOL, V155, P703; Voeller HJ, 1998, CANCER RES, V58, P2520; Wei Y, 1998, J VIROL, V72, P2089, DOI 10.1128/JVI.72.3.2089-2096.1998; WEINBERG AG, 1983, HUM PATHOL, V14, P512, DOI 10.1016/S0046-8177(83)80005-7; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	32	127	129	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					498	504		10.1038/sj.onc.1203356	http://dx.doi.org/10.1038/sj.onc.1203356			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698519	Bronze			2022-12-28	WOS:000085104200003
J	Sandy, P; Gostissa, M; Fogal, V; De Cecco, L; Szalay, K; Rooney, RJ; Schneider, C; Del Sal, G				Sandy, P; Gostissa, M; Fogal, V; De Cecco, L; Szalay, K; Rooney, RJ; Schneider, C; Del Sal, G			p53 is involved in the p120E4F-mediated growth arrest	ONCOGENE			English	Article						E4F; p53; growth suppression; transcriptional repression	TRANSCRIPTION FACTOR E4F; DNA-BINDING ACTIVITY; WILD-TYPE P53; NUCLEAR-LOCALIZATION; PROTEIN; IDENTIFICATION; CELLS; GENE; MODULATION; EXPRESSION	Control of cell growth and division by the p53 tumor suppressor protein requires its abilities to transactivate and repress specific target genes and to associate in complex with other proteins. Here we demonstrate that p53 binds to the E1A-regulated transcription factor p120E4F, a transcriptional repressor of the adenovirus E4 promoter. The interaction involves carboxy-terminal half of p120E4F and sequences located at the end of the sequence-specific DNA-binding domain of p53, Ectopic expression of p120E4F leads to a block of cell proliferation in several human and murine cell lines and this effect requires the association with wild-type (wt) p53, Although p120E4F can also bind to mutant p53, the growth suppression induced by overexpression of the protein is severely reduced in a cell line that contains mutant p53. These data suggest that p120E4F may represent an important element within the complex network of p53 checkpoint functions.	Consorzio Interuniv Biotecnol, Lab Nazl, I-34012 Trieste, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci & Technol Biomed, I-33100 Udine, Italy; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA	University of Trieste; University of Udine; Duke University	Del Sal, G (corresponding author), Consorzio Interuniv Biotecnol, Lab Nazl, Padriciano 99,AREA Sci Pk, I-34012 Trieste, Italy.		De Cecco, Loris/K-7036-2016	De Cecco, Loris/0000-0002-7066-473X; DEL SAL, GIANNINO/0000-0003-2185-6003				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; FOGNANI C, 1993, EMBO J, V12, P1985; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Muller H, 1997, MOL CELL BIOL, V17, P5508; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; PAVIETICH NP, 1993, GENE DEV, V7, P2556; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; Rooney RJ, 1998, MAMM GENOME, V9, P320, DOI 10.1007/s003359900758; Rooney RJ, 1998, NUCLEIC ACIDS RES, V26, P1681, DOI 10.1093/nar/26.7.1681; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Saccone S, 1998, CYTOGENET CELL GENET, V82, P99, DOI 10.1159/000015075; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TARUNINA M, 1993, ONCOGENE, V8, P3165; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	40	39	44	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					188	199		10.1038/sj.onc.1203250	http://dx.doi.org/10.1038/sj.onc.1203250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644996				2022-12-28	WOS:000084844400003
J	Baasiri, RA; Glasser, SR; Steffen, DL; Wheeler, DA				Baasiri, RA; Glasser, SR; Steffen, DL; Wheeler, DA			The Breast Cancer Gene Database: a collaborative information resource	ONCOGENE			English	Article						electronic publishing; breast cancer; database; information retrieval		The Breast Cancer Gene Database (BCGD) is a compendium of molecular genetic data relating to genes involved in breast cancer, and which is freely available via the World Wide Web. The data in BCGD is extracted from the published biomedical research literature and stored as a collection of 'Facts', which in turn are collected into topical categories organized by gene, This organization facilitates quick searches and rapid retrievals of specific data such as gene characteristics, functions and role in oncogenesis, and is an important factor allowing for continuous updates, BCGD can be searched either by gene name or keyword, Data is deposited and retrieved from the database through a set of interactive Web forms, making it both platform-independent and universally accessible in facilitating worldwide collaborative authoring of the database. Data in BCGD is linked to other on-line resources such as Entrez, GeneCards and On-Line Mendelian Inheritance in Man, BCGD is located at http://mbcr.bcm.tmc.edu/ ermb/bcgd/bcgd.html.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Biomed Comp Inc, Houston, TX 77005 USA	Baylor College of Medicine	Wheeler, DA (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Wheeler, David A/M-9740-2018	Wheeler, David A/0000-0002-9056-6299	NCI NIH HHS [CA70532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA070532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; Barker WC, 1999, NUCLEIC ACIDS RES, V27, P39, DOI 10.1093/nar/27.1.39; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; Blake JA, 1999, NUCLEIC ACIDS RES, V27, P95, DOI 10.1093/nar/27.1.95; BUHLE EL, 1994, J AM MED INFORM ASSN, P103; Kuska B, 1996, J NATL CANCER I, V88, P1801, DOI 10.1093/jnci/88.24.1801; OHKAWA H, 1995, ISMB, V3, P259; Rebhan M, 1998, BIOINFORMATICS, V14, P656, DOI 10.1093/bioinformatics/14.8.656; Stoesser G, 1999, NUCLEIC ACIDS RES, V27, P18, DOI 10.1093/nar/27.1.18; Tateno Y, 1997, NUCLEIC ACIDS RES, V25, P14, DOI 10.1093/nar/25.1.14	10	39	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 23	1999	18	56					7958	7965		10.1038/sj.onc.1203335	http://dx.doi.org/10.1038/sj.onc.1203335			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637506				2022-12-28	WOS:000084634600004
J	Bell, MV; Frampton, J				Bell, MV; Frampton, J			v-Myb can transform and regulate the differentiation of melanocyte precursors	ONCOGENE			English	Article						Myb; progenitor; melanocyte; differentiation	MULTIPOTENT HEMATOPOIETIC PROGENITORS; CREST CELL-CULTURES; E26 LEUKEMIA-VIRUS; C-MYB; NEURAL CREST; NEURORETINA CELLS; MONOCLONAL-ANTIBODIES; WAARDENBURG-SYNDROME; MALIGNANT-MELANOMA; LINEAGE COMMITMENT	The activity of the c-Myb transcription factor is essential for the development of definitive multi- and uni-lineage progenitors of the haemopoietic system. Reflecting this requirement, c-Myb has been oncogenically activated by transduction in the E26 avian retrovirus which elicits an acute leukaemia by transforming haemopoietic progenitors, Here, we report the novel finding that Myb in cooperation with EGF receptor signalling can be used to generate clonally expanded populations of transformed cells which have the phenotype of melanocyte precursors. Through the use of a conditional temperature sensitive mutant of Myb, we show that in the transformed cells Myb regulates commitment to melanocyte differentiation and possibly proliferation. These results add to our understanding of the roles of c-Myb beyond the haemopoietic system and to our knowledge and means of investigating the importance of transcription factors in the melanocyte linage.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Frampton, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO T, 1981, J IMMUNOL, V127, P1024; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; Boissy RE, 1997, PIGM CELL RES, V10, P12, DOI 10.1111/j.1600-0749.1997.tb00461.x; BROWN KE, 1992, J BIOL CHEM, V267, P4625; DASGUPTA P, 1989, ONCOGENE, V4, P1201; Eisen TG, 1996, MELANOMA RES, V6, P277, DOI 10.1097/00008390-199608000-00001; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; FRAMPTON J, 1995, EMBO J, V14, P2866, DOI 10.1002/j.1460-2075.1995.tb07286.x; Frampton J, 1997, MOL B INT U, P287; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Gadson PF, 1997, EXP CELL RES, V230, P169, DOI 10.1006/excr.1996.3398; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HORTON MA, 1985, CANCER RES, V45, P5663; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; LAHAV R, 1994, DIFFERENTIATION, V58, P133; Lecoin L, 1998, P NATL ACAD SCI USA, V95, P3024, DOI 10.1073/pnas.95.6.3024; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Li M, 1998, INT J CANCER, V76, P430; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; McNagny KM, 1996, BLOOD, V87, P1343, DOI 10.1182/blood.V87.4.1343.bloodjournal8741343; Miglarese MR, 1997, CELL GROWTH DIFFER, V8, P1199; MOCHII M, 1988, CELL DIFFER DEV, V24, P67, DOI 10.1016/0045-6039(88)90087-5; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NATAF V, 1993, EXP CELL RES, V207, P171, DOI 10.1006/excr.1993.1177; NATAF V, 1995, EXP CELL RES, V218, P394, DOI 10.1006/excr.1995.1171; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TRENT JM, 1989, CANCER RES, V49, P420; Vainio O, 1996, J CELL BIOL, V135, P1655, DOI 10.1083/jcb.135.6.1655; VINCENT M, 1984, DEV BIOL, V103, P468, DOI 10.1016/0012-1606(84)90334-8; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; YASUMOTO K, 1995, J BIOCHEM-TOKYO, V118, P874, DOI 10.1093/jb/118.5.874	52	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7226	7233		10.1038/sj.onc.1203161	http://dx.doi.org/10.1038/sj.onc.1203161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602476				2022-12-28	WOS:000084119400006
J	Reymond, A; Volorio, S; Merla, G; Al-Maghtheh, M; Zuffardi, O; Bulfone, A; Ballabio, A; Zollo, M				Reymond, A; Volorio, S; Merla, G; Al-Maghtheh, M; Zuffardi, O; Bulfone, A; Ballabio, A; Zollo, M			Evidence for interaction between human PRUNE and nm23-H1 NDPKinase	ONCOGENE			English	Article						PRUNE; NDPK; nm 23-H1	NUCLEOSIDE-DIPHOSPHATE KINASE; DROSOPHILA MUTANT-GENES; TUMOR-METASTASIS; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; POINT MUTATION; MESSENGER-RNA; LOCUS RP18; IN-VITRO; PROTEIN	We have isolated a human and murine homologue of the Drosophila prune gene through dbEST searches. The gene is ubiquitously expressed in human adult tissues, while in mouse developing embryos a high level of expression is confined to the nervous system particularly in the dorsal root ganglia, cranial nerves, and neural retina. The gene is composed of eight exons and is located in the 1q21.3 chromosomal region. A pseudogene has been sequenced and mapped to chromosomal region 13q12, PRUNE protein retains the four characteristic domains of DHH phosphoesterases. The synergism between prune and awd(K-pn) in Drosophila has led various authors to propose an interaction between these genes. However, such an interaction has never been supported by biochemical data. By using interaction-mating and in vitro co-immunoprecipitation experiments, we show for the first time the ability of human PRUNE to interact with the human homologue of awd protein (nm23-H1). In contrast, PRUNE is impaired in its interaction with nm23-H1-S120G mutant, a gain-of-function mutation associated with advanced neuroblastoma stages. Consistently, PRUNE and nm23-H1 proteins partially colocalize in the cytoplasm, The data presented are consistent with the view that PRUNE acts as a negative regulator of the nm23-H1 protein. We discuss how PRUNE regulates nm23-H1 protein and postulate possible implications of PRUNE in neuroblastoma progression.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Univ Milan, Osped San Raffaele, Lab Citogenet, I-20127 Milan, Italy; Univ Milan, Osped San Raffaele, Serv Genet Med, I-20127 Milan, Italy; UCL, Inst Ophthalmol, Ophthalmol Dept Mol Genet, London, England	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; University College London	Zollo, M (corresponding author), Telethon Inst Genet & Med, San Raffaele Biomed Sci Pk, I-20132 Milan, Italy.		merla, giuseppe/K-4627-2012; BALLABIO, Andrea/AAL-2672-2020	merla, giuseppe/0000-0001-5078-928X; BALLABIO, Andrea/0000-0003-1381-4604; zuffardi, orsetta/0000-0002-1466-4559; Reymond, Alexandre/0000-0003-1030-8327	Telethon [TGM06S01, TGM97000] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; Betke Herbert, 1998, Polish Journal of Pathology, V49, P93; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; Bulfone A, 1998, HUM MOL GENET, V7, P1997, DOI 10.1093/hmg/7.13.1997; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; Chiarelli I, 1998, MOL CELL PROBE, V12, P125, DOI 10.1006/mcpr.1998.0159; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FERRE J, 1986, BIOCH GENET, V7, P545; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Gazzeri S, 1996, LAB INVEST, V74, P158; GILLES AM, 1991, J BIOL CHEM, V266, P8784; Gregory-Evans K, 1998, TRENDS GENET, V14, P103, DOI 10.1016/S0168-9525(98)01402-4; Guo X, 1998, INT J CANCER, V79, P596, DOI 10.1002/(SICI)1097-0215(19981218)79:6<596::AID-IJC7>3.0.CO;2-Y; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hartsough MT, 1998, AM J HUM GENET, V63, P6, DOI 10.1086/301942; Inglehearn CF, 1998, J MED GENET, V35, P788, DOI 10.1136/jmg.35.9.788; Jensen SL, 1996, WORLD J UROL, V14, pS21; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1993, ONCOGENE, V8, P855; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MACDONALD NJ, 1995, EUR J CANCER, V31A, P1096, DOI 10.1016/0959-8049(95)00152-9; MARTINEZ JA, 1995, GUT, V37, P712, DOI 10.1136/gut.37.5.712; MERLO GR, 1989, CANCER RES, V49, P6966; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Mesnildrey S, 1998, J BIOL CHEM, V273, P4436, DOI 10.1074/jbc.273.8.4436; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; Muller W, 1998, CANCER-AM CANCER SOC, V83, P2481, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2481::AID-CNCR11>3.0.CO;2-P; Munier A, 1998, FEBS LETT, V434, P289, DOI 10.1016/S0014-5793(98)00996-X; ODONNELL JM, 1989, DEV GENET, V10, P273, DOI 10.1002/dvg.1020100316; OREVI N, 1975, MUTAT RES, V33, P193, DOI 10.1016/0027-5107(75)90195-5; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; REYMOND A, 1995, ONCOGENE, V11, P1173; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Russell RL, 1998, BRIT J CANCER, V78, P710, DOI 10.1038/bjc.1998.566; Sambrook J., 2002, MOL CLONING LAB MANU; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SASTREGARAU X, 1992, B CANCER, V79, P465; Shimada M, 1998, LIVER, V18, P337; STAHL JA, 1991, CANCER RES, V51, P445; STURTEVANT AH, 1956, GENETICS, V41, P118; Tagashira H, 1998, INT J MOL MED, V2, P65; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; Timmons L, 1996, GENETICS, V144, P1589; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; Volorio S, 1998, DNA SEQUENCE, V9, P307, DOI 10.3109/10425179809008469; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; Xu SY, 1996, HUM MOL GENET, V5, P1193, DOI 10.1093/hmg/5.8.1193; Xu SY, 1998, HUM GENET, V102, P493, DOI 10.1007/s004390050728; Yoshida H, 1998, INT J ONCOL, V13, P1141; Zheng XY, 1998, J EXP CLIN CANC RES, V17, P337	66	71	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7244	7252		10.1038/sj.onc.1203140	http://dx.doi.org/10.1038/sj.onc.1203140			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602478				2022-12-28	WOS:000084119400008
J	Takada, S; Shirakata, Y; Kaneniwa, N; Koike, K				Takada, S; Shirakata, Y; Kaneniwa, N; Koike, K			Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death	ONCOGENE			English	Article						HBV X protein; cytoplasmic location; mitochondrial aggregation; p53 protein; cell death	GENE-PRODUCT; TRANSACTIVATOR PX; SERINE-PROTEASE; DNA; TRANSFORMATION; ACTIVATION; INHIBITOR; PROMOTER; RAS	Hepatitis B virus (HBV) X protein activates many viral and cellular genes in trans and functional disruption of the p53 tumor suppressor gene product occurs when X protein is transiently expressed in the cytoplasm of cultured cells. We have carried out investigations to determine the exact location of X protein in X gene transfected cells by using a fluorescent staining technique as well as by biochemical analyses. Aggregation of mitochondrial structures became evident at the periphery of nucleus in the cytoplasm of X transfected cells. X protein was found associated with the aggregated mitochondrial structures. Furthermore, transiently expressed p53 protein co-localized with X protein in X transfected cells, However, the appearance of aggregated mitochondrial structures at the nuclear periphery was independent of the presence of p53 protein in X transfected cells. X protein expression also caused an appearance of TUNEL positive nucleus, cytochrome c release from mitochondrial, the decrease of mitochondrial membrane potential and the membrane blebbing of X transfected cells, which are characteristic of cell death. Our data suggest that X protein causes an abnormal aggregation of mitochondrial structures in the cell, which may be eventually connected with cell death.	Japanese Fdn Canc Res, Inst Canc, Dept Gene Res, Toshima Ku, Tokyo 1708455, Japan	Japanese Foundation for Cancer Research	Koike, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Gene Res, Toshima Ku, Tokyo 1708455, Japan.							ARII M, 1992, ONCOGENE, V7, P397; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1994, ONCOGENE, V9, P2837; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Sambrook J., 2002, MOL CLONING LAB MANU; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; TAKADA S, 1994, ONCOGENE, V9, P341; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; TANAKA S, 1978, BIOCHEM BIOPH RES CO, V81, P791, DOI 10.1016/0006-291X(78)91421-3; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	30	149	157	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6965	6973		10.1038/sj.onc.1203188	http://dx.doi.org/10.1038/sj.onc.1203188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597295				2022-12-28	WOS:000083901900001
J	Liu, JL; Huang, C; Zhan, X				Liu, JL; Huang, C; Zhan, X			Src is required for cell migration and shape changes induced by fibroblast growth factor 1	ONCOGENE			English	Article						Src; FGF-1; cortactin	TYROSINE KINASE; ACTIN CYTOSKELETON; FACTOR RECEPTOR; POINT MUTATION; EGF-RECEPTOR; FACTOR-I; C-SRC; PROTEIN; CORTACTIN; ASSOCIATION	Fibroblast growth factor 1 (FGF-1) is a potent chemotactic factor and induces tyrosine phosphorylation of a cortical actin-associated protein (cortactin). The tyrosine phosphorylation of cortactin induced by FGF-1 requires the tyrosine residues 421, 482 and 466, which are targeted by the protein tyrosine kinase Src irt vitro. Furthermore, FGF-1 is unable to induce tyrosine phosphorylation of cortactin within the cells derived from Src knockout mice (Src(-/-)), indicating that Src is required for the tyrosine phosphorylation of cortactin induced by FGF-1. Although Src-/- cells are able to undergo rapid proliferation, they are impaired to respond to FGF-1 for the shape change and cell migration. Morphological analysis further reveals that FGF-1 fails to induce the formation of polarized lamellipodia and the translocation of cortactin into the leading edge of Src(-/-) cells. Consistent with the mitogenic response to FGF-1, the lack of Src does not affect the tyrosine phosphorylation of Snt (or Frs2), a FGF-1 early signaling protein that links to Ras, Therefore, our data support the notion that Src and cortactin participate in a FGF signal pathway for cell migration and shape change rather than mitogenesis.	Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; George Washington Univ, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; George Washington University	Zhan, X (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [R29 HL52753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Cramer Louise P., 1997, Frontiers in Bioscience (online), V2, pD260; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HUANG SS, 1986, J BIOL CHEM, V261, P9568; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; MACIAG T, 1982, J BIOL CHEM, V257, P5333; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Weed SA, 1998, J CELL SCI, V111, P2433; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	38	74	74	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6700	6706		10.1038/sj.onc.1203050	http://dx.doi.org/10.1038/sj.onc.1203050			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597276				2022-12-28	WOS:000083792000010
J	Russell, A; Hendley, J; Germain, D				Russell, A; Hendley, J; Germain, D			Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilization with D-type cyclins	ONCOGENE			English	Article						D-type cyclins; p21; SCF; Skp2; ubiquitin; proteolysis, breast cancer	HUMAN BREAST-CARCINOMA; SUBCELLULAR-LOCALIZATION; OVEREXPRESSION; PROTEOLYSIS; TRANSITION; G(1); DIFFERENTIATION; P21(WAF1/CIP1); ABUNDANCE; RECEPTORS	Coordinated accumulation of cyclin D1 and D3 is observed in 15% of primary breast cancers and in the breast cancer cell line MCF-7 this simultaneous overexpression is due to a defect in their ubiquitin-mediated proteolysis. The F-box protein Skp2 is a component of an SCF ubiquitin ligase complex and can associate with cyclin D1 and the cdk inhibitor p21 (Zhong-Kang ct al., 1998). We extend this observation and show that cyclin D3 can also associate with Skp2 suggesting that cyclins D1, D3 and p21 may share the same SCF complex. In agreement with this hypothesis we report here that in primary breast cancers and in MCF-7 cells where cyclins D1 and D3 are elevated the level of p21 is also elevated. Further, we demonstrate that the turnover of p21 protein is reduced in MCF-7 cells. We show that p21 is active as a cdk inhibitor in this cell line but that the presence of elevated levels of cyclin D3 titrates p21 away from cyclin D1-cdk4/6 complexes and cdk2 complexes resulting in increased kinase activities. Our results suggest that a defect in the SCF complex may occur in 15-20% of breast cancers and that the resulting coordinated elevation of cyclins D1 and D3 overcomes the inhibition of cell cycle progression by p21. We propose that in the context of cyclins D1 and D3 overexpression, p21 may promote cell cycle progression.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; University of Melbourne	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St-Andrews Pl, Melbourne, Vic 3002, Australia.							ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; GILLETT C, 1994, CANCER RES, V54, P1812; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Rey MJ, 1998, J PATHOL, V184, P265, DOI 10.1002/(SICI)1096-9896(199803)184:3<265::AID-PATH8>3.0.CO;2-8; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; ZHONGKANG Y, 1998, P NATL ACAD SCI USA, V95, P11324	23	25	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6454	6459		10.1038/sj.onc.1203030	http://dx.doi.org/10.1038/sj.onc.1203030			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597247				2022-12-28	WOS:000083709200007
J	Wang, J; Shou, J; Chen, XB				Wang, J; Shou, J; Chen, XB			Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53	ONCOGENE			English	Article						p53; Dickkopf-1; Wnt	GLYCOGEN-SYNTHASE KINASE-3; IN-VIVO; APOPTOTIC RESPONSE; SPEMANN ORGANIZER; MICE DEFICIENT; HEAD INDUCTION; BINDING-SITE; BETA-CATENIN; PROTEIN; DROSOPHILA	Dickkopf-1 (Dkk-1), a secreted glycoprotein, has been found to be necessary and sufficient for inducing amphibian head formation. Interestingly, the mechanism by which Dkk-1 does this is the ability of Dkk-1 to antagonize the Wnt signaling pathway. Wnt, itself a proto-oncoprotein, can promote cell proliferation and transformation when mutated or overexpressed, leading to tumor formation. p53 is a tumor suppressor and loss of p53 function accelerates mammary tumorigenesis by Wnt. In this study, we found that Dkk-1 is induced by wild-type p53 but not mutant p53(R249S). In addition, DNA damage upregulates Dkk-1 in cell lines that harbor an endogenous wild-type p53 gene but not in cell lines that are p53-null or harbor an endogenous mutant p53 gene. We also found a potential p53 responsive element located approximately 2100 nucleotides upstream of the Dkk-1 transcription start site and we show that p53 binds specifically to this element both in vitro and in vivo. Furthermore, we have established several cell lines derived from H1299 lung carcinoma and U118 glioma cells that inducibly express Dkk-1 under a tetracycline-regulated promoter. We found that Dkk-1 has no effect on proliferation of cells that are not transformed by Wnt. Taken together, these results suggest that Dkk-1 may mediate p53 tumor suppression by antagonizing the Wnt signaling pathway.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NCI NIH HHS [CA 76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076069, R01CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pai LM, 1997, DEVELOPMENT, V124, P2255; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THEISEN H, 1994, DEVELOPMENT, V120, P347; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	54	139	153	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1843	1848		10.1038/sj.onc.1203503	http://dx.doi.org/10.1038/sj.onc.1203503			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777218				2022-12-28	WOS:000086292500012
J	Mussman, JG; Horn, HF; Carroll, PE; Okuda, M; Tarapore, P; Donehower, LA; Fukasawa, K				Mussman, JG; Horn, HF; Carroll, PE; Okuda, M; Tarapore, P; Donehower, LA; Fukasawa, K			Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression	ONCOGENE			English	Article						centrosome hyperamplification; cancer; p53; Cdk2; cyclin E	HUMAN CELL-CYCLE; DEPENDENT KINASES; DNA-REPLICATION; PROTEIN-KINASE; GAMMA-TUBULIN; MAMMALIAN FIBROBLASTS; PHASE-TRANSITION; S-PHASE; EXPRESSION; AMPLIFICATION	Centrosome hyperamplification and the consequential mitotic defects contribute to chromosome instability in cancers. Loss or mutational inactivation of p53 has been shown to induce chromosome instability through centrosome hyperamplification. It has recently been found that Cdk2-cyclin E is involved in the initiation of centrosome duplication, and that constitutive activation of Cdk2-cyclin E results in the uncoupling of the centrosome duplication cycle and the DNA replication cycle. Cyclin E overexpression and p53 mutations occur frequently in tumors. Here, we show that cyclin E overexpression and loss of p53 synergistically increase the frequency of centrosome hyperamplification in cultured cells as well as in tumors developed in p53-null, heterozygous, and wildtype mice, Through examination of cells derived from Waf1-null mice, we further found that Waf1, a potent inhibitor of Cdk2-cyclin E and a major target of p53's transactivation function, is involved in coordinating the initiation of centrosome duplication and DNA replication, suggesting that Waf1 may act as a molecular link between p53 and Cdk2-cyclin E in the control of the centrosome duplication cycle.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	University System of Ohio; University of Cincinnati; Baylor College of Medicine	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.		Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Okuda, Masaru/0000-0003-4690-8244; Horn, Henning/0000-0002-5885-8996				Bornens Michel, 1992, P1; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; CARBONAROHALL D, 1993, ONCOGENE, V9, P71; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLOW E, 1998, ANTIBODIES LAB MANUA, P380; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pihan GA, 1998, CANCER RES, V58, P3974; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RITTLING SR, 1992, ONCOGENE, V7, P935; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tanaka T, 1999, CANCER RES, V59, P2041; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tournier Frederic, 1994, V13, P303; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	75	120	131	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2000	19	13					1635	1646		10.1038/sj.onc.1203460	http://dx.doi.org/10.1038/sj.onc.1203460			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763820				2022-12-28	WOS:000086083800003
J	Zenklusen, JC; Hodges, LC; LaCava, M; Green, ED; Conti, CJ				Zenklusen, JC; Hodges, LC; LaCava, M; Green, ED; Conti, CJ			Definitive functional evidence for a tumor suppressor gene on human chromosome 7q31.1 neighboring the Fra7G site	ONCOGENE			English	Article						human chromosome 7; prostate carcinoma; tumor suppressor gene; microcell fusion; tumorigenesis	COMMONLY DELETED REGION; PRIMARY BREAST-CANCER; LONG ARM; SQUAMOUS-CELL; FREQUENT LOSS; HETEROZYGOSITY; HUMAN-CHROMOSOME-7; CARCINOMAS; ADENOCARCINOMA; TUMORIGENICITY	We have previously shown that loss of heterozygosity (LOH) on human chromosome (hchr) 7 at q31.1 is common in a variety of tumors of epithelial origin. Frequent LOH of a specific chromosomal marker is indicative of a closely linked tumor suppressor gene (TSG). However, recent reports have also indicated that such a high frequency of LOH could be due to the presence in this region of the second most common aphidicolin-inducible fragile site in the human genome (Fra7G), To address this controversy, we introduced single copies of hchr7 or hchr12 into a highly aggressive human prostate carcinoma cell line (PC3) by microcell-mediated transfer. The tumorigenicity of six clones of PC3/hchr7 hybrids and three clones of PCRhchr12 hybrids, obtained in four separate fusion experiments, were studied in BALB/c nude mice. All but one of the PC3/hchr7 hybrids increased tumor latency by at least twofold, whereas none of the PC3/hchr12 hybrids delayed tumor onset. No differences in the in vitro growth rate Here observed among any of the cell lines assayed (parental and hybrids) suggesting that the observed tumor suppression was due to factors other than cell cycle regulation. Deletion mapping of the PC3/hchr7 tumors obtained after reversion to the malignant phenotype revealed a common region of loss centred around 7q31.1, supporting the TSG hypothesis. The smallest commonly deleted region was similar to 1.5 Mb in size and flanked by the markers D7S486 and D7S655.	Natl Human Genome Res Inst, Genome Technol Branch, NIH, Bethesda, MD 20982 USA; Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Texas System; UTMD Anderson Cancer Center	Zenklusen, JC (corresponding author), Natl Human Genome Res Inst, Genome Technol Branch, NIH, 49 Convent Dr,Room 2C28, Bethesda, MD 20982 USA.							Achille A, 1996, CANCER RES, V56, P3808; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cunningham JM, 1996, CANCER RES, V56, P4475; EWING CM, 1995, CANCER RES, V55, P4813; Gupta PK, 1997, CANCER RES, V57, P1188; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Huebner K, 1997, BBA-REV CANCER, V1332, pM65, DOI 10.1016/S0304-419X(97)00009-7; Kaighn M E, 1978, Natl Cancer Inst Monogr, P17; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; Matsuda T, 1997, ONCOGENE, V15, P2773, DOI 10.1038/sj.onc.1201461; NEUMAN WL, 1992, BLOOD, V79, P1501; Nishizuka S, 1997, BRIT J CANCER, V76, P1567, DOI 10.1038/bjc.1997.598; OAKAHASHI S, 1995, CANCER RES, V55, P4114; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Sanchez Y, 1996, P NATL ACAD SCI USA, V93, P2551, DOI 10.1073/pnas.93.6.2551; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Zar JH, 1996, BIOSTAT ANAL, P162; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen Jean C., 1999, Neoplasia (New York), V1, P16, DOI 10.1038/sj.neo.7900011	29	35	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1729	1733		10.1038/sj.onc.1203488	http://dx.doi.org/10.1038/sj.onc.1203488			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763831				2022-12-28	WOS:000086083800014
J	Ariumi, Y; Kaida, A; Lin, JY; Hirota, M; Masui, O; Yamaoka, S; Taya, Y; Shimotohno, K				Ariumi, Y; Kaida, A; Lin, JY; Hirota, M; Masui, O; Yamaoka, S; Taya, Y; Shimotohno, K			HTLV-1 Tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration	ONCOGENE			English	Article						p53; Tax; HTLV-1; CBP; CREB; NF-kappa B	T-CELL LEUKEMIA; P53 TUMOR-SUPPRESSOR; VIRUS TYPE-1 TAX; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; ABERRANT EXPRESSION; BINDING PROTEIN; PHOSPHORYLATION; DNA; TRANSACTIVATION	The human T-cell leukemia virus type 1 (HTLV-1) Tax oncoprotein repressed the transcriptional activity of wildtype p53 through its N-terminal trans-activation domain, Although Tax did not directly bind to p53, this repression required the activation of CREB pathway by Tax, In contrast to a recent report by Pise-Masison et al, (1998a,b) we found that the phosphorylation of p53 on Ser 15 is not a major cause of the Tax-mediated inactivation of p53, However, Tax with a mutation in the coactivator CBP-binding site (K88A), which activates NF-kappa B but not the CREB pathway, could not repress the p53 trans-activation function, Moreover, Tax inhibited p53 binding to CBP in vitro and inhibited synergistic activation of transcription by CBP and p53, Thus, Tax is likely to compete with p53 in binding with CBP, thereby repressing its trans-activation function.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo 1138519, Japan; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan	Kyoto University; Tokyo Medical & Dental University (TMDU); National Cancer Center - Japan	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.		Masui, Osamu/AAH-4111-2019; Ariumi, Yasuo/F-5804-2013					Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Akagi T, 1996, ONCOGENE, V12, P1645; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; FUCHS B, 1995, ONCOGENE, V10, P789; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; ORDEN KV, 1999, J BIOL CHEM, V274, P26321; ORDEN KV, 1999, ONCOGENE, V18, P3766; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; REID RL, 1993, ONCOGENE, V8, P3029; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Scolnick DM, 1997, CANCER RES, V57, P3693; SEGAWA K, 1993, ONCOGENE, V8, P543; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAKEUCHI K, 1985, J GEN VIROL, V66, P1825, DOI 10.1099/0022-1317-66-8-1825; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	55	105	107	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1491	1499		10.1038/sj.onc.1203450	http://dx.doi.org/10.1038/sj.onc.1203450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734308				2022-12-28	WOS:000086108100001
J	Gil, J; Alcami, J; Esteban, M				Gil, J; Alcami, J; Esteban, M			Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex	ONCOGENE			English	Article						PKR; NF-kappa B; IKK; dsRNA	DOUBLE-STRANDED-RNA; VACCINIA VIRUS; TRANSCRIPTIONAL ACTIVATION; PROTEOLYTIC DEGRADATION; INDUCED APOPTOSIS; IKK-ALPHA; PHOSPHORYLATION; EXPRESSION; CELLS; REPLICATION	Besides its known role as a translational controlling factor, the double stranded RNA-dependent protein kinase (PKR) is a key transcriptional regulator exerting antiviral and antitumoural activities. We have recently described that induction of NF-kappa B by PKR is involved in apoptosis commitment. To define how PKR mediates NF-kappa B activation by dsRNA, we have used two different approaches, one based on expression of PKR by a vaccinia virus (VV) recombinant and the other based on induction of endogenous PKR by poly I:C (pIC) treatment. We found that NF-kappa B complexes induced by PKR are composed primarily of p50-p65 heterodimers and also of c-rel-p50 heterodimers. As described for other stimuli, following pIC treatment, PKR phosphorylates the NF-kappa B inhibitor I kappa B alpha at serine 32 before degradation. Expression by VV recombinants of IKK1 or IKK2 dominant negative mutants together with PKR showed inhibition of PER-induced NF-kappa B activation, as measured both by gel shift and luciferase reporter assays. Immunoprecipitation analysis revealed that PKR interacts with the IKK complex. Our findings demonstrate that physiological function(s) of PKR involve activation of the I kappa B kinase complex.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain; Hosp 12 Octubre, Ctr Invest, E-28041 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Hospital Universitario 12 de Octubre	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, Madrid 28049, Spain.		Esteban, Mariano/ABG-5375-2020; Alcami, Pepe/T-2242-2018; Gil, Jesus/C-7739-2012	Esteban, Mariano/0000-0003-0846-2827; Alcami, Pepe/0000-0003-0023-7377; Gil, Jesus/0000-0002-4303-6260				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Braganca J, 1998, BIOCHIMIE, V80, P673, DOI 10.1016/S0300-9084(99)80021-2; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Foo SY, 1999, TRENDS GENET, V15, P229; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gil J, 1999, MOL CELL BIOL, V19, P4653; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; LEAMAN DW, 1998, P NATL ACAD SCI USA, V219, P339; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEURS EF, 1993, CELL, V62, P379; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROBINSON RA, 1976, JNCI-J NATL CANCER I, V57, P599, DOI 10.1093/jnci/57.3.599; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Salazar AM, 1996, NEUROSURGERY, V38, P1096, DOI 10.1097/00006123-199606000-00006; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Vazquez MI, 1998, J VIROL, V72, P10126; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; YOSHIDA I, 1992, ACTA VIROL, V36, P347; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	76	110	115	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1369	1378		10.1038/sj.onc.1203448	http://dx.doi.org/10.1038/sj.onc.1203448			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723127	Bronze			2022-12-28	WOS:000085942700001
J	White, JR; Weston, K				White, JR; Weston, K			Myb is required for self-renewal in a model system of early hematopoiesis	ONCOGENE			English	Article						Myb; hematopoiesis; differentiation; apoptosis; bcl-2	C-MYB; STEM-CELLS; B-CELLS; PROGENITOR CELLS; LEUKEMIA-VIRUS; V-MYB; DIFFERENTIATION; EXPRESSION; APOPTOSIS; GENE	In hematopoiesis, self-renewal, proliferation, differentiation and apoptosis represent opposing decisions made by stem cells and progenitor cells, which when dysregulated can result in leukaemia, Here, we have investigated the function of;Myb proteins in regulating these key cellular decisions, using the cell line FDCP-mix A4 as a model of early hematopoiesis, High concentrations of IL-3 in these cells favour self-renewal ol er differentiation and apoptosis, However when endogenous Myb activity was inhibited with an inducible dominant interfering protein, self-renewal was replaced by apoptosis and differentiation. Differentiation was to granulocytes and monocyte/macrophages and was closely associated with a G(1)-S phase block in the cell cycle. As for normal hematopoiesis, cytokine-induced terminal differentiation of FDCP-mix cells is associated with concomitant proliferation prior to its completion, However, when Myb activity was inhibited during this process, proliferation and survival were both reduced, resulting in a much lower yield of mature cells. These results indicate multiple cellular roles of Myb proteins during normal hematopoiesis.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weston, K (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England.							Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FORD AM, 1992, BLOOD, V79, P1962, DOI 10.1182/blood.V79.8.1962.bloodjournal7981962; FRAMPTON J, 1995, EMBO J, V14, P2866, DOI 10.1002/j.1460-2075.1995.tb07286.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HATHCOCK KS, 1992, J IMMUNOL, V149, P2286; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HEYWORTH CM, 1995, BRIT J HAEMATOL, V91, P15, DOI 10.1111/j.1365-2141.1995.tb05238.x; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MCMAHON J, 1988, ONCOGENE, V3, P717; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA I, 1995, BLOOD, V85, P1246, DOI 10.1182/blood.V85.5.1246.bloodjournal8551246; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Necas E, 1998, STEM CELLS, V16, P107; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TESTA NG, 1993, HAEMOPOIESIS PRACTIC, P267; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	41	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1196	1205		10.1038/sj.onc.1203394	http://dx.doi.org/10.1038/sj.onc.1203394			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713708				2022-12-28	WOS:000085567800010
J	Bouvard, V; Zaitchouk, T; Vacher, M; Duthu, A; Canivet, M; Choisy-Rossi, C; Nieruchalski, M; May, E				Bouvard, V; Zaitchouk, T; Vacher, M; Duthu, A; Canivet, M; Choisy-Rossi, C; Nieruchalski, M; May, E			Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice	ONCOGENE			English	Article						p53-target genes; tissue and cell-specific expression; gamma irradiation	WILD-TYPE P53; IN-VIVO; INDUCED APOPTOSIS; DNA-DAMAGE; TRANSGENIC MICE; BINDING-SITE; MUTANT P53; PROTEIN; ACTIVATION; RADIATION	The mechanisms by which the p53 tumour suppressor protein would, in vivo, co-ordinate the adaptive response to genotoxic stress is poorly understood. p53 has been shown to transactivate several genes that could be involved in two main cellular responses, growth arrest and apoptosis. To get further insight into the tissue-specific regulation of p53 transcriptional activity, we performed an extensive study looking at the expression of four well characterized p53-responsive genes, before and after gamma-irradiation in p53 wild-type (p53 +/+) and p53-deficient (p53 -/-) mice. The waf1, bax, fas and mdm2 genes were chosen for their different potential roles in the cellular response to stress. Our data demonstrate the strict p53-dependence of mRNA up-regulation for bax, fas and mdm2 in irradiated tissues and confirm such findings for wafl. They further highlight complex levels of regulatory mechanisms that could lead, in vivo, to selective transcriptional activation of genes by p53. In addition, our results provide arguments for the involvement of p53 in the basal mRNA expression of the four genes in some organs. Finally, in situ expression of Bax and p21Waf-1 protein suggests, at least in lymphoid organs, a direct correlation between selective p53-target gene expression and particular response of a cell to ionising radiation.	CEA, Ctr Etud Nucl, DSV,DRR,Lab Cancerogenese Mol, CNRS,UMR 217, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS)	May, E (corresponding author), CEA, Ctr Etud Nucl, DSV,DRR,Lab Cancerogenese Mol, CNRS,UMR 217, F-92265 Fontenay Aux Roses, France.							Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JACKSON P, 1993, ONCOGENE, V8, P589; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kitada S, 1996, ONCOGENE, V12, P187; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mayo LD, 1997, CANCER RES, V57, P5013; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; MUNSCH D, 2000, IN PRESS J BIOL CHEM, V275; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Prives C, 1999, J PATHOL, V187, P112; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHICH SY, 1997, CELL, V91, P325; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; TAMURA T, 1995, ONCOGENE, V11, P1939; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WALDMAN T, 1995, CANCER RES, V55, P5187; Walker PR, 1997, J IMMUNOL, V158, P4521; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	74	164	170	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					649	660		10.1038/sj.onc.1203366	http://dx.doi.org/10.1038/sj.onc.1203366			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698510				2022-12-28	WOS:000085192000007
J	Nikolopoulos, SN; Spengler, BA; Kisselbach, K; Evans, AE; Biedler, JL; Ross, RA				Nikolopoulos, SN; Spengler, BA; Kisselbach, K; Evans, AE; Biedler, JL; Ross, RA			The human non-muscle alpha-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells	ONCOGENE			English	Article						alpha-actinin; chromosome #4; tumor suppression; human neuroblastoma	NEURO-BLASTOMA CELLS; RAS-TRANSFORMED FIBROBLASTS; SIGNALING PATHWAYS; CYTOPLASMIC DOMAIN; BETA-CATENIN; EXPRESSION; ADHESION; CDNA; CYTOSKELETAL; GROWTH	alpha-Actinins are actin-binding proteins important in organization of the cytoskeleton and in cell adhesion. We have cloned and characterized a cDNA from human neuroblastoma cell variants which encodes the second non-muscle alpha-actinin isoform designated ACTN4 (actinin-4), mRNA encoded by the ACTN4 gene, mapped to chromosome 4, is abundant in non-tumorigenic, substrate-adherent human neuroblastoma cell variants but absent or only weakly expressed in malignant, poorly substrate-adherent neuroblasts, It is also present in many adherent tumor cell lines of diverse tissue origins. Cell lines typically co-express ACTN4 and ACTN1, a second non-muscle alpha-actinin gene. Expression is correlated with substrate adhesivity, Analysis of deduced amino acid sequences suggests that the two isoforms may differ in function and in regulation by calcium. Moreover, ACTN4 exhibits tumor suppressor activity. Stable clones containing increased levels of alpha-actinin, isolated from highly malignant neuroblastoma stem cells [BE(2)-C] after transfection with a full-length ACTN4 cDNA, show decreased anchorage-independent growth ability, loss of tumorigenicity in nude mice, and decreased expression of the N-myc proto-oncogene.	Fordham Univ, Dept Biol Sci, Neurobiol Lab, Bronx, NY 10458 USA; Childrens Hosp Philadelphia, Div Oncol, Abramson Pediat Res Ctr, Philadelphia, PA 19104 USA	Fordham University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, Neurobiol Lab, 441 E Fordham Road, Bronx, NY 10458 USA.							Akamatsu H, 1996, CANCER RES, V56, P4541; BARON MD, 1987, J BIOL CHEM, V262, P2558; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; BURN P, 1985, NATURE, V314, P469, DOI 10.1038/314469a0; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Chan YM, 1998, BIOCHEM BIOPH RES CO, V248, P134, DOI 10.1006/bbrc.1998.8920; CICCARONE V, 1989, CANCER RES, V49, P219; Dosaka-Akita H, 1998, CANCER RES, V58, P322; EBASHI S, 1964, NATURE, V203, P645, DOI 10.1038/203645a0; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Han X, 1997, BIOCHEMISTRY-US, V36, P10364, DOI 10.1021/bi962929v; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; IMAMURA M, 1994, EUR J BIOCHEM, V223, P395, DOI 10.1111/j.1432-1033.1994.tb19006.x; IMAMURA M, 1992, J BIOL CHEM, V267, P25927; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kretsinger R H, 1980, Ann N Y Acad Sci, V356, P14, DOI 10.1111/j.1749-6632.1980.tb29594.x; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; Nikolopoulos S. N., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P510; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHULTHEISS T, 1992, P NATL ACAD SCI USA, V89, P9282, DOI 10.1073/pnas.89.19.9282; Spengler BA, 1997, ONCOL RES, V9, P467; SPENGLER BA, 1994, P AM ASSOC CANC RES, V35, P302; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; TANAKA M, 1995, CANCER RES, V55, P3228; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	59	63	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					380	386		10.1038/sj.onc.1203310	http://dx.doi.org/10.1038/sj.onc.1203310			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656685				2022-12-28	WOS:000084873700008
J	Morimoto, AM; Tomlinson, MG; Nakatani, K; Bolen, JB; Roth, RA; Herbst, R				Morimoto, AM; Tomlinson, MG; Nakatani, K; Bolen, JB; Roth, RA; Herbst, R			The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase-activity	ONCOGENE			English	Article						MMAC1; PTEN; TEP1; ILK; PLC	PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GLIOBLASTOMA CELLS; GERMLINE MUTATIONS; PTEN; GENE; GROWTH; GAMMA; DOMAIN; ACTIVATION	Loss of the tumor suppressor MMAC1 has been shown to be involved in breast, prostate and brain cancer, Consistent with its identification as a tumor suppressor, expression of MMAC1 has been demonstrated to reduce cell proliferation, tumorigenicity, and motility as well as affect cell-cell and cell-matrix interactions of malignant human glioma cells. Subsequently, MMAC1 was shown to have lipid phosphatase activity towards PIP, and protein phosphatase activity against focal adhesion kinase (FAK), The lipid phosphatase activity of MMAC1 results in decreased activation of the PIP3- dependent, anti-apoptotic kinase, AKT. It is thought that this inhibition of AKT culminates with reduced glioma cell proliferation, In contrast, MMAC1's effects on cell motility, cell-cell and cell-matrix interactions are thought to be due to its protein phosphatase activity towards FAK, However, recent studies suggest that the lipid phosphatase activity of MMAC1 correlates with its ability to be a tumor suppressor. The high rate of mutation of MMAC1 in late stage metastatic tumors suggests that effects of MMAC1 on motility, cell-cell and cell-matrix interactions are due to its tumor suppressor activity, Therefore the Lipid phosplratase activity of MMAC1 may affect PIP, dependent signaling pathways and result in reduced motility and altered cell-cell and cell-matrix interactions. We demonstrate here that expression of MMAC1 in human glioma cells reduced intracellular levels of inositol trisphosphate and inhibited extracellular Ca2+ influx, suggesting that MMAC1 affects the phospholipase C signaling pathway, In addition, we show that MMAC1 expression inhibits integrin-linked kinase activity. Furthermore, we show that these effects require the catalytic activity of MMAC1. Our data thus provide a link of MMAC1 to PIP, dependent signaling pathways that regulate cell-matrix and cell-cell interactions as well as motility. Lastly, we demonstrate that AKT3, an isoform of AKT highly expressed in the brain, is also a target for MMAC1 repression. These data suggest an important role for AKT3 in glioblastoma multiforme, We therefore propose that repression of multiple PIP, dependent signaling pathways may be required for MMAC1 to act as a tumor suppressor.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signalling, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Hoechst Marion Roussel, Dept Oncol, Bridgewater, NJ 08807 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University	Herbst, R (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signalling, 901 Calif Ave, Palo Alto, CA 94304 USA.			Tomlinson, Michael/0000-0002-1189-0091				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Cheney IW, 1998, CANCER RES, V58, P2331; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki M, 1998, J VESTIBUL RES-EQUIL, V8, P169, DOI 10.1016/S0957-4271(97)00003-7; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Turner T, 1997, CLIN CANCER RES, V3, P2275; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	38	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					200	209		10.1038/sj.onc.1203288	http://dx.doi.org/10.1038/sj.onc.1203288			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644997				2022-12-28	WOS:000084844400004
J	Fueyo, J; Gomez-Manzano, C; Alemany, R; Lee, PSY; McDonnell, TJ; Mitlianga, P; Shi, YX; Levin, VA; Yung, WKA; Kyritsis, AP				Fueyo, J; Gomez-Manzano, C; Alemany, R; Lee, PSY; McDonnell, TJ; Mitlianga, P; Shi, YX; Levin, VA; Yung, WKA; Kyritsis, AP			A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo	ONCOGENE			English	Article						oncolytic virus; gene therapy; Rb; E2F; E1A	GENE-TRANSFER; CANCER-CELLS; BRAIN-TUMORS; P53 GENE; IN-VIVO; GROWTH; TRANSFORMATION; REPLICATION; APOPTOSIS; PROTEINS	Effective anti cancer strategies necessitate the use of agents that target tumor cells rather than normal tissues, In this study, we constructed a tumor-selective adenovirus, Delta 24, that carries a 24-bp deletion in the E1A region responsible for binding Rb protein. Immunoprecipitation analyses verified that this deletion rendered Delta 24 unable to bind the Rb protein. However, titration experiments in 293 cells demonstrated that the Delta 24 adenovirus could replicate in and Iyse cancer cells with great efficiency. Lysis of most human glioma cells was observed within 10-14 days after infection with Delta 24 at 10 PFU/cell. In vivo, a single dose of the Delta 24 virus induced a 66.3% inhibition (P<0.005) and multiple injections, an 83.8% inhibition (P<0.01) of tumor growth in nude mice. However, normal fibroblasts or cancer cells with restored Rb activity were resistant to the Delta 24 adenovirus. These results suggest that the E1A-mutant Delta 24 adenovirus may be clinically and therapeutically useful against gliomas and possibly other cancers with disrupted Rb pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Box 100,1515 Holcombe Blvd, Houston, TX 77030 USA.		Mitlianga, Paraskevi/AAU-1541-2020	Mitlianga, Paraskevi/0000-0003-3145-5596; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335				Alemany R, 1997, J VIROL METHODS, V68, P147, DOI 10.1016/S0166-0934(97)00129-8; Alemany R, 1996, CANCER GENE THER, V3, P296; Andreansky S, 1997, CANCER RES, V57, P1502; ARAP W, 1995, CANCER RES, V55, P1351; Attia M, 1996, CANCER RES, V126, P1787; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Chase M, 1998, NAT BIOTECHNOL, V16, P444, DOI 10.1038/nbt0598-444; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; Costello JF, 1996, CANCER RES, V56, P2405; Costello JF, 1997, CANCER RES, V57, P1250; DYSON N, 1992, CANCER SURV, V12, P161; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Fueyo J, 1998, NEUROLOGY, V50, P1307, DOI 10.1212/WNL.50.5.1307; Fueyo J, 1996, ONCOGENE, V12, P103; Fueyo J, 1996, ONCOGENE, V13, P1615; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Furnari FB, 1995, CANCER SURV, V25, P233; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; GomezManzano C, 1996, CANCER RES, V56, P694; GOMEZMANZANO C, 1998, GENE TRANSFER THERAP, P201; HAMER AJ, 1993, J PEDIATR ORTHOP B, V2, P159, DOI 10.1097/01202412-199302020-00012; Hay JG, 1999, HUM GENE THER, V10, P579, DOI 10.1089/10430349950018652; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JEN J, 1994, CANCER RES, V54, P6353; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; Kyritsis AP, 1996, ONCOGENE, V12, P63; Kyritsis AP, 1996, MOL CARCINOGEN, V15, P1; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; NEVINS JR, 1992, SCIENCE, V258, P424; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; Ridgway PJ, 1997, VIROLOGY, V237, P404, DOI 10.1006/viro.1997.8782; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Ueki K, 1996, CANCER RES, V56, P150; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988	48	593	648	3	45	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					2	12		10.1038/sj.onc.1203251	http://dx.doi.org/10.1038/sj.onc.1203251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644974				2022-12-28	WOS:000084844300001
J	Dasika, GK; Lin, SCJ; Zhao, S; Sung, P; Tomkinson, A; Lee, EYHP				Dasika, GK; Lin, SCJ; Zhao, S; Sung, P; Tomkinson, A; Lee, EYHP			DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis	ONCOGENE			English	Review						checkpoint; homologous recombination; non-homologous end joining; knockout; tumor suppressor genes	REPLICATION PROTEIN-A; ATM-DEFICIENT MICE; SEVERE COMBINED IMMUNODEFICIENCY; EARLY EMBRYONIC LETHALITY; TUMOR-SUPPRESSOR GENE; V(D)J RECOMBINATION; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; SACCHAROMYCES-CEREVISIAE; LIGASE-IV	Several newly identified tumor suppressor genes including ATM, NBS1, BRCA1 and BRCA2 are involved in DNA double-strand break repair (DSBR) and DNA damage-induced:checkpoint activation. Many of the gene products involved in checkpoint control and DSBR have been studied-in great detail in yeast. In addition to evolutionarily conserved proteins such as Chk1 and Chk2, studies in mammalian cells have identified novel proteins such as p53 in executing checkpoint control. DSBR:proteins including Mre11, Rad50, Rad51, Rad54, and Ku are present in yeast and in mammals. Many of the tumor suppressor gene products interact with these repair proteins as well as checkpoint regulators, thus providing a biochemical explanation for the pleiotropic phenotypes of mutant cells. This review focuses on the proteins mediating G1/S, S, and G2/M checkpoint control in mammalian cells. In addition, mammalian DSBR proteins and their activities are discussed. An intricate network among DNA damage signal transducers, cell cycle regulators and the DSBR pathways is illustrated. Mouse knockout models for genes involved in these processes have provided valuable insights into their function, establishing genomic instability as a major contributing factor in tumorigenesis.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Lee, EYHP (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA.				NINDS NIH HHS [1R01NS378381] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 1999, CANCER RES, V59, P2023; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CARROLL D, 1998, DNA DAMAGE REPAIR; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Eilam R, 1998, P NATL ACAD SCI USA, V95, P12653, DOI 10.1073/pnas.95.21.12653; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Friedman LS, 1998, CANCER RES, V58, P1338; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Gong JG, 1999, NATURE, V399, P806; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Grenon M, 1999, MOL GEN GENET, V260, P522, DOI 10.1007/s004380050925; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Han JO, 1997, MOL CELL BIOL, V17, P2226, DOI 10.1128/MCB.17.4.2226; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; IVANOV EL, 1992, GENETICS, V132, P651; JEGGO PA, 1998, DNA DAMAGE REPAIR; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1998, CELLULAR RESPONSES D; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Labhart P, 1999, MOL CELL BIOL, V19, P2585; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Larner JM, 1997, CANCER SURV, V29, P25; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lavin Martin F., 1999, Cancer Research, V59, P3845; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Liao MJ, 1999, GENE DEV, V13, P1246, DOI 10.1101/gad.13.10.1246; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIN WC, 1995, IMMUNOL TODAY, V16, P279, DOI 10.1016/0167-5699(95)80182-0; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Liu YL, 1999, CURR BIOL, V9, P975, DOI 10.1016/S0960-9822(99)80427-8; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MATEOS S, 1994, MUTAT RES-DNA REPAIR, V315, P181, DOI 10.1016/0921-8777(94)90017-5; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MEYN MS, 1995, CANCER RES, V55, P5991; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Moreau S, 1999, MOL CELL BIOL, V19, P556; Morgan SE, 1997, CANCER RES, V57, P3386; Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988; Nacht M, 1998, CELL GROWTH DIFFER, V9, P131; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; NICKOLOFF JA, 1998, DNA DAMAGE REPAIR; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; PETUKHOVA G, 1999, DNA DAMAGE REPAIR; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; RATHMELL WK, 1998, DNA DAMAGE REPAIR; REED SI, 1994, J CELL SCI, P69; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1994, J CELL SCI, P57; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shimada A, 1999, CANCER RES, V59, P2781; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; SHULMAN MJ, 1995, EMBO J, V14, P4102, DOI 10.1002/j.1460-2075.1995.tb00082.x; Siede W, 1996, GENETICS, V142, P91; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Verkade HM, 1998, MOL GEN GENET, V260, P426, DOI 10.1007/s004380050913; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WEINERT T, 1989, J CELL SCI, P145; WEINERT TA, 1993, GENETICS, V134, P63; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wuerffel RA, 1997, J IMMUNOL, V159, P4139; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Yuan SSF, 1999, CANCER RES, V59, P3547; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	202	346	362	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7883	7899		10.1038/sj.onc.1203283	http://dx.doi.org/10.1038/sj.onc.1203283			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630641				2022-12-28	WOS:000084405900005
J	Panagopoulos, I; Mencinger, M; Dietrich, CU; Bjerkehagen, B; Saeter, G; Mertens, F; Mandahl, N; Heim, S				Panagopoulos, I; Mencinger, M; Dietrich, CU; Bjerkehagen, B; Saeter, G; Mertens, F; Mandahl, N; Heim, S			Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11)	ONCOGENE			English	Article						chondrosarcoma; gene fusion; translocation genetics; karyotyping	RNA-BINDING PROTEIN; EWINGS-SARCOMA TRANSLOCATION; ORPHAN NUCLEAR RECEPTOR; CHROMOSOME-TRANSLOCATION; EWS GENE; MYELOID-LEUKEMIA; FAMILY; TUMORS; CHOP; ERG	Although most extraskeletal myxoid chondrosarcomas (EMC) are cytogenetically characterized by the translocation t(9;22)(q22;q12), another subset has recently been identified carrying a t(9;17)(q22;q11). Whereas the t(9;22) is known to result in fusion of the CHN (TEC) gene from 9q22 with the EWS gene from 22q12, creating a chimeric EWS/CHN, the genes involved in the t(9;17) of EMC are unknown. We examined two EMC with t(9;17)(q22;q11) and found that the CHN gene was recombined with the RBP56 gene from 17q11 to generate a chimeric RBP56/CHN, RBP56 has not previously been shown to be involved in tumorigenesis but it encodes a putative RNA-binding protein similar to the EWS and FUS (TLS) proteins known to play a pathogenetic role in several sarcomas, The presence of the RBP56/CHN chimeric gene in EMC with t(9;17)(q22;q11) shows that the N-terminal parts of EWS and RBP56 have similar oncogenic potential making them pathogenetically equivalent in oncoproteins arising from fusions with certain transcription factors.	Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Genet, N-0310 Oslo, Norway; Inst Canc Res, N-0310 Oslo, Norway	Lund University; Skane University Hospital; University of Oslo; University of Oslo; University of Oslo	Panagopoulos, I (corresponding author), Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.		Mencinger, Marina/AAC-9468-2022	Mencinger, Marina/0000-0002-4349-1511; Mertens, Fredrik/0000-0002-6278-5232; Panagopoulos, Ioannis/0000-0003-2159-5341				Antonescu CR, 1998, CANCER, V83, P1504, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1504::AID-CNCR5>3.0.CO;2-B; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BJERKEHAGEN B, 1999, IN PRESS VIRCHOWS AR; Brody RI, 1997, AM J PATHOL, V150, P1049; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ELIZALDE JM, 1993, TUMORI, V79, P283, DOI 10.1177/030089169307900413; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KLIJANIENKO J, 1990, HISTOPATHOLOGY, V16, P196; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LIUSHINDO M, 1989, OTOLARYNG HEAD NECK, V101, P485, DOI 10.1177/019459988910100414; MITELMAN F, 1998, CATALOG CHROMOSOME A; Morohoshi F, 1996, GENOMICS, V38, P51, DOI 10.1006/geno.1996.0591; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STEFFEN CM, 1992, J SURG ONCOL, V50, P58, DOI 10.1002/jso.2930500116; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	30	60	62	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7594	7598		10.1038/sj.onc.1203155	http://dx.doi.org/10.1038/sj.onc.1203155			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602519				2022-12-28	WOS:000084119600021
J	Kang, SH; Bang, YJ; Im, YH; Yang, HK; Lee, DA; Lee, HY; Lee, HS; Kim, NK; Kim, SJ				Kang, SH; Bang, YJ; Im, YH; Yang, HK; Lee, DA; Lee, HY; Lee, HS; Kim, NK; Kim, SJ			Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer	ONCOGENE			English	Article						transforming growth factor-beta; CpG methylation; cancer; receptor	TUMOR-SUPPRESSOR GENE; COLON-CARCINOMA CELLS; MICROSATELLITE INSTABILITY; CPG ISLAND; COLORECTAL-CANCER; MISMATCH REPAIR; EXPRESSION; ACTIVATION; MALIGNANCY; PROMOTER	The transforming growth factor-beta (TGF-beta) signaling pathway subserves an essential tumor suppressor function in various cell types. A heteromeric complex composed of TGF-beta type I (RI) and type II (RII) receptors is required for TGF-beta signaling. We have identified a subset of human gastric cancer cell lines which are insensitive to TGF-beta and which express a low level of TGF-beta type I receptor mRNA relative to a gastric cancer cell line which is highly responsive to TGF-beta. Using these cells, we show that hypermethylation of a CpG island in the 5' region of the TGF-beta RI gene provides another potentially important mechanism of escape from negative growth control by TGF-beta, This hypermethylation was found in four of five human gastric cancer cell lines and five out of 40 (12.5%) primary tumors examined, In human gastric cancer cell lines, treatment with the demethylating agent, 5-aza-2'-deoxycytidine, resulted in increased expression of the TGF-beta RI gene, but not the RII gene, Transient transfection of an RI expression vector into the TGF-beta resistant SNU-601 cell line restores TGF-beta responsiveness. These findings suggest that one of the mechanisms of escape from autocrine or paracrine growth control by TGF-beta during carcinogenesis could involve aberrant methylation of CpG islands in the 5' region of the TGF-beta RI gene.	Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kim, SJ (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea.		Bang, Yung Jue/J-2759-2012; Yang, Han-Kwang/J-2767-2012	Bang, Yung Jue/0000-0001-6000-4597; 				BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; Chang J, 1997, CANCER RES, V57, P2856; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3892; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jones PA, 1996, CANCER RES, V56, P2463; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK K, 1994, P NATL ACAD SCI USA, V81, P8772; PARSONS R, 1995, CANCER RES, V55, P5548; Reiss M, 1997, ONCOL RES, V9, P447; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SAKAI T, 1991, AM J HUM GENET, V48, P880; SUARDET L, 1992, CANCER RES, V52, P3705; SUN LZ, 1994, J BIOL CHEM, V269, P26449; WAKEFIELD LM, 1991, TUMOR SUPPRESSOR GEN, P217; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	41	103	114	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7280	7286		10.1038/sj.onc.1203146	http://dx.doi.org/10.1038/sj.onc.1203146			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602482				2022-12-28	WOS:000084119400012
J	Lopez, P; Vidal, F; Rassoulzadegan, M; Cuzin, F				Lopez, P; Vidal, F; Rassoulzadegan, M; Cuzin, F			A role of inhibin as a tumor suppressor in Sertoli cells: down-regulation upon aging and repression by a viral oncogene	ONCOGENE			English	Article						testis; gonadal tumor; inhibin-activin; polyoma virus; T antigen; gene regulation	LARGE T-ANTIGEN; RECOMBINANT HUMAN INHIBIN; ALPHA-INHIBIN; BINDING-SITE; PROTEIN; GENE; MICE; DNA; EXPRESSION; ACTIVIN	Inhibin, a member of the TGF-beta superfamily, is synthesized in the testis by Sertoli cells and exerts an endocrine regulatory function on pituitary hormone synthesis, A distinct local function has been proposed, negatively controlling cellular growth in the testis (tumor suppressor activity). A critical test for the identification of a tumor suppressor is the reversal of transformed growth properties upon re-expression of the gene in tumor-derived cell lines. Sertoli cell-derived tumoral lines were previously established from tumors that develop in elderly transgenic males which express in the testis the large T antigen of polyoma virus. Both the tumors and the cells in culture exhibited reduced levels of the inhibin alpha subunit mRNA, Stable transfectants were generated, in which this subunit was expressed from a heterologous promoter. All of them exhibited a strict inhibition of growth at confluency, On the other hand, in addition to an aging-related decrease in inhibin synthesis, the alpha subunit gene was down regulated in vivo in cells expressing the viral protein. The conjunction of these two factors accounts for the age-related occurrence of testicular cancers in the transgenic model, again pointing to inhibin as a potent cell growth regulator in the seminiferous epithelium.	Univ Nice, INSERM, U470, F-06108 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Cuzin, F (corresponding author), Univ Nice, INSERM, U470, F-06108 Nice, France.		Rassoulzadegan, Minoo/O-7939-2016	Lopez, Pascal/0000-0002-3936-3058				BARUT B, 1993, J CLIN INVEST, V92, P2346, DOI 10.1172/JCI116839; BOITANI C, 1995, ENDOCRINOLOGY, V136, P5438, DOI 10.1210/en.136.12.5438; CHEN CLC, 1993, ENDOCRINOLOGY, V132, P4, DOI 10.1210/en.132.1.4; CHEN CLC, 1992, MOL BIOL REPROD SERO, P97; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWIE A, 1984, J VIROL, V52, P750, DOI 10.1128/JVI.52.3.750-760.1984; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GAUDRAY P, 1981, NUCLEIC ACIDS RES, V9, P5697, DOI 10.1093/nar/9.21.5697; Grandjean V, 1997, BIOL REPROD, V57, P1115, DOI 10.1095/biolreprod57.5.1115; Grimaldi P, 1996, MOL CELL ENDOCRINOL, V117, P167, DOI 10.1016/0303-7207(95)03744-6; GUERRAGARCIA R, 1989, ARCH ANDROLOGY, V22, P35, DOI 10.3109/01485018908986748; HAKOVIRTA H, 1993, ENDOCRINOLOGY, V133, P1664, DOI 10.1210/en.133.4.1664; HANGOC G, 1992, EXP HEMATOL, V20, P1243; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JAKUBOWIAK A, 1991, MOL CELL ENDOCRINOL, V82, P265, DOI 10.1016/0303-7207(91)90040-Y; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; PAL D, 1991, BIOL REPROD, V45, P869, DOI 10.1095/biolreprod45.6.869; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; PECH N, 1993, BLOOD, V82, P1502; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; RASSOULZADEGAN M, 1981, VIROLOGY, V114, P489, DOI 10.1016/0042-6822(81)90228-2; RICH KA, 1983, ENDOCRINOLOGY, V113, P2284, DOI 10.1210/endo-113-6-2284; SKINNER MK, 1993, SERTOLI CELL, P237; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; VANDISSELEMILIANI FMF, 1989, ENDOCRINOLOGY, V125, P1899, DOI 10.1210/endo-125-4-1898; Vincent S, 1998, DEVELOPMENT, V125, P4585; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	33	11	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7303	7309		10.1038/sj.onc.1203143	http://dx.doi.org/10.1038/sj.onc.1203143			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602485				2022-12-28	WOS:000084119400015
J	Topcu, Z; Mack, DL; Hromas, RA; Borden, KLB				Topcu, Z; Mack, DL; Hromas, RA; Borden, KLB			The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control	ONCOGENE			English	Article						PML; PRH; HEX; APL; Z	ALPHA FUSION PROTEIN; HOMEOBOX GENE PRH; NUCLEAR-BODIES; SACCHAROMYCES-CEREVISIAE; ONCOPROTEIN PML; BINDING-PROTEIN; FINGER DOMAIN; CELLS; EXPRESSION; MOUSE	Acute promyelocytic leukemia (APL) is characterized by a block in myeloid cell differentiation. As a result of a chromosomal translocation in these patients, the promyelocytic leukemia protein PML is disrupted as are the nuclear bodies it forms. Disruption of PML and PML nuclear bodies in APL is linked to a loss of growth control and subsequent leukemogenesis, PML contains a zinc-binding domain known as the RING which is required for formation of these bodies. Using yeast 2-hybrid techniques, we found that PML and a related RING protein, Z, bind the proline rich homeodomain protein (PRH) through their RING domains, Previous reports indicate that PRH functions in hematopoiesis and may act as a transcriptional repressor. Our data indicate that PML and Z both bind the repressor domain of PRH and are the first protein partners reported for PRH, We observe that PRH has a punctate pattern in both the nucleus and cytoplasm of chronic myelogenous leukemia K562 cells and in the APL cell line, NB4. Immunoprecipitation and co-localization studies indicate that PML and PRH interact in both cell lines. The effect on cell growth by PML and the hematopoietic actions of PRH raises the possibility that the interaction between PML and PRH represents a link between growth control and hematopoiesis.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Indiana Canc Res Inst, Indianapolis, IN 46202 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Borden, KLB (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1218, New York, NY 10029 USA.		Mack, David/AAE-5437-2022		NATIONAL CANCER INSTITUTE [R01CA080728] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80728-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Borden KLB, 1998, J VIROL, V72, P3819, DOI 10.1128/JVI.72.5.3819-3826.1998; Carlile GW, 1998, BIOCHEM J, V335, P691, DOI 10.1042/bj3350691; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; GRIGNANI F, 1995, CANCER RES, V55, P440; Guthrie C, 1991, GUIDE YEAST GENETICS; Harlow E., 1988, ANTIBODIES LAB MANUA; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; Mayfield S, 1996, CHEM BIOL, V3, P415, DOI 10.1016/S1074-5521(96)90088-5; MELNICK A, 1999, IN PRESS BLOOD; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Miller J.H., 1972, EXPT MOL GENETICS; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Petter R, 1997, INFECT IMMUN, V65, P4909, DOI 10.1128/IAI.65.12.4909-4917.1997; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; ROGAIA D, 1995, LEUKEMIA, V9, P1467; SALVATO MS, 1996, ARENAVIRUSES, P629; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; STUURMAN N, 1992, J CELL SCI, V101, P773; TABILIO A, 1983, CANCER RES, V43, P4569; Tanaka T, 1999, BIOCHEM J, V339, P111, DOI 10.1042/0264-6021:3390111; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; TERRIS B, 1995, CANCER RES, V55, P1590; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073	49	56	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7091	7100		10.1038/sj.onc.1203201	http://dx.doi.org/10.1038/sj.onc.1203201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597310				2022-12-28	WOS:000083901900016
J	Suzuki, S; Higuchi, M; Proske, RJ; Oridate, N; Hong, WK; Lotan, R				Suzuki, S; Higuchi, M; Proske, RJ; Oridate, N; Hong, WK; Lotan, R			Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells	ONCOGENE			English	Article						reactive oxygen species; 4HPR; apoptosis; mitochondrial respiratory chain; caspase-3; cytochrome c	TUMOR-NECROSIS-FACTOR; TRANS-RETINOIC ACID; RESPIRATORY-CHAIN; ELECTRON-TRANSPORT; FREE-RADICALS; PERMEABILITY TRANSITION; SUPEROXIDE FORMATION; HEART-MITOCHONDRIA; MEDIATED APOPTOSIS; COMPLEX-I	N-(4-Hydroxyphenyl)retinamide (4HPR) is currently used in cancer prevention and therapy trials. It is thought that its effects result from induction of apoptosis, 4HPR-induced apoptosis in human cervical carcinoma C33A cells involves enhanced generation of reactive oxygen species (ROS). In this study we explored the mechanism by which 4HPR increases ROS and induces apoptosis in these cells. 4HPR induced cytochrome c release from mitochondria to cytoplasm, activated caspase-3, and caused a membrane permeability transition (MPT). All these 4HPR's effects, as web as the induction of apoptosis, were inhibited by antioxidants, which decrease ROS. Thenoyltrifluoroacetone, a mitochondrial respiratory chain (MRC) complex II inhibitor, and carbonylcyanide m-chlorophenyl hydrazone, which uncouples electron transfer and ATP synthesis and inhibits ROS generation by MRC, inhibited 4HPR-induced ROS generation very effectively. Rotenone, an MRC complex I inhibitor was less effective and azide, an MRC complex IV inhibitor, exhibited a marginal effect, In contrast, antimycin A, an MRC complex III inhibitor, enhanced 4HPR-induced ROS generation. These findings suggest that 4HPR enhances ROS generation by affecting a target between complex II and complex III, presumably coenzyme Q. This effect is followed by release of cytochrome c, increased caspase-3 activity, induction of MPT and eventual DNA fragmentation and cell death.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Suzuki, Seigo/G-5378-2012; Oridate, Nobuhiko/ABC-4116-2020; Oridate, Nobuhiko/G-5365-2012	Oridate, Nobuhiko/0000-0002-6968-3028; 	NCI NIH HHS [P01 CA52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; BEYER RE, 1992, BIOCHEM CELL BIOL, V70, P390, DOI 10.1139/o92-061; BEZKOROVAINY A, 1996, METABOLISM OXIDATIVE; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CARACENI P, 1995, BBA-MOL CELL RES, V1268, P249, DOI 10.1016/0167-4889(95)00077-6; DAWSON TL, 1993, AM J PHYSIOL, V264, P961; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; FEDYK ER, 1994, INT J IMMUNOPHARMACO, V16, P533, DOI 10.1016/0192-0561(94)90105-8; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOODMAN Y, 1994, BRAIN RES, V654, P171, DOI 10.1016/0006-8993(94)91586-5; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; Higuchi M, 1996, J IMMUNOL, V157, P297; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HU HP, 1992, BIOCHIM BIOPHYS ACTA, V1112, P161, DOI 10.1016/0005-2736(92)90387-2; HUNT NH, 1992, BIOCHIM BIOPHYS ACTA, V1133, P261, DOI 10.1016/0167-4889(92)90046-E; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kruidering M, 1997, J PHARMACOL EXP THER, V280, P638; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; NOHL H, 1987, FEBS LETT, V214, P269, DOI 10.1016/0014-5793(87)80068-6; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; Oishi K, 1997, SCAND J IMMUNOL, V45, P21, DOI 10.1046/j.1365-3083.1997.d01-365.x; Oridate N, 1996, CLIN CANCER RES, V2, P855; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; ORIDATE N, 1995, INT J ONCOL, V7, P433; ORMEROD MG, 1993, ACTA ONCOL, V32, P417, DOI 10.3109/02841869309093620; SANFORD KK, 1992, J CLIN INVEST, V90, P2069, DOI 10.1172/JCI116089; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Schweizer M., 1997, OXIDATIVE STRESS MOL, P169; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SUN SY, 1999, IN PRESS CANC RES; TAYLOR DE, 1995, ARCH BIOCHEM BIOPHYS, V316, P70, DOI 10.1006/abbi.1995.1011; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou CP, 1998, CLIN CANCER RES, V4, P1345	59	134	136	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6380	6387		10.1038/sj.onc.1203024	http://dx.doi.org/10.1038/sj.onc.1203024			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597238				2022-12-28	WOS:000083934100023
J	Lindenboim, L; Yuan, JY; Stein, R				Lindenboim, L; Yuan, JY; Stein, R			Bcl-x(S) and Bax induce different apoptotic pathways in PC12 cells	ONCOGENE			English	Article						bcl-x(S); bax; bcl-2; Bcl-x(L); apoptosis; caspases; NGF	NERVE GROWTH-FACTOR; BCL-X-L; SYMPATHETIC NEURONS; PHOSPHATIDYLINOSITOL 3-KINASE; INDEPENDENT MECHANISMS; PROTEIN-KINASE; DEATH AGONIST; BH3 DOMAIN; FAMILY; INHIBITION	Apoptosis is regulated by the action of the Bcl-2 family of proteins, which includes anti- and pro-apoptotic members such as Bcl-x(S) and Bax. These proteins may differ from each other in structure, mechanism of action and interactions with anti-apoptotic signaling. The mechanism whereby Bax induces cell death has been studied in some cellular systems, but the mechanism of Bcl-x(S)-induced apoptosis is largely unknown. In this study we investigated and compared the apoptotic effects of Bcl-x(S) and Bax in the pheochromocytoma cell line, PC12 (a useful model system for studying neuronal apoptosis), and the extent to which they are protected by the survival factor, nerve growth factor (NGF), PC12 cells express endogenous Bcl-x(S), Bax and Bcl-x(L) proteins. Subcellular fractionation revealed that Bax is presented mainly in the cytosolic and the heavy membrane fractions, Bcl-x(S) is present only in the cytosol, and the anti-apoptotic protein Bcl-x(L) is located mainly in the heavy membrane fraction. In contrast to the cytosolic localization of endogenous Bcl-x(S), the exogenously overexpressed Bcl-x(S) is localized to the mitochondria, Overexpression of Bcl-x(S) or Bax induces cell death in the transfected cells. The cell death induced by overexpression of Bcl-x(S) was inhibited by coexpression of Bcl-x(S) with Bcl-2 or Bcl-x(L), or by treatment with the broad-spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoro-methylketone (Z-VAD-FMK) or with NGF. The Bcl-2 mutants Delta C22, which lacks the transmembrane domain, and G145A (mI-3) were able to inhibit the death-inducing effect of Bcl-x(S). These results therefore suggest that the apoptotic pathway induced by overexpression of Bcl-x(S) in PC12 cells can be controlled by Bcl-2 and Bcl-x(L), is mediated by caspases, and can be inhibited by the NGF signaling pathway. The Bax-induced cell death was inhibited by co-expression of Bax with Bcl-2 or Bcl-x(L), but was not inhibited by Z-VAD-FMK, NGF, or the Bcl-2 mI-3 or Delta C22 mutants. These results therefore suggest that Bax induces a caspase-independent cell death pathway which is blocked by Bcl-2 but not by the NGF signaling pathway. They further suggest that Bcl-x(S) and Bax induce different cell death pathways in PC12 cells.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Tel Aviv University; Harvard University; Harvard Medical School	Stein, R (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.							Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; Dole MG, 1996, CANCER RES, V56, P5734; Ealovega MW, 1996, CANCER RES, V56, P1965; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrell MJ, 1996, CLIN J PAIN, V12, P6, DOI 10.1097/00002508-199603000-00003; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Igase M, 1999, CLIN SCI, V96, P605, DOI 10.1042/CS19980279; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; Katoh S, 1996, BIOCHEM BIOPH RES CO, V229, P653, DOI 10.1006/bbrc.1996.1859; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LINDENBOIM L, 1995, J NEUROCHEM, V64, P1054; Maroto R, 1997, J NEUROCHEM, V69, P514; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Martinou I, 1998, NEUROREPORT, V9, P15, DOI 10.1097/00001756-199801050-00004; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Middleton G, 1996, DEVELOPMENT, V122, P695; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Orth R, 1997, J BIOL CHEM, V272, P8841; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Spear N, 1997, J NEUROCHEM, V69, P53; StClair EG, 1997, J BIOL CHEM, V272, P29347; Stefanis L, 1998, J NEUROSCI, V18, P9204; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	68	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1783	1793		10.1038/sj.onc.1203495	http://dx.doi.org/10.1038/sj.onc.1203495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777212				2022-12-28	WOS:000086292500006
J	Kim, KE; Gu, CY; Thakur, S; Vieira, E; Lin, JC; Rabson, AB				Kim, KE; Gu, CY; Thakur, S; Vieira, E; Lin, JC; Rabson, AB			Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes	ONCOGENE			English	Article						NF-kappa B; NF-kappa B-2; lymphoma transcription; protooncogene	NF-KAPPA-B; DNA-BINDING ACTIVITY; T-CELL LYMPHOMA; FUNCTIONAL-CHARACTERIZATION; CHROMOSOMAL TRANSLOCATION; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; REL PROTEINS; NFKB2 GENE	C-terminal truncations of the NFKB2 p100 gene product have been observed in a number of cases of human cutaneous T cell lymphomas, as well as human B-cell lymphomas and myelomas, The contribution of these alterations to lymphomagenesis is not understood; however, truncation at amino acid 666 to generate 80-85 kh) proteins in the HUT78 cell line is associated with addition of a short (serine-alanine-serine) fusion at the 3' end of p80HT, as well as with increased expression of NFKB2 mRNA, We therefore examined the effects of p80HT on the regulation of NFKB2 expression, as well ms the properties of a series of other tumor-associated, and site directed mutations of NFKB2, While p80HT had not itself acquired novel transcriptional activation properties with respect to the NFKB2 Pt or P2 promoters or the IL-6 kappa B promoter, p80HT had lost tate potent inhibitory (I kappa B-like) activity associated with the wild-type, p100 gene product. Loss of the inhibitory property depended on the SAS residues in the fusion protein, direct truncation at aa666 was fully inhibitory, as was a substitution of three alanines for the SAS residues. The presence of as few as two C-terminal ankyrin motifs was sufficient for inhibition of NF-kappa B-mediated transcriptional activation, Assays of a series of additional lymphoma-associated NF-kappa B-2 truncation suggested that the C-terminal truncation associated with these proteins was also associated with a loss of the I kappa B-like activities of p100 NF-kappa B-2, for at least some NF-kappa B target promoters. Thus, the loss of I kappa B-like activity of lymphoma-associated NFKB2 mutations may play an important role in the genesis of a subset of human lymphomas.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Inst Canc, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rabson, AB (corresponding author), CABM, 679 Hoes Lane, Piscataway, NJ 08854 USA.				NATIONAL CANCER INSTITUTE [R01CA068333] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; LUQUE I, 1977, SEMIN CANCER BIOL, V8, P103; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; MARTIN MA, 1981, P NATL ACAD SCI-BIOL, V78, P4892, DOI 10.1073/pnas.78.8.4892; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; NAGATANI T, 1994, SEMIN DERMATOL, V13, P216; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1993, ONCOGENE, V8, P2275; NERI A, 1995, BLOOD, V86, P3160, DOI 10.1182/blood.V86.8.3160.bloodjournal8683160; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; THAKUR S, 1994, ONCOGENE, V9, P2335; Tolomeo M, 1998, CELL DEATH DIFFER, V5, P735, DOI 10.1038/sj.cdd.4400406; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547; ZHANG JD, 1994, ONCOGENE, V9, P1931; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148	80	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1334	1345		10.1038/sj.onc.1203432	http://dx.doi.org/10.1038/sj.onc.1203432			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713675				2022-12-28	WOS:000085743800010
J	Mazars, A; Tournigand, C; Mollat, P; Prunier, C; Ferrand, N; Bourgeade, MF; Gespach, C; Atfi, A				Mazars, A; Tournigand, C; Mollat, P; Prunier, C; Ferrand, N; Bourgeade, MF; Gespach, C; Atfi, A			Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-beta	ONCOGENE			English	Article						apoptosis; c-Myc; JNK; Smad2; TGF-beta	TRANSFORMING-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; SELECTIVE ACTIVATION; CYCLE PROGRESSION; INDUCED APOPTOSIS; GENE-EXPRESSION; RAC; RECEPTOR; INDUCTION; SAPK/JNK	The transforming growth factor beta (TGF-beta) plays an important role in constraining cellular proliferation, but it is also a potent inducer of programmed cell death or apoptosis. Here, we demonstrate that TGF-beta can have an opposite effect, acting as a survival factor to prevent c-Myc-induced cell death in Rat-1 fibroblasts, However, in marked contrast to TCF-beta, Smad2, which is a critical intracellular mediator of the TGF-beta signaling pathway, functions as an antagonist to induce increased cell death. The protective activity of TGF-beta was associated with the activation of c-Jun N-terminal Kinase (JNK) and was not linked to the ability of TGF-beta to promote cell cycle progression. Expression of dominant-interfering forms of various components of the JNK signaling pathway, including Rac1, Cdc42, mitogen-activated protein kinase kinase 4 (MKK4), and c-Jun, abolished TGF-beta-mediated cell survival. Furthermore, overexpression of the constitutively activated mutant RacL61F37A, which selectively stimulates JNK cascade but not G1 cell cycle progression or actin polymerization, was sufficient to prevent apoptosis induced by c-Myc. These findings describe a differential effect of two separated signaling pathways of TGF-beta and indicate for the first time that Smad2 can act as antagonist to suppress TGF-beta-dependent cell survival.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Hop St Antoine, INSERM, U417, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Atfi, A (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Frottier, Celine Prunier/G-8259-2017; Tournigand, Christophe/Q-2831-2018	Frottier, Celine Prunier/0000-0002-7784-0273; 				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ASKEW DS, 1991, ONCOGENE, V6, P1915; Atfi A, 1999, ONCOGENE, V18, P3878, DOI 10.1038/sj.onc.1202734; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Frey RS, 1997, CANCER RES, V57, P628; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAPP UR, 1994, ONCOGENE, V9, P3493; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SACHINIDIS A, 1993, FEBS LETT, V319, P221, DOI 10.1016/0014-5793(93)80550-E; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	55	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1277	1287		10.1038/sj.onc.1203420	http://dx.doi.org/10.1038/sj.onc.1203420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713669				2022-12-28	WOS:000085743800004
J	Eichmann, A; Yuan, L; Breant, C; Alitalo, K; Koskinen, PJ				Eichmann, A; Yuan, L; Breant, C; Alitalo, K; Koskinen, PJ			Developmental expression of Pim kinases suggests functions also outside of the hematopoietic system	ONCOGENE			English	Article						pim kinases; quail; expression; embryonic development	E-MU-MYC; TRANSGENIC MICE; INHIBITS APOPTOSIS; ENDOTHELIAL-CELLS; LYMPHOID TUMORS; HIGH-FREQUENCY; MYELOID CELLS; BONE-MARROW; C-MYC; N-MYC	We have cloned a novel quail cDNA with strong homology to the pint family of proto-oncogenes. The deduced amino acid (aa) sequence of the cDNA, named qpim, is more closely related to Xenopus Pim and to the recently identified rat Pim-3 than to human or rodent Pim-1 or Pim-2. The protein encoded by the qpim cDNA can autophosphorylate itself and share substrates with murine Pim-l, suggesting functional redundancy to other Pim family serine/threonine kinases. We have compared the expression of qpim in avian embryos to mouse pim-1, -2 and -3 by in situ hybridization. qpim shows a highly dynamic expression pattern, particularly at early developmental stages. Surprisingly, its expression pattern is not identical to any of the murine pint genes, which show complementary and/or partially overlapping expression sites both in- and outside of the hematopoietic system. Altogether, our results suggest novel functions for Pim family kinases during embryonic development, in particular in epithelia and in the central nervous system.	CNRS, Inst Embryol Cellulaire & Mol, F-94736 Nogent Sur Marne, France; Coll France, F-94736 Nogent Sur Marne, France; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, FIN-20520 Turku, Finland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; University of Helsinki; Abo Akademi University; University of Turku	Eichmann, A (corresponding author), CNRS, Inst Embryol Cellulaire & Mol, 49Bis,Ave de la Belle Gabrielle, F-94736 Nogent Sur Marne, France.		Alitalo, Kari K/J-5013-2014; Koskinen, Päivi J/G-8939-2014	Alitalo, Kari K/0000-0002-7331-0902; Koskinen, Paivi/0000-0002-6864-4457				Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; CUYPERS HT, 1984, CELL, V37, P141; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Feldman JD, 1998, J NEUROSCI RES, V53, P502, DOI 10.1002/(SICI)1097-4547(19980815)53:4<502::AID-JNR13>3.0.CO;2-3; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Konietzko U, 1999, EMBO J, V18, P3359, DOI 10.1093/emboj/18.12.3359; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1991, ONCOGENE, V6, P1941; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wilting J, 1996, DEV BIOL, V176, P76, DOI 10.1006/dbio.1996.9993; Wingett D, 1996, J IMMUNOL, V156, P549; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183	36	87	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2000	19	9					1215	1224		10.1038/sj.onc.1203355	http://dx.doi.org/10.1038/sj.onc.1203355			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713710				2022-12-28	WOS:000085567800012
J	Dankort, DL; Muller, WJ				Dankort, DL; Muller, WJ			Signal transduction in mammary tumorigenesis: a transgenic perspective	ONCOGENE			English	Review						review; transgenic; ErbB-2/Neu; breast cancer	HUMAN-BREAST-CANCER; EPIDERMAL GROWTH-FACTOR; MIDDLE-T-ANTIGEN; PROTEIN-TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; FACTOR RECEPTOR STATUS; HA-RAS ONCOGENE; C-SRC; POLYOMA-VIRUS; NEU PROTOONCOGENE	A number of genes have been implicated in breast cancer development, yet few have been demonstrated to play causative roles in mammary tumor formation. The advent of transgenic mouse and embryonic stem cell technologies now permits manipulation of the mouse genome in such a way as to temporally and spatially control a gene product's expression. Thus, the basic researcher now can directly assess the involvement of particular genes in tumorigenesis and disease progression and, in the process, to develop mouse models of human genetic disease. The utility of such technologies is emphasized in transgenic mice expressing genes thought to play important roles in the initiation and progression of mammary carcinomas. As these transgenic strains have been the subject of several reviews, here we focus on two mouse mammary tumor models, Polyomavirus middle T antigen and the Neu/ErbB-2 receptor tyrosine kinase, which are most amenable to study specific signaling pathways in process of mammary tumorigenesis.	McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Dept Pathol, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University	Muller, WJ (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.			Dankort, David/0000-0002-5862-6829				ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; ALMANDI M, 1995, ONCOGENE, V10, P1813; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BEREBBI M, 1990, ONCOGENE, V5, P505; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BOS JL, 1989, CANCER RES, V49, P4862; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CARDIFF RD, 1993, CANCER SURV, V16, P97; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DALY RJ, 1994, ONCOGENE, V9, P2723; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DANKORT DL, 1996, MAMMARY TUMOR CELL C; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; Dougall WC, 1996, DNA CELL BIOL, V15, P31, DOI 10.1089/dna.1996.15.31; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GASPARINI G, 1992, BRIT J CANCER, V66, P970, DOI 10.1038/bjc.1992.394; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ISRAEL MA, 1979, P NATL ACAD SCI USA, V76, P3713, DOI 10.1073/pnas.76.8.3713; JACOBS C, 1983, CANCER RES, V43, P1696; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JANES PW, 1994, ONCOGENE, V9, P3601; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; Krane IM, 1996, ONCOGENE, V12, P1781; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LEMOINE NR, 1990, ONCOGENE, V5, P237; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUCHINI F, 1992, CANC LETT, V64, P203; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANSOUR EG, 1994, CANCER, V74, P381, DOI 10.1002/cncr.2820741326; MARKLAND W, 1986, J VIROL, V59, P384, DOI 10.1128/JVI.59.2.384-391.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MORRISON BW, 1994, HEMATOL ONCOL CLIN N, V8, P15, DOI 10.1016/S0889-8588(18)30185-0; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; NIELSEN LL, 1991, CANCER RES, V51, P3762; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATCHEFSKY AS, 1989, CANCER, V63, P731, DOI 10.1002/1097-0142(19890215)63:4<731::AID-CNCR2820630422>3.0.CO;2-#; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELES E, 1992, J BIOL CHEM, V267, P12266; PELLICI G, 1995, ONCOGENE, V11, P899; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; ROCHLITZ CF, 1989, CANCER RES, V49, P357; ROSEN N, 1996, J BIOL CHEM, V2261, P11754; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAINSBURY JRC, 1988, BRIT J CANCER, V58, P458, DOI 10.1038/bjc.1988.240; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, CANCER RES, V52, P5229; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1992, ONCOGENE, V7, P1339; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STOCKLIN E, 1993, J CELL BIOL, V122, P199, DOI 10.1083/jcb.122.1.199; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WU K, 1994, ONCOGENE, V9, P3139; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU DJ, 1988, ONCOGENE, V2, P279; ZOLL B, 1992, J CANCER RES CLIN, V118, P468, DOI 10.1007/BF01629432	121	81	81	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1038	1044		10.1038/sj.onc.1203272	http://dx.doi.org/10.1038/sj.onc.1203272			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713687				2022-12-28	WOS:000085796400009
J	Cass, LA; Meinkoth, JL				Cass, LA; Meinkoth, JL			Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation	ONCOGENE			English	Article						cAMP; PI3K; differentiation; proliferation; thyroid cells	THYROID EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; DNA-SYNTHESIS; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; NA+/I SYMPORTER; SKELETAL MYOGENESIS; DISTINCT EFFECTORS; GENE-EXPRESSION	Hormones are specialized mitogens that stimulate proliferation in their differentiated target cells. Thyrotropin (TSH), the physiologic regulator of thyroid cells, stimulates cAMP-mediated proliferation and thyroidspecific gene expression. The mitogenic effects of TSH require Ras, therefore Ras activation should be compatible with the maintenance of thyroid differentiation. However, expression of activated Ras extinguishes the differentiated phenotype of thyroid cells, One explanation for this apparent paradox is the selective utilization of Res effector pathways. We tested the hypothesis that Ras signaling through PI3K mediates the mitogenic effects of TSH in cells which retain their differentiated character. Expression of a Ras effector mutant (RasV12S35) that signals preferentially through Raf-1, although sufficient to confer TSH-independent proliferation, abolished hormone-regulated expression of thyroglobulin and the sodium/iodide symporter, In contrast, expression of a Ras mutant (RasV12C40) that binds selectively to PI3K conferred TSH-independent proliferation without marked effects on thyroid-specific gene expression. Unlike the inhibitory effects of TSH on the proliferation of RasV12S35-expressing cells, TSH enhanced RasV12C40-stimulated proliferation by further increasing the activity of p70s6k, an important mediator of the mitogenic effects of TSH and RasV12C40. These results demonstrate that channeling Ras-dependent signals to PI3K confers TSH with the ability to stimulate proliferation in differentiated cells.	Univ Penn, Dept Pharmacol, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Dept Pharmacol, Sch Med, 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.		Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [DK02494, DK45696] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K02DK002494, R01DK045696] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; BATTISTA S, 1995, ONCOGENE, V11, P2029; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Downey P, 1997, BUCINA HIST BRAS SOC, V2, P1; Dumont F J, 1996, Life Sci, V58, P373; FAGIN JA, 1994, ANNU REV MED, V45, P45; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Goi T, 1999, MOL CELL BIOL, V19, P1731; Heldin N E, 1991, Thyroidology, V3, P127; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kita Y, 1998, J CELL SCI, V111, P907; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; MARIAS R, 1996, CANCER SURV, V27, P101; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Matsuguchi T, 1998, ONCOGENE, V17, P2701, DOI 10.1038/sj.onc.1202201; MEINKOTH JL, 1991, THYROIDOLOGY, V3, P97; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; Ohmori M, 1998, MOL ENDOCRINOL, V12, P727, DOI 10.1210/me.12.5.727; Ohno M, 1999, MOL CELL BIOL, V19, P2051; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ptasznik A, 1997, J CELL BIOL, V137, P1127, DOI 10.1083/jcb.137.5.1127; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Uyttersprot N, 1997, MOL CELL ENDOCRINOL, V131, P195, DOI 10.1016/S0303-7207(97)00108-1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458	61	47	48	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					924	932		10.1038/sj.onc.1203393	http://dx.doi.org/10.1038/sj.onc.1203393			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702801				2022-12-28	WOS:000085567700010
J	Chausovsky, A; Waterman, H; Elbaum, M; Yarden, Y; Geiger, B; Bershadsky, AD				Chausovsky, A; Waterman, H; Elbaum, M; Yarden, Y; Geiger, B; Bershadsky, AD			Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization	ONCOGENE			English	Article						neuregulin; ErbB-3/ErbB-2 heterodimers; cell spreading; PI3-kinase; MAPK kinase; microtubules	HEPATOCYTE GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; RAT PC12 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; SCATTER FACTOR; EPITHELIAL-CELLS; MAMMARY-GLAND	Neuregulin can trigger morphogenetic signals in cells both in vivo and in culture through the activation of receptors from the ErbB family. We have ectopically expressed various ErbB-receptors in 32D myeloid cells lacking endogenous ErbB-proteins, and in CHO cells, which express only ErbB-2. We show here that activation of ErbB-3/ErbB-2 heterodimeric receptors triggers PI3-kinase-dependent lamellipodia formation and spreading, while individual ErbB-receptor homodimers as well as ErbB-3/ErbB-1 heterodimers are much less effective. CHO cells expressing ErB3/ErbB-2 together with N-cadherin, an adhesion receptor, form epithelioid colonies. Neuregulin activates cell motility leading to transition of these colonies into ring-shaped multicellular arrays, similar to those induced by neuregulin in epithelial cells of different types (Chausovsky et al., 1998), This process requires both PI3-kinase and MAP kinase kinase activity and depends on coordinated changes in the actin- and microtubule-based cytoskeleton. Transactivation of ErbB-2 is not sufficient for the activation of cell motility and ring formation, and the C-terminal domain of ErbB-3 bearing the docking sites for the p85 subunit of PI3-kinase is essential for these morphogenetic effects. Thus, ErbB-3 in conjunction with ErbB-2 mediates, via its C-terminal domain, cytoskeletal and adhesion alterations which activate cell spreading and motility, leading to the formation of complex structures such as multicellular rings.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science	Bershadsky, AD (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012	Bershadsky, Alexander/0000-0002-9571-7375				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BERSHADSKY AD, 1993, SYM SOC EXP BIOL, V47, P353; Birchmeier C, 1997, CIBA F SYMP, V212, P169; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bray D., 1992, CELL MOVEMENTS; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; Chausovsky A, 1998, MOL BIOL CELL, V9, P3195, DOI 10.1091/mbc.9.11.3195; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDELMAN G, 1990, MORPHOREGLATORY MOL; Elbaum M, 1999, BIOCHEM SOC SYMP, V65, P147; Gabay L, 1997, DEVELOPMENT, V124, P3535; GHERARDI E, 1993, SYM SOC EXP BIOL, V47, P163; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hay ED, 1995, ACTA ANAT, V154, P8; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim HH, 1998, BIOCHEM J, V334, P189, DOI 10.1042/bj3340189; Kita Y, 1998, J CELL SCI, V111, P907; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Levenberg S, 1998, J CELL SCI, V111, P347; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; PELES E, 1992, J BIOL CHEM, V267, P12266; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Schaefer G, 1999, J BIOL CHEM, V274, P859, DOI 10.1074/jbc.274.2.859; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SORIANO JV, 1995, J CELL SCI, V108, P413; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Trinkaus J. P., 1984, CELLS ORGANS FORCES; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	55	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					878	888		10.1038/sj.onc.1203410	http://dx.doi.org/10.1038/sj.onc.1203410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702796				2022-12-28	WOS:000085567700005
J	Islam, A; Kageyama, H; Takada, N; Kawamato, T; Takayasu, H; Isogai, E; Ohira, M; Hashizume, K; Kobayashi, H; Kaneko, Y; Nakagawara, A				Islam, A; Kageyama, H; Takada, N; Kawamato, T; Takayasu, H; Isogai, E; Ohira, M; Hashizume, K; Kobayashi, H; Kaneko, Y; Nakagawara, A			High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma	ONCOGENE			English	Article						Survivin; prognostic factor; apoptosis; 17q gain; neuroblastoma	ANTI-APOPTOSIS GENE; DEATH; CHROMOSOME-17; HYBRIDIZATION; MARKERS; CANCER	Survivin (SVV) is a family member of inhibitor of apoptosis proteins (IAPs) and its expression is cell cycle regulated. The gene is mapped to chromosome 17q25, the region of which is frequently gained in advanced stages of neuroblastoma (NBL). However, the role of SVV in NBL is poorly understood. Here we studied the clinical and biological role of SVV in NBL. A 1.9 kb SVV transcript was expressed in all of 9 NBL cell lines at higher levels than those in adult cancer cell lines. In 34 primary NBLs, high levels of SVV expression was significantly associated with age greater than 12 months (two sample t-test: P = 0.0003), advanced stages (P = 0.0136), sporadic tumors (P = 0.0027) and low levels of TrkA expression (P = 0.0030). In NBL cell lines, SVV mRNA expression was dramatically down-regulated in CHP134 and IMR32 cells undergoing apoptosis after treatment with all-tr mls retinoic acid (RA) or serum deprivation, It was only moderately decreased in cells (SH-SY5Y and CHP901) undergoing RA-induced differentiation, On the other hand, in proliferating NBL cells or RA-treated SK-N-AS line which is refractory to RA, the SVV mRNA remained at steady state levels or rather up-regulated. Furthermore, transfection of SVV into CHP134 cells induced remarkable inhibition of the RA-induced apoptosis, Collectively, our results suggest that high expression of SVV is a strong prognostic indicator for the advanced stage neuroblastomas, and that it could be one of the candidate genes for the 17q gain.	Chiba Canc Ctr, Inst Res, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Univ Tokyo, Dept Pediat Surg, Bunkyo Ku, Tokyo 1130033, Japan; Saitama Canc Ctr Hosp, Dept Canc Chemotherapy, Ina, Saitama 3620806, Japan	Chiba Cancer Center; University of Tokyo	Nakagawara, A (corresponding author), Chiba Canc Ctr, Inst Res, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.		Islam, Ashraful/GYR-1579-2022	Islam, Ashraful/0000-0002-1742-6804				Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 1998, AM J PATHOL, V152, P43; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN H, 1992, GENE CHROMOSOME CANC, V5, P141, DOI 10.1002/gcc.2870050208; Hoehner JC, 1997, BRIT J CANCER, V75, P1185, DOI 10.1038/bjc.1997.203; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kaneko M, 1998, MED PEDIATR ONCOL, V31, P1, DOI 10.1002/(SICI)1096-911X(199807)31:1<1::AID-MPO1>3.0.CO;2-H; Kobayashi H, 1996, BRIT J HAEMATOL, V94, P105, DOI 10.1046/j.1365-2141.1996.d01-1762.x; Lastowska M, 1997, GENE CHROMOSOME CANC, V19, P143; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lu CD, 1998, CANCER RES, V58, P1808; Nakagawara A, 1997, CANCER RES, V57, P4578; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakagawara A, 1998, MED PEDIATR ONCOL, V31, P113, DOI 10.1002/(SICI)1096-911X(199808)31:2<113::AID-MPO14>3.0.CO;2-O; Nakagawara A, 1998, Hum Cell, V11, P115; Plantaz D, 1997, AM J PATHOL, V150, P81; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	26	335	372	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					617	623		10.1038/sj.onc.1203358	http://dx.doi.org/10.1038/sj.onc.1203358			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698506				2022-12-28	WOS:000085192000003
J	Tamrakar, S; Mittnacht, S; Ludlow, JW				Tamrakar, S; Mittnacht, S; Ludlow, JW			Binding of select forms of pRB to protein phosphatase type 1 independent of catalytic activity	ONCOGENE			English	Article						retinoblastoma protein; protein phosphatase type 1; pRB dephosphorylation; PPI activity; phosphatase inhibitors	RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; OKADAIC ACID; SUSCEPTIBILITY GENE; SPONGE TOXIN; PHOSPHORYLATION; SUBUNIT; DEPHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION	The product of the retinoblastoma susceptibility gene, pRB, is a demonstrated substrate for the type 1 serine/threonine protein phosphatases (PPI). Curiously, there has been a paucity of data supporting the idea that phosphorylated pRB can be found in a complex with PP1. To more fully characterize the association between these two proteins, we utilized a PP1-affinity chromatography approach to increase our ability to capture from mammalian cell lysate populations of pRB capable of binding to PPI. Western blot analysis of the bound proteins indicates that both faster migrating, hypophosphorylated pRB, as web as slower migrating, hyperphosphorylated pRB can bind. Phosphorylated pRB binding was confirmed by immunoprecipitation of eluted P-32-labeled pRB. In addition, Western blotting of eluted proteins with pRB phosphorylated-site-specific antibodies revealed select phosphorylated forms of pRB binding to PP1. Similar binding studies performed with toxin-inhibited PP1 indicate that catalytic activity of PPI is not required for pRB binding. The significance of this finding with respect to the functional importance of this interaction is discussed.	Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Inst Canc Res, Dept Cell & Mol Biol, London SW3 6JB, England	University of Rochester; University of Rochester; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ludlow, JW (corresponding author), Univ Rochester, Ctr Canc, Box 704,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; Ludlow JW, 1996, J VIROL METHODS, V59, P105, DOI 10.1016/0166-0934(96)02027-7; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUSSOW AR, 1991, EUR J IMMUNOL, V21, P2297, DOI 10.1002/eji.1830211002; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Siegert JL, 1999, MOL CELL BIOL, V19, P846; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Tognarini M, 1998, METH MOL B, V93, P169; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396	41	19	19	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7803	7809		10.1038/sj.onc.1203211	http://dx.doi.org/10.1038/sj.onc.1203211			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618721				2022-12-28	WOS:000084256900010
J	Feldkamp, MM; Lau, N; Guha, A				Feldkamp, MM; Lau, N; Guha, A			Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects	ONCOGENE			English	Article						farnesyl transferase inhibitor, FTI; L-744,832; astrocytoma; glioma; Ras	RAS-TRANSFORMED-CELLS; HUMAN-BRAIN-TUMORS; NIH 3T3 CELLS; FARNESYLTRANSFERASE INHIBITORS; FACTOR RECEPTOR; PROTEIN TRANSFERASE; ACTIN CYTOSKELETON; TRANSGENIC MICE; KINASE-KINASE; ONCOGENIC RAS	While 25% of human cancers harbor oncogenic Ras mutations, such mutations are not found in astrocytomas. We have previously demonstrated that the activation of receptor tyrosine kinases expressed by malignant human astrocytoma cells and specimens results in functional upregulation of the Ras signalling pathway and increased levels of activated Ras GTP. Farnesyl transferase inhibitors (FTIs) are promising anti-cancer agents in early clinical trials, which may exert their effect through pharmacological inhibition of the Ras signalling pathway, In this study we establish the anti-tumorigenic properties of the FTI L-744,832 against a panel of malignant human astrocytoma cell Lines. Furthermore, we demonstrate the multiple mechanisms by which L744,832 exerts its effect. L-744,832 demonstrates both cytostatic and cytotoxic effects on astrocytoma cells, and cells expressing a truncated constitutively phosphorylated Epidermal Growth Factor Receptor common in high-grade astrocytomas (EGFRvIII/p140(EGF-R)) demonstrate increased sensitivity to the agent. L-744,832 is capable of inducing apoptosis in astrocytoma cells under anchorage-dependent conditions; this process occurs in a p53-independent manner and is associated with increased expression of Bax and Bak, L-744,832 also induces cell cycle arrest at both the G(1)/M and G(2)/S checkpoints; this process is also independent of p53 mutational status. Cell cycle arrest in drug-treated cells can be accompanied by induction of p21(WAF1/CIP1), but this induction is not necessary for the cell cycle inhibitory effects, nor is it dependent on functional p53, Finally, angiogenesis in astrocytomas has been shown to be dependent on secretion of Vascular Endothelial Growth Factor (VEGF) by tumour cells, particularly under hypoxic conditions, L-744,832 potently inhibits the secretion of VEGF under hypoxic conditions. These combinations of mechanisms suggest that these tumours, despite the absence of oncogenic Ras mutations, will be amenable to growth inhibition by FTIs, through a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects.	Toronto Western Hosp, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON, Canada; Princess Margaret Hosp, Ontario Canc Inst, Dept Surg Oncol, Toronto, ON M4X 1K9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Guha, A (corresponding author), Toronto Western Hosp, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada.							ASANO M, 1995, CANCER RES, V55, P5296; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BOS JL, 1989, CANCER RES, V49, P4682; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; Du W, 1999, MOL CELL BIOL, V19, P1831; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.3.CO;2-X; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FLEMING TP, 1992, CANCER RES, V52, P4550; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GomezManzano C, 1996, CANCER RES, V56, P694; GOODWIN CJ, 1995, J IMMUNOL METHODS, V179, P95, DOI 10.1016/0022-1759(94)00277-4; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; GUHA A, 1995, J NEUROL NEUROSUR PS, V58, P711, DOI 10.1136/jnnp.58.6.711; Gutmann DH, 1996, ONCOGENE, V12, P2121; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Izawa I, 1996, FEBS LETT, V382, P53, DOI 10.1016/0014-5793(96)00137-8; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Law BK, 1999, J BIOL CHEM, V274, P4743, DOI 10.1074/jbc.274.8.4743; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LIBERMANN TA, 1984, CANCER RES, V44, P753; MANNE V, 1995, ONCOGENE, V10, P1763; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Melnyk O, 1996, CANCER RES, V56, P921; Millauer B, 1996, CANCER RES, V56, P1615; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; NAGASU T, 1995, CANCER RES, V55, P5310; NISTER M, 1988, CANCER RES, V48, P3910; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RAK J, 1995, CANCER RES, V55, P4575; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Saleh M, 1996, CANCER RES, V56, P393; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Sepp-Lorenzino L, 1998, J BIOL CHEM, V273, P20243, DOI 10.1074/jbc.273.32.20243; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TUZI NL, 1991, BRIT J CANCER, V63, P227, DOI 10.1038/bjc.1991.54; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Zhang FL, 1997, J BIOL CHEM, V272, P10232; ZIMMERMA.HM, 1969, ANN NY ACAD SCI, V159, P337, DOI 10.1111/j.1749-6632.1969.tb48290.x	71	98	98	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7514	7526		10.1038/sj.onc.1203105	http://dx.doi.org/10.1038/sj.onc.1203105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602510				2022-12-28	WOS:000084119600012
J	Van Keymeulen, A; Bartek, J; Dumont, JE; Roger, PP				Van Keymeulen, A; Bartek, J; Dumont, JE; Roger, PP			Cyclin D3 accumulation and activity integrate and rank the comitogenic pathways of thyrotropin and insulin in thyrocytes in primary culture	ONCOGENE			English	Article						cell cycle; cyclins D; p27(kipl); cAMP; thyroid; synergy	THYROID EPITHELIAL-CELLS; GROWTH-FACTOR-I; CDK-ACTIVATING KINASE; G1 PHASE PROGRESSION; RETINOBLASTOMA PROTEIN; DEPENDENT KINASE; SUBCELLULAR-LOCALIZATION; INHIBITOR P27(KIP1); MITOGENIC PATHWAYS; SIGNALING CASCADES	The proliferation of most normal cells depends on the synergistic interaction of several growth factors and hormones, but the cell cycle basis for this combined requirement remains largely uncharacterized, We have addressed the question of the requirement for insulin/IGF-1 also observed in many cell culture systems in the physiologically relevant system of primary cultures of dog thyroid epithelial cells stimulated by TSH, which exerts its mitogenic activity only via cAMP, The induction of cyclin A and cdc2, the phosphorylation of cdk2, the nuclear translocation of cdk4 and the assembly of cyclin D3-cdk4 complexes required the synergy of TSH and insulin. Cyclin D3 (the most abundant cyclin D) was necessary for the proliferation stimulated by TSH in the presence of insulin as shown by microinjection of a neutralizing antibody, Cyclin D3 accumulation and activity mere differentially regulated by insulin and TSH, which points out this cyclin as an integrator that ranks these comitogenic pathways as supportive and activatory, respectively. Paradoxically TSH alone strongly repressed cyclin D3 accumulation. This inhibition was overridden by insulin, which markedly stimulated cyclin D3 mRNA and protein accumulation, but failed to assemble cyclin D3-cdk4 complexes in the absence of TSH. TSH unmasked the DCS-22 epitope of cyclin D3 and assembled cyclin D3-cdk4 in the presence of insulin. These data demonstrate that cyclin D synthesis and cyclin D-cdk assembly can be dissociated and complementarily regulated by different agents and signalling pathways.	Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Danish Canc Soc, Div Canc Biol, DK-2100 Copenhagen, Denmark	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Danish Cancer Society	Roger, PP (corresponding author), Free Univ Brussels, Inst Interdisciplinary Res, 808 Route Lennik,Campus Erasme, B-1070 Brussels, Belgium.		Bartek, Jiri/G-5870-2014	Roger, Pierre/0000-0002-5812-1783				Baptist M, 1996, J CELL PHYSIOL, V166, P256; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Burikhanov R, 1996, J BIOL CHEM, V271, P29400, DOI 10.1074/jbc.271.46.29400; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheung NW, 1996, J CLIN ENDOCR METAB, V81, P1179, DOI 10.1210/jc.81.3.1179; Coppee F, 1998, ONCOGENE, V17, P631, DOI 10.1038/sj.onc.1201966; Coulonval K, 1997, EXP CELL RES, V233, P395, DOI 10.1006/excr.1997.3582; de Asua L J, 1977, Proc Natl Acad Sci U S A, V74, P3845; Deleu S, 1999, MOL CELL ENDOCRINOL, V149, P41, DOI 10.1016/S0303-7207(99)00005-2; DELEU S, 1999, IN PRESS J CELL PHYS; Depoortere F, 1996, J CELL SCI, V109, P1759; Depoortere F, 1998, J CELL BIOL, V140, P1427, DOI 10.1083/jcb.140.6.1427; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAMY F, 1989, J CELL PHYSIOL, V138, P568, DOI 10.1002/jcp.1041380318; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; REUSE S, 1991, EXP CELL RES, V196, P210, DOI 10.1016/0014-4827(91)90253-Q; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROGER P, 1988, J CLIN ENDOCR METAB, V66, P1158, DOI 10.1210/jcem-66-6-1158; Roger PP, 1997, EUR J ENDOCRINOL, V137, P579, DOI 10.1530/eje.0.1370579; ROGER PP, 1987, EXP CELL RES, V172, P282, DOI 10.1016/0014-4827(87)90387-9; ROGER PP, 1987, J CELL PHYSIOL, V130, P58, DOI 10.1002/jcp.1041300110; ROGER PP, 1992, J CELL BIOL, V117, P383, DOI 10.1083/jcb.117.2.383; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TAKAHASHI SI, 1991, J BIOL CHEM, V266, P7834; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMAS GA, 1994, J PATHOL, V173, P355, DOI 10.1002/path.1711730411; TOMINAGA T, 1994, ENDOCRINOLOGY, V135, P1212, DOI 10.1210/en.135.3.1212; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; Ward AC, 1996, BIOCHEM BIOPH RES CO, V224, P10, DOI 10.1006/bbrc.1996.0976; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1998, CANCER RES, V58, P5053; WERNER H, 1994, VITAM HORM, V48, P1, DOI 10.1016/S0083-6729(08)60495-1; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	58	28	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7351	7359		10.1038/sj.onc.1203164	http://dx.doi.org/10.1038/sj.onc.1203164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602491				2022-12-28	WOS:000084119400021
J	Gassmann, MG; Stanzel, A; Werner, S				Gassmann, MG; Stanzel, A; Werner, S			Growth factor-regulated expression of enzymes involved in nucleotide biosynthesis: a novel mechanism of growth factor action	ONCOGENE			English	Article						keratinocyte growth factor; keratinocytes; purine; pyrimidine; nucleotide biosynthesis; salvage pathway	INFLAMMATORY BOWEL-DISEASE; HUMAN KERATINOCYTES; MOLECULAR-CLONING; ADENYLOSUCCINATE LYASE; FACTOR RECEPTOR; CDNA SEQUENCE; HUMAN HOMOLOG; FACTOR-ALPHA; GENE; SYNTHETASE	Keratinocyte growth factor (KGF) is a potent and specific mitogen for epithelial cells, including the keratinocytes of the skin, We investigated the mechanisms of action of KGF by searching for genes which are regulated by this growth factor in cultured human keratinocytes. Using the differential display RT-PCR technology we identified the gene encoding adenylosuccinate lyase [EC 4.3.2.2] as a novel KGF-regulated gene, Adenylosuccinate lyase plays an important role in purine de novo synthesis. To gain further insight into the potential role of nucleotide biosynthesis in the mitogenic effect of KGF, we cloned cDNA fragments of the key regulatory enzymes involved in purine and pyrimidine metabolism (adenylosuccinate synthetase [EC 6.3.4.4], phosphoribosyl pyrophosphate synthetase [EC 2.7.6.1], amidophosphoribosyl transferase [EC 2.4.2.14], hypoxanthine guanine phosphoribosyl transferase [EC 2.4.2.8] and the multifunctional protein CAD which includes the enzymatic activities of carbamoyl-phosphate synthetase II [EC 6.3.5.59], aspartate transcarbamylase [EC 2.1.3.2] and dihydroorotase [EC 3.5.2.3]), Expression of all of these enzymes was upregulated after treatment with KGF and also with epidermal growth factor (EGF), indicating that these mitogens stimulate nucleotide production by induction of these enzymes. To determine a possible in vivo correlation between the expression of KGF, EGF and the enzymes mentioned above, we analysed the expression of the enzymes during cutaneous wound repair, where high levels of these mitogens are present. Indeed, we found a strong mRNA expression of all of these enzymes in the EGF- and KGF-responsive keratinocytes of the hyperproliferative epithelium at the wound edge, indicating that their expression might also be regulated by growth factors during wound healing.	ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society	Werner, S (corresponding author), ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland.			Werner, Sabine/0000-0001-7397-8710				Ashcroft GS, 1997, J ANAT, V190, P351, DOI 10.1046/j.1469-7580.1997.19030351.x; BAUER D, 1994, PCR METH APPL, V4, P97; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brauchle M, 1996, AM J PATHOL, V149, P521; Carrey EA, 1995, BIOCHEM SOC T, V23, P899, DOI 10.1042/bst0230899; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DETMAR M, 1990, ARCH DERMATOL RES, V282, P238, DOI 10.1007/BF00371643; ERNER S, 1998, CYTOKINE GROWTH F R, V9, P153; Finch PW, 1997, AM J PATHOL, V151, P1619; Finch PW, 1996, GASTROENTEROLOGY, V110, P441, DOI 10.1053/gast.1996.v110.pm8566591; FON EA, 1993, CYTOGENET CELL GENET, V64, P201, DOI 10.1159/000133575; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Frank S, 1996, J BIOL CHEM, V271, P24337, DOI 10.1074/jbc.271.40.24337; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; Gold LI, 1997, AM J PATHOL, V150, P209; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; IWAHANA H, 1993, J BIOL CHEM, V268, P7225; IWAHANA H, 1993, BIOCHEM BIOPH RES CO, V190, P192, DOI 10.1006/bbrc.1993.1030; IWAHANA H, 1995, BBA-GENE STRUCT EXPR, V1261, P369, DOI 10.1016/0167-4781(95)00036-G; Iwahana H, 1996, BIOCHEM BIOPH RES CO, V219, P249, DOI 10.1006/bbrc.1996.0213; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; LIAO WSL, 1986, J BIOL CHEM, V261, P5577; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Ogura R, 1983, Curr Probl Dermatol, V11, P145; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RAO GN, 1988, EXP CELL RES, V178, P449, DOI 10.1016/0014-4827(88)90413-2; RAO GN, 1988, DNA-J MOLEC CELL BIO, V7, P423, DOI 10.1089/dna.1.1988.7.423; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Schmid P, 1998, AM J PATHOL, V152, P485; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SONODA T, 1991, J BIOCHEM-TOKYO, V109, P361; TODD R, 1991, AM J PATHOL, V138, P1307; TREFZER U, 1991, J INVEST DERMATOL, V97, P911, DOI 10.1111/1523-1747.ep12491668; Voet D VJ, 1990, BIOCHEMISTRY; WENCZAK BA, 1992, J CLIN INVEST, V90, P2392, DOI 10.1172/JCI116130; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WONG LJC, 1995, GENOMICS, V28, P341, DOI 10.1006/geno.1995.1152; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	49	22	22	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6667	6676		10.1038/sj.onc.1203120	http://dx.doi.org/10.1038/sj.onc.1203120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597272				2022-12-28	WOS:000083792000006
J	Fan, W; Richter, G; Cereseto, A; Beadling, C; Smith, KA				Fan, W; Richter, G; Cereseto, A; Beadling, C; Smith, KA			Cytokine response gene 6 induces p21 and regulates both cell growth and arrest	ONCOGENE			English	Article						cytokine; cell cycle; G1 and G2 progression	HUMAN INTERLEUKIN-2; TUMOR-SUPPRESSOR; DNA-REPLICATION; CYCLE; GADD45; P53; PROTEIN; EXPRESSION; INHIBITOR; INTERACTS	Cytokine response gene #6 (CR6), cloned from interleukin 2-stimulated T lymphocytes, is homologous to GADD45 and MyD118, genes which promote cell cycle arrest and apoptosis, To determine how this gene family could possibly mediate both cell survival/proliferation and cell cycle arrest/death, transfectants were generated so that the genes could be expressed ectopically, independently from their normal inducing agents. In cycling retinoblastoma protein-negative (pRb-) cells, ectopic CR6 expression blocked G2/M transition, but did not prevent G1/S transition so that endoreduplication resulted. By comparison, when CR6, GADD45, and MyD118 genes were expressed ectopically in proliferating pRb(+) cells, either G1/S or G2/M transition was effectively blocked, so that there was no endoreduplication, Consistent with these findings, in proliferating pRb-cells, ectopic expression of CR6 promoted the expression of both G1 and G2/M cyclins, By comparison, in pRb+ cells, the expression of G1 cyclins was increased, while expression of the mitotic cyclins was decreased. However, in pRb(+) cells, cyclin-dependent kinase activities associated with both G1 and G2/M cyclins were decreased. Moreover, ectopic expression of all three genes resulted in the expression of the CKI, p21, both in pRb- and pRb(+) cells. The physiologic induction of CR6 expression by IL2 in quiescent normal human T cells occurs transiently in the first half of G1, coordinately with the expression of p21, Therefore, this gene family regulates G1 and G2, and promotes either cell growth or arrest by a common mechanism.	Cornell Univ, Weill Med Coll & Grad Sch Med Sci, New York Presbyterian Cornell Med Ctr, New York, NY 10021 USA; New York Presbyterian Cornell Med Ctr, Dept Med, Div Immunol, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), Cornell Univ, Weill Med Coll & Grad Sch Med Sci, New York Presbyterian Cornell Med Ctr, 1300 York Ave, New York, NY 10021 USA.			Cereseto, Anna/0000-0003-4453-2597	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032031] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 32031-23] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CorreaBordes J, 1997, EMBO J, V16, P4657, DOI 10.1093/emboj/16.15.4657; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P421; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; HALL PA, 1995, ONCOGENE, V10, P2427; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Smith KA, 1995, ANN NY ACAD SCI, V766, P263, DOI 10.1111/j.1749-6632.1995.tb26674.x; SMITH KA, 1983, J IMMUNOL, V131, P1808; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; Vairapandi M, 1996, ONCOGENE, V12, P2579; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	33	50	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6573	6582		10.1038/sj.onc.1203054	http://dx.doi.org/10.1038/sj.onc.1203054			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597261				2022-12-28	WOS:000083709200021
J	Quinlan, MP				Quinlan, MP			Rac regulates the stability of the adherens junction and its components, thus affecting epithelial cell differentiation and transformation	ONCOGENE			English	Article						adhesion; actin; cadherin; catenin; GTPase	ACTIN FILAMENT ORGANIZATION; CADHERIN-CATENIN COMPLEX; SMALL GTPASES; TUMOR PROGRESSION; ALPHA-CATENIN; MDCK CELLS; MOLECULAR-INTERACTIONS; INDEPENDENT PATHWAYS; PROTEIN INTERACTIONS; SIGNAL-TRANSDUCTION	We have previously reported that activated rac (V12rac) can bring about hypertransformation of ras-transformed epithelial cells, which can be suppressed by the dominant negative form of I ac (N17rac). Starting with primary epithelial cells, a series of cell lines expressing wild type (WT) or mutated forms of rns or rac were generated and analysed for their adhesive function and expression and association of adherens junction (AJ) proteins. Normal, primary epithelial cells were self-adhesive and expressed AJs that were very stable. The expression of constitutively active ras resulted in a decrease in, but not loss of, cell-cell adhesion, with concomitantly decreased stability of AJ components. This was extremely exacerbated by the co-expression of constitutively activate rac, but was suppressed by dominant negative rac, which resulted in increased cell-cell adhesion and extremely stable AJs. alpha-catenin also failed to associate,vith E-cadherin-beta-catenin complexes in cells expressing V12rac. Expression of V12rac resulted in the loss of epithelial morphology. The extent of transformation of each cell type corresponded to the stability of the respective AJ complexes. Thus, I ac seems to be involved in regulating the stability of AJs, which promote epithelial cell differentiation, and consequently, modulating tumor progression.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Quinlan, MP (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, 858 Madison Ave, Memphis, TN 38163 USA.							Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; del Peso L, 1997, ONCOGENE, V15, P3047; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P209; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P905; FRIXEN U, 1991, J CELL BIOL, V111, P173; Geiger B, 1995, ACTA ANAT, V154, P46; GOPALAKRISHNAN S, 1995, CELL GROWTH DIFFER, V6, P985; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hay ED, 1995, ACTA ANAT, V154, P8; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Jankowski JA, 1997, J CLIN PATHOL-MOL PA, V50, P289; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZR, 1998, CANCER RES, V58, P4282; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G; MAREEL M, 1995, CANCER DETECT PREV, V19, P451; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; QUI RG, 1995, NATURE, V374, P457; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schoenenberger C A, 1991, Trends Cell Biol, V1, P87, DOI 10.1016/0962-8924(91)90035-8; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Steinberg MS, 1996, DEV BIOL, V180, P377, DOI 10.1006/dbio.1996.0312; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsukatani Y, 1997, J CELL PHYSIOL, V173, P54, DOI 10.1002/(SICI)1097-4652(199710)173:1<54::AID-JCP7>3.3.CO;2-G; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wittinghofer A, 1998, BIOL CHEM, V379, P933; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; YONEMURA S, 1995, J CELL SCI, V108, P127; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	86	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6434	6442		10.1038/sj.onc.1203026	http://dx.doi.org/10.1038/sj.onc.1203026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597245				2022-12-28	WOS:000083709200005
J	Nikiforov, YE; Koshoffer, A; Nikiforova, M; Stringer, J; Fagin, JA				Nikiforov, YE; Koshoffer, A; Nikiforova, M; Stringer, J; Fagin, JA			Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas	ONCOGENE			English	Article						RET; gene rearrangement; illegitimate recombination; radiation-induced; thyroid	CHERNOBYL NUCLEAR ACCIDENT; IN-SITU HYBRIDIZATION; IONIZING-RADIATION; MAMMALIAN-CELLS; CHILDREN; DNA; MECHANISMS; MUTATIONS; RET/PTC3; ONCOGENE	The RET/PTC3 rearrangement is formed by fusion of the ELE1 and RET genes, and is highly prevalent in radiation-induced post-Chernobyl papillary thyroid carcinomas. We characterized the breakpoints in the ELE1 and RET genes in 12 post-Chernobyl pediatric papillary carcinomas with known RET/PTC3 rearrangement. We found that the breakpoints within each intron were distributed in a relatively random fashion, except for clustering in the Alu regions of ELE1. None of the breakpoints occurred at the same base or within a similar sequence. There was also no evidence of preferential cleavage in AT-rich regions or other target DNA sites implicated in illegitimate recombination in mammalian cells. Modification of sequences at the cleavage sites was minimal, typically involving a 1-3 nucleotide deletion and/or duplication Surprisingly, the alignment of ELE1 and RET introns in opposite orientation revealed that in each tumor the position of the break in one gene corresponded to the position of the break in the other gene, This tendency suggests that the two genes may he next to each other but point in opposite directions in the nucleus, Such a structure would facilitate formation of RET/PTC3 rearrangements because a single radiation track could produce concerted breaks in both genes, leading to inversion due to reciprocal exchange via end-joining.	Univ Cincinnati, Coll Med, Dept Pathol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Nikiforov, YE (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol, POB 670529, Cincinnati, OH 45267 USA.		Koshoffer, Amy E/N-2278-2014	Koshoffer, Amy E/0000-0001-8130-103X	NCI NIH HHS [CA 72597, CA 50706] Funding Source: Medline; NIEHS NIH HHS [ES 05652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050706, R01CA072597, R29CA050706] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Cremer C, 1996, MUTAT RES-REV GENET, V366, P97, DOI 10.1016/S0165-1110(96)90031-7; EHRLICH SD, 1993, GENE, V135, P161, DOI 10.1016/0378-1119(93)90061-7; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; GROSOVSKY AJ, 1988, P NATL ACAD SCI USA, V85, P185, DOI 10.1073/pnas.85.1.185; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; KOVACS MS, 1994, RADIAT RES, V137, P34, DOI 10.2307/3578788; LICHTER P, 1988, HUM GENET, V80, P222; MANUELIDIS L, 1984, P NATL ACAD SCI-BIOL, V81, P3123, DOI 10.1073/pnas.81.10.3123; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 1996, ONCOGENE, V13, P687; NIKIFOROV YE, 1998, ADV MOL CELL ENDOCR, V2, P169; Pacini F, 1997, J CLIN ENDOCR METAB, V82, P3563, DOI 10.1210/jc.82.11.3563; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; Suchy B, 1998, BRIT J CANCER, V77, P952, DOI 10.1038/bjc.1998.157; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239	28	81	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6330	6334		10.1038/sj.onc.1203019	http://dx.doi.org/10.1038/sj.onc.1203019			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597232				2022-12-28	WOS:000083934100017
J	Noel, A; Boulay, A; Kebers, F; Kannan, R; Hajitou, A; Calberg-Bacq, CM; Basset, P; Rio, MC; Foidart, JM				Noel, A; Boulay, A; Kebers, F; Kannan, R; Hajitou, A; Calberg-Bacq, CM; Basset, P; Rio, MC; Foidart, JM			Demonstration in vivo that stromelysin-3 functions through its proteolytic activity	ONCOGENE			English	Article						metalloproteases; tumor growth; stromelysin-3; MMP inhibitors	BREAST-CANCER; GELATINASE-A; STRUCTURAL DETERMINANTS; MOUSE STROMELYSIN-3; GENE-EXPRESSION; GROWTH-FACTOR; CELLS; METALLOPROTEINASE; CARCINOMA; TUMOR	Stromelysin-3 (ST3), a matrix metalloproteinase (MMP) expressed in aggressive carcinomas, has been shown to promote tumor development in different in vivo experimental models. However, the inability of its mature form to degrade extracellular matrix components casts doubt on whether ST3 functions in vivo as protease, In this study, we evaluated whether the ST3 tumor-promoting effect could be ascribed to its proteolytic activity and whether this putative protease could be targeted with MMP inhibitors. Catalytically inactive mutant cDNA of human (h) ST3 or mouse (m) ST3 were generated and transfected into MCF7 cells, When injected into nude mice in the presence of matrigel, the mutant-bearing cells did not exhibit the enhanced tumorigenicity elicited by MCF7 cells transfected with wild-type ST3 cDNA, In a second approach, TIMP2 overproduction in MCF7 cells expressing hST3 was induced by retroviral infection. The co-expression of ST3 and TIMP2 failed to enhance the tumorigenicity of MCF7 cells. Notably, matrigel depleted of low-molecuiar-weight proteins and growth factors failed to promote the tumorigenicity of ST3-expressing MCF7 cells. These findings provide the first in vivo evidence that ST3 is indeed a protease that can modulate cancer progression by remodeling extracellular matrix and probably by inducing it to release the necessary microenvironmental factors. Thus, ST3 represents an interesting target for specific MMP inhibition.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; Univ Liege, Virol Lab, B-4000 Liege, Belgium	University of Liege; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Liege	Noel, A (corresponding author), Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.			Noel, Agnes/0000-0002-7670-6179				Ahmad A, 1998, AM J PATHOL, V152, P721; Ahmad A, 1997, INT J CANCER, V73, P290, DOI 10.1002/(SICI)1097-0215(19971009)73:2<290::AID-IJC21>3.0.CO;2-I; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Chenard MP, 1996, INT J CANCER, V69, P448, DOI 10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.3.CO;2-4; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; DECLERCK YA, 1998, CHEM BIOL SERPINS, P89; GARTNER MFRM, 1992, INT J CANCER, V51, P788, DOI 10.1002/ijc.2910510520; Gill LJ, 1997, BRIT J HEALTH PSYCH, V2, P131, DOI 10.1111/j.2044-8287.1997.tb00529.x; Guerin E, 1997, J BIOL CHEM, V272, P11088; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MURPHY G, 1993, J BIOL CHEM, V268, P15435; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; Noel A, 1998, INT J CANCER, V76, P267, DOI 10.1002/(SICI)1097-0215(19980413)76:2<267::AID-IJC15>3.3.CO;2-Y; NOEL AC, 1994, INT J CANCER, V56, P331, DOI 10.1002/ijc.2910560306; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; ROUYER N, 1994, INVAS METAST, V14, P269; Rudolph-Owen LA, 1998, J MAMMARY GLAND BIOL, V3, P177, DOI 10.1023/A:1018746923474; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; Tetu B, 1998, HUM PATHOL, V29, P979, DOI 10.1016/S0046-8177(98)90204-0; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201	30	65	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1605	1612		10.1038/sj.onc.1203465	http://dx.doi.org/10.1038/sj.onc.1203465			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734321	Green Submitted			2022-12-28	WOS:000086108100014
J	Spence, HJ; Johnston, I; Ewart, K; Buchanan, SJ; Fitzgerald, U; Ozanne, BW				Spence, HJ; Johnston, I; Ewart, K; Buchanan, SJ; Fitzgerald, U; Ozanne, BW			Krp1, a novel kelch related protein that is involved in pseudopod elongation in transformed cells	ONCOGENE			English	Article						Kelch; Krp1; v-fos; pseudopodia; cytoskeleton	CROSS-LINKING PROTEIN; OSTEO-SARCOMA VIRUS; C-JUN; CELLULAR-TRANSFORMATION; HYALURONAN RECEPTOR; NEGATIVE REGULATION; GENE-EXPRESSION; LIMULUS SPERM; AP-1 FUNCTION; FOS	We have previously shown that the transcription factor AP-1 regulates the expression of genes which allow neoplastically transformed rat fibroblasts to become invasive. Searches for further AP-1 target genes led to the identification of a gene encoding a novel rat kelch family member, named kelch related protein 1 (Krp1), Reich family members are characterized by a series of repeats at their carboxyl terminus and a BTB/POZ domain near their amino terminus. Rat Krp1 has a primarily cytoplasmic localization, and a small fraction appears to accumulate and co-localize with F-actin at membrane ruffle-like structures in the tips of pseudopodia. Overexpression of Krp1 in transformed rat fibroblasts led to the formation of dramatically elongated pseudopodia, while expression of truncated Krp1 polypeptides resulted in a reduction in the length of pseudopodia. We propose that the transformation-specific expression of Krp1 is required for pseudopod elongation, which are structures that are required for cell motility and invasion.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ozanne, BW (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Fitzgerald, Una/0000-0002-8019-6546				Adams JC, 1998, EMBO J, V17, P4964, DOI 10.1093/emboj/17.17.4964; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BUSHEL P, 1995, ONCOGENE, V10, P1361; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DECESARE D, 1995, ONCOGENE, V11, P365; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; GUIRGUIS R, 1987, NATURE, V329, P261, DOI 10.1038/329261a0; HAY ED, 1989, CELL MOTIL CYTOSKEL, V14, P455, DOI 10.1002/cm.970140403; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Hernandez MC, 1998, EXP CELL RES, V242, P470, DOI 10.1006/excr.1998.4109; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOOSS KU, 1995, ONCOGENE, V10, P603; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Liotta L A, 1991, Semin Cancer Biol, V2, P111; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; Nabi IR, 1999, J CELL SCI, V112, P1803; Philips J, 1998, J CELL BIOL, V143, P375, DOI 10.1083/jcb.143.2.375; RAPP UR, 1994, ONCOGENE, V9, P3493; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Taylor A, 1998, MOL CELL BIOCHEM, V183, P105, DOI 10.1023/A:1006824331819; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; Vega LR, 1997, CELL, V89, P825, DOI 10.1016/S0092-8674(00)80266-4; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WAY M, 1995, J CELL SCI, V108, P3155; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497	49	46	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1266	1276		10.1038/sj.onc.1203433	http://dx.doi.org/10.1038/sj.onc.1203433			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713668				2022-12-28	WOS:000085743800003
J	Hofmann, TG; Hehner, SP; Droge, W; Schmitz, ML				Hofmann, TG; Hehner, SP; Droge, W; Schmitz, ML			Caspase-dependent cleavage and inactivation of the Vav1 proto-oncogene product during apoptosis prevents IL-2 transcription	ONCOGENE			English	Article						apoptosis; caspase; IL-2; NF-kappa B; Vav	T-CELL RECEPTOR; POLY(ADP-RIBOSE) POLYMERASE; SIGNAL-TRANSDUCTION; DEATH; ACTIVATION; PROTOONCOGENE; REQUIREMENT; THYMOCYTES; EXCHANGE; PATHWAYS	Here we identify the hematopoietic proto-oncogene Vav1 as a caspase substrate during apoptosis in lymphoid cells. Cleavage of Vav1 is prevented by the caspase inhibitors zDEVD and zVAD as well as by expression of CrmA, Vav1 is cleaved in vivo at the evolutionary conserved caspase consensus cleavage site (DLYDC)-C-161, generating the carboxy-terminal cleavage product Vav1p76 of intermediate stability. In vitro caspase assays reveal cleavage of Vav1 at position 161 either by apoptotic cell lysates or by recombinant caspase-3, Mutation of Asp 161 to Ala leads to the usage of the adjacent alternative cleavage sequence DQID(150)D. Mutation of both cleavage sites at position 150 and 161 protects Vav1 from caspase-mediated proteolysis in vitro and in vivo. The cleavage product Vav1p76 is capable of activating JNK in T-cells, but fails to induce the phosphorylation of p38/HOG1, Vav1p76 displays a diminished capacity to activate the transcription factors NF-AT, AP-1 and NF-kappa B, and thus completely fails to activate IL-2 transcription. Since Vav1 is essential for IL-2 production and plays a central role for cytoskeletal reorganization, its proteolytic inactivation during apoptosis affects multiple downstream targets.	German Canc Res Ctr, Dept Immunochem, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schmitz, ML (corresponding author), German Canc Res Ctr, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				Baichwal V. R., 1997, CURR BIOL, V7, P94; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Cosulich SC, 1997, EMBO J, V16, P6182, DOI 10.1093/emboj/16.20.6182; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Germani A, 1999, MOL CELL BIOL, V19, P3798; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Katzav S, 1995, CRIT REV ONCOGENESIS, V6, P87; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Salojin KV, 1999, J IMMUNOL, V163, P844; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Song JS, 1999, J IMMUNOL, V163, P802; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WU J, 1995, MOL CELL BIOL, V15, P4337; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	54	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1153	1163		10.1038/sj.onc.1203406	http://dx.doi.org/10.1038/sj.onc.1203406			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713703				2022-12-28	WOS:000085567800005
J	Reynaud, EG; Guillier, M; Leibovitch, MP; Leibovitch, SA				Reynaud, EG; Guillier, M; Leibovitch, MP; Leibovitch, SA			Dimerization of the amino terminal domain of p57(Kip2) inhibits cyclin D1-Cdk4 kinase activity	ONCOGENE			English	Article						p57(Kip2); homodimerization; cyclin-Cdk inhibition	DEPENDENT KINASES; CDK INHIBITORS; P27(KIP1); P21; GENE; PROTEIN; CANCER; FAMILY; CELLS	Previous studies have led to the proposal that a single molecule of Cki can associate with the cyclin/Cdk complex to repress its activity. On the other hand, multiple inhibitor molecules are required to inhibit Cdks. In the present work, by using differently tagged p57(Kip2) proteins we demonstrate that p57(Kip2),,, bind to itself in vitro and in vivo. Mutational deletion analysis showed that the NH2 terminal domain of p57(Kip2) is necessary and sufficient to dimerization, Using an in vitro competition/association assay, we demonstrate that cyclin D1 alone, Cdk4 alone and/or cyclin D1/Cdk4 complexes do not compete for the p57(Kip2) homodimers formation. However, a mutation in the cc-helix domain of p57(Kip2) (R33L) strongly reduced homodimer formation but did not modify interaction with cyclin D1-Cdk4 complexes. Also, increasing amounts of p57(Kip2) lead in vivo to a significant augmentation in the level of p57(Kip2) homodimerization associated with cyclin D1-Cdk4 complexes and to a marked inhibition of the cyclin D1-Cdk4 kinase activity. Altogether, these data suggest a model whereby p57(Kip2) associates with itself by using the NH2 domain to form a homodimeric species which interacts with and inhibits the cyclin D1-Cdk4 complexes.	Inst Gustave Roussy, Lab Genet Oncol, CNRS, UMR 1599, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Leibovitch, SA (corresponding author), Inst Gustave Roussy, Lab Genet Oncol, CNRS, UMR 1599, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Reynaud, Emamnuel/H-2928-2019	Reynaud, Emamnuel/0000-0003-1502-661X				Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chen IT, 1996, ONCOGENE, V12, P595; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hashimoto Y, 1998, J BIOL CHEM, V273, P16544, DOI 10.1074/jbc.273.26.16544; HENGST L, 1998, CURR OPIN MICROBIOL, V227, P57; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LASSAR AB, 1995, CELL, V92, P7297; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LENORMAND JL, 1997, MOL CELL BIOL, V17, P583; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	29	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1147	1152		10.1038/sj.onc.1203403	http://dx.doi.org/10.1038/sj.onc.1203403			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713702				2022-12-28	WOS:000085567800004
J	Santos, SCR; Dumon, S; Mayeux, P; Gisselbrecht, S; Gouilleux, F				Santos, SCR; Dumon, S; Mayeux, P; Gisselbrecht, S; Gouilleux, F			Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line	ONCOGENE			English	Article						apoptosis; STAT5; PI3-kinase; Bad; Bcl-x	COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; HEMATOPOIETIC-CELLS; INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; ERYTHROPOIETIN RECEPTOR; INDUCED PROLIFERATION; TYROSINE RESIDUES; GROWTH-HORMONE	Cytokine-dependent activation of distinct signaling pathways is a common scheme thought to be required for the subsequent programmation into cell proliferation and survival. The PI 3-kinase/Akt, Ras/MAP kinase, Ras/NFIL3 and JAK/STAT pathways have been shown to participate in cytokine mediated suppression of apoptosis in various cell types. However the relative importance of these signaling pathways seems to depend on the cellular context. In several cases, individual inhibition of each pathway is not sufficient to completely abrogate cytokine mediated cell survival suggesting that cooperation en these pathways is required. Here we showed individual inhibition of STAT5, PI 3-kinase or MEK activities did not or weakly affected the IL-3 dependent survival of the bone marrow derived Ba/F3 cell line. However, the simultaneous inhibition of STAT5 and PI 3-kinase activities but not that of STAT5 and MEK reduced the IL-3 dependent survival of Ba/F3, Analysis of the expression of the Bcl-2 members indicated that phosphorylation of Bad and Bcl-x expression which are respectively regulated by the PI 3-kinase/Akt pathway and STAT5 probably explain this cooperation. Furthermore, me showed by co-immunoprecipitation studies and pull down experiments with fusion proteins encoding the GST-SH2 domains of p85 that STAT5 in its phosphorylated form interacts with the p85 subunit of the PI 3-kinase, These results indicate that the activations of STAT5 and the PI 3-kinase by IL-3 in Ba/F3 cells are tightly connected and cooperate to mediate IL-3-dependent suppression of apoptosis by modulating Bad phosphorylation and Bcl-x expression.	Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gouilleux, F (corresponding author), Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Santos, Susana/AAM-8902-2021	Constantino Rosa Santos, Susana/0000-0002-5711-1292; Gouilleux, Fabrice/0000-0001-6047-1718				Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Liu CB, 1999, J BIOL CHEM, V274, P6342, DOI 10.1074/jbc.274.10.6342; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lotem J, 1996, LEUKEMIA, V10, P925; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Miike S, 1999, J LEUKOCYTE BIOL, V65, P700, DOI 10.1002/jlb.65.5.700; MIURA O, 1994, J BIOL CHEM, V269, P614; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Onishi M, 1998, Int Rev Immunol, V16, P617, DOI 10.3109/08830189809043011; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Ozaki K, 1998, BLOOD, V92, P4652; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Park J R, 1996, Curr Opin Hematol, V3, P191; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; Zamorano J, 1998, J IMMUNOL, V160, P3502; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	56	59	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2000	19	9					1164	1172		10.1038/sj.onc.1203418	http://dx.doi.org/10.1038/sj.onc.1203418			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713704	Green Published			2022-12-28	WOS:000085567800006
J	Bearss, DJ; Subler, MA; Hundley, JE; Troyer, DA; Salinas, RA; Windle, JJ				Bearss, DJ; Subler, MA; Hundley, JE; Troyer, DA; Salinas, RA; Windle, JJ			Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors	ONCOGENE			English	Article						p53; MMTV-ras; MMTV-myc; doxorubicin; paclitaxel; apoptosis	PROGRAMMED CELL-DEATH; C-MYC; GROWTH ARREST; CANCER-THERAPY; INDUCED APOPTOSIS; MICE DEFICIENT; HA-RAS; P53; TAXOL; TUMORIGENESIS	Several transgenic mouse tumor models were utilized to explore how specific genetic alterations affect the tumor cell response to chemotherapeutic agents in vivo. Specifically, MMTV-ras transgenic mice were interbred to p53 knock-out mice to create a model for assessing the role of p53 in chemotherapeutic responses. In addition, MMTV-ras tumors were compared to MMTV-myc and MMTV-ras/myc tumors. Mice of each genotype reproducibly develop mammary and/or salivary tumors, but tumor growth dynamics vary considerably between genotypes, MMTV-ras/p53(-/-) tumors exhibit higher S phase fractions than MMTV-ras/p53(+/+) tumors, although both tumor types display very low apoptosis levels. In contrast, MMTV-myc tumors exhibit both high S phase fractions and spontaneous apoptosis levels. Tumor-bearing mice of each genotype mere treated with either doxorubicin or paclitaxel, and effects on overall tumor growth, cell cycle distribution and apoptosis were evaluated. Surprisingly, neither agent efficiently induced apoptosis in any of the tumor models, including those with wildtype p53. Rather, tumor responses were mediated primarily by changes in cell cycle distribution. However, the spontaneous apoptosis levels did serve as a predictor of tumor growth response, in that only those tumors with high pretreatment apoptosis levels underwent significant regression following treatment with either agent.	Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Windle, JJ (corresponding author), Canc Therapy & Res Ctr, Inst Drug Dev, 8122 Datapoint Dr,Suite 700, San Antonio, TX 78229 USA.		Bearss, David/Q-9141-2019	Bearss, David/0000-0002-4280-5670; Bearss, David/0000-0002-4458-826X; Windle, Jolene/0000-0001-6690-385X	NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA54174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BHALLA K, 1993, LEUKEMIA, V7, P563; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; CARDIFF RD, 1993, CANCER SURV, V16, P97; Chabner B., 1993, CANC PRINCIPLES PRAC, P325; DARZYNKIEWICZ Z, 1994, J CELL BIOCHEM, V56, P1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dorr R.T., 1994, CANC CHEMOTHERAPY HD; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAN SJ, 1994, CANCER RES, V54, P5824; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Hundley JE, 1997, CANCER RES, V57, P600; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MILAS L, 1995, CANCER CHEMOTH PHARM, V35, P297, DOI 10.1007/BF00689448; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NOOTER K, 1995, BRIT J CANCER, V71, P556, DOI 10.1038/bjc.1995.109; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SHAO ZM, 1995, ONCOGENE, V11, P493; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109	43	38	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1114	1122		10.1038/sj.onc.1203275	http://dx.doi.org/10.1038/sj.onc.1203275			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713698				2022-12-28	WOS:000085796400020
J	Deng, CX; Scott, F				Deng, CX; Scott, F			Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation	ONCOGENE			English	Article						Brca1; p53; centrosome; G(2)-M checkpoint; tumorigenesis	CANCER-SUSCEPTIBILITY GENES; EARLY EMBRYONIC LETHALITY; FAMILIAL BREAST-CANCER; SPLICE VARIANTS BRCA1A; CELL-CYCLE; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; CENTROSOME AMPLIFICATION; NUCLEAR PHOSPHOPROTEIN; MEIOTIC CELLS	Germline mutations in the tumor suppressor BRCA1 predispose women to breast and ovarian cancers. Current evidence demonstrates that mutations in BRCA1 do not directly result in tumor formation, but instead cause genetic instability, subjecting cells to high risks of malignant transformation, In an animal model in which Brca1 is mutated specifically in mammary epithelium, tumorigenesis occurs in mutant glands at low frequency after a long latency. Notably, introduction of a p53-null allele significantly enhanced mammary gland tumor formation in Brca1 conditional mutant mice. These results are consistent with a model that Brca1 is a caretaker gene, whose absence causes genetic instability and triggers further alterations, including inactivation of tumor suppressor genes and/or activation of oncogenes, leading to tumor formation.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1996, CANCER RES, V56, P3168; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Cui JQ, 1998, ONCOL REP, V5, P585; Cui JQ, 1998, ONCOL REP, V5, P591; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; Dennis C, 1999, NAT GENET, V22, P10, DOI 10.1038/8714; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; Eisinger F, 1997, LANCET, V350, P1101, DOI 10.1016/S0140-6736(05)70461-X; Ellisen LW, 1998, ANNU REV MED, V49, P425; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hagmann M, 1999, SCIENCE, V284, P723, DOI 10.1126/science.283.5403.777; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Larson JS, 1997, CANCER RES, V57, P3351; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lu ML, 1996, CANCER RES, V56, P4578; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paterson JWE, 1998, DIS MARKERS, V13, P261, DOI 10.1155/1998/298530; Pihan GA, 1998, CANCER RES, V58, P3974; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tanaka T, 1999, CANCER RES, V59, P2041; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	77	122	125	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1059	1064		10.1038/sj.onc.1203269	http://dx.doi.org/10.1038/sj.onc.1203269			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713690				2022-12-28	WOS:000085796400012
J	Green, JE; Shibata, MA; Yoshidome, K; Liu, ML; Jorcyk, C; Anver, MR; Wigginton, J; Wiltrout, R; Shibata, E; Kaczmarczyk, S; Wang, W; Liu, ZY; Calvo, A; Couldrey, C				Green, JE; Shibata, MA; Yoshidome, K; Liu, ML; Jorcyk, C; Anver, MR; Wigginton, J; Wiltrout, R; Shibata, E; Kaczmarczyk, S; Wang, W; Liu, ZY; Calvo, A; Couldrey, C			The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma	ONCOGENE			English	Article						transgenic mice; C3(1); SV40 T-antigen; mammary cancer; prostate cancer; rat prostate steroid binding protein; tumor progression; DCIS	TUMOR PROGRESSION; BREAST-CANCER; RESPONSE ELEMENTS; MICE; GENE; VIRUS; SV40; PROSTATE; EXPRESSION; BINDING	The 5' flanking region of the C3(1) component of the rat prostate steroid binding protein (PSBP) has been used to successfully target the expression of the SV40 large T-antigen (Tag) to the epithelium of both the mammary and prostate glands resulting in models of mammary and prostate cancers which histologically resemble the human diseases. Atypia of the mammary ductal epithelium develops at about 8 weeks of age, progressing to mammary intraepithelial neoplasia (resembling human ductal carcinoma in situ [DCIS]) at about 12 weeks of age with the development of invasive carcinomas at about 16 weeks of age in 100% of female mice. The carcinomas share features to what has been classified in human breast cancer as infiltrating ductal carcinomas. All FVB/N female mice carrying the transgene develop mammary cancer with about a 15% incidence of lung metastases. Approximately 10% of older male mice develop anaplastic mammary carcinomas. Unlike many other transgenic models in which hormones and pregnancy are used to induce a mammary phenotype, C3(1)/Tag mice develop mammary tumors in the mammary epithelium of virgin animals without hormone supplementation or pregnancy. Although mammary tumor development appears hormone-responsive at early stages, invasive carcinomas are hormone-independent, which corresponds to the loss of estrogen receptor-a expression during tumor progression. Molecular and biologic factors related to mammary tumor progression can be studied in this model since lesions evolve over a predictable time course. Genomic alterations have been identified during tumor progression, including an amplification of the distal portion of chromosome 6 containing ki-ras and loss of heterozygosity (LOH) in other chromosomal regions. We have demonstrated that stage specific alterations in the expression of genes which are critical regulators of the cell cycle and apoptosis are functionally important in vivo. C3(1)/Tag mice appear useful for testing particular therapies since growth of the mammary tumors can be reduced using chemopreventive agents, cytokines, and an anti-angiogenesis agent.	NCI, Transgen Oncogenesis Grp, Lab Cell Regulat & Carcinogneesis, Bethesda, MD 20892 USA; Boise State Univ, Dept Biol, Boise, ID 83725 USA; SAIC, Pathol Histopathol Lab, Frederick, MD 21712 USA; NCI, Lab Expt Immunol, Frederick, MD 21712 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Idaho; Boise State University; Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Green, JE (corresponding author), NCI, Transgen Oncogenesis Grp, Lab Cell Regulat & Carcinogneesis, Bldg 41,Room C629, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019; Calvo, Alfonso/V-7945-2017	Shibata, Masa-Aki/0000-0002-3350-7305; Calvo, Alfonso/0000-0003-4074-4242	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009262] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON J, 1989, MOL CELL BIOL, V9, P2254, DOI 10.1128/MCB.9.5.2254; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Carbone M, 1999, J CELL PHYSIOL, V180, P167, DOI 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CATO ACB, 1989, J STEROID BIOCHEM, V34, P139, DOI 10.1016/0022-4731(89)90074-5; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CLAESSENS F, 1990, MOL CELL ENDOCRINOL, V74, P203, DOI 10.1016/0303-7207(90)90225-W; COX LA, 1994, BREAST CANCER RES TR, V32, P19, DOI 10.1007/BF00666203; DCOLE CH, 1998, FIELDS VIROLOGY, V2, P1997; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Furth PA, 1998, DEV BIOL STAND, V94, P281; HEYNS W, 1977, EUR J BIOCHEM, V78, P221, DOI 10.1111/j.1432-1033.1977.tb11733.x; Hodi F S, 1998, Surg Oncol Clin N Am, V7, P471; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Maroulakou IG, 1997, MOL CARCINOGEN, V20, P168, DOI 10.1002/(SICI)1098-2744(199710)20:2<168::AID-MC3>3.0.CO;2-J; MAROULAKOU IG, 1999, IN PRESS ONCOGENE; Martini F, 1998, DEV BIOLOGICALS, V94, P55; MERLINO G, 1994, SEMIN CANCER BIOL, V5, P13; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Moens U, 1997, VIRUS GENES, V15, P135, DOI 10.1023/A:1007962908248; PARKER MG, 1987, J CELL BIOCHEM, V35, P285, DOI 10.1002/jcb.240350403; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; RUSHMERE NK, 1987, MOL CELL ENDOCRINOL, V51, P259, DOI 10.1016/0303-7207(87)90036-0; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 1998, CARCINOGENESIS, V19, P195, DOI 10.1093/carcin/19.1.195; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Shibata MA, 1998, TOXICOL PATHOL, V26, P177, DOI 10.1177/019262339802600121; Shibata MA, 1996, CANCER RES, V56, P4894; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; TAN JA, 1992, J BIOL CHEM, V267, P4456; Tehranian A, 1996, AM J PATHOL, V149, P1177; VANAKEN H, 1996, MOL CELL ENDOCRINOL, V121, P1967; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581; Watson MA, 1996, CANCER RES, V56, P860; YINB C, 1997, NATURE, V385, P637; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	39	175	180	0	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1020	1027		10.1038/sj.onc.1203280	http://dx.doi.org/10.1038/sj.onc.1203280			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713685				2022-12-28	WOS:000085796400007
J	Schulze-Garg, C; Lohler, J; Gocht, A; Deppert, W				Schulze-Garg, C; Lohler, J; Gocht, A; Deppert, W			A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland	ONCOGENE			English	Article						DCIS; ductal carcinoma in situ; mouse model; SV40 large T-antigen	LARGE T-ANTIGEN; BREAST-CONSERVING SURGERY; PROTEIN GENE PROMOTER; IN-SITU; INTRADUCTAL CARCINOMA; RESTRICTION ELEMENT; BALB/C MICE; HYBRID GENE; HA-RAS; EXPRESSION	The ductal carcinoma in situ (DCIS) of the mammary gland represents an early, pre-invasive stage in the development of invasive breast carcinoma and is increasingly diagnosed since the introduction of high-quality mammography screening. Uncertainties in the prognosis for patients with DCIS have caused a controversial discussion about adequate treatment, and it is suspected that most patients undergoing mastectomy may be overtreated, In order to improve treatment and treatment decision, it therefore is highly desirable to identify prognostic markers and therapeutic targets for DCIS. We here introduce a set of transgenic mice (WAP-T and WAP-T-NP lines) presenting with various morphological forms of DCLS-like lesions. In these mite the SV40 large tumor antigen is specifically induced in epithelial cells of the terminal duct lobular units (TDLU), As a consequence of continuous expression of the oncogene, the animals develop multifocal DCIS and consequently invasive carcinoma within strain specific periods of latency. DCIS lesions in transgenic mire exhibit distinct architectural and cytological features which closely resemble those commonly present in humans, We therefore propose these transgenic lines as an experimental model to study the underlying molecular events leading to DCIS and its progression to invasive disease.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Mice & More, D-20251 Hamburg, Germany; Marienkrankenhaus, Inst Pathol, D-22087 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; St. Marien Hospital	Schulze-Garg, C (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; BRIGHT RK, 1994, J IMMUNOL, V153, P2064; BURDON T, 1991, J BIOL CHEM, V266, P6909; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; DEPPERT W, 1979, NATURE, V277, P322, DOI 10.1038/277322a0; Ernster V L, 1997, J Natl Cancer Inst Monogr, P151; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; Fanning E, 1998, DEV BIOL STAND, V94, P3; FRELINGER JA, 1983, TRANSPLANT P, V15, P2024; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P167; Husler MR, 1998, TRANSGENIC RES, V7, P253, DOI 10.1023/A:1008865911660; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; ORN A, 1982, NATURE, V297, P415, DOI 10.1038/297415a0; PFIZENMAIER K, 1980, J IMMUNOL, V124, P1888; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; RAVDIN PM, 1997, DUCTAL CARCINOMA IN; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SANDGREN EP, 1995, CANCER RES, V55, P3915; SCHIRMBECK R, 1993, EUR J IMMUNOL, V23, P1528, DOI 10.1002/eji.1830230720; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; Scott MA, 1997, HUM PATHOL, V28, P967, DOI 10.1016/S0046-8177(97)90013-7; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SILVERSTEIN MJ, 1990, CANCER, V66, P102, DOI 10.1002/1097-0142(19900701)66:1<102::AID-CNCR2820660119>3.0.CO;2-5; SILVERSTEIN MJ, 1995, EUR J CANCER, V31A, P1425, DOI 10.1016/0959-8049(95)00283-O; SILVERSTEIN MJ, 1997, DUCTAL CARCINOMA IN; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Talamonti MS, 1996, SEMIN SURG ONCOL, V12, P300; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; Zerrahn J, 1996, J IMMUNOL, V156, P3919	45	69	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1028	1037		10.1038/sj.onc.1203281	http://dx.doi.org/10.1038/sj.onc.1203281			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713686				2022-12-28	WOS:000085796400008
J	Gartel, AL; Najmabadi, F; Goufman, E; Tyner, AL				Gartel, AL; Najmabadi, F; Goufman, E; Tyner, AL			A role for E2F1 in Ras activation of p21((WAF1/CIP1)) transcription	ONCOGENE			English	Article						p21; Ras; E2F; transient transfection; CAT assay	CELL-CYCLE PROGRESSION; INHIBITOR P21 GENE; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; DEREGULATED EXPRESSION; P53; D1; P21(WAF1/CIP1); APOPTOSIS	We recently reported that E2F1 could transactivate the p21 promoter via cis-acting elements between -119 to +16 bp of the p21 gene. Here we show that activated V12-H-Ras can induce the p21 promoter through the same region of the p21 promoter by a p53-independent mechanism in NIH3T3 cells. In contrast, activated Ras was not able to induce the p21 promoter in E2F1(-/-) fibroblasts, suggesting that E2F1 is required for induction of the p21 promoter by activated Ras, Cotransfection of increasing concentrations of dominant negative E2F1 alone, or with dominant negative DP1 into NIH3T3 cells suppressed induction of the p21 promoter by activated Pas. These data suggest that p53-independent induction of the p21 promoter by activated Ras is mediated at least in part by E2F1.	Univ Illinois, Coll Med, Dept Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Coll Med, Dept Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.		Goufman, Eugene/AAG-6882-2019	Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048836, R01DK056283] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056283, R01 DK056283-05, DK48836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Halaban R, 1998, ONCOGENE, V16, P2489, DOI 10.1038/sj.onc.1201773; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; SCHULZE A, 1994, ONCOGENE, V9, P3475; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Wang ZM, 1998, P NATL ACAD SCI USA, V95, P15583, DOI 10.1073/pnas.95.26.15583; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	45	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					961	964		10.1038/sj.onc.1203411	http://dx.doi.org/10.1038/sj.onc.1203411			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702805				2022-12-28	WOS:000085567700014
J	Parker, GA; Touitou, R; Allday, MJ				Parker, GA; Touitou, R; Allday, MJ			Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis	ONCOGENE			English	Article						EBV; EBNA3C; cell cycle checkpoints; multinucleated cells; p27(KIP1)	CANCER; DNA; P27(KIP1); PROTEIN; TRANSCRIPTION; ONCOPROTEIN	Expression of EBNA3C is essential for the immortalization of B cells by EBV in vitro and, in co-operation with activated ras, EBNA3C has oncogenic activity in primary rodent fibroblasts. This suggested that this viral oncoprotein might disrupt the cyclin/CDK-pRb-E2F pathway, which regulates cell cycle progression at the restriction point (R-point) in G1 of the proliferation cycle. An assay was established in which transfected EBNA3C-positive cells could be sorted and simultaneously analysed for their distribution in the cell cycle, This revealed that in NIH3T3 fibroblasts compelled to arrest by serum-withdrawal. EBNA3C induces nuclear division that is often divorced from cytokinesis and so produces bi- and multinucleated cells. This was confirmed using the ecdysone-inducible system for expression of EBNA3C in human U2OS cells and by microinjection of expression vectors into NIH3T3 and U2OS, Further analysis revealed that in the inducible system, EBNA3C expression inhibits the accumulation of p27(KIP1) but not the dephosphorylation of pRb, Experiments using the microtubule destabilizing drug nocodazole, showed that EBNA3C could abrogate the mitotic spindle checkpoint.	Univ London Imperial Coll Sci Technol & Med, Sect Virol & Cell Biol, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Virol & Cell Biol, St Marys Campus,Norfolk Pl, London W2 1PG, England.							Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bain M, 1996, J VIROL, V70, P2481, DOI 10.1128/JVI.70.4.2481-2489.1996; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; KIEFF E, 1996, FIELDS VIROLOGY; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Parker GA, 1996, ONCOGENE, V13, P2541; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; Rickinson A. B., 1996, FIELDS VIROLOGY; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	24	78	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					700	709		10.1038/sj.onc.1203327	http://dx.doi.org/10.1038/sj.onc.1203327			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698515				2022-12-28	WOS:000085192000012
J	Imatani, A; Callahan, R				Imatani, A; Callahan, R			Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines	ONCOGENE			English	Article						NOTCH-4/INT-3; activated gene product; human	MAMMARY EPITHELIAL-CELLS; SPLIT COMPLEX GENES; TRUNCATED INT3 GENE; NOTCH-GENE; NEOPLASTIC TRANSFORMATION; DROSOPHILA NOTCH; MAMMALIAN NOTCH; HUMAN HOMOLOG; C-MYC; DIFFERENTIATION	Ectopic expression of the intracellular domain of NOTCH-4/INT-3 leads to tumorigenesis in the mouse mammary gland. This results from a gain-of-function mutation. To evaluate gain-of-function NOTCH-4/INT-3 activity in human cancers we have surveyed human breast, lung, and colon carcinoma tissue culture cell lines for evidence of increased NOTCH-4/INT-3 RNA expression. High levels of a 1.8 Kb NOTCH-4/INT-3 RNA species are detected in normal human testis but not in other tissues where a 6.5 Kb species is prevalent. Transformed human cancer cell lines express the 1.8 Kb NOTCH-4/INT-3 RNA species. We show that this RNA species encodes a truncated form of the NOTCH-4/INT3 intracellular domain (ICD), This novel NOTCH-4/ INT-3 protein includes the CDC10 repeats and amino acid residues C-terminal to them, but is missing the CBF-1 binding region of the NOTCH-4/INT-3 ICD, This suggests that it has a different mode of action, Furthermore, we show that a transgene which expresses the 1.8 Kb NOTCH-4/INT-3 RNA species in the 'normal' human mammary epithelial cell line MCF-10A enables these cells to grow in soft agar.	NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Callahan, R (corresponding author), NCI, Tumor Immunol & Biol Lab, NIH, Bldg 10,Room 5B50, Bethesda, MD 20892 USA.							Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Hardy J, 1999, NATURE, V398, P466, DOI 10.1038/18979; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Jolicoeur P, 1998, BIOCHEM SOC SYMP, P159; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Matsuno K, 1997, DEVELOPMENT, V124, P4265; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; SARKAR NH, 1994, VIROLOGY, V203, P52, DOI 10.1006/viro.1994.1454; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Shawber C, 1996, DEVELOPMENT, V122, P3765; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SMITHIES O, 1981, CELL, V26, P345, DOI 10.1016/0092-8674(81)90203-8; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	38	87	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					223	231		10.1038/sj.onc.1203295	http://dx.doi.org/10.1038/sj.onc.1203295			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645000				2022-12-28	WOS:000084844400007
J	Weterman, MAJ; von Groningen, JJM; Jansen, A; van Kessel, AG				Weterman, MAJ; von Groningen, JJM; Jansen, A; van Kessel, AG			Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins	ONCOGENE			English	Article						TFE3; PRCC; renal cell carcinoma; t(X;1) translocation	HELIX-LOOP-HELIX; HEAVY-CHAIN GENE; ACTIVATION DOMAINS; TRANSLOCATION X-1; PROLINE-RICH; DNA-BINDING; TRANSCRIPTION; ENHANCER; IDENTIFICATION; EXPRESSION	The papillary renal cell carcinoma-associated t(X;1)(p11;q21) leads to fusion of the transcription factor TFE3 gene on the X-chromosome to a novel gene, PRCC, on chromosome 1, As a result, two putative fusion proteins are formed: PRCCTFE3, which contains all known domains for DNA binding, dimerization, and transactivation of the TFE3 protein, and the reciprocal product TFE3PRCC, Upon transfection into COS cells, both wild type and fusion proteins were found to be located in the nucleus, When comparing the transactivating capacities of these (fusion) proteins, significant differences were noted. PRCCTFE3 acted as a threefold better transactivator than wild type TFE3 both in a TFE3-specific and in a general (Zebra) reporter assay. In addition, PRCC and the two fusion proteins were found to he potent transactivators in the Zebra reporter assay. We propose that, as a result of the (X;1) translocation, fusion of the N-terminal PRCC sequences to TFE3 alters the transactivation capacity of the transcription factor thus leading to aberrant gene regulation and, ultimately, tumor formation.	Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Weterman, MAJ (corresponding author), Univ Nijmegen Hosp, Dept Human Genet 417, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kessel, Ad Geurts/A-2810-2010					ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; Askovic S, 1997, BIOTECHNIQUES, V22, P948, DOI 10.2144/97225rr02; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dijkhuizen T, 1998, CANCER GENET CYTOGEN, V104, P74; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rogaia D, 1997, CANCER RES, V57, P799; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; TONK V, 1995, CANCER GENET CYTOGEN, V81, P72, DOI 10.1016/S0165-4608(94)00195-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 1996, CYTOGENET CELL GENET, V75, P2, DOI 10.1159/000134444	30	61	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					69	74		10.1038/sj.onc.1203255	http://dx.doi.org/10.1038/sj.onc.1203255			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644981				2022-12-28	WOS:000084844300008
J	Meek, DW				Meek, DW			Mechanisms of switching on p53: a role for covalent modification?	ONCOGENE			English	Article						p53 activation; DNA damage; phosphorylation	DEPENDENT PROTEIN-KINASE; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; CELL-CYCLE ARREST; PHOSPHORYLATED IN-VITRO; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; ULTRAVIOLET-RADIATION; V(D)J RECOMBINATION	The p53 protein plays a pivotal role in activating and integrating adaptive cellular responses to a wide range of environmental stresses, Activation of p53 can occur by different molecular routes, depending on the nature of the activating signal. Central to the activation process, by whichever route, is the destabilization of the p53-MDM2 interaction, The molecular mechanisms which activate p53 involve elements of post-translational modification, protein stabilization and protein-protein interaction. Two central themes are emerging from recent work in this area. The first is that there are common events in the p53 activation process among different activating pathways. The second is that activation involves not just a single molecular event such as disruption of the p53-MDM2 interaction, but a series of sequential events the nature of which is governed by the type of activating stimulus. This review summarizes our current knowledge of the p53 activation process in response to two stimuli, DNA damage and activated oncogenes, and considers the contribution made by multisite phosphorylation in determining the nature of the p53 response.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.							Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jongmans W, 1996, ONCOGENE, V13, P1133; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meek DW, 1997, PATHOL BIOL, V45, P804; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1999, J PATHOL, V187, P112; QUELLE DE, 1995, CELL, V83, P993; Rathmell WK, 1997, CANCER RES, V57, P68; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	91	205	207	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	1999	18	53					7666	7675		10.1038/sj.onc.1202951	http://dx.doi.org/10.1038/sj.onc.1202951			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618706				2022-12-28	WOS:000084634500005
J	Doitsh, G; Shaul, Y				Doitsh, G; Shaul, Y			HBV transcription repression in response to genotoxic stress is p53-dependent and abrogated by pX	ONCOGENE			English	Article						HBV transcription; DNA-damage; cisplatin; HCC; pX and p53; HBV RNA half life	HEPATITIS-B-VIRUS; SUPPRESSOR GENE-PRODUCT; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; C-ABL; ENCODED COACTIVATOR; ENHANCER ELEMENT; BINDING PROTEIN; TRANSGENIC MICE; P53	Transcription of hepatitis B Virus (HBV), an important risk factor of hepatocellular carcinoma (HCC), is controlled by cellular transcription activators including some of the cellular signaling targets, Consequently, HBV transcription rate changes in response to the cellular physiological conditions. In this report we investigated HBV gene expression and the role of physiological levels of the viral X protein (pX) under cisplatin induced genotoxic stress. We show that under these conditions the RNA level of an HBV mutant which does not express pX is sharply reduced. Studies revealed that transcription repression is responsible for the observed reduction in HBV RNA level. Repression of HBV transcription was obtained only in the p53 proficient cells. Furthermore, HBV transcription rate is recovered by the cotransfected p53 dominant negative plasmid, indicating that p53 is directly responsible for HBV transcription repression. Unexpectedly, p73, the recent p53 homologue, does not repress but rather activates HBV transcription. Interestingly, pX produced either by the HBV genome or by a cotransfected plasmid, relieves the p53 mediated repression. Collectively, these results attribute a physiological role to p53-inactivation by pX, and explain how pX may support HCC development.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.							Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; CHEONG JH, 1995, EMBO J, V14, P142; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Haviv I, 1998, GENE DEV, V12, P1217, DOI 10.1101/gad.12.8.1217; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; HOSONO S, 1991, ONCOGENE, V6, P237; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lin Y, 1997, CANCER RES, V57, P5137; LIU X, 1995, MOL CELL BIOL, V15, P6474; LUBER B, 1993, RES VIROLOGY, V144, P311, DOI 10.1016/S0923-2516(06)80047-6; NATOLI G, 1994, ONCOGENE, V9, P2837; Ohno H, 1997, J MED VIROL, V52, P413, DOI 10.1002/(SICI)1096-9071(199708)52:4<413::AID-JMV12>3.0.CO;2-H; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Raney AK, 1997, J VIROL, V71, P1058, DOI 10.1128/JVI.71.2.1058-1071.1997; ROBERTS JJ, 1981, BIOCHIM BIOPHYS ACTA, V655, P146, DOI 10.1016/0005-2787(81)90004-6; Sambrook J., 2002, MOL CLONING LAB MANU; Schaefer S, 1998, J GEN VIROL, V79, P767, DOI 10.1099/0022-1317-79-4-767; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHAUL Y, 1981, EUR J BIOCHEM, V116, P461, DOI 10.1111/j.1432-1033.1981.tb05358.x; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHAULIAN E, 1995, ONCOGENE, V10, P671; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Takada S, 1996, VIROLOGY, V216, P80, DOI 10.1006/viro.1996.0036; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Zhu JH, 1998, CANCER RES, V58, P5061	57	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7506	7513		10.1038/sj.onc.1203209	http://dx.doi.org/10.1038/sj.onc.1203209			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602509				2022-12-28	WOS:000084119600011
J	del Peso, L; Gonzalez, VM; Hernandez, R; Barr, FG; Nunez, G				del Peso, L; Gonzalez, VM; Hernandez, R; Barr, FG; Nunez, G			Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt	ONCOGENE			English	Article						Akt; FKHR; PAX3-FKHR; transcription	TUMOR ALVEOLAR RHABDOMYOSARCOMA; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN; PAX3; PHOSPHORYLATION; SIGNALS; DAF-16; GENE; TRANSLOCATION	Akt, a proto-oncogene that encodes a cytosolic serine/threonine kinase, can phosphorylate and modulate the activity of several proteins involved in cellular metabolism and survival. Recently, two mammalian highly related forkhead transcription factors FKHRL1 and AFX and their nematode homologue Daf-16 have been found to be targets of this kinase, Here we show that Akt, but not inactive Akt, represses the transcriptional activity of FKHR, another member of the forkhead family. FKHR mutants with alanine substitutions at three Akt phosphorylation consensus sites (T24, S256 and S319) were inhibited by Akt, but mutation of all three sites rendered FKHR resistant to suppression. By contrast, the transcriptional activity of the oncogenic PAX3-FKHR fusion protein, containing two consensus phosphorylation sites, was not inhibited by Akt, Importantly, Akt inhibited the translocation of FKHR to the nucleus, providing a mechanism by which Akt might regulate the transcriptional activity of FKHR, Consistent with this model, the localization of the PAX3-FKHR fusion protein was nuclear and was not altered by Akt, These results provide evidence that Akt inhibits the transcriptional activity of FKHR by controlling its trafficking into the nucleus and that oncogenic PAX3-FKHR can escape this negative regulation by Akt.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		del Peso, Luis/K-9391-2014; Gonzalez, Victor M/F-7396-2010; Nuñez, Gabriel/A-7160-2014	del Peso, Luis/0000-0003-4014-5688; Gonzalez, Victor M/0000-0001-7538-0552; 	NATIONAL CANCER INSTITUTE [P01CA075136, K04CA064421, R01CA064202] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64202, P01-CA75136-01A1, CA-64421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SUBLETT JE, 1995, ONCOGENE, V11, P545; Wang W, 1998, CANCER RES, V58, P4426	24	107	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7328	7333		10.1038/sj.onc.1203159	http://dx.doi.org/10.1038/sj.onc.1203159			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602488				2022-12-28	WOS:000084119400018
J	Powell, AJ; Darmon, AJ; Gonos, ES; Lam, EWF; Peden, KWC; Jat, PS				Powell, AJ; Darmon, AJ; Gonos, ES; Lam, EWF; Peden, KWC; Jat, PS			Different functions are required for initiation and maintenance of immortalization of rat embryo fibroblasts by SV40 large T antigen	ONCOGENE			English	Article						SV40 T antigen; immortalization; REFs	VIRUS-40 LARGE-T; SIMIAN-VIRUS-40 LARGE-T; LARGE TUMOR-ANTIGEN; SIMIAN VIRUS-40; ADENOVIRUS E1A; J-DOMAIN; TRANSFORMING FUNCTION; CELLULAR PROTEIN-P53; HYDROPHOBIC REGION; P53 BINDING	We have used two different, but complementary assays to characterize functions of SV40 T antigen that are necessary for its ability to immortalize rat embryo fibroblasts. In accordance with previous work, we found that several functions were required. These include activities that map to the p53 binding domain and the amino terminal 176 amino acids which contain the J domain as well as the CR1 and CR2 domain required for binding and sequestering the RE family of pocket proteins. Moreover, we found that even though activities dependent only upon the amino terminus were sufficient for immortalization they were unable to maintain it. This suggests that immortalization by these amino terminal functions requires either additional events or immortalization of a subset of cells within the heterogeneous rat embryo fibroblast population, We further found that an activity dependent upon amino acids 17-27 which remove a portion of the CR1 domain and the predicted alpha-1 helix of the J domain was not necessary to maintain growth but was required for direct immortalization suggesting that at least one of the functions required initially was not required to maintain the immortal state. This represents the first demonstration that some of the functions required for maintenance of the immortal state differ from those required for initiation of immortalization.	Royal Free & Univ Coll Med Sch, Sch Med, Ludwig Inst Canc Res, London W1P 8BT, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Cell Biol & Virol, London W2 1PG, England; US FDA, Ctr Biol Evaluat & Res, Lab Retrovirus Res, Bethesda, MD 20892 USA; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; US Food & Drug Administration (FDA); University of London; University College London	Jat, PS (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.		Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Powell, Andrew/0000-0003-1540-537X				Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; CAVENDER JF, 1995, J VIROL, V69, P923, DOI 10.1128/JVI.69.2.923-934.1995; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; Conzen SD, 1995, ONCOGENE, V11, P2295; CONZEN SD, 1994, SEMIN VIROL, V5, P349, DOI 10.1006/smvy.1994.1039; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1989, ONCOGENE, V4, P1103; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1992, ONCOGENE, V7, P1885; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; Peden KWC, 1998, VIRUS GENES, V16, P153, DOI 10.1023/A:1007941622680; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; Porras A, 1996, J VIROL, V70, P6902; Powell AJ, 1998, EXP CELL RES, V240, P252, DOI 10.1006/excr.1998.3937; RILEY TEW, 1990, MOL CELL BIOL, V10, P6664, DOI 10.1128/MCB.10.12.6664; Salminen A, 1997, BIOCHEM BIOPH RES CO, V238, P712, DOI 10.1006/bbrc.1997.7371; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOULE HR, 1979, J VIROL, V30, P523, DOI 10.1128/JVI.30.2.523-532.1979; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; Tevethia MJ, 1998, VIROLOGY, V243, P303, DOI 10.1006/viro.1998.9056; TEVETHIA MJ, 1988, VIROLOGY, V162, P79; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VOUSDEN KH, 1989, ONCOGENE, V4, P153; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	56	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7343	7350		10.1038/sj.onc.1203154	http://dx.doi.org/10.1038/sj.onc.1203154			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602490				2022-12-28	WOS:000084119400020
J	Greeve, J; Lellek, H; Apostel, F; Hundoegger, K; Barialai, A; Kirsten, R; Welker, S; Greten, H				Greeve, J; Lellek, H; Apostel, F; Hundoegger, K; Barialai, A; Kirsten, R; Welker, S; Greten, H			Absence of APOBEC-1 mediated mRNA editing in human carcinomas	ONCOGENE			English	Article						mRNA editing; APOBEC-1; human carcinoma; apo B; NAT1	B MESSENGER-RNA; TISSUE-SPECIFIC EXPRESSION; CATALYTIC SUBUNIT; KINETOPLASTID PROTOZOA; CYTIDINE DEAMINASE; PROTEIN; GENE; ENZYME; CLONING; MOTIF	The transgene expression of the catalytic subunit APOBEC-1 of the apo B mRNA editing enzyme-complex can cause hepatocellular carcinoma in mice and rabbits. It has been proposed that aberrant editing of mRNA may represent a novel oncogenic principle. This investigation aimed to define whether such aberrant hyperediting mediated by APOBEC-1 occurs in human carcinomas. Editing and hyperediting of apo B, NAT1 or NF1 mRNA was not identified in any of 28 resected tumor specimens, including hepatocellular, bile duct, gastric, colorectal, pancreatic adeno- and neuroendocrine, lung adeno-, medullary thyroid and breast carcinoma, soft tissue sarcoma and neuroblastoma. In most types of carcinoma, significant length for full-length APOBEC-1 mRNA could not be detected. Low level expression of APOBEC-1 was found in colorectal and gastric carcinoma where most of the APOBEC-1 mRNA is inactivated by alternate splicing. The 'auxiliary' components of the apo B mRNA editing enzyme-complex are missing in many tumors including colorectal and gastric carcinoma, but are highly expressed in hepatocellular, lung adeno- and breast carcinoma all of which lack APOBEC-1. Taken together, either APOBEC-1 or the 'auxiliary' components of the apo B mRNA editing enzyme-complex or both are missing in human carcinomas resulting in the absence of mRNA editing. Currently, there is no evidence that aberrant editing mediated by APOBEC-1 contributes to the tumorigenesis of natural human carcinomas.	Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, D-20246 Hamburg, Germany	University of Hamburg	Greeve, J (corresponding author), Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, Martinistr 52, D-20246 Hamburg, Germany.							ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Cappione AJ, 1997, AM J HUM GENET, V60, P305; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Fujino T, 1998, GENOMICS, V47, P266, DOI 10.1006/geno.1997.5110; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; Greeve J, 1998, ARTERIOSCL THROM VAS, V18, P1079, DOI 10.1161/01.ATV.18.7.1079; Greeve J, 1996, J LIPID RES, V37, P2001; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; GREEVE J, 1993, J LIPID RES, V34, P1367; Hirano H, 1997, J LIPID RES, V38, P847; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lee RM, 1998, GASTROENTEROLOGY, V115, P1096, DOI 10.1016/S0016-5085(98)70080-0; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Qian XB, 1997, J BIOL CHEM, V272, P18060, DOI 10.1074/jbc.272.29.18060; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; Skuse GR, 1996, NUCLEIC ACIDS RES, V24, P478, DOI 10.1093/nar/24.3.478; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321	33	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6357	6366		10.1038/sj.onc.1203039	http://dx.doi.org/10.1038/sj.onc.1203039			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597235				2022-12-28	WOS:000083934100020
J	Grignani, F; Gelmetti, V; Fanelli, M; Rogaia, D; De Matteis, S; Ferrara, FF; Bonci, D; Grignani, F; Nervi, C; Pelicci, PG				Grignani, F; Gelmetti, V; Fanelli, M; Rogaia, D; De Matteis, S; Ferrara, FF; Bonci, D; Grignani, F; Nervi, C; Pelicci, PG			Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response	ONCOGENE			English	Article						retinoic acid; leukaemia; protein complexes; PML/RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; PLZF-RAR-ALPHA; RECEPTOR-ALPHA; FUSION PROTEINS; HISTONE DEACETYLASE; GENE-PRODUCT; CELLS; TRANSLOCATION; ONCOPROTEIN; BINDING	Retinoic Acid (RA) treatment induces disease remission of Acute Promyelocytic Leukaemia (APL) patients by triggering terminal differentiation of neoplastic cells. RA-sensitivity in APL is mediated by its oncogenic protein, which results from the recombination of the PML and the RA receptor alpha (RAR alpha) genes (PML/RAR alpha fusion protein). Ectopic expression of PML/RAR alpha into haemopoietic cell lines results in increased response to RA-induced differentiation. By structure-function analysis of PML/RAR alpha-mediated RA-differentiation, we demonstrated that fusion of PML and RAR alpha sequences and integrity of the PML dimerization domain and of the RAR alpha DNA binding region are required for the effect of PML/RAR alpha on RA-differentiation. Indeed, direct fusion of the PML dimerization domain to the Nor C-terminal extremities' of RAR alpha retained full biological activity. All the biologically active PML/RAR alpha mutants formed high molecular weight complexes in vivo. Functional analysis of mutations within the PML dimerization domain revealed that the capacity to form PML/RAR alpha homodimers, but not PML/RAR alpha-PML heterodimers, correlated with the RA response. These results suggest that targeting of RAR alpha sequences by the PML dimerization domain and formation of nuclear PML/RAR alpha homodimeric complexes are crucial for the ability of PML/RAR alpha to mediate RA-response.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Univ La Sapienza, Dipartimento Istol & Embriol Umana, I-00161 Rome, Italy	IRCCS European Institute of Oncology (IEO); University of Perugia; Istituto Superiore di Sanita (ISS); Sapienza University Rome	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Grignani, Francesco/AAC-2565-2022; Bonci, Desiree/K-6488-2016; Fanelli, Mirco/F-2665-2011	Bonci, Desiree/0000-0002-2472-5140; Fanelli, Mirco/0000-0002-9649-8661; NERVI, Clara/0000-0001-9341-0188				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CASINI T, 1998, IN PRESS ONCOGENE; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FANELLI M, 1998, IN PRESS BLOOD; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; GAUB MP, 1989, P NATL ACAD SCI USA, V86, P3089, DOI 10.1073/pnas.86.9.3089; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; GRIGNANI F, 1993, CELL, V74, P1; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LIZHEN H, 1997, PNAS, V94, P5302; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NERVI C, 1992, CANCER RES, V52, P3687; NERVI C, 1998, IN PRESS BLOOD; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945	35	39	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6313	6321		10.1038/sj.onc.1203029	http://dx.doi.org/10.1038/sj.onc.1203029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597230				2022-12-28	WOS:000083934100015
J	Preudhomme, C; Roumier, C; Hildebrand, MP; Dallery-Prudhomme, E; Lantoine, D; Lai, JL; Daudignon, A; Adenis, C; Bauters, F; Fenaux, P; Kerckaert, JP; Galiegue-Zouitina, S				Preudhomme, C; Roumier, C; Hildebrand, MP; Dallery-Prudhomme, E; Lantoine, D; Lai, JL; Daudignon, A; Adenis, C; Bauters, F; Fenaux, P; Kerckaert, JP; Galiegue-Zouitina, S			Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma	ONCOGENE			English	Article						non Hodgkin's lymphoma; translocation; RhoH/TTF; small G protein; LAZ3/BCL6	GERMINAL-CENTER FORMATION; CHROMOSOMAL TRANSLOCATIONS; RAS TRANSFORMATION; LAZ3/BCL6 ONCOPROTEIN; B-CELLS; EXPRESSION; BCL-6; RHO; DOMAIN; LAZ3	We recently isolated the RhoH/TTF gene by its fusion to the LAZ3/BCL6 gene, in a non-Hodgkin's lymphoma (NHL) cell line, which bore a t(3;4)(q27;p11-13) translocation, This gene encodes a novel Rho GTP-binding protein and is specifically expressed in hematopoietic tissues. We made its precise mapping at band 4p13, and described its partial genomic structure, Using fluorescence ill situ hybridization and molecular analyses, we report here on the rearrangement of the RhoH/TTF gene, at band 4p13, in four cases of NHL with t(3;4)(q27;p13) translocation and its fusion to the LAZ3/BCL6 gene at band 3q27, in three of these cases. RT-PCR analysis of two cases allowed the detection of variable fusion transcripts emerging from the rearranged alleles, and in one case, a deregulated expression of both RhoH/TTF and LAZ3/BCL6 genes, by promoter substitution, was observed, We also show here another rearrangement of the RhoH/TTF gene in a patient with multiple myeloma slid t(4;14)(p13;q32) translocation, with breakage within the IGH gene. It is the first report which describes the recurrent chromosomal alteration of a GTP-binding protein encoding gene, in patients with hematopoietic malignancies.	Inst Rech Canc, INSERM U524, F-59045 Lille, France; CHU Lille, Lab Hematol A, F-59037 Lille, France; CHU Lille, Lab Cytogenet, F-59037 Lille, France; CHG Valenciennes, Dept Hematol & Cytogenet, Valenciennes, France; Ctr Oscar Lambret, Lab Cytogenet, F-59020 Lille, France; CHU Lille, Serv Malad Sang, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; CH de Valenciennes; UNICANCER; Centre Oscar Lambret; Universite de Lille - ISITE; CHU Lille	Galiegue-Zouitina, S (corresponding author), Inst Rech Canc, INSERM U524, Pl Verdun, F-59045 Lille, France.		Preudhomme, Claude/T-8553-2018	Preudhomme, Claude/0000-0002-1267-9546				Akasaka T, 1997, CANCER RES, V57, P7; BajalicaLagercrantz S, 1997, LEUKEMIA, V11, P594, DOI 10.1038/sj.leu.2400577; BASTARD C, 1994, BLOOD, V83, P2423; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; CalletBauchu E, 1996, GENE CHROMOSOME CANC, V17, P185, DOI 10.1002/(SICI)1098-2264(199611)17:3<185::AID-GCC7>3.0.CO;2-0; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALLERY E, 1995, ONCOGENE, V10, P2171; DalleryPrudhomme E, 1997, GENOMICS, V43, P89, DOI 10.1006/geno.1997.4788; Daudignon A, 1999, CANCER GENET CYTOGEN, V111, P157, DOI 10.1016/S0165-4608(98)00239-8; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Galiegue-Zouitina S, 1999, GENE CHROMOSOME CANC, V26, P97, DOI 10.1002/(SICI)1098-2264(199910)26:2<97::AID-GCC1>3.0.CO;2-9; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; MANOLOVA Y, 1979, HEREDITAS, V90, P5; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MITELMAN F, 1991, GUIDELINES CANC CY S; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; STORSKI T, 1998, P NATL ACAD SCI USA, V95, P11858; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BHH, 1993, CANCER RES, V53, P2732; Zandecki M, 1996, BRIT J HAEMATOL, V94, P217	39	87	90	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2023	2032		10.1038/sj.onc.1203521	http://dx.doi.org/10.1038/sj.onc.1203521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803463				2022-12-28	WOS:000086613200006
J	Yamane, K; Katayama, E; Sugasawa, K; Tsuruo, T				Yamane, K; Katayama, E; Sugasawa, K; Tsuruo, T			Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity	ONCOGENE			English	Article						Rb; BRCT; BRCA1; cell cycle checkpoint; DNA damage sensor	LARGE T-ANTIGEN; REPLICATION CHECKPOINT CONTROL; FISSION YEAST; GENE-PRODUCT; DAMAGE; REPAIR; DOMAIN; MICE; P53; APOPTOSIS	The BRCT region, the carboxyl-terminus of BRCA1 (the breast cancer susceptibility gene I product), is ubiquitous in several proteins that participate in cell cycle checkpoints and DNA repair. We have previously shown that the BRCT regions pf TopBP1 (DNA topoisomerase II binding protein 1) and BRCA1 bound DNA breaks. A BRCT-related region, BRCT-W1, in the retinoblastoma susceptibility gene product (Rb) also could bind DNA fragments, independently of DNA sequences. Five BRCT-W regions were found in the Rb family. All BRCT-Ws of Rb bound DNA fragments. Electron microscopy and treatment with an exonuclease showed that BRCT-Ws bound double-strand DIVA breaks. Since some BRCTs are exceptional common relating elements in tumor suppression, our findings reveal novel aspects of the tumor suppression mechanism.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	University of Tokyo; Japanese Foundation for Cancer Research; University of Tokyo; RIKEN	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan.							Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Ito K, 1999, BIOPHYS J, V76, P985, DOI 10.1016/S0006-3495(99)77262-0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wang J, 1997, CANCER RES, V57, P351; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	39	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					1982	1991		10.1038/sj.onc.1203528	http://dx.doi.org/10.1038/sj.onc.1203528			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803459				2022-12-28	WOS:000086613200002
J	Ren, FG; Zhang, SB; Mitchell, SH; Butler, R; Young, CYF				Ren, FG; Zhang, SB; Mitchell, SH; Butler, R; Young, CYF			Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells	ONCOGENE			English	Article						tea polyphenols; androgen receptor; theaflavins; prostate specific antigen; human glandular kallikrein; Sp1	THERAPY FAILURE; MESSENGER-RNA; ANTIGEN GENE; CARCINOMA; INDUCTION; PROTEIN; PHOSPHORYLATION; ADENOCARCINOMA; PROMOTER; LINE	Androgens via their cognate receptor may be involved in the development and progression of prostate cancer. The aim of this study was to determine whether tea polyphenols have inhibitory effects on androgen action in an androgen-responsive, prostate cancer cell line, LNCaP, The tea polyphenol, EGCG, inhibited LNCaP cell growth and the expression of androgen regulated PSA and hK2 genes. Moreover, EGCG had a significant inhibitory effect on the androgenic inducibility of the PSA promoter. Immunoblotting detected a decrease in androgen receptor protein with treatments of the tea polyphenols EGCG, GCG and theaflavins, Northern blot analysis showed decreased levels of androgen receptor mRNA by EGCG, Transient transfections demonstrated that EGCG and theaflavins could repress the transcriptional activities of the androgen receptor promoter region. An Spl binding site in the androgen receptor gene promoter is an important regulatory component for its expression. This study suggests Spl is the target for the tea polyphenols because treatments of EGCG decreased the expression, DNA binding activity and transactivation activity of Spl protein. In conclusion, we have described a new property of tea polyphenols that inhibits androgen action by repressing the transcription of the androgen receptor gene.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Urol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Young, CYF (corresponding author), Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Urol, 200 1st St SW, Rochester, MN 55905 USA.				NCI NIH HHS [CA 70982] Funding Source: Medline; NIDDK NIH HHS [DK 41995] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Alroy I, 1999, MOL CELL BIOL, V19, P1961; ANDREWS PE, 1992, CANCER RES, V52, P1525; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Blok LJ, 1996, ENDOCR RES, V22, P197, DOI 10.3109/07435809609030508; Blot WJ, 1996, EUR J CANCER PREV, V5, P425; BRAWER MK, 1995, CANCER-AM CANCER SOC, V75, P1783, DOI 10.1002/1097-0142(19950401)75:7+<1783::AID-CNCR2820751606>3.0.CO;2-U; Charlesworth MC, 1997, UROLOGY, V49, P487; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; Darson MF, 1997, UROLOGY, V49, P857, DOI 10.1016/S0090-4295(97)00108-8; Dorgan JF, 1996, AM J CLIN NUTR, V64, P850, DOI 10.1093/ajcn/64.6.850; FEIGL P, 1995, CONTROL CLIN TRIALS, V16, P150, DOI 10.1016/0197-2456(94)00XXX-M; FLESHNER NE, 1995, J UROLOGY, V154, P1646; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Gregory CW, 1998, CANCER RES, V58, P5718; Gupta S, 1999, CANCER RES, V59, P2115; HAMALAINEN E, 1984, J STEROID BIOCHEM, V20, P459, DOI 10.1016/0022-4731(84)90254-1; Hsieh ML, 1997, CANCER RES, V57, P2651; Huggins C, 1941, CANCER RES, V1, P293; KAISARY AV, 1995, EUR UROL, V28, P215; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kemppainen JA, 1996, UROLOGY, V48, P157, DOI 10.1016/S0090-4295(96)00117-3; Koivisto P, 1997, CANCER RES, V57, P314; Koivisto P, 1998, AM J PATHOL, V152, P1; KRONGRAD A, 1991, MOL CELL ENDOCRINOL, V76, P79, DOI 10.1016/0303-7207(91)90262-Q; LABRIE F, 1993, CLIN INVEST MED, V16, P475; LIAO SS, 1995, BIOCHEM BIOPH RES CO, V214, P833, DOI 10.1006/bbrc.1995.2362; LIAO SS, 1995, CANCER LETT, V96, P239, DOI 10.1016/0304-3835(95)03948-V; LINDZEY J, 1994, VITAM HORM, V49, P383; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; Paschka AG, 1998, CANCER LETT, V130, P1, DOI 10.1016/S0304-3835(98)00084-6; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; PIENTA KJ, 1993, ANN INTERN MED, V118, P793, DOI 10.7326/0003-4819-118-10-199305150-00007; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SOLOWAY MS, 1993, CANCER, V71, P1083, DOI 10.1002/1097-0142(19930201)71:3+<1083::AID-CNCR2820711430>3.0.CO;2-1; Spitzweg C, 1999, CANCER RES, V59, P2136; STONER GD, 1995, J CELL BIOCHEM, P169; Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; THOMPSON L, 1995, IMPORTAN ADV ONCOLOG, P57; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Zhang JY, 1997, NUCLEIC ACIDS RES, V25, P3143, DOI 10.1093/nar/25.15.3143; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197; Zhang SB, 1999, ENDOCRINOLOGY, V140, P1665, DOI 10.1210/en.140.4.1665; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	50	114	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1924	1932		10.1038/sj.onc.1203511	http://dx.doi.org/10.1038/sj.onc.1203511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773882				2022-12-28	WOS:000086424300008
J	Yang, HS; Jiang, DH; Li, WH; Liang, JR; Gentry, LE; Brattain, MG				Yang, HS; Jiang, DH; Li, WH; Liang, JR; Gentry, LE; Brattain, MG			Defective cleavage of membrane bound TGF alpha leads to enhanced activation of the EGF receptor in malignant cells	ONCOGENE			English	Article						tethered TGF alpha; EGFR activation; phosphatase resistance	TRANSFORMING-GROWTH-FACTOR; PROTEIN TYROSINE PHOSPHATASES; HUMAN-COLON-CARCINOMA; TRANSGENIC MICE; MAMMALIAN-CELLS; FACTOR-BETA; EXPRESSION; PRECURSOR; NEOPLASIA; BREAST	Transforming growth factor alpha (TGF alpha) is widely expressed in malignant as well as normal cells and is involved in regulating cell growth and differentiation. Although processing of TGF alpha has been extensively studied in normal cells, there is little information regarding TGF alpha cleavage in malignant cells. Therefore, we compared the processing of TGF alpha in two human colon carcinoma cell lines. We found that there was a defective cleavage pattern for the TGF alpha precursor resulting in retention of partially processed TGF alpha on the cell surface of both the HCT116a2 alpha S3 and CBS4 alpha S2 cell lines. This raised the possibility that signaling from the resulting defective cleavage species could differ from that of soluble TGF alpha, The membrane-associated TGF alpha induced higher phosphorylation of EGFR on the cell surface of adjacent cells than equivalent levels of mature TGF alpha. The interaction of membrane bound TGF alpha precursor with the EGFR caused a slower internalization of activated EGFR relative to the internalization of the soluble TGF alpha/EGFR complexes. In addition, the tethered TGF alpha was resistant to the ability of protein-tyrosine phosphatases (PTPs) to reduce EGFR tyrosine phosphorylation, also contributing to higher activation of EGFR, The enhanced activation of EGFR by the tethered form of TGF alpha was reflected by higher activation of Grb2, SHC and Erk downstream mediators of EGF receptor signaling. The higher activation of EGFR by membrane tethered TGF alpha indicates that defective TGF alpha processing provides a mechanism whereby malignant cells can obtain a growth advantage over normal cells.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Brattain, MG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Liang, Carol Jiurong/AAI-4963-2021; Jiang, Dianhua/B-1421-2009	Jiang, Dianhua/0000-0002-4508-3829; Liang, Jiurong/0000-0001-5179-5016	NATIONAL CANCER INSTITUTE [R01CA034432, R01CA054807] Funding Source: NIH RePORTER; NCI NIH HHS [CA54807, CA34432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LINSLEY PS, 1985, P NATL ACAD SCI USA, V82, P356, DOI 10.1073/pnas.82.2.356; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MARQUARDT H, 1982, J BIOL CHEM, V257, P5220; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; Mulder K. M., 1989, CELL MOL BIOL COLON, P45; Nagane M, 1996, CANCER RES, V56, P5079; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sorby M, 1996, J BIOL CHEM, V271, P10963; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SUNADA H, 1990, J CELL PHYSIOL, V142, P284, DOI 10.1002/jcp.1041420210; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	48	25	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1901	1914		10.1038/sj.onc.1203513	http://dx.doi.org/10.1038/sj.onc.1203513			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773880				2022-12-28	WOS:000086424300006
J	de Rozieres, S; Maya, R; Oren, M; Lozano, G				de Rozieres, S; Maya, R; Oren, M; Lozano, G			The loss of mdm2 induces p53 mediated apoptosis	ONCOGENE			English	Article						apoptosis; temperature sensitive p53; mdm2; mouse embryo fibroblasts	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; TUMOR-SUPPRESSOR P53; CELL-CYCLE CONTROL; GROWTH ARREST; DNA-DAMAGE; HEMATOPOIETIC-CELLS; MICE DEFICIENT; BAX GENE; IN-VIVO	The p53 tumor suppressor gene product is negatively regulated by the product of its downstream target, mdm2. The deletion of mdm2 in the mouse results in embryonic lethality at 5.5 days post coitum (d.p.c.) which can be overcome by simultaneous loss of the p53 tumor suppressor, substantiating the importance of the negative regulatory function of MDM2 on p53 function ill rho. Hence, the loss of MDM2 allowed the unregulated p53 protein to continuously exert its growth-suppressing activity, which either led to a complete G1 arrest or induced the p53-dependent apoptotic pathway, resulting in the death of the mdm2-/- embryos. To determine which of these possibilities is occurring, mouse embryo fibroblasts (MEFs) from p53 null and p53/mdm2 double null embryos were transfected with a retroviral vector carrying a temperature-sensitive p53 (tsp53) cDNA. Shifting of single-cell clonal populations to the permissive temperature caused the p53-/-mdr2-/- fibroblasts expressing tsp53 to undergo apoptosis in a dose-dependent manner. This phenotype was not observed in the tsp53 expressing p53-/- clones nor the parental cell lines. Thus, our data indicate that the simple loss of mdm2 can induce the p53-dependent apoptotic pathway in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	University of Texas System; UTMD Anderson Cancer Center; Weizmann Institute of Science	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [CA40099, CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047296, R37CA040099, R01CA040099, R01CA047296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Caron De Fromentel Claude, 1992, Genes Chromosomes and Cancer, V4, P1; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDONCARDO C, 1994, CANCER RES, V54, P794; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; DEOCALUNA R, 1995, NATURE, V0378; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lozano G, 1998, BBA-REV CANCER, V1377, pM55, DOI 10.1016/S0304-419X(97)00037-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mayo LD, 1997, CANCER RES, V57, P5013; McMasters KM, 1996, ONCOGENE, V13, P1731; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHEIKH MS, 1993, CANCER RES, V53, P3226; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TAMURA T, 1995, ONCOGENE, V11, P1939; TISHLER RB, 1993, CANCER RES, V53, P2212; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	71	114	116	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1691	1697		10.1038/sj.onc.1203468	http://dx.doi.org/10.1038/sj.onc.1203468			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763826				2022-12-28	WOS:000086083800009
J	Kong, FM; Anscher, MS; Washington, MK; Killian, JK; Jirtle, RL				Kong, FM; Anscher, MS; Washington, MK; Killian, JK; Jirtle, RL			M6P/IGF2R is mutated in squamous cell carcinoma of the lung	ONCOGENE			English	Article						M6P/IGF2R; loss of heterozygosity; lung cancer; mutation; tumor suppressor	FACTOR-II RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; BINDING-SITE; IGF-II; MANNOSE-6-PHOSPHATE RECEPTOR; MICROSATELLITE INSTABILITY; MOLECULAR PATHOGENESIS; LIVER CARCINOGENESIS	In addition to the intracellular sorting of lysosomal enzymes, the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors. It has also been shown to be mutated in a number of human cancers, and to suppress cancer cell growth. The purpose of this study was to determine if the M6P/IGF2R is mutated in lung cancer, a leading cause of cancer death worldwide. Archival pathology specimens were obtained on 22 patients with newly diagnosed, untreated squamous cell carcinoma of the lung. Two polymorphisms in the 3'-untranslated region of the M6P/IGF2R were used to screen lung tumors for loss of heterozygosity (LOH) by PCR amplification of DNA, Nineteen of 22 (86%) patients were informative (heterozygous), and 11/19 (58%) squamous cell carcinomas of the lung had LOH at the M6P/IGF2R locus, The remaining allele in 6/11 (55%) LOH patients contained mutations in either the mannose 6-phosphate or the IGF2 binding domain of the M6P/ IGF2R. Thus, the M6P/IGF2R is mutated frequently in squamous cell carcinoma of the lung, providing further support for its function as a tumor suppressor.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Duke University; Vanderbilt University	Jirtle, RL (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.		Wang, Weili/D-1546-2011; Kong, Feng-Ming/Y-2825-2019	Kong, Feng-Ming/0000-0003-2652-098X; Anscher, Mitchell/0000-0003-4480-111X	NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008823] Funding Source: NIH RePORTER; NCI NIH HHS [CA25951] Funding Source: Medline; NIEHS NIH HHS [ES08823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Bepler G, 1995, CANCER GENET CYTOGEN, V84, P39, DOI 10.1016/0165-4608(95)00063-1; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Chappell SA, 1997, BRIT J CANCER, V76, P1558, DOI 10.1038/bjc.1997.596; CZECH MP, 1989, CIBA F SYMP, V145, P27; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; Devi GR, 1999, CANCER RES, V59, P4314; Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6; Fong KM, 1995, PATHOLOGY, V27, P295, DOI 10.1080/00313029500169173; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GINSBERG RJ, 1997, PRINCIPLES PRACTICE, P858; Gotoh K, 1999, CARCINOGENESIS, V20, P499, DOI 10.1093/carcin/20.3.499; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hankins GR, 1996, ONCOGENE, V12, P2003; Hol F. A., 1992, Human Molecular Genetics, V1, P347, DOI 10.1093/hmg/1.5.347; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; Jirtle RL, 1999, EXP CELL RES, V248, P18, DOI 10.1006/excr.1999.4453; JIRTLE RL, 1999, ENCY MOL BIOL, P1441; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; Killian JK, 1999, MAMM GENOME, V10, P74, DOI 10.1007/s003359900947; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Mills JJ, 1998, ONCOGENE, V16, P2797, DOI 10.1038/sj.onc.1201801; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; O'Gorman DB, 1999, CANCER RES, V59, P5692; Ouyang H, 1997, CANCER RES, V57, P1851; Petersen I, 1997, CANCER RES, V57, P2331; RIMER BK, 1997, PRINCIPLES PRACTICE, P619; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SCOTT CD, 1987, ENDOCRINOLOGY, V120, P1; Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Xu YQ, 1997, ONCOGENE, V14, P1041, DOI 10.1038/sj.onc.1200926; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; ZHOU M, 1995, P NATL ACAD SCI USA, V92, P9762, DOI 10.1073/pnas.92.21.9762	55	95	102	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	2000	19	12					1572	1578		10.1038/sj.onc.1203437	http://dx.doi.org/10.1038/sj.onc.1203437			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734317				2022-12-28	WOS:000086108100010
J	Madireddi, MT; Dent, P; Fisher, PB				Madireddi, MT; Dent, P; Fisher, PB			Regulation of mda-7 gene expression during human melanoma differentiation	ONCOGENE			English	Article						human melanoma; posttranscriptional gene regulation; 3 '-UTR; AUUUA	MESSENGER-RNA STABILITY; C-FOS PROTEIN; INTERFERON-GAMMA; GM-CSF; GROWTH; CELLS; TRANSCRIPTION; PROGRESSION; CANCER; MECHANISMS	]Induction of irreversible growth arrest and terminal differentiation in human melanoma cells following treatment with recombinant human fibroblast interferon (IFN-beta) and mezerein (MEZ) results in elevated expression of a specific melanoma differentiation associated gene, mda-7. Experiments were conducted to define the mechanism involved in the regulation of mda-7 expression in differentiating human melanoma cells. The mda-7 gene is actively transcribed in uninduced HO-1 human melanoma cells and the rate of transcription of nInn-7 is not significantly enhanced by treatment with IFN-beta, MEZ or IFN-beta+MEZ. The high basal activity of the mda-7 promoter in uninduced melanoma cells and the absence of enhancing effect upon treatment with differentiation inducers is corroborated by transfection studies using the promoter region of mda-7 linked to a luciferase reporter gene containing the SV40 polyadenylation signal sequence. RT-PCR analysis detects the presence of low levels of mda-7 transcripts in uninduced and concomitant increases in differentiation inducer treated HO-1 cells. However, steady-state mda-7 mRNA is detected only in IFN-beta+MEZ and to a lesser degree in MEZ, treated cells, We show that induction of terminal differentiation of HO-1 cells with IFN-beta + MEZ dramatically increases the half-life of mcCn-7 mRNA while treatment with cycloheximide results in detectable mda-7 mRNA in control and inducer treated cells. These observations confirm constitative activity of the mda-7 promoter in HO-1 cells irrespective of differentiation status suggesting posttranscriptional processes as important determinants of mda-7 expression during terminal differentiation, The 3' UTR region of mda-7 contains AU-rich elements (ARE) that contribute to rapid mda-7 mRNA turnover during proliferation and reversible differentiation, a process controlled by a labile protein factor(s), Substitution of the SV40 polyadenylation signal sequence in the luciferase reporter plasmid with the mda-7-ARE-3'-UTR renders the Luciferase message unstable,when expressed in proliferating and reversibly differentiated melanoma cells. In contrast, the luciferase message is stabilized when the mda-7-ARE-3'-UTR construct is expressed in terminally differentiated HO-1 cells. These results provide compelling evidence that mda-7 expression during terminal differentiation in human melanoma cells is regulated predominantly at a posttranscriptional level.	Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA	Columbia University; Columbia University; Virginia Commonwealth University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675] Funding Source: Medline; NIDDK NIH HHS [R01DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FISHER PB, 1985, INTERFERON RES, V5, P11; Fontes AM, 1999, CURR TOP DEV BIOL, V44, P171; GOEDDEL DV, 1981, NATURE, V290, P20, DOI 10.1038/290020a0; Gopalkrishnan RV, 1999, NUCLEIC ACIDS RES, V27, P4775, DOI 10.1093/nar/27.24.4775; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; ISHIKAWA M, 1989, INT J CANCER, V43, P134, DOI 10.1002/ijc.2910430125; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kang DC, 1998, INT J ONCOL, V13, P1117; KROWCZYNSKA A, 1985, J MOL BIOL, V181, P231, DOI 10.1016/0022-2836(85)90087-7; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MADIREDDI M, 2000, IN PRESS CANC GENE T; MILLER AD, 1984, CELL, V36, P51; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NEDWIN GE, 1985, J IMMUNOL, V135, P2492; Patterson A, 1999, DRUG AGING, V14, P75, DOI 10.2165/00002512-199914020-00001; RAJ NBK, 1981, P NATL ACAD SCI-BIOL, V78, P7426, DOI 10.1073/pnas.78.12.7426; RJAGOPALAN LE, 1997, PROG NUCL ACID RES M, V256, P257; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; SACHS L, 1980, P NATL ACAD SCI-BIOL, V77, P6152, DOI 10.1073/pnas.77.10.6152; SCOTT RE, 1985, P NATL ACAD SCI USA, V82, P2995, DOI 10.1073/pnas.82.9.2995; Scott RE, 1997, PHARMACOL THERAPEUT, V73, P51, DOI 10.1016/S0163-7258(96)00120-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Wada RK, 1997, CANCER LETT, V121, P181, DOI 10.1016/S0304-3835(97)00351-0; WAXMAN S, 1995, DIFFERENTIATION THER; WAXMAN S, 1991, STATUS DIFFERENTIATI; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	42	47	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1362	1368		10.1038/sj.onc.1203424	http://dx.doi.org/10.1038/sj.onc.1203424			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713678				2022-12-28	WOS:000085743800013
J	Frost, GI; Mohapatra, G; Wong, TM; Csoka, AB; Gray, JW; Stern, R				Frost, GI; Mohapatra, G; Wong, TM; Csoka, AB; Gray, JW; Stern, R			HYAL1(LUCA-1), a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA	ONCOGENE			English	Article						hyaluronidase; 3p21.3; tumor suppressor gene; aberrant splicing; squamous cell carcinoma; head and neck tumors	COMPARATIVE GENOMIC HYBRIDIZATION; HYALURONIDASE ACTIVITY; LUNG-CANCER; MESSENGER-RNA; LINES; DNA; 3P; PURIFICATION; EXPRESSION; DELETION	The hyaluronidase first isolated from human plasma, Hyal-1, is expressed in many somatic tissues. The Hyal-1 gene, HYAL1, also known as LUCA-1, maps to chromosome 3p21.3 within a candidate tumor suppressor gene locus defined by homozygous deletions and by functional tumor suppressor activity. Hemizygosity in this region occurs in many malignancies, including squamous cell carcinomas of the head and neck, We have investigated whether cell lines derived from such malignancies expressed Hyal-1 activity, using normal human keratinocytes as controls. Hyal-1 enzyme activity and protein were absent or markedly reduced in six of seven carcinoma cell lines examined. Comparative genomic and fluorescence ill situ hybridization identified chromosomal deletions of one allele of HYAL1 in six of se, en cell lines. Initial RT-PCR analyses demonstrated marked discrepancies between levels of HYAL1 mRNA and protein. Despite repeated sequence analyses, no mutations were found, However, two species of transcripts were identified when primers were used that included the 5' untranslated region. The predominant mRNA species did not correlate with protein translation and contained a retained intron, A second spliced form lacking this intron was found only in cell lines that produced Hyal-1 protein. Inactivation of HYAL1 in these tumor lines is a result of incomplete splicing of its pre-mRNA that appears to be epigenetic in nature.	Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Stern, R (corresponding author), Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA.				NIDCR NIH HHS [P50 DE/CA11912, T32DE07204] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011912, T32DE007204] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Buchhagen DL, 1996, HEAD NECK-J SCI SPEC, V18, P529; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka TB, 1997, FEBS LETT, V417, P307, DOI 10.1016/S0014-5793(97)01309-4; Csoka TB, 1998, GENOMICS, V48, P63, DOI 10.1006/geno.1997.5158; Druck T, 1998, ONCOL RES, V10, P341; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Frost GI, 1997, ANAL BIOCHEM, V251, P263, DOI 10.1006/abio.1997.2262; Frost GL, 1996, TRENDS GLYCOSCI GLYC, V8, P419, DOI 10.4052/tigg.8.419; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; Granadino B, 1997, P NATL ACAD SCI USA, V94, P7343, DOI 10.1073/pnas.94.14.7343; GUNTENHONER MW, 1992, MATRIX, V12, P388, DOI 10.1016/S0934-8832(11)80035-1; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; HIBI K, 1992, ONCOGENE, V7, P445; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Maquat LE, 1996, AM J HUM GENET, V59, P279; Mohapatra G, 1997, GENE CHROMOSOME CANC, V20, P311, DOI 10.1002/(SICI)1098-2264(199712)20:4<311::AID-GCC1>3.0.CO;2-4; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCALONI A, 1992, J LAB CLIN MED, V120, P546; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Todd S, 1997, CANCER RES, V57, P1344; Wei MH, 1996, CANCER RES, V56, P1487; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	32	68	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					870	877		10.1038/sj.onc.1203317	http://dx.doi.org/10.1038/sj.onc.1203317			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702795				2022-12-28	WOS:000085567700004
J	Noda, A; Toma-Aiba, Y; Fujiwara, Y				Noda, A; Toma-Aiba, Y; Fujiwara, Y			A unique, short sequence determines p53 gene basal and UV-inducible expression in normal human cells	ONCOGENE			English	Article						p53; UV; X-ray; stress response; transcription; promoter	DEPENDENT PROTEIN-KINASE; CELLULAR TUMOR-ANTIGEN; KAPPA-B ACTIVATION; RNA POLYMERASE-II; DNA-DAMAGE; NUCLEAR ACCUMULATION; IONIZING-RADIATION; GLIOBLASTOMA CELLS; TRANSCRIPTION; GROWTH	The p53 tumor suppressor protein plays a central role in the cellular defence against agents which cause genetic damage. The induction and activation of p53 upon stress has been shown at post-transcription level by multiple mechanisms, while the regulatory role of p53 gene transcription is still poorly understood. Here we show that the causative mechanisms underlying this activation are attributed in part to the promoter function of p53, In various normal human cells, p53 gene expression is induced transcriptionally by ultraviolet (UV) but not X-ray irradiation. We determined that, by p53 promoter dissection, the 21 bp element (PE21) responsible for this UV activation resides adjacent to, and upstream to the putative NF kappa B binding site. Moreover, the PE21 sequence,vas found to be a primary determinant for human p53 gene basal expression carrying bi-directional transcriptional initiation activity, which controls the initiation of RNA synthesis about 50 bases downstream, indicating that the sequence plays a critical role in both basal and inducible transcription. Finally, we detected the putative PE21 binding factor(s) in nuclear extracts from non-irradiated and irradiated cells, Since the PE21 sequence does not show any homologies to the conventional TATA or GC box, or to an 'initiatior', all of which determine the initiation site for transcription, the PE21 sequence appears to be a new class in eukaryotic promoter elements. Our results indicate that the mechanism of PE21-directed p53 mRNA transcription has an important role in the cellular stress response as well as tumor suppression.	Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, Kobe, Hyogo 6500017, Japan; Meiji Cell Technol Ctr, Odawara 250, Japan	Kobe University; Meiji Holdings Co., Ltd.	Noda, A (corresponding author), Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.			Noda, Asao/0000-0002-9029-9813				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHODOSH LA, 1991, CURRENT PROTOCOLS MO, V2; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FORNACE AJ, 1982, MUTAT RES, V94, P263, DOI 10.1016/0027-5107(82)90290-1; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRITSCHE M, 1993, ONCOGENE, V8, P307; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JAYARAMAN L, 1997, GENE DEV, V11, P588; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MALZMAN W, 1984, MOL CELL BIOL, V4, P1689; MCKNIGHT SL, 1984, CELL, V37, P253, DOI 10.1016/0092-8674(84)90321-0; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MONSNER J, 1995, EMBO J, V14, P4442; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PORTER MB, 1990, J CELL PHYSIOL, V142, P425, DOI 10.1002/jcp.1041420228; Rathmell WK, 1997, CANCER RES, V57, P68; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID P, 1991, DEVELOPMENT, V113, P857; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU HY, 1994, J BIOL CHEM, V269, P20067; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; XU LC, 1991, NUCLEIC ACIDS RES, V19, P6699, DOI 10.1093/nar/19.24.6699; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	56	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					21	31		10.1038/sj.onc.1203230	http://dx.doi.org/10.1038/sj.onc.1203230			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644976				2022-12-28	WOS:000084844300003
J	Wicking, C; Smyth, I; Bale, A				Wicking, C; Smyth, I; Bale, A			The hedgehog signalling pathway in tumorigenesis and development	ONCOGENE			English	Article						patched; hedgehog; basal cell carcinoma	BASAL-CELL CARCINOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; SONIC-HEDGEHOG; HUMAN HOMOLOG; SIGNALING PATHWAY; PATCHED GENE; CUBITUS-INTERRUPTUS; CHOLESTEROL HOMEOSTASIS; CHRONIC ARSENICISM	The hedgehog signalling pathway is responsible for the embryonic patterning of a range of tissues, and it is now known that dysregulation of this pathway can result in the formation of several tumour types. This cascade is regulated at the cell surface by the opposing actions of the patched and smoothened molecules which together form a receptor complex for hedgehog. The discovery that inactivation of the human patched gene is responsible for familial and sporadic forms of basal cell carcinoma firmly established a role for dysregulation of hedgehog signalling in tumorigenesis. Other key members of this pathway have also been shown to be involved in tumour formation, as have more distal downstream targets of hedgehog signalling. Since it appears that tumorigenesis results from constitutive activation of hedgehog responsive genes, the identification of novel downstream targets of hedgehog signalling in given cell types is likely to increase our understanding of the molecular processes underlying tumour formation.	Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	University of Queensland; Yale University	Wicking, C (corresponding author), Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia.		; Wicking, Carol/J-1814-2014	Smyth, Ian/0000-0002-1727-7829; Wicking, Carol/0000-0002-7225-3803				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; ASZTERBAUM M, 1998, AM J HUM GENET, V63, pA39; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Bellusci S, 1997, DEVELOPMENT, V124, P53; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; CHONGHAI T, 1975, MED J AUSTRALIA, V2, P424, DOI 10.5694/j.1326-5377.1975.tb105939.x; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAH H, 1997, NAT MED, V3, P788; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1999, DEV BIOL, V211, P323, DOI 10.1006/dbio.1999.9311; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; McGarvey TW, 1998, ONCOGENE, V17, P1167, DOI 10.1038/sj.onc.1202045; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Motoyama J, 1998, MECH DEVELOP, V78, P81, DOI 10.1016/S0925-4773(98)00149-X; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nakjang Yaovares, 1994, Journal of Dermatology (Tokyo), V21, P660; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pietsch T, 1997, CANCER RES, V57, P2085; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Radhakrishna U, 1997, NAT GENET, V17, P269, DOI 10.1038/ng1197-269; Raffel C, 1997, CANCER RES, V57, P842; Reifenberger J, 1998, CANCER RES, V58, P1798; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCOTTO J, 1996, CANC EPIDEMIOLOGY PR, P1313; SHANLEY S, 1994, AM J MED GENET, V50, P282, DOI 10.1002/ajmg.1320500312; Sidransky D, 1996, NAT GENET, V14, P7, DOI 10.1038/ng0996-7; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Smyth I, 1999, HUM MOL GENET, V8, P291, DOI 10.1093/hmg/8.2.291; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Takabatake T, 1997, FEBS LETT, V410, P485, DOI 10.1016/S0014-5793(97)00645-5; Unden AB, 1997, CANCER RES, V57, P2336; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Vasiliauskas D, 1999, MECH DEVELOP, V82, P79, DOI 10.1016/S0925-4773(99)00014-3; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; Vorechovsky I, 1997, CANCER RES, V57, P4677; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WEEDON D, 1991, MALIGNANT SKIN TUMOU, P109; Wicking C, 1997, AM J HUM GENET, V60, P21; Wicking C, 1998, ONCOGENE, V16, P1091, DOI 10.1038/sj.onc.1201644; Wolter M, 1997, CANCER RES, V57, P2581; Wong SS, 1998, J AM ACAD DERMATOL, V38, P179, DOI 10.1016/S0190-9622(98)70596-1; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; YEH S, 1973, HUM PATHOL, V4, P469, DOI 10.1016/S0046-8177(73)80060-7; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	93	127	140	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7844	7851		10.1038/sj.onc.1203282	http://dx.doi.org/10.1038/sj.onc.1203282			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630637	Bronze			2022-12-28	WOS:000084405900001
J	Cong, F; Zou, XM; Hinrichs, K; Calame, K; Goff, SP				Cong, F; Zou, XM; Hinrichs, K; Calame, K; Goff, SP			Inhibition of v-Abl transformation by p53 and p19ARF	ONCOGENE			English	Article						v-Abl; p53; p19ARF; transformation	MURINE LEUKEMIA-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; ARF TUMOR-SUPPRESSOR; TYROSINE KINASE; P53-DEPENDENT APOPTOSIS; GENE-PRODUCT; CELLS; P19(ARF); DNA; SENESCENCE	Tumorigenesis is a multistep process that involves the activation of oncogenes and the inactivation of tumor suppressor genes. The transforming activity of the v-Abl oncogene of Abelson murine leukemia virus (A-MuLV) in immortal cell lines has been well studied, while the effects of v-Abl in primary fibroblasts are less clear. Here we show that v-Abl causes cell cycle arrest in primary mouse embryonic fibroblasts (MEFs) and elevated levels of both p53 and the cyclin-dependent kinase inhibitor p21(Cip). p53(-/-) or p19ARF(-/-) MEFs were resistant to v-Abl-induced cell cycle arrest. Although wild-type MEFs were resistant to v-Abl transforming activity, p53(-/-) or p19ARF(-/-) MEFs were susceptible. The results indicate that loss of p19ARF and p53 function plays an important role during the transformation of primary cells by v-Abl. We suggest that although v-Abl is a potent oncogene, its full potential transforming activity cannot be realized until the ARF-, and p53-dependent growth inhibitory pathway is disabled. We also show that p53 is not the mediator of v-Abl toxicity in immortal fibroblasts and does not determine the susceptibility of immortal fibroblasts to v-Abl transformation.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Biol Sci, New York, NY 10025 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Goff, SP (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, Room 1127 HHSC,701 W 168th St, New York, NY 10032 USA.		Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NATIONAL CANCER INSTITUTE [P01CA075399] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Chen Y, 1996, J BIOL CHEM, V271, P19637, DOI 10.1074/jbc.271.33.19637; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, ONCOGENE, V11, P791; GREEN PL, 1989, J VIROL, V63, P1989, DOI 10.1128/JVI.63.5.1989-1994.1989; GREEN PL, 1987, J VIROL, V61, P2192, DOI 10.1128/JVI.61.7.2192-2197.1987; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Huang TS, 1996, ONCOGENE, V13, P625; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PRATT DM, 1977, CELL, V12, P683, DOI 10.1016/0092-8674(77)90268-9; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; PROKOCIMER M, 1994, BLOOD, V84, P2391; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Thome KC, 1997, J VIROL, V71, P8149, DOI 10.1128/JVI.71.11.8149-8156.1997; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Unnikrishnan I, 1999, MOL CELL BIOL, V19, P4825, DOI 10.1128/mcb.19.7.4825; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	51	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7731	7739		10.1038/sj.onc.1203290	http://dx.doi.org/10.1038/sj.onc.1203290			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618713	Bronze			2022-12-28	WOS:000084256900002
J	Page, G; Kogel, D; Rangnekar, V; Scheidtmann, KH				Page, G; Kogel, D; Rangnekar, V; Scheidtmann, KH			Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis	ONCOGENE			English	Article						Dlk/ZIP kinase; two hybrid interaction screen; leucine zipper; Par-4; actin filaments; apoptosis	ATAXIA-TELANGIECTASIA GENE; SERINE THREONINE KINASE; ZIPPER PROTEIN PAR-4; LEUCINE-ZIPPER; SERINE/THREONINE KINASE; MOLECULAR-CLONING; CATALYTIC DOMAIN; DNA-BINDING; HUMAN BRAIN; CELL-DEATH	Dlk/ZIP kinase is a newly discovered serine/threonine kinase which, due to its homology to DAP kinase, was named DAP like kinase, Dlk. This kinase is tightly associated with nuclear structures, it undergoes extensive autophosphorylation and phosphorylates myosin light chain and core histones H3, H2A and H4 in vitro. Moreover, it possesses a leucine zipper which mediates interaction with transcription factor ATF-4, therefore it was called ZIP kinase. We employed the yeast two-hybrid system to identify interaction partners of Dlk that might serve as regulators or targets. Besides ATF-4 and others we found Par-4, a modulator of transcription factor WT1 and mediator of apoptosis. Complex formation between Dlk and Par-4 was confirmed by GST pull-down experiments and kinase reactions in vitro and coexpression experiments in vivo. The interaction domain within Dlk was mapped to an arginine-rich region between residues 338-417, rather than to the leucine zipper. Strikingly, coexpression of Dlk and Par-4 lead to relocation of Dlk from the nucleus to the cytoplasm, particularly to actin filaments. These interactions provoked a dramatic reorganization of the cytoskeleton and morphological symptoms of apoptosis, thus suggesting a functional relationship between Dlk and Par-4 in the control of apoptosis.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany; Univ Kentucky, Lexington, KY 40536 USA	University of Bonn; University of Kentucky	Scheidtmann, KH (corresponding author), Univ Bonn, Inst Genet, Roemerstr 164, D-53117 Bonn, Germany.			Kogel, Donat/0000-0003-1209-0210				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blouin R, 1996, DNA CELL BIOL, V15, P631, DOI 10.1089/dna.1996.15.631; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hunter Tony, 1994, Seminars in Cell Biology, V5, P367, DOI 10.1006/scel.1994.1044; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MULLER E, 1995, ONCOGENE, V10, P1175; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Sambrook J., 2002, MOL CLONING LAB MANU; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854	48	92	99	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7265	7273		10.1038/sj.onc.1203170	http://dx.doi.org/10.1038/sj.onc.1203170			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602480				2022-12-28	WOS:000084119400010
J	Pritchard, DM; Potten, CS; Korsmeyer, SJ; Roberts, S; Hickman, JA				Pritchard, DM; Potten, CS; Korsmeyer, SJ; Roberts, S; Hickman, JA			Damage-induced apoptosis in intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo	ONCOGENE			English	Article						apoptosis; bcl-2; bax; 5-fluorouracil; gamma-irradiation; intestinal epithelia	RADIATION-INDUCED APOPTOSIS; HUMAN COLORECTAL ADENOMAS; MURINE SMALL-INTESTINE; CELL-DEATH; GAMMA-IRRADIATION; P53-DEPENDENT APOPTOSIS; GASTROINTESTINAL-TRACT; HIERARCHICAL STATUS; CRYPT CELLS; P53	The influence of bcl-2 and bax expression on apoptotic cell death in mouse intestinal epithelia was assessed using homozygously null mice. Apoptosis was induced in vivo by the enterotoxin 5-fluorouracil (5FU) or by gamma-irradiation and its cell positional incidence was assessed. 5FU and gamma-radiation treated bax-null mice surprisingly showed no reductions in apoptotic yield in the small intestine or midcolon at 4.5 h at cell positions in which both agents had previously been shown to strongly induce p53 protein expression. The colonic epithelia of 5FU treated bcl-2-null mice showed elevated levels of apoptosis at 4.5 h: from 48 apoptotic events in wild-type mice to 273 in the nulls, scoring 200 half crypts. The increase occurred specifically in the cell positions considered to harbour colonic stem cells, at the base of crypts, where there is selective expression of bcl-2. There was a modest but significant increase in apoptosis in the small intestine of the bcl-2-null mice although the epithelia of wild-type mice here are not immunohistochemically positive for bcl-2 protein. These findings show that bcl-2 plays a key role in determining the sensitivity of colonic stem cells to damage-induced death but that bax is not responsible for the p53-dependent induction of apoptosis in this context.	Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England; Christie Hosp NHS Trust, Paterson Inst, Dept Epithelial Biol, CRC, Manchester M20 9BX, Lancs, England; Dana Farber Canc Inst, Boston, MA 02115 USA; Christie Hosp NHS Trust, Paterson Inst, CRC, Biomath & Comp Unit, Manchester M20 9BX, Lancs, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Harvard University; Dana-Farber Cancer Institute; Christie NHS Foundation Trust; Christie Hospital	Hickman, JA (corresponding author), Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Stopford Bldg G38, Manchester M13 9PT, Lancs, England.			Pritchard, David Mark/0000-0001-7971-3561				CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chresta CM, 1996, CANCER RES, V56, P1834; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; HAGUE A, 1994, ONCOGENE, V9, P3367; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IJIRI K, 1983, BRIT J CANCER, V47, P175, DOI 10.1038/bjc.1983.25; IJIRI K, 1987, BRIT J CANCER, V55, P113, DOI 10.1038/bjc.1987.25; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Lamb JR, 1997, NAT MED, V3, P962, DOI 10.1038/nm0997-962; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MERRITT AJ, 1995, J CELL SCI, V108, P2261; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; Merritt Anita J., 1996, P269; MIYASHITA T, 1995, CELL, V80, P293; NAKAMURA H, 1994, DEV HYDROB, V91, P3; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; POTTEN CS, 1990, INT J RADIAT BIOL, V57, P185, DOI 10.1080/09553009014550431; Potten CS, 1996, BRIT J CANCER, V74, P1743, DOI 10.1038/bjc.1996.624; Potten CS, 1998, BRIT J CANCER, V78, P993, DOI 10.1038/bjc.1998.618; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Pritchard DM, 1998, CANCER RES, V58, P5453; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 1999, CANC DRUG DISC DEV, V5, P99; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Simms LA, 1998, ONCOGENE, V17, P2003, DOI 10.1038/sj.onc.1202109; Watson AJM, 1996, BRIT J CANCER, V73, P889, DOI 10.1038/bjc.1996.178; WILSON JW, 1996, APOPTOSIS, V1, P183; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	38	87	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7287	7293		10.1038/sj.onc.1203150	http://dx.doi.org/10.1038/sj.onc.1203150			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602483				2022-12-28	WOS:000084119400013
J	Suhasini, M; Pilz, RB				Suhasini, M; Pilz, RB			Transcriptional elongation of c-myb is regulated by NF-kappa B (p50/RelB)	ONCOGENE			English	Article						c-myb; NF-kappa B; transcriptional regulation; erythroid differentiation; murine erythroleukemia cells	ERYTHROLEUKEMIA CELL-DIFFERENTIATION; MESSENGER-RNA; UP-REGULATION; EXPRESSION; PROMOTER; BINDING; FAMILY; GENE; IDENTIFICATION; ONCOGENE	High levels of c-myb expression are necessary for the proliferation of hematopoietic precursor cells whereas do,vn-regulation of c-myb is required for terminal differentiation; this down-regulation occurs through a conditional block to transcriptional elongation in intron I, We previously observed that cAMP analogs prevented the late down-regulation of c-myb during hexamethylene bisacetamide (HMBA)-induced differentiation of murine erythroleukemia (MEL) cells and blocked differentiation; this correlated with the induction of NF-kappa B (p50/RelB) complexes which were shown to bind to NF-kappa B recognition sites flanking the transcriptional pause site of c-myb. We now selected stably-transfected MEL cells which overexpressed p50, RelB or both at levels similar to those induced by cAMP to determine whether these NF-kappa B proteins regulate c-myb expression in intact cells, We demonstrate that transcriptionally active NF-kappa B (p50/RelB) complexes, but not p50 or RelB alone, prevented the early and late down-regulation of c-myb mRNA and increased c-myb transcriptional elongation in HMBA-induced MEL cells. The increase in c-myb expression was sufficient to block erythroid differentiation and allow continuous proliferation of cells in the presence of HMBA, Steady-state c-myb mRNA levels in untreated cells were not affected by overexpression of NF-kappa B, suggesting that p50/RelB specifically modulated the efficiency of transcriptional attenuation during MEL cell differentiation.	Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM55586] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIL OL, 1993, EMBO J, V12, P5043; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; DANISH R, 1992, ONCOGENE, V7, P901; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dooley S, 1996, LEUKEMIA RES, V20, P429, DOI 10.1016/0145-2126(96)00012-4; Gonda TJ, 1998, INT J BIOCHEM CELL B, V30, P547, DOI 10.1016/S1357-2725(98)00003-X; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; JACOBS SM, 1994, ONCOGENE, V9, P227; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOUNTZ JD, 1993, MOL IMMUNOL, V30, P787, DOI 10.1016/0161-5890(93)90001-R; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Phan SC, 1996, MOL CELL BIOL, V16, P2387; PILZ RB, 1992, J BIOL CHEM, V267, P16161; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Shain KH, 1999, J CELL BIOCHEM, V73, P237, DOI 10.1002/(SICI)1097-4644(19990501)73:2<237::AID-JCB10>3.0.CO;2-H; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; VALTIERI M, 1991, BLOOD, V77, P1181; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; Wang ZB, 1999, EMBO J, V18, P2218, DOI 10.1093/emboj/18.8.2218; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144	41	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7360	7369		10.1038/sj.onc.1203158	http://dx.doi.org/10.1038/sj.onc.1203158			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602492				2022-12-28	WOS:000084119400022
J	Shang, YF; Baumrucker, CR; Green, MH				Shang, YF; Baumrucker, CR; Green, MH			The induction and activation of STAT1 by all-trans-retinoic acid are mediated by RAR beta signaling pathways in breast cancer cells	ONCOGENE			English	Article						retinoic acid; RAR; STAT1; breast cancer; gene expression	PROMYELOCYTIC LEUKEMIA-CELLS; GROWTH-INHIBITION; RECEPTOR-BETA; INTERFERON-ALPHA; GENE-EXPRESSION; UP-REGULATION; LUNG-CANCER; APOPTOSIS; PROTEIN; ARREST	Retinoic acid receptor-beta (RAR beta) and signal transducer and activator of transcription 1 (STAT1) are important mediators of the antiproliferative and apoptotic actions of retinoids and cytokines/growth factors, respectively. Expression of both RAR beta and STAT1 is lost in most breast cancer cell lines but it can be induced by retinoids in estrogen receptor-positive cells, We investigated a possible functional connection between these two mediators and present evidence supporting RAR beta as a tumor suppressor. First, by using different receptor-selective retinoids, we demonstrated that RAR beta induction in MCF-7 cells by all-trans-retinoic acid (atRA) was associated with the activation of STAT1 gene transcription. The direct involvement of RAR beta in atRA-induced STAT1 gene activation was further demonstrated by showing that transfection with an anti-sense RAR beta construct blocked atRA-induced STAT1 expression in MCF-7 cells whereas introduction of a sense-RAR beta construct resulted in STAT1 induction by atRA in MDA-MB 231 cells. In addition, we showed that STAT1 was phosphorylated/activated under atRA treatment of MCF-7 cells; this process required the involvement of RAR beta and protein synthesis. STAT1 phosphorylation/ activation was accompanied by increased tyrosine kinase activity that was not due to the activation of JAK1, JAK2 or Tyk 2, suggesting the possible involvement of an unidentified tyrosine kinase.	Penn State Univ, Dept Nutr, University Pk, PA 16802 USA; Penn State Univ, Dept Dairy & Anim Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Green, MH (corresponding author), Penn State Univ, Dept Nutr, S-126 Henderson Bldg S, University Pk, PA 16802 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032500] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD32500] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fitzgerald P, 1997, CANCER RES, V57, P2642; GEIER A, 1992, IN VITRO CELL DEV-AN, V28A, P725; GERBERT JF, 1991, ONCOGENE, V6, P1859; GIANNI M, 1995, BIOCHEM BIOPH RES CO, V208, P846, DOI 10.1006/bbrc.1995.1413; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; HIGUCHI T, 1991, CANCER RES, V51, P3958; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LANGENFELD J, 1997, P NATL ACAD SCI USA, V94, P12071; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Mangelsdorf David J., 1994, P319; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Widschwendter M, 1997, CANCER RES, V57, P4158; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Zhang XK, 1996, MUTAT RES-FUND MOL M, V350, P267, DOI 10.1016/0027-5107(95)00102-6	28	33	33	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6725	6732		10.1038/sj.onc.1203084	http://dx.doi.org/10.1038/sj.onc.1203084			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597280				2022-12-28	WOS:000083792000014
J	Singh, KK; Russell, J; Sigala, B; Zhang, YG; Williams, J; Keshav, KF				Singh, KK; Russell, J; Sigala, B; Zhang, YG; Williams, J; Keshav, KF			Mitochondrial DNA determines the cellular response to cancer therapeutic agents	ONCOGENE			English	Article						mitochondria; mitochondrial DNA; cell death; adriamycin	PHOTODYNAMIC THERAPY; CELLS; DOXORUBICIN; APOPTOSIS; AMPLIFICATION; BIOENERGETICS; EXPRESSION; PORPHYRIN; FAILURE; REPAIR	Mutations in the mitochondrial genome leading to mitochondrial dysfunction have been reported in a variety of cancers. However, the potential implication of these findings in the cellular response to cancer therapeutic agents is unclear. To examine the importance of mitochondrial DNA (mitDNA) encoded functions in cancer therapeutic response, we determined the clonogenic survival of HSL2 (Rho(+), HeLa subline), and its derivative cell line lacking mitDNA (Rho(o)) after exposure to different anticancer agents. We found that isogenic Rho(o) cells lacking mitDNA were extremely resistant to adriamycin and photodynamic therapy (PDT) induced cell death, whereas the Rho(+) cell line was sensitive. However, there was no measurable difference in the responses of these cell lines to either alkylating agent or gamma-radiation. We show that the development of resistance to adriamycin was not due to changes in apoptotic cell death, cell cycle response or to the uptake of adriamycin in isogenic Rho(o) cells. We also demonstrate that exposure of HeLa cells to adriamycin leads to mutations in mitDNA. These studies provide direct evidence that mitDNA plays an important role in cellular sensitivity to cancer therapeutic agents.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA; Drexel Univ, Dept Biosci & Biotechnol, Philadelphia, PA 19104 USA	Johns Hopkins University; Johns Hopkins Medicine; Drexel University	Singh, KK (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, 600 N Wolfe St,Room 2-121, Baltimore, MD 21287 USA.				NCI NIH HHS [CA/ES 66204] Funding Source: Medline; NIEHS NIH HHS [ES 09714-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boultwood J, 1996, BRIT J HAEMATOL, V95, P426, DOI 10.1046/j.1365-2141.1996.d01-1922.x; CHEVILLARD S, 1990, J CANCER RES CLIN, V116, P633, DOI 10.1007/BF01637086; Eguchi Y, 1997, CANCER RES, V57, P1835; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; Fisher AMR, 1999, CANCER RES, V59, P331; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; HILF R, 1987, PHOTOCHEM PHOTOBIOL, V46, P806; Isaacs JS, 1997, ONCOGENE, V14, P1669, DOI 10.1038/sj.onc.1201001; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; KESHAV KF, 1998, MITOCHONDRIAL DNA MU; Kiberstis PA, 1999, SCIENCE, V283, P1475; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KULE C, 1994, MOL PHARMACOL, V46, P1234; Liang BC, 1996, MUTAT RES-FUND MOL M, V354, P27, DOI 10.1016/0027-5107(96)00004-8; Liang BC, 1998, CELL DEATH DIFFER, V5, P694, DOI 10.1038/sj.cdd.4400401; Marchetti P, 1996, CANCER RES, V56, P2033; ModicaNapolitano JS, 1996, CANCER RES, V56, P544; MORAIS R, 1994, CANCER RES, V54, P3889; Munday AD, 1996, BBA-MOL CELL RES, V1311, P1, DOI 10.1016/0167-4889(96)00008-0; NASS MMK, 1972, EXP CELL RES, V72, P211, DOI 10.1016/0014-4827(72)90583-6; Palmeira CM, 1997, BBA-BIOENERGETICS, V1321, P101, DOI 10.1016/S0005-2728(97)00055-8; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 1997, J BIOENERG BIOMEMBR, V29, P301, DOI 10.1023/A:1022417911796; PETIT PX, 1998, MITOCHONDRIAL DNA MU; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Rempel A, 1996, CANCER RES, V56, P2468; RICHTER C, 1988, FEBS LETT, V241, P1, DOI 10.1016/0014-5793(88)81018-4; SCHATZ G, 1995, BBA-MOL BASIS DIS, V1271, P123, DOI 10.1016/0925-4439(95)00018-Y; SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982; Shan K, 1996, ANN INTERN MED, V125, P47, DOI 10.7326/0003-4819-125-1-199607010-00008; SHARKEY SM, 1993, CANCER RES, V53, P4994; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; Singal PK, 1997, FASEB J, V11, P931, DOI 10.1096/fasebj.11.12.9337145; SINGH KK, 1998, MITOCHONDRIAL DNA MU; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; TALLINI G, 1997, VIRCHOWS ARCH, V433, P5; Tanaka M, 1996, Methods Enzymol, V264, P407, DOI 10.1016/S0076-6879(96)64037-3; Toffoli G, 1996, EUR J CANCER, V32A, P1591, DOI 10.1016/0959-8049(96)00113-X; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; Wallace KB, 1997, FUND APPL TOXICOL, V38, P23, DOI 10.1006/faat.1997.2320; WELTER C, 1989, GENE CHROMOSOME CANC, V1, P79, DOI 10.1002/gcc.2870010112; WOODBURN KW, 1992, PHOTOCHEM PHOTOBIOL, V55, P697	43	152	162	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6641	6646		10.1038/sj.onc.1203056	http://dx.doi.org/10.1038/sj.onc.1203056			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597269				2022-12-28	WOS:000083792000003
J	Thant, AA; Sein, TT; Liu, EB; Machida, K; Kikkawa, F; Koike, T; Seiki, M; Matsuda, S; Hamaguchi, M				Thant, AA; Sein, TT; Liu, EB; Machida, K; Kikkawa, F; Koike, T; Seiki, M; Matsuda, S; Hamaguchi, M			Ras pathway is required for the activation of MMP-2 secretion and for the invasion of src-transformed 3Y1	ONCOGENE			English	Article						Ras; v-Src; matrix metalloproteinase-2; invasion; signaling pathway	ROUS-SARCOMA VIRUS; V-SRC; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; STAT3 ACTIVATION; INFECTED CELLS; MESSENGER-RNA; GENE-PRODUCT; TUMOR-CELLS	To search for the signaling pathway critical for tumor invasion, we examined the effects of dominant negative ras (S17N ras) expression on the activation of matrix metalloproteinase-2 (MMP-2) in spc-transformed 3Y1, SR3Y1, under the control of conditionally inducible promoter. In SR3Y1 clones transfected with S17N pas, augmented secretion and proteolytic activation of MMP-2 were dramatically suppressed by S17N Ras expression, while tyrosine phosphorylation of cellular proteins was not suppressed. We found that invasiveness of SR3Y1 cells assayed by the modified Boyden Chamber method was strongly suppressed by S17N Ras expression. In contrast, cell morphology reverted partially and glucose uptake remained unchanged by S17N Ras expression. In addition, treatment of SR3Y1 with manumycin A, a potent inhibitor of Ras farnesyltransferase, strongly suppressed both augmented secretion and proteolytic activation of MMP-2. Contrary, treatment of SR3Y1 with wortmannin or TPA showed no clear effect on MMP-2 activation. Thus, these results strongly suggest that Ras-signaling, but neither P13 kinase- nor protein kinase C-signalings, plays a critical role in activation of MMP-2 and, subsequently, in the invasiveness of src-transformed cells.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Obstet & Gynecol, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	Nagoya University; Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		KIKKAWA, Fumitaka/I-7341-2014; Seiki, Motoharu/K-9443-2015					Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALBINI A, 1987, CANCER RES, V47, P3239; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HATANAKA M, 1970, VIROLOGY, V41, P647, DOI 10.1016/0042-6822(70)90429-0; Kataoka M, 1996, INT J ONCOL, V8, P773; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLINS DE, 1983, BIOCHIM BIOPHYS ACTA, V695, P177, DOI 10.1016/0304-419X(83)90011-2; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; OHTANI H, 1995, JPN J CANCER RES, V86, P833, DOI 10.1111/j.1349-7006.1995.tb03093.x; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PYKE C, 1992, CANCER RES, V52, P1336; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XIAO HY, 1995, INT J ONCOL, V6, P405; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	42	32	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6555	6563		10.1038/sj.onc.1203049	http://dx.doi.org/10.1038/sj.onc.1203049			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597259	Bronze			2022-12-28	WOS:000083709200019
J	Trautwein, C; Will, M; Kubicka, S; Rakemann, T; Flemming, P; Manns, MP				Trautwein, C; Will, M; Kubicka, S; Rakemann, T; Flemming, P; Manns, MP			2-acetaminofluorene blocks cell cycle progression after hepatectomy by p21 induction and lack of Cyclin E expression	ONCOGENE			English	Article						2-acetaminofluorene; hepatectomy; liver regeneration; cell cycle progression; P21; Cyclin E	LIVER STEM-CELLS; RETINOBLASTOMA PROTEIN; OVAL CELLS; DEPENDENT KINASES; G(1) ARREST; TRANSCRIPTION FACTORS; REGENERATING LIVER; GENE-TRANSCRIPTION; DOWN-REGULATION; GROWTH	In the Solt-Faber model DENA and 2-Acetaminofluorene (AAF) treatment combined with hepatectomy induces hepatocellular carcinoma in rats. In this model AAF blocks proliferation of hepatocytes, while oval cells restore liver mass. Here we studied the molecular mechanism involved in blocking AAF-dependent cell cycle progression of hepatocytes. AAF inhibits cell proliferation of hepatocytes shown by the lack of Cyclin E expression before the G1/S phase restriction point. Immunfluorescence studies revealed that Cyclin E positive signals mere restricted to oval cells, while hepatocytes remained negative. Additionally, AAF treatment induces strong nuclear p53 expression which is associated with increased p21 mRNA levels. Inhibition of active Cyclin/CdK (cyclin dependent kinase) complexes is reflected in AAF-treated animals by decreased RE expression and phosphorylation. The decrease in RE expression and phosphorylation, which is essential in triggering DNA synthesis and Cyclin A expression, leads to a deficiency in transcriptionally active E2F complex formation after hepatectomy. Thus, two molecular explanations are evident to account for AAF-dependent cell cycle progression of hepatocytes in vivo: first, induction of p53 expression which leads to higher p21 mRNA levels, and second, a lack of Cyclin E expression at the G1/S phase restriction point after hepatectomy.	Med Hsch Hannover, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Med Hsch Hannover, Dept Pathol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Trautwein, C (corresponding author), Med Hsch Hannover, Dept Gastroenterol & Hepatol, Carl-Neuberg-Str 1, D-30625 Hannover, Germany.							Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Alison MR, 1996, CELL PROLIFERAT, V29, P373, DOI 10.1111/j.1365-2184.1996.tb00982.x; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; Bisgaard HC, 1996, HEPATOLOGY, V23, P62, DOI 10.1002/hep.510230110; Bock CT, 1997, GASTROENTEROLOGY, V113, P1976, DOI 10.1016/S0016-5085(97)70018-0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHIOU K, 1994, MOL CELL BIOL, V15, P2556; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVARTS RP, 1987, CARCINOGENESIS, V8, P1737, DOI 10.1093/carcin/8.11.1737; FARIS RA, 1991, CANCER RES, V51, P1308; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; GANNON JV, 1990, EMBO J, V9, P15905; GRANA X, 1995, ONCOGENE, V11, P211; GRISHAM JW, 1962, CANCER RES, V22, P842; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KASTAN MB, 1991, CANCER RES, V51, P6304; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Petersen BE, 1998, HEPATOLOGY, V27, P433, DOI 10.1002/hep.510270218; SCHIRMACHER P, 1993, VIRCHOWS ARCH B, V63, P71, DOI 10.1007/BF02899246; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SELL S, 1994, MODERN PATHOL, V7, P105; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIGAL HS, 1992, AM J PHYSIOL, V26, pG139; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SOLT D, 1976, NATURE, V263, P701, DOI 10.1038/263701a0; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THORGEIRSSON SS, 1993, AM J PATHOL, V142, P1331; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	59	32	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6443	6453		10.1038/sj.onc.1203045	http://dx.doi.org/10.1038/sj.onc.1203045			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597246				2022-12-28	WOS:000083709200006
J	Ikeda, S; Kishida, M; Matsuura, Y; Usui, H; Kikuchi, A				Ikeda, S; Kishida, M; Matsuura, Y; Usui, H; Kikuchi, A			GSK-3 beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin	ONCOGENE			English	Article						APC; axin; GSK-3 beta; beta-catenin; PP2A	TUMOR-SUPPRESSOR PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; WNT SIGNALING PATHWAY; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; XENOPUS EMBRYOS; APC; TRANSCRIPTION; ASSOCIATION; GSK3-BETA	Axin forms a complex with adenomatous polyposis coli gene product (APC), glycogen synthase kinase-3 beta (GSK-3 beta), and beta-catenin through different binding sites and downregulates beta-catenin. GSK-3 beta-dependent phosphorylation of APC-(1211-2075) which has the Axin-binding site was facilitated by Axin, but that of APC-(959-1338) which lacks the Axin-binding site was not, Axin-(298-506) or Axin-(298-832), which has the GSK-3 beta- and beta-catenin- but not APC-binding sites, did not enhance GSK-3 beta-dependent phosphorylation of either APC(1211-2075) or APC-(959-1338), Furthermore, beta-catenin stimulated the phosphorylation of APC-(959-1338) and APC-(1211-2075) by GSK-3 beta in the presence of Axin, Consistent with these in vitro observations, expression of beta-catenin or Axin in COS cells promoted an SDS gel band shift of APC. These results indicate that APC complexed with Axin is effectively phosphorylated by GSK-3 beta and that beta-catenin may modulate this phosphorylation, In addition, the heterodimeric form of protein phosphatase 2A (PP2A) directly bound to Axin, and PP2A complexed with Axin dephosphorylated APC phosphorylated by GSK-3 beta. Taken together, these results suggest that GSK-3 beta-dependent phosphorylation of APC can be modulated by beta-catenin and PP2A complexed with Axin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Natl Inst Infect Dis, Dept Virol 2, Shinjuku Ku, Tokyo 1628640, Japan	Hiroshima University; National Institute of Infectious Diseases (NIID)	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dale TC, 1998, BIOCHEM J, V329, P209; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; USUI H, 1988, J BIOL CHEM, V263, P3752; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	43	154	158	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					537	545		10.1038/sj.onc.1203359	http://dx.doi.org/10.1038/sj.onc.1203359			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698523				2022-12-28	WOS:000085104200007
J	Tomita, A; Towatari, M; Tsuzuki, S; Hayakawa, F; Kosugi, H; Tamai, K; Miyazaki, T; Kinoshita, T; Saito, H				Tomita, A; Towatari, M; Tsuzuki, S; Hayakawa, F; Kosugi, H; Tamai, K; Miyazaki, T; Kinoshita, T; Saito, H			c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300	ONCOGENE			English	Article						c-Myb; p300; GCN5; acetylation; bromodomain	NEGATIVE REGULATORY DOMAIN; GENE V-MYB; HISTONE ACETYLTRANSFERASES; DNA-BINDING; PHOSPHORYLATION SITE; B-MYB; CBP; PROTOONCOGENE; EXPRESSION; TRANSACTIVATION	Transcription factor c-Myb plays important roles in cell survival and differentiation in immature hematopoietic cells, Here we demonstrate that c-Myb is acetylated at the carboxyl-terminal conserved domain by histone acetyltransferase p300 both in vitro and in vivo. The acetylation sites in Pho have been located at the lysine residues of the conserved domain (K471, K480, K485) by the use of the mutant Myb (Myb-KAmut), in which all three lysine residues are substituted into alanine. Electrophoretic mobility shift assay reveals that Myb-KAmut shows higher DNA binding activity than wild type c-Myb and that acetylation of c-Myb in vitro by p300 causes dramatic increase in DNA binding activity, Accordingly, transactivation activity of both mim-1 and CD34 promoters by Myb-KAmut is higher than that driven by wild type c-Myb. Furthermore, the bromodomain of p300, in addition to the histone acetyltransferase (HAT) domain, is required for effective acetylation of Myb, and hGCN5 is revealed to be a factor acetyltransferase for c-Myb in vitro. We present a new manner of post-translational modification of the c-Myb protein and the potential significance of the acetylation in c-Myb.	Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Med & Biol Labs Co Ltd, Nagano, Japan; CycLex Inc, Nagano, Japan	Nagoya University	Towatari, M (corresponding author), Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668550, Japan.		Tamai, Katsuyuki/F-4743-2013; Hayakawa, Fumihiko/I-7288-2014	Tamai, Katsuyuki/0000-0003-4094-3911; Tsuzuki, Shinobu/0000-0002-3209-3550				AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BURN TC, 1992, BLOOD, V80, P3051; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; Gonda TJ, 1998, INT J BIOCHEM CELL B, V30, P547, DOI 10.1016/S1357-2725(98)00003-X; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HU YL, 1991, ONCOGENE, V6, P1549; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Liu L, 1999, MOL CELL BIOL, V19, P1202; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Nakahara Y, 1999, INT J HEMATOL, V69, P237; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; NESS SA, 1989, CELL, V59, P115; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tanaka Y, 1997, FEBS LETT, V413, P162, DOI 10.1016/S0014-5793(97)00900-9; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	44	103	103	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					444	451		10.1038/sj.onc.1203329	http://dx.doi.org/10.1038/sj.onc.1203329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656693				2022-12-28	WOS:000084873700016
J	Nakagawa, H; Koyama, K; Murata, Y; Morito, M; Akiyama, T; Nakamura, Y				Nakagawa, H; Koyama, K; Murata, Y; Morito, M; Akiyama, T; Nakamura, Y			EB3, a novel member of the EB1 family preferentially expressed in the central nervous system, binds to a CNS-specific APC homologue	ONCOGENE			English	Article						APC; APCL; EB1; EB3; microtubules; central nervous system	TUMOR-SUPPRESSOR PROTEIN; GENE; CHROMOSOME-5Q21; IDENTIFICATION; MUTATIONS; FAP	APCL, a homologue of the adenomatous polyposis coli (APC) tumor suppressor, can deplete cytoplasmic betacatenin like APC, However, as its biological function remains unclear, we have been using a yeast two-hybrid system to search for proteins that associate with its carboxyl region. Among several cDNA clones we isolated from a fetal-brain cDNA library as candidates, six included an identical sequence with significant homology to EB1, a protein known to bind to APC, The full-length cDNA of this novel homologue of EB1, named EB3, encoded a protein of 282 amino acids with 54% identity to EB1, and it was expressed preferentially in brain tissue on Northern blots. Confocal microscopy demonstrated that exogenous EB3, like EB1, is associated with the cytoplasmic microtubule network, Moreover, in these experiments EB3 and APCL appeared together in the perinucleus and the cytoplasmic microtubule network. Since APCL is also expressed highly and specifically in the central nervous system, APCL;EB3 interaction may be specific to the CNS, possibly involving stability and/or extension of microtubules during neuritogenesis.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Sch Med, Div Clin Genet, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Ongone Res, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Surg 2, Osaka 5650871, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Dept Human Genome Anal, Tokyo 1708544, Japan	University of Tokyo; Osaka University; Osaka University; Osaka University; Japanese Foundation for Cancer Research	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			Murata, Yoji/0000-0002-9576-7030				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; BHAT RV, 1994, J NEUROSCI, V14, P3059; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Laurent-Puig P, 1998, NUCLEIC ACIDS RES, V26, P269, DOI 10.1093/nar/26.1.269; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MINEMATSU S, 1995, P NATL ACAD SCI USA, V92, P3046; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Nakagawa H, 1998, CANCER RES, V58, P5176; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972	19	83	89	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					210	216		10.1038/sj.onc.1203308	http://dx.doi.org/10.1038/sj.onc.1203308			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644998				2022-12-28	WOS:000084844400005
J	Perissi, V; Menini, N; Cottone, E; Capello, D; Sacco, M; Montaldo, F; De Bortoli, M				Perissi, V; Menini, N; Cottone, E; Capello, D; Sacco, M; Montaldo, F; De Bortoli, M			AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen	ONCOGENE			English	Article						ERBB2; oestrogen repression; AP-2; ER	BREAST-CANCER CELLS; ESTROGEN-RECEPTOR; PROTEIN EXPRESSION; MAMMARY-CARCINOMA; GROWTH; AP2; OVEREXPRESSION; AMPLIFICATION; SUPPRESSION; MECHANISMS	Transcription of the ERBB2 oncogene is repressed by oestrogen in human breast cancer cells. We show that a 218 bp fragment of the human ERBB2 gene promoter is responsive to oestrogen in transient transfection in ZR75.1 and SKBR.3 cells when the oestrogen receptor is expressed. Deletion analysis of this fragment shows that a sequence located at the 5' end, which is known to mediate ERBB2 overexpression in breast cancer, is also responsible for the oestrogen response. This sequence binds AP-2 transcription factors and appears functionally identical to an element of the oestrogen-dependent enhancer described in the first intron of human ERBB2, We observed that oestrogen treatment down-regulates expression of AP-2 proteins but does not affect the DNA binding activity of AP-2. Constitutive expression of AP-2 beta or AP-2 gamma, but not AP-2 alpha, abrogates the estrogenic repression. Our results demonstrate that AP-2 transcription factors are implicated in the oestrogenic regulation of ERBB2 gene expression and suggest a complex interplay involving the different AP-2 isoforms and other unidentified factors.	Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Univ Turin, Dept Anim & Human Biol, I-10124 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	De Bortoli, M (corresponding author), Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Capello, Daniela/J-4110-2012; De Bortoli, Michele/B-5418-2013	Capello, Daniela/0000-0001-9157-8753; De Bortoli, Michele/0000-0002-6666-9052; Perissi, Valentina/0000-0002-3716-0003				ANTONIOTTI S, 1992, EUR J CANCER, V28A, P318, DOI 10.1016/S0959-8049(05)80045-0; ANTONIOTTI S, 1994, BRIT J CANCER, V70, P1095, DOI 10.1038/bjc.1994.454; Bates NP, 1997, J MAMMARY GLAND BIOL, V2, P153, DOI 10.1023/A:1026303814855; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; Bisgrove DA, 1999, DEV DYNAM, V214, P195, DOI 10.1002/(SICI)1097-0177(199903)214:3<195::AID-AJA3>3.0.CO;2-8; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; DATI C, 1990, ONCOGENE, V5, P1001; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DRUEGE PM, 1986, NUCLEIC ACIDS RES, V14, P9329, DOI 10.1093/nar/14.23.9329; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Kannan F, 1999, MOL CELL BIOL, V19, P899; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; READ LD, 1990, CANCER RES, V50, P3947; RUSSEL KS, 1992, CANCER RES, V50, P3947; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Turner BC, 1998, CANCER RES, V58, P5466; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; WARRI AM, 1991, INT J CANCER, V49, P616, DOI 10.1002/ijc.2910490425; WHITE MRA, 1992, ONCOGENE, V7, P677; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	38	56	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					280	288		10.1038/sj.onc.1203303	http://dx.doi.org/10.1038/sj.onc.1203303			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645007				2022-12-28	WOS:000084844400014
J	Gonin, S; Diaz-Latoud, C; Richard, MJ; Ursini, MV; Imbo, A; Manero, F; Arrigo, AP				Gonin, S; Diaz-Latoud, C; Richard, MJ; Ursini, MV; Imbo, A; Manero, F; Arrigo, AP			p53/T-antigen complex disruption in T-antigen transformed NIH3T3 fibroblasts exposed to oxidative stress: correlation with the appearance of a Fas/APO-1/CD95 dependent, caspase independent, necrotic pathway	ONCOGENE			English	Article						T-antigen; oxidative stress; necrosis; p53; Fas	FAS-MEDIATED APOPTOSIS; LARGE TUMOR-ANTIGEN; APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; KAPPA-B ACTIVATION; DNA-DAMAGE; GLUTATHIONE-PEROXIDASE; LIGAND EXPRESSION; 3T3 FIBROBLASTS; HEAT-SHOCK	Simian Virus 40 Large T-antigen expressed in NIH3T3 cells increases p53 level and interacts with this tumor suppressor to form large nuclear complexes, We show here that T-antigen sensitizes NIH3T3 cells to loa doses of the oxidative stress inducer menadione, This oxidant increased p53 accumulation and disrupted p53/T-antigen interaction, but not T-antigen/pRb, T-antigen/Hsc70 and p53/Hsc70 complexes; a phenomenon inhibited by the anti-oxidant N-acetyl-cysteine. Analysis of several p53 downstream gene products revealed that the level of Fas receptor, which was sharply reduced by T-antigen expression, was drastically increased in response to menadione treatment. Menadione also induced a T-antigen dependent cleavage of Fas ligand. Analysis performed with Fas receptor antagonist antibody and metalloproteinases inhibitor revealed that menadione triggers a Fas-dependent death of a fraction of T-antigen expressing cells, This Fas pathway does not activate caspase 8 or 3, probably because of the inhibition induced by T-antigen, and leads to a necrotic cell death which contributes at least in part to the hypersensitivity of T-antigen transformed cells to oxidative stress.	Univ Lyon 1, CNRS UMR 5534, Ctr Genet Mol & Cellulaire, Villeurbanne, France; Ctr Hosp Univ, Biochim Lab C, Grenoble, France; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Arrigo, AP (corresponding author), Univ Lyon 1, CNRS UMR 5534, Ctr Genet Mol & Cellulaire, Villeurbanne, France.							ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BRAVARD A, 1993, CARCINOGENESIS, V14, P21, DOI 10.1093/carcin/14.1.21; Butler LM, 1998, BRIT J CANCER, V77, P1454, DOI 10.1038/bjc.1998.239; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eguchi Y, 1997, CANCER RES, V57, P1835; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FABREJONCA N, 1995, EUR J BIOCHEM, V232, P118, DOI 10.1111/j.1432-1033.1995.tb20789.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fenton RG, 1998, CANCER RES, V58, P3391; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gonin S, 1997, CELL STRESS CHAPERON, V2, P238, DOI 10.1379/1466-1268(1997)002<0238:TBTAAO>2.3.CO;2; Green DR, 1998, NATURE, V396, P629, DOI 10.1038/25248; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAINAUT P, 1995, ONCOGENE, V10, P27; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KHANDJIAN EW, 1995, ONCOGENE, V10, P359; KLAUSING K, 1994, CUR TOP MICROBIOL IM, V144, P31; Koike M, 1996, CANCER LETT, V108, P185, DOI 10.1016/S0304-3835(96)04408-4; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Kristjuhan A, 1998, ONCOGENE, V16, P2413, DOI 10.1038/sj.onc.1201749; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MIYASHITA T, 1995, CELL, V80, P293; Moorwood K, 1996, EXP CELL RES, V223, P308, DOI 10.1006/excr.1996.0086; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paley EL, 1996, CARCINOGENESIS, V17, P939, DOI 10.1093/carcin/17.5.939; Parat MO, 1997, BIOL TRACE ELEM RES, V60, P187, DOI 10.1007/BF02784439; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; ROUQUET N, 1995, ONCOGENE, V11, P1061; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sompayrac L, 1997, VIROLOGY, V233, P130, DOI 10.1006/viro.1997.8610; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Reyher U, 1998, CANCER RES, V58, P526; Wendel A, 1981, Methods Enzymol, V77, P325; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	66	20	20	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 23	1999	18	56					8011	8023		10.1038/sj.onc.1203319	http://dx.doi.org/10.1038/sj.onc.1203319			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637512				2022-12-28	WOS:000084634600010
J	Attwooll, C; Tariq, M; Harris, M; Coyne, JD; Telford, N; Varley, JM				Attwooll, C; Tariq, M; Harris, M; Coyne, JD; Telford, N; Varley, JM			Identification of a novel fusion gene involving hTAF(II)68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma	ONCOGENE			English	Article						t(9;17)(q22;q11.2); RBP56/hTAF(II)68; CHN; extraskeletal myxoid chrondrosarcoma	RNA-BINDING PROTEIN; ORPHAN NUCLEAR RECEPTOR; POLYMERASE-II; EWS; LIPOSARCOMA; CHOP; TLS/FUS; FUS/TLS; FAMILY; MEMBER	A proportion of extraskeletal myxoid chondrosarcomas (EMC) have been shown to have a characteristic translocation t(9;22)(q22;q12) involving the EWS gene at 22q12 and the CHN orphan nuclear receptor gene at 9q22, This translocation appears to be largely specific for EMC, but has not been detected in all such tumours. We report here a case of EMC with a t(9;17)(q22;q11.2) as the sole chromosome abnormality. We have determined that the translocation results in the fusion of the entire coding region of CHN to the N-terminal transactivation domain of RBP56/hTAF(II)68. This is the first report of a translocation involving RBP56/hTAF(II) 68, a protein with sequence homology to both EWS and TLS/FUS, The involvement of RBP56/hTAF(II)68 may explain some unusual features of the tumour.	Withington Hosp, Dept Histopathol, Manchester M20 8LR, Lancs, England; Paterson Inst Canc Res, CRC, Dept Canc Genet, Manchester M20 9BX, Lancs, England; Christie Hosp, Dept Oncol Cytogenet, Manchester, Lancs, England; Christie Hosp, Dept Histopathol, Manchester, Lancs, England	Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital	Varley, JM (corresponding author), Withington Hosp, Dept Histopathol, Manchester M20 8LR, Lancs, England.							Antonescu CR, 1998, CANCER, V83, P1504, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1504::AID-CNCR5>3.0.CO;2-B; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Brody RI, 1997, AM J PATHOL, V150, P1049; Chhieng DC, 1998, MODERN PATHOL, V11, p8A; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; ICHIKAWA H, 1994, CANCER RES, V54, P2865; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; MARKVENDEL E, 1991, CANCER GENET CYTOGEN, V52, P267; Morohoshi F, 1996, GENOMICS, V38, P51, DOI 10.1006/geno.1996.0591; Morohoshi F, 1998, GENE, V221, P191, DOI 10.1016/S0378-1119(98)00463-6; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; Panagopoulos I, 1996, ONCOGENE, V12, P489; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SCOTT JE, 1965, HISTOCHEMISTRY, V5, P221, DOI 10.1007/BF00306130	17	75	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7599	7601		10.1038/sj.onc.1203156	http://dx.doi.org/10.1038/sj.onc.1203156			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602520				2022-12-28	WOS:000084119600022
J	Koike, M; Ikuta, T; Miyasaka, T; Shiomi, T				Koike, M; Ikuta, T; Miyasaka, T; Shiomi, T			Ku80 can translocate to the nucleus independent of the translocation of Ku70 using its own nuclear localization signal	ONCOGENE			English	Article						cell cycle; GFP; Ku; NLS; PTAC58/PTAC97	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; SV40-TRANSFORMED HUMAN KERATINOCYTES; SEVERE COMBINED IMMUNODEFICIENCY; PORE-TARGETING COMPLEX; DNA-BINDING PROTEINS; V(D)J RECOMBINATION; IN-VIVO; MONOCLONAL-ANTIBODIES; INTERACTION REGIONS	Ku antigen is a complex of Ku70 and Ku80 subunits and plays an important role in not only DNA double-strand breaks (DSB) repair and V(D)J recombination, but also in growth regulation, Ku is generally believed to always form and function as heterodimers on the basis of in vitro observations. Here we demonstrate that the localization of Ku80 does not completely coincide with that of Ku70, Ku70 and Ku80 were colocalized in the nucleus in the interphase but not in the late telophase/early G1 phase of the cell cycle, Since the in vivo function of Ku might be partially regulated by the control of its transport, we attempted to investigate the molecular mechanisms underlying the nuclear translocation of Ku. The nuclear translocation of Ku80 started during the late telophase/early G1 phase after the nuclear envelope was formed and this was preceded by the nuclear translocation of Ku70, Furthermore, we found that the Ku80 protein was transported to the nucleus without heterodimerization with Ku70, To understand in detail the mechanism of transport of Ku80, we attempted to identify the nuclear localization signal (NLS) of Ku80 and defined to a region spanning nine amino acid residues (positions 561-569), The Ku80 NLS was demonstrated to be mediated to the nuclear rim by two components of PTAC58 and PTAC97. All these findings support the idea that Ku80 can translocate to the nucleus using its own NLS independent of the translocation of Ku70.	Natl Inst Radiol Sci, Genome Res Grp, Inage Ku, Chiba 2638555, Japan; Saitama Canc Ctr, Res Ctr, Ina, Saitama 3620806, Japan	National Institutes for Quantum Science & Technology	Koike, M (corresponding author), Natl Inst Radiol Sci, Genome Res Grp, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.		Koike, Manabu/AAP-3107-2021					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; Cary RB, 1998, NUCLEIC ACIDS RES, V26, P974, DOI 10.1093/nar/26.4.974; DANZIEL RG, 1992, AUTOIMMUNITY, V13, P265; Errami A, 1996, MOL CELL BIOL, V16, P1519; Fewell JW, 1996, J CELL SCI, V109, P1937; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1996, EUR J BIOCHEM, V241, P931, DOI 10.1111/j.1432-1033.1996.00931.x; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Koike M, 1998, BIOCHEM BIOPH RES CO, V252, P679, DOI 10.1006/bbrc.1998.9368; Koike M, 1999, EXP CELL RES, V250, P401, DOI 10.1006/excr.1999.4507; KOIKE M, 1995, ONCOGENE, V10, P117; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; KOIKE M, 1993, MOL CARCINOGEN, V8, P105, DOI 10.1002/mc.2940080207; Koike M, 1996, GENOMICS, V38, P38, DOI 10.1006/geno.1996.0589; Koike M, 1996, CANCER LETT, V108, P185, DOI 10.1016/S0304-3835(96)04408-4; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Osipovich O, 1997, J BIOL CHEM, V272, P27259, DOI 10.1074/jbc.272.43.27259; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; REEVES WH, 1994, RHEUM DIS CLIN N AM, V20, P1; Reeves WH, 1997, ANTIBODIES, P33; SATOH M, 1995, EUR J CELL BIOL, V66, P127; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tovari J, 1998, CELL SIGNAL, V10, P277, DOI 10.1016/S0898-6568(97)00128-9; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; Yoneda Y, 1997, J BIOCHEM, V121, P811; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	55	61	63	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7495	7505		10.1038/sj.onc.1203247	http://dx.doi.org/10.1038/sj.onc.1203247			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602508				2022-12-28	WOS:000084119600010
J	McFarland, EDC; Izumi, KM; Mosialos, G				McFarland, EDC; Izumi, KM; Mosialos, G			Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappa B	ONCOGENE			English	Review						Rel; NF-kappa B; herpesvirus; LMP1; Epstein-Barr virus; TRAF; TRADD; RIP; transformation; TNF	LYMPHOCYTE GROWTH TRANSFORMATION; TERMINAL CYTOPLASMIC DOMAIN; FACTOR RECEPTOR; NUCLEAR-PROTEIN; INFECTION MEMBRANE-PROTEIN-1; BCL-2 EXPRESSION; GENETIC-ANALYSIS; FINGER PROTEIN; BINDING-SITE; CELL-LINES	Epstein-Barr virus (EBV) transforms resting primary human B lymphocytes into indefinitely proliferating lymphoblastoid cell lines irt vitro and is associated with several human malignancies in vivo. Recombinant EBV genetic analyses combined with in vitro B lymphocyte transformation assays demonstrate that latent infection membrane protein 1 (LMP1) is essential for EBV-mediated lymphocyte transformation. LMP1 has no intrinsic enzymatic activity but instead aggregates cellular proteins of the tumor necrosis factor receptor signaling pathway to activate transcription factor NF-kappa B. Mutants rendering LMP1 defective in these protein interactions are impaired in their abilities to activate NF-kappa B in reporter gene assays. Concordantly, EBV recombinants with LMP1 mutations that are compromised for NF-kappa B activation are impaired for growth transformation. Thus, EBV-mediated growth transformation is genetically and biochemically linked to LMP1-mediated activation of NF-kappa B.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Mosialos, G (corresponding author), Brigham & Womens Hosp, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA047006, R29CA071705, R35CA047006, F32CA076727] Funding Source: NIH RePORTER; NCI NIH HHS [CA47006, CA71705, CA76727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asso-Bonnet M, 1998, ONCOGENE, V17, P1607, DOI 10.1038/sj.onc.1202365; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Busch LK, 1999, J IMMUNOL, V162, P2555; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; EPSTEIN MA, 1967, BRIT MED J, V2, P290, DOI 10.1136/bmj.2.5547.290; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FINKE J, 1992, BLOOD, V80, P459; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; HAMILTONDUTOIT SJ, 1991, J CLIN PATHOL, V44, P676, DOI 10.1136/jcp.44.8.676; HAMILTONDUTOIT SJ, 1993, AM J PATHOL, V143, P1072; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hatzivassiliou E, 1998, J IMMUNOL, V160, P1116; HELLER M, 1982, J VIROL, V44, P311, DOI 10.1128/JVI.44.1.311-320.1982; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1969, J NATL CANCER I, V43, P1147; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE W, 1967, SCIENCE, V157, P1064, DOI 10.1126/science.157.3792.1064; HENLE W, 1979, SCI AM, V241, P48, DOI 10.1038/scientificamerican0779-48; Henle W., 1970, BIBL HAEMATOL, P706; HENNESSY K, 1985, P NATL ACAD SCI USA, V82, P5944, DOI 10.1073/pnas.82.17.5944; HENNESSY K, 1986, P NATL ACAD SCI USA, V83, P5693, DOI 10.1073/pnas.83.15.5693; HENNESSY K, 1983, SCIENCE, V220, P1396, DOI 10.1126/science.6304878; HENNESSY K, 1985, SCIENCE, V227, P1238, DOI 10.1126/science.2983420; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HO M, 1985, J INFECT DIS, V152, P876, DOI 10.1093/infdis/152.5.876; HUEN DS, 1995, ONCOGENE, V10, P549; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kawanishi M, 1997, VIROLOGY, V228, P244, DOI 10.1006/viro.1996.8370; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANG DJ, 1977, AM J EPIDEMIOL, V105, P480, DOI 10.1093/oxfordjournals.aje.a112407; Lee MA, 1999, J VIROL, V73, P2974, DOI 10.1128/JVI.73.4.2974-2982.1999; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LONGNECKER R, 1990, J VIROL, V64, P2319, DOI 10.1128/JVI.64.5.2319-2326.1990; LONGNECKER R, 1993, J VIROL, V67, P2006, DOI 10.1128/JVI.67.4.2006-2013.1993; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MACMAHON EME, 1991, LANCET, V338, P969, DOI 10.1016/0140-6736(91)91837-K; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NIEDOBITEK G, 1991, J PATHOL, V165, P17, DOI 10.1002/path.1711650105; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; POPE JH, 1969, INT J CANCER, V4, P255, DOI 10.1002/ijc.2910040302; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; RICKINSON AB, 1975, NATURE, V258, P236, DOI 10.1038/258236a0; RICKINSON AB, 1980, INT J CANCER, V25, P59, DOI 10.1002/ijc.2910250108; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROBERTSON ES, 1994, J VIROL, V68, P1449, DOI 10.1128/JVI.68.3.1449-1458.1994; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SHIBATA D, 1992, AM J PATHOL, V140, P769; SMITH PR, 1993, J VIROL, V67, P3217, DOI 10.1128/JVI.67.6.3217-3225.1993; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TOMKINSON B, 1992, J VIROL, V66, P2893, DOI 10.1128/JVI.66.5.2893-2903.1992; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEISS LM, 1987, AM J PATHOL, V129, P86; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; ZimberStrobl U, 1996, EMBO J, V15, P7070, DOI 10.1002/j.1460-2075.1996.tb01098.x	95	135	138	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6959	6964		10.1038/sj.onc.1203217	http://dx.doi.org/10.1038/sj.onc.1203217			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602470				2022-12-28	WOS:000083896500012
J	Fu, LN; Ma, WL; Benchimol, S				Fu, LN; Ma, WL; Benchimol, S			A translation repressor element resides in the 3 ' untranslated region of human p53 mRNA	ONCOGENE			English	Article						p53; translational control; 3 ' UTR	CELLULAR TUMOR-ANTIGEN; DNA-DAMAGING AGENTS; MESSENGER-RNA; ADULT TISSUES; PROTEIN; EXPRESSION; APOPTOSIS; RADIATION; BINDING; CELLS	The 3' untranslated region of human p53 mRNA represses translation both irt vitro and in vivo. Here, we identify a cis-acting 66-nucleotide U-rich sequence in the human p53 mRNA 3' untranslated region that mediates translational repression. Using UV crosslinking, we detect a 40 kDa protein that interacts specifically with the p53 3'UTR containing the repressor element. Enhanced translation of p53 mRNA contributes to the accumulation of p53 protein in cells exposed to gamma-radiation and could be a consequence of relieving the inhibition mediated by the repressor element.	Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Benchimol, S (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X				Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; BAUM EZ, 1988, DEV BIOL, V126, P141, DOI 10.1016/0012-1606(88)90247-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HERZOG H, 1990, NUCLEIC ACIDS RES, V18, P4600, DOI 10.1093/nar/18.15.4600; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOSNER J, 1995, EMBO J, V14, P442; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; TISHLER RB, 1993, CANCER RES, V53, P2212; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3	33	36	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6419	6424		10.1038/sj.onc.1203064	http://dx.doi.org/10.1038/sj.onc.1203064			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597243				2022-12-28	WOS:000083709200003
